Torsade	Torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
intermittent	intermittent	i5306503053	JJ	I-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
dilated	dilated	d040303	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
56	56	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
,	,	,000	,	I-NP	O
severe	severe	s01060	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
dilated	dilate	d040303	VBN	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
one	one	o500	CD	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
of	of	o100	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mcg	mcg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
min	min	m050	NN	B-NP	O
)	)	)000	)	O	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
unpredictable	unpredictable	u516030230140	JJ	B-NP	O
fatal	fatal	f0304	JJ	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
even	even	e105	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
proarrhythmic	proarrhythmic	p606030502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Dubutamine	Dubutamine	d010305050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Positive	Positive	p0203010	JJ	B-NP	O
skin	skin	s205	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
late	late	l030	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
radiographic	radiographic	r030260102	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
media	medium	m030	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
few	few	f000	JJ	I-NP	O
years	year	y062	NNS	I-NP	O
delayed	delay	d0403	VBD	B-VP	O
reactions	reaction	r023052	NNS	B-NP	O
several	several	s010604	JJ	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
radiographic	radiographic	r030260102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
materials	material	m0306042	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
PRC	PRC	p620	NN	B-NP	B-Chemical
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
report	report	r01063	VBP	B-VP	O
two	two	t000	CD	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
intradermoreactions	intradermoreaction	i5360306506023052	NNS	B-NP	O
(	(	(000	(	O	O
IDR	IDR	i360	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
patch	patch	p0320	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
ionic	ionic	i0502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
non	non	n050	JJ	I-NP	O
ionic	ionic	i0502	JJ	I-NP	O
PRC	PRC	p620	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
venous	venous	v0502	JJ	I-NP	O
route	route	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
n	n	n000	NN	I-NP	O
degree	degree	d0260	NN	I-NP	O
1	1	1000	CD	I-NP	O
a	a	a000	DT	B-NP	O
biphasic	biphasic	b010202	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
(	(	(000	(	O	O
dyspnea	dyspnea	d02150	NN	B-NP	B-Disease
,	,	,000	,	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
consciousness	consciousness	c05202502	NN	B-NP	I-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
delayed	delay	d0403	VBN	B-VP	O
macro	macro	m0260	AFX	O	B-Disease
-	-	-000	HYPH	O	I-Disease
papular	papular	p010406	JJ	B-NP	I-Disease
rash	rash	r020	NN	I-NP	I-Disease
appeared	appear	a10603	VBD	B-VP	O
,	,	,000	,	O	O
whilst	whilst	w0423	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
n	n	n000	NN	I-NP	O
degree	degree	d0260	NN	I-NP	O
2	2	2000	CD	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
generalised	generalise	g0506040203	VBN	I-NP	O
sensation	sensation	s0520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heat	heat	h030	NN	B-NP	O
,	,	,000	,	O	O
persistent	persistent	p062023053	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
generalised	generalise	g0506040203	VBN	I-NP	O
macro	macro	m0260	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
papular	papular	p010406	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
positive	positive	p0203010	JJ	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
by	by	b000	IN	B-PP	O
IDR	IDR	i360	NN	B-NP	O
and	and	a530	CC	I-NP	O
patch	patch	p0320	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
to	to	t000	TO	B-PP	O
only	only	o540	RB	B-NP	O
some	some	s050	DT	I-NP	O
PRC	PRC	p620	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
chains	chain	c052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
skin	skin	s205	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
in	in	i500	IN	B-PP	O
favour	favour	f0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
immunological	immunological	i50504020204	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
help	help	h041	VB	I-VP	O
in	in	i500	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
allergy	allergy	a40620	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
hyperammonemic	hyperammonemic	h010605050502	JJ	I-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dehydration	dehydration	d0360305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
1986	1986	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1998	1998	0000	CD	B-NP	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
32	32	0000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
hyperammonemic	hyperammonemic	h010605050502	JJ	I-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
decompensated	decompensate	d020510520303	VBN	I-VP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Onset	Onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
hyperammonemic	hyperammonemic	h010605050502	JJ	B-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
varied	vary	v0603	VBD	B-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
ammonium	ammonium	a50505	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
248	248	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2387	2387	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
:	:	:000	:	O	O
626	626	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
431	431	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
32	32	0000	CD	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
(	(	(000	(	O	O
81	81	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
various	various	v0602	JJ	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
azotemia	azotemia	a203050	NN	B-NP	B-Disease
,	,	,000	,	O	O
18	18	0000	CD	B-NP	O
(	(	(000	(	O	O
56	56	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
bacterial	bacterial	b0230604	JJ	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
14	14	0000	CD	B-NP	O
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
infection	infection	i5102305	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
periods	period	p06032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
dehydration	dehydration	d0360305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Higher	High	h0206	JJR	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
ammonium	ammonium	a50505	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
bacterial	bacterial	b0230604	JJ	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
003	003	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
0006	0006	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
2600	2600	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
1800	1800	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
and	and	a530	CC	O	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
25	25	0000	CD	B-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
32	32	0000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
(	(	(000	(	O	O
78	78	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
ammonium	ammonium	a50505	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
within	within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
hyperammonemic	hyperammonemic	h010605050502	JJ	B-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
can	can	c050	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Azotemia	Azotemia	a203050	NN	B-NP	B-Disease
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
fluid	fluid	f403	NN	I-NP	O
insufficiency	insufficiency	i5201020520	NN	I-NP	O
and	and	a530	CC	O	O
bacterial	bacterial	b0230604	JJ	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
therefore	therefore	t0601060	RB	B-ADVP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
recognize	recognize	r02025020	VB	I-VP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
conditioned	condition	c053030503	VBN	B-NP	O
place	place	p4020	NN	I-NP	O
preference	preference	p601060520	NN	I-NP	O
and	and	a530	CC	O	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
unselective	unselective	u5204023010	JJ	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
25	25	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
conditioned	condition	c053030503	VBN	B-NP	O
place	place	p4020	NN	I-NP	O
preference	preference	p601060520	NN	I-NP	O
and	and	a530	CC	O	O
biphasic	biphasic	b010202	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Quinine	Quinine	q05050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
block	block	b402	VB	I-VP	O
voltage	voltage	v043020	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
,	,	,000	,	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channels	channel	c05042	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
block	block	b402	VB	I-VP	O
voltage	voltage	v043020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channels	channel	c05042	NNS	I-NP	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
counterbalanced	counterbalanced	c0530610405203	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
,	,	,000	,	O	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
attenuated	attenuate	a3050303	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
place	place	p4020	NN	I-NP	O
preference	preference	p601060520	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
test	test	t023	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
Animex	Animex	a50502	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
activity	activity	a2301030	NN	I-NP	O
meter	meter	m0306	NN	I-NP	O
neither	neither	n0306	CC	B-PP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
affected	affect	a102303	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypoactivity	hypoactivity	h0102301030	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
both	both	b030	CC	O	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
sensitive	sensitive	s05203010	JJ	B-ADJP	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channels	channel	c05042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
reward	reward	r063	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channels	channel	c05042	NNS	I-NP	O
sensitive	sensitive	s05203010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypoactivity	hypoactivity	h0102301030	NN	I-NP	B-Disease
whereas	whereas	w0602	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
connected	connect	c0502303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
channels	channel	c05042	NNS	I-NP	O
.	.	.000	.	O	O

Nociceptin	Nociceptin	n020201305	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
orphanin	orphanin	o610505	NN	I-NP	B-Chemical
FQ	FQ	f200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
nocistatin	nocistatin	n020230305	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
learning	learning	l065052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

Nociceptin	Nociceptin	n020201305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
also	also	a420	RB	B-VP	O
known	know	k505	VBN	I-VP	O
as	as	a200	IN	B-PP	O
orphanin	orphanin	o610505	NN	B-NP	B-Chemical
FQ	FQ	f200	NN	I-NP	I-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
ligand	ligand	l02053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
orphan	orphan	o6105	NN	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
ORL1	ORL1	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
involves	involve	i5104102	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
nocistatin	nocistatin	n020230305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
recently	recently	r0205340	RB	I-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
precursor	precursor	p60206206	NN	I-NP	O
as	as	a200	IN	B-PP	O
nociceptin	nociceptin	n020201305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
blocks	block	b402	VBZ	B-VP	O
nociceptin	nociceptin	n020201305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
ORL1	ORL1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
display	display	d02140	VBP	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
sequence	sequence	s020520	NN	B-NP	O
homology	homology	h0504020	NN	I-NP	O
with	with	w030	IN	B-PP	O
classical	classical	c4020204	JJ	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
abundant	abundant	a1053053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
,	,	,000	,	O	O
little	little	l0340	JJ	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
regarding	regard	r02063052	VBG	I-VP	O
their	their	t060	PRP$	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
nociceptin	nociceptin	n020201305	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
orphanin	orphanin	o610505	NN	I-NP	B-Chemical
FQ	FQ	f200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
nocistatin	nocistatin	n020230305	NN	I-NP	B-Chemical
could	could	c043	MD	B-VP	O
modulate	modulate	m0304030	VB	I-VP	O
impairment	impairment	i51065053	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Y	Y	y000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
maze	maze	m020	NN	I-NP	O
and	and	a530	CC	I-NP	O
step	step	s301	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
down	down	d050	RP	B-PRT	O
type	type	t010	NN	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
tasks	task	t020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
nocistatin	nocistatin	n020230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
nmol	nmol	n504	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
-	-	-000	HYPH	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBD	B-VP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
training	training	t605052	NN	I-NP	O
session	session	s0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
or	or	o600	CC	O	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
behaviours	behaviour	b01062	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	O	O
lower	low	l060	JJR	O	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
and	and	a530	CC	O	O
shorter	short	s06306	JJR	B-NP	O
median	median	m0305	JJ	I-NP	O
step	step	s301	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
down	down	d050	RP	B-PRT	O
latency	latency	l030520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
retention	retention	r0305305	NN	I-NP	O
test	test	t023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
nociceptin	nociceptin	n020201305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
-	-	-000	HYPH	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
normal	normal	n06504	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

5	5	5000	LS	B-LST	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nocistatin	nocistatin	n020230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
-	-	-000	HYPH	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
training	training	t605052	NN	I-NP	O
session	session	s0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
,	,	,000	,	O	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
and	and	a530	CC	O	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
behaviours	behaviour	b01062	NNS	I-NP	O
.	.	.000	.	O	O

6	6	6000	CD	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
nocistatin	nocistatin	n020230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
biologically	biologically	b040202040	RB	I-NP	O
active	active	a23010	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
,	,	,000	,	O	O
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
impairments	impairment	i510650532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
alternation	alternation	a430650305	NN	I-NP	O
and	and	a530	CC	O	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
peptides	peptide	p0130302	NNS	I-NP	O
play	play	p400	VBP	B-VP	O
opposite	opposite	o102030	JJ	B-NP	O
roles	role	r0402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
.	.	.000	.	O	O

Meloxicam	Meloxicam	m04020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
female	female	f05040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
cytolytic	cytolytic	c03040302	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
meloxicam	meloxicam	m04020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
introduced	introduce	i536030203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
Belgium	Belgium	b04205	NN	B-NP	O
,	,	,000	,	O	O
meloxicam	meloxicam	m04020205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	I-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
with	with	w030	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inducible	inducible	i53020140	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
cytolytic	cytolytic	c03040302	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
meloxicam	meloxicam	m04020205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
antinuclear	antinuclear	a530502406	JJ	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
suggesting	suggest	s02023052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
meloxicam	meloxicam	m04020205	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
by	by	b000	IN	B-PP	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
HL60	HL60	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
CD34	CD34	0000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
CD19	CD19	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
human	human	h0505	JJ	I-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
:	:	:000	:	O	O
potential	potential	p0305304	JJ	B-NP	O
relevance	relevance	r04010520	NN	I-NP	O
to	to	t000	TO	B-PP	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
[	[	[000	(	O	O
(	(	(000	(	O	B-Chemical
S	S	s000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
-	-	-000	SYM	O	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
bromo	bromo	b6050	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
(	(	(000	(	O	I-Chemical
1	1	1000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ethyl	ethyl	e304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pyrrolidinyl	pyrrolidinyl	p0604030504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
methyl	methyl	m0304	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dimethoxybenz	dimethoxybenz	d05030201052	NN	I-NP	I-Chemical
amide	amide	a5030	NN	I-NP	I-Chemical
]	]	]000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
acquired	acquire	a20603	VBN	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
pyrrolidine	pyrrolidine	p060403050	NN	I-NP	B-Chemical
ring	ring	r052	NN	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
aromatic	aromatic	a6050302	JJ	I-NP	O
ring	ring	r052	NN	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
parent	parent	p06053	NN	I-NP	O
compound	compound	c051053	NN	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
in	in	i500	IN	B-PP	O
HL60	HL60	0000	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
human	human	h0505	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
(	(	(000	(	O	O
HBMP	HBMP	h151	NN	B-NP	O
)	)	)000	)	O	O
cells	cell	c042	NNS	B-NP	O
.	.	.000	.	O	O

Cells	Cell	c042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
with	with	w030	IN	B-PP	O
each	each	e020	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
200	200	0000	CD	I-NP	O
microM	microM	m02605	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Apoptosis	Apoptosis	a10130202	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
fluorescence	fluorescence	f406020520	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
in	in	i500	IN	B-PP	O
Hoechst	Hoechst	h02023	NNP	B-NP	B-Chemical
33342	33342	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
propidium	propidium	p6010305	NN	I-NP	B-Chemical
iodide	iodide	i03030	NN	I-NP	I-Chemical
stained	stain	s30503	VBD	B-VP	O
cell	cell	c040	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
internucleosomal	internucleosomal	i53065024020504	JJ	B-NP	O
DNA	DNA	d500	NN	I-NP	O
fragmentation	fragmentation	f60250530305	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
gel	gel	g040	NN	B-NP	O
electrophoresis	electrophoresis	e4023601060202	NN	I-NP	O
for	for	f060	IN	B-PP	O
HL60	HL60	0000	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
and	and	a530	CC	O	O
terminal	terminal	t0650504	JJ	B-NP	O
deoxynucleotidyl	deoxynucleotidyl	d0205024030304	NN	I-NP	O
transferase	transferase	t6052106020	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
in	in	i500	IN	B-PP	O
HBMP	HBMP	h151	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
catechol	catechol	c030204	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
hydroquinone	hydroquinone	h0360205050	NN	I-NP	B-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
,	,	,000	,	O	O
NCQ436	NCQ436	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
NCQ344	NCQ344	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
in	in	i500	IN	B-PP	O
HL60	HL60	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
HBMP	HBMP	h151	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
concentration	concentration	c05205360305	NN	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
phenols	phenol	p05042	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
NCR181	NCR181	0000	NN	B-NP	O
,	,	,000	,	O	O
FLA873	FLA873	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
FLA797	FLA797	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
derivatives	derivative	d0601030102	NNS	I-NP	O
formed	form	f06503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
oxidation	oxidation	o2030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pyrrolidine	pyrrolidine	p060403050	NN	I-NP	B-Chemical
ring	ring	r052	NN	I-NP	O
,	,	,000	,	O	O
FLA838	FLA838	0000	NN	B-NP	O
,	,	,000	,	O	O
NCM001	NCM001	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
NCL118	NCL118	0000	NN	B-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
NCQ436	NCQ436	0000	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
NCQ344	NCQ344	0000	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
biphasic	biphasic	b010202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
cell	cell	c040	NN	I-NP	O
types	type	t0102	NNS	I-NP	O
,	,	,000	,	O	O
inducing	induce	i5302052	VBG	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
at	at	a300	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
catechol	catechol	c030204	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
hydroquinone	hydroquinone	h0360205050	NN	I-NP	B-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
direct	direct	d06023	JJ	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
HL60	HL60	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
HBMP	HBMP	h151	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
phenol	phenol	p0504	NN	I-NP	B-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
inactive	inactive	i5023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
benzene	benzene	b052050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
derived	derive	d060103	VBN	I-NP	O
catechol	catechol	c030204	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
hydroquinone	hydroquinone	h0360205050	NN	I-NP	B-Chemical
,	,	,000	,	B-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
phenol	phenol	p0504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
induce	induce	i53020	VBP	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
in	in	i500	IN	B-PP	O
HBMP	HBMP	h151	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
[	[	[000	(	O	O
Moran	Moran	m0605	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
.	.	.000	FW	I-NP	O
,	,	,000	,	O	O
Mol	Mol	m040	NNP	B-NP	O
.	.	.000	.	I-NP	O
Pharmacol	Pharmacol	p0650204	NNP	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
50	50	0000	CD	B-NP	O
(	(	(000	(	O	O
1996	1996	0000	CD	B-NP	O
)	)	)000	)	O	O
610	610	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
615	615	0000	CD	B-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
propose	propose	p601020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
benzene	benzene	b052050	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
via	via	v000	IN	B-PP	O
production	production	p60302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NCQ436	NCQ436	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
NCQ344	NCQ344	0000	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
in	in	i500	IN	B-PP	O
HBMP	HBMP	h151	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
acquired	acquire	a20603	VBN	I-VP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
remoxipride	remoxipride	r0502016030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Synthesis	Synthesis	s0530202	NN	B-NP	O
and	and	a530	CC	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
(	(	(000	(	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydro	dihydro	d0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acenaphthylenyl	acenaphthylenyl	a2050103040504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
piperazine	piperazine	p010602050	NN	B-NP	I-Chemical
derivatives	derivative	d0601030102	NNS	I-NP	O
as	as	a200	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
research	research	r020620	NN	B-NP	O
towards	towards	t0632	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
strategy	strategy	s3603020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
modulated	modulate	m03040303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
manipulation	manipulation	m0501040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
and	and	a530	CC	I-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
structure	structure	s36023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
(	(	(000	(	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydro	dihydro	d0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acenaphthylenyl	acenaphthylenyl	a2050103040504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
piperazine	piperazine	p010602050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Compound	Compound	c051053	NN	B-NP	O
7e	7e	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
{	{	{000	SYM	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
(	(	(000	(	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydro	dihydro	d0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acenaphthylenyl	acenaphthylenyl	a2050103040504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
piperazinyl	piperazinyl	p0106020504	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
ethyl	ethyl	e304	NN	B-NP	I-Chemical
}	}	}000	AFX	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dihy	dihy	d000	JJ	I-NP	I-Chemical
dro	dro	d600	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1H	1H	1000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
indol	indol	i5304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
one	one	o500	CD	I-NP	I-Chemical
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
series	series	s0602	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
affinities	affinity	a1050302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
HT1A	HT1A	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
HT2A	HT2A	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
moderate	moderate	m0306030	JJ	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

7e	7e	7000	NN	B-NP	O
exhibits	exhibit	e201032	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
indicating	indicate	i530203052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
nature	nature	n03060	NN	I-NP	O
.	.	.000	.	O	O

Sub	Sub	s010	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
modifies	modify	m030102	VBZ	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
NADPH	NADPH	n0310	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
diaphorase	diaphorase	d0106020	NN	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
NG	NG	n200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitro	nitro	n0360	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NOARG	NOARG	n062	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
NOS	NOS	n020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
induces	induce	i530202	VBZ	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
undergoes	undergo	u5306202	VBZ	B-VP	O
rapid	rapid	r0103	JJ	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
chronic	chronic	c060502	JJ	B-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NOARG	NOARG	n062	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Nitric	Nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
influence	influence	i5140520	VB	I-VP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
block	block	b402	VBP	B-VP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
also	also	a420	RB	B-ADVP	O
cause	cause	c020	VBP	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
subchronic	subchronic	s012060502	JJ	B-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NOARG	NOARG	n062	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
NOS	NOS	n020	NN	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
areas	area	a602	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
motor	motor	m0306	NN	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	JJ	B-NP	O
albino	albino	a41050	JJ	I-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
sub	sub	s010	AFX	O	O
-	-	-000	HYPH	O	O
chronically	chronically	c060502040	RB	B-ADVP	O
(	(	(000	(	O	O
twice	twice	t020	RB	B-NP	O
a	a	a000	DT	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NOARG	NOARG	n062	NN	B-NP	I-Chemical
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Catalepsy	Catalepsy	c03040120	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
beginning	beginning	b0205052	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
.	.	.000	.	O	O

Reduced	Reduce	r030203	VBN	B-NP	O
nicotinamide	nicotinamide	n02030505030	NN	I-NP	B-Chemical
adenine	adenine	a305050	NN	I-NP	I-Chemical
dinucleotide	dinucleotide	d0502403030	NN	I-NP	I-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
diaphorase	diaphorase	d0106020	NN	I-NP	O
(	(	(000	(	O	O
NADPH	NADPH	n0310	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
d	d	d000	NN	I-NP	O
)	)	)000	)	O	O
histochemistry	histochemistry	h023020502360	NN	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
employed	employ	e51403	VBN	I-VP	O
to	to	t000	TO	I-VP	O
visualize	visualize	v0204020	VB	I-VP	O
NOS	NOS	n020	NN	B-NP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
enzyme	enzyme	e52050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
motor	motor	m0306	NN	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NOARG	NOARG	n062	NN	I-NP	I-Chemical
sub	sub	s010	AFX	O	O
-	-	-000	HYPH	O	O
chronic	chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
tolerance	tolerance	t04060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NOARG	NOARG	n062	NN	I-NP	I-Chemical
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
NADPH	NADPH	n0310	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
d	d	d000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
caudate	caudate	c03030	NN	I-NP	O
and	and	a530	CC	O	O
accumbens	accumben	a2051052	VBZ	B-VP	O
nuclei	nucleus	n0240	NNS	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pedunculopontine	pedunculopontine	p030520401053050	JJ	I-NP	O
tegmental	tegmental	t02505304	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
NADPH	NADPH	n0310	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
d	d	d000	JJ	I-NP	O
neuron	neuron	n0605	NN	I-NP	O
number	number	n05106	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
,	,	,000	,	O	O
pars	par	p062	NNS	B-NP	O
compacta	compacta	c0510230	VBP	B-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-VP	O
and	and	a530	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NOARG	NOARG	n062	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
give	give	g010	VBP	B-VP	O
further	further	f06306	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
NO	NO	n000	NN	B-NP	B-Chemical
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
control	control	c053604	VBP	B-VP	O
and	and	a530	CC	I-VP	O
suggest	suggest	s02023	VBP	I-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
take	take	t020	VB	I-VP	O
part	part	p063	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
antipsychotic	antipsychotic	a53012020302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Prolonged	Prolong	p60405203	VBN	B-VP	O
left	leave	l013	VBD	B-VP	B-Disease
ventricular	ventricular	v0536020406	JJ	B-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
after	after	a1306	IN	B-SBAR	O
both	both	b030	CC	O	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
exercise	exercise	e2062020	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischaemia	ischaemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
but	but	b030	CC	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
crossover	crossover	c6020106	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
and	and	a530	CC	I-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
ischaemia	ischaemia	i2050	NN	B-NP	B-Disease
.	.	.000	.	O	O

SUBJECTS	SUBJECTS	s0120232	NNS	B-NP	O
:	:	:000	:	O	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
,	,	,000	,	O	O
angiographically	angiographically	a520260102040	RB	B-NP	O
proven	prove	p60105	VBN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
normal	normal	n06504	JJ	B-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

INTERVENTIONS	INTERVENTIONS	i53061053052	NNS	B-NP	O
:	:	:000	:	O	O
Treadmill	Treadmill	t603504	NN	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
and	and	a530	CC	O	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
transthoracic	transthoracic	t60523060202	JJ	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
intervals	interval	i53061042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	DT	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stress	stress	s3602	NN	B-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
but	but	b030	CC	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
double	double	d0140	JJ	I-NP	O
product	product	p603023	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
53	53	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
ST	ST	s300	NN	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
63	63	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
form	form	f065	NN	B-NP	O
of	of	o100	IN	B-PP	O
stress	stress	s3602	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
,	,	,000	,	O	O
ejection	ejection	e202305	NN	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
(	(	(000	(	O	O
SEM	SEM	s050	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
(	(	(000	NN	I-NP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	O	O
.	.	.000	.	O	O
2	2	2000	CD	O	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
45	45	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
(	(	(000	NN	I-NP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Regional	Regional	r020504	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
worst	worst	w0623	JJS	I-NP	O
affected	affect	a102303	VBN	I-NP	O
segment	segment	s025053	NN	I-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
27	27	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
28	28	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	O	O
32	32	0000	CD	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
isovolumic	isovolumic	i201040502	JJ	I-NP	O
relaxation	relaxation	r04020305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
was	be	w020	VBD	B-VP	O
prolonged	prolonged	p60405203	JJ	B-ADJP	O
45	45	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
stress	stress	s3602	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
ischaemia	ischaemia	i2050	NN	B-NP	B-Disease
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
presumed	presume	p6020503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
myocardial	myocardial	m0206304	JJ	B-ADJP	B-Disease
stunning	stunning	s305052	JJ	B-ADJP	I-Disease
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
.	.	.000	.	O	O

Dobutamine	Dobutamine	d010305050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
ischaemia	ischaemia	i2050	NN	B-NP	B-Disease
could	could	c043	MD	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
further	further	f06306	RBR	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Anorexigens	Anorexigen	a5060202052	NNS	B-NP	O
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
:	:	:000	:	O	O
results	result	r020432	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
North	North	n0630	JJ	B-NP	O
American	American	a5060205	JJ	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
appetite	appetite	a103030	JJ	B-NP	O
suppressants	suppressant	s016020532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Europe	Europe	e06010	NNP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
(	(	(000	(	O	O
PPH	PPH	p100	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
fenfluramine	fenfluramine	f05140605050	NN	B-NP	B-Chemical
appetite	appetite	a103030	NN	I-NP	O
suppressants	suppressant	s016020532	NNS	I-NP	O
became	become	b02050	VBD	B-VP	O
widely	widely	w03040	RB	B-ADJP	O
used	use	u203	VBN	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
but	but	b030	CC	O	O
were	be	w060	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
in	in	i500	IN	B-PP	O
September	September	s01305106	NNP	B-NP	O
1997	1997	0000	CD	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
concerns	concern	c0520652	NNS	B-NP	O
over	over	o106	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
diagnosed	diagnose	d0250203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
12	12	0000	CD	B-NP	O
large	large	l0620	JJ	I-NP	O
referral	referral	r010604	JJ	I-NP	O
centers	center	c053062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
North	North	n0630	NNP	B-NP	O
America	America	a506020	NNP	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
collected	collect	c0402303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
seen	see	s050	VBN	B-VP	O
from	from	f605	IN	B-PP	O
September	September	s01305106	NNP	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
1996	1996	0000	CD	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
December	December	d0205106	NNP	B-NP	O
31	31	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1997	1997	0000	CD	I-NP	O
,	,	,000	,	O	O
included	include	i5240303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
identifiable	identifiable	i3053010140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
classed	class	c40203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
PPH	PPH	p100	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
with	with	w030	IN	B-PP	O
special	special	s10204	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	O
,	,	,000	,	O	O
anorexigens	anorexigen	a5060202052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
amphetamines	amphetamine	a5103050502	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Five	Five	f010	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
seventy	seventy	s010530	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
nine	nine	n050	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
,	,	,000	,	O	O
205	205	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
PPH	PPH	p100	NN	B-NP	B-Disease
and	and	a530	CC	O	O
374	374	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
other	other	o306	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
(	(	(000	(	O	O
secondary	secondary	s02053060	JJ	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
[	[	[000	(	O	O
SPH	SPH	s100	NN	B-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
anorexigens	anorexigen	a5060202052	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
surveyed	survey	s06103	VBN	B-VP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
the	the	t000	DT	I-NP	O
fenfluramines	fenfluramine	f051406050502	NNS	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
preferential	preferential	p6010605304	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
PPH	PPH	p100	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
SPH	SPH	s100	NN	B-NP	O
(	(	(000	(	O	O
adjusted	adjust	a3202303	VBN	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
>	>	>000	SYM	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
32	32	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stronger	strong	s3605206	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
longer	long	l05206	JJR	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
shorter	short	s06306	JJR	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
remote	remote	r05030	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
unexpectedly	unexpectedly	u50210230340	RB	I-NP	O
high	high	h020	JJ	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
number	number	n05106	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SPH	SPH	s100	NN	B-NP	O
had	have	h030	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
anorexigens	anorexigen	a5060202052	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
PPH	PPH	p100	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
specificity	specificity	s1020102030	NN	I-NP	O
for	for	f060	IN	B-PP	O
fenfluramines	fenfluramine	f051406050502	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
fenfluramines	fenfluramine	f051406050502	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
causally	causally	c02040	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
PPH	PPH	p100	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
anorexigen	anorexigen	a506020205	NN	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SPH	SPH	s100	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
raises	raise	r0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
precipitate	precipitate	p6020103030	VBP	B-VP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
conditions	condition	c05303052	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
SPH	SPH	s100	NN	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
aspects	aspect	a210232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
first	first	f0623	RB	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
clotting	clotting	c403052	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
clinically	clinically	c40502040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
several	several	s010604	JJ	B-NP	O
new	new	n000	JJ	I-NP	O
anticoagulant	anticoagulant	a53020204053	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
in	in	i500	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
,	,	,000	,	O	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
meritorious	meritorious	m06030602	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
exist	exist	e2023	VB	I-VP	O
.	.	.000	.	O	O

Bleeding	Bleeding	b403052	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
untoward	untoward	u53063	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Major	Major	m0206	JJ	B-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
concern	concern	c052065	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
additional	additional	a3030504	JJ	B-NP	O
important	important	i51063053	JJ	I-NP	O
untoward	untoward	u53063	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
include	include	i524030	VBP	B-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
,	,	,000	,	O	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
,	,	,000	,	O	O
skin	skin	s205	NN	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
allergic	allergic	a406202	JJ	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
,	,	,000	,	O	O
alopecia	alopecia	a401020	NN	B-NP	B-Disease
,	,	,000	,	O	O
transaminasemia	transaminasemia	t6052050502050	NN	B-NP	O
,	,	,000	,	O	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
,	,	,000	,	O	O
hypoaldosteronism	hypoaldosteronism	h010430230605025	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
priapism	priapism	p601025	NN	B-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
rare	rare	r060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
given	give	g0105	VBN	I-NP	O
individual	individual	i53010304	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
given	give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
extremely	extremely	e23605040	RB	I-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
some	some	s050	DT	B-NP	O
are	be	a600	VBP	B-VP	O
quite	quite	q030	RB	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-NP	O
HITT	HITT	h030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
osteoporosis	osteoporosis	o2301060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
reasonable	reasonable	r02050140	JJ	B-NP	O
incidences	incidence	i520305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
many	many	m050	JJ	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
"	"	"000	``	O	O
softly	softly	s01340	RB	B-ADVP	O
"	"	"000	''	O	O
deduced	deduce	d030203	VBN	B-VP	O
from	from	f605	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
dealing	deal	d04052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
unfractionated	unfractionated	u516023050303	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
present	present	p602053	JJ	B-ADJP	O
the	the	t000	DT	B-NP	O
incidences	incidence	i520305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
newer	new	n060	JJR	B-NP	O
low	low	l000	JJ	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
heparins	heparin	h0106052	NNS	I-NP	B-Chemical
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
much	much	m020	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
common	common	c0505	JJ	I-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
longer	long	l05206	JJR	I-NP	O
experience	experience	e21060520	NN	I-NP	O
will	will	w040	MD	B-VP	O
more	more	m060	RBR	I-VP	O
clearly	clearly	c40640	RB	I-VP	O
define	define	d01050	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
on	on	o500	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
Prograf	Prograf	p602601	NNP	B-NP	O
;	;	;000	:	O	O
Fujisawa	Fujisawa	f02020	NNP	B-NP	O
USA	USA	u200	NNP	I-NP	O
,	,	,000	,	O	O
Inc	Inc	i520	NNP	B-NP	O
,	,	,000	,	O	O
Deerfield	Deerfield	d061043	NNP	B-NP	O
,	,	,000	,	O	O
Illinois	Illinois	i40502	NNP	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
immunosuppression	immunosuppression	i505020160205	NN	B-NP	O
after	after	a1306	IN	B-PP	O
orthotropic	orthotropic	o630360102	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
58	58	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
orthotropic	orthotropic	o630360102	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
serial	serial	s0604	JJ	B-NP	O
neuro	neuro	n060	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
ophthalmologic	ophthalmologic	o103045040202	JJ	I-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
and	and	a530	CC	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
episodic	episodic	e1020302	JJ	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vision	vision	v0205	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
resembling	resemble	r020514052	VBG	B-VP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
optic	optic	o1302	JJ	I-NP	I-Disease
neuropathies	neuropathy	n06010302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Deterioration	Deterioration	d0306060305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
despite	despite	d021030	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Tacrolimus	Tacrolimus	t026040502	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hypercalcemia	Hypercalcemia	h01062042050	NN	B-NP	B-Disease
,	,	,000	,	O	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
mood	mood	m030	NN	B-NP	O
stabilizers	stabilizer	s3010402062	NNS	I-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
maintenance	maintenance	m053050520	NN	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
bradyarrhythmia	bradyarrhythmia	b6030603050	NN	I-NP	B-Disease
prompted	prompt	p6051303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
to	to	t000	TO	B-VP	O
conduct	conduct	c053023	VB	I-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
printout	printout	p605303	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
presented	present	p60205303	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
was	be	w020	VBD	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
eliminating	eliminate	e4050503052	VBG	B-VP	O
spurious	spurious	s10602	JJ	B-NP	O
hypercalcemias	hypercalcemia	h010620420502	NNS	I-NP	B-Disease
or	or	o600	CC	O	O
those	those	t020	DT	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluids	fluid	f4032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
18	18	0000	CD	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hypercalcemias	hypercalcemia	h010620420502	NNS	B-NP	B-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
malignancies	malignancy	m0402505202	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
were	be	w060	VBD	B-VP	O
medically	medically	m0302040	RB	I-VP	O
compromised	compromise	c0516050203	VBN	I-VP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
pharmacotherapies	pharmacotherapy	p0650203060102	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
:	:	:000	:	O	O
group	group	g601	NN	B-NP	O
C1	C1	0000	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
sex	sex	s020	NN	B-NP	O
-	-	-000	HYPH	O	O
comparable	comparable	c051060140	JJ	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
normocalcemic	normocalcemic	n065020420502	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
group	group	g601	NN	B-NP	O
C2	C2	0000	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
normocalcemic	normocalcemic	n065020420502	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
mood	mood	m030	NN	I-NP	O
stabilizers	stabilizer	s3010402062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
findings	finding	f053052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
C1	C1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
C2	C2	0000	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
overall	overall	o10604	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
conduction	conduction	c05302305	NN	B-NP	O
defects	defect	d010232	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
diseases	disease	d020202	NNS	I-NP	O
and	and	a530	CC	O	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
higher	high	h0206	JJR	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
conduction	conduction	c05302305	NN	B-NP	O
defects	defect	d010232	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
zero	zero	z060	CD	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
three	three	t060	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
implications	implication	i5140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Attenuation	Attenuation	a3050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
nanosphere	nanosphere	n05021060	NN	I-NP	O
(	(	(000	(	O	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
718	718	0000	CD	I-NP	O
)	)	)000	)	O	O
incorporating	incorporate	i520610603052	VBG	B-VP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	O	O
718	718	0000	CD	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
nanosphere	nanosphere	n05021060	NN	I-NP	O
incorporating	incorporate	i520610603052	VBG	B-VP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
pathogenic	pathogenic	p03020502	JJ	B-NP	O
fungi	fungus	f0520	NNS	I-NP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
low	low	l000	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	O	O
718	718	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
Fungizone	Fungizone	f05202050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
deoxycholate	deoxycholate	d020204030	NN	I-NP	I-Chemical
;	;	;000	:	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
AmB	AmB	a510	NN	B-NP	I-Chemical
)	)	)000	)	O	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
using	use	u2052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
by	by	b000	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
and	and	a530	CC	I-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
following	follow	f04052	VBG	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
formulation	formulation	f065040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Incubation	Incubation	i52010305	NN	B-NP	O
with	with	w030	IN	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
718	718	0000	CD	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-NP	O
less	less	l020	JJR	I-NP	O
damage	damage	d05020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cultured	culture	c0430603	VBN	B-NP	O
human	human	h0505	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
tubular	tubular	t010406	JJ	I-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
AmB	AmB	a510	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-PP	O
an	an	a500	DT	B-NP	O
iv	iv	i100	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
AmB	AmB	a510	NN	B-NP	I-Chemical
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-VP	O
kg	kg	k200	NN	B-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
those	those	t020	DT	B-NP	O
given	give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
718	718	0000	CD	I-NP	O
.	.	.000	.	O	O

Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
tubular	tubular	t010406	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
AmB	AmB	a510	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
718	718	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Amphotericin	Amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
in	in	i500	IN	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
718	718	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
AmB	AmB	a510	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
incorporation	incorporation	i52061060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
into	into	i530	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
nanospheres	nanosphere	n050210602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
718	718	0000	CD	I-NP	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Patterns	Pattern	p030652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
sulfadiazine	sulfadiazine	s0410302050	NN	B-NP	B-Chemical
acute	acute	a2030	JJ	I-NP	B-Disease
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sulfadiazine	Sulfadiazine	s0410302050	NN	B-NP	B-Chemical
acute	acute	a2030	JJ	I-NP	B-Disease
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
reviving	revive	r0101052	VBG	I-VP	O
specially	specially	s102040	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
toxoplasmosis	toxoplasmosis	t020140250202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
4	4	4000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
person	person	p06205	NN	I-NP	O
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
sulfadiazine	sulfadiazine	s0410302050	NN	B-NP	B-Chemical
they	they	t000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
oliguria	oliguria	o402060	NN	B-NP	B-Disease
,	,	,000	,	O	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
showed	show	s030	VBD	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
radiolucent	radiolucent	r030402053	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
calculi	calculus	c042040	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
echography	echography	e2026010	NN	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
previous	previous	p60102	JJ	I-NP	O
normal	normal	n06504	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
hydration	hydration	h0360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
alcalinization	alcalinization	a420405020305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
nephrostomy	nephrostomy	n0106023050	NN	I-NP	O
tube	tube	t010	NN	I-NP	O
had	have	h030	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
placed	place	p40203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
ureteral	ureteral	u6030604	JJ	B-NP	B-Disease
lithiasis	lithiasis	l030202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
needed	need	n0303	VBD	B-VP	O
dialysis	dialysis	d040202	NN	B-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
benign	benign	b05025	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
sulfadiazine	sulfadiazine	s0410302050	NN	B-NP	B-Chemical
requires	require	r020602	VBZ	B-VP	O
exquisite	exquisite	e202030	NN	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
water	water	w0306	NN	B-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
and	and	a530	CC	O	O
possibly	possibly	p020140	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
alcalinization	alcalinization	a420405020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
communicate	communicate	c050502030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
person	person	p06205	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
not	not	n030	RB	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Probably	Probably	p6010140	RB	B-NP	O
many	many	m050	JJ	I-NP	O
more	more	m060	JJR	I-NP	O
cases	case	c0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
think	think	t052	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
.	.	.000	.	O	O

Downbeat	Downbeat	d05103	NN	B-NP	B-Disease
nystagmus	nystagmus	n02302502	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

IMPLICATIONS	IMPLICATIONS	i5140203052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
documents	document	d02050532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
downbeating	downbeate	d05103052	VBG	B-VP	B-Disease
nystagmus	nystagmus	n02302502	NN	B-NP	I-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
large	large	l0620	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
IV	IV	i100	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
case	case	c020	NN	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
signs	sign	s0252	NNS	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
documented	document	d020505303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
IV	IV	i100	CD	B-NP	O
or	or	o600	CC	O	O
patient	patient	p03053	NN	B-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Hemodynamic	Hemodynamic	h0503050502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
antiadrenergic	antiadrenergic	a530360506202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dronedarone	dronedarone	d6050306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
healed	healed	h0403	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antiadrenergic	antiadrenergic	a530360506202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dronedarone	dronedarone	d6050306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
noniodinated	noniodinated	n0503050303	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
structurally	structurally	s3602306040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
both	both	b030	CC	B-PP	O
at	at	a300	IN	I-PP	O
rest	rest	r023	NN	B-NP	O
and	and	a530	CC	O	O
during	during	d06052	IN	B-PP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
dogs	dog	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
healed	healed	h0403	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
dogs	dog	d020	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
randomly	randomly	r0530540	RB	B-VP	O
received	receive	r020103	VBD	I-VP	O
orally	orally	o6040	RB	B-NP	O
dronedarone	dronedarone	d6050306050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
washout	washout	w0203	NN	I-NP	O
between	between	b0305	IN	B-PP	O
consecutive	consecutive	c0520203010	JJ	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MBP	MBP	m100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
positive	positive	p0203010	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
increase	increase	i526020	NN	B-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
LVdP	LVdP	l131	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dt	dt	d300	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
echocardiographically	echocardiographically	e2020630260102040	RB	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
(	(	(000	(	O	O
LVEF	LVEF	l101	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fractional	fractional	f60230504	JJ	B-NP	O
shortening	shortening	s06305052	NN	I-NP	O
(	(	(000	(	O	O
FS	FS	f200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
chronotropic	chronotropic	c06050360102	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
under	under	u5306	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	I-NP	O
posttreatment	posttreatment	p0236035053	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Resting	Rest	r023052	VBG	B-VP	O
values	value	v0402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
LVEF	LVEF	l101	NN	B-NP	O
,	,	,000	,	O	O
FS	FS	f200	NN	B-NP	O
,	,	,000	,	O	O
+	+	+000	SYM	B-NP	O
LVdP	LVdP	l131	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dt	dt	d300	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
MBP	MBP	m100	NN	B-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
whatever	whatever	w030106	WDT	B-NP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	B-PP	O
resting	rest	r023052	VBG	B-NP	O
HR	HR	h600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-VP	O
lowered	lower	l0603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
dronedarone	dronedarone	d6050306050	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
after	after	a1306	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
dronedarone	dronedarone	d6050306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
dronedarone	dronedarone	d6050306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
displayed	display	d021403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
antiadrenergic	antiadrenergic	a530360506202	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
impair	impair	i5106	VB	I-VP	O
the	the	t000	DT	B-NP	O
resting	resting	r023052	NN	I-NP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Consequently	Consequently	c0520205340	RB	B-ADVP	O
,	,	,000	,	O	O
dronedarone	dronedarone	d6050306050	NN	B-NP	B-Chemical
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
particularly	particularly	p06302040640	RB	B-ADJP	O
suitable	suitable	s030140	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
compromising	compromise	c05160502052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Phase	Phase	p020	NN	B-NP	O
2	2	2000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
platinum	platinum	p4030505	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
fallopian	fallopian	f040105	JJ	I-NP	I-Disease
tube	tube	t010	NN	I-NP	I-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
primary	primary	p605060	JJ	B-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
peritoneum	peritoneum	p06030505	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Several	Several	s010604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Doxil	Doxil	d0204	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
platinum	platinum	p4030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
limiting	limit	l0503052	VBG	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
q	q	q000	NN	B-NP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
being	be	b052	VBG	B-VP	O
severe	severe	s01060	JJ	B-NP	O
erythrodysesthesia	erythrodysesthesia	e603060302023020	NN	I-NP	B-Disease
(	(	(000	(	O	O
"	"	"000	``	O	O
hand	hand	h053	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
foot	foot	f030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
"	"	"000	''	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
stomatitis	stomatitis	s305030302	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
wished	wish	w0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
develop	develop	d010401	VB	I-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
tolerable	tolerable	t04060140	JJ	I-NP	O
liposomal	liposomal	l01020504	JJ	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
and	and	a530	CC	O	O
document	document	d0205053	VB	B-VP	O
its	its	i320	PRP$	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
defined	define	d010503	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
platinum	platinum	p4030505	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
MATERIALS	MATERIALS	m0306042	NNS	I-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
fallopian	fallopian	f040105	JJ	I-NP	I-Disease
tube	tube	t010	NN	I-NP	I-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
or	or	o600	CC	O	O
primary	primary	p605060	JJ	B-NP	O
peritoneal	peritoneal	p06030504	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
platinum	platinum	p4030505	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
(	(	(000	(	O	O
stable	stable	s30140	JJ	B-NP	O
or	or	o600	CC	I-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
or	or	o600	CC	O	O
previous	previous	p60102	JJ	B-NP	O
objective	objective	o12023010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
<	<	<000	SYM	B-NP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
duration	duration	d060305	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
q	q	q000	NN	B-NP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
49	49	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
:	:	:000	:	O	O
60	60	0000	CD	B-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
41	41	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
81	81	0000	CD	I-NP	O
)	)	)000	)	O	O
entered	enter	e530603	VBD	B-VP	O
this	this	t020	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
2	2	2000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
2	2	2000	CD	I-NP	O
hand	hand	h053	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
foot	foot	f030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
stomatitis	stomatitis	s305030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
no	no	n000	DT	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
diarrhea	diarrhea	d060	NN	I-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
for	for	f060	IN	B-PP	O
hydration	hydration	h0360305	NN	B-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
individuals	individual	i530103042	NNS	B-NP	O
required	require	r020603	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
courses	course	c06202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
of	of	o100	IN	B-PP	O
44	44	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
objective	objective	o12023010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
modified	modify	m030103	VBN	I-NP	O
liposomal	liposomal	l01020504	JJ	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
less	less	l020	JJR	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
stomatitis	stomatitis	s305030302	NN	B-NP	B-Disease
,	,	,000	,	O	O
hand	hand	h053	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
foot	foot	f030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
FDA	FDA	f300	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
approved	approve	a160103	VBN	B-NP	O
dose	dose	d020	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
.	.	.000	.	O	O

Definite	Definite	d0105030	NN	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
limited	limited	l050303	JJ	B-NP	O
,	,	,000	,	I-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
well	well	w040	RB	B-ADVP	O
-	-	-000	HYPH	I-ADVP	O
defined	define	d010503	VBN	B-NP	O
platinum	platinum	p4030505	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
of	of	o100	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Olanzipine	Olanzipine	o405201050	NNP	I-NP	B-Chemical
HGGW	HGGW	h200	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
vs	vs	v200	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Four	Four	f060	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
parallel	parallel	p060404	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
115	115	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
DSM	DSM	d250	NN	I-NP	O
-	-	-000	HYPH	O	O
IV	IV	i100	CD	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
manic	manic	m0502	JJ	B-ADJP	B-Disease
or	or	o600	CC	I-ADJP	O
mixed	mixed	m0203	JJ	I-ADJP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
d	d	d000	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
55	55	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
60	60	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
measure	measure	m02060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
Young	Young	y052	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Mania	Mania	m050	NNP	I-NP	B-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
Y	Y	y000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
MRS	MRS	m620	NN	I-NP	O
)	)	)000	)	I-NP	O
total	total	t0304	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
and	and	a530	CC	I-NP	O
euthymia	euthymia	e03050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
priori	priori	p6060	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
to	to	t000	TO	B-VP	O
end	end	e530	VB	I-VP	O
point	point	p053	NN	B-NP	O
and	and	a530	CC	B-PP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
no	no	n000	DT	B-NP	O
less	less	l020	JJR	I-NP	O
than	than	t050	IN	I-NP	O
12	12	0000	CD	I-NP	O
at	at	a300	IN	B-PP	O
end	end	e530	NN	B-NP	O
point	point	p053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Y	Y	y000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
MRS	MRS	m620	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
Extrapyramidal	Extrapyramidal	e2360106050304	NNP	B-NP	B-Disease
Symptom	Symptom	s051305	NNP	I-NP	I-Disease
(	(	(000	(	O	O
EPS	EPS	e120	NNP	O	B-Disease
)	)	)000	)	O	O
rating	rating	r03052	NN	B-NP	O
scales	scale	s20402	NNS	I-NP	O
,	,	,000	,	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
electrocardiograms	electrocardiogram	e4023602063026052	NNS	B-NP	O
,	,	,000	,	O	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
weight	weight	w0203	NN	B-NP	O
change	change	c0520	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Olanzapine	Olanzapine	o405201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
greater	great	g60306	JJR	I-NP	O
mean	mean	m050	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
improvement	improvement	i5160105053	NN	B-NP	O
in	in	i500	IN	B-PP	O
Y	Y	y000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MRS	MRS	m620	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
postbaseline	postbaseline	p02310204050	NN	I-NP	O
observation	observation	o120610305	NN	I-NP	O
1	1	1000	CD	I-NP	O
week	week	w020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
randomization	randomization	r05305020305	NN	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
last	last	l023	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
carried	carry	c0603	VBD	B-VP	O
forward	forward	f06063	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Olanzapine	Olanzapine	o405201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
(	(	(000	(	O	O
65	65	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
euthymia	euthymia	e03050	NN	B-NP	O
(	(	(000	(	O	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
EPSs	EPS	e120	NNS	B-NP	B-Disease
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
greater	great	g60306	JJR	I-NP	O
mean	mean	m050	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
vs	vs	v200	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
45	45	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
experienced	experience	e210605203	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	O	O
emergent	emergent	e5062053	NN	B-NP	O
somnolence	somnolence	s05040520	NN	I-NP	B-Disease
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
[	[	[000	(	O	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
vs	vs	v200	IN	B-PP	O
5	5	5000	CD	B-NP	O
[	[	[000	(	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Olanzapine	Olanzapine	o405201050	NN	B-NP	B-Chemical
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
greater	great	g60306	JJR	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
generally	generally	g0506040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
pupil	pupil	p0104	NN	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
tropicamide	tropicamide	t6010205030	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
vision	vision	v0205	NN	B-NP	O
and	and	a530	CC	O	O
driving	drive	d601052	VBG	B-VP	O
simulator	simulator	s05040306	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
pupil	pupil	p0104	NN	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
vision	vision	v0205	NN	B-NP	O
and	and	a530	CC	O	O
driving	drive	d601052	VBG	B-VP	O
ability	ability	a104030	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
tests	test	t0232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
driving	drive	d601052	VBG	B-VP	O
simulator	simulator	s05040306	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
12	12	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
drivers	driver	d601062	NNS	I-NP	O
,	,	,000	,	O	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
pupil	pupil	p0104	NN	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
using	use	u2052	VBG	B-VP	O
guttae	gutta	g030	NNS	B-NP	O
tropicamide	tropicamide	t6010205030	NN	I-NP	B-Chemical
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
driving	drive	d601052	VBG	I-NP	O
simulator	simulator	s05040306	NN	I-NP	O
(	(	(000	(	O	O
Transport	Transport	t60521063	NNP	B-NP	O
Research	Research	r020620	NNP	I-NP	O
Laboratory	Laboratory	l010603060	NNP	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
reaction	reaction	r02305	NN	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
RT	RT	r300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
speed	speed	s103	NN	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
and	and	a530	CC	I-NP	O
steering	steering	s306052	NN	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
.	.	.000	.	O	O

Tests	Test	t0232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
basic	basic	b0202	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
visual	visual	v0204	JJ	I-NP	O
acuity	acuity	a2030	NN	I-NP	O
(	(	(000	(	O	O
HCVA	HCVA	h210	NN	B-NP	O
and	and	a530	CC	O	O
LCVA	LCVA	l210	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Pelli	Pelli	p040	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Robson	Robson	r01205	NNP	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
(	(	(000	(	O	O
CT	CT	c300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Goldmann	Goldmann	g043505	NNP	B-NP	O
perimetry	perimetry	p06050360	NN	I-NP	O
(	(	(000	(	O	O
FIELDS	FIELDS	f0432	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Useful	Useful	u20104	NNP	B-NP	O
Field	Field	f043	NNP	I-NP	O
of	of	o100	IN	B-PP	O
View	View	v000	NNP	B-NP	O
(	(	(000	(	O	O
UFOV	UFOV	u101	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
test	test	t023	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
dilatation	dilatation	d04030305	NN	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
level	level	l0104	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
one	one	o500	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
tail	tail	t040	NN	I-NP	O
paired	paired	p0603	JJ	I-NP	O
t	t	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Pupillary	Pupillary	p0104060	JJ	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
and	and	a530	CC	I-NP	O
HCVA	HCVA	h210	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
drivers	driver	d601062	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
deterioration	deterioration	d0306060305	NN	B-NP	O
in	in	i500	IN	B-PP	O
LCVA	LCVA	l210	NN	B-NP	O
,	,	,000	,	I-NP	O
CT	CT	c300	NN	I-NP	O
and	and	a530	CC	I-NP	O
RT	RT	r300	NN	I-NP	O
.	.	.000	.	O	O

Little	Little	l0340	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
emerged	emerge	e506203	VBD	B-VP	O
for	for	f060	IN	B-PP	O
deterioration	deterioration	d0306060305	NN	B-NP	O
in	in	i500	IN	B-PP	O
FIELDS	FIELDS	f0432	NN	B-NP	O
and	and	a530	CC	I-NP	O
UFOV	UFOV	u101	NN	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
drivers	driver	d601062	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
adjust	adjust	a32023	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
driving	driving	d601052	NN	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
by	by	b000	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
speed	speed	s103	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
driving	drive	d601052	VBG	I-NP	O
simulator	simulator	s05040306	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
improved	improve	i5160103	VBN	B-NP	O
steering	steering	s306052	NN	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Pupillary	Pupillary	p0104060	JJ	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
vision	vision	v0205	NN	B-NP	O
and	and	a530	CC	I-NP	O
daylight	daylight	d040203	NN	I-NP	O
driving	drive	d601052	VBG	B-VP	O
performance	performance	p0610650520	NN	B-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
people	people	p0140	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
larger	large	l06206	JJR	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
broader	broad	b60306	JJR	I-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
of	of	o100	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
before	before	b01060	IN	B-SBAR	O
guidelines	guideline	g03040502	NNS	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
isotretinoin	isotretinoin	i2036030505	NN	B-NP	B-Disease
embryopathy	embryopathy	e51601030	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
anotia	anotia	a5030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
Taussig	Taussig	t0202	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
Bing	Be	b052	VBG	B-VP	I-Disease
malformation	malformation	m0410650305	NN	B-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
newborn	newborn	n01065	JJ	I-NP	O
infant	infant	i51053	NN	I-NP	O
with	with	w030	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
congenital	congenital	c052050304	JJ	I-NP	O
anomalies	anomaly	a5050402	NNS	I-NP	O
(	(	(000	(	O	O
anotia	anotia	a5030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
Taussig	Taussig	t0202	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
Bing	Be	b052	VBG	B-VP	I-Disease
malformation	malformation	m0410650305	NN	B-NP	I-Disease
)	)	)000	)	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
isotretinoin	isotretinoin	i2036030505	NN	B-NP	B-Chemical
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
trimester	trimester	t60502306	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
we	we	w000	PRP	B-NP	O
aim	aim	a050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
draw	draw	d600	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
caution	caution	c0305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
drugs	drug	d602	NNS	B-NP	O
to	to	t000	TO	B-PP	O
women	woman	w0505	NNS	B-NP	O
of	of	o100	IN	B-PP	O
childbearing	childbeare	c043106052	VBG	B-VP	O
years	year	y062	NNS	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
methoxamine	methoxamine	m030205050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
maximum	maximum	m020505	JJ	B-NP	O
urethral	urethral	u6030604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
genuine	genuine	g05050	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
crossover	crossover	c6020106	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
alpha1	alpha1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
stress	stress	s3602	NN	I-NP	I-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
crossover	crossover	c6020106	NN	B-NP	O
study	study	s3030	NN	I-NP	O
design	design	d02025	NN	I-NP	O
was	be	w020	VBD	B-VP	O
employed	employ	e51403	VBN	I-VP	O
.	.	.000	.	O	O

Half	Half	h041	NN	B-NP	O
log	log	l020	NN	I-NP	O
incremental	incremental	i5260505304	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
methoxamine	methoxamine	m030205050	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
saline	saline	s04050	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
genuine	genuine	g05050	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
measuring	measure	m0206052	VBG	B-VP	O
maximum	maximum	m020505	JJ	B-NP	O
urethral	urethral	u6030604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MUP	MUP	m010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Methoxamine	Methoxamine	m030205050	NN	B-NP	B-Chemical
evoked	evoke	e10203	VBD	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
MUP	MUP	m010	NN	B-NP	O
and	and	a530	CC	O	O
diastolic	diastolic	d0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
but	but	b030	CC	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	B-Disease
significant	significant	s0250102053	JJ	I-NP	I-Disease
rise	rise	r020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	I-Disease
systolic	systolic	s0230402	JJ	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
at	at	a300	IN	B-PP	O
maximum	maximum	m020505	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
piloerection	piloerection	p040602305	NN	B-NP	O
,	,	,000	,	O	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cold	cold	c043	JJ	B-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
usefulness	usefulness	u20104502	NN	I-NP	O
of	of	o100	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
,	,	,000	,	O	O
peripherally	peripherally	p060106040	RB	B-VP	O
acting	act	a23052	VBG	I-VP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
alpha1	alpha1	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
adrenoceptor	adrenoceptor	a36050201306	NN	B-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
stress	stress	s3602	NN	B-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
limited	limit	l050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
piloerection	piloerection	p040602305	NN	I-NP	O
and	and	a530	CC	O	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Hyperglycemic	Hyperglycemic	h010624020502	JJ	B-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amino	amino	a5050	JJ	B-NP	B-Chemical
compounds	compound	c0510532	NNS	I-NP	O
structurally	structurally	s3602306040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
caproate	caproate	c016030	VB	I-VP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
feeding	feeding	f03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
small	small	s504	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
diet	diet	d030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
amino	amino	a5050	NN	I-NP	B-Chemical
derivatives	derivative	d0601030102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caproate	caproate	c016030	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
hyperglycemia	hyperglycemia	h01062402050	NN	B-NP	B-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
tolerance	tolerance	t04060520	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
,	,	,000	,	O	O
glucosuria	glucosuria	g40202060	NN	B-NP	B-Disease
.	.	.000	.	O	O

Effective	Effective	e1023010	JJ	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
norleucine	norleucine	n06402050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
norvaline	norvaline	n06104050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
epsilon	epsilon	e120405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminocaproate	aminocaproate	a50502016030	NN	B-NP	I-Chemical
,	,	,000	,	O	O
methionine	methionine	m0305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
leucine	leucine	l02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Toleration	Toleration	t04060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
:	:	:000	:	O	O
results	result	r020432	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
ATLAS	ATLAS	a3402	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Assessment	Assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
Lisinopril	Lisinopril	l020501604	NNP	B-NP	B-Chemical
and	and	a530	CC	O	O
Survival	Survival	s0610104	NN	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
(	(	(000	(	O	I-Chemical
ACE	ACE	a200	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
inhibitors	inhibitor	i50103062	NNS	B-NP	I-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
and	and	a530	CC	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHF	CHF	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
most	most	m023	JJS	B-VP	O
affected	affect	a102303	VBN	I-VP	O
patients	patient	p030532	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
receiving	receive	r0201052	VBG	I-VP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
or	or	o600	CC	O	O
are	be	a600	VBP	B-VP	O
being	be	b052	VBG	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
found	find	f053	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
efficacious	efficacious	e1020202	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
trials	trial	t6042	NNS	B-NP	O
,	,	,000	,	O	O
primarily	primarily	p60506040	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
concerns	concern	c0520652	NNS	B-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
examines	examine	e2050502	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
lisinopril	lisinopril	l020501604	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
Assessment	Assessment	a2025053	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Lisinopril	Lisinopril	l020501604	NNP	B-NP	B-Chemical
and	and	a530	CC	O	O
Survival	Survival	s0610104	NN	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
stabilized	stabilize	s301040203	VBN	I-VP	O
receiving	receive	r0201052	VBG	B-VP	O
medium	medium	m0305	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
lisinopril	lisinopril	l020501604	NN	I-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
[	[	[000	(	O	O
OD	OD	o300	NN	B-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-VP	O
randomized	randomize	r053050203	VBD	I-VP	O
to	to	t000	TO	B-PP	O
high	high	h020	JJ	O	O
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
32	32	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
OD	OD	o300	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
OD	OD	o300	NN	I-NP	O
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
New	New	n000	NNP	B-NP	O
York	York	y062	NNP	I-NP	O
Heart	Heart	h063	NNP	I-NP	O
Association	Association	a2020305	NNP	I-NP	O
classes	class	c40202	NNS	I-NP	O
II	II	i000	CD	I-NP	O
to	to	t000	TO	I-NP	O
IV	IV	i100	CD	I-NP	O
CHF	CHF	c010	NN	I-NP	B-Disease
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fractions	fraction	f6023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
no	no	n000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
30	30	0000	CD	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3164	3164	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
and	and	a530	CC	O	O
followed	follow	f0403	VBN	B-VP	O
up	up	u100	RP	B-PRT	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
46	46	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
and	and	a530	CC	I-NP	O
dose	dose	d020	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
focus	focus	f0202	NN	I-NP	O
on	on	o500	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-PP	O
405	405	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
not	not	n030	RB	O	O
previously	previously	p6010240	RB	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
an	an	a500	DT	B-NP	O
ACE	ACE	a200	NN	I-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
,	,	,000	,	O	O
doses	dose	d0202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
titrated	titrate	t0360303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
medium	medium	m0305	NN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
required	require	r020603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
randomization	randomization	r05305020305	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
possibly	possibly	p020140	RB	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
or	or	o600	CC	O	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Doses	Dose	d0202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
90	90	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
randomized	randomize	r053050203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
titrated	titrate	t0360303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
assigned	assign	a202503	VBN	I-NP	O
target	target	t06203	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blinded	blinded	b405303	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Withdrawals	Withdrawal	w03036042	NNS	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
27	27	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Subgroups	Subgroup	s0126012	NNS	B-NP	O
presumed	presume	p6020503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
ACE	ACE	a200	NN	B-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
intolerance	intolerance	i5304060520	NN	I-NP	O
(	(	(000	(	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
<	<	<000	SYM	B-NP	O
120	120	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
;	;	;000	:	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
132	132	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	I-NP	O
L	L	l000	NN	I-NP	O
[	[	[000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
]	]	]000	)	O	O
;	;	;000	:	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
70	70	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
)	)	)000	)	O	O
generally	generally	g0506040	RB	B-ADVP	O
tolerated	tolerate	t04060303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ACE	ACE	a200	NN	B-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
successfully	successfully	s02021040	RB	I-VP	O
titrated	titrate	t0360303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	O	O
maintained	maintain	m0530503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
more	more	m060	RBR	B-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
cocaethylene	cocaethylene	c020304050	NN	B-NP	B-Chemical
cardiotoxity	cardiotoxity	c0630302030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
ethanol	ethanol	e30504	NN	I-NP	I-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
Simultaneous	Simultaneous	s050430502	JJ	B-NP	O
abuse	abuse	a1020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
cocaine	cocaine	c02050	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
ethanol	ethanol	e30504	NN	I-NP	I-Disease
affects	affect	a10232	VBZ	B-VP	O
12	12	0000	CD	B-NP	O
million	million	m0405	CD	I-NP	O
Americans	American	a50602052	NNPS	I-NP	O
annually	annually	a5040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
substances	substance	s012305202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
substantially	substantially	s0123053040	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
toxic	toxic	t0202	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
either	either	e0306	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
independent	independent	i5301053053	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cocaethylene	cocaethylene	c020304050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CE	CE	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
formed	form	f06503	VBN	B-VP	O
only	only	o540	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
delineate	delineate	d0405030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
CE	CE	c000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
simulating	simulate	s050403052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
abuse	abuse	a1020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
three	three	t060	CD	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
(	(	(000	(	O	O
IV	IV	i100	CD	O	O
)	)	)000	)	O	O
boluses	bolus	b040202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
with	with	w030	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
IV	IV	i100	CD	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
C	C	c000	NN	B-NP	O
+	+	+000	SYM	O	O
E	E	e000	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
three	three	t060	CD	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
boluses	bolus	b040202	NNS	I-NP	O
only	only	o540	RB	B-ADVP	O
(	(	(000	(	O	O
C	C	c000	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
3	3	3000	LS	B-LST	O
)	)	)000	)	O	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
(	(	(000	(	O	O
E	E	e000	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
4	4	4000	CD	O	O
)	)	)000	)	O	O
placebo	placebo	p402010	NN	B-NP	O
boluses	bolus	b040202	NNS	I-NP	O
and	and	a530	CC	O	O
infusion	infusion	i510205	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Hemodynamic	Hemodynamic	h0503050502	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
,	,	,000	,	O	O
electrocardiograms	electrocardiogram	e4023602063026052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
serum	serum	s0605	NN	B-NP	O
drug	drug	d602	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
fixed	fix	f0203	VBN	B-NP	O
time	time	t050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
E	E	e000	NN	I-NP	O
group	group	g601	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
collapse	collapse	c040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
each	each	e020	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
bolus	bolus	b0402	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
+	+	+000	SYM	B-VP	O
E	E	e000	NN	B-NP	O
and	and	a530	CC	I-NP	O
C	C	c000	NN	I-NP	O
only	only	o540	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
persistent	persistent	p062023053	JJ	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
E	E	e000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Peak	Peak	p020	JJ	B-NP	O
CE	CE	c000	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
69	69	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
cardiac	cardiac	c06302	JJ	B-NP	I-Disease
output	output	o03103	NN	I-NP	I-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
56	56	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
32	32	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
80	80	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	O	O
dt	dt	d300	NN	B-NP	O
(	(	(000	(	O	O
max	max	m020	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
006	006	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
23	23	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
SVO	SVO	s100	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
025	025	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ventricular	Ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
primarily	primarily	p60506040	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
E	E	e000	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
four	four	f060	CD	B-NP	O
of	of	o100	IN	I-NP	O
eight	eight	e0203	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
toxic	toxic	t0202	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
either	either	e0306	DT	B-NP	O
substance	substance	s01230520	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Co	Co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
dysrhythmogenic	dysrhythmogenic	d0260305020502	JJ	B-ADJP	O
.	.	.000	.	O	O

Peak	Peak	p020	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
cocaethylene	cocaethylene	c020304050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Worsening	Worsening	w06205052	NN	B-NP	O
of	of	o100	IN	B-PP	O
Parkinsonism	Parkinsonism	p06205205025	NNP	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
veralipride	veralipride	v0604016030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
menopause	menopause	m0501020	NN	B-NP	O
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
female	female	f05040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
has	have	h020	VBZ	B-VP	O
shown	show	s050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
worsening	worsening	w06205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
motor	motor	m0306	NN	I-NP	O
functions	function	f0523052	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
of	of	o100	IN	B-PP	O
menopause	menopause	m0501020	NN	B-NP	O
related	relate	r040303	VBN	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
veralipride	veralipride	v0604016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
back	back	b020	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
emphasize	emphasize	e5102020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
veralipride	veralipride	v0604016030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Viracept	Viracept	v0602013	JJ	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
irregular	irregular	i6020406	JJ	I-NP	B-Disease
heartbeat	heartbeat	h063103	NN	I-NP	I-Disease
warning	warning	w065052	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
doctors	doctor	d023062	NNS	B-NP	O
in	in	i500	IN	B-PP	O
Boston	Boston	b02305	NNP	B-NP	O
warn	warn	w065	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protease	protease	p603020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
Viracept	Viracept	v0602013	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
an	an	a500	DT	B-NP	O
irregular	irregular	i6020406	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
beat	beat	b030	NN	I-NP	I-Disease
,	,	,000	,	O	O
known	know	k505	VBN	B-VP	O
as	as	a200	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
people	people	p0140	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NNP	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
Viracept	Viracept	v0602013	VBN	I-VP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
HIV	HIV	h010	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
ceased	cease	c0203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
another	another	a50306	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
.	.	.000	.	O	O

Frequency	Frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
appearance	appearance	a1060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
myeloperoxidase	myeloperoxidase	m0401060203020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
(	(	(000	(	O	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
Graves	Graves	g60102	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Myeloperoxidase	Myeloperoxidase	m0401060203020	NN	B-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
(	(	(000	(	O	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Graves	Graves	g60102	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PTU	PTU	p300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
of	of	o100	IN	B-PP	O
being	be	b052	VBG	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
because	because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
titres	titre	t03602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Nevertheless	Nevertheless	n010630402	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
no	no	n000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
and	and	a530	CC	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
in	in	i500	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
Graves	Graves	g60102	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
address	address	a3602	VB	I-VP	O
these	these	t020	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Graves	Graves	g60102	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
102	102	0000	CD	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
Graves	Graves	g60102	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
later	later	l0306	RB	I-VP	O
excluded	exclude	e240303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
because	because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
73	73	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
55	55	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
18	18	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
adopted	adopt	a301303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
was	be	w020	VBD	B-VP	O
23	23	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
:	:	:000	:	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
37	37	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
:	:	:000	:	O	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
intervals	interval	i53061042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Before	Before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MPO	MPO	m100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titres	titre	t03602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
102	102	0000	CD	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
Graves	Graves	g60102	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
range	range	r0520	NN	I-NP	O
(	(	(000	(	O	O
below	below	b040	IN	B-PP	O
10	10	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
73	73	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
at	at	a300	IN	B-PP	O
13	13	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
16	16	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
17	17	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MPO	MPO	m100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titres	titre	t03602	NNS	I-NP	O
transiently	transiently	t605205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
and	and	a530	CC	I-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	O	O
ml	ml	m400	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
continued	continue	c0530503	VBN	B-NP	O
PTU	PTU	p300	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
vasculitic	vasculitic	v02040302	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MPO	MPO	m100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titre	titre	t0360	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
204	204	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
polyarthralgia	polyarthralgia	p04063060420	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
MPO	MPO	m100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titre	titre	t0360	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	O	O
ml	ml	m400	NN	B-NP	O
by	by	b000	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
PTU	PTU	p300	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
MPO	MPO	m100	NN	B-NP	O
-	-	-000	HYPH	O	O
ANCA	ANCA	a520	NN	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
closely	closely	c402040	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
vasculitis	vasculitis	v02040302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Prevalence	Prevalence	p601040520	NN	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
outpatient	outpatient	o03103053	NN	B-NP	O
young	young	y052	JJ	I-NP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
35	35	0000	CD	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	O	O
32	32	0000	CD	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
matched	match	m03203	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
resting	rest	r023052	VBG	I-VP	O
and	and	a530	CC	O	O
exercise	exercise	e2062020	NN	B-NP	O
electrocardiography	electrocardiography	e4023602063026010	NN	I-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Doppler	Doppler	d01406	NN	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Findings	Finding	f053052	NNS	B-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
(	(	(000	(	O	O
34	34	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
(	(	(000	NN	I-NP	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Decreased	Decrease	d0260203	VBN	B-VP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
055	055	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
resting	rest	r023052	VBG	B-NP	O
and	and	a530	CC	I-NP	O
peak	peak	p020	JJ	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	B-Disease
left	left	l013	JJ	I-NP	I-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
filling	filling	f04052	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
38	38	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
35	35	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
19	19	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
11	11	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
or	or	o600	CC	O	I-Disease
myocardial	myocardial	m0206304	JJ	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
common	common	c0505	JJ	B-ADJP	O
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
screening	screen	s2605052	VBG	B-VP	O
ECG	ECG	e200	NN	B-NP	O
and	and	a530	CC	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Cardioprotective	Cardioprotective	c06301603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Picrorrhiza	Picrorrhiza	p02606020	NNP	B-NP	O
kurroa	kurroa	k060	NN	I-NP	O
against	against	a20523	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
extract	extract	e236023	NN	I-NP	O
of	of	o100	IN	B-PP	O
Picrorrhiza	Picrorrhiza	p02606020	NNP	B-NP	O
kurroa	kurroa	k060	NN	I-NP	O
rhizomes	rhizome	r020502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
roots	root	r032	NNS	I-NP	O
(	(	(000	(	O	O
PK	PK	p200	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	O	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
PK	PK	p200	NN	B-NP	O
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
day	day	d000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
maintained	maintain	m0530503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
at	at	a300	IN	B-PP	O
near	near	n060	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
.	.	.000	.	O	O

Phase	Phase	p020	NN	B-NP	O
2	2	2000	CD	I-NP	O
early	early	e0640	JJ	I-NP	O
afterdepolarization	afterdepolarization	a13063010406020305	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
trigger	trigger	t60206	NN	I-NP	O
of	of	o100	IN	B-PP	O
polymorphic	polymorphic	p040506102	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
acquired	acquire	a20603	VBN	B-NP	O
long	long	l052	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
:	:	:000	:	O	O
direct	direct	d06023	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
from	from	f605	IN	B-PP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
2	2	2000	CD	I-NP	O
early	early	e0640	JJ	I-NP	O
afterdepolarization	afterdepolarization	a13063010406020305	NN	I-NP	O
(	(	(000	(	O	O
EAD	EAD	e030	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
producing	produce	p60302052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
trigger	trigger	t60206	NN	I-NP	O
to	to	t000	TO	B-VP	O
initiate	initiate	i503030	VB	I-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
TdP	TdP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
dl	dl	d400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
sotalol	sotalol	s030404	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
azimilide	azimilide	a20504030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
transmural	transmural	t605250604	JJ	B-NP	O
dispersion	dispersion	d02106205	NN	I-NP	O
of	of	o100	IN	B-PP	O
repolarization	repolarization	r010406020305	NN	B-NP	O
(	(	(000	(	O	O
TDR	TDR	t360	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
transmural	transmural	t605250604	JJ	B-NP	O
propagation	propagation	p601020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
EAD	EAD	e030	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TdP	TdP	t310	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
Transmembrane	Transmembrane	t605250516050	NN	B-NP	O
action	action	a2305	NN	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
from	from	f605	IN	B-PP	O
epicardium	epicardium	e10206305	NN	B-NP	O
,	,	,000	,	O	O
midmyocardium	midmyocardium	m0350206305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
endocardium	endocardium	e530206305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
transmural	transmural	t605250604	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
arterially	arterially	a6306040	RB	B-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
canine	canine	c05050	NN	I-NP	O
and	and	a530	CC	I-NP	O
rabbit	rabbit	r0103	NN	I-NP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

dl	dl	d400	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
Sotalol	Sotalol	s030404	NN	I-NP	B-Chemical
preferentially	preferentially	p60106053040	RB	B-ADVP	O
prolonged	prolong	p60405203	VBD	B-VP	O
action	action	a2305	NN	B-NP	O
potential	potential	p0305304	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
(	(	(000	(	O	O
APD	APD	a130	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
M	M	m000	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-ADVP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	O	O
100	100	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
TDR	TDR	t360	NN	B-NP	O
.	.	.000	.	O	O

Azimilide	Azimilide	a20504030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
prolonged	prolong	p60405203	VBD	I-VP	O
APD	APD	a130	NN	B-NP	O
and	and	a530	CC	I-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
at	at	a300	IN	B-PP	O
concentrations	concentration	c052053603052	NNS	B-NP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	I-NP	O
L	L	l000	NN	I-NP	O
but	but	b030	CC	O	O
shortened	shorten	s0630503	VBD	B-VP	O
them	them	t050	PRP	B-NP	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
.	.	.000	.	O	O

Unlike	Unlike	u54020	IN	B-PP	O
dl	dl	d400	NN	B-NP	O
-	-	-000	HYPH	O	O
sotalol	sotalol	s030404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
azimilide	azimilide	a20504030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
3	3	3000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
epicardial	epicardial	e10206304	JJ	B-NP	O
APD	APD	a130	NN	I-NP	O
markedly	markedly	m0620340	RB	B-ADVP	O
,	,	,000	,	O	O
causing	cause	c02052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
diminished	diminished	d05050203	JJ	I-NP	O
TDR	TDR	t360	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
both	both	b030	CC	O	O
dl	dl	d400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
sotalol	sotalol	s030404	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
azimilide	azimilide	a20504030	NN	I-NP	B-Chemical
rarely	rarely	r06040	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
EADs	EAD	e032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
canine	canine	c05050	JJ	B-NP	O
left	left	l013	JJ	I-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
frequent	frequent	f602053	JJ	B-NP	O
EADs	EAD	e032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rabbits	rabbit	r01032	NNS	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
more	more	m060	RBR	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
QT	QT	q300	NN	I-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
TDR	TDR	t360	NN	B-NP	O
by	by	b000	IN	B-PP	O
dl	dl	d400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
sotalol	sotalol	s030404	NN	I-NP	B-Chemical
facilitated	facilitate	f0204030303	VBD	B-VP	O
transmural	transmural	t605250604	JJ	B-NP	O
propagation	propagation	p601020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
EADs	EAD	e032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
initiated	initiate	i5030303	VBD	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
TdP	TdP	t310	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
rabbit	rabbit	r0103	NN	I-NP	O
left	left	l013	JJ	I-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
note	note	n030	NN	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
azimilide	azimilide	a20504030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	I-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
APD	APD	a130	NN	B-NP	O
more	more	m060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
dl	dl	d400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
sotalol	sotalol	s030404	NN	I-NP	B-Chemical
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
EADs	EAD	e032	NNS	I-NP	O
often	often	o1305	RB	B-ADVP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
propagate	propagate	p60102030	VB	I-VP	O
transmurally	transmurally	t6052506040	RB	B-ADVP	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
diminished	diminished	d05050203	JJ	I-NP	O
TDR	TDR	t360	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
direct	direct	d06023	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
from	from	f605	IN	B-PP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
that	that	t030	IN	B-SBAR	O
phase	phase	p020	NN	B-NP	O
2	2	2000	CD	I-NP	O
EAD	EAD	e030	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
generated	generate	g05060303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
and	and	a530	CC	O	O
produce	produce	p603020	VBP	B-VP	O
a	a	a000	DT	B-NP	O
trigger	trigger	t60206	NN	I-NP	O
to	to	t000	TO	B-VP	O
initiate	initiate	i503030	VB	I-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
TdP	TdP	t310	NN	B-NP	B-Disease
under	under	u5306	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
Chest	Ch	c023	JJS	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
poses	pose	p0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
dilemma	dilemma	d04050	NN	I-NP	O
.	.	.000	.	O	O

Dobutamine	Dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
(	(	(000	(	O	O
DSE	DSE	d200	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
available	available	a1040140	JJ	I-NP	O
and	and	a530	CC	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
theoretical	theoretical	t06030204	JJ	I-NP	O
concern	concern	c052065	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pilot	pilot	p0403	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
DSE	DSE	d200	NN	B-NP	O
in	in	i500	IN	B-PP	O
emergency	emergency	e50620520	NN	B-NP	O
department	department	d010635053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
case	case	c020	NN	I-NP	O
series	series	s0602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
diagnostic	diagnostic	d02502302	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ED	ED	e300	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
urban	urban	u6105	JJ	I-NP	O
tertiary	tertiary	t063060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
care	care	c060	NN	I-NP	O
teaching	teaching	t02052	NN	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
eligible	eligible	e4020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
DSE	DSE	d200	NN	B-NP	O
if	if	i100	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
preceding	precede	p60203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
and	and	a530	CC	I-NP	O
tropinin	tropinin	t6010505	NN	I-NP	O
I	I	i000	CD	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
exhibiting	exhibit	e20103052	VBG	B-VP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
continuing	continue	c05305052	VBG	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
DSE	DSE	d200	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
diagnostic	diagnostic	d02502302	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
inadequate	inadequate	i50302030	JJ	B-NP	O
resting	rest	r023052	VBG	I-NP	O
images	image	i50202	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
DSE	DSE	d200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
inferior	inferior	i510606	JJ	B-NP	O
hypokinesis	hypokinesis	h0102050202	NN	I-NP	B-Disease
,	,	,000	,	O	O
another	another	a50306	DT	B-NP	O
DSE	DSE	d200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
because	because	b02020	RB	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
atrial	atrial	a3604	JJ	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
deficit	deficit	d010203	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reach	reach	r020	VB	I-VP	O
the	the	t000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
19	19	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
completed	complete	c05140303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
DSE	DSE	d200	NN	I-NP	O
and	and	a530	CC	O	O
reached	reach	r0203	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
target	target	t06203	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
exaggerated	exaggerated	e202060303	JJ	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
of	of	o100	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
200	200	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
tachydysrhythmias	tachydysrhythmia	t0203026030502	NNS	B-NP	B-Disease
(	(	(000	(	O	O
excluding	exclude	e2403052	VBG	B-VP	O
sinus	sinus	s0502	NN	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-ADVP	O
suggesting	suggest	s02023052	VBG	B-VP	O
lack	lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
exaggerated	exaggerated	e202060303	JJ	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
(	(	(000	(	O	O
65	65	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
required	require	r020603	VBD	B-VP	O
supplemental	supplemental	s0140505304	JJ	B-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
reach	reach	r020	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
target	target	t06203	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
No	No	n000	DT	B-NP	O
exaggerated	exaggerated	e202060303	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Prenatal	Prenatal	p6050304	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
cranial	cranial	c60504	JJ	B-NP	O
sonographic	sonographic	s050260102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
infants	infant	i510532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Prenatal	Prenatal	p6050304	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
linked	link	l05203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
subependymal	subependymal	s01010530504	JJ	B-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cysts	cyst	c0232	NNS	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
detectable	detectable	d030230140	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
cranial	cranial	c60504	JJ	B-NP	O
sonography	sonography	s05026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
neonates	neonate	n050302	NNS	B-NP	O
born	bear	b065	VBN	B-VP	O
at	at	a300	IN	B-PP	O
term	term	t065	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
prenatal	prenatal	p6050304	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
subependymal	subependymal	s01010530504	JJ	B-NP	B-Disease
cysts	cyst	c0232	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
infants	infant	i510532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
reviewed	review	r0103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
and	and	a530	CC	O	O
cranial	cranial	c60504	JJ	B-NP	O
sonograms	sonogram	s05026052	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
on	on	o500	IN	B-PP	O
122	122	0000	CD	B-NP	O
premature	premature	p60503060	JJ	I-NP	B-Disease
(	(	(000	(	O	I-Disease
<	<	<000	SYM	O	I-Disease
36	36	0000	CD	B-NP	I-Disease
weeks	week	w020	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
gestation	gestation	g0230305	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
infants	infant	i510532	NNS	B-NP	I-Disease
.	.	.000	.	O	O

Infants	Infant	i510532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
categorized	categorize	c0302060203	VBN	I-VP	O
into	into	i530	IN	B-PP	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
those	those	t020	DT	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
not	not	n030	RB	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Infants	Infant	i510532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
exposed	expose	e210203	VBN	B-NP	O
group	group	g601	NN	I-NP	O
if	if	i100	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
maternal	maternal	m0306504	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
or	or	o600	CC	O	O
if	if	i100	IN	B-SBAR	O
maternal	maternal	m0306504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
neonatal	neonatal	n050304	JJ	I-NP	O
urine	urine	u6050	NN	I-NP	O
toxicology	toxicology	t020204020	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
delivery	delivery	d0401060	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
122	122	0000	CD	I-NP	O
infants	infant	i510532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
insufficient	insufficient	i520102053	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
histories	history	h0230602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
subependymal	subependymal	s01010530504	JJ	B-NP	B-Disease
cysts	cyst	c0232	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
117	117	0000	CD	I-NP	O
remaining	remain	r0505052	VBG	I-NP	O
infants	infant	i510532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
117	117	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
subependymal	subependymal	s01010530504	JJ	B-NP	B-Disease
cysts	cyst	c0232	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
prenatally	prenatally	p60503040	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
of	of	o100	IN	B-PP	O
18	18	0000	CD	B-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
of	of	o100	IN	B-PP	O
99	99	0000	CD	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
unexposed	unexposed	u50210203	JJ	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
subependymal	subependymal	s01010530504	JJ	B-NP	B-Disease
cyst	cyst	c023	NN	I-NP	I-Disease
formation	formation	f0650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
infants	infant	i510532	NNS	I-NP	I-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
prenatally	prenatally	p60503040	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
result	result	r02043	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
term	term	t065	NN	B-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

Thalidomide	Thalidomide	t040305030	NN	B-NP	B-Chemical
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
using	use	u2052	VBG	B-VP	O
electrodiagnostic	electrodiagnostic	e402360302502302	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
men	man	m050	NNS	I-NP	O
with	with	w030	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
androgen	androgen	a5360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
underwent	undergo	u5306053	VBD	B-VP	O
neurologic	neurologic	n06040202	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
and	and	a530	CC	O	O
nerve	nerve	n0610	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
(	(	(000	(	O	O
NCS	NCS	n200	NNS	B-NP	O
)	)	)000	)	O	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	I-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

NCS	NCS	n200	NN	B-NP	O
included	include	i5240303	VBD	B-VP	O
recording	recording	r02063052	NN	B-NP	O
of	of	o100	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
action	action	a2305	NN	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
(	(	(000	(	O	O
SNAPs	SNAP	s5012	NNS	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
median	median	m0305	JJ	B-NP	O
,	,	,000	,	I-NP	O
radial	radial	r0304	JJ	I-NP	O
,	,	,000	,	I-NP	O
ulnar	ulnar	u4506	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sural	sural	s0604	JJ	B-NP	O
nerves	nerve	n06102	NNS	I-NP	O
.	.	.000	.	O	O

SNAP	SNAP	s501	NN	B-NP	O
amplitudes	amplitude	a514030302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
were	be	w060	VBD	B-VP	O
expressed	express	e2160203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
was	be	w020	VBD	B-VP	O
termed	term	t06503	VBN	I-VP	O
the	the	t000	DT	B-NP	O
SNAP	SNAP	s501	NN	I-NP	O
index	index	i5302	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SNAP	SNAP	s501	NN	I-NP	O
index	index	i5302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
clinically	clinically	c40502040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
.	.	.000	.	O	O

Thalidomide	Thalidomide	t040305030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
55	55	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
lack	lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
67	67	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
initially	initially	i503040	RB	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
remained	remain	r050503	VBD	B-VP	O
on	on	o500	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
remained	remain	r050503	VBD	B-VP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
remained	remain	r050503	VBD	B-VP	O
at	at	a300	IN	B-PP	O
9	9	9000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
neuropathy	neuropathy	n0601030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SNAP	SNAP	s501	NN	I-NP	O
index	index	i5302	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
concurrently	concurrently	c0520605340	RB	B-ADVP	O
.	.	.000	.	O	O

Older	Old	o4306	JJR	B-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	O	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
possible	possible	p020140	JJ	B-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Neuropathy	Neuropathy	n0601030	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
thus	thus	t020	RB	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
SNAP	SNAP	s501	NN	I-NP	O
index	index	i5302	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
monitor	monitor	m050306	VB	I-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-PP	O
for	for	f060	IN	I-PP	O
early	early	e0640	JJ	B-NP	O
detection	detection	d0302305	NN	I-NP	O
.	.	.000	.	O	O

Overexpression	Overexpression	o10602160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
copper	copper	c0106	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
zinc	zinc	z052	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
protects	protect	p6030232	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
participation	participation	p06302010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
deduced	deduce	d030203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
observations	observation	o1206103052	NNS	B-NP	O
that	that	t030	IN	B-SBAR	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
iron	iron	i605	NN	B-NP	B-Chemical
complexes	complex	c05140202	NNS	I-NP	O
catalyze	catalyze	c0304020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
radicals	radical	r0302042	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
antioxidants	antioxidant	a5302030532	NNS	B-NP	O
attenuate	attenuate	a305030	VBP	B-VP	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
overexpression	overexpression	o10602160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
Cu	Cu	c000	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
Zn	Zn	z500	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
(	(	(000	(	O	O
h	h	h000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
SOD1	SOD1	0000	NN	I-NP	O
)	)	)000	)	O	O
should	should	s043	MD	B-VP	O
protect	protect	p603023	VB	I-VP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
from	from	f605	IN	B-PP	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Immunocytochemistry	Immunocytochemistry	i5050203020502360	NN	B-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
h	h	h000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
SOD1	SOD1	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
inner	inner	i506	JJ	B-NP	O
ear	ear	e060	JJ	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
C57BL	C57BL	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
TgN	TgN	t250	NN	I-NP	O
[	[	[000	(	I-NP	O
SOD1	SOD1	0000	NN	I-NP	O
]	]	]000	)	I-NP	O
3Cje	3Cje	3200	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Transgenic	Transgenic	t60520502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
nontransgenic	nontransgenic	n05360520502	JJ	I-NP	O
littermates	littermate	l030650302	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
beginning	begin	b0205052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
10	10	0000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
birth	birth	b0630	NN	B-NP	O
.	.	.000	.	O	O

Auditory	Auditory	a0303060	JJ	B-NP	O
thresholds	threshold	t06020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
evoked	evoke	e10203	VBN	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
after	after	a1306	IN	B-PP	O
birth	birth	b0630	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
nontransgenic	nontransgenic	n05360520502	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kanamycin	kanamycin	k05050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
45	45	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
transgenic	transgenic	t60520502	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
by	by	b000	IN	B-PP	O
only	only	o540	RB	B-NP	O
15	15	0000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
respective	respective	r021023010	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
12	12	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
24	24	0000	CD	I-NP	O
kHz	kHz	k020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
overexpression	overexpression	o10602160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
oxidant	oxidant	o203053	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
as	as	a200	IN	B-PP	O
suitable	suitable	s030140	JJ	B-NP	O
models	model	m03042	NNS	I-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
.	.	.000	.	O	O

Fatty	Fatty	f030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
response	response	r0210520	NN	I-NP	O
relationships	relationship	r0403052012	NNS	I-NP	O
and	and	a530	CC	O	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
sex	sex	s020	NN	B-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
response	response	r0210520	NN	I-NP	O
relationships	relationship	r0403052012	NNS	I-NP	O
,	,	,000	,	O	O
biochemical	biochemical	b02050204	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sex	sex	s020	NN	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
fatty	fatty	f030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
liver	liver	l0106	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
provision	provision	p6010205	NN	B-NP	O
of	of	o100	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
oleic	oleic	o402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
substrate	substrate	s01236030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
liver	liver	l0106	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
both	both	b030	CC	O	O
accumulation	accumulation	a205040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
output	output	o03103	NN	B-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
livers	liver	l01062	NNS	B-NP	O
from	from	f605	IN	B-PP	O
male	male	m040	JJ	B-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Marked	Marked	m06203	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
and	and	a530	CC	I-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
base	base	b020	NN	B-NP	O
line	line	l050	NN	I-NP	O
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
output	output	o03103	NN	I-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Accumulation	Accumulation	a205040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
triglyceride	triglyceride	t60240206030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	O	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
graded	grade	g60303	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
between	between	b0305	IN	B-PP	O
male	male	m040	JJ	B-NP	O
,	,	,000	,	I-NP	O
female	female	f05040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
livers	liver	l01062	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
livers	liver	l01062	NNS	B-NP	O
from	from	f605	IN	B-PP	O
female	female	f05040	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
especially	especially	e2102040	RB	B-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
strikingly	strikingly	s360205240	RB	B-ADJP	O
resistant	resistant	r02023053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
output	output	o03103	NN	B-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
under	under	u5306	IN	B-PP	O
these	these	t020	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
sexes	sex	s0202	NNS	I-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
altered	altered	a430603	JJ	B-NP	O
disposition	disposition	d021020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
altered	altered	a430603	JJ	B-NP	O
uptake	uptake	u13020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oleic	oleic	o402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Depressed	Depress	d0160203	VBN	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
accounted	account	a205303	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
accumulated	accumulate	a205040303	VBN	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
triglyceride	triglyceride	t60240206030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
additional	additional	a3030504	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
triglyceride	triglyceride	t60240206030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
rich	rich	r020	JJ	I-NP	O
fatty	fatty	f030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	I-PP	O
to	to	t000	TO	I-PP	O
tetracycline	tetracycline	t03602024050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Prednisone	Prednisone	p603502050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
glial	glial	g404	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
prednisone	prednisone	p603502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PDN	PDN	p350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
produces	produce	p6030202	VBZ	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	O
glial	glial	g404	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	NNP	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
formed	form	f06503	VBN	I-VP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
per	per	p060	IN	B-PP	O
group	group	g601	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
PDN	PDN	p350	NN	I-NP	B-Chemical
released	release	r040203	VBN	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
implant	implant	i514053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
implants	implant	i5140532	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
PDN	PDN	p350	NN	B-NP	B-Chemical
equivalent	equivalent	e20104053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
implants	implant	i5140532	NNS	I-NP	O
contained	contain	c0530503	VBD	B-VP	O
no	no	n000	DT	B-NP	O
PDN	PDN	p350	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Anxiety	Anxiety	a52030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
field	field	f043	NN	I-NP	O
and	and	a530	CC	O	O
elevated	elevate	e4010303	VBN	B-VP	O
plus	plus	p402	CC	O	O
-	-	-000	HYPH	B-NP	O
maze	maze	m020	NN	I-NP	O
devices	device	d010202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
and	and	a530	CC	O	O
cytoplasmic	cytoplasmic	c0301402502	JJ	B-NP	O
transformation	transformation	t605210650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
and	and	a530	CC	O	O
microglia	microglia	m0260240	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Anxiety	Anxiety	a52030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PDN	PDN	p350	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
transformation	transformation	t605210650305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
microglia	microglia	m0260240	NNS	I-NP	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
intersections	intersection	i53062023052	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PDN	PDN	p350	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
(	(	(000	(	O	O
moderate	moderate	m0306030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
;	;	;000	:	O	O
controls	control	c0536042	NNS	B-NP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
striatum	striatum	s360305	NN	B-NP	O
(	(	(000	(	O	O
moderate	moderate	m0306030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
25	25	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
;	;	;000	:	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
26	26	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
;	;	;000	:	O	O
controls	control	c0536042	NNS	B-NP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
stained	stain	s30503	VBN	B-NP	O
microglia	microglia	m0260240	NNS	I-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PDN	PDN	p350	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
groups	group	g6012	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
moderate	moderate	m0306030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
28	28	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
;	;	;000	:	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
per	per	p060	IN	B-PP	O
field	field	f043	NN	B-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Stained	Stain	s30503	VBN	B-NP	O
microglia	microglia	m0260240	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	B-NP	O
numerous	numerous	n050602	JJ	I-NP	O
striatum	striatum	s360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Subacute	Subacute	s0102030	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
PDN	PDN	p350	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
microglia	microglia	m0260240	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
relevance	relevance	r04010520	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
features	feature	f030602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
PDN	PDN	p350	NN	B-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
elucidated	elucidate	e402030303	VBN	I-VP	O
.	.	.000	.	O	O

Phase	Phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
squamous	squamous	s20502	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
cervix	cervix	c06102	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
Phase	Phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
cervical	cervical	c0610204	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
area	area	a600	NN	B-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
[	[	[000	(	O	O
AUC	AUC	a020	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Doxil	Doxil	d0204	NNP	B-NP	B-Chemical
;	;	;000	:	O	O
starting	start	s3063052	VBG	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-NP	O
every	every	e1060	DT	I-NP	O
28	28	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
squamous	squamous	s20502	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
cervical	cervical	c0610204	JJ	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
profile	profile	p601040	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessable	assessable	a2020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
35	35	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessable	assessable	a2020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
response	response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
10	10	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
26	26	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
37	37	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
neutropenic	neutropenic	n036010502	JJ	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
five	five	f010	CD	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Grade	Grade	g6030	NN	B-NP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
nonhematologic	nonhematologic	n050503040202	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
included	include	i5240303	VBD	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
17	17	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
emesis	emesis	e50202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
fatigue	fatigue	f03020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
9	9	9000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
mucositis	mucositis	m02020302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
stomatitis	stomatitis	s305030302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
constipation	constipation	c0523010305	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
hand	hand	h053	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
foot	foot	f030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
skin	skin	s205	NN	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
liposomal	liposomal	l01020504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
modest	modest	m03023	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
cervical	cervical	c0610204	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Antimicrobial	Antimicrobial	a53050260104	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
mania	mania	m050	NN	I-NP	B-Disease
(	(	(000	(	O	O
antibiomania	antibiomania	a530105050	NN	B-NP	B-Disease
)	)	)000	)	O	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
reviewed	review	r0103	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
antibiotic	antibiotic	a53010302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
manic	manic	m0502	JJ	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
MEDLINE	MEDLINE	m034050	NNP	I-NP	O
and	and	a530	CC	I-NP	O
PsychLit	PsychLit	p2020403	NNP	I-NP	O
search	search	s0620	NN	I-NP	O
for	for	f060	IN	B-PP	O
reports	report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
antibiotic	antibiotic	a53010302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
mania	mania	m050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Unpublished	Unpublished	u510140203	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
requested	request	r0202303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
World	World	w0643	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
(	(	(000	(	O	O
WHO	WHO	w000	WP	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Food	Food	f030	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
(	(	(000	(	O	O
FDA	FDA	f300	NNP	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antimicrobial	antimicrobial	a53050260104	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
mania	mania	m050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
6	6	6000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
implicating	implicate	i5140203052	VBG	B-VP	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
implicating	implicate	i5140203052	VBG	I-NP	O
isoniazid	isoniazid	i2050203	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
case	case	c020	NN	I-NP	O
each	each	e020	DT	B-NP	O
implicating	implicate	i5140203052	VBG	I-NP	O
erythromycin	erythromycin	e60306050205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
amoxicillin	amoxicillin	a502020405	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
WHO	WHO	w000	NNP	I-NP	O
reported	report	r0106303	VBD	B-VP	O
82	82	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
,	,	,000	,	O	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
(	(	(000	(	O	O
27	27	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
cases	case	c0202	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
ofloxacin	ofloxacin	o14020205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
cases	case	c0202	NNS	B-NP	O
.	.	.000	.	O	O

Cotrimoxazole	Cotrimoxazole	c036050202040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
erythromycin	erythromycin	e60306050205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
reported	report	r0106303	VBD	B-VP	O
manic	manic	m0502	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
.	.	.000	.	O	O

Cases	Case	c0202	NNS	B-NP	O
reported	report	r0106303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
FDA	FDA	f300	NNP	I-NP	O
showed	show	s030	VBD	B-VP	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequently	frequently	f60205340	RB	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mania	mania	m050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Statistical	Statistical	s3030230204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
would	would	w043	MD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
correlative	correlative	c060403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
not	not	n030	RB	I-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
mania	mania	m050	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
antimicrobials	antimicrobial	a530502601042	NNS	B-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
,	,	,000	,	O	O
physicians	physician	p0202052	NNS	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	I-NP	O
reversibility	reversibility	r010620104030	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
clearly	clearly	c40640	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
antimicrobial	antimicrobial	a53050260104	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
mania	mania	m050	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
antimicrobial	antimicrobial	a53050260104	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
manic	manic	m0502	JJ	I-NP	B-Disease
episode	episode	e102030	NN	I-NP	O
among	among	a5052	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
demographic	demographic	d050260102	JJ	I-NP	O
populations	population	p010403052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
continue	continue	c053050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
persistent	persistent	p062023053	JJ	B-NP	O
affective	affective	a1023010	JJ	I-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
once	once	o520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
taking	take	t02052	VBG	I-VP	O
antibiotics	antibiotic	a53010302	NNS	B-NP	O
,	,	,000	,	O	O
subsides	subside	s0120302	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
elected	elect	e402303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
name	name	n050	VB	I-VP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
"	"	"000	``	O	O
antibiomania	antibiomania	a530105050	NN	B-NP	B-Disease
.	.	.000	.	O	O
"	"	"000	''	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
very	very	v060	RB	B-ADJP	O
uncommon	uncommon	u520505	JJ	I-ADJP	O
.	.	.000	.	O	O

Usually	Usually	u2040	RB	B-ADVP	O
they	they	t000	PRP	B-NP	O
occur	occur	o206	VBP	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
limb	limb	l051	NN	B-NP	O
peak	peak	p020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
choreatic	choreatic	c060302	JJ	I-NP	B-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
leftward	leftward	l013063	JJ	B-NP	O
and	and	a530	CC	I-NP	O
upward	upward	u1063	JJ	I-NP	O
deviations	deviation	d0103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gaze	gaze	g020	NN	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypothesize	hypothesize	h010302020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
denervation	denervation	d050610305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
caudate	caudate	c03030	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induce	induce	i53020	VBP	B-VP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
dysmenorrhea	dysmenorrhea	d02505060	NN	I-NP	B-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
over	over	o106	IN	B-PP	O
trial	trial	t604	NN	B-NP	O
.	.	.000	.	O	O

Primary	Primary	p605060	JJ	B-NP	O
dysmenorrhea	dysmenorrhea	d02505060	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
painful	painful	p05104	JJ	B-NP	O
uterine	uterine	u306050	JJ	I-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
hypersecretion	hypersecretion	h010620260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	O
prostaglandins	prostaglandin	p6023024053052	NNS	I-NP	B-Chemical
;	;	;000	:	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
choice	choice	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
myometrial	myometrial	m0503604	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	B-ADVP	O
targets	target	t062032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
relaxant	relaxant	r0402053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
donor	donor	d0506	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
dysmenorrhea	dysmenorrhea	d02505060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DCF	DCF	d210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
primary	primary	p605060	JJ	I-NP	O
dysmenorrhea	dysmenorrhea	d02505060	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
two	two	t000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
menstrual	menstrual	m0523604	JJ	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
,	,	,000	,	O	O
cross	cross	c602	AFX	O	O
-	-	-000	HYPH	B-VP	O
over	over	o106	RP	B-PRT	O
,	,	,000	,	O	O
controlled	control	c05360403	VBN	B-VP	O
design	design	d02025	NN	B-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	O	O
DCF	DCF	d210	NN	B-NP	B-Chemical
per	per	p060	IN	B-PP	O
os	o	o200	NNS	B-NP	O
or	or	o600	CC	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
patches	patch	p03202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
menses	mens	m05202	NNS	B-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
menstrual	menstrual	m0523604	JJ	B-NP	O
cramps	cramp	c60512	NNS	I-NP	O
became	become	b02050	VBD	B-VP	O
unendurable	unendurable	u5053060140	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
doses	dose	d0202	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
DCF	DCF	d210	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
transdermal	transdermal	t6052306504	JJ	I-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
3	3	3000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
needs	need	n032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
recorded	record	r0206303	VBD	B-VP	O
menstrual	menstrual	m0523604	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
at	at	a300	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
60	60	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
120	120	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
score	score	s2060	NN	I-NP	O
(	(	(000	(	O	O
DPI	DPI	d100	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
variable	variable	v060140	JJ	B-ADJP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
DPI	DPI	d100	NN	B-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
30th	30th	0000	JJ	I-NP	O
minute	minute	m05030	NN	I-NP	O
(	(	(000	(	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
;	;	;000	:	O	O
DCF	DCF	d210	NN	B-NP	B-Chemical
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
DCF	DCF	d210	NN	B-NP	B-Chemical
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
pelvic	pelvic	p04102	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
scores	score	s20602	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
or	or	o600	CC	I-ADVP	O
less	less	l020	RBR	B-ADJP	O
stable	stable	s30140	JJ	I-ADJP	O
after	after	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
for	for	f060	IN	B-PP	O
DFC	DFC	d120	NN	B-NP	O
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
:	:	:000	:	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
;	;	;000	:	O	O
DFC	DFC	d120	NN	B-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
two	two	t000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
:	:	:000	:	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
23	23	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
20	20	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
;	;	;000	:	O	O
DFC	DFC	d120	NN	B-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
59	59	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	B-Disease
back	back	b020	JJ	I-NP	I-Disease
pain	pain	p050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
relieved	relieve	r040103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Headache	Headache	h03020	PRP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
GTN	GTN	g350	NN	B-NP	B-Chemical
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
by	by	b000	IN	I-PP	O
DCF	DCF	d210	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
stopped	stop	s30103	VBD	B-VP	O
using	use	u2052	VBG	I-VP	O
GTN	GTN	g350	NN	B-NP	B-Chemical
because	because	b02020	IN	B-SBAR	O
headache	headache	h03020	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
-	-	-000	HYPH	I-NP	O
attributed	attribute	a36010303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	SYM	B-NP	O
became	become	b02050	VBD	B-VP	O
intolerable	intolerable	i5304060140	JJ	B-ADJP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
GTN	GTN	g350	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
by	by	b000	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
DCF	DCF	d210	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
dysmenorrhea	dysmenorrhea	d02505060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Temocapril	Temocapril	t050201604	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
long	long	l052	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
SH	SH	s000	NN	I-NP	O
group	group	g601	NN	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
modulates	modulate	m03040302	VBZ	B-VP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
temocapril	temocapril	t050201604	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
long	long	l052	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
SH	SH	s000	NN	I-NP	O
group	group	g601	NN	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
ACE	ACE	a200	NN	B-NP	O
)	)	)000	)	O	O
inhibitor	inhibitor	i5010306	NN	B-NP	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBN	B-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
,	,	,000	,	O	O
inhibited	inhibit	i5010303	VBD	B-VP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
and	and	a530	CC	O	O
prevented	prevent	p60105303	VBD	B-VP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Nephrosis	Nephrosis	n01060202	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15mg	15mg	0000	NN	B-NP	O
/	/	/000	SYM	O	O
100g	100g	0000	NN	B-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NNP	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
,	,	,000	,	O	O
i	i	i000	LS	B-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ii	ii	i000	LS	B-LST	O
)	)	)000	)	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
temocapril	temocapril	t050201604	NN	B-NP	B-Chemical
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
iii	iii	i000	LS	B-LST	O
)	)	)000	)	O	O
temocapril	temocapril	t050201604	NN	B-NP	B-Chemical
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
iv	iv	i100	NN	B-NP	O
)	)	)000	)	O	O
untreated	untreated	u5360303	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Temocapril	Temocapril	t050201604	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
at	at	a300	IN	B-PP	O
weeks	week	w020	NNS	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
14	14	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
each	each	e020	DT	B-NP	O
time	time	t050	NN	I-NP	O
point	point	p053	NN	I-NP	O
,	,	,000	,	O	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
histopathological	histopathological	h023010304020204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
morphometric	morphometric	m0610503602	JJ	B-NP	O
image	image	i5020	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
.	.	.000	.	O	O

Systolic	Systolic	s0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
high	high	h020	JJ	I-ADJP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
14	14	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
temocapril	temocapril	t050201604	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
,	,	,000	,	O	O
peaking	peak	p02052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
then	then	t050	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
rose	rise	r020	VBD	B-VP	O
again	again	a205	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
14	14	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Temocapril	Temocapril	t050201604	NNP	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
it	it	i300	PRP	B-NP	O
from	from	f605	IN	B-PP	O
weeks	week	w020	NNS	B-NP	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	B-PP	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	B-Disease
index	index	i5302	NN	I-NP	O
(	(	(000	(	O	O
GSI	GSI	g200	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
respectively	respectively	r02102301040	RB	B-NP	O
25	25	0000	CD	I-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
14	14	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	O	O
GSI	GSI	g200	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
808	808	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
tuft	tuft	t013	NN	I-NP	O
area	area	a600	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
Bowman	Bowman	b0505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
capsules	capsule	c0120402	NNS	I-NP	O
(	(	(000	(	O	O
GT	GT	g300	NN	B-NP	O
/	/	/000	SYM	B-NP	O
BC	BC	b200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
temocapril	temocapril	t050201604	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
temocapril	temocapril	t050201604	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
retarding	retard	r03063052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	O
progression	progression	p60260205	NN	I-NP	O
and	and	a530	CC	O	O
protected	protect	p60302303	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
neprotic	neprotic	n0160302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Pulmonary	Pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
in	in	i500	IN	B-PP	O
very	very	v060	RB	B-NP	O
preterm	preterm	p603065	JJ	I-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
three	three	t060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypoxaemia	hypoxaemia	h0102050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patent	patent	p03053	NN	B-NP	B-Disease
ductus	ductus	d02302	NN	I-NP	I-Disease
arteriosus	arteriosus	a63060202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
premature	premature	p60503060	JJ	B-NP	O
infants	infant	i510532	NNS	I-NP	O
born	bear	b065	VBN	B-VP	O
at	at	a300	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
28	28	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
.	.	.000	.	O	O

Echocardiography	Echocardiography	e202063026010	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
severely	severely	s0106040	RB	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
.	.	.000	.	O	O

Hypoxaemia	Hypoxaemia	h0102050	NN	B-NP	B-Disease
resolved	resolve	r0204103	VBD	B-VP	O
quickly	quickly	q0240	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
inhaled	inhale	i50403	VBN	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
investigators	investigator	i510230203062	NNS	B-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
pay	pay	p000	VBP	B-VP	O
close	close	c4020	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
to	to	t000	TO	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
if	if	i100	IN	B-SBAR	O
hypoxaemia	hypoxaemia	h0102050	NN	B-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
after	after	a1306	IN	B-SBAR	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Hyponatremia	Hyponatremia	h0105036050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
anti	anti	a530	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
diuretic	diuretic	d060302	JJ	I-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
reported	report	r0106303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
Vincristine	Vincristine	v0526023050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
over	over	o106	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
representation	representation	r016020530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Asians	Asian	a2052	NNPS	B-NP	O
?	?	?000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
used	use	u203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pharmaceutical	pharmaceutical	p06502030204	JJ	I-NP	O
company	company	c051050	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
global	global	g40104	JJ	B-NP	O
safety	safety	s01030	NN	I-NP	O
database	database	d0301020	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
reporting	reporting	r01063052	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
syndrome	syndrome	s0536050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
anti	anti	a530	AFX	B-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
diuretic	diuretic	d060302	JJ	I-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
(	(	(000	(	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
at	at	a300	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
risk	risk	r020	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
subgroups	subgroup	s0126012	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
searched	search	s06203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
Eli	Eli	e400	NNP	I-NP	O
Lilly	Lilly	l040	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Company	Company	c051050	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
computerized	computerize	c05103060203	VBD	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
event	event	e1053	NN	I-NP	O
database	database	d0301020	NN	I-NP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
November	November	n0105106	NNP	I-NP	O
1999	1999	0000	CD	I-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
76	76	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
reporting	reporting	r01063052	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
35	35	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
28	28	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
62	62	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
males	male	m0402	NNS	B-NP	O
.	.	.000	.	O	O

Approximately	Approximately	a16020503040	RB	B-NP	O
75	75	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
leukemia	leukemia	l02050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
lymphoma	lymphoma	l051050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
39	39	0000	CD	I-NP	O
reports	report	r010632	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
information	information	i510650305	NN	B-NP	O
on	on	o500	IN	B-PP	O
race	race	r020	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
racial	racial	r0204	JJ	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
Black	Black	b402	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
35	35	0000	CD	B-NP	O
Asian	Asian	a205	JJ	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
Asian	Asian	a205	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
at	at	a300	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
,	,	,000	,	O	O
physicians	physician	p0202052	NNS	B-NP	O
caring	care	c06052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
Asian	Asian	a205	JJ	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
serious	serious	s0602	JJ	I-NP	O
but	but	b030	CC	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
of	of	o100	IN	B-PP	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	O	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	O	O
6	6	6000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
mouse	mouse	m020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
susceptible	susceptible	s020130140	JJ	I-NP	O
strain	strain	s3605	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
a	a	a000	DT	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
strain	strain	s3605	NN	I-NP	O
(	(	(000	(	O	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
both	both	b030	DT	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CY	CY	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Inbred	Inbreed	i51603	VBN	B-NP	O
DBA	DBA	d100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	O	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	O	O
6	6	6000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
CY	CY	c000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
100	100	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
by	by	b000	IN	B-PP	O
light	light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
different	different	d0106053	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
by	by	b000	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	JJ	B-NP	O
CY	CY	c000	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
haemorrhagic	haemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
strains	strain	s36052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
repaired	repair	r010603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
about	about	a103	RB	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CY	CY	c000	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
ulcerous	ulcerous	u420602	JJ	B-ADJP	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
ulcerous	ulcerous	u420602	JJ	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
but	but	b030	CC	O	O
only	only	o540	RB	B-PP	O
in	in	i500	IN	I-PP	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	O	O
6	6	6000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
infiltration	infiltration	i5104360305	NN	B-NP	O
and	and	a530	CC	O	O
transepithelial	transepithelial	t605201030404	JJ	B-NP	O
passage	passage	p02020	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
lumen	lumen	l0505	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
frequent	frequent	f602053	JJ	B-NP	O
exfoliation	exfoliation	e21040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
urothelium	urothelium	u6030405	NN	I-NP	O
.	.	.000	.	O	O

Mast	Mast	m023	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
connective	connective	c05023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
muscular	muscular	m020406	JJ	I-NP	O
layers	layer	l062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
much	much	m020	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
number	number	n05106	NN	I-NP	O
in	in	i500	IN	B-PP	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	O	O
6	6	6000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
or	or	o600	CC	O	O
untreated	untreated	u5360303	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
disclosed	disclose	d0240203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
discoidal	discoidal	d020304	JJ	I-NP	O
vesicles	vesicle	v0202402	NNS	I-NP	O
normally	normally	n065040	RB	B-ADJP	O
present	present	p602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytoplasm	cytoplasm	c03014025	NN	I-NP	O
of	of	o100	IN	B-PP	O
surface	surface	s061020	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Instead	Instead	i52303	RB	B-ADVP	O
,	,	,000	,	O	O
numerous	numerous	n050602	JJ	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
vesicles	vesicle	v0202402	NNS	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	O	O
several	several	s010604	JJ	B-NP	O
dark	dark	d062	JJ	I-NP	O
granules	granule	g6050402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytoplasm	cytoplasm	c03014025	NN	I-NP	O
of	of	o100	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
from	from	f605	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
layers	layer	l062	NNS	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
still	still	s304	RB	B-ADVP	O
persisted	persist	p06202303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
100	100	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
delayed	delay	d0403	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
CY	CY	c000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
DBA	DBA	d100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	O	O
6	6	6000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
pathology	pathology	p0304020	NN	I-NP	O
resembles	resemble	r02051402	VBZ	B-VP	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
and	and	a530	CC	O	O
could	could	c043	MD	B-VP	O
perhaps	perhaps	p06012	RB	I-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
three	three	t060	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
weekly	weekly	w0240	JJ	I-NP	O
mitomycin	mitomycin	m03050205	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
gastric	gastric	g023602	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
FA	FA	f000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
new	new	n000	JJ	I-NP	O
multidrug	multidrug	m04303602	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
gastric	gastric	g023602	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
AGC	AGC	a200	NN	B-NP	B-Disease
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
weekly	weekly	w0240	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
FA	FA	f000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
mitomycin	mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MMC	MMC	m520	NN	B-NP	B-Chemical
)	)	)000	)	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
response	response	r0210520	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
regimens	regimen	r0205052	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
ELF	ELF	e410	NN	B-NP	O
,	,	,000	,	I-NP	O
FAM	FAM	f050	NN	I-NP	O
or	or	o600	CC	I-NP	O
FAMTX	FAMTX	f0532	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
promising	promising	p60502052	JJ	I-NP	O
median	median	m0305	JJ	I-NP	O
overall	overall	o10604	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
this	this	t020	DT	B-NP	O
MMC	MMC	m520	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
we	we	w000	PRP	B-NP	O
initiated	initiate	i5030303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	O
FA	FA	f000	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
weekly	weekly	w0240	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
MMC	MMC	m520	NN	I-NP	B-Chemical
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
From	From	f605	IN	B-PP	O
February	February	f016060	NNP	B-NP	O
,	,	,000	,	O	O
1998	1998	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
September	September	s01305106	NNP	B-NP	O
,	,	,000	,	O	O
2000	2000	0000	CD	B-NP	O
we	we	w000	PRP	B-NP	O
recruited	recruit	r0260303	VBD	B-VP	O
33	33	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
AGC	AGC	a200	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
weekly	weekly	w0240	RB	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
600	600	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
preceded	precede	p6020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
FA	FA	f000	NN	I-NP	B-Chemical
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
rest	rest	r023	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Bolus	Bolus	b0402	NN	B-NP	O
MMC	MMC	m520	NN	I-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
added	add	a303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
weekly	weekly	w0240	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
given	give	g0105	VBN	B-PP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
basis	basis	b0202	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
portable	portable	p0630140	JJ	B-NP	O
pump	pump	p051	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
57	57	0000	CD	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
male	male	m040	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
female	female	f05040	JJ	I-NP	O
ratio	ratio	r030	NN	I-NP	O
20	20	0000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
13	13	0000	CD	I-NP	O
;	;	;000	:	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
57	57	0000	CD	I-NP	O
(	(	(000	(	O	O
27	27	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
75	75	0000	CD	O	O
)	)	)000	)	O	O
years	year	y062	NNS	B-NP	O
;	;	;000	:	O	O
median	median	m0305	JJ	B-NP	O
WHO	WHO	w000	NN	I-NP	O
status	status	s30302	NN	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
AGC	AGC	a200	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
relapsed	relapsed	r0401203	JJ	I-NP	O
AGC	AGC	a200	NN	I-NP	B-Disease
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
was	be	w020	VBD	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
surviving	survive	s06101052	VBG	B-VP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
32	32	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
remission	remission	r050205	NN	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
partial	partial	p06304	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
45	45	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
15	15	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
27	27	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
progressive	progressive	p602602010	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
overall	overall	o10604	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
time	time	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
CI	CI	c000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-NP	O
progression	progression	p60260205	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
time	time	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
worst	worst	w0623	JJS	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
(	(	(000	(	O	O
%	%	%000	NN	B-NP	O
)	)	)000	)	O	O
observed	observe	o1206103	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
(	(	(000	(	O	O
CTC	CTC	c320	NN	B-NP	O
-	-	-000	HYPH	O	O
NCI	NCI	n200	NN	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
leukopenia	leukopenia	l0201050	NN	B-NP	B-Disease
45	45	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
33	33	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
vomitus	vomitus	v050302	NN	I-NP	B-Disease
24	24	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
36	36	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
stomatitis	stomatitis	s305030302	NN	B-NP	B-Disease
18	18	0000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
hand	hand	h053	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
foot	foot	f030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
12	12	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
HUS	HUS	h020	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
High	High	h020	JJ	O	O
-	-	-000	HYPH	O	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	O
FA	FA	f000	NN	I-NP	B-Chemical
/	/	/000	SYM	O	O
MMC	MMC	m520	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	B-VP	O
tolerated	tolerate	t04060303	VBN	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
AGC	AGC	a200	NN	B-NP	B-Disease
(	(	(000	(	O	O
objective	objective	o12023010	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
54	54	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
regimens	regimen	r0205052	NNS	B-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
possibly	possibly	p020140	RB	B-NP	O
HUS	HUS	h020	NNS	I-NP	B-Disease
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
.	.	.000	.	O	O

Persistent	Persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
type	type	t010	NN	I-NP	I-Disease
1	1	1000	CD	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
children	child	c043605	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Prolonged	Prolonged	p60405203	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
documented	document	d020505303	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
restricted	restrict	r023602303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
protease	protease	p603020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
monitor	monitor	m050306	VB	I-VP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
human	human	h0505	JJ	I-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
type	type	t010	NN	I-NP	I-Disease
1	1	1000	CD	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
children	child	c043605	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Urinary	Urinary	u605060	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
,	,	,000	,	O	O
albumin	albumin	a410505	NN	B-NP	O
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythrocytes	erythrocyte	e60306020302	NNS	B-NP	O
,	,	,000	,	I-NP	O
leukocytes	leukocyte	l02020302	NNS	I-NP	O
,	,	,000	,	I-NP	O
bacteria	bacteria	b023060	NNS	I-NP	O
and	and	a530	CC	I-NP	O
crystals	crystal	c6023042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
culture	culture	c043060	NN	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
96	96	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
routinely	routinely	r0305040	RB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
.	.	.000	.	O	O

Steady	Steady	s3030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
4	4	4000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
75	75	0000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
micro	micro	m0260	NN	B-NP	O
L	L	l000	NN	I-NP	O
in	in	i500	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
2	2	2000	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
visits	visit	v02032	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
96	96	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
53	53	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Persistent	Persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mild	mild	m043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
/	/	/000	SYM	B-VP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
ratio	ratio	r030	NN	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
microscopic	microscopic	m026020102	JJ	B-NP	O
hematuria	hematuria	h0503060	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
>	>	>000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
above	above	a1010	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
was	be	w020	VBD	B-VP	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
96	96	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Children	Child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
had	have	h030	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
above	above	a1010	IN	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
younger	young	y05206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
curve	curve	c0610	NN	I-NP	O
>	>	>000	JJR	B-NP	O
19	19	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
x	x	x000	SYM	B-NP	O
h	h	h000	NN	B-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
>	>	>000	SYM	O	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
,	,	,000	,	O	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Subsequently	Subsequently	s0120205340	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
/	/	/000	SYM	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
ratios	ratio	r0302	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
zero	zero	z060	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Children	Child	c043605	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Children	Child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
above	above	a1010	IN	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

Younger	Younger	y05206	NN	B-NP	O
children	child	c043605	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nephrolithiasis	nephrolithiasis	n010604030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Indinavir	Indinavir	i53050106	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
closely	closely	c402040	RB	B-ADVP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
sterile	sterile	s306040	JJ	I-NP	O
leukocyturia	leukocyturia	l020203060	NN	I-NP	B-Disease
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
<	<	<000	SYM	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
curve	curve	c0610	NN	I-NP	O
of	of	o100	IN	B-PP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
>	>	>000	SYM	O	O
19	19	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
x	x	x000	SYM	O	O
h	h	h000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
C	C	c000	NN	I-NP	O
(	(	(000	(	O	O
max	max	m020	NN	B-NP	O
)	)	)000	)	O	O
>	>	>000	SYM	O	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
.	.	.000	.	O	O

Utility	Utility	u304030	NN	B-NP	O
of	of	o100	IN	B-PP	O
troponin	troponin	t6010505	NN	B-NP	O
I	I	i000	CD	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NN	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
and	and	a530	CC	O	O
market	market	m06203	NN	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
not	not	n030	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
make	make	m020	VBP	B-VP	O
accurate	accurate	a206030	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MI	MI	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
difficult	difficult	d0102043	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Troponin	Troponin	t6010505	NN	B-NP	O
sampling	sampling	s0514052	NN	I-NP	O
may	may	m000	MD	B-VP	O
offer	offer	o106	VB	I-VP	O
greater	great	g60306	JJR	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
utility	utility	u304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
outcomes	outcome	o0320502	NNS	B-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
troponin	troponin	t6010505	NN	B-NP	O
positivity	positivity	p020301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
admitted	admit	a350303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
exclusion	exclusion	e240205	NN	B-NP	O
of	of	o100	IN	B-PP	O
MI	MI	m000	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Outcomes	Outcome	o0320502	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
admitted	admit	a350303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
MI	MI	m000	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
rule	rule	r040	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
in	in	i500	IN	B-PP	O
protocol	protocol	p6030204	NN	B-NP	O
that	that	t030	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
serial	serial	s0604	JJ	B-NP	O
sampling	sampling	s0514052	NN	I-NP	O
of	of	o100	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
(	(	(000	(	O	O
CK	CK	c200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
troponin	troponin	t6010505	NN	I-NP	O
I	I	i000	CD	I-NP	O
(	(	(000	(	O	O
cTnI	cTnI	c350	NN	B-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Outcomes	Outcome	o0320502	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	O	O
MB	MB	m100	NN	B-NP	O
MI	MI	m000	NN	I-NP	B-Disease
(	(	(000	(	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
[	[	[000	(	O	O
(	(	(000	(	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
x	x	x000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
total	total	t0304	JJ	B-NP	O
CK	CK	c200	NN	I-NP	O
]	]	]000	)	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
246	246	0000	CD	I-NP	O
admitted	admit	a350303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
34	34	0000	CD	B-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
met	meet	m030	VBD	B-VP	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
MI	MI	m000	NN	B-NP	B-Disease
and	and	a530	CC	O	O
38	38	0000	CD	B-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
cTnI	cTnI	c350	NN	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
.	.	.000	.	O	O

Angiography	Angiography	a52026010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
29	29	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
38	38	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
cTnI	cTnI	c350	NN	B-NP	O
-	-	-000	HYPH	O	O
positive	positive	p0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
25	25	0000	CD	B-NP	O
(	(	(000	(	O	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
cTnI	cTnI	c350	NN	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
met	meet	m030	VBD	B-VP	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	O	O
MB	MB	m100	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
MI	MI	m000	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
CK	CK	c200	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
MB	MB	m100	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
.	.	.000	.	O	O

Sensitivities	Sensitivity	s05203010302	NNS	B-NP	O
,	,	,000	,	O	O
specificities	specificity	s10201020302	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
positive	positive	p0203010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
predicting	predict	p603023052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
or	or	o600	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
both	both	b030	CC	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
cTnI	cTnI	c350	NN	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cTnI	cTnI	c350	NN	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
meet	meet	m030	VBP	B-VP	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
MB	MB	m100	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
MI	MI	m000	NN	B-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
have	have	h010	VB	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Troponin	Troponin	t6010505	NN	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
an	an	a500	DT	B-NP	O
equivalent	equivalent	e20104053	JJ	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
for	for	f060	IN	B-PP	O
diagnosing	diagnose	d02502052	VBG	B-VP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
suspected	suspect	s02102303	VBN	B-NP	O
MI	MI	m000	NN	I-NP	B-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
nicergoline	nicergoline	n0206204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Sermion	Sermion	s06505	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
(	(	(000	(	O	O
AIN	AIN	a050	NN	B-NP	B-Disease
)	)	)000	)	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
nicergoline	nicergoline	n0206204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Sermion	Sermion	s06505	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
fever	fever	f0106	NN	B-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Before	Before	b01060	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
nicergoline	nicergoline	n0206204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bendazac	bendazac	b0530202	NN	I-NP	B-Chemical
lysine	lysine	l02050	NN	I-NP	I-Chemical
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
retinal	retinal	r030504	JJ	B-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
ophthalmologic	ophthalmologic	o103045040202	JJ	B-NP	O
department	department	d010635053	NN	I-NP	O
.	.	.000	.	O	O

Thereafter	Thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
skin	skin	s205	NN	I-NP	B-Disease
rash	rash	r020	NN	I-NP	I-Disease
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
arthralgia	arthralgia	a63060420	NN	B-NP	B-Disease
and	and	a530	CC	O	O
fever	fever	f0106	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
findings	finding	f053052	NNS	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
)	)	)000	)	O	O
suggested	suggest	s0202303	VBD	B-VP	O
AIN	AIN	a050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pathologic	pathologic	p03040202	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
transformation	transformation	t605210650305	NN	I-NP	O
test	test	t023	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
result	result	r02043	NN	I-NP	O
against	against	a20523	IN	B-PP	O
nicergoline	nicergoline	n0206204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
consisted	consist	c05202303	VBN	I-VP	O
of	of	o100	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
nicergoline	nicergoline	n0206204050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
his	his	h020	PRP$	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
recovered	recover	r02010603	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicergoline	nicergoline	n0206204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
AIN	AIN	a050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
complicated	complicate	c0514020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CRF	CRF	c610	NN	B-NP	B-Disease
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NMS	NMS	n520	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
levomepromazine	levomepromazine	l01050160502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NMS	NMS	n520	NN	B-NP	B-Disease
,	,	,000	,	O	O
massive	massive	m02010	JJ	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
NMS	NMS	n520	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
CRF	CRF	c610	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
complicated	complicate	c0514020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intestinal	intestinal	i530230504	JJ	B-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
and	and	a530	CC	O	O
needs	need	n032	VBZ	B-VP	O
special	special	s10204	JJ	B-NP	O
caution	caution	c0305	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
in	in	i500	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	O	O
left	leave	l013	VBN	B-VP	O
-	-	-000	HYPH	O	O
pawed	paw	p030	VBN	B-VP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
staining	staining	s305052	NN	I-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
asymmetrical	asymmetrical	a2050360204	JJ	I-NP	O
breakdown	breakdown	b602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
(	(	(000	(	O	O
BBB	BBB	b100	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Paw	Paw	p000	NN	B-NP	O
preference	preference	p601060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
food	food	f030	NN	I-NP	O
reaching	reach	r02052	VBG	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Adrenaline	Adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
destroy	destroy	d02360	VB	I-VP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
triphenyltetrazolium	triphenyltetrazolium	t60105043036020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TTC	TTC	t320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
staining	staining	s305052	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
slices	slice	s40202	NNS	I-NP	O
just	just	j023	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
giving	give	g01052	VBG	B-VP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
s	s	s000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
whole	whole	w040	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
sections	section	s023052	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
with	with	w030	IN	B-PP	O
TTC	TTC	t320	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
large	large	l0620	JJ	B-NP	O
unstained	unstained	u5230503	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
in	in	i500	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
pawed	paw	p030	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
vice	vice	v020	NN	B-NP	O
versa	versa	v0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
pawed	paw	p030	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
breakdown	breakdown	b602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
BBB	BBB	b100	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
explained	explain	e2140503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
asymmetric	asymmetric	a20503602	JJ	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
depending	depend	d01053052	VBG	B-VP	O
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
paw	paw	p000	NN	I-NP	O
preference	preference	p601060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
contralateral	contralateral	c053604030604	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
control	control	c053604	NN	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
determining	determine	d0306505052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dominant	dominant	d0505053	JJ	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
hemisphere	hemisphere	h05021060	NN	I-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

Carvedilol	Carvedilol	c061030404	NN	B-NP	B-Chemical
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
cytopathic	cytopathic	c03010302	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
mediate	mediate	m03030	VB	I-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
key	key	k000	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenic	pathogenic	p03020502	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-NP	O
carvedilol	carvedilol	c061030404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
nonselective	nonselective	n05204023010	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
with	with	w030	IN	B-PP	O
potent	potent	p03053	JJ	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
,	,	,000	,	O	O
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
bioenergetic	bioenergetic	b050620302	JJ	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
subchronic	subchronic	s012060502	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
carvedilol	carvedilol	c061030404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
depressed	depressed	d0160203	JJ	B-NP	O
rates	rate	r0302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
state	state	s3030	NN	B-NP	O
3	3	3000	CD	I-NP	O
respiration	respiration	r021060305	NN	I-NP	O
(	(	(000	(	O	O
336	336	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
26	26	0000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
425	425	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
53	53	0000	CD	B-NP	O
natom	natom	n0305	NN	I-NP	O
O	O	o000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
/	/	/000	SYM	I-NP	O
mg	mg	m200	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
(	(	(000	(	O	O
RCR	RCR	r260	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
versus	versus	v06202	IN	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
loading	load	l03052	VBG	B-VP	O
capacity	capacity	c0102030	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NADH	NADH	n030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
from	from	f605	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
RCR	RCR	r260	NN	B-NP	O
for	for	f060	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
versus	versus	v06202	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
for	for	f060	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Coadministration	Coadministration	c0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
carvedilol	carvedilol	c061030404	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cellular	cellular	c040406	JJ	B-NP	O
vacuolization	vacuolization	v0204020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
and	and	a530	CC	O	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
respiration	respiration	r021060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
heart	heart	h063	NN	B-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

Carvedilol	Carvedilol	c061030404	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
loading	load	l03052	VBG	B-VP	O
capacity	capacity	c0102030	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
complexes	complex	c05140202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Carvedilol	Carvedilol	c061030404	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
itself	itself	i32041	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
or	or	o600	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
carvedilol	carvedilol	c061030404	NN	B-NP	B-Chemical
against	against	a20523	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
may	may	m000	MD	B-VP	O
afford	afford	a1063	VB	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
advantage	advantage	a31053020	NN	I-NP	O
in	in	i500	IN	B-PP	O
minimizing	minimize	m050502052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
accompanies	accompany	a20510502	VBZ	B-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
influenced	influence	i51405203	VBN	I-ADJP	O
by	by	b000	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
and	and	a530	CC	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	B-Disease
the	the	t000	DT	B-NP	I-Disease
locomotor	locomotor	l02050306	NN	I-NP	I-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
seems	seem	s052	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
A1	A1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
A2	A2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxyethyl	carboxyethyl	c061020304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
phenethylamino	phenethylamino	p05030405050	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
5	5	5000	CD	B-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
ethylcarboxamidoadenosine	ethylcarboxamidoadenosine	e3042061020503030502050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
CGS	CGS	c200	NN	B-NP	B-Chemical
21680	21680	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
A2A	A2A	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
N6	N6	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
cyclopentyladenosine	cyclopentyladenosine	c0240105304030502050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
A1	A1	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
ethylcarboxamidoadenosine	ethylcarboxamidoadenosine	e3042061020503030502050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NECA	NECA	n020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
A2	A2	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
A1	A1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
dependently	dependently	d0105305340	RB	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

CPA	CPA	c100	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
action	action	a2305	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
motility	motility	m0304030	NN	B-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
CGS	CGS	c200	NN	B-NP	B-Chemical
21680	21680	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
NECA	NECA	n020	NNP	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBN	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
although	although	a43020	IN	B-SBAR	O
agonists	agonist	a2050232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
A1	A1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
seem	seem	s050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
stronger	strong	s3605206	JJR	B-NP	O
influence	influence	i5140520	NN	I-NP	O
on	on	o500	IN	B-PP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
A2	A2	0000	NN	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
by	by	b000	IN	B-PP	O
DMPX	DMPX	d512	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dimethyl	dimethyl	d050304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
propargylxanthine	propargylxanthine	p601062042053050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
enhanced	enhance	e505203	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
.	.	.000	.	O	O

CPT	CPT	c130	NN	B-NP	B-Chemical
(	(	(000	(	O	O
8	8	8000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
cyclopentyltheophylline	cyclopentyltheophylline	c024010530430104050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
A1	A1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
any	any	a500	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
doses	dose	d0202	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
active	active	a23010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
A2	A2	0000	NN	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
DMPX	DMPX	d512	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
all	all	a400	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
(	(	(000	(	O	O
A1	A1	0000	NN	B-NP	O
and	and	a530	CC	O	O
A2	A2	0000	NN	B-NP	O
)	)	)000	)	O	O
reduce	reduce	r03020	VBP	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
influenced	influence	i51405203	VBN	I-ADJP	O
by	by	b000	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
(	(	(000	(	O	O
particularly	particularly	p06302040640	RB	B-NP	O
A1	A1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-SBAR	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradyarrhythmia	bradyarrhythmia	b6030603050	NN	B-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
prior	prior	p606	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
(	(	(000	(	O	O
AF	AF	a100	NN	B-NP	B-Disease
)	)	)000	)	O	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradyarrhythmia	bradyarrhythmia	b6030603050	NN	B-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Reports	Report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
bradyarrhythmia	bradyarrhythmia	b6030603050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
are	be	a600	VBP	B-VP	O
infrequent	infrequent	i51602053	JJ	B-ADJP	O
and	and	a530	CC	O	O
limited	limited	l050303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
studies	study	s30302	NNS	B-NP	O
assessing	assess	a202052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
,	,	,000	,	O	O
770	770	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
age	age	a200	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
65	65	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
AF	AF	a100	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
provincewide	provincewide	p601052030	JJ	I-NP	O
database	database	d0301020	NN	I-NP	O
of	of	o100	IN	B-PP	O
Quebec	Quebec	q0102	NNP	B-NP	O
residents	resident	r02030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MI	MI	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
between	between	b0305	IN	B-PP	O
1991	1991	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1999	1999	0000	CD	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
nested	nest	n02303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
design	design	d02025	NN	I-NP	O
,	,	,000	,	O	O
477	477	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bradyarrhythmia	bradyarrhythmia	b6030603050	NN	B-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
were	be	w060	VBD	B-VP	O
matched	match	m03203	VBN	I-VP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
:	:	:000	:	O	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
908	908	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Multivariable	Multivariable	m04301060140	JJ	B-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
pacemaker	pacemaker	p02050206	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
controlling	control	c053604052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
and	and	a530	CC	O	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
sotalol	sotalol	s030404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Class	Class	c402	NN	B-NP	O
I	I	i000	CD	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
blockers	blocker	b402062	NNS	B-NP	O
,	,	,000	,	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pacemaker	pacemaker	p02050206	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
14	14	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
30	30	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
54	54	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
modified	modify	m030103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
gender	gender	g05306	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
versus	versus	v06202	IN	B-PP	O
men	man	m050	NNS	B-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
:	:	:000	:	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
86	86	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
70	70	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
75	75	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	I-NP	O
OR	OR	o600	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
52	52	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
80	80	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
89	89	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Digoxin	Digoxin	d020205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
other	other	o306	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pacemaker	pacemaker	p02050206	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
78	78	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
37	37	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
31	31	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
AF	AF	a100	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradyarrhythmia	bradyarrhythmia	b6030603050	NN	B-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
augmented	augmented	a02505303	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pacemaker	pacemaker	p02050206	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
requires	require	r020602	VBZ	B-VP	O
further	further	f06306	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
morphologic	morphologic	m061040202	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
morphologic	morphologic	m061040202	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
urothelium	urothelium	u6030405	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Nonsteroidal	Nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
poorly	poorly	p0640	RB	I-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
and	and	a530	CC	O	O
under	under	u5306	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
reported	report	r0106303	VBN	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
tiaprofenic	tiaprofenic	t016010502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
established	establish	e230140203	VBN	I-VP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
oral	oral	o604	JJ	B-NP	O
indomethacin	indomethacin	i5305030205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
killed	kill	k0403	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
bladders	bladder	b403062	NNS	I-NP	O
removed	remove	r050103	VBN	B-VP	O
for	for	f060	IN	B-PP	O
light	light	l0203	NN	B-NP	O
and	and	a530	CC	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
light	light	l0203	NN	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
some	some	s050	DT	B-NP	O
focal	focal	f0204	JJ	I-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
prominent	prominent	p60505053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
indomethacin	indomethacin	i5305030205	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mast	mast	m023	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mucosa	mucosa	m02020	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
penetration	penetration	p050360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lanthanum	lanthanum	l0530505	NN	B-NP	B-Chemical
nitrate	nitrate	n036030	NN	I-NP	I-Chemical
through	through	t06020	IN	B-PP	O
intercellular	intercellular	i53062040406	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
mast	mast	m023	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
and	and	a530	CC	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
histopathologic	histopathologic	h0230103040202	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
typical	typical	t010204	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
leaky	leaky	l020	JJ	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
and	and	a530	CC	O	O
mucosal	mucosal	m020204	JJ	B-NP	O
mastocytosis	mastocytosis	m02302030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
true	true	t600	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
clarified	clarify	c4060103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prospective	prospective	p6021023010	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antiangiogenic	antiangiogenic	a53052020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
solid	solid	s0403	JJ	I-NP	O
and	and	a530	CC	I-NP	O
haematological	haematological	h050304020204	JJ	I-NP	B-Disease
malignancies	malignancy	m0402505202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Thalidomide	Thalidomide	t040305030	NN	B-NP	B-Chemical
blocks	block	b402	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiogenic	angiogenic	a52020502	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
bFGF	bFGF	b121	NN	B-NP	O
,	,	,000	,	I-NP	O
VEGF	VEGF	v021	NN	I-NP	O
and	and	a530	CC	I-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
undertook	undertake	u5306302	VBD	B-VP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
study	study	s3030	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
thalidomide	thalidomide	t040305030	IN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
with	with	w030	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
109	109	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
107	107	0000	CD	I-NP	O
,	,	,000	,	O	O
range	range	r0520	NN	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	O	O
184	184	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
regular	regular	r020406	JJ	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
(	(	(000	(	O	O
PSA	PSA	p200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
urea	urea	u600	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
electrolytes	electrolyte	e40236040302	NNS	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
bFGF	bFGF	b121	NN	I-NP	O
and	and	a530	CC	I-NP	O
VEGF	VEGF	v021	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
men	man	m050	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
PSA	PSA	p200	NN	I-NP	O
of	of	o100	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
sustained	sustain	s0230503	VBN	B-VP	O
throughout	throughout	t060203	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
16	16	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
2	2	2000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
six	six	s020	CD	B-NP	O
(	(	(000	(	O	O
37	37	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
absolute	absolute	a1204030	JJ	B-NP	O
PSA	PSA	p200	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
48	48	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Increasing	Increase	i52602052	VBG	B-VP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
bFGF	bFGF	b121	NN	I-NP	O
and	and	a530	CC	I-NP	O
VEGF	VEGF	v021	NN	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
;	;	;000	:	O	O
five	five	f010	CD	B-NP	O
of	of	o100	IN	I-NP	O
six	six	s020	CD	I-NP	O
men	man	m050	NNS	I-NP	O
who	who	w000	WP	B-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
PSA	PSA	p200	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
bFGF	bFGF	b121	NN	B-NP	O
and	and	a530	CC	I-NP	O
VEGF	VEGF	v021	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	I-NP	O
four	four	f060	CD	I-NP	O
men	man	m050	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
rising	rise	r02052	VBG	I-NP	O
PSA	PSA	p200	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
growth	growth	g6030	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
constipation	constipation	c0523010305	NN	B-NP	B-Disease
,	,	,000	,	O	O
morning	morning	m065052	NN	B-NP	O
drowsiness	drowsiness	d6020502	NN	I-NP	B-Disease
,	,	,000	,	O	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
rash	rash	r020	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
by	by	b000	IN	B-PP	O
three	three	t060	CD	B-NP	O
men	man	m050	NNS	I-NP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
sensory	sensory	s052060	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
seven	seven	s0105	CD	I-NP	O
men	man	m050	NNS	I-NP	O
who	who	w000	WP	B-NP	O
completed	complete	c05140303	VBD	B-VP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
subclinical	subclinical	s0124050204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
before	before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
seven	seven	s0105	CD	I-NP	O
at	at	a300	IN	B-PP	O
repeat	repeat	r0103	NN	B-NP	O
testing	testing	t023052	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
option	option	o1305	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
failed	fail	f0403	VBN	I-VP	O
other	other	o306	JJ	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
provided	provide	p6010303	VBN	B-VP	O
close	close	c4020	RB	B-ADVP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
is	be	i200	VBZ	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
lumbar	lumbar	l05106	NN	B-NP	O
plexus	plexus	p40202	NN	I-NP	O
block	block	b402	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
OBJECTIVES	OBJECTIVES	o120230102	NNS	I-NP	O
:	:	:000	:	O	O
Central	Central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
cardiac	cardiac	c06302	JJ	B-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Levobupivacaine	Levobupivacaine	l0101010102050	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pure	pure	p060	JJ	I-NP	O
S	S	s000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
enantiomer	enantiomer	e50530506	NN	B-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
safety	safety	s01030	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
grand	grand	g6053	JJ	B-NP	B-Disease
mal	mal	m040	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
accidental	accidental	a20305304	JJ	B-NP	O
intravascular	intravascular	i53601020406	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
REPORT	REPORT	r01063	NN	I-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
presenting	present	p602053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
elective	elective	e4023010	JJ	B-NP	O
orthopedic	orthopedic	o63010302	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
limb	limb	l051	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
blockade	blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lumbar	lumbar	l05106	JJ	I-NP	O
plexus	plexus	p40202	NN	I-NP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
.	.	.000	.	O	O

Immediately	Immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
grand	grand	g6053	JJ	B-NP	B-Disease
mal	mal	m040	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
aspiration	aspiration	a21060305	NN	I-NP	O
for	for	f060	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
thiopental	thiopental	t0105304	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
masked	mask	m0203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
unintentional	unintentional	u50530530504	JJ	I-NP	O
intravascular	intravascular	i53601020406	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
safer	safe	s0106	JJR	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
profile	profile	p601040	NN	I-NP	O
than	than	t050	IN	B-PP	O
racemic	racemic	r020502	JJ	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
adequate	adequate	a302030	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
reach	reach	r020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
circulation	circulation	c062040305	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
will	will	w040	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
central	central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
manifestations	manifestation	m050102303052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
2	2	2000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-ADVP	O
(	(	(000	(	O	O
within	within	w0305	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
TdP	TdP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Consistent	Consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
TdP	TdP	t310	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
context	context	c053023	NN	I-NP	O
of	of	o100	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
exacerbating	exacerbating	e20206103052	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
digoxin	digoxin	d020205	NN	I-NP	B-Chemical
excess	excess	e202	NN	I-NP	O
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
QT	QT	q300	NN	I-NP	O
during	during	d06052	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
prompted	prompt	p6051303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
TdP	TdP	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
exacerbates	exacerbate	e2020610302	NNS	I-NP	O
acquired	acquire	a20603	VBN	B-VP	O
TdP	TdP	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
speculate	speculate	s10204030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
vagal	vagal	v0204	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
during	during	d06052	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
vagal	vagal	v0204	JJ	I-NP	O
maneuver	maneuver	m050106	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
context	context	c053023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
proarrhythmia	proarrhythmia	p60603050	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
TdP	TdP	t310	NN	B-NP	B-Disease
despite	despite	d021030	IN	B-PP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hypomagnesemia	hypomagnesemia	h010502502050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Anaesthetic	Anaesthetic	a50230302	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
myotonia	myotonia	m03050	NN	B-NP	B-Disease
congenita	congenita	c05205030	NN	I-NP	I-Disease
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	O	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
myotonic	myotonic	m030502	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Myotonia	Myotonia	m03050	NN	B-NP	B-Disease
congenita	congenita	c05205030	NN	I-NP	I-Disease
(	(	(000	(	O	O
MC	MC	m200	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
defect	defect	d01023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
skeletal	skeletal	s2040304	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
chloride	chloride	c0406030	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
sustained	sustained	s0230503	JJ	B-NP	B-Disease
membrane	membrane	m0516050	NN	I-NP	I-Disease
depolarisation	depolarisation	d010406020305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
32	32	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
and	and	a530	CC	O	O
secondary	secondary	s02053060	JJ	B-NP	O
ventilation	ventilation	v053040305	NN	I-NP	O
difficulties	difficulty	d010204302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
preoperative	preoperative	p6010603010	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
spasms	spasm	s10252	NNS	I-NP	I-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
proceeded	proceed	p6020303	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
subsequently	subsequently	s0120205340	RB	B-VP	O
questioned	question	q0230503	VBN	I-VP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
minor	minor	m0506	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
suggesting	suggest	s02023052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
myotonic	myotonic	m030502	JJ	I-NP	B-Disease
condition	condition	c0530305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Myotonia	Myotonia	m03050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
on	on	o500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
EMG	EMG	e520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
MC	MC	m200	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
genetically	genetically	g050302040	RB	B-ADVP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
nor	nor	n060	CC	O	O
the	the	t000	DT	B-NP	O
anaesthetist	anaesthetist	a502303023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
before	before	b01060	IN	B-PP	O
this	this	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
give	give	g010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
overview	overview	o10610	NN	I-NP	O
of	of	o100	IN	B-PP	O
ion	ion	i050	NN	B-NP	B-Disease
channel	channel	c0504	NN	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
including	include	i52403052	VBG	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
hyperthermia	hyperthermia	h010630650	NN	I-NP	I-Disease
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
considerations	consideration	c052030603052	NNS	I-NP	O
.	.	.000	.	O	O

Respiratory	Respiratory	r0210603060	JJ	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Apnea	Apnea	a150	NNP	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
occur	occur	o206	VB	I-VP	O
during	during	d06052	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
systematic	systematic	s023050302	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ictal	ictal	i2304	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
few	few	f000	JJ	B-ADJP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
regarding	regard	r02063052	VBG	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
interictal	interictal	i530602304	JJ	B-NP	O
periods	period	p06032	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
are	be	a600	VBP	B-VP	O
scarce	scarce	s20620	JJ	B-ADJP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
generate	generate	g0506030	VB	I-VP	O
information	information	i510650305	NN	B-NP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
interictal	interictal	i530602304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Twelve	Twelve	t0410	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
six	six	s020	CD	B-NP	O
chronically	chronically	c060502040	RB	I-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
anesthetized	anesthetize	a5023030203	VBN	I-VP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-NP	O
tracheotomies	tracheotomy	t602030502	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
hyperventilation	hyperventilation	h01061053040305	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
hypoventilation	hypoventilation	h0101053040305	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Breathing	Breathing	b603052	NN	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
thoracic	thoracic	t060202	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
and	and	a530	CC	O	O
forced	force	f06203	VBN	B-NP	O
air	air	a060	NN	I-NP	O
to	to	t000	TO	B-VP	O
flow	flow	f400	VB	I-VP	O
tidally	tidally	t03040	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
pneumotachograph	pneumotachograph	p5050302026010	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
flow	flow	f400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
transducer	transducer	t605230206	NN	I-NP	O
,	,	,000	,	O	O
passed	pass	p0203	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
polygraph	polygraph	p04026010	NN	I-NP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
computer	computer	c0510306	NN	I-NP	O
with	with	w030	IN	B-PP	O
custom	custom	c02305	NN	B-NP	O
software	software	s013060	NN	I-NP	O
that	that	t030	WDT	B-NP	O
derived	derive	d060103	VBD	B-VP	O
ventilation	ventilation	v053040305	NN	B-NP	O
(	(	(000	(	O	O
VE	VE	v000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
tidal	tidal	t0304	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
(	(	(000	(	O	O
VT	VT	v300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
inspiratory	inspiratory	i5210603060	JJ	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
TI	TI	t000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
expiratory	expiratory	e210603060	JJ	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
TE	TE	t000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
breathing	breathing	b603052	NN	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
(	(	(000	(	O	O
f	f	f000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
mean	mean	m050	JJ	B-NP	O
inspiratory	inspiratory	i5210603060	JJ	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
VT	VT	v300	NN	B-NP	O
/	/	/000	SYM	O	O
TI	TI	t000	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
breath	breath	b6030	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
by	by	b000	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
breath	breath	b6030	NN	I-NP	O
basis	basis	b0202	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
hyperventilation	hyperventilation	h01061053040305	NN	I-NP	B-Disease
maneuver	maneuver	m050106	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
ventilation	ventilation	v053040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
VE	VE	v000	NN	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
VE	VE	v000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
increase	increase	i526020	NN	B-NP	O
in	in	i500	IN	B-PP	O
TE	TE	t000	NN	B-NP	O
peak	peak	p020	NN	I-NP	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypoventilation	hypoventilation	h0101053040305	NN	I-NP	O
maneuver	maneuver	m050106	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
Paco2	Paco2	0000	NN	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
VE	VE	v000	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
VE	VE	v000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
TE	TE	t000	NN	B-NP	O
peak	peak	p020	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
KCN	KCN	k250	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
chemoreception	chemoreception	c05060201305	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
ventilation	ventilation	v053040305	NN	B-NP	O
,	,	,000	,	O	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
VE	VE	v000	NN	B-NP	O
for	for	f060	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
altered	altered	a430603	JJ	I-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
react	react	r023	VB	I-VP	O
to	to	t000	TO	B-PP	O
(	(	(000	(	O	O
or	or	o600	CC	O	O
compensate	compensate	c051052030	VB	B-VP	O
for	for	f060	IN	B-PP	O
)	)	)000	)	O	O
blood	blood	b403	NN	B-NP	O
gas	gas	g020	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
ventilation	ventilation	v053040305	NN	B-NP	O
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
centrally	centrally	c0536040	RB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
speculate	speculate	s10204030	VBP	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
relation	relation	r040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
different	different	d0106053	JJ	B-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
myeloencephalopathy	myeloencephalopathy	m04052010401030	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
vincristine	vincristine	v0526023050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Vincristine	Vincristine	v0526023050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
accidentally	accidentally	a203053040	RB	I-VP	O
given	give	g0105	VBN	I-VP	O
intrathecally	intrathecally	i5360302040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
child	child	c043	NN	I-NP	O
with	with	w030	IN	B-PP	O
leukaemia	leukaemia	l02050	NN	B-NP	B-Disease
,	,	,000	,	O	O
producing	produce	p60302052	VBG	B-VP	O
sensory	sensory	s052060	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
motor	motor	m0306	NN	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

Separate	Separate	s0106030	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
for	for	f060	IN	B-PP	O
administering	administer	a350502306052	VBG	B-VP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

Progesterone	Progesterone	p60202306050	NN	B-NP	B-Chemical
potentiation	potentiation	p030530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
arrhythmogenicity	arrhythmogenicity	a60305020502030	NN	I-NP	O
in	in	i500	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
beating	beat	b03052	VBG	B-VP	O
rat	rat	r030	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
arrhythmogenicity	arrhythmogenicity	a60305020502030	NN	I-NP	O
in	in	i500	IN	B-PP	O
beating	beat	b03052	VBG	B-VP	O
rat	rat	r030	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
myocyte	myocyte	m02030	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
determining	determine	d0306505052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
AD50	AD50	0000	NN	I-NP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
caused	cause	c0203	VBD	B-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
beating	beat	b03052	VBG	I-NP	O
rat	rat	r030	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
myocyte	myocyte	m02030	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
to	to	t000	TO	B-VP	O
become	become	b02050	VB	I-VP	O
arrhythmic	arrhythmic	a6030502	JJ	B-ADJP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
determined	determine	d030650503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
progesterone	progesterone	p60202306050	NN	I-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
on	on	o500	IN	B-PP	O
myocyte	myocyte	m02030	NN	B-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
25	25	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
AD50	AD50	0000	NN	I-NP	O
for	for	f060	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Estradiol	Estradiol	e2360304	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
arrhythmogenicity	arrhythmogenicity	a60305020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
myocyte	myocyte	m02030	NN	B-NP	O
cultures	culture	c0430602	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
fourth	fourth	f0630	JJ	I-NP	O
as	as	a200	IN	B-PP	O
potent	potent	p03053	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
nor	nor	n060	CC	O	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
arrhythmogenicity	arrhythmogenicity	a60305020502030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
progesterone	progesterone	p60202306050	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
21	21	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
arrhythmogenicity	arrhythmogenicity	a60305020502030	NN	I-NP	O
in	in	i500	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
pentobarbital	pentobarbital	p053010610304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
nonprogesterone	nonprogesterone	n05160202306050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SE	SE	s000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
arrhythmogenicity	arrhythmogenicity	a60305020502030	NN	I-NP	O
both	both	b030	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

Potentiation	Potentiation	p030530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
myocyte	myocyte	m02030	NN	B-NP	O
cultures	culture	c0430602	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
partly	partly	p06340	RB	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocyte	myocyte	m02030	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
serum	serum	s0605	NN	I-NP	O
soluble	soluble	s040140	JJ	I-NP	O
Fas	Fas	f020	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
/	/	/000	SYM	I-NP	O
AIMS	AIMS	a052	NNS	I-NP	O
:	:	:000	:	O	O
Experimental	Experimental	e21060505304	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Fas	Fas	f020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
Fas	Fas	f020	NN	I-NP	O
Ligand	Ligand	l02053	NN	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
system	system	s02305	NN	I-NP	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
soluble	soluble	s040140	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fas	Fas	f020	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODOLOGY	METHODOLOGY	m030304020	NN	B-NP	O
:	:	:000	:	O	O
Serum	Serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sFas	sFas	s102	NN	B-NP	O
(	(	(000	(	O	O
soluble	soluble	s040140	JJ	B-NP	O
Fas	Fas	f020	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ELISA	ELISA	e4020	NN	B-NP	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
and	and	a530	CC	O	O
interferon	interferon	i530610605	NN	B-NP	O
-	-	-000	HYPH	O	O
gamma	gamma	g050	SYM	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ELISA	ELISA	e4020	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Serum	Serum	s0605	NN	B-NP	O
sFas	sFas	s102	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
52	52	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	O	O
mL	mL	m400	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Levels	Level	l01042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
28	28	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
52	52	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	O	O
mL	mL	m400	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
A	A	a000	NN	I-NP	O
to	to	t000	TO	B-PP	O
E	E	e000	NN	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
46	46	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	O	O
mL	mL	m400	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
sFas	sFas	s102	NN	B-NP	O
to	to	t000	TO	B-PP	O
eventual	eventual	e105304	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
sFas	sFas	s102	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
613	613	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sFas	sFas	s102	NN	B-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
reflect	reflect	r014023	VB	I-VP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Fas	Fas	f020	NN	B-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
together	together	t020306	NN	I-NP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
subthalamic	subthalamic	s013040502	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subthalamic	subthalamic	s013040502	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
(	(	(000	(	O	O
STN	STN	s350	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
ameliorate	ameliorate	a50406030	VB	I-VP	O
the	the	t000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
STN	STN	s350	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	O	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
Stages	Stage	s30202	NNS	B-NP	O
III	III	i000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
V	V	v000	NN	I-NP	O
on	on	o500	IN	B-PP	O
Hoehn	Hoehn	h050	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Yahr	Yahr	y060	NNP	I-NP	O
scale	scale	s2040	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
bradykinesia	bradykinesia	b6030205020	NN	B-NP	B-Disease
,	,	,000	,	O	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
underwent	undergo	u5306053	VBD	B-VP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
implantation	implantation	i5140530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
electrodes	electrode	e402360302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
STN	STN	s350	NN	I-NP	O
.	.	.000	.	O	O

Preoperative	Preoperative	p6010603010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
assessments	assessment	a20250532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
"	"	"000	``	O	O
on	on	o500	IN	B-PP	O
"	"	"000	''	O	O
and	and	a530	CC	O	O
"	"	"000	``	O	O
off	off	o100	RP	B-PRT	O
"	"	"000	''	O	O
drug	drug	d602	NN	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
using	use	u2052	VBG	B-VP	O
Unified	Unified	u50103	NNP	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NNP	I-NP	I-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
,	,	,000	,	O	O
Hoehn	Hoehn	h050	NNP	B-NP	O
and	and	a530	CC	O	O
Yahr	Yahr	y060	NNP	B-NP	O
staging	staging	s302052	NN	I-NP	O
,	,	,000	,	O	O
England	England	e524053	NNP	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
living	living	l01052	NN	I-NP	O
score	score	s2060	NN	I-NP	O
and	and	a530	CC	I-NP	O
video	video	v030	NN	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
After	After	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
of	of	o100	IN	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
STN	STN	s350	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
'	'	'000	POS	B-NP	O
scores	score	s20602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
activities	activity	a23010302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
living	living	l01052	NN	I-NP	O
and	and	a530	CC	I-NP	O
motor	motor	m0306	NN	I-NP	O
examination	examination	e205050305	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
(	(	(000	(	O	O
Unified	Unified	u50103	NNP	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NNP	I-NP	I-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
parts	part	p0632	NNS	I-NP	O
II	II	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
III	III	i000	CD	I-NP	O
)	)	)000	)	O	O
off	off	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
improved	improve	i5160103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
62	62	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0005	0005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subscores	subscore	s0120602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
akinesia	akinesia	a205020	NN	I-NP	B-Disease
,	,	,000	,	O	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	O	O
gait	gait	g030	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0005	0005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
813	813	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
to	to	t000	TO	B-PP	O
359	359	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
functions	function	f0523052	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
device	device	d01020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
weight	weight	w0203	NN	I-NP	O
gain	gain	g050	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Bilateral	Bilateral	b04030604	JJ	B-NP	O
subthalamic	subthalamic	s013040502	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
advanced	advanced	a3105203	JJ	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	B-NP	O
off	off	o100	JJ	I-NP	O
"	"	"000	''	I-NP	O
phase	phase	p020	NN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
improves	improve	i5160102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
axial	axial	a204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
reduces	reduce	r030202	VBZ	B-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
requirements	requirement	r0206050532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
drug	drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
induced	induce	i530203	VBN	I-NP	I-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
desferrioxamine	desferrioxamine	d021060205050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
recovery	recovery	r0201060	NN	B-NP	O
after	after	a1306	IN	B-PP	O
haemodialysis	haemodialysis	h0503040202	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
transfusion	transfusion	t605210205	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
thalassemia	thalassemia	t0402050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
undergoing	undergo	u53062052	VBG	I-VP	O
home	home	h050	NN	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
desferrioxamine	desferrioxamine	d021060205050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DFX	DFX	d120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
totally	totally	t03040	RB	I-NP	O
implanted	implant	i51405303	VBN	I-NP	O
system	system	s02305	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
his	his	h020	PRP$	B-NP	O
poor	poor	p060	JJ	I-NP	O
compliance	compliance	c05140520	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
nightly	nightly	n020340	RB	I-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Due	Due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
accidental	accidental	a20305304	JJ	I-NP	O
malfunctioning	malfunctioning	m041052305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
pump	pump	p051	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
inadvertently	inadvertently	i503106305340	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
which	which	w020	WDT	B-NP	O
caused	cause	c0203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
decision	decision	d020205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
to	to	t000	TO	B-VP	O
introduce	introduce	i53603020	VB	I-VP	O
haemodialytical	haemodialytical	h050304030204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
remove	remove	r05010	VB	I-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
reduce	reduce	r03020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
,	,	,000	,	O	O
haemodialysis	haemodialysis	h0503040202	NN	B-NP	O
can	can	c050	MD	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
be	be	b000	VB	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
rare	rare	r060	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
desferrioxamine	desferrioxamine	d021060205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Ocular	Ocular	o20406	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
subtenon	subtenon	s0130505	NN	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
retinoblastoma	retinoblastoma	r0305014023050	NN	B-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Focal	Focal	f0204	JJ	B-NP	O
subtenon	subtenon	s0130505	NN	I-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
recently	recently	r0205340	RB	I-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
presumably	presumably	p602050140	RB	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
adjunct	adjunct	a320523	NN	I-NP	O
to	to	t000	TO	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
intraocular	intraocular	i536020406	JJ	B-NP	O
retinoblastoma	retinoblastoma	r0305014023050	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
our	our	o060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
experience	experience	e21060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
ocular	ocular	o20406	JJ	I-NP	I-Disease
motility	motility	m0304030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
subtenon	subtenon	s0130505	NN	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
noted	note	n0303	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
ocular	ocular	o20406	JJ	I-NP	I-Disease
motility	motility	m0304030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
retinoblastoma	retinoblastoma	r0305014023050	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
subtenon	subtenon	s0130505	NN	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
manipulation	manipulation	m0501040305	NN	I-NP	O
under	under	u5306	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
eyes	eye	e020	NNS	I-NP	O
by	by	b000	IN	B-PP	O
forced	force	f06203	VBN	B-NP	O
duction	duction	d02305	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
,	,	,000	,	O	O
comparing	compare	c05106052	VBG	B-VP	O
ocular	ocular	o20406	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
control	control	c053604	NN	I-NP	O
with	with	w030	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
at	at	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
.	.	.000	.	O	O

Eyes	Eye	e020	NNS	B-NP	O
subsequently	subsequently	s0120205340	RB	B-VP	O
enucleated	enucleate	e50240303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
treatment	treatment	t6035053	NN	B-NP	O
failure	failure	f04060	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
histologically	histologically	h023040202040	RB	B-ADVP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Limitation	Limitation	l05030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
12	12	0000	CD	I-NP	O
eyes	eye	e020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
intraocular	intraocular	i536020406	JJ	B-NP	O
retinoblastoma	retinoblastoma	r0305014023050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
6	6	6000	CD	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
subtenon	subtenon	s0130505	NN	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
multimodality	multimodality	m043050304030	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
many	many	m050	JJ	B-NP	O
lipophages	lipophage	l01010202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
periorbital	periorbital	p060610304	JJ	I-NP	O
fat	fat	f030	NN	I-NP	O
surrounding	surround	s06053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
eye	eye	e000	NN	I-NP	O
,	,	,000	,	O	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
phagocytosis	phagocytosis	p0202030202	NN	B-NP	O
of	of	o100	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
existing	exist	e2023052	VBG	I-NP	O
fat	fat	f030	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
prior	prior	p606	JJ	B-NP	O
fat	fat	f030	NN	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
enucleations	enucleation	e502403052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
technically	technically	t020502040	RB	B-ADJP	O
difficult	difficult	d0102043	JJ	I-ADJP	O
and	and	a530	CC	I-ADJP	O
hazardous	hazardous	h0206302	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
globe	globe	g4010	NN	B-NP	O
rupture	rupture	r013060	NN	I-NP	B-Disease
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
extensive	extensive	e23052010	JJ	B-NP	O
orbital	orbital	o610304	JJ	I-NP	O
soft	soft	s013	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
adhesions	adhesion	a302052	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Subtenon	Subtenon	s0130505	NN	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
orbital	orbital	o610304	JJ	B-NP	O
soft	soft	s013	JJ	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
restriction	restriction	r023602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
eye	eye	e000	NN	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
and	and	a530	CC	O	O
making	make	m02052	VBG	B-VP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
enucleation	enucleation	e50240305	NN	I-NP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
.	.	.000	.	O	O

Subtenon	Subtenon	s0130505	NN	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
best	well	b023	RBS	B-ADJP	O
restricted	restricted	r023602303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
indications	indication	i530203052	NNS	I-NP	O
.	.	.000	.	O	O

Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Thirteen	Thirteen	t06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
tuberculosis	tuberculosis	t01062040202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
lymph	lymph	l0510	NN	I-NP	I-Disease
node	node	n030	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
Siriraj	Siriraj	s060602	NNP	B-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
between	between	b0305	IN	B-PP	O
1997	1997	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2001	2001	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
retrospectively	retrospectively	r03602102301040	RB	I-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
and	and	a530	CC	O	O
initial	initial	i50304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
final	final	f0504	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	O
acuity	acuity	a2030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
visual	visual	v0204	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
between	between	b0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
13	13	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
=	=	=000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
visual	visual	v0204	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
irreversible	irreversible	i6010620140	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
heavy	heavy	h010	JJ	B-NP	O
smoking	smoking	s502052	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Early	Early	e0640	JJ	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
of	of	o100	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	O	O
prompt	prompt	p60513	JJ	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
individuals	individual	i530103042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
or	or	o600	CC	O	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
heavy	heavy	h010	JJ	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
gustatory	gustatory	g02303060	JJ	I-NP	B-Disease
hyperhidrosis	hyperhidrosis	h01060360202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Gustatory	Gustatory	g02303060	JJ	B-NP	B-Disease
hyperhidrosis	hyperhidrosis	h01060360202	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
facial	facial	f0204	JJ	B-NP	O
sweating	sweating	s03052	NN	I-NP	B-Disease
usually	usually	u2040	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
eating	eating	e03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
hot	hot	h030	JJ	B-NP	O
spicy	spicy	s1020	NN	I-NP	O
food	food	f030	NN	I-NP	O
or	or	o600	CC	O	O
even	even	e105	RB	B-ADVP	O
smelling	smell	s504052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
food	food	f030	NN	I-NP	O
.	.	.000	.	O	O

Current	Current	c06053	JJ	B-NP	O
options	option	o13052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
include	include	i524030	VBP	B-VP	O
oral	oral	o604	JJ	B-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
topical	topical	t010204	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticholinergics	anticholinergic	a5302040506202	NNS	B-NP	O
or	or	o600	CC	O	O
aluminum	aluminum	a4050505	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
botulinum	botulinum	b03040505	NN	B-NP	O
toxin	toxin	t0205	NN	I-NP	O
.	.	.000	.	O	O

Thirteen	Thirteen	t06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
topical	topical	t010204	JJ	I-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
gustatory	gustatory	g02303060	JJ	B-NP	B-Disease
hyperhidrosis	hyperhidrosis	h01060360202	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
interfered	interfere	i530610603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
social	social	s0204	JJ	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
transthroacic	transthroacic	t60523060202	JJ	B-NP	O
endoscopic	endoscopic	e53020102	JJ	I-NP	O
sympathectomy	sympathectomy	s05103023050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
focal	focal	f0204	JJ	I-NP	O
hyperhidrosis	hyperhidrosis	h01060360202	NN	I-NP	B-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
applying	apply	a14052	VBG	B-VP	O
topical	topical	t010204	JJ	B-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
excellent	excellent	e204053	JJ	B-ADJP	O
(	(	(000	(	O	O
no	no	n000	DT	B-NP	O
sweating	sweating	s03052	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
eating	eat	e03052	VBG	B-VP	O
hot	hot	h030	JJ	B-NP	O
spicy	spicy	s1020	NN	I-NP	O
food	food	f030	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
77	77	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fair	fair	f060	JJ	B-ADJP	O
(	(	(000	(	O	O
clearly	clearly	c40640	RB	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
sweating	sweating	s03052	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
had	have	h030	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
incidents	incident	i52030532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
being	be	b052	VBG	B-VP	O
very	very	v060	RB	B-ADJP	O
embarrassed	embarrassed	e51060203	JJ	I-ADJP	O
whilst	whilst	w0423	IN	B-PP	O
eating	eat	e03052	VBG	B-VP	O
hot	hot	h030	JJ	B-NP	O
spicy	spicy	s1020	NN	I-NP	O
foods	food	f032	NNS	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mildly	mildly	m04340	RB	I-NP	O
dry	dry	d600	JJ	I-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
sore	sore	s060	JJ	I-NP	B-Disease
throat	throat	t0603	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
light	light	l0203	JJ	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
topical	topical	t010204	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
pad	pad	p030	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
safe	safe	s010	JJ	B-ADJP	O
,	,	,000	,	O	O
efficacious	efficacious	e1020202	JJ	B-ADJP	O
,	,	,000	,	O	O
well	well	w040	RB	B-ADJP	O
tolerated	tolerate	t04060303	VBN	I-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
convenient	convenient	c05105053	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gustatory	gustatory	g02303060	JJ	B-NP	B-Disease
hyperhidrosis	hyperhidrosis	h01060360202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
post	post	p023	NN	B-NP	O
transthoracic	transthoracic	t60523060202	JJ	I-NP	O
endoscopic	endoscopic	e53020102	JJ	I-NP	O
sympathectomy	sympathectomy	s05103023050	NN	I-NP	O
or	or	o600	CC	I-NP	O
sympathicotomy	sympathicotomy	s051030203050	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
few	few	f000	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Can	Can	c050	MD	O	O
it	it	i300	PRP	B-NP	O
be	be	b000	VB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
?	?	?000	.	O	O

Six	Six	s020	CD	B-NP	O
stable	stable	s30140	JJ	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	O
outpatients	outpatient	o031030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
amenorrhea	amenorrhea	a505060	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
oligomenorrhea	oligomenorrhea	o4020505060	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	B-Chemical
medications	medication	m030203052	NNS	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Daily	Daily	d040	JJ	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
corrected	correct	c0602303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
restored	restore	r0230603	VBD	B-VP	O
menstruation	menstruation	m052360305	NN	B-NP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
six	six	s020	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
woman	woman	w0505	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
developed	develop	d01040103	VBN	B-VP	O
worsened	worsen	w0620503	VBD	B-VP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	I-NP	O
six	six	s020	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
menstrual	menstrual	m0523604	JJ	I-NP	O
irregularity	irregularity	i6020406030	NN	I-NP	O
successfully	successfully	s02021040	RB	B-VP	O
corrected	correct	c0602303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
further	further	f06306	RBR	B-ADJP	O
evaluated	evaluate	e1040303	VBN	I-ADJP	O
as	as	a200	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
amenorrhea	amenorrhea	a505060	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
galactorrhea	galactorrhea	g04023060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Ethacrynic	Ethacrynic	e30260502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
neurotransmitters	neurotransmitter	n06036052503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Intracerebroventricular	Intracerebroventricular	i5360206016010536020406	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethacrynic	ethacrynic	e30260502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
dose	dose	d020	NN	I-NP	O
;	;	;000	:	O	O
50	50	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
)	)	)000	)	O	O
accelerated	accelerate	a204060303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
/	/	/000	SYM	B-NP	O
turnover	turnover	t0650106	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine	hydroxytryptamine	h0360203601305050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
)	)	)000	)	O	O
but	but	b030	CC	O	O
suppressed	suppress	s0160203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
of	of	o100	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartate	aspartate	a21063030	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
aminophosphonovaleric	aminophosphonovaleric	a505010210501040602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
ethacrynic	ethacrynic	e30260502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
differentially	differentially	d0106053040	RB	I-VP	O
modulated	modulate	m03040303	VBN	I-VP	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
glutaminergic	glutaminergic	g403050506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Pharmacology	Pharmacology	p0650204020	NN	B-NP	O
of	of	o100	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	I-NP	I-Chemical
acidA	acidA	a2030	NN	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
complex	complex	c051402	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anxioselective	anxioselective	a520204023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboline	carboline	c06104050	NN	I-NP	I-Chemical
derivative	derivative	d060103010	NN	I-NP	O
abecarnil	abecarnil	a10206504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboline	carboline	c06104050	NN	I-NP	I-Chemical
derivative	derivative	d060103010	JJ	I-NP	O
isopropyl	isopropyl	i20160104	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
benzyloxy	benzyloxy	b05204020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methoxymethyl	methoxymethyl	m0302050304	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
beta	beta	b030	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
carboline	carboline	c06104050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxylate	carboxylate	c0610204030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
abecarrnil	abecarrnil	a10206504	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
ligand	ligand	l02053	NN	I-NP	O
for	for	f060	IN	B-PP	O
benzodiazepine	benzodiazepine	b052030201050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
possessing	possess	p0202052	VBG	B-VP	O
anxiolytic	anxiolytic	a52040302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
A	A	a000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
complex	complex	c051402	NN	I-NP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Added	Add	a303	VBN	B-VP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
to	to	t000	TO	B-PP	O
rat	rat	r030	NN	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
preparation	preparation	p601060305	NN	I-NP	O
,	,	,000	,	O	O
abecarnil	abecarnil	a10206504	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
[	[	[000	(	O	O
3H	3H	3000	NN	B-NP	O
]	]	]000	)	I-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
,	,	,000	,	O	O
enhanced	enhance	e505203	VBD	B-VP	O
muscimol	muscimol	m020504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
stimulated	stimulate	s305040303	VBN	B-NP	O
36Cl	36Cl	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
uptake	uptake	u13020	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
binding	binding	b053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
t	t	t000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
35S	35S	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
butylbicyclophosphorothionate	butylbicyclophosphorothionate	b030410202401021060305030	JJ	I-NP	I-Chemical
(	(	(000	(	O	O
[	[	[000	(	O	B-Chemical
35S	35S	0000	NN	B-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
TBPS	TBPS	t120	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
Ro	Ro	r000	NN	I-NP	B-Chemical
16	16	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
6028	6028	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
tert	tert	t063	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
butyl	butyl	b0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
S	S	s000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
bromo	bromo	b6050	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
11	11	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
12	12	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
13	13	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
13a	13a	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydro	tetrahydro	t0360360	AFX	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
oxo	oxo	o200	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9H	9H	9000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
imidazo	imidazo	i503020	NN	I-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
a	a	a000	DT	B-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pyrrolo	pyrrolo	p06040	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
1	1	1000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
c	c	c000	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
[	[	[000	(	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxylate	carboxylate	c0610204030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
very	very	v060	RB	B-NP	O
weak	weak	w020	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
abecarnil	abecarnil	a10206504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-ADJP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
manner	manner	m0506	NN	B-NP	O
[	[	[000	(	I-NP	B-Chemical
35S	35S	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
TBPS	TBPS	t120	NN	I-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
ex	ex	e200	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
convulsant	convulsant	c051042053	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	B-NP	B-Chemical
35S	35S	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
TBPS	TBPS	t120	NN	I-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoniazide	isoniazide	i20502030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
350	350	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	B-NP	B-Chemical
35S	35S	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
TBPS	TBPS	t120	NN	I-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
foot	foot	f030	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
shock	shock	s020	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
better	well	b0306	RBR	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
the	the	t000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
abecarnil	abecarnil	a10206504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
[	[	[000	(	B-NP	B-Chemical
35S	35S	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
TBPS	TBPS	t120	NN	I-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
,	,	,000	,	O	O
exploratory	exploratory	e2140603060	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
abecarnil	abecarnil	a10206504	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
paralleled	parallel	p06040403	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
dependent	dependent	d01053053	JJ	B-ADJP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
motor	motor	m0306	NN	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
and	and	a530	CC	O	O
cortical	cortical	c0630204	JJ	B-NP	O
[	[	[000	(	I-NP	O
35S	35S	0000	NN	I-NP	O
]	]	]000	)	I-NP	O
TBPS	TBPS	t120	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
beta	beta	b030	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboline	carboline	c06104050	NN	I-NP	I-Chemical
reduced	reduce	r030203	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	B-NP	B-Chemical
35S	35S	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
TBPS	TBPS	t120	NN	I-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
postpartum	postpartum	p023106305	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
puerperium	puerperium	p0610605	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
infrequently	infrequently	i5160205340	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Spasm	Spasm	s1025	NN	B-NP	B-Disease
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	O
dissection	dissection	d0202305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
atheromatous	atheromatous	a306050302	JJ	B-NP	O
etiology	etiology	e304020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Bromocriptine	Bromocriptine	b605026013050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
previous	previous	p60102	JJ	I-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
puerperium	puerperium	p0610605	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
(	(	(000	(	O	O
including	include	i52403052	VBG	B-PP	O
an	an	a500	DT	B-NP	O
inadvertent	inadvertent	i5031063053	JJ	I-NP	O
rechallenge	rechallenge	r02040520	NN	I-NP	O
)	)	)000	)	O	O
suggests	suggest	s020232	VBZ	B-VP	O
such	such	s020	PDT	B-NP	O
a	a	a000	DT	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
generally	generally	g0506040	RB	B-ADVP	O
regarded	regard	r0206303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
"	"	"000	``	O	O
safe	safe	s010	JJ	B-ADJP	O
,	,	,000	,	O	O
"	"	"000	''	O	O
possible	possible	p020140	JJ	B-NP	O
serious	serious	s0602	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
acknowledged	acknowledge	a250403203	VBN	I-VP	O
.	.	.000	.	O	O

Asterixis	Asterixis	a23060202	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
very	very	v060	RB	B-NP	O
few	few	f000	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
about	about	a103	IN	B-PP	O
asterixis	asterixis	a23060202	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
psychopharmacologic	psychopharmacologic	p2020106502040202	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
we	we	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
psychotropic	psychotropic	p2020360102	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
asterixis	asterixis	a23060202	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
triggered	trigger	t6020603	VBN	I-VP	O
either	either	e0306	CC	O	O
by	by	b000	IN	B-PP	O
adding	add	a3052	VBG	B-VP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
dosage	dosage	d02020	NN	B-NP	O
nor	nor	n060	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
consider	consider	c0520306	VBP	B-VP	O
asterixis	asterixis	a23060202	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
easily	easily	e02040	RB	I-NP	O
overlooked	overlook	o10640203	VBN	I-NP	O
sign	sign	s025	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
or	or	o600	CC	I-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
certain	certain	c06305	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
as	as	a200	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pharmacodynamics	Pharmacodynamic	p0650203050502	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
and	and	a530	CC	I-NP	O
fluctuating	fluctuating	f402303052	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
concentration	concentration	c05205360305	NN	B-NP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
fit	fit	f030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
Emax	Emax	e502	NN	I-NP	O
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
fluctuating	fluctuate	f402303052	VBG	B-VP	O
responders	responder	r021053062	NNS	B-NP	O
.	.	.000	.	O	O

Stable	Stable	s30140	JJ	B-NP	O
responders	responder	r021053062	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
fluctuating	fluctuate	f402303052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
baseline	baseline	b0204050	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Antiparkinsonian	Antiparkinsonian	a53010620520505	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
temporally	temporally	t05106040	RB	B-ADVP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

Phenylalanine	Phenylalanine	p05040405050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
neutral	neutral	n03604	JJ	I-NP	O
amino	amino	a5050	NN	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
LNAA	LNAA	l500	NN	B-NP	O
)	)	)000	)	O	O
competing	compete	c05103052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
transport	transport	t60521063	NN	B-NP	O
across	across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
parallels	parallel	p0604042	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
fluctuating	fluctuate	f402303052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
baseline	baseline	b0204050	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
fluctuating	fluctuate	f402303052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
relative	relative	r0403010	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
stable	stable	s30140	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Syndrome	Syndrome	s0536050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
antidiuretic	antidiuretic	a5303060302	JJ	B-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
infusional	infusional	i51020504	JJ	B-NP	O
vincristine	vincristine	v0526023050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
77	77	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
second	second	s02053	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
she	she	s000	PRP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
lethargy	lethargy	l030620	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
weakness	weakness	w02502	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
antidiuretic	antidiuretic	a5303060302	JJ	B-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
vincristine	vincristine	v0526023050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
,	,	,000	,	O	O
further	further	f06306	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
without	without	w0303	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
:	:	:000	:	O	O
to	to	t000	TO	B-VP	O
digitalise	digitalise	d020304020	VB	I-VP	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
?	?	?000	.	O	O

The	The	t000	DT	B-NP	O
view	view	v000	NN	I-NP	O
against	against	a20523	IN	B-PP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
extensive	extensive	e23052010	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
experience	experience	e21060520	NN	I-NP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
not	not	n030	RB	O	O
well	well	w040	RB	B-ADJP	O
defined	define	d010503	VBN	I-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
digoxin	digoxin	d020205	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
beneficial	beneficial	b05010204	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	VBP	B-VP	I-Disease
the	the	t000	DT	B-NP	O
situation	situation	s030305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
less	less	l020	RBR	B-ADJP	O
clear	clear	c406	JJ	I-ADJP	O
.	.	.000	.	O	O

Digoxin	Digoxin	d020205	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
narrow	narrow	n060	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
:	:	:000	:	O	O
toxic	toxic	t0202	JJ	B-NP	O
ratio	ratio	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
undesirable	undesirable	u5302060140	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
increasing	increase	i52602052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
demands	demand	d050532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
causing	cause	c02052	VBG	B-VP	O
arrhythmias	arrhythmia	a6030502	NNS	B-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
paucity	paucity	p02030	NN	I-NP	O
of	of	o100	IN	B-PP	O
data	data	d030	NN	B-NP	O
from	from	f605	IN	B-PP	O
well	well	w040	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
designed	design	d0202503	VBN	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
trials	trial	t6042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
are	be	a600	VBP	B-VP	O
generally	generally	g0506040	RB	B-ADJP	O
small	small	s504	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
limitations	limitation	l050303052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
design	design	d02025	NN	B-NP	O
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
show	show	s000	NN	I-NP	O
variation	variation	v060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
.	.	.000	.	O	O

More	More	m060	RBR	B-NP	O
convincing	convincing	c051052052	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
showing	show	s052	VBG	I-VP	O
that	that	t030	IN	B-SBAR	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
improves	improve	i5160102	VBZ	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
or	or	o600	CC	O	O
exercise	exercise	e2062020	NN	B-NP	O
capacity	capacity	c0102030	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
had	have	h030	VBN	I-VP	O
sufficient	sufficient	s0102053	JJ	B-NP	O
power	power	p060	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
mortality	mortality	m06304030	NN	B-NP	O
.	.	.000	.	O	O

Pooled	Pool	p0403	VBN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
inotropic	inotropic	i50360102	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
shows	show	s020	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
excess	excess	e202	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
mortality	mortality	m06304030	NN	B-NP	O
after	after	a1306	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MI	MI	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Angiotensin	Angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
ACE	ACE	a200	NN	B-NP	O
)	)	)000	)	O	O
inhibitors	inhibitor	i50103062	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
first	first	f0623	RB	B-ADVP	O
as	as	a200	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
safer	safe	s0106	JJR	B-ADJP	O
,	,	,000	,	O	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
require	require	r02060	VB	I-VP	O
blood	blood	b403	NN	B-NP	O
level	level	l0104	NN	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
,	,	,000	,	O	O
modify	modify	m03010	VBP	B-VP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
,	,	,000	,	O	O
relieve	relieve	r04010	VB	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
,	,	,000	,	O	O
improve	improve	i516010	VB	B-VP	O
exercise	exercise	e2062020	NN	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
and	and	a530	CC	O	O
reduce	reduce	r03020	VB	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
.	.	.000	.	O	O

Caution	Caution	c0305	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
exercised	exercise	e20620203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
until	until	u5304	IN	B-SBAR	O
large	large	l0620	JJ	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
trials	trial	t6042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
completed	complete	c05140303	VBN	I-VP	O
showing	show	s052	VBG	I-VP	O
either	either	e0306	CC	O	O
benefit	benefit	b050103	NN	B-NP	O
or	or	o600	CC	I-NP	O
harm	harm	h065	NN	I-NP	O
.	.	.000	.	O	O

Until	Until	u5304	IN	B-PP	O
then	then	t050	RB	B-NP	O
digoxin	digoxin	d020205	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Isradipine	Isradipine	i260301050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
in	in	i500	IN	B-PP	O
Hong	Hong	h052	NNP	B-NP	O
Kong	Kong	k052	NNP	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
open	open	o105	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isradipine	isradipine	i260301050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
in	in	i500	IN	B-PP	O
Hong	Hong	h052	NNP	B-NP	O
Kong	Kong	k052	NNP	I-NP	O
.	.	.000	.	O	O

303	303	0000	CD	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
entered	enter	e530603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
caused	cause	c0203	VBD	B-VP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
dizziness	dizziness	d020502	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
palpitation	palpitation	p041030305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
flushing	flushing	f402052	NN	I-NP	B-Disease
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
than	than	t050	IN	B-SBAR	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
isradipine	isradipine	i260301050	NN	B-NP	B-Chemical
or	or	o600	CC	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

Supine	Supine	s01050	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
170	170	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
20	20	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
102	102	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
to	to	t000	TO	B-PP	O
153	153	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
19	19	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
92	92	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	I-NP	O
147	147	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
18	18	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
88	88	0000	CD	I-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-ADVP	O
-	-	-000	SYM	B-NP	O
7	7	7000	CD	B-NP	O
and	and	a530	CC	I-NP	O
144	144	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
87	87	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
evaluable	evaluable	e1040140	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
standing	stand	s3053052	VBG	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postural	postural	p0230604	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Normalization	Normalization	n06504020305	NN	B-NP	O
and	and	a530	CC	I-NP	O
responder	responder	r02105306	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
69	69	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Dosage	Dosage	d02020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
90	90	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
further	further	f06306	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
remaining	remain	r0505052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Pharmacological	Pharmacological	p0650204020204	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
and	and	a530	CC	O	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
galenic	galenic	g040502	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
without	without	w0303	IN	B-PP	O
soyabean	soyabean	s0105	JJ	B-NP	O
oil	oil	o040	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
,	,	,000	,	O	O
pharmacodynamics	pharmacodynamic	p0650203050502	NNS	B-NP	O
and	and	a530	CC	O	O
safety	safety	s01030	NN	B-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
galenic	galenic	g040502	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AM149	AM149	0000	NN	B-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
contain	contain	c05305	VB	I-VP	O
soyabean	soyabean	s0105	JJ	B-NP	O
oil	oil	o040	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Disoprivan	Disoprivan	d020160105	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	O	O
cross	cross	c602	AFX	O	O
-	-	-000	HYPH	O	O
over	over	o106	IN	B-PP	O
study	study	s3030	NN	B-NP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
evaluated	evaluate	e1040303	VBD	B-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
three	three	t060	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
assessed	assess	a20203	VBN	B-VP	O
included	include	i5240303	VBD	B-VP	O
induction	induction	i5302305	NN	B-NP	O
and	and	a530	CC	O	O
emergence	emergence	e50620520	NN	B-NP	O
times	time	t0502	NNS	I-NP	O
,	,	,000	,	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pain	pain	p050	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
over	over	o106	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Owing	Owe	o052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
prematurely	prematurely	p6050306040	RB	B-ADVP	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
the	the	t000	DT	I-NP	O
data	datum	d030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
parallel	parallel	p060404	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
formulations	formulation	f0650403052	NNS	I-NP	O
.	.	.000	.	O	O

Anaesthesia	Anaesthesia	a5023020	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
and	and	a530	CC	O	O
emergence	emergence	e50620520	NN	B-NP	O
times	time	t0502	NNS	I-NP	O
,	,	,000	,	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	B-NP	B-Disease
(	(	(000	(	O	O
93	93	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
vs	vs	v200	CC	O	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
AM149	AM149	0000	NN	B-NP	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
Disoprivan	Disoprivan	d020160105	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
formulations	formulation	f0650403052	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
the	the	t000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
suitable	suitable	s030140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
use	use	u200	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
.	.	.000	.	O	O

Pure	Pure	p060	NN	B-NP	B-Disease
red	red	r030	JJ	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
aplasia	aplasia	a14020	NN	I-NP	I-Disease
,	,	,000	,	O	O
toxic	toxic	t0202	JJ	B-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
lymphadenopathy	lymphadenopathy	l051030501030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
taking	take	t02052	VBG	B-VP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
taking	take	t02052	VBG	B-VP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
skin	skin	s205	NN	I-NP	B-Disease
rash	rash	r020	NN	I-NP	I-Disease
,	,	,000	,	O	O
lymphadenopathy	lymphadenopathy	l051030501030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
pure	pure	p060	JJ	B-NP	B-Disease
red	red	r030	JJ	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
aplasia	aplasia	a14020	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pharmacon	pharmacon	p0650205	NN	I-NP	O
all	all	a400	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	B-Disease
rash	rash	r020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
is	be	i200	VBZ	B-VP	O
benign	benign	b05025	JJ	B-NP	O
and	and	a530	CC	I-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
lymphadenopathy	lymphadenopathy	l051030501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Pure	Pure	p060	NN	B-NP	B-Disease
red	red	r030	JJ	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
aplasia	aplasia	a14020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
medication	medication	m03020305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
exact	exact	e2023	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
exerts	exert	e20632	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	B-Disease
rash	rash	r020	NN	I-NP	I-Disease
,	,	,000	,	O	O
lymphadenopathy	lymphadenopathy	l051030501030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
pure	pure	p060	JJ	B-NP	B-Disease
red	red	r030	JJ	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
aplasia	aplasia	a14020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
suggestive	suggestive	s02023010	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
connection	connection	c0502305	NN	I-NP	O
.	.	.000	.	O	O

Vinorelbine	Vinorelbine	v0506041050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
meta	meta	m030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
randomized	randomize	r053050203	VBN	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
vinorelbine	vinorelbine	v0506041050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VNR	VNR	v560	NN	B-NP	B-Chemical
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
meta	meta	m030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
comparing	compare	c05106052	VBG	B-VP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
malignancies	malignancy	m0402505202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Randomized	Randomize	r053050203	VBN	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
comparing	compare	c05106052	VBG	B-VP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
searched	search	s06203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Medline	Medline	m034050	NN	B-NP	O
,	,	,000	,	O	O
Embase	Embase	e51020	NN	B-NP	O
,	,	,000	,	O	O
Evidence	Evidence	e1030520	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
based	base	b0203	VBN	B-NP	O
Medicine	Medicine	m0302050	NN	I-NP	O
Reviews	Reviews	r0102	NNP	I-NP	O
databases	database	d03010202	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Cochrane	Cochrane	c0206050	NN	I-NP	O
library	library	l016060	NN	I-NP	O
from	from	f605	IN	B-PP	O
1987	1987	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
2002	2002	0000	CD	B-NP	O
.	.	.000	.	O	O

Outcomes	Outcome	o0320502	NNS	B-NP	O
of	of	o100	IN	B-PP	O
interest	interest	i5306023	NN	B-NP	O
were	be	w060	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
toxic	toxic	t0202	JJ	B-NP	O
deaths	death	d0302	NNS	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
event	event	e1053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
deaths	death	d0302	NNS	I-NP	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
publication	publication	p014020305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
19	19	0000	CD	B-NP	O
trials	trial	t6042	NNS	I-NP	O
,	,	,000	,	O	O
involving	involve	i51041052	VBG	B-VP	O
2441	2441	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
2050	2050	0000	CD	B-NP	O
control	control	c053604	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
CI	CI	c000	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
67	67	0000	CD	O	O
)	)	)000	)	O	O
]	]	]000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
[	[	[000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
92	92	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
54	54	0000	CD	I-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	O	O
)	)	)000	)	O	O
]	]	]000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
cardiac	cardiac	c06302	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
vindesine	vindesine	v05302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VDS	VDS	v320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
drugs	drug	d602	NNS	I-NP	O
[	[	[000	(	O	O
fluorouracil	fluorouracil	f406060204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
anthracyclines	anthracycline	a5306020240502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
GEM	GEM	g050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
em	em	e500	NN	B-NP	O
leader	leader	l0306	NN	I-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

Even	Even	e105	RB	B-SBAR	O
if	if	i100	IN	I-SBAR	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reach	reach	r020	VB	I-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
trials	trial	t6042	NNS	B-NP	O
excluding	exclude	e2403052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
trials	trial	t6042	NNS	B-NP	O
including	include	i52403052	VBG	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-PP	O
existing	exist	e2023052	VBG	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Vinorelbine	Vinorelbine	v0506041050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
concern	concern	c052065	NN	I-NP	O
about	about	a103	IN	B-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
VNR	VNR	v560	NN	B-NP	B-Chemical
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
indications	indication	i530203052	NNS	I-NP	O
.	.	.000	.	O	O

MRI	MRI	m600	NN	B-NP	O
findings	finding	f053052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypoxic	hypoxic	h010202	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
laminar	laminar	l050506	JJ	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
child	child	c043	NN	I-NP	O
with	with	w030	IN	B-PP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
crisis	crisis	c60202	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
girl	girl	g064	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rapidly	rapidly	r010340	RB	I-NP	O
installing	instal	i52304052	VBG	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
crisis	crisis	c60202	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
trimethoprim	trimethoprim	t6050301605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sulfomethoxazole	sulfomethoxazole	s04105030202040	NN	I-NP	I-Chemical
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
anoxia	anoxia	a5020	NN	I-NP	I-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
permanent	permanent	p06505053	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Magnetic	Magnetic	m0250302	JJ	B-NP	O
Resonance	Resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
cortical	cortical	c0630204	JJ	B-NP	O
laminar	laminar	l050506	JJ	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
border	border	b06306	NN	I-NP	O
zones	zone	z0502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
hemispheres	hemisphere	h050210602	NNS	I-NP	O
,	,	,000	,	O	O
ischemic	ischemic	i20502	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
subcortical	subcortical	s0120630204	JJ	B-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
hemisphere	hemisphere	h05021060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
putamen	putaman	p030505	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
cortical	cortical	c0630204	JJ	B-NP	O
laminar	laminar	l050506	JJ	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
classic	classic	c40202	JJ	I-NP	O
entity	entity	e53030	NN	I-NP	O
in	in	i500	IN	B-PP	O
adulthood	adulthood	a304303	NN	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
conditions	condition	c05303052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
energy	energy	e50620	NN	B-NP	O
depletions	depletion	d01403052	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
few	few	f000	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
available	available	a1040140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
natural	natural	n030604	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
Vigabatrin	Vigabatrin	v020103605	NN	B-NP	B-Chemical
associated	associated	a2020303	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
electing	elect	e4023052	VBG	B-VP	O
to	to	t000	TO	I-VP	O
continue	continue	c053050	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
natural	natural	n030604	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
Vigabatrin	Vigabatrin	v020103605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
who	who	w000	WP	B-NP	O
elected	elect	e402303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
continue	continue	c053050	VB	I-VP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
good	good	g030	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
Vigabatrin	Vigabatrin	v020103605	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
12	12	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
entered	enter	e530603	VBN	I-VP	O
into	into	i530	IN	B-PP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
programme	programme	p6026050	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
up	up	u100	RP	B-PRT	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
monthly	monthly	m053040	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
not	not	n030	RB	B-NP	O
less	less	l020	JJR	I-NP	O
than	than	t050	IN	I-NP	O
18	18	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
18	18	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
43	43	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
unequivocal	unequivocal	u502010204	JJ	B-NP	O
defects	defect	d010232	NNS	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-VP	O
already	already	a46030	RB	I-VP	O
published	publish	p0140203	VBN	I-VP	O
methodology	methodology	m030304020	NN	B-NP	O
(	(	(000	(	O	O
Eye	Eye	e000	NN	B-NP	O
2002	2002	0000	CD	I-NP	O
;	;	;000	:	O	O
16	16	0000	CD	B-NP	O
;	;	;000	:	O	O
567	567	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
571	571	0000	CD	I-NP	O
)	)	)000	)	O	O
monocular	monocular	m05020406	JJ	B-NP	O
mean	mean	m050	JJ	I-NP	O
radial	radial	r0304	JJ	I-NP	O
degrees	degree	d02602	NNS	I-NP	O
(	(	(000	(	O	O
MRDs	MRD	m632	NNS	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
I	I	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
4e	4e	4000	NN	I-NP	O
isopter	isopter	i201306	NN	I-NP	O
on	on	o500	IN	B-PP	O
Goldmann	Goldmann	g043505	NNP	B-NP	O
perimetry	perimetry	p06050360	NN	I-NP	O
was	be	w020	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
eye	eye	e000	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
discovery	discovery	d0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defect	defect	d01023	NN	I-NP	I-Disease
and	and	a530	CC	O	O
again	again	a205	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
not	not	n030	RB	B-NP	O
less	less	l020	JJR	I-NP	O
than	than	t050	IN	I-NP	O
18	18	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Mean	Mean	m050	JJ	B-NP	O
right	right	r0203	JJ	I-NP	O
eye	eye	e000	NN	I-NP	O
MRD	MRD	m630	NN	I-NP	O
at	at	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
36	36	0000	CD	B-NP	O
.	.	.000	.	O	O
98	98	0000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
22	22	0000	CD	I-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
-	-	-000	:	O	O
51	51	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
40	40	0000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
22	22	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
49	49	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
75	75	0000	CD	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-SBAR	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
338	338	0000	CD	B-NP	O
unpaired	unpaired	u510603	JJ	I-NP	O
t	t	t000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
visual	visual	v0204	JJ	B-NP	I-Disease
field	field	f043	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
period	period	p0603	NN	I-NP	O
and	and	a530	CC	O	O
discontinued	discontinue	d020530503	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Established	Establish	e230140203	VBN	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
presumed	presume	p6020503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
Vigabatrin	Vigabatrin	v020103605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
usually	usually	u2040	RB	I-VP	O
progress	progress	p602602	VBP	I-VP	O
in	in	i500	IN	B-PP	O
spite	spite	s1030	NN	B-NP	O
of	of	o100	IN	B-PP	O
continuing	continue	c05305052	VBG	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
give	give	g010	VBP	B-VP	O
support	support	s01063	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
Vigabatrin	Vigabatrin	v020103605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
idiosyncratic	idiosyncratic	i30205260302	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
rosaceiform	rosaceiform	r020201065	JJ	B-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	B-Disease
inflammatory	inflammatory	i5140503060	JJ	I-NP	I-Disease
dermatoses	dermatos	d065030202	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
ointment	ointment	o0535053	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Tacrolimus	Tacrolimus	t026040502	NN	B-NP	B-Chemical
ointment	ointment	o0535053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
increasingly	increasingly	i5260205240	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensitive	sensitive	s05203010	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
the	the	t000	DT	B-NP	O
face	face	f020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
recent	recent	r02053	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
aggravated	aggravate	a26010303	VBN	I-NP	O
rosacea	rosacea	r02020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
perioral	perioral	p060604	JJ	I-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
rosaceiform	rosaceiform	r020201065	NN	B-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
ointment	ointment	o0535053	NN	I-NP	O
.	.	.000	.	O	O

OBSERVATIONS	OBSERVATIONS	o1206103052	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	B-Disease
facial	facial	f0204	JJ	I-NP	I-Disease
dermatoses	dermatos	d065030202	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
ointment	ointment	o0535053	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
ineffectiveness	ineffectiveness	i501023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
initially	initially	i503040	RB	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	O	O
well	well	w040	RB	B-VP	O
-	-	-000	HYPH	I-VP	O
tolerated	tolerate	t04060303	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
rosacea	rosacea	r02020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
acne	acne	a250	NN	B-NP	B-Disease
experienced	experience	e210605203	VBD	B-VP	O
sudden	sudden	s0305	JJ	B-NP	O
worsening	worsen	w06205052	VBG	I-NP	O
with	with	w030	IN	B-PP	O
pustular	pustular	p0230406	JJ	B-NP	O
rosaceiform	rosaceiform	r020201065	NN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

Biopsy	Biopsy	b0120	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
an	an	a500	DT	B-NP	O
abundance	abundance	a10530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
Demodex	Demodex	d050302	NN	B-NP	O
mites	mite	m0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
eyelid	eyelid	e0403	JJ	B-NP	O
eczema	eczema	e2050	NN	I-NP	B-Disease
,	,	,000	,	O	O
rosaceiform	rosaceiform	r020201065	VBP	B-VP	O
periocular	periocular	p06020406	JJ	B-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
gradually	gradually	g603040	RB	B-ADVP	O
appeared	appear	a10603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
atopic	atopic	a30102	JJ	B-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
telangiectatic	telangiectatic	t040520230302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
papular	papular	p010406	JJ	I-NP	B-Disease
rosacea	rosacea	r02020	NN	I-NP	I-Disease
insidiously	insidiously	i52030240	RB	B-ADVP	O
appeared	appear	a10603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
of	of	o100	IN	B-PP	O
rosaceiform	rosaceiform	r020201065	JJ	B-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
ointment	ointment	o0535053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
heterogeneous	heterogeneous	h0306020502	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
vasoactive	vasoactive	v02023010	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
proliferation	proliferation	p60401060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Demodex	Demodex	d050302	NN	B-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
local	local	l0204	JJ	B-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
occlusive	occlusive	o2402010	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ointment	ointment	o0535053	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
phenomena	phenomenon	p0505050	NNS	I-NP	O
.	.	.000	.	O	O

Future	Future	f03060	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
individual	individual	i53010304	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Intravascular	Intravascular	i53601020406	JJ	B-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
rifampin	rifampin	r0105105	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Intravascular	Intravascular	i53601020406	JJ	B-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
extremely	extremely	e23605040	RB	B-ADJP	O
rare	rare	r060	JJ	I-ADJP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
leprosy	leprosy	l016020	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Structural	Structural	s360230604	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brains	brain	b6052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
use	use	u200	VBP	B-VP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
visualize	visualize	v0204020	VBP	B-VP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
human	human	h0505	JJ	I-NP	I-Disease
brain	brain	b605	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MA	MA	m000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
abuse	abuse	a1020	NN	B-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
MA	MA	m000	NN	B-NP	B-Chemical
chronically	chronically	c060502040	RB	B-ADVP	O
have	have	h010	VBP	B-VP	O
revealed	reveal	r010403	VBN	I-VP	O
deficits	deficit	d0102032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
new	new	n000	JJ	B-NP	O
computational	computational	c05103030504	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
-	-	-000	HYPH	O	O
mapping	map	m01052	VBG	B-VP	O
techniques	technique	t02050202	NNS	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
determined	determine	d030650503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
MA	MA	m000	JJ	I-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
related	relate	r040303	VBN	B-VP	O
these	these	t020	DT	B-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
MRI	MRI	m600	NN	I-NP	O
and	and	a530	CC	I-NP	O
surface	surface	s061020	NN	I-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-VP	O
computational	computational	c05103030504	JJ	B-NP	O
image	image	i5020	NN	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
to	to	t000	TO	B-VP	O
map	map	m010	VB	I-VP	O
regional	regional	r020504	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
cortex	cortex	c06302	NN	I-NP	I-Disease
,	,	,000	,	O	I-Disease
hippocampus	hippocampus	h010205102	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
white	white	w030	JJ	B-NP	I-Disease
matter	matter	m0306	NN	I-NP	I-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
ventricles	ventricle	v053602402	NNS	B-NP	I-Disease
in	in	i500	IN	B-PP	O
22	22	0000	CD	B-NP	O
human	human	h0505	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
MA	MA	m000	JJ	B-ADJP	B-Chemical
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
matched	match	m03203	VBN	I-VP	O
,	,	,000	,	O	O
healthy	healthy	h0430	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Cortical	Cortical	c0630204	JJ	B-NP	O
maps	map	m012	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
gray	gray	g600	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
matter	matter	m0306	NN	I-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cingulate	cingulate	c05204030	NN	I-NP	O
,	,	,000	,	O	O
limbic	limbic	l05102	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
paralimbic	paralimbic	p060405102	JJ	B-NP	O
cortices	cortex	c0630202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MA	MA	m000	JJ	B-NP	B-Chemical
abusers	abuser	a102062	NNS	I-NP	O
(	(	(000	(	O	O
averaging	average	a10602052	VBG	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
below	below	b040	IN	B-PP	O
control	control	c053604	NN	B-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
average	average	a106020	NN	B-NP	O
,	,	,000	,	O	O
MA	MA	m000	JJ	B-NP	B-Chemical
abusers	abuser	a102062	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
smaller	small	s50406	JJR	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
volumes	volume	v040502	NNS	I-NP	O
than	than	t050	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
;	;	;000	:	O	O
left	leave	l013	VBN	B-VP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
;	;	;000	:	O	O
right	right	r0203	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
white	white	w030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
matter	matter	m0306	NN	I-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Hippocampal	Hippocampal	h010205104	JJ	B-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
mapped	map	m0103	VBN	I-VP	O
and	and	a530	CC	O	O
correlated	correlate	c06040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
word	word	w063	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
recall	recall	r0204	NN	I-NP	O
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MRI	MRI	m600	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
maps	map	m012	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
memory	memory	m05060	NN	I-NP	I-Disease
performance	performance	p0610650520	NN	I-NP	I-Disease
.	.	.000	.	O	O

MA	MA	m000	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
selectively	selectively	s0402301040	RB	I-VP	O
damage	damage	d05020	VB	I-VP	O
the	the	t000	DT	B-NP	O
medial	medial	m0304	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
lobe	lobe	l010	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
metabolic	metabolic	m03010402	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cingulate	cingulate	c05204030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
limbic	limbic	l05102	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
inducing	induce	i5302052	VBG	B-VP	O
neuroadaptation	neuroadaptation	n06030130305	NN	B-NP	O
,	,	,000	,	O	O
neuropil	neuropil	n060104	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
cell	cell	c040	NN	B-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

Prominent	Prominent	p60505053	JJ	B-NP	O
white	white	w030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
matter	matter	m0306	NN	I-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
altered	alter	a430603	VBN	B-NP	O
myelination	myelination	m04050305	NN	I-NP	O
and	and	a530	CC	O	O
adaptive	adaptive	a3013010	JJ	B-NP	O
glial	glial	g404	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
gliosis	gliosis	g40202	NN	B-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
substrates	substrate	s012360302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
help	help	h041	VB	I-VP	O
account	account	a2053	VB	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MA	MA	m000	JJ	B-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
,	,	,000	,	O	O
providing	provide	p60103052	VBG	B-VP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
targets	target	t062032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
brain	brain	b605	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Disruption	Disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
homeostasis	homeostasis	h050230202	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
peroxisome	peroxisome	p060202050	NN	B-NP	O
proliferator	proliferator	p60401060306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
activated	activate	a23010303	VBN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
target	target	t06203	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
efficacious	efficacious	e1020202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
gain	gain	g050	VB	I-VP	O
insight	insight	i520203	NN	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
unwanted	unwanted	u505303	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
various	various	v0602	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
examined	examine	e2050503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
histology	histology	h02304020	NN	I-NP	O
and	and	a530	CC	I-NP	O
gene	gene	g050	NN	I-NP	O
regulation	regulation	r02040305	NN	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hepatomegaly	hepatomegaly	h01030502040	RB	B-ADVP	B-Disease
,	,	,000	,	O	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
microvesicular	microvesicular	m0260102020406	JJ	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
triglycerides	triglyceride	t602402060302	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Northern	Northern	n063065	NN	B-NP	O
blot	blot	b403	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
genes	gene	g0502	NNS	B-NP	O
critical	critical	c6030204	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
fatty	fatty	f030	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
oxidation	oxidation	o2030305	NN	I-NP	O
,	,	,000	,	O	O
lipoprotein	lipoprotein	l010160305	NN	B-NP	O
assembly	assembly	a205140	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
lipid	lipid	l0103	NN	B-NP	O
transport	transport	t60521063	NN	I-NP	O
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
genes	gene	g0502	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
regulated	regulate	r02040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
peroxisome	peroxisome	p060202050	NN	I-NP	O
proliferator	proliferator	p60401060306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
activated	activate	a23010303	VBN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
(	(	(000	(	O	O
PPARalpha	PPARalpha	p1060410	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
ligand	ligand	l02053	NN	I-NP	O
-	-	-000	HYPH	O	O
activated	activate	a23010303	VBN	B-VP	O
nuclear	nuclear	n02406	JJ	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
transcription	transcription	t6052601305	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
genes	gene	g0502	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
hepatomegaly	hepatomegaly	h01030502040	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
PPARalpha	PPARalpha	p1060410	NN	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
[	[	[000	(	O	O
PPARalpha	PPARalpha	p1060410	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
]	]	]000	)	I-NP	O
mice	mouse	m020	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
PPARalpha	PPARalpha	p1060410	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
PPARalpha	PPARalpha	p1060410	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
inability	inability	i50104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
directly	directly	d0602340	RB	I-VP	O
activate	activate	a2301030	VB	I-VP	O
either	either	e0306	CC	O	O
human	human	h0505	JJ	O	O
or	or	o600	CC	O	O
mouse	mouse	m020	NN	B-NP	O
PPARalpha	PPARalpha	p1060410	NN	I-NP	O
transiently	transiently	t605205340	RB	B-VP	O
expressed	express	e2160203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
HepG2	HepG2	0000	NN	I-NP	O
hepatoma	hepatoma	h0103050	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
indirect	indirect	i5306023	JJ	B-ADJP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-VP	O
upon	upon	u105	IN	B-PP	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
disrupts	disrupt	d0260132	VBZ	B-VP	O
hepatic	hepatic	h010302	JJ	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
homeostasis	homeostasis	h050230202	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPARalpha	PPARalpha	p1060410	NN	B-NP	O
target	target	t06203	NN	I-NP	O
genes	gene	g0502	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
important	important	i51063053	JJ	B-NP	O
new	new	n000	JJ	I-NP	O
mechanistic	mechanistic	m020502302	JJ	I-NP	O
information	information	i510650305	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
hepatotoxic	hepatotoxic	h0103030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
PPARalpha	PPARalpha	p1060410	NN	B-NP	O
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
and	and	a530	CC	I-NP	O
compliance	compliance	c05140520	NN	I-NP	O
with	with	w030	IN	B-PP	O
once	once	o520	RB	B-ADVP	O
-	-	-000	HYPH	I-ADVP	O
daily	daily	d040	JJ	B-NP	O
niacin	niacin	n0205	NN	I-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
release	release	r04020	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
lovastatin	lovastatin	l010230305	NN	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Impact	Impact	i51023	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Medical	Medical	m030204	NNP	B-NP	O
Subspecialty	Subspecialty	s0121020430	NNP	I-NP	O
on	on	o500	IN	B-PP	O
Patient	Patient	p03053	NNP	B-NP	O
Compliance	Compliance	c05140520	NN	I-NP	O
to	to	t000	TO	B-PP	O
Treatment	Treatment	t6035053	NN	B-NP	O
(	(	(000	(	O	O
IMPACT	IMPACT	i51023	NN	B-NP	O
)	)	)000	)	O	O
study	study	s3030	NN	B-NP	O
.	.	.000	.	O	O

Niacin	Niacin	n0205	NN	B-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
release	release	r04020	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
lovastatin	lovastatin	l010230305	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
product	product	p603023	NN	I-NP	O
approved	approve	a160103	VBN	B-VP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
hypercholesterolemia	hypercholesterolemia	h01062040230604050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
mixed	mixed	m0203	JJ	B-NP	O
dyslipidemia	dyslipidemia	d0240103050	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
labeled	label	l010403	VBN	B-VP	O
,	,	,000	,	O	O
multicenter	multicenter	m0430205306	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bedtime	bedtime	b03050	NN	B-NP	O
niacin	niacin	n0205	NN	I-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
release	release	r04020	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
lovastatin	lovastatin	l010230305	NN	I-NP	I-Chemical
when	when	w050	WRB	B-ADVP	O
dosed	dose	d0203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
patient	patient	p03053	NN	B-NP	O
compliance	compliance	c05140520	NN	I-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
practice	practice	p6023020	NN	I-NP	O
settings	setting	s03052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
499	499	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
dyslipidemia	dyslipidemia	d0240103050	NN	B-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
drug	drug	d602	NN	B-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
081	081	0000	CD	B-NP	O
sites	site	s0302	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
tablet	tablet	t01403	NN	I-NP	O
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
niacin	niacin	n0205	NN	B-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
release	release	r04020	NN	I-NP	O
/	/	/000	SYM	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
)	)	)000	)	O	O
once	once	o520	RB	B-ADVP	O
nightly	nightly	n020340	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	O	O
2	2	2000	CD	B-NP	O
tablets	tablet	t014032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
dietary	dietary	d03060	JJ	B-NP	O
counseling	counseling	c05204052	NN	I-NP	O
,	,	,000	,	O	O
educational	educational	e302030504	JJ	B-NP	O
materials	material	m0306042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
reminders	reminder	r05053062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
call	call	c040	VB	I-VP	O
a	a	a000	DT	B-NP	O
toll	toll	t040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
that	that	t030	WDT	B-NP	O
provided	provide	p6010303	VBD	B-VP	O
further	further	f06306	JJ	B-NP	O
education	education	e3020305	NN	I-NP	O
about	about	a103	IN	B-PP	O
dyslipidemia	dyslipidemia	d0240103050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
niacin	niacin	n0205	NN	I-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
release	release	r04020	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
lovastatin	lovastatin	l010230305	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Primary	Primary	p605060	JJ	B-NP	O
end	end	e530	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
study	study	s3030	NN	B-NP	O
compliance	compliance	c05140520	NN	I-NP	O
,	,	,000	,	O	O
increases	increase	i5260202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transaminases	transaminase	t605205050202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
>	>	>000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Final	Final	f0504	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
status	status	s30302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
217	217	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
94	94	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Compliance	Compliance	c05140520	NN	B-NP	O
to	to	t000	TO	B-PP	O
niacin	niacin	n0205	NN	B-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
release	release	r04020	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
lovastatin	lovastatin	l010230305	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
77	77	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
245	245	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
completing	complete	c051403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
southeast	southeast	s03023	NN	I-NP	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
enrolled	enrol	e560403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
endocrinologists	endocrinologist	e530260504020232	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
lowest	low	l023	JJS	I-NP	O
compliance	compliance	c05140520	NN	I-NP	O
and	and	a530	CC	O	O
highest	high	h02023	JJS	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

Flushing	Flushing	f402052	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
,	,	,000	,	O	O
reported	report	r0106303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
by	by	b000	IN	B-PP	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
alanine	alanine	a405050	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
>	>	>000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
was	be	w020	VBD	B-VP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
to	to	t000	TO	B-PP	O
>	>	>000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Niacin	Niacin	n0205	NN	B-NP	B-Chemical
extended	extend	e2305303	VBN	B-VP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
release	release	r04020	NN	I-NP	I-Chemical
/	/	/000	SYM	B-VP	I-Chemical
lovastatin	lovastatin	l010230305	NN	B-NP	I-Chemical
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
dosed	dose	d0203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
good	good	g030	JJ	B-NP	O
compliance	compliance	c05140520	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
very	very	v060	RB	B-NP	O
low	low	l000	JJ	I-NP	O
incidences	incidence	i520305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
Terminalia	Terminalia	t06505040	NNP	B-NP	B-Chemical
chebula	chebula	c01040	NN	I-NP	I-Chemical
against	against	a20523	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cardioprotective	Cardioprotective	c06301603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethanolic	ethanolic	e3050402	JJ	B-NP	B-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
of	of	o100	IN	B-PP	I-Chemical
Terminalia	Terminalia	t06505040	NNP	B-NP	I-Chemical
chebula	chebula	c01040	NN	I-NP	I-Chemical
fruits	fruit	f6032	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxides	peroxide	p06020302	NNS	I-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
.	.	.000	.	O	O

Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
to	to	t000	TO	B-VP	O
confirm	confirm	c051065	VB	I-VP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
.	.	.000	.	O	O

T	T	t000	NN	B-NP	B-Chemical
.	.	.000	VBD	B-VP	I-Chemical
chebula	chebula	c01040	NN	B-NP	I-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
ameliorate	ameliorate	a50406030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxide	peroxide	p0602030	NN	I-NP	B-Chemical
formation	formation	f0650305	NN	I-NP	O
and	and	a530	CC	O	O
retained	retain	r030503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
droperidol	droperidol	d601060304	NN	I-NP	B-Chemical
used	use	u203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
multiparous	multiparous	m043010602	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
in	in	i500	IN	B-PP	O
good	good	g030	JJ	B-NP	O
psychological	psychological	p20204020204	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
urgent	urgent	u62053	JJ	B-NP	O
caesarean	caesarean	c020605	JJ	I-NP	O
section	section	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
labour	labour	l0106	NN	B-NP	O
.	.	.000	.	O	O

Postoperatively	Postoperatively	p02301060301040	RB	B-ADVP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
device	device	d01020	NN	I-NP	O
delivering	deliver	d040106052	VBG	B-VP	O
boluses	bolus	b040202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
diamorphine	diamorphine	d05061050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
droperidol	droperidol	d601060304	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
025	025	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Whilst	Whilst	w0423	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
device	device	d01020	NN	I-NP	O
she	she	s000	PRP	B-NP	O
gradually	gradually	g603040	RB	B-ADVP	O
became	become	b02050	VBD	B-VP	O
anxious	anxious	a5202	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
feeling	feeling	f04052	NN	I-NP	O
worsening	worsen	w06205052	VBG	B-VP	O
after	after	a1306	IN	B-SBAR	O
each	each	e020	DT	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
droperidol	droperidol	d601060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychological	psychological	p20204020204	JJ	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
made	make	m030	VBN	I-VP	O
straight	straight	s360203	RB	B-ADVP	O
away	away	a000	RB	I-ADVP	O
although	although	a43020	IN	B-SBAR	O
on	on	o500	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
close	close	c4020	NN	I-NP	O
questioning	question	q02305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
gave	give	g010	VBD	B-VP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
clear	clear	c406	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
only	only	o540	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
droperidol	droperidol	d601060304	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
syringe	syringe	s060520	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
diamorphine	diamorphine	d05061050	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
substituted	substitute	s0123030303	VBN	I-VP	O
and	and	a530	CC	O	O
her	her	h060	PRP$	B-NP	O
unease	unease	u5020	NN	I-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
feel	feel	f040	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
antiemetics	antiemetic	a53050302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
,	,	,000	,	O	O
more	more	m060	RBR	B-NP	O
subtle	subtle	s01340	JJ	I-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
easily	easily	e02040	RB	I-VP	O
be	be	b000	VB	I-VP	O
overlooked	overlook	o10640203	VBN	I-VP	O
.	.	.000	.	O	O

Accurate	Accurate	a206030	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
history	history	h023060	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
differentiating	differentiate	d010605303052	VBG	B-VP	O
diabetes	diabete	d010302	NNS	B-NP	B-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
highlights	highlight	h020402032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nursing	nursing	n062052	NN	B-NP	O
in	in	i500	IN	B-PP	O
obtaining	obtain	o1305052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
accurate	accurate	a206030	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
history	history	h023060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
discussed	discuss	d020203	VBD	B-VP	O
herein	herein	h0605	RB	B-ADVP	O
initially	initially	i503040	RB	B-ADVP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
neurogenic	neurogenic	n06020502	JJ	B-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
(	(	(000	(	O	O
DI	DI	d000	NN	B-NP	B-Disease
)	)	)000	)	O	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
traumatic	traumatic	t6050302	JJ	I-NP	B-Disease
brain	brain	b605	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nursing	nursing	n062052	NN	I-NP	O
staff	staff	s301	NN	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
reviewing	review	r01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
health	health	h0430	NN	I-NP	O
history	history	h023060	NN	I-NP	O
with	with	w030	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
family	family	f05040	NN	I-NP	O
,	,	,000	,	O	O
discovered	discover	d02010603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
polydipsia	polydipsia	p04030120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
long	long	l052	RB	B-ADVP	O
-	-	-000	HYPH	O	O
standing	stand	s3053052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
DI	DI	d000	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
because	because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
received	receive	r020103	VBN	I-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
since	since	s0520	IN	B-PP	O
being	be	b052	VBG	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
,	,	,000	,	O	O
his	his	h020	PRP$	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
changed	change	c05203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
focus	focus	f0202	VB	I-VP	O
on	on	o500	IN	B-PP	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	B-Disease
DI	DI	d000	NNP	I-NP	I-Disease
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
combining	combine	c05105052	VBG	B-VP	O
information	information	i510650305	NN	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
physical	physical	p020204	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
radiologic	radiologic	r03040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
care	care	c060	NN	I-NP	O
team	team	t050	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
self	self	s041	AFX	B-ADJP	O
-	-	-000	HYPH	O	O
treating	treat	t603052	VBG	B-VP	O
his	his	h020	PRP$	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
DI	DI	d000	NN	I-NP	I-Disease
and	and	a530	CC	O	O
developed	develop	d01040103	VBD	B-VP	O
neurogenic	neurogenic	n06020502	JJ	B-NP	B-Disease
DI	DI	d000	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
trauma	trauma	t6050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-NP	O
successful	successful	s0202104	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
required	require	r020603	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neurogenic	neurogenic	n06020502	JJ	I-NP	B-Disease
DI	DI	d000	NN	I-NP	I-Disease
be	be	b000	VB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
concomitantly	concomitantly	c052050305340	RB	B-ADVP	O
.	.	.000	.	O	O

Factors	Factor	f023062	NNS	B-NP	O
contributing	contribute	c05360103052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
AIM	AIM	a050	NN	I-NP	O
:	:	:000	:	O	O
Interferon	Interferon	i530610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
produces	produce	p6030202	VBZ	B-VP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
factors	factor	f023062	NNS	I-NP	O
contributing	contribute	c05360103052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	O	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
interferon	interferon	i530610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
2b	2b	2100	NN	B-NP	I-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
MU	MU	m000	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
or	or	o600	CC	O	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
participated	participate	p06302010303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
<	<	<000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Ribavirin	Ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
2	2	2000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
2	2	2000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
even	even	e105	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
week	week	w020	NN	B-NP	O
2	2	2000	CD	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
<	<	<000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
as	as	a200	IN	B-PP	O
sex	sex	s020	NN	B-NP	O
(	(	(000	(	O	O
female	female	f05040	JJ	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
by	by	b000	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
univariate	univariate	u50106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Careful	Careful	c060104	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
experience	experience	e21060520	VBP	B-VP	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
2	2	2000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
care	care	c060	NN	I-NP	O
.	.	.000	.	O	O

Zidovudine	Zidovudine	z030103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
38	38	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
whereby	whereby	w06010	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
known	know	k505	VBN	B-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
tolerated	tolerate	t04060303	VBD	B-VP	O
well	well	w040	RB	B-ADVP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
reverse	reverse	r010620	JJ	I-NP	O
transcriptase	transcriptase	t60526013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	B-Chemical
'	'	'000	SYM	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
dideoxyinosine	dideoxyinosine	d03020502050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
caring	care	c06052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
hitherto	hitherto	h030630	NN	I-NP	O
rarely	rarely	r06040	RB	B-ADVP	O
reported	report	r0106303	VBD	B-VP	O
complication	complication	c0514020305	NN	B-NP	O
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
precedes	precede	p6020302	VBZ	B-VP	O
nitrative	nitrative	n03603010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
elevated	elevated	e4010303	JJ	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
ROS	ROS	r020	NN	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
nitrogen	nitrogen	n0360205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
(	(	(000	(	O	O
RNS	RNS	r520	NNS	B-NP	O
)	)	)000	)	O	O
reported	report	r0106303	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
actually	actually	a23040	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
nitrative	nitrative	n03603010	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
quantitatively	quantitatively	q053030301040	RB	I-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
and	and	a530	CC	O	O
subcellular	subcellular	s012040406	JJ	B-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
postulated	postulate	p023040303	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
approach	approach	a16020	NN	I-NP	O
.	.	.000	.	O	O

B6C3	B6C3	0000	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Ultrastructural	Ultrastructural	u43602360230604	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
and	and	a530	CC	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nonenal	nonenal	n050504	JJ	I-NP	I-Chemical
(	(	(000	(	O	O
4HNE	4HNE	4050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
protein	protein	p60305	NN	I-NP	O
adducts	adduct	a30232	NNS	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nitrotyrosine	nitrotyrosine	n036030602050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
3NT	3NT	3530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
computerized	computerized	c05103060203	JJ	B-NP	O
image	image	i5020	NN	I-NP	O
techniques	technique	t02050202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
as	as	a200	RB	B-ADVP	O
early	early	e0640	RB	I-ADVP	O
as	as	a200	IN	B-PP	O
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
extensively	extensively	e2305201040	RB	I-NP	O
and	and	a530	CC	O	O
progressively	progressively	p60260201040	RB	B-NP	O
injured	injure	i520603	VBN	I-NP	O
subcellular	subcellular	s012040406	JJ	I-NP	O
organelle	organelle	o6205040	NN	I-NP	O
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
4HNE	4HNE	4050	NN	B-NP	B-Chemical
protein	protein	p60305	NN	I-NP	O
adducts	adduct	a30232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
immunogold	immunogold	i50502043	NN	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
appearance	appearance	a1060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
4HNE	4HNE	4050	NN	B-NP	B-Chemical
protein	protein	p60305	NN	I-NP	O
adducts	adduct	a30232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
as	as	a200	RB	B-ADVP	O
early	early	e0640	RB	I-ADVP	O
as	as	a200	IN	B-PP	O
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
peak	peak	p020	NN	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
decline	decline	d024050	NN	I-NP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

3NT	3NT	3530	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
subcellular	subcellular	s012040406	JJ	I-NP	O
compartments	compartment	c05106350532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
and	and	a530	CC	O	O
subsequently	subsequently	s0120205340	RB	B-VP	O
declined	decline	d0240503	VBD	I-VP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
4HNE	4HNE	4050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
protein	protein	p60305	NN	I-NP	O
adducts	adduct	a30232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
point	point	p053	NN	I-NP	O
as	as	a200	IN	B-PP	O
when	when	w050	WRB	B-ADVP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
initially	initially	i503040	RB	B-ADVP	O
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
document	document	d0205053	VBP	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
that	that	t030	IN	B-SBAR	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
oxidative	oxidative	o20303010	JJ	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
precedes	precede	p6020302	VBZ	B-VP	O
nitrative	nitrative	n03603010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
nature	nature	n03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
,	,	,000	,	B-NP	O
not	not	n030	RB	I-NP	O
other	other	o306	JJ	B-NP	O
subcellular	subcellular	s012040406	JJ	I-NP	O
organelles	organelle	o62050402	NNS	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	O
.	.	.000	.	O	O

Sotalol	Sotalol	s030404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
dilated	dilated	d040303	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
dilated	dilate	d040303	VBN	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
incessant	incessant	i5202053	NN	I-NP	O
sustained	sustain	s0230503	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
(	(	(000	(	O	O
VT	VT	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nifekalant	nifekalant	n010204053	JJ	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
sustained	sustained	s0230503	JJ	B-NP	O
VT	VT	v300	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
alternate	alternate	a43065030	JJ	I-NP	O
class	class	c402	NN	I-NP	O
III	III	i000	CD	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
sotalol	sotalol	s030404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
effective	effective	e1023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
VT	VT	v300	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
after	after	a1306	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
over	over	o106	IN	B-PP	O
nifekalant	nifekalant	n010204053	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
sotalol	sotalol	s030404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ST	ST	s300	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
at	at	a300	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
the	the	t000	DT	I-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
for	for	f060	IN	B-PP	O
three	three	t060	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

ST	ST	s300	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
with	with	w030	IN	B-PP	O
chest	chest	c023	NN	B-NP	O
discomfort	discomfort	d02051063	NN	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
since	since	s0520	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
began	begin	b0205	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	B-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocking	block	b402052	VBG	B-VP	O
properties	property	p60106302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
sotalol	sotalol	s030404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
trazodone	trazodone	t60203050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2A	2A	2000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
2C	2C	2000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Hydroxytryptamine	Hydroxytryptamine	h0360203601305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
via	via	v000	IN	B-PP	O
stimulation	stimulation	s305040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2C	2C	2000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
exerts	exert	e20632	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
tonic	tonic	t0502	JJ	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
influence	influence	i5140520	NN	I-NP	O
on	on	o500	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2A	2A	2000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
enhances	enhance	e505202	VBZ	B-VP	O
stimulated	stimulate	s305040303	VBN	I-VP	O
DAergic	DAergic	d06202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
trazodone	trazodone	t60203050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2A	2A	2000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
2C	2C	2000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
behaviors	behavior	b01062	NNS	B-NP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
DAergic	DAergic	d06202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
dexamphetamine	dexamphetamine	d020510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
oral	oral	o604	JJ	I-NP	B-Disease
stereotypies	stereotypy	s306030102	NNS	I-NP	I-Disease
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
ergometrine	ergometrine	e6205036050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
wet	wet	w030	JJ	I-NP	O
dog	dog	d020	NN	I-NP	O
shake	shake	s020	NN	I-NP	O
(	(	(000	(	O	O
WDS	WDS	w320	NN	B-NP	O
)	)	)000	)	O	O
behavior	behavior	b0106	NN	B-NP	O
and	and	a530	CC	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
penile	penile	p05040	JJ	I-NP	O
erections	erection	e6023052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Trazodone	Trazodone	t60203050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
stereotypy	stereotypy	s30603010	NN	B-NP	O
and	and	a530	CC	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
trazodone	trazodone	t60203050	NN	I-NP	B-Chemical
enhanced	enhance	e505203	VBD	B-VP	O
dexamphetamine	dexamphetamine	d020510305050	NN	B-NP	B-Chemical
stereotypy	stereotypy	s30603010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
ergometrine	ergometrine	e6205036050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
WDS	WDS	w320	NN	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
and	and	a530	CC	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
penile	penile	p05040	JJ	I-NP	O
erections	erection	e6023052	NNS	I-NP	O
.	.	.000	.	O	O

Trazodone	Trazodone	t60203050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
40	40	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
induced	induce	i530203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamphetamine	dexamphetamine	d020510305050	NN	I-NP	B-Chemical
stereotypies	stereotypy	s306030102	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
block	block	b402	VB	I-VP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
postsynaptic	postsynaptic	p02320501302	JJ	I-NP	O
striatal	striatal	s360304	JJ	I-NP	O
D2	D2	0000	NN	I-NP	O
DA	DA	d000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
40	40	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
it	it	i300	PRP	B-NP	O
blocks	block	b402	VBZ	B-VP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
striatal	striatal	s360304	JJ	I-NP	O
D2	D2	0000	NN	I-NP	O
DA	DA	d000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
blocks	block	b402	NNS	I-NP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2A	2A	2000	NN	I-NP	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2C	2C	2000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
blocking	block	b402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
2C	2C	2000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
releases	release	r040202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
DAergic	DAergic	d06202	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
tonic	tonic	t0502	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
thereby	thereby	t06010	RB	B-VP	O
potentiates	potentiate	p030530302	VBZ	I-VP	O
dexamphetamine	dexamphetamine	d020510305050	NN	B-NP	B-Chemical
stereotypy	stereotypy	s30603010	NN	I-NP	O
and	and	a530	CC	O	O
antagonizes	antagonize	a5302050202	VBZ	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Swallowing	Swallow	s04052	VBG	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Gastrointestinal	Gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
known	know	k505	VBN	I-VP	O
for	for	f060	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
two	two	t000	CD	I-NP	O
centuries	century	c0530602	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
many	many	m050	JJ	B-NP	O
aspects	aspect	a210232	NNS	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
completely	completely	c051403040	RB	B-ADJP	O
clarified	clarify	c4060103	VBN	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
characterize	characterize	c0602306020	VB	I-VP	O
the	the	t000	DT	B-NP	O
oropharyngeal	oropharyngeal	o6010605204	JJ	I-NP	O
dynamics	dynamic	d050502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	I-PP	O
without	without	w0303	IN	I-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
nondyskinetic	nondyskinetic	n05302050302	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
asked	ask	a203	VBN	I-VP	O
about	about	a103	IN	B-PP	O
dysphagia	dysphagia	d021020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
evaluated	evaluate	e1040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
Unified	Unified	u50103	NNP	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NNP	I-NP	I-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
Parts	Parts	p0632	NNP	I-NP	O
II	II	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
III	III	i000	CD	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Hoehn	Hoehn	h050	NNP	I-NP	O
and	and	a530	CC	O	O
Yahr	Yahr	y060	NN	B-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

Deglutition	Deglutition	d024030305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
modified	modify	m030103	VBN	B-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
swallow	swallow	s040	NN	I-NP	O
with	with	w030	IN	B-PP	O
videofluoroscopy	videofluoroscopy	v030140602010	NN	B-NP	O
.	.	.000	.	O	O

Nondyskinetic	Nondyskinetic	n05302050302	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
ones	one	o502	NNS	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
less	less	l020	RBR	B-NP	O
oropharyngeal	oropharyngeal	o6010605204	JJ	I-NP	O
swallowing	swallow	s04052	VBG	I-NP	O
efficiency	efficiency	e1020520	NN	I-NP	O
(	(	(000	(	O	O
OPSE	OPSE	o120	NN	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
liquid	liquid	l0203	JJ	B-NP	O
food	food	f030	NN	I-NP	O
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
Dunnett	Dunnett	d0503	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Dyskinetic	Dyskinetic	d02050302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
OPSE	OPSE	o120	NN	I-NP	O
than	than	t050	IN	B-PP	O
nondyskinetic	nondyskinetic	n05302050302	JJ	B-NP	O
(	(	(000	(	O	O
Dunnett	Dunnett	d0503	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
06	06	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
using	use	u2052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
OPSE	OPSE	o120	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
trend	trend	t6053	NN	I-NP	O
toward	toward	t063	IN	B-PP	O
a	a	a000	DT	B-NP	O
smaller	small	s50406	JJR	I-NP	O
oral	oral	o604	JJ	I-NP	O
transit	transit	t605203	NN	I-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
Pearson	Pearson	p06205	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
08	08	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
the	the	t000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
dysphagia	dysphagia	d021020	NN	B-NP	B-Disease
nor	nor	n060	CC	O	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
PD	PD	p300	NN	I-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
videofluoroscopic	videofluoroscopic	v0301406020102	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
dyskinetic	dyskinetic	d02050302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
better	well	b0306	RBR	B-ADVP	O
in	in	i500	IN	B-PP	O
swallowing	swallow	s04052	VBG	B-VP	O
function	function	f052305	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
explained	explain	e2140503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
deglutition	deglutition	d024030305	NN	B-NP	O
and	and	a530	CC	O	O
confirm	confirm	c051065	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
dysphagia	dysphagia	d021020	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
predictor	predictor	p60302306	NN	I-NP	O
of	of	o100	IN	B-PP	O
deglutition	deglutition	d024030305	NN	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
.	.	.000	.	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nuclear	nuclear	n02406	JJ	B-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	B-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Animals	Animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
show	show	s000	VB	I-VP	O
residual	residual	r020304	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
interstitial	interstitial	i5306230304	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
nuclear	nuclear	n02406	JJ	B-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	O	O
kappaB	kappaB	k0101	NN	B-NP	O
(	(	(000	(	O	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mitogen	mitogen	m030205	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
activated	activate	a23010303	VBN	B-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
kinases	kinase	k050202	NNS	B-NP	O
and	and	a530	CC	O	O
macrophages	macrophage	m026010202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
and	and	a530	CC	O	O
structural	structural	s360230604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
pyrrolidine	pyrrolidine	p060403050	NN	B-NP	B-Chemical
dithiocarbamate	dithiocarbamate	d030206105030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PDTC	PDTC	p320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
NF	NF	n100	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
38	38	0000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
twice	twice	t020	RB	B-NP	O
a	a	a000	DT	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
9	9	9000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
38	38	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
PDTC	PDTC	p320	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
28	28	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
M	M	m000	NN	I-NP	O
NaCl	NaCl	n024	NN	I-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
these	these	t020	DT	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
removed	remove	r050103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
scored	score	s20603	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
staining	staining	s305052	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
area	area	a600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
morphometry	morphometry	m061050360	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
presented	present	p60205303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
transitory	transitory	t605203060	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-VP	O
ED	ED	e300	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
MAP	MAP	m010	NN	B-NP	O
kinases	kinase	k050202	NNS	I-NP	O
and	and	a530	CC	O	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
staining	staining	s305052	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
from	from	f605	IN	B-PP	O
all	all	a400	DT	B-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
killed	kill	k0403	VBN	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
30	30	0000	CD	I-NP	O
also	also	a420	RB	B-VP	O
presented	present	p60205303	VBN	I-VP	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
despite	despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
PDTC	PDTC	p320	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	O	O
kappaB	kappaB	k0101	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	B-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Glucose	Glucose	g402020	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
sampled	sample	s051403	VBN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
tolerance	tolerance	t04060520	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
minimal	minimal	m050504	JJ	B-NP	O
model	model	m0304	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
increasing	increase	i52602052	VBG	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
remains	remain	r05052	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
whether	whether	w0306	IN	B-SBAR	O
atypical	atypical	a3010204	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
directly	directly	d0602340	RB	I-VP	O
affecting	affect	a1023052	VBG	I-VP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
or	or	o600	CC	O	O
simply	simply	s05140	RB	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
known	know	k505	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
diabetes	diabete	d010302	NNS	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
most	most	m023	RBS	B-VP	O
clearly	clearly	c40640	RB	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
sampled	sample	s051403	VBN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
tolerance	tolerance	t04060520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
design	design	d02025	NN	I-NP	O
in	in	i500	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
,	,	,000	,	O	O
treated	treat	t60303	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
evaluated	evaluate	e1040303	VBN	B-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
sampled	sample	s051403	VBN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
tolerance	tolerance	t04060520	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Bergman	Bergman	b062505	NNP	I-NP	O
minimal	minimal	m050504	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Subjects	Subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
recruited	recruit	r0260303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
urban	urban	u6105	JJ	I-NP	O
community	community	c0505030	NN	I-NP	O
mental	mental	m05304	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
clinic	clinic	c40502	NN	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
research	research	r020620	NN	I-NP	O
center	center	c05306	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
Fifty	Fifty	f0130	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
signed	sign	s02503	VBD	B-VP	O
informed	inform	i5106503	VBN	B-NP	O
consent	consent	c052053	NN	I-NP	O
and	and	a530	CC	O	O
41	41	0000	CD	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
the	the	t000	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
sampled	sample	s051403	VBN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
tolerance	tolerance	t04060520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
nonobese	nonobese	n0501020	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
or	or	o600	CC	O	O
schizoaffective	schizoaffective	s20201023010	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
matched	match	m03203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
body	body	b030	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
index	index	i5302	NN	I-NP	O
and	and	a530	CC	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NNP	B-NP	O
OUTCOME	OUTCOME	o032050	NNP	I-NP	O
MEASURES	MEASURES	m020602	NNP	I-NP	O
:	:	:000	:	O	O
Fasting	Fast	f023052	VBG	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
fasting	fast	f023052	VBG	B-VP	O
serum	serum	s0605	NN	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
insulin	insulin	i520405	NN	B-NP	B-Disease
sensitivity	sensitivity	s0520301030	NN	I-NP	I-Disease
index	index	i5302	NN	I-NP	O
,	,	,000	,	O	O
homeostasis	homeostasis	h050230202	NN	B-NP	O
model	model	m0304	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
effectiveness	effectiveness	e1023010502	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
identified	identify	i30530103	VBN	I-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
68	68	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
28	28	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
17	17	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
40	40	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
33	33	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
(	(	(000	(	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Fasting	Fast	f023052	VBG	B-VP	O
serum	serum	s0605	NN	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
differed	differ	d010603	VBD	B-VP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
(	(	(000	(	O	O
F	F	f000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
35	35	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
047	047	0000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
>	>	>000	SYM	B-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
>	>	>000	SYM	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	JJ	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
32	32	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	JJ	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
15	15	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	B-Disease
sensitivity	sensitivity	s0520301030	NN	I-NP	I-Disease
index	index	i5302	NN	I-NP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
(	(	(000	(	O	O
F	F	f000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
66	66	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	O	O
001	001	0000	CD	O	O
)	)	)000	)	O	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
<	<	<000	SYM	B-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
<	<	<000	SYM	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
exhibiting	exhibit	e20103052	VBG	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
insulin	insulin	i520405	NN	I-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
vs	vs	v200	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
29	29	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
;	;	;000	:	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
vs	vs	v200	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
62	62	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
[	[	[000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	O	O
001	001	0000	CD	O	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
homeostasis	homeostasis	h050230202	NN	I-NP	O
model	model	m0304	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
also	also	a420	RB	B-ADVP	O
differed	differ	d010603	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
(	(	(000	(	O	O
F	F	f000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
92	92	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
>	>	>000	SYM	B-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
>	>	>000	SYM	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
vs	vs	v200	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	JJ	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
94	94	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
006	006	0000	CD	I-NP	O
;	;	;000	:	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
vs	vs	v200	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	JJ	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
42	42	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
in	in	i500	IN	B-PP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
effectiveness	effectiveness	e1023010502	NN	I-NP	O
(	(	(000	(	O	O
F	F	f000	NN	B-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
18	18	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
<	<	<000	SYM	B-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
<	<	<000	SYM	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
59	59	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
34	34	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
nonobese	nonobese	n0501020	JJ	B-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
displayed	display	d021403	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
insulin	insulin	i520405	NN	I-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
effectiveness	effectiveness	e1023010502	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
.	.	.000	.	O	O

Thoracic	Thoracic	t060202	JJ	B-NP	B-Disease
hematomyelia	hematomyelia	h050305040	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
coumadin	coumadin	c050305	NN	B-NP	B-Chemical
anticoagulant	anticoagulant	a53020204053	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thoracic	thoracic	t060202	JJ	B-NP	B-Disease
hematomyelia	hematomyelia	h050305040	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
anticoagulant	anticoagulant	a53020204053	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
other	other	o306	JJ	I-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
suspicion	suspicion	s0210205	NN	B-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
quick	quick	q020	JJ	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
and	and	a530	CC	O	O
successful	successful	s0202104	JJ	B-NP	O
decompressive	decompressive	d02051602010	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Mania	Mania	m050	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
adolescents	adolescent	a304020532	NNS	B-NP	O
.	.	.000	.	O	O

Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
gaining	gain	g05052	VBG	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
acceptance	acceptance	a20130520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
adolescent	adolescent	a30402053	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Generally	Generally	g0506040	RB	B-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
and	and	a530	CC	O	O
well	well	w040	RB	B-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
,	,	,000	,	O	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
induce	induce	i53020	VB	I-VP	O
mania	mania	m050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
five	five	f010	CD	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
adolescents	adolescent	a304020532	NNS	I-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
16	16	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
mania	mania	m050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
pharmacotherapy	pharmacotherapy	p065020306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
here	here	h060	RB	B-ADVP	O
.	.	.000	.	O	O

Apparent	Apparent	a106053	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mania	mania	m050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
hypomania	hypomania	h0105050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
pharmacotherapy	pharmacotherapy	p065020306010	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
attention	attention	a305305	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
and	and	a530	CC	O	O
affective	affective	a1023010	JJ	B-NP	O
instability	instability	i5230104030	NN	I-NP	O
;	;	;000	:	O	O
major	major	m0206	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
features	feature	f030602	NNS	I-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
family	family	f05040	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
affective	affective	a1023010	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
;	;	;000	:	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
increase	increase	i526020	VBP	B-VP	O
individual	individual	i53010304	JJ	B-NP	O
vulnerability	vulnerability	v045060104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
mania	mania	m050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adolescents	adolescent	a304020532	NNS	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
melphalan	melphalan	m0410405	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
systemic	systemic	s0230502	JJ	I-NP	I-Disease
amyloidosis	amyloidosis	a504030202	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
stem	stem	s305	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
systemic	systemic	s0230502	JJ	I-NP	I-Disease
amyloidosis	amyloidosis	a504030202	NN	I-NP	I-Disease
(	(	(000	(	O	O
AL	AL	a400	NN	B-NP	B-Disease
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
time	time	t050	NN	I-NP	O
from	from	f605	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
only	only	o540	RB	B-NP	O
17	17	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
melphalan	melphalan	m0410405	NN	I-NP	B-Chemical
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
(	(	(000	(	O	O
PBSCT	PBSCT	p123	NN	B-NP	O
)	)	)000	)	O	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
promising	promising	p60502052	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
high	high	h020	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
noted	note	n0303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
melphalan	melphalan	m0410405	NN	B-NP	B-Chemical
conditioning	conditioning	c0530305052	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
further	further	f06306	RB	I-VP	O
examine	examine	e205050	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
and	and	a530	CC	O	O
impact	impact	i51023	NN	B-NP	O
on	on	o500	IN	B-PP	O
posttransplant	posttransplant	p023605214053	NN	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Consecutive	Consecutive	c0520203010	JJ	B-NP	O
AL	AL	a400	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
PBSCT	PBSCT	p123	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
(	(	(000	(	O	O
ARI	ARI	a600	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
melphalan	melphalan	m0410405	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
conditioning	condition	c0530305052	VBG	B-VP	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
sediment	sediment	s0305053	NN	I-NP	O
score	score	s2060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
sum	sum	s050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
individual	individual	i53010304	JJ	I-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sediment	sediment	s0305053	NN	B-NP	O
identified	identify	i30530103	VBN	B-VP	O
on	on	o500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
80	80	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
,	,	,000	,	O	O
ARI	ARI	a600	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
melphalan	melphalan	m0410405	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Univariate	Univariate	u50106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
hypoalbuminemia	hypoalbuminemia	h010410505050	NN	B-NP	B-Disease
,	,	,000	,	O	O
heavy	heavy	h010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
,	,	,000	,	O	O
diuretic	diuretic	d060302	JJ	B-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
urine	urine	u6050	NN	B-NP	O
sediment	sediment	s0305053	NN	I-NP	O
score	score	s2060	NN	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
sediment	sediment	s0305053	NN	I-NP	O
score	score	s2060	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
independently	independently	i530105305340	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
multivariate	multivariate	m0430106030	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
ARI	ARI	a600	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
melphalan	melphalan	m0410405	NN	I-NP	B-Chemical
underwent	undergo	u5306053	VBD	B-VP	O
dialysis	dialysis	d040202	NN	B-NP	O
more	more	m060	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
007	007	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
worse	worse	w0620	JJR	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
timing	timing	t05052	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
strongly	strongly	s3605240	RB	B-ADVP	O
suggests	suggest	s020232	VBZ	B-VP	O
melphalan	melphalan	m0410405	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
causative	causative	c0203010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Ongoing	Ongoe	o52052	VBG	B-VP	O
tubular	tubular	t010406	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
prerequisite	prerequisite	p6060202030	NN	I-NP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
melphalan	melphalan	m0410405	NN	B-NP	B-Chemical
as	as	a200	IN	B-SBAR	O
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
sediment	sediment	s0305053	NN	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
ARI	ARI	a600	NN	B-NP	B-Disease
adversely	adversely	a31062040	RB	B-VP	O
affected	affect	a102303	VBD	I-VP	O
the	the	t000	DT	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
PBSCT	PBSCT	p123	NN	B-NP	O
.	.	.000	.	O	O

Effective	Effective	e1023010	JJ	B-NP	O
preventive	preventive	p601053010	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
may	may	m000	MD	B-VP	O
help	help	h041	VB	I-VP	O
decrease	decrease	d026020	VB	I-VP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
PBSCT	PBSCT	p123	NN	B-NP	O
in	in	i500	IN	B-PP	O
AL	AL	a400	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Focal	Focal	f0204	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
:	:	:000	:	O	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
reperfusion	reperfusion	r010610205	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
180	180	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
temporary	temporary	t05106060	JJ	B-NP	O
middle	middle	m0340	JJ	I-NP	B-Disease
cerebral	cerebral	c0601604	JJ	I-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
brain	brain	b605	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
manipulated	manipulate	m0501040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
120	120	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
reperfusion	reperfusion	r010610205	NN	B-NP	O
:	:	:000	:	O	O
Control	Control	c053604	NN	B-NP	O
,	,	,000	,	O	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
reperfusion	reperfusion	r010610205	NN	I-NP	O
;	;	;000	:	O	O
90	90	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
90	90	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
35	35	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
90	90	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
reperfusion	reperfusion	r010610205	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
;	;	;000	:	O	O
15	15	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
reperfusion	reperfusion	r010610205	NN	I-NP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
75	75	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
normotension	normotension	n0650305205	NN	B-NP	O
.	.	.000	.	O	O

Part	Part	p063	NNP	B-NP	O
A	A	a000	NNP	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
brain	brain	b605	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
staining	stain	s305052	VBG	B-VP	O
tissue	tissue	t020	NN	B-NP	O
using	use	u2052	VBG	B-VP	O
2	2	2000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
triphenyltetrazolium	triphenyltetrazolium	t60105043036020405	NN	I-NP	I-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
microgravimetry	microgravimetry	m02602601050360	NN	B-NP	O
.	.	.000	.	O	O

Part	Part	p063	NNP	B-NP	O
B	B	b000	NNP	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
and	and	a530	CC	I-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
extravasation	extravasation	e23601020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Evans	Evans	e1052	NNP	B-NP	O
Blue	Blue	b400	NNP	I-NP	O
dye	dye	d000	NN	I-NP	O
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
percentage	percentage	p062053020	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
hemisphere	hemisphere	h05021060	NN	I-NP	I-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
,	,	,000	,	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
the	the	t000	DT	B-NP	O
90	90	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
turn	turn	t065	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
42	42	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Specific	Specific	s1020102	JJ	B-NP	O
gravity	gravity	g601030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
043	043	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
the	the	t000	DT	B-NP	O
90	90	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
036	036	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
003	003	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
037	037	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
003	003	0000	CD	I-NP	O
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Evans	Evans	e1052	NNP	B-NP	B-Chemical
Blue	Blue	b400	NNP	I-NP	I-Chemical
(	(	(000	(	O	O
mug	mug	m020	NN	B-NP	O
g	g	g000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
90	90	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
turn	turn	t065	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
HTN	HTN	h350	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-NP	O
during	during	d06052	IN	B-PP	O
reperfusion	reperfusion	r010610205	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
decreases	decrease	d0260202	VBZ	B-VP	O
brain	brain	b605	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
;	;	;000	:	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
sustained	sustained	s0230503	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasogenic	vasogenic	v02020502	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
.	.	.000	.	O	O

People	People	p0140	NNS	B-NP	O
aged	age	a203	VBN	B-VP	O
over	over	o106	IN	B-PP	O
75	75	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
500	500	0000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
people	people	p0140	NNS	B-NP	O
aged	age	a203	VBN	B-VP	O
76	76	0000	CD	B-NP	O
and	and	a530	CC	O	O
older	old	o4306	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
adjusted	adjust	a3202303	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
recently	recently	r0205340	RB	I-VP	O
been	be	b050	VBN	I-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
observational	observational	o12061030504	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
healthcare	healthcare	h04302060	NN	I-NP	O
network	network	n03062	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
four	four	f060	CD	B-NP	O
tertiary	tertiary	t063060	JJ	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
.	.	.000	.	O	O

PARTICIPANTS	PARTICIPANTS	p06302010532	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
thirty	thirty	t0630	CD	I-NP	O
-	-	-000	HYPH	O	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
aged	age	a203	VBN	B-ADJP	O
76	76	0000	CD	B-NP	O
and	and	a530	CC	O	O
older	old	o4306	JJR	B-ADJP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
healthcare	healthcare	h04302060	NN	I-NP	O
network	network	n03062	NN	I-NP	O
between	between	b0305	IN	B-PP	O
July	July	j040	NNP	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
2001	2001	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
June	June	j050	NNP	B-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2002	2002	0000	CD	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
:	:	:000	:	O	O
Information	Information	i510650305	NN	B-NP	O
regarding	regard	r02063052	VBG	B-PP	O
major	major	m0206	JJ	B-NP	O
bleeding	bleed	b403052	VBG	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
,	,	,000	,	O	O
strokes	stroke	s360202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
relatives	relative	r04030102	NNS	B-NP	O
,	,	,000	,	O	O
primary	primary	p605060	JJ	B-NP	O
physicians	physician	p0202052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
medical	medical	m030204	JJ	B-NP	O
records	record	r020632	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
twenty	twenty	t0530	CD	I-NP	O
-	-	-000	HYPH	O	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
men	man	m050	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
81	81	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
76	76	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
94	94	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
on	on	o500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
530	530	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
28	28	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
53	53	0000	CD	B-NP	O
major	major	m0206	JJ	I-NP	O
hemorrhages	hemorrhage	h05060202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
annual	annual	a504	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
24	24	0000	CD	B-NP	O
(	(	(000	(	O	O
45	45	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
fatal	fatal	f0304	JJ	B-NP	O
bleeds	bleed	b4032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
annual	annual	a504	JJ	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
rate	rate	r030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
old	old	o430	JJ	I-NP	O
,	,	,000	,	I-NP	O
frail	frail	f604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
excluding	exclude	e2403052	VBG	B-PP	O
fatalities	fatality	f03040302	NNS	B-NP	O
,	,	,000	,	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
no	no	n000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
rate	rate	r030	NN	I-NP	O
on	on	o500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
,	,	,000	,	O	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
how	how	h000	WRB	B-ADVP	O
effective	effective	e1023010	JJ	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
of	of	o100	IN	B-PP	O
celecoxib	celecoxib	c04020201	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
skin	skin	s205	NN	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
to	to	t000	TO	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	B-VP	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
with	with	w030	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Acetaminophen	Acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
Nimesulide	Nimesulide	n050204030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
analgesic	analgesic	a50420202	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
antipyretic	antipyretic	a5301060302	JJ	I-NP	O
/	/	/000	SYM	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	JJ	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

Celecoxib	Celecoxib	c04020201	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CE	CE	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
selectivity	selectivity	s0402301030	NN	I-NP	O
and	and	a530	CC	O	O
affinity	affinity	a105030	NN	B-NP	O
for	for	f060	IN	B-PP	O
COX	COX	c020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
CE	CE	c000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
documented	document	d020505303	VBN	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
to	to	t000	TO	B-PP	O
P	P	p000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
associated	associate	a2020303	VBN	B-VP	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
to	to	t000	TO	B-PP	O
classic	classic	c40202	JJ	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
9	9	9000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
P	P	p000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
associated	associated	a2020303	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
classic	classic	c40202	JJ	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
P	P	p000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
skin	skin	s205	NN	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
based	base	b0203	VBN	I-VP	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
blindly	blindly	b405340	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
beginning	beginning	b0205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
three	three	t060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
CE	CE	c000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
refracted	refracted	r01602303	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
controlled	control	c05360403	VBN	B-VP	O
again	again	a205	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
to	to	t000	TO	B-VP	O
exclude	exclude	e24030	VB	I-VP	O
delayed	delayed	d0403	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
if	if	i100	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	following	f04052	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
:	:	:000	:	O	O
erythema	erythema	e603050	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
rush	rush	r020	NN	I-NP	O
or	or	o600	CC	I-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
No	No	n000	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
and	and	a530	CC	O	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
88	88	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
tolerated	tolerate	t04060303	VBD	B-VP	O
CE	CE	c000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lips	lip	l012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Only	Only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
CE	CE	c000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
among	among	a5052	IN	B-PP	O
9	9	9000	CD	B-NP	O
P	P	p000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
highly	highly	h02040	RB	B-ADVP	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
intolerant	intolerant	i530406053	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CE	CE	c000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reasonably	reasonably	r02050140	RB	I-NP	O
safe	safe	s010	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
who	who	w000	WP	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
P	P	p000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	I-NP	O
end	end	e530	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Studies	Study	s30302	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
given	give	g0105	VBN	I-VP	O
conflicting	conflict	c0514023052	VBG	I-VP	O
results	result	r020432	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
this	this	t020	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
incident	incident	i5203053	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
entering	enter	e5306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
program	program	p602605	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
area	area	a600	NN	I-NP	O
between	between	b0305	IN	B-PP	O
June	June	j050	NNP	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
1995	1995	0000	CD	I-NP	O
and	and	a530	CC	O	O
November	November	n0105106	NNP	B-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1997	1997	0000	CD	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
classified	classify	c4020103	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
disease	disease	d02020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
presumably	presumably	p602050140	RB	I-VP	O
led	lead	l030	VBN	I-VP	O
them	them	t050	PRP	B-NP	O
to	to	t000	TO	B-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
.	.	.000	.	O	O

Controls	Control	c0536042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
patients	patient	p030532	NNS	B-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
from	from	f605	IN	B-PP	O
where	where	w060	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
arose	arise	a6020	VBD	B-VP	O
,	,	,000	,	O	O
also	also	a420	RB	B-ADVP	O
matched	match	m03203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	I-NP	O
sex	sex	s020	NN	I-NP	O
.	.	.000	.	O	O

Odds	Odd	o320	NNS	B-NP	O
ratios	ratio	r0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
conditional	conditional	c053030504	JJ	I-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
confounding	confound	c051053052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-PP	O
for	for	f060	IN	I-PP	O
the	the	t000	DT	B-NP	O
whole	whole	w040	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
various	various	v0602	JJ	I-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
diseases	disease	d020202	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Five	Five	f010	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	I-NP	O
eighty	eighty	e02030	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
1190	1190	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
analgesic	analgesic	a50420202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
22	22	0000	CD	O	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
89	89	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
66	66	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
risks	risk	r020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
56	56	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
30	30	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
60	60	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
76	76	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
pyrazolones	pyrazolone	p0602040502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
80	80	0000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
39	39	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
63	63	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
94	94	0000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
57	57	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
56	56	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
nonaspirin	nonaspirin	n050210605	JJ	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cumulated	cumulate	c05040303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
particularly	particularly	p06302040640	RB	B-ADJP	O
high	high	h020	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
subset	subset	s01203	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
disease	disease	d02020	NN	B-NP	O
[	[	[000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
17	17	0000	CD	B-NP	O
-	-	-000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
72	72	0000	CD	I-NP	O
)	)	)000	)	O	O
]	]	]000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonaspirin	nonaspirin	n050210605	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	O	O
poisoning	poison	p0205052	VBG	B-VP	B-Disease
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	O
g	g	g000	NN	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
g	g	g000	NN	I-NP	O
of	of	o100	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hypocalcaemia	hypocalcaemia	h0102042050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
QT	QT	q300	NN	I-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
respond	respond	r021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
gluconate	gluconate	g40205030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Growth	Growth	g6030	NN	B-NP	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
protein	protein	p60305	NN	B-NP	O
43	43	0000	CD	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cycloheximide	cycloheximide	c0240205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
GAP43	GAP43	0000	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
linked	link	l05203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
mossy	mossy	m020	NN	B-NP	O
fiber	fiber	f0106	NN	I-NP	O
sprouting	sprouting	s1603052	NN	I-NP	O
(	(	(000	(	O	O
MFS	MFS	m120	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
how	how	h000	WRB	B-ADVP	O
GAP43	GAP43	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
(	(	(000	(	O	O
GAP43	GAP43	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ir	ir	i600	NN	I-NP	O
)	)	)000	)	O	O
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
MFS	MFS	m120	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
(	(	(000	(	O	O
densitometry	densitometry	d05203050360	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
extension	extension	e2305205	NN	B-NP	O
(	(	(000	(	O	O
width	width	w030	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
GAP43	GAP43	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ir	ir	i600	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
(	(	(000	(	O	O
IML	IML	i540	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
subject	subject	s012023	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Pilo	Pilo	p040	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
previously	previously	p6010240	RB	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
with	with	w030	IN	B-PP	O
cycloheximide	cycloheximide	c0240205030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CHX	CHX	c020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
MFS	MFS	m120	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
CHX	CHX	c020	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
Pilo	Pilo	p040	NNP	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Pilo	Pilo	p040	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
CHX	CHX	c020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
30	30	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
60	60	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
brain	brain	b605	NN	B-NP	O
sections	section	s023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
processed	process	p6020203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
GAP43	GAP43	0000	NN	B-NP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Densitometry	Densitometry	d05203050360	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
GAP43	GAP43	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
ir	ir	i600	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IML	IML	i540	NNP	I-NP	O
between	between	b0305	IN	B-PP	O
Pilo	Pilo	p040	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
CHX	CHX	c020	NNP	B-NP	B-Chemical
+	+	+000	SYM	B-VP	O
Pilo	Pilo	p040	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
width	width	w030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GAP43	GAP43	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ir	ir	i600	NN	I-NP	O
band	band	b053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IML	IML	i540	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
CHX	CHX	c020	NN	B-NP	B-Chemical
+	+	+000	CC	I-NP	O
Pilo	Pilo	p040	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
larger	large	l06206	JJR	I-NP	O
band	band	b053	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Pilo	Pilo	p040	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
current	current	c06053	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
animals	animal	a505042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CHX	CHX	c020	NNP	I-NP	B-Chemical
+	+	+000	SYM	I-NP	O
Pilo	Pilo	p040	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
GAP43	GAP43	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
ir	ir	i600	NN	I-NP	O
band	band	b053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IML	IML	i540	NN	I-NP	O
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
reinforces	reinforce	r05106202	VBZ	B-VP	O
prior	prior	p606	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
MFS	MFS	m120	NN	B-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
GAP43	GAP43	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ir	ir	i600	NN	I-NP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
Pilo	Pilo	p040	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
thinning	thinning	t05052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
band	band	b053	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
narrow	narrow	n060	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
just	just	j023	RB	B-PP	O
above	above	a1010	IN	I-PP	O
the	the	t000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hilar	hilar	h0406	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
projections	projection	p602023052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
express	express	e21602	VBP	B-VP	O
GAP	GAP	g010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
43	43	0000	CD	I-NP	O
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
antagonizes	antagonize	a5302050202	VBZ	B-VP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
widely	widely	w03040	RB	I-VP	O
consumed	consume	c0520503	VBN	I-VP	O
licit	licit	l0203	NN	B-NP	O
psychoactive	psychoactive	p202023010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
worldwide	worldwide	w0643030	RB	B-ADVP	O
.	.	.000	.	O	O

Epidemiological	Epidemiological	e1030504020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
generally	generally	g0506040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
concurrently	concurrently	c0520605340	RB	B-ADVP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
clear	clear	c406	JJ	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
them	them	t050	PRP	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
on	on	o500	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
investigates	investigate	i51023020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
another	another	a50306	DT	B-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
plus	plus	p402	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
maze	maze	m020	NN	I-NP	O
(	(	(000	(	O	O
EPM	EPM	e150	NN	B-NP	O
)	)	)000	)	O	O
test	test	t023	NN	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
on	on	o500	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Adult	Adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
Webster	Webster	w012306	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
32	32	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
10	10	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injections	injection	i52023052	NNS	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
closed	close	c40203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
arm	arm	a650	NN	I-NP	O
time	time	t050	NN	I-NP	O
and	and	a530	CC	O	O
entries	entry	e53602	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
EPM	EPM	e150	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
session	session	s0205	NN	I-NP	O
.	.	.000	.	O	O

Locomotor	Locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
EPM	EPM	e150	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
itself	itself	i32041	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
any	any	a500	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
EPM	EPM	e150	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
produced	produce	p6030203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
apparent	apparent	a106053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
open	open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
arm	arm	a650	NN	I-NP	O
time	time	t050	NN	I-NP	O
and	and	a530	CC	I-NP	O
entry	entry	e5360	NN	I-NP	O
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
blocked	block	b40203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
any	any	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
specific	specific	s1020102	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
instead	instead	i52303	RB	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
anxiolytic	anxiolytic	a52040302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
extend	extend	e23053	VB	I-VP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
term	term	t065	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
perimenopausal	perimenopausal	p060505010204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hormone	Hormone	h065050	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
HT	HT	h300	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
menopausal	menopausal	m05010204	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
and	and	a530	CC	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
women	woman	w0505	NNS	I-NP	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
supporting	support	s01063052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
indications	indication	i530203052	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
largely	largely	l062040	RB	B-ADJP	O
observational	observational	o12061030504	JJ	I-ADJP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
HT	HT	h300	NN	I-NP	O
on	on	o500	IN	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
,	,	,000	,	O	O
transient	transient	t6052053	JJ	B-NP	B-Disease
ischaemic	ischaemic	i20502	JJ	I-NP	I-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
colorectal	colorectal	c040602304	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
dementia	dementia	d050530	NN	B-NP	B-Disease
,	,	,000	,	O	O
fractures	fracture	f60230602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

SEARCH	SEARCH	s0620	NN	B-NP	O
STRATEGY	STRATEGY	s3603020	NN	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
searched	search	s06203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
databases	database	d03010202	NNS	I-NP	O
up	up	u100	RB	B-PP	O
to	to	t000	TO	B-PP	O
November	November	n0105106	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
Cochrane	Cochrane	c0206050	NNP	I-NP	O
Menstrual	Menstrual	m0523604	NNP	I-NP	O
Disorders	Disorders	d02063062	NNP	I-NP	O
and	and	a530	CC	O	O
Subfertility	Subfertility	s0106304030	NNP	B-NP	O
Group	Group	g601	NNP	I-NP	O
Trials	Trials	t6042	NNP	I-NP	O
Register	Register	r0202306	NNP	I-NP	O
,	,	,000	,	O	O
Cochrane	Cochrane	c0206050	NNP	B-NP	O
Central	Central	c053604	NNP	I-NP	O
Register	Register	r0202306	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Controlled	Controlled	c05360403	NNP	B-NP	O
Trials	Trials	t6042	NNP	I-NP	O
(	(	(000	(	O	O
CENTRAL	CENTRAL	c053604	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
MEDLINE	MEDLINE	m034050	NNP	B-NP	O
,	,	,000	,	O	O
EMBASE	EMBASE	e51020	NNP	B-NP	O
,	,	,000	,	O	O
Biological	Biological	b04020204	NNP	B-NP	O
Abstracts	Abstract	a12360232	NNPS	I-NP	O
.	.	.000	.	O	O

Relevant	Relevant	r0401053	JJ	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
indexed	indexed	i530203	JJ	I-NP	O
journals	journal	j065042	NNS	I-NP	O
and	and	a530	CC	O	O
conference	conference	c051060520	NN	B-NP	O
abstracts	abstract	a12360232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
searched	search	s06203	VBN	I-VP	O
.	.	.000	.	O	O

SELECTION	SELECTION	s0402305	NN	B-NP	O
CRITERIA	CRITERIA	c603060	NN	I-NP	O
:	:	:000	:	O	O
Randomised	Randomise	r053050203	VBN	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HT	HT	h300	NN	B-NP	O
(	(	(000	(	O	O
oestrogens	oestrogen	o023602052	NNS	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
progestogens	progestogen	p60202302052	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
taken	take	t0205	VBN	B-VP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
by	by	b000	IN	B-PP	O
perimenopausal	perimenopausal	p060505010204	JJ	B-NP	O
or	or	o600	CC	I-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

DATA	DATA	d030	NNP	B-NP	O
COLLECTION	COLLECTION	c0402305	NNP	I-NP	O
AND	AND	a530	CC	O	O
ANALYSIS	ANALYSIS	a5040202	NNP	B-NP	O
:	:	:000	:	O	O
Fifteen	Fifteen	f01305	CD	B-NP	O
RCTs	RCT	r232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

Trials	Trial	t6042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
quality	quality	q04030	NN	B-NP	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
review	review	r010	NN	I-NP	O
authors	author	a03062	NNS	I-NP	O
extracted	extract	e23602303	VBD	B-VP	O
data	datum	d030	NNS	B-NP	O
independently	independently	i530105305340	RB	B-ADVP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
calculated	calculate	c042040303	VBD	B-VP	O
risk	risk	r020	NN	B-NP	O
ratios	ratio	r0302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
dichotomous	dichotomous	d02030502	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
and	and	a530	CC	O	O
weighted	weight	w020303	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
heterogeneity	heterogeneity	h03060205030	NN	I-NP	O
precluded	preclude	p60240303	VBD	B-VP	O
meta	meta	m030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
for	for	f060	IN	B-PP	O
most	most	m023	JJS	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NN	B-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
derived	derive	d060103	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
biggest	big	b02023	JJS	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
or	or	o600	CC	O	O
coronary	coronary	c0605060	JJ	B-NP	O
event	event	e1053	NN	I-NP	O
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
use	use	u200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
only	only	o540	RB	B-NP	O
HT	HT	h300	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-VP	O
increased	increase	i5260203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
gallbladder	gallbladder	g04140306	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HT	HT	h300	NN	B-NP	O
were	be	w060	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
fractures	fracture	f60230602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
colon	colon	c0405	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
over	over	o106	IN	B-PP	O
65	65	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
HT	HT	h300	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
dementia	dementia	d050530	NN	B-NP	B-Disease
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
trials	trial	t6042	NNS	I-NP	O
focussed	focusse	f020203	VBD	B-VP	O
specifically	specifically	s1020102040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
younger	young	y05206	JJR	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
trial	trial	t604	NN	I-NP	O
analysed	analyse	a5040203	VBN	B-VP	O
subgroups	subgroup	s0126012	NNS	B-NP	O
of	of	o100	IN	B-PP	O
2839	2839	0000	CD	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
50	50	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
59	59	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
and	and	a530	CC	O	O
1637	1637	0000	CD	B-NP	O
taking	take	t02052	VBG	I-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
only	only	o540	RB	B-NP	O
HT	HT	h300	NN	I-NP	O
,	,	,000	,	O	O
versus	versus	v06202	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sized	sized	s0203	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
significantly	significantly	s025010205340	RB	I-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
risk	risk	r020	NN	B-NP	O
reported	report	r0106303	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
for	for	f060	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
;	;	;000	:	O	O
their	their	t060	PRP$	B-NP	O
absolute	absolute	a1204030	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
very	very	v060	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
.	.	.000	.	O	O

AUTHORS	AUTHORS	a03062	NNS	B-NP	O
'	'	'000	POS	B-NP	O
CONCLUSIONS	CONCLUSIONS	c052402052	NNS	I-NP	O
:	:	:000	:	O	O
HT	HT	h300	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
routine	routine	r03050	JJ	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
need	need	n030	VBP	B-VP	O
more	more	m060	JJR	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
HT	HT	h300	NN	B-NP	O
for	for	f060	IN	B-PP	O
menopausal	menopausal	m05010204	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
control	control	c053604	NN	I-NP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
younger	young	y05206	JJR	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	B-PP	I-Disease
induced	induce	i530203	VBN	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
461	461	0000	CD	B-NP	O
incidences	incidence	i520305202	NNS	I-NP	O
submitted	submit	s0150303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Spanish	Spanish	s105020	JJ	I-NP	O
registry	registry	r0202360	NN	I-NP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
&	&	&000	CC	I-NP	O
AIMS	AIMS	a052	NNS	I-NP	O
:	:	:000	:	O	O
Progress	Progress	p602602	NNP	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
understanding	understanding	u530623053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
induced	induce	i530203	VBN	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
DILI	DILI	d040	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
outcome	outcome	o032050	NN	B-NP	O
predictability	predictability	p6030230104030	NN	I-NP	O
are	be	a600	VBP	B-VP	O
hampered	hamper	h0510603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
systematic	systematic	s023050302	JJ	B-NP	O
programs	program	p6026052	NNS	I-NP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
bona	bona	b050	NN	B-NP	O
fide	fide	f030	NN	I-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
cooperative	cooperative	c010603010	JJ	I-NP	O
network	network	n03062	NN	I-NP	O
was	be	w020	VBD	B-VP	O
created	create	c60303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
Spain	Spain	s105	NNP	B-NP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
all	all	a400	DT	B-NP	O
suspicions	suspicion	s02102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DILI	DILI	d040	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
structured	structure	s360230603	VBN	I-NP	O
report	report	r01063	NN	I-NP	O
form	form	f065	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	O
,	,	,000	,	I-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
mixed	mixed	m0203	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
histologic	histologic	h023040202	JJ	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
available	available	a1040140	JJ	B-ADJP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
causality	causality	c0204030	NN	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
centrally	centrally	c0536040	RB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Since	Since	s0520	IN	B-PP	O
April	April	a1604	NNP	B-NP	O
1994	1994	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
August	August	a02023	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
461	461	0000	CD	I-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
570	570	0000	CD	B-NP	O
submitted	submit	s0150303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
involving	involve	i51041052	VBG	B-VP	O
505	505	0000	CD	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
deemed	deem	d0503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
DILI	DILI	d040	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antiinfective	antiinfective	a53051023010	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	O	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
incriminated	incriminate	i52605050303	VBN	B-VP	O
,	,	,000	,	O	O
amoxicillin	amoxicillin	a502020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
clavulanate	clavulanate	c4010405030	NN	I-NP	I-Chemical
accounting	accounting	a2053052	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
whole	whole	w040	JJ	I-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
(	(	(000	(	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
inversely	inversely	i51062040	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
worst	worst	w0623	JJS	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
(	(	(000	(	O	O
Cox	Cox	c020	NNP	B-NP	O
regression	regression	r0260205	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
034	034	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Indeed	Indeed	i5303	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
if	if	i100	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
figure	figure	f02060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
nonjaundiced	nonjaundiced	n0520530203	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Factors	Factor	f023062	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
female	female	f05040	JJ	B-NP	O
sex	sex	s020	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
151	151	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
-	-	-000	:	O	O
37	37	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
009	009	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
value	value	v040	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
15	15	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
09	09	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
22	22	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	O
jaundice	jaundice	j053020	NNS	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
chance	chance	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
progressing	progress	p602602052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
death	death	d030	NN	B-NP	O
or	or	o600	CC	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Amoxicillin	Amoxicillin	a502020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
clavulanate	clavulanate	c4010405030	NN	I-NP	I-Chemical
stands	stand	s30532	VBZ	B-VP	O
out	out	o030	RP	B-PRT	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
DILI	DILI	d040	NN	B-NP	B-Disease
.	.	.000	.	O	O

Morphological	Morphological	m06104020204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ribose	ribose	r01020	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ribose	ribose	r01020	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardiopathy	myocardiopathy	m0206301030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
evoked	evoke	e10203	VBD	B-VP	O
fully	fully	f040	RB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ribose	ribose	r01020	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
evidences	evidence	e10305202	NNS	I-NP	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
pathogenesis	pathogenesis	p0302050202	NN	B-NP	O
of	of	o100	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
protection	protection	p60302305	NN	B-NP	O
by	by	b000	IN	B-PP	O
erdosteine	erdosteine	e63023050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aims	aim	a052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VCM	VCM	v250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
that	that	t030	WDT	B-NP	O
promotes	promote	p6050302	VBZ	B-VP	O
production	production	p60302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
(	(	(000	(	O	O
ROS	ROS	r020	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
erdosteine	erdosteine	e63023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
expectorant	expectorant	e2102306053	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	B-ADVP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
VCM	VCM	v250	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
sham	sham	s050	NN	B-NP	O
,	,	,000	,	I-NP	O
VCM	VCM	v250	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
VCM	VCM	v250	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
erdosteine	erdosteine	e63023050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

VCM	VCM	v250	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administrated	administrate	a350502360303	VBN	I-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
200mgkg	200mgkg	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Erdosteine	Erdosteine	e63023050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
.	.	.000	.	O	O

VCM	VCM	v250	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MDA	MDA	m300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
d	d	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
(	(	(000	(	O	O
NAG	NAG	n020	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
)	)	)000	)	O	O
excretion	excretion	e260305	NN	B-NP	O
but	but	b030	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
(	(	(000	(	O	O
SOD	SOD	s030	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
catalase	catalase	c0304020	NN	B-NP	O
(	(	(000	(	O	O
CAT	CAT	c030	NN	B-NP	O
)	)	)000	)	O	O
activities	activity	a23010302	NNS	B-NP	O
.	.	.000	.	O	O

Erdosteine	Erdosteine	e63023050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
with	with	w030	IN	B-PP	O
VCM	VCM	v250	NN	B-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
MDA	MDA	m300	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
NAG	NAG	n020	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
SOD	SOD	s030	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
CAT	CAT	c030	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
VCM	VCM	v250	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Erdosteine	Erdosteine	e63023050	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
VCM	VCM	v250	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
dilatation	dilatation	d04030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
lumens	lumen	l05052	NNS	I-NP	O
,	,	,000	,	O	O
extensive	extensive	e23052010	JJ	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
vacuolization	vacuolization	v0204020305	NN	I-NP	O
,	,	,000	,	O	O
atrophy	atrophy	a36010	NN	B-NP	B-Disease
,	,	,000	,	O	O
desquamation	desquamation	d02050305	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
VCM	VCM	v250	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
more	more	m060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
erdosteine	erdosteine	e63023050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Erdosteine	Erdosteine	e63023050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
oxidative	oxidative	o20303010	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
VCM	VCM	v250	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
with	with	w030	IN	B-PP	O
erdosteine	erdosteine	e63023050	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
VCM	VCM	v250	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
kidney	kidney	k0350	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
both	both	b030	CC	B-PP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
histological	histological	h02304020204	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Gemfibrozil	Gemfibrozil	g0510160204	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
lovastatin	lovastatin	l010230305	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
hyperlipoproteinemias	hyperlipoproteinemia	h010640101603050502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
observational	observational	o12061030504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
safety	safety	s01030	NN	B-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
patient	patient	p03053	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
open	open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
,	,	,000	,	O	O
gemfibrozil	gemfibrozil	g0510160204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
lovastatin	lovastatin	l010230305	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
80	80	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
mixed	mixed	m0203	JJ	I-NP	O
hyperlipidemia	hyperlipidemia	h010640103050	NN	I-NP	B-Disease
(	(	(000	(	O	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	B-NP	B-Disease
vascular	vascular	v020406	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
ideal	ideal	i304	JJ	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
targets	target	t062032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reached	reach	r0203	VBN	I-VP	O
(	(	(000	(	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
density	density	d052030	NN	I-NP	O
lipoprotein	lipoprotein	l010160305	NN	I-NP	O
(	(	(000	(	O	O
LDL	LDL	l340	NN	B-NP	O
)	)	)000	)	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
130	130	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
dl	dl	d400	NN	I-NP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
density	density	d052030	NN	I-NP	O
lipoprotein	lipoprotein	l010160305	NN	I-NP	O
(	(	(000	(	O	O
HDL	HDL	h340	NN	B-NP	O
)	)	)000	)	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
35	35	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
dl	dl	d400	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
total	total	t0304	JJ	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
HDL	HDL	h340	NN	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
diet	diet	d030	NN	B-NP	O
plus	plus	p402	CC	O	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
gemfibrozil	gemfibrozil	g0510160204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
lovastatin	lovastatin	l010230305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
primarily	primarily	p60506040	RB	B-NP	O
20	20	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

Follow	Follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
visits	visit	v02032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
scheduled	schedule	s2030403	VBN	I-VP	O
with	with	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
every	every	e1060	DT	B-NP	O
6	6	6000	CD	I-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
visits	visit	v02032	NNS	I-NP	O
per	per	p060	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
741	741	0000	CD	B-NP	O
batteries	battery	b030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
and	and	a530	CC	O	O
714	714	0000	CD	B-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
446	446	0000	CD	I-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
gamma	gamma	g050	NN	I-NP	O
glutamyl	glutamyl	g4030504	NN	I-NP	O
transferase	transferase	t6052106020	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
normal	normal	n06504	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
714	714	0000	CD	I-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
;	;	;000	:	O	O
only	only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
normal	normal	n06504	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
total	total	t0304	JJ	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
from	from	f605	IN	B-PP	O
255	255	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
from	from	f605	IN	B-PP	O
236	236	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
154	154	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
LDL	LDL	l340	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
from	from	f605	IN	B-PP	O
176	176	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
131	131	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
/	/	/000	SYM	B-VP	O
HDL	HDL	h340	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
ratio	ratio	r030	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
from	from	f605	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
p	p	p000	NN	I-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
0001	0001	0000	CD	B-NP	O
.	.	.000	.	O	O

Myositis	Myositis	m020302	NN	B-NP	B-Disease
,	,	,000	,	O	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
and	and	a530	CC	O	O
symptomatic	symptomatic	s0513050302	JJ	B-ADJP	O
enough	enough	e5020	RB	I-ADJP	O
to	to	t000	TO	B-VP	O
discontinue	discontinue	d02053050	VB	I-VP	O
it	it	i300	PRP	B-NP	O
,	,	,000	,	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
(	(	(000	(	O	O
769	769	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liter	liter	l0306	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
no	no	n000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
myoglobinuria	myoglobinuria	m0240105060	NN	I-NP	B-Disease
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Does	Do	d020	VBZ	O	O
domperidone	domperidone	d0510603050	NN	B-NP	B-Chemical
potentiate	potentiate	p03053030	NN	I-NP	O
mirtazapine	mirtazapine	m0630201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
restless	restless	r023402	JJ	I-NP	B-Disease
legs	leg	l020	NNS	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
?	?	?000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
now	now	n000	RB	B-ADVP	O
evidence	evidence	e1030520	NN	B-NP	O
to	to	t000	TO	B-VP	O
suggest	suggest	s02023	VB	I-VP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
restless	restless	r023402	JJ	B-NP	B-Disease
legs	leg	l020	NNS	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
RLS	RLS	r420	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
example	example	e205140	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
RLS	RLS	r420	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
dramatically	dramatically	d6050302040	RB	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonists	agonist	a2050232	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
central	central	c053604	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
or	or	o600	CC	I-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
RLS	RLS	r420	NN	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
domperidone	domperidone	d0510603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
also	also	a420	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
or	or	o600	CC	I-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
RLS	RLS	r420	NN	B-NP	B-Disease
.	.	.000	.	O	O

Mirtazapine	Mirtazapine	m0630201050	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
noradrenergic	noradrenergic	n060360506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
(	(	(000	(	O	O
NaSSA	NaSSA	n020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
RLS	RLS	r420	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
recent	recent	r02053	JJ	I-NP	O
publications	publication	p0140203052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
report	report	r01063	VBP	B-VP	O
here	here	h060	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
comorbid	comorbid	c0506103	NN	I-NP	O
with	with	w030	IN	B-PP	O
postprandial	postprandial	p0231605304	JJ	B-NP	B-Disease
dyspepsia	dyspepsia	d0210120	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
RLS	RLS	r420	NN	B-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
mirtazapine	mirtazapine	m0630201050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
added	add	a303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
his	his	h020	PRP$	B-NP	O
domperidone	domperidone	d0510603050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
started	start	s306303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
RLS	RLS	r420	NN	B-NP	B-Disease
only	only	o540	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
mirtazapine	mirtazapine	m0630201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
his	his	h020	PRP$	B-NP	O
RLS	RLS	r420	NN	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
upon	upon	u105	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
mirtazapine	mirtazapine	m0630201050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Such	Such	s020	PDT	B-NP	O
a	a	a000	DT	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
mirtazapine	mirtazapine	m0630201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
RLS	RLS	r420	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
support	support	s01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
potentiating	potentiating	p0305303052	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
domperione	domperione	d05106050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
mirtazapine	mirtazapine	m0630201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
RLS	RLS	r420	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
physicians	physician	p0202052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
mirtazapine	mirtazapine	m0630201050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
RLS	RLS	r420	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
those	those	t020	DT	B-NP	O
receiving	receive	r0201052	VBG	I-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

Antiandrogenic	Antiandrogenic	a530536020502	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
arterial	arterial	a630604	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
by	by	b000	IN	B-PP	O
antiandrogen	antiandrogen	a5305360205	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
cholesterols	cholesterol	c0402306042	NNS	I-NP	B-Chemical
(	(	(000	(	O	O
C	C	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
triglycerides	triglyceride	t602402060302	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
TG	TG	t200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
lipoproteins	lipoprotein	l0101603052	NNS	B-NP	O
(	(	(000	(	O	O
LP	LP	l100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
apolipoproteins	apolipoprotein	a1040101603052	NNS	B-NP	O
(	(	(000	(	O	O
Apo	Apo	a100	NN	B-NP	O
)	)	)000	)	O	O
B	B	b000	NN	B-NP	O
-	-	-000	HYPH	O	O
100	100	0000	CD	B-NP	O
,	,	,000	,	O	O
A	A	a000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
A	A	a000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
II	II	i000	CD	I-NP	O
pro	pro	p600	JJ	I-NP	O
fi	fi	f000	NN	I-NP	O
les	le	l020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
stage	stage	s3020	NN	B-NP	O
:	:	:000	:	O	O
T1cN0M0	T1cN0M0	0000	NN	B-NP	O
,	,	,000	,	O	O
Gleason	Gleason	g40205	NNP	B-NP	O
score	score	s2060	NN	I-NP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyproterone	cyproterone	c0160306050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
surgical	surgical	s0620204	JJ	B-NP	O
management	management	m050205053	NN	I-NP	O
or	or	o600	CC	I-NP	O
radiation	radiation	r030305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Significant	Significant	s0250102053	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
C	C	c000	NN	I-NP	O
,	,	,000	,	O	O
Apo	Apo	a100	IN	B-PP	O
A	A	a000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	O	O
Apo	Apo	a100	NNP	B-NP	O
A	A	a000	NNP	I-NP	O
-	-	-000	:	O	O
II	II	i000	CD	B-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
VLDL	VLDL	v434	NN	B-NP	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
twenty	twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Ischaemic	Ischaemic	i20502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
arteriosclerosis	arteriosclerosis	a6306024060202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
CPA	CPA	c100	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
,	,	,000	,	O	O
Apo	Apo	a100	IN	B-PP	O
A	A	a000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	O	O
Apo	Apo	a100	NNP	B-NP	O
A	A	a000	NNP	I-NP	O
-	-	-000	HYPH	B-NP	O
II	II	i000	CD	I-NP	O
pro	pro	p600	JJ	I-NP	O
fi	fi	f000	NN	I-NP	O
les	le	l020	NNS	I-NP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
hyperglyceridemic	hyperglyceridemic	h0106240206030502	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Fluorouracil	Fluorouracil	f406060204	NN	I-NP	I-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
fluoro	fluoro	f4060	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
beta	beta	b030	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
alanine	alanine	a405050	NN	B-NP	I-Chemical
.	.	.000	.	O	O

Cardiotoxicity	Cardiotoxicity	c063030202030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
malignancies	malignancy	m0402505202	NNS	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
herein	herein	h0605	RB	B-ADVP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
fluoro	fluoro	f4060	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
beta	beta	b030	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
alanine	alanine	a405050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
FBAL	FBAL	f104	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
unresectable	unresectable	u56020230140	JJ	B-NP	O
colon	colon	c0405	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
metastases	metastasis	m030230202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	I-NP	O
lung	lung	l052	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
us	us	u200	PRP	B-NP	O
for	for	f060	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
affiliated	affiliated	a1040303	JJ	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
;	;	;000	:	O	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1000	1000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
which	which	w020	WDT	B-NP	O
precordial	precordial	p60206304	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
right	right	r0203	JJ	B-NP	B-Disease
bundle	bundle	b05340	NN	I-NP	I-Disease
branch	branch	b60520	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
concomitantly	concomitantly	c052050305340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
FBAL	FBAL	f104	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1955	1955	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
the	the	t000	DT	B-NP	O
precordial	precordial	p60206304	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
precordial	precordial	p60206304	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
abandoned	abandon	a10530503	VBN	I-VP	O
.	.	.000	.	O	O

Instead	Instead	i52303	RB	B-ADVP	O
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
derivative	derivative	d060103010	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
instituted	institute	i523030303	VBN	I-VP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
dihydropyrimidine	dihydropyrimidine	d03601060503050	NN	B-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
catalyzes	catalyze	c03040202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
degradative	degradative	d0260303010	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
into	into	i530	IN	B-PP	O
FBAL	FBAL	f104	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
FBAL	FBAL	f104	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
subsequently	subsequently	s0120205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
352	352	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
value	value	v040	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Thereafter	Thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
experience	experience	e21060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
FBAL	FBAL	f104	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

S	S	s000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
safely	safely	s01040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Hepatocellular	Hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
11	11	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
androgens	androgen	a53602052	NNS	B-NP	B-Chemical
,	,	,000	,	I-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
transfusions	transfusion	t6052102052	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
death	death	d030	NN	I-NP	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
readmitted	readmitte	r0350303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	O
crisis	crisis	c60202	NN	I-NP	O
with	with	w030	IN	B-PP	O
septicemia	septicemia	s01302050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
marked	marked	m06203	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
bronchopneumonia	bronchopneumonia	b605201505050	NN	I-NP	I-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
autopsy	autopsy	a030120	NN	B-NP	O
peliosis	peliosis	p040202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
multiple	multiple	m0430140	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
which	which	w020	WDT	B-NP	O
histologically	histologically	h023040202040	RB	B-ADVP	O
proved	prove	p60103	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
well	well	w040	RB	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
differentiated	differentiate	d01060530303	VBN	B-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
that	that	t030	IN	B-NP	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
metastasizing	metastasize	m030230202052	VBG	B-VP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
neoplasms	neoplasm	n0140252	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
peliosis	peliosis	p040202	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
between	between	b0305	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Despite	Despite	d021030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
well	well	w040	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
known	know	k505	VBN	I-VP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
anthracyclin	anthracyclin	a53060202405	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
continues	continue	c0530502	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
presumably	presumably	p602050140	RB	B-ADVP	O
results	result	r020432	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
free	free	f600	JJ	B-NP	O
radicals	radical	r0302042	NNS	I-NP	O
by	by	b000	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Reactive	Reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
particularly	particularly	p06302040640	RB	B-ADVP	O
affect	affect	a1023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
because	because	b02020	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
seem	seem	s050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
poor	poor	p060	JJ	I-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
defense	defense	d010520	NN	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
semisynthetic	semisynthetic	s05020530302	JJ	I-NP	O
flavonoid	flavonoid	f4010503	NN	I-NP	B-Chemical
monohydroxyethylrutoside	monohydroxyethylrutoside	m0503602030460302030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
cardioprotection	cardioprotection	c0630160302305	NN	B-NP	O
against	against	a20523	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
radical	radical	r030204	JJ	I-NP	O
scavenging	scavenging	s201052052	NN	I-NP	O
and	and	a530	CC	I-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
chelating	chelating	c0403052	NN	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
short	short	s063	JJ	I-NP	O
final	final	f0504	JJ	I-NP	O
half	half	h041	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
of	of	o100	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
(	(	(000	(	O	O
about	about	a103	RB	B-NP	O
30	30	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
expected	expect	e2102303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
between	between	b0305	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
influence	influence	i5140520	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
this	this	t020	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-NP	O
c	c	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
preceded	precede	p6020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
60	60	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
120	120	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
and	and	a530	CC	O	O
additional	additional	a3030504	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
processed	process	p6020203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
light	light	l0203	JJ	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
which	which	w020	WDT	B-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
Billingham	Billingham	b0405205	NNP	B-NP	O
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
Cancer	Cancer	c05206	NNP	B-NP	B-Disease
Treat	Treat	t603	NNP	I-NP	O
Rep	Rep	r010	NNP	I-NP	O
62	62	0000	CD	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
865	865	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
872	872	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1978	1978	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Microscopic	Microscopic	m026020102	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
damaged	damage	d050203	VBN	B-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	:	O	O
21	21	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
aberrant	aberrant	a106053	JJ	B-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
preceded	precede	p6020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
019	019	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
by	by	b000	IN	B-PP	O
adding	add	a3052	VBG	B-VP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
before	before	b01060	IN	B-SBAR	O
DOX	DOX	d020	NN	B-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
depend	depend	d01053	VB	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
between	between	b0305	IN	B-PP	O
monoHER	monoHER	m0506	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
345	345	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
setting	set	s03052	VBG	I-NP	O
monoHER	monoHER	m0506	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
shortly	shortly	s06340	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
for	for	f060	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Bepridil	Bepridil	b0160304	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Bpd	Bpd	b130	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
attracted	attract	a3602303	VBN	I-VP	O
attention	attention	a305305	NN	B-NP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
(	(	(000	(	O	O
AF	AF	a100	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
(	(	(000	(	O	O
AFL	AFL	a140	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
serious	serious	s0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
Tdp	Tdp	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Bpd	Bpd	b130	NN	B-NP	B-Chemical
requiring	require	r0206052	VBG	B-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Bpd	Bpd	b130	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
459	459	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
361	361	0000	CD	B-NP	O
males	male	m0402	NNS	I-NP	O
,	,	,000	,	O	O
63	63	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
12	12	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
)	)	)000	)	O	O
comprising	comprise	c051602052	VBG	B-VP	O
378	378	0000	CD	B-NP	O
AF	AF	a100	NN	I-NP	B-Disease
and	and	a530	CC	O	O
81	81	0000	CD	B-NP	O
AFL	AFL	a140	NN	I-NP	B-Disease
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	NNP	B-NP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
and	and	a530	CC	O	O
atrial	atrial	a3604	JJ	B-NP	O
dimension	dimension	d0505205	NN	I-NP	O
(	(	(000	(	O	O
LAD	LAD	l030	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
66	66	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
40	40	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
19	19	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
QT	QT	q300	NN	I-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	B-NP	O
s	s	s000	NN	I-NP	O
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
40	40	0000	CD	I-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
and	and	a530	CC	O	O
general	general	g050604	JJ	B-NP	O
fatigue	fatigue	f03020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
each	each	e020	DT	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
,	,	,000	,	O	O
Tdp	Tdp	t310	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
triggering	triggering	t60206052	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Tdp	Tdp	t310	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
sudden	sudden	s0305	JJ	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
backgrounds	background	b0260532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
Tdp	Tdp	t310	NN	B-NP	B-Disease
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
LAD	LAD	l030	NN	B-NP	O
and	and	a530	CC	I-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
larger	large	l06206	JJR	B-ADJP	O
and	and	a530	CC	I-ADJP	O
older	old	o4306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Tdp	Tdp	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Careful	Careful	c060104	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
should	should	s043	MD	B-VP	O
always	always	a402	RB	I-VP	O
be	be	b000	VB	I-VP	O
done	do	d050	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
Bpd	Bpd	b130	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Enhanced	Enhance	e505203	VBN	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
previously	previously	p6010240	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
deficiency	deficiency	d01020520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
RAS	RAS	r020	NN	B-NP	O
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
baroreflex	baroreflex	b060601402	NN	I-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
at	at	a300	IN	B-PP	O
studying	study	s303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
RAS	RAS	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
(	(	(000	(	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
AR	AR	a600	NN	I-NP	O
)	)	)000	)	O	O
agonist	agonist	a205023	NN	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Iso	Iso	i200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Transgenic	Transgenic	t60520502	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
(	(	(000	(	O	O
TGR	TGR	t260	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
,	,	,000	,	O	O
Iso	Iso	i200	NNP	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
greater	great	g60306	JJR	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
(	(	(000	(	O	O
LV	LV	l100	NN	B-NP	O
)	)	)000	)	O	O
pressure	pressure	p602060	NN	B-NP	O
and	and	a530	CC	O	O
maximal	maximal	m020504	JJ	B-NP	O
contraction	contraction	c053602305	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
dP	dP	d100	NN	I-NP	O
/	/	/000	SYM	O	O
dt	dt	d300	NN	B-NP	O
(	(	(000	(	O	O
max	max	m020	NN	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
TGR	TGR	t260	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NNP	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

LV	LV	l100	NN	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Iso	Iso	i200	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
TGR	TGR	t260	NN	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
SD	SD	s300	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
g	g	g000	NN	B-NP	O
LV	LV	l100	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
/	/	/000	SYM	O	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
28	28	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
004	004	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
24	24	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
004	004	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
LV	LV	l100	NN	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
TGR	TGR	t260	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
more	more	m060	RBR	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
downregulation	downregulation	d05602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
AR	AR	a600	NN	I-NP	O
and	and	a530	CC	I-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
AR	AR	a600	NN	B-NP	O
kinase	kinase	k05020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
SD	SD	s300	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
AR	AR	a600	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
TGR	TGR	t260	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
SD	SD	s300	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
-	-	-000	SYM	O	O
18	18	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
parasympathetic	parasympathetic	p0602051030302	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
by	by	b000	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
HR	HR	h600	NN	B-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
strains	strain	s36052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
TGR	TGR	t260	NN	B-NP	O
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
AR	AR	a600	NN	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
inotropic	inotropic	i50360102	JJ	I-NP	I-Disease
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	I-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
chronically	chronically	c060502040	RB	B-NP	O
low	low	l000	JJ	I-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
outflow	outflow	o03140	NN	I-NP	O
directed	direct	d0602303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
long	long	l052	JJ	I-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
drug	drug	d602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
high	high	h020	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
in	in	i500	IN	B-PP	O
hospitalized	hospitalize	h02103040203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
long	long	l052	JJ	I-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

Methadone	Methadone	m0303050	NN	B-NP	B-Chemical
prolongs	prolong	p604052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inpatient	inpatient	i5103053	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
dose	dose	d020	NN	I-NP	O
dependence	dependence	d010530520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cofactors	cofactor	c01023062	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
remain	remain	r0505	VBP	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
,	,	,000	,	I-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
comparing	compare	c05106052	VBG	B-VP	O
active	active	a23010	JJ	B-NP	O
or	or	o600	CC	I-NP	O
former	former	f06506	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
not	not	n030	RB	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
among	among	a5052	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
hospitalized	hospitalize	h02103040203	VBD	B-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
tertiary	tertiary	t063060	JJ	I-NP	O
care	care	c060	NN	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
167	167	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
fulfilled	fulfil	f0410403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
inclusion	inclusion	i5240205	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
80	80	0000	CD	B-NP	O
injection	injection	i5202305	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
not	not	n030	RB	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
demographic	demographic	d050260102	JJ	I-NP	O
,	,	,000	,	I-NP	O
biological	biological	b04020204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Among	Among	a5052	IN	B-NP	O
167	167	0000	CD	I-NP	O
methadone	methadone	m0303050	NN	I-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
QTc	QTc	q320	NN	B-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
second	second	s02053	JJ	I-NP	O
(	(	(000	(	O	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
longer	long	l05206	JJR	B-NP	O
was	be	w020	VBD	B-VP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
80	80	0000	CD	B-NP	O
control	control	c053604	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
methadone	methadone	m0303050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
.	.	.000	.	O	O

QTc	QTc	q320	NN	B-NP	O
length	length	l05230	NN	I-NP	O
was	be	w020	VBD	B-VP	O
weakly	weakly	w0240	RB	B-VP	O
but	but	b030	CC	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
Spearman	Spearman	s106505	NN	B-NP	O
rank	rank	r052	NN	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
coefficient	coefficient	c0102053	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
20	20	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
allowed	allow	a403	VBD	B-VP	O
attribution	attribution	a36010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
31	31	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
QTc	QTc	q320	NN	B-NP	O
variability	variability	v060104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
450	450	0000	CD	I-NP	O
3A4	3A4	0000	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
,	,	,000	,	O	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
altered	alter	a430603	VBD	B-VP	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
QT	QT	q300	NN	B-NP	B-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
hospitalized	hospitalize	h02103040203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
tertiary	tertiary	t063060	JJ	I-NP	O
care	care	c060	NN	I-NP	O
center	center	c05306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
.	.	.000	.	O	O

Methadone	Methadone	m0303050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
450	450	0000	CD	I-NP	O
3A4	3A4	0000	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
,	,	,000	,	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
can	can	c050	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Mechanisms	Mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
deficiency	deficiency	d01020520	NN	B-NP	O
:	:	:000	:	O	O
focus	focus	f0202	NN	B-NP	O
on	on	o500	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Loss	Loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	O	O
derived	derive	d060103	VBN	B-VP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
hallmark	hallmark	h045062	NN	I-NP	O
of	of	o100	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
created	create	c60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
removal	removal	r050104	NN	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
involves	involve	i5104102	VBZ	B-VP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
vasodilator	vasodilator	v0203040306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
include	include	i524030	VBP	B-VP	O
augmented	augmented	a02505303	JJ	B-NP	O
endothelin	endothelin	e53030405	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
ET	ET	e300	NN	O	O
-	-	-000	HYPH	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
release	release	r04020	NN	B-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBD	B-VP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
elevated	elevate	e4010303	VBD	B-VP	O
tissue	tissue	t020	NN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
increased	increase	i5260203	VBN	B-NP	O
venous	venous	v0502	JJ	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
(	(	(000	(	O	O
venomotor	venomotor	v05050306	NN	B-NP	O
)	)	)000	)	O	O
tone	tone	t050	NN	B-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
Nomega	Nomega	n05020	NNP	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
nitro	nitro	n0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
through	through	t06020	IN	B-PP	O
these	these	t020	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
LNNA	LNNA	l500	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
in	in	i500	IN	B-PP	O
drinking	drinking	d6052052	NN	B-NP	O
water	water	w0306	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
of	of	o100	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
119	119	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	O	O
194	194	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
in	in	i500	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Carotid	Carotid	c060303	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
and	and	a530	CC	O	O
vena	vena	v050	NN	B-NP	O
cava	cava	c010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
removed	remove	r050103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
isometric	isometric	i20503602	JJ	B-NP	O
contraction	contraction	c053602305	NN	I-NP	O
.	.	.000	.	O	O

Maximal	Maximal	m020504	JJ	B-NP	O
contraction	contraction	c053602305	NN	I-NP	O
to	to	t000	TO	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
modestly	modestly	m0302340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
arteries	artery	a630602	NNS	B-NP	O
from	from	f605	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
whereas	whereas	w0602	IN	B-PP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
contraction	contraction	c053602305	NN	I-NP	O
to	to	t000	TO	B-PP	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
control	control	c053604	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Maximum	Maximum	m020505	JJ	B-NP	O
contraction	contraction	c053602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vena	vena	v050	NN	B-NP	O
cava	cava	c010	NN	I-NP	O
to	to	t000	TO	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
37	37	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
control	control	c053604	NN	I-NP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
circulatory	circulatory	c0620403060	JJ	I-NP	O
filling	filling	f04052	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
venomotor	venomotor	v05050306	NN	B-NP	O
tone	tone	t050	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
scavenger	scavenger	s20105206	NN	I-NP	O
tempol	tempol	t05104	NN	I-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
300	300	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
IV	IV	i100	CD	B-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
arterial	arterial	a630604	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
but	but	b030	CC	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
26	26	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
54	54	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
11	11	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
ganglionic	ganglionic	g05240502	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
with	with	w030	IN	B-PP	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
greater	great	g60306	JJR	I-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
76	76	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
9	9	9000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
10	10	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Carotid	Carotid	c060303	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
,	,	,000	,	O	O
vena	vena	v050	NN	B-NP	O
cava	cava	c010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
from	from	f605	IN	B-PP	O
LNNA	LNNA	l500	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
basal	basal	b0204	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
while	while	w040	IN	B-SBAR	O
NO	NO	n000	NN	B-NP	B-Chemical
deficiency	deficiency	d01020520	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
venous	venous	v0502	JJ	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
on	on	o500	IN	B-PP	O
veins	vein	v052	NNS	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
make	make	m020	VB	I-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Association	Association	a2020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
DRD2	DRD2	0000	NN	B-NP	O
polymorphisms	polymorphism	p04050610252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
chlorpromazine	chlorpromazine	c0406160502050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
Extrapyramidal	Extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
EPS	EPS	e120	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	I-VP	O
commonly	commonly	c050540	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
typical	typical	t010204	JJ	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
many	many	m050	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
variations	variation	v0603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DRD2	DRD2	0000	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
variations	variation	v0603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
in	in	i500	IN	B-PP	O
modulating	modulate	m030403052	VBG	B-VP	O
receptor	receptor	r0201306	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
evaluate	evaluate	e104030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
DRD2	DRD2	0000	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
chlorpromazine	chlorpromazine	c0406160502050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
EPS	EPS	e120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
schizophrenic	schizophrenic	s20201060502	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
identified	identify	i30530103	VBD	B-VP	O
seven	seven	s0105	CD	B-NP	O
SNP	SNP	s510	NN	I-NP	O
(	(	(000	(	O	O
single	single	s05240	JJ	B-NP	O
nucleotide	nucleotide	n02403030	NN	I-NP	O
polymorphism	polymorphism	p0405061025	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
141Cins	141Cins	0000	NN	I-NP	O
>	>	>000	SYM	I-NP	O
del	del	d040	NN	I-NP	O
,	,	,000	,	O	O
TaqIB	TaqIB	t0201	NN	B-NP	O
,	,	,000	,	O	O
TaqID	TaqID	t0203	NN	B-NP	O
,	,	,000	,	O	O
Ser311Cys	Ser311Cys	0000	NN	B-NP	O
,	,	,000	,	O	O
rs6275	rs6275	0000	NN	B-NP	O
,	,	,000	,	O	O
rs6277	rs6277	0000	NN	B-NP	O
and	and	a530	CC	O	O
TaqIA	TaqIA	t020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DRD2	DRD2	0000	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
in	in	i500	IN	B-PP	O
146	146	0000	CD	B-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
inpatients	inpatient	i51030532	NNS	I-NP	O
(	(	(000	(	O	O
59	59	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
EPS	EPS	e120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
87	87	0000	CD	B-NP	O
without	without	w0303	IN	B-PP	O
EPS	EPS	e120	NN	B-NP	B-Disease
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Simpson	Simpson	s051205	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Angus	Angus	a5202	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chlorpromazine	chlorpromazine	c0406160502050	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
alleles	allele	a40402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
loci	locus	l020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
PCR	PCR	p260	NN	B-NP	O
(	(	(000	(	O	O
polymerase	polymerase	p040506020	NN	B-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Polymorphisms	Polymorphism	p04050610252	NNS	B-NP	O
TaqID	TaqID	t0203	NN	I-NP	O
,	,	,000	,	I-NP	O
Ser311Cys	Ser311Cys	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
rs6277	rs6277	0000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
polymorphic	polymorphic	p040506102	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
recruited	recruit	r0260303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
significance	significance	s02501020520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
allele	allele	a4040	NN	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	SYM	B-NP	O
141Cins	141Cins	0000	NN	I-NP	O
>	>	>000	SYM	B-NP	O
del	del	d040	NN	I-NP	O
,	,	,000	,	I-NP	O
TaqIB	TaqIB	t0201	NN	I-NP	O
,	,	,000	,	I-NP	O
rs6275	rs6275	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
TaqIA	TaqIA	t020	NN	I-NP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
estimated	estimate	e23050303	VBN	I-NP	O
haplotypes	haplotype	h014030102	NNS	I-NP	O
(	(	(000	(	O	O
constituted	constitute	c0523030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
TaqIB	TaqIB	t0201	NN	B-NP	O
,	,	,000	,	O	O
rs6275	rs6275	0000	NN	B-NP	O
and	and	a530	CC	O	O
TaqIA	TaqIA	t020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
linkage	linkage	l052020	NN	B-NP	O
disequilibrium	disequilibrium	d02020401605	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
lend	lend	l053	VB	I-VP	O
strong	strong	s36052	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
view	view	v000	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
variation	variation	v060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DRD2	DRD2	0000	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
individually	individually	i530103040	RB	I-NP	O
variable	variable	v060140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chlorpromazine	chlorpromazine	c0406160502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
DRD2	DRD2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
EPS	EPS	e120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Caucasians	Caucasian	c0202052	NNPS	B-NP	O
.	.	.000	.	O	O

Physical	Physical	p020204	JJ	B-NP	O
training	training	t605052	NN	I-NP	O
decreases	decrease	d0260202	VBZ	B-VP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Regular	Regular	r020406	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
many	many	m050	JJ	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
physical	physical	p020204	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
still	still	s304	RB	B-ADVP	O
controversial	controversial	c05360106204	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
this	this	t020	DT	B-NP	O
problem	problem	p601405	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
studied	study	s30303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
physical	physical	p020204	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
on	on	o500	IN	B-PP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
training	training	t605052	NN	I-NP	O
sessions	session	s02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
treadmill	treadmill	t603504	NN	I-NP	O
and	and	a530	CC	I-NP	O
swimming	swimming	s05052	NN	I-NP	O
pool	pool	p040	NN	I-NP	O
.	.	.000	.	O	O

Thereafter	Thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
trained	trained	t60503	JJ	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
trained	train	t60503	VBN	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
sign	sign	s025	NN	I-NP	O
,	,	,000	,	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
4	4	4000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
ended	end	e5303	VBN	B-VP	O
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
these	these	t020	DT	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
regular	regular	r020406	JJ	B-NP	O
physical	physical	p020204	JJ	I-NP	O
exercises	exercise	e20620202	NNS	I-NP	O
decrease	decrease	d026020	VBP	B-VP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
subsequently	subsequently	s0120205340	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
ameliorate	ameliorate	a50406030	VB	B-VP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Tonic	Tonic	t0502	JJ	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
impairs	impair	i51062	VBZ	B-VP	B-Disease
associative	associative	a20203010	JJ	B-NP	I-Disease
learning	learning	l065052	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Endogenous	Endogenous	e53020502	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
salience	salience	s040520	NN	B-NP	O
coding	coding	c03052	NN	I-NP	O
during	during	d06052	IN	B-PP	O
associative	associative	a20203010	JJ	B-NP	O
learning	learning	l065052	NN	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
precursor	precursor	p60206206	NN	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
enhances	enhance	e505202	VBZ	B-VP	O
learning	learning	l065052	NN	B-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
increases	increase	i5260202	VBZ	B-VP	O
both	both	b030	CC	O	O
phasic	phasic	p0202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
tonic	tonic	t0502	JJ	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
mediating	mediate	m0303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
unresolved	unresolved	u560204103	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
here	here	h060	RB	B-ADVP	O
probed	probe	p60103	VBD	B-VP	O
how	how	h000	WRB	B-ADVP	O
selective	selective	s04023010	JJ	B-NP	O
tonic	tonic	t0502	JJ	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
affects	affect	a10232	VBZ	B-VP	O
associative	associative	a20203010	JJ	B-NP	O
learning	learning	l065052	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
trained	train	t60503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
vocabulary	vocabulary	v020104060	NN	I-NP	O
of	of	o100	IN	B-PP	O
45	45	0000	CD	B-NP	O
concrete	concrete	c0526030	JJ	I-NP	O
nouns	noun	n052	NNS	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
training	training	t605052	NN	I-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
design	design	d02025	NN	I-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tonically	tonically	t0502040	RB	I-NP	O
stimulating	stimulate	s3050403052	VBG	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
pergolide	pergolide	p06204030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
vs	vs	v200	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
120	120	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
training	training	t605052	NN	B-NP	O
on	on	o500	IN	B-PP	O
each	each	e020	DT	B-NP	O
training	training	t605052	NN	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
impaired	impair	i510603	VBD	B-VP	B-Disease
novel	novel	n0104	JJ	B-NP	I-Disease
word	word	w063	NN	I-NP	I-Disease
learning	learning	l065052	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
learning	learn	l065052	VBG	I-NP	O
decrement	decrement	d02605053	NN	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
up	up	u100	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
training	training	t605052	NN	B-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
restricted	restricted	r023602303	JJ	B-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
PLACEBO	PLACEBO	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
'	'	'000	``	O	O
flattened	flatten	f4030503	VBN	B-VP	O
'	'	'000	POS	B-NP	O
affect	affect	a1023	NN	I-NP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
learning	learn	l065052	VBG	B-VP	O
inhibition	inhibition	i5010305	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
tonic	tonic	t0502	JJ	B-NP	O
occupation	occupation	o2010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
impairs	impair	i51062	VBZ	B-VP	O
learning	learning	l065052	NN	B-NP	O
by	by	b000	IN	B-PP	O
competition	competition	c051030305	NN	B-NP	O
with	with	w030	IN	B-PP	O
phasic	phasic	p0202	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
signals	signal	s025042	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
phasic	phasic	p0202	JJ	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
enhances	enhance	e505202	VBZ	B-VP	O
associative	associative	a20203010	JJ	B-NP	O
learning	learning	l065052	NN	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Minocycline	Minocycline	m0502024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
fulfilling	fulfil	f04104052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
of	of	o100	IN	B-PP	O
polyarteritis	polyarteritis	p04063060302	NN	B-NP	B-Disease
nodosa	nodosa	n03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
minocycline	minocycline	m0502024050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
palmoplantar	palmoplantar	p04501405306	JJ	B-NP	B-Disease
pustulosis	pustulosis	p023040202	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
fever	fever	f0106	NN	B-NP	B-Disease
,	,	,000	,	O	O
myalgias	myalgia	m04202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
polyneuropathy	polyneuropathy	p04050601030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
testicular	testicular	t023020406	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
elevated	elevate	e4010303	VBN	B-NP	O
C	C	c000	NN	I-NP	O
-	-	-000	HYPH	O	O
reactive	reactive	r023010	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
CRP	CRP	c610	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
myeloperoxidase	myeloperoxidase	m0401060203020	NN	B-NP	O
-	-	-000	HYPH	O	O
nor	nor	n060	CC	O	O
proteinase	proteinase	p60305020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
met	meet	m030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
American	American	a5060205	NNP	I-NP	O
College	College	c04020	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Rheumatology	Rheumatology	r050304020	NNP	B-NP	O
1990	1990	0000	CD	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
classification	classification	c40201020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
polyarteritis	polyarteritis	p04063060302	NN	B-NP	B-Disease
nodosa	nodosa	n03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Stopping	Stop	s301052	VBG	B-NP	O
minocycline	minocycline	m0502024050	NN	I-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
amelioration	amelioration	a504060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	O	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CRP	CRP	c610	NN	B-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
minocycline	minocycline	m0502024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
satisfying	satisfy	s03021052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
for	for	f060	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
disease	disease	d02020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
invaluable	invaluable	i51040140	JJ	B-ADJP	O
even	even	e105	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
classical	classical	c4020204	JJ	B-NP	O
polyarteritis	polyarteritis	p04063060302	NN	I-NP	B-Disease
nodosa	nodosa	n03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intramuscular	Intramuscular	i53605020406	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
recurrence	recurrence	r02060520	NN	I-NP	O
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Combined	Combine	c0510503	VBN	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
(	(	(000	(	O	O
HBIg	HBIg	h102	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
prophylaxis	prophylaxis	p601040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
the	the	t000	DT	B-NP	O
survival	survival	s0610104	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
positive	positive	p0203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
chart	chart	c063	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
organ	organ	o6205	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
database	database	d0301020	NN	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
51	51	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
43	43	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
transplanted	transplant	t60521405303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
benign	benign	b05025	JJ	B-NP	O
HBV	HBV	h100	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
cirrhotic	cirrhotic	c060302	JJ	I-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
between	between	b0305	IN	B-PP	O
June	June	j050	NNP	B-NP	O
2002	2002	0000	CD	I-NP	O
and	and	a530	CC	O	O
December	December	d0205106	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
survived	survive	s0610103	VBN	I-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

HBIg	HBIg	h102	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
week	week	w020	NN	I-NP	O
and	and	a530	CC	O	O
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
thereafter	thereafter	t0601306	RB	I-ADVP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
At	At	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
51	51	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	O	O
51	51	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
88	88	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
82	82	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
enabled	enable	e501403	VBD	B-VP	O
57	57	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
62	62	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
DNA	DNA	d500	NN	I-NP	O
and	and	a530	CC	I-NP	O
HBeAg	HBeAg	h102	NN	I-NP	B-Chemical
positive	positive	p0203010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
convert	convert	c051063	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

Intramuscular	Intramuscular	i53605020406	JJ	B-NP	O
HBIg	HBIg	h102	NN	I-NP	O
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intramuscular	intramuscular	i53605020406	JJ	B-NP	O
HBIg	HBIg	h102	NN	I-NP	O
can	can	c050	MD	B-VP	O
effectively	effectively	e102301040	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
allograft	allograft	a4026013	NN	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Anticonvulsant	Anticonvulsant	a5302051042053	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
eslicarbazepine	eslicarbazepine	e24020610201050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BIA	BIA	b000	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
093	093	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
microperfusion	microperfusion	m026010610205	NN	B-NP	O
of	of	o100	IN	B-PP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
of	of	o100	IN	B-PP	O
freely	freely	f6040	RB	B-ADVP	O
moving	move	m01052	VBG	B-VP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Eslicarbazepine	Eslicarbazepine	e24020610201050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BIA	BIA	b000	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
093	093	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
-	-	-000	SYM	O	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
10	10	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acetoxy	acetoxy	a203020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
10	10	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
11	11	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydro	dihydro	d0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5H	5H	5000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dibenzo	dibenzo	d010520	NN	I-NP	I-Chemical
/	/	/000	SYM	I-NP	I-Chemical
b	b	b000	NN	I-NP	I-Chemical
,	,	,000	,	O	I-Chemical
f	f	f000	NN	B-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
azepine	azepine	a201050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxamide	carboxamide	c0610205030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
now	now	n000	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
Phase	Phase	p020	NN	B-NP	O
III	III	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
,	,	,000	,	O	O
designed	design	d0202503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
efficacy	efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
structurally	structurally	s3602306040	RB	I-NP	O
related	relate	r040303	VBN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
oxcarbazepine	oxcarbazepine	o20610201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
OXC	OXC	o200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
studied	study	s30303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
eslicarbazepine	eslicarbazepine	e24020610201050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
whole	whole	w040	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
partial	partial	p06304	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
elicited	elicit	e4020303	VBN	I-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
threshold	threshold	t0602043	NN	B-NP	O
or	or	o600	CC	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
patterns	pattern	p030652	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
threshold	threshold	t0602043	NN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
average	average	a106020	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
duration	duration	d060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
39	39	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
4s	4	4200	NNS	I-NP	O
.	.	.000	.	O	O

Pre	Pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
2h	2h	2000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
microperfusion	microperfusion	m026010610205	NN	I-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
75	75	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Lower	Low	l060	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10mg	10mg	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
suppress	suppress	s01602	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
10mg	10mg	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
duration	duration	d060305	NN	I-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8s	8	8200	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
number	number	n05106	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
34	34	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
eslicarbazepine	eslicarbazepine	e24020610201050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	NN	I-NP	O
/	/	/000	SYM	B-VP	O
EEG	EEG	e020	NN	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
sleep	sleep	s401	NN	B-NP	O
/	/	/000	SYM	B-NP	O
wakefulness	wakefulness	w020104502	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
slimming	slimme	s405052	VBG	B-VP	O
pills	pill	p042	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
anthraquinones	anthraquinone	a530602050502	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Chinese	Chinese	c05020	JJ	B-NP	B-Chemical
herbal	herbal	h06104	JJ	I-NP	I-Chemical
medicine	medicine	m0302050	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
widely	widely	w03040	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
and	and	a530	CC	O	O
often	often	o1305	RB	B-VP	O
regarded	regard	r0206303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
public	public	p01402	NN	I-NP	O
as	as	a200	IN	B-PP	O
natural	natural	n030604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
safe	safe	s010	JJ	I-NP	O
remedies	remedy	r050302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Nephropathy	Nephropathy	n010601030	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	B-Chemical
herbs	herb	h0612	NNS	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
,	,	,000	,	O	O
usually	usually	u2040	RB	B-ADVP	O
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
aristolochic	aristolochic	a6023040202	JJ	B-NP	B-Chemical
acids	acid	a2032	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
23	23	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
proprietary	proprietary	p601603060	JJ	I-NP	O
Chinese	Chinese	c05020	JJ	I-NP	B-Chemical
herbal	herbal	h06104	JJ	I-NP	I-Chemical
slimming	slimming	s405052	JJ	I-NP	O
pill	pill	p040	NN	I-NP	O
that	that	t030	WDT	B-NP	O
contained	contain	c0530503	VBD	B-VP	O
anthraquinone	anthraquinone	a53060205050	NN	B-NP	B-Chemical
derivatives	derivative	d0601030102	NNS	I-NP	O
,	,	,000	,	O	O
extracted	extract	e23602303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
Rhizoma	Rhizoma	r02050	NNP	B-NP	O
Rhei	Rhei	r000	NNP	I-NP	O
(	(	(000	(	O	O
rhubarb	rhubarb	r01061	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
probably	probably	p6010140	RB	I-VP	O
aggravated	aggravate	a26010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
pathology	pathology	p0304020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
of	of	o100	IN	B-PP	O
hypocellular	hypocellular	h0102040406	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Spontaneous	Spontaneous	s10530502	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
upon	upon	u105	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
slimming	slimming	s405052	JJ	I-NP	O
pills	pill	p042	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
mild	mild	m043	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
tubular	tubular	t010406	JJ	B-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
still	still	s304	RB	B-ADVP	O
evident	evident	e103053	JJ	B-NP	O
histologically	histologically	h023040202040	RB	I-NP	O
4	4	4000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
causal	causal	c0204	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
anthraquinone	anthraquinone	a53060205050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
herbal	herbal	h06104	JJ	B-NP	O
agent	agent	a2053	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
proven	prove	p60105	VBN	I-VP	O
,	,	,000	,	O	O
phytotherapy	phytotherapy	p030306010	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
present	present	p602053	VBP	B-VP	O
with	with	w030	IN	B-PP	O
unexplained	unexplained	u502140503	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Chloroacetaldehyde	Chloroacetaldehyde	c04060203043030	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
sulfhydryl	sulfhydryl	s04103604	NN	I-NP	B-Chemical
reagent	reagent	r02053	NN	I-NP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
critical	critical	c6030204	JJ	B-NP	O
thiol	thiol	t040	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Chloroacetaldehyde	Chloroacetaldehyde	c04060203043030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CAA	CAA	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
alkylating	alkylate	a420403052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
IFO	IFO	i100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
putatively	putatively	p030301040	RB	B-ADJP	O
responsible	responsible	r0210520140	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
IFO	IFO	i100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Depletion	Depletion	d0140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sulfhydryl	sulfhydryl	s04103604	NN	B-NP	B-Chemical
(	(	(000	(	O	O
SH	SH	s000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
culture	culture	c043060	NN	I-NP	O
,	,	,000	,	O	O
animal	animal	a50504	NN	B-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
tubule	tubule	t01040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
culture	culture	c043060	NN	I-NP	O
(	(	(000	(	O	O
hRPTEC	hRPTEC	h61302	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Toxicity	Toxicity	t0202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
protein	protein	p60305	NN	B-NP	O
content	content	c053053	NN	I-NP	O
,	,	,000	,	O	O
cell	cell	c040	NN	B-NP	O
number	number	n05106	NN	I-NP	O
,	,	,000	,	O	O
LDH	LDH	l300	NN	B-NP	O
release	release	r04020	NN	I-NP	O
,	,	,000	,	O	O
trypan	trypan	t60105	NN	B-NP	B-Chemical
blue	blue	b400	JJ	I-NP	I-Chemical
exclusion	exclusion	e240205	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
and	and	a530	CC	I-NP	O
caspase	caspase	c021020	NN	I-NP	O
-	-	-000	HYPH	O	O
3	3	3000	CD	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Free	Free	f600	JJ	B-NP	O
thiols	thiol	t042	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ellman	Ellman	e4505	NNP	B-NP	O
.	.	.000	.	O	O

CAA	CAA	c000	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
hRPTEC	hRPTEC	h61302	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
number	number	n05106	NN	I-NP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
in	in	i500	IN	B-PP	O
free	free	f600	JJ	B-NP	O
intracellular	intracellular	i53602040406	JJ	I-NP	O
thiols	thiol	t042	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
markers	marker	m062062	NNS	I-NP	O
.	.	.000	.	O	O

CAA	CAA	c000	NN	B-NP	B-Chemical
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
acrolein	acrolein	a260405	NN	B-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cysteine	cysteine	c023050	NN	I-NP	B-Chemical
proteases	protease	p6030202	VBZ	B-VP	O
caspase	caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
caspase	caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
and	and	a530	CC	I-NP	O
cathepsin	cathepsin	c0301205	NN	I-NP	O
B	B	b000	NN	I-NP	O
.	.	.000	.	O	O

Caspase	Caspase	c021020	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
by	by	b000	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
stained	stain	s30503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fluorescent	fluorescent	f40602053	JJ	B-NP	O
dyes	dye	d020	NNS	I-NP	O
targeting	target	t06203052	VBG	B-VP	O
lysosomes	lysosome	l02020502	NNS	B-NP	O
,	,	,000	,	O	O
CAA	CAA	c000	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
lysosomal	lysosomal	l02020504	JJ	B-NP	O
size	size	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
lysosomal	lysosomal	l02020504	JJ	I-NP	O
leakage	leakage	l02020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
cysteine	cysteine	c023050	NN	B-NP	B-Chemical
protease	protease	p603020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
thiols	thiol	t042	NNS	I-NP	B-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reproduced	reproduce	r016030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
lysate	lysate	l02030	NN	I-NP	O
.	.	.000	.	O	O

Acidification	Acidification	a20301020305	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
slowed	slow	s403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
thiol	thiol	t040	NN	B-NP	B-Chemical
donors	donor	d05062	NNS	I-NP	O
,	,	,000	,	O	O
could	could	c043	MD	B-VP	O
also	also	a420	RB	I-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
markers	marker	m062062	NNS	I-NP	O
,	,	,000	,	O	O
thiol	thiol	t040	NN	B-NP	B-Chemical
depletion	depletion	d0140305	NN	I-NP	O
and	and	a530	CC	I-NP	O
cysteine	cysteine	c023050	NN	I-NP	B-Chemical
protease	protease	p603020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
living	live	l01052	VBG	B-VP	O
cells	cell	c042	NNS	B-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
CAA	CAA	c000	NN	B-NP	B-Chemical
directly	directly	d0602340	RB	B-ADVP	O
reacts	react	r0232	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
cellular	cellular	c040406	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
protein	protein	p60305	NN	I-NP	O
thiols	thiol	t042	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
mediating	mediate	m0303052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
hRPTEC	hRPTEC	h61302	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
acidification	acidification	a20301020305	NN	B-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
acidification	acidification	a20301020305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
option	option	o1305	NN	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
IFO	IFO	i100	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Stereological	Stereological	s30604020204	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
reveal	reveal	r0104	VBP	B-VP	O
the	the	t000	DT	B-NP	O
robust	robust	r01023	JJ	I-NP	O
size	size	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
stability	stability	s30104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
ectopic	ectopic	e230102	JJ	B-NP	O
hilar	hilar	h0406	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
,	,	,000	,	O	O
dentate	dentate	d053030	NN	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
neurogenesis	neurogenesis	n0602050202	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
greatly	greatly	g60340	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
many	many	m050	JJ	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
develop	develop	d010401	VB	I-VP	O
ectopically	ectopically	e230102040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilar	hilar	h0406	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
ectopic	ectopic	e230102	JJ	I-NP	O
hilar	hilar	h0406	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
could	could	c043	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
ultimately	ultimately	u430503040	RB	B-ADVP	O
develop	develop	d010401	VBP	B-VP	O
after	after	a1306	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
never	never	n0106	RB	I-VP	O
been	be	b050	VBN	I-VP	O
quantified	quantify	q0530103	VBN	I-VP	O
,	,	,000	,	O	O
so	so	s000	IN	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
whether	whether	w0306	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
substantial	substantial	s012305304	JJ	B-ADJP	O
enough	enough	e5020	RB	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
influence	influence	i5140520	NN	I-NP	O
on	on	o500	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
ectopic	ectopic	e230102	JJ	B-NP	O
hilar	hilar	h0406	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
unbiased	unbiased	u510203	JJ	B-NP	O
stereology	stereology	s30604020	NN	I-NP	O
at	at	a300	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
hilar	hilar	h0406	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
immunoreactive	immunoreactive	i50506023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
Prox	Prox	p602	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
optical	optical	o130204	JJ	I-NP	O
fractionator	fractionator	f6023050306	NN	I-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilar	hilar	h0406	JJ	I-NP	O
ectopic	ectopic	e230102	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
substantial	substantial	s012305304	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
stable	stable	s30140	JJ	B-ADJP	O
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
.	.	.000	.	O	O

Interestingly	Interestingly	i530602305240	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
animals	animal	a505042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
more	more	m060	RBR	B-NP	O
ectopic	ectopic	e230102	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
have	have	h010	VBP	B-VP	O
more	more	m060	RBR	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hilar	hilar	h0406	JJ	I-NP	O
ectopic	ectopic	e230102	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
vary	vary	v060	VB	I-VP	O
systematically	systematically	s023050302040	RB	B-ADVP	O
across	across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
septotemporal	septotemporal	s013030510604	JJ	I-NP	O
axis	axis	a202	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
volume	volume	v04050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
new	new	n000	JJ	B-NP	O
insight	insight	i520203	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
ectopic	ectopic	e230102	JJ	B-NP	O
hilar	hilar	h0406	JJ	I-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
galantamine	galantamine	g0405305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
autistic	autistic	a0302302	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Post	Post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
mortem	mortem	m06305	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
galantamine	galantamine	g0405305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
and	and	a530	CC	O	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
modulator	modulator	m03040306	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
interfering	interfere	i5306106052	VBG	B-VP	O
behaviors	behavior	b01062	NNS	B-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Thirteen	Thirteen	t06305	CD	B-NP	O
medication	medication	m03020305	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
participated	participate	p06302010303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
open	open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
galantamine	galantamine	g0405305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
rated	rat	r0303	VBN	I-VP	O
monthly	monthly	m053040	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
parents	parent	p060532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Aberrant	Aberrant	a106053	NNP	I-NP	O
Behavior	Behavior	b0106	NNP	I-NP	O
Checklist	Checklist	c024023	NNP	I-NP	O
(	(	(000	(	O	O
ABC	ABC	a120	NNP	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Conners	Conner	c05062	NNPS	I-NP	O
'	'	'000	POS	B-NP	O
Parent	Parent	p06053	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
-	-	-000	HYPH	O	O
Revised	Revise	r010203	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
physician	physician	p020205	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Psychiatric	Psychiatric	p20203602	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Clinical	Clinical	c4050204	NNP	I-NP	O
Global	Global	g40104	NNP	I-NP	O
Impressions	Impressions	i51602052	NNP	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
parent	parent	p06053	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
rated	rat	r0303	VBN	B-NP	O
irritability	irritability	i6030104030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
social	social	s0204	JJ	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ABC	ABC	a120	NNP	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
significant	significant	s0250102053	JJ	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
emotional	emotional	e5030504	JJ	B-NP	O
lability	lability	l0104030	NN	I-NP	O
and	and	a530	CC	I-NP	O
inattention	inattention	i50305305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Conners	Conner	c05062	NNPS	I-NP	O
'	'	'000	POS	B-NP	O
Parent	Parent	p06053	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
Revised	Revise	r010203	VBN	B-VP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
clinician	clinician	c4050205	JJ	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
reductions	reduction	r03023052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anger	anger	a5206	NN	I-NP	O
subscale	subscale	s012040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Psychiatric	Psychiatric	p20203602	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
rated	rat	r0303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
responders	responder	r021053062	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Clinical	Clinical	c4050204	NNP	I-NP	O
Global	Global	g40104	NNP	I-NP	O
Impressions	Impressions	i51602052	NNP	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
galantamine	galantamine	g0405305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	B-VP	O
-	-	-000	HYPH	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
apart	apart	a1063	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
headaches	headache	h030202	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
open	open	o105	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
galantamine	galantamine	g0405305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	B-VP	O
-	-	-000	HYPH	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
appeared	appear	a10603	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
beneficial	beneficial	b05010204	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
interfering	interfere	i5306106052	VBG	B-VP	O
behaviors	behavior	b01062	NNS	B-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-NP	O
aggression	aggression	a260205	NN	I-NP	B-Disease
,	,	,000	,	O	O
behavioral	behavioral	b010604	JJ	B-NP	B-Disease
dyscontrol	dyscontrol	d02053604	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
inattention	inattention	i50305305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
controlled	controlled	c05360403	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Randomized	Randomize	r053050203	VBN	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
versus	versus	v06202	CC	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
episode	episode	e102030	NN	I-NP	O
schizophrenia	schizophrenia	s2020106050	NN	I-NP	B-Disease
:	:	:000	:	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
compared	compare	c0510603	VBD	B-VP	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
outcomes	outcome	o0320502	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
versus	versus	v06202	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
episode	episode	e102030	NN	I-NP	O
schizophrenia	schizophrenia	s2020106050	NN	I-NP	B-Disease
spectrum	spectrum	s1023605	NN	I-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
twelve	twelve	t0410	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
male	male	m040	NN	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
=	=	=000	SYM	B-VP	O
23	23	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
[	[	[000	(	O	O
SD	SD	s300	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
episode	episode	e102030	NN	I-NP	O
schizophrenia	schizophrenia	s2020106050	NN	I-NP	B-Disease
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
schizophreniform	schizophreniform	s20201060501065	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
schizoaffective	schizoaffective	s20201023010	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Response	Response	r0210520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
differ	differ	d0106	VBP	I-VP	O
between	between	b0305	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
43	43	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
28	28	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
58	58	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
39	39	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
68	68	0000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
those	those	t020	DT	B-NP	O
responding	respond	r021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
more	more	m060	JJR	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
16	16	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	O	O
65	65	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
39	39	0000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
not	not	n030	RB	B-VP	O
meeting	meet	m03052	VBG	I-VP	O
response	response	r0210520	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
.	.	.000	.	O	O

Negative	Negative	n0203010	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
measures	measure	m020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
between	between	b0305	IN	B-PP	O
medications	medication	m030203052	NNS	B-NP	O
.	.	.000	.	O	O

Extrapyramidal	Extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptom	symptom	s051305	NN	I-NP	I-Disease
severity	severity	s0106030	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Significantly	Significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
relative	relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Body	Body	b030	JJ	B-NP	O
mass	mass	m020	NN	I-NP	O
index	index	i5302	NN	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
24	24	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
22	22	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
28	28	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
26	26	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
29	29	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
23	23	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
22	22	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
26	26	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
28	28	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Clinical	Clinical	c4050204	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
response	response	r0210520	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
more	more	m060	RBR	B-ADJP	O
stable	stable	s30140	JJ	I-ADJP	O
.	.	.000	.	O	O

Olanzapine	Olanzapine	o405201050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
an	an	a500	DT	B-NP	O
advantage	advantage	a31053020	NN	I-NP	O
for	for	f060	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
substantial	substantial	s012305304	JJ	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Early	Early	e0640	RB	B-NP	O
paracentral	paracentral	p0602053604	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
hydroxychloroquine	hydroxychloroquine	h0360202040602050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
review	review	r010	VB	I-VP	O
the	the	t000	DT	B-NP	O
natural	natural	n030604	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
and	and	a530	CC	O	O
ocular	ocular	o20406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
hydroxychloroquine	hydroxychloroquine	h0360202040602050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
who	who	w000	WP	B-NP	O
attended	attend	a305303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
ophthalmic	ophthalmic	o10304502	JJ	I-NP	O
screening	screening	s2605052	NN	I-NP	O
program	program	p602605	NN	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Retrospective	Retrospective	r036021023010	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Records	Record	r020632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
262	262	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
hydroxychloroquine	hydroxychloroquine	h0360202040602050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
screened	screen	s260503	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Department	Department	d010635053	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Ophthalmology	Ophthalmology	o10304504020	NNP	B-NP	O
were	be	w060	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
262	262	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
76	76	0000	CD	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
treatment	treatment	t6035053	NN	B-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ocular	ocular	o20406	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
visual	visual	v0204	JJ	B-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
hydroxychloroquine	hydroxychloroquine	h0360202040602050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
test	test	t023	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
used	use	u203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
acuity	acuity	a2030	NN	I-NP	O
and	and	a530	CC	I-NP	O
color	color	c0406	NN	I-NP	O
vision	vision	v0205	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
,	,	,000	,	O	O
funduscopy	funduscopy	f05302010	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Humphrey	Humphrey	h051060	NNP	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
and	and	a530	CC	O	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
visual	visual	v0204	JJ	B-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
appeared	appear	a10603	VBD	B-VP	O
before	before	b01060	IN	B-SBAR	O
any	any	a500	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
other	other	o306	JJ	I-NP	O
tested	test	t02303	VBN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
defects	defect	d010232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reproducible	reproducible	r01603020140	JJ	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reliable	reliable	r040140	JJ	B-ADJP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
hydroxychloroquine	hydroxychloroquine	h0360202040602050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
a	a	a000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
retina	retina	r03050	NN	I-NP	O
despite	despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
known	known	k505	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Screening	Screening	s2605052	NN	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
Humphrey	Humphrey	h051060	NNP	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
recommended	recommended	r020505303	JJ	B-NP	O
2	2	2000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
baseline	baseline	b0204050	NN	I-NP	O
and	and	a530	CC	O	O
yearly	yearly	y0640	RB	B-ADVP	O
thereafter	thereafter	t0601306	RB	I-ADVP	O
.	.	.000	.	O	O

Peri	Peri	p060	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
epirubicin	epirubicin	e106010205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
presented	present	p60205303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
mastectomy	mastectomy	m023023050	NN	B-NP	O
and	and	a530	CC	O	O
immediate	immediate	i503030	JJ	B-NP	O
latissimus	latissimus	l03020502	JJ	I-NP	O
dorsi	dorsi	d0620	NN	I-NP	O
flap	flap	f401	NN	I-NP	O
reconstruction	reconstruction	r020523602305	NN	I-NP	O
having	have	h01052	VBG	B-VP	O
been	be	b050	VBN	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
breast	breast	b6023	NN	I-NP	I-Disease
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
preceding	precede	p60203052	VBG	I-NP	O
months	month	m05302	NNS	I-NP	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
neo	neo	n000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
adjuvant	adjuvant	a3201053	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
with	with	w030	IN	B-PP	O
epirubicin	epirubicin	e106010205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Taxol	Taxol	t0204	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
apparently	apparently	a10605340	RB	I-VP	O
uncomplicated	uncomplicate	u520514020303	VBN	I-VP	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
a	a	a000	DT	B-NP	O
remarkably	remarkably	r050620140	RB	I-NP	O
high	high	h020	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
physical	physical	p020204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
bradycardic	bradycardic	b6030206302	JJ	B-ADJP	B-Disease
at	at	a300	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Second	Second	s02053	NNP	B-NP	O
degree	degree	d0260	VBP	B-VP	O
Mobitz	Mobitz	m01032	NNP	B-NP	O
type	type	t010	NN	I-NP	O
II	II	i000	CD	I-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
temporary	temporary	t05106060	JJ	B-NP	O
transvenous	transvenous	t605210502	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pacing	pacing	p02052	NN	I-NP	O
instituted	institute	i523030303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peri	peri	p060	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
discuss	discuss	d0202	VBP	B-VP	O
how	how	h000	WRB	B-ADVP	O
evidence	evidence	e1030520	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
guidelines	guideline	g03040502	NNS	I-NP	O
would	would	w043	MD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
helpful	helpful	h04104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
how	how	h000	WRB	B-ADVP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
can	can	c050	MD	B-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
substantial	substantial	s012305304	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
over	over	o106	IN	B-PP	O
many	many	m050	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
received	receive	r020103	VBN	I-VP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
time	time	t050	NN	I-NP	O
should	should	s043	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
even	even	e105	RB	B-SBAR	O
if	if	i100	IN	I-SBAR	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-ADJP	O
.	.	.000	.	O	O

Risks	Risk	r020	NNS	B-NP	O
and	and	a530	CC	I-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
COX	COX	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
vs	vs	v200	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
:	:	:000	:	O	O
does	do	d020	VBZ	B-VP	O
their	their	t060	PRP$	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
exceed	exceed	e203	VBP	B-VP	O
their	their	t060	PRP$	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	O
benefit	benefit	b050103	NN	I-NP	O
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
AMI	AMI	a500	NN	B-NP	B-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
COX	COX	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
offset	offset	o1203	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	O
(	(	(000	(	O	O
GI	GI	g000	NN	B-NP	O
)	)	)000	)	O	O
benefit	benefit	b050103	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
(	(	(000	(	O	O
NS	NS	n200	NN	B-NP	O
)	)	)000	)	O	O
non	non	n050	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
steroidal	steroidal	s3060304	JJ	B-NP	I-Chemical
anti	anti	a530	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
inflammatory	inflammatory	i5140503060	JJ	I-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
for	for	f060	IN	B-PP	O
AMI	AMI	a500	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
GI	GI	g000	NN	I-NP	B-Disease
bleeding	bleeding	b403052	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
COX	COX	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
administrative	administrative	a3505023603010	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
65	65	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
who	who	w000	WP	B-NP	O
filled	fill	f0403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prescription	prescription	p602601305	NN	I-NP	O
for	for	f060	IN	B-PP	O
NSAID	NSAID	n203	NN	B-NP	O
or	or	o600	CC	I-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
during	during	d06052	IN	B-PP	O
1999	1999	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2002	2002	0000	CD	I-NP	O
.	.	.000	.	O	O

Outcomes	Outcome	o0320502	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
Cox	Cox	c020	NNP	B-NP	O
regression	regression	r0260205	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Person	Person	p06205	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
among	among	a5052	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
users	user	u2062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
75	75	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
761	761	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
42	42	0000	CD	B-NP	O
,	,	,000	,	O	O
671	671	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
rofecoxib	rofecoxib	r01020201	NN	B-NP	B-Chemical
65	65	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
860	860	0000	CD	I-NP	O
to	to	t000	TO	B-VP	O
celecoxib	celecoxib	c04020201	VB	I-VP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
37	37	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
495	495	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
14	14	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
671	671	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
rofecoxib	rofecoxib	r01020201	NN	B-NP	B-Chemical
,	,	,000	,	O	O
22	22	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
875	875	0000	CD	I-NP	O
to	to	t000	TO	B-VP	O
celecoxib	celecoxib	c04020201	VB	I-VP	B-Chemical
,	,	,000	,	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	I-NP	O
832	832	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
NS	NS	n200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
and	and	a530	CC	O	O
38	38	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
048	048	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
users	user	u2062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
hazard	hazard	h02063	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
for	for	f060	IN	B-PP	O
AMI	AMI	a500	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
GI	GI	g000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
the	the	t000	DT	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
aspirin	aspirin	a210605	NN	I-NP	B-Chemical
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
rofecoxib	rofecoxib	r01020201	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
27	27	0000	CD	O	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
13	13	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
42	42	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
celecoxib	celecoxib	c04020201	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
93	93	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
83	83	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
59	59	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
31	31	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
93	93	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
17	17	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
99	99	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
38	38	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
74	74	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
51	51	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
rofecoxib	rofecoxib	r01020201	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
73	73	0000	CD	O	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
52	52	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
98	98	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
celecoxib	celecoxib	c04020201	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
34	34	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
52	52	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
51	51	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
95	95	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
41	41	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
69	69	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
10	10	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
35	35	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
97	97	0000	CD	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
88	88	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
29	29	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
17	17	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
42	42	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Among	Among	a5052	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
carry	carry	c060	VB	I-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
AMI	AMI	a500	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
GI	GI	g000	NN	I-NP	B-Disease
bleeding	bleeding	b403052	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
AMI	AMI	a500	NN	I-NP	B-Disease
/	/	/000	SYM	B-VP	O
GI	GI	g000	NN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
celecoxib	celecoxib	c04020201	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
better	good	b0306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
rofecoxib	rofecoxib	r01020201	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
NS	NS	n200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
both	both	b030	CC	O	O
celecoxib	celecoxib	c04020201	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
naproxen	naproxen	n0160205	NN	I-NP	B-Chemical
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
least	least	l023	JJS	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
.	.	.000	.	O	O

Quinine	Quinine	q05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	B-Disease
malaria	malaria	m04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	B-Disease
malaria	malaria	m04060	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
(	(	(000	(	O	O
premature	premature	p60503060	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
contraction	contraction	c053602305	NN	I-NP	I-Disease
)	)	)000	)	O	O
while	while	w040	IN	B-SBAR	O
getting	get	g03052	VBG	B-VP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
25	25	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
,	,	,000	,	O	O
chill	chill	c040	NN	B-NP	B-Disease
,	,	,000	,	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
,	,	,000	,	O	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
fully	fully	f040	RB	B-ADJP	O
conscious	conscious	c05202	JJ	I-ADJP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
120	120	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
80	80	0000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
,	,	,000	,	O	O
pulse	pulse	p0420	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
100	100	0000	CD	I-NP	O
x	x	x000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
minute	minute	m05030	NN	I-NP	O
,	,	,000	,	O	O
regular	regular	r020406	JJ	B-ADJP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
examination	examination	e205050305	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
Plasmodium	Plasmodium	p40250305	NN	B-NP	O
falciparum	falciparum	f042010605	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
+	+	+000	SYM	O	O
+	+	+000	SYM	B-NP	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
,	,	,000	,	O	O
conjugated	conjugate	c052020303	VBD	B-VP	O
bilirubin	bilirubin	b04060105	NN	B-NP	B-Chemical
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O
36	36	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
,	,	,000	,	O	O
unconjugated	unconjugated	u52052020303	JJ	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
89	89	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
dL	dL	d400	NN	B-NP	O
,	,	,000	,	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
52	52	0000	CD	B-NP	O
meq	meq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
Patient	Patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	B-Disease
malaria	malaria	m04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
got	get	g030	VBD	B-VP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
dextrose	dextrose	d0236020	NN	B-NP	B-Chemical
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
8	8	8000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
day	day	d000	NN	I-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
vomitus	vomitus	v050302	NN	B-NP	B-Disease
,	,	,000	,	O	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
,	,	,000	,	O	O
tinnitus	tinnitus	t050302	NN	B-NP	B-Disease
,	,	,000	,	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
hearing	hearing	h06052	NN	B-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
felt	feel	f043	VBD	B-VP	O
palpitation	palpitation	p041030305	NN	B-NP	B-Disease
and	and	a530	CC	O	O
electrocardiography	electrocardiography	e4023602063026010	NN	B-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
recording	recording	r02063052	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
premature	premature	p60503060	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
contraction	contraction	c053602305	NN	I-NP	I-Disease
(	(	(000	(	O	O
PVC	PVC	p120	NN	B-NP	B-Disease
)	)	)000	)	O	O
>	>	>000	SYM	O	O
5	5	5000	CD	B-NP	O
x	x	x000	NN	I-NP	O
/	/	/000	SYM	B-VP	O
minute	minute	m05030	NN	B-NP	O
,	,	,000	,	O	O
trigemini	trigemini	t60205050	NN	B-NP	O
,	,	,000	,	O	O
constant	constant	c0523053	JJ	B-NP	O
type	type	t010	NN	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
,	,	,000	,	O	O
positive	positive	p0203010	JJ	B-NP	O
U	U	u000	NN	I-NP	O
wave	wave	w010	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
intravenously	intravenously	i53601050240	RB	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
1500	1500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
in	in	i500	IN	B-PP	O
dextrose	dextrose	d0236020	NN	B-NP	B-Chemical
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
and	and	a530	CC	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
aspartate	aspartate	a21063030	NN	I-NP	I-Chemical
tablet	tablet	t01403	NN	I-NP	O
.	.	.000	.	O	O

Quinine	Quinine	q05050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
changed	change	c05203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sulfate	sulfate	s041030	NN	B-NP	O
quinine	quinine	q05050	NN	I-NP	B-Chemical
tablets	tablet	t014032	NNS	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
felt	feel	f043	VBD	B-VP	O
better	well	b0306	RBR	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PVC	PVC	p120	NN	B-NP	B-Disease
reduced	reduce	r030203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
x	x	x000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
minute	minute	m05030	NN	I-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
day	day	d000	NN	I-NP	O
ECG	ECG	e200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
,	,	,000	,	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
34	34	0000	CD	B-NP	O
meq	meq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
7th	7th	7300	JJ	B-NP	O
day	day	d000	NN	I-NP	O
in	in	i500	IN	B-PP	O
good	good	g030	JJ	B-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

Quinine	Quinine	q05050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
quinidine	quinidine	q0503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
chincona	chincona	c052050	NN	I-NP	O
alkaloid	alkaloid	a420403	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arrhythmic	arrhythmic	a6030502	JJ	I-NP	B-Disease
property	property	p6010630	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
pro	pro	p600	AFX	B-VP	O
-	-	-000	HYPH	B-ADJP	O
arrhythmic	arrhythmic	a6030502	JJ	I-ADJP	B-Disease
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
various	various	v0602	JJ	B-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
severe	severe	s01060	JJ	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
PVC	PVC	p120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
parenteral	parenteral	p060530604	JJ	B-NP	O
quinine	quinine	q05050	NN	I-NP	B-Chemical
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
done	do	d050	VBN	I-VP	O
carefully	carefully	c0601040	RB	B-ADVP	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
good	good	g030	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
pro	pro	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
arrhythmic	arrhythmic	a6030502	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
heart	heart	h063	NN	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
or	or	o600	CC	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
electrolyte	electrolyte	e4023604030	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
frequently	frequently	f60205340	RB	B-ADVP	O
occurs	occur	o2062	VBZ	B-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
and	and	a530	CC	O	O
or	or	o600	CC	O	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
malaria	malaria	m04060	NN	B-NP	B-Disease
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Penicillamine	Penicillamine	p05020405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
related	relate	r040303	VBN	B-NP	O
lichenoid	lichenoid	l020503	NN	I-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
zinc	zinc	z052	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
Wilson	Wilson	w04205	NNP	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
,	,	,000	,	O	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
.	.	.000	.	O	O

Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
autosomal	autosomal	a03020504	JJ	I-NP	O
recessive	recessive	r0202010	JJ	I-NP	O
disorder	disorder	d0206306	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
copper	copper	c0106	NN	I-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
with	with	w030	IN	B-PP	O
consequent	consequent	c05202053	JJ	B-NP	O
copper	copper	c0106	NN	I-NP	B-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
many	many	m050	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
and	and	a530	CC	O	O
consequent	consequent	c05202053	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
neurologic	neurologic	n06040202	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
psychiatric	psychiatric	p20203602	JJ	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
;	;	;000	:	O	O
moreover	moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
presenting	present	p602053052	VBG	B-VP	O
also	also	a420	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
state	state	s3030	NN	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
,	,	,000	,	O	O
99mTc	99mTc	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ECD	ECD	e230	NN	I-NP	O
-	-	-000	HYPH	O	O
SPECT	SPECT	s1023	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
cortical	cortical	c0630204	JJ	B-NP	O
hypoperfusion	hypoperfusion	h01010610205	NN	I-NP	O
in	in	i500	IN	B-PP	O
frontal	frontal	f605304	JJ	B-NP	O
lobes	lobe	l0102	NNS	I-NP	O
,	,	,000	,	O	O
more	more	m060	JJR	B-NP	O
marked	marked	m06203	JJ	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
frontal	frontal	f605304	JJ	I-NP	O
lobe	lobe	l010	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
interrupted	interrupt	i530601303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
lichenoid	lichenoid	l020503	JJ	I-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
zinc	zinc	z052	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
permitted	permit	p0650303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
continue	continue	c053050	VB	I-VP	O
the	the	t000	DT	B-NP	O
successful	successful	s0202104	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
without	without	w0303	IN	B-PP	O
side	side	s030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
the	the	t000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
zinc	zinc	z052	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
represented	represent	r0160205303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
Wilson	Wilson	w04205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
related	relate	r040303	VBN	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
zinc	zinc	z052	NN	I-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
allowed	allow	a403	VBD	B-VP	O
us	us	u200	PRP	B-NP	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
other	other	o306	JJ	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
chelating	chelate	c0403052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
line	line	l050	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
growing	grow	g6052	VBG	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
penicillamine	penicillamine	p05020405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	I-VP	O
develop	develop	d010401	VB	I-VP	O
this	this	t020	DT	B-NP	O
skin	skin	s205	NN	I-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
conceivable	conceivable	c052010140	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
genetic	genetic	g050302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
better	good	b0306	JJR	I-NP	O
clarification	clarification	c40601020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
differentiate	differentiate	d0106053030	VB	I-VP	O
specific	specific	s1020102	JJ	B-NP	O
therapies	therapy	t060102	NNS	I-NP	O
for	for	f060	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
Wilson	Wilson	w04205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
phenotypes	phenotype	p05030102	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
drop	drop	d601	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
prehospital	prehospital	p60210304	NN	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
male	male	m040	NN	I-NP	O
in	in	i500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
sixties	sixty	s02302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
awoke	awoke	a020	NN	I-NP	O
with	with	w030	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
an	an	a500	DT	B-NP	O
afternoon	afternoon	a1306505	NN	I-NP	O
sleep	sleep	s401	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
self	self	s041	VB	I-VP	O
medicate	medicate	m0302030	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
limits	limit	l05032	NNS	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
a	a	a000	DT	B-NP	O
face	face	f020	NN	I-NP	O
mask	mask	m020	NN	I-NP	O
and	and	a530	CC	O	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
sudden	sudden	s0305	JJ	I-NP	O
drop	drop	d601	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
rectified	rectify	r0230103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
fluid	fluid	f403	NN	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
transport	transport	t60521063	NN	B-NP	O
to	to	t000	TO	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
very	very	v060	RB	B-NP	O
few	few	f000	JJ	I-NP	O
documented	document	d020505303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
like	like	l020	IN	B-PP	O
this	this	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prehospital	prehospital	p60210304	NN	I-NP	O
scientific	scientific	s20530102	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
Bezold	Bezold	b02043	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Jarish	Jarish	j06020	JJ	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
,	,	,000	,	O	O
stimulation	stimulation	s305040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
walls	wall	w042	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
in	in	i500	IN	B-PP	O
turn	turn	t065	NN	B-NP	O
decreases	decrease	d0260202	VBZ	B-VP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
outflow	outflow	o03140	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasomotor	vasomotor	v02050306	NN	I-NP	O
centre	centre	c05360	NN	I-NP	O
.	.	.000	.	O	O

Prehospital	Prehospital	p60210304	NN	B-NP	O
care	care	c060	NN	I-NP	O
providers	provider	p60103062	NNS	I-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
managing	manage	m0502052	VBG	I-VP	O
any	any	a500	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
syncopal	syncopal	s0520104	JJ	I-NP	B-Disease
episode	episode	e102030	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
fails	fail	f042	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
recover	recover	r020106	VB	I-VP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
reasonable	reasonable	r02050140	JJ	I-NP	O
time	time	t050	NN	I-NP	O
frame	frame	f6050	NN	I-NP	O
should	should	s043	MD	B-VP	O
consider	consider	c0520306	VB	I-VP	O
the	the	t000	DT	B-NP	O
Bezold	Bezold	b02043	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Jarisch	Jarisch	j06020	NNP	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
and	and	a530	CC	O	O
manage	manage	m05020	VB	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
accordingly	accordingly	a206305240	RB	B-ADVP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
rostral	rostral	r023604	JJ	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
in	in	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
rostral	rostral	r023604	JJ	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
on	on	o500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
neurogenic	neurogenic	n06020502	JJ	B-NP	O
tone	tone	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
,	,	,000	,	I-NP	O
unrestrained	unrestrained	u5602360503	JJ	I-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
placed	place	p40203	VBN	I-VP	O
via	via	v000	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
microinjections	microinjection	m026052023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
200	200	0000	CD	B-NP	O
nl	nl	n400	NN	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartic	aspartic	a2106302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
restimulation	restimulation	r02305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
area	area	a600	NN	I-NP	O
with	with	w030	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartic	aspartic	a2106302	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
postlesion	postlesion	p02340205	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
produce	produce	p603020	VB	I-VP	O
a	a	a000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
postlesion	postlesion	p02340205	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
resting	rest	r023052	VBG	I-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
lesioned	lesione	l020503	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
sham	sham	s050	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
173	173	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
lesioned	lesione	l020503	VBN	I-NP	O
group	group	g601	NN	I-NP	O
still	still	s304	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
values	value	v0402	NNS	B-NP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
sham	sham	s050	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
versus	versus	v06202	IN	I-NP	O
167	167	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
sham	sham	s050	NN	I-NP	O
and	and	a530	CC	O	O
lesioned	lesione	l020503	VBD	B-VP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ganglionic	ganglionic	g05240502	JJ	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
trimethaphan	trimethaphan	t605030105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
lesioned	lesione	l020503	VBN	I-NP	O
and	and	a530	CC	I-NP	O
sham	sham	s050	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
trimethaphan	trimethaphan	t605030105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
lesioned	lesione	l020503	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
32	32	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
13	13	0000	CD	B-NP	O
beats	beat	b032	NNS	I-NP	O
per	per	p060	IN	B-PP	O
minute	minute	m05030	NN	B-NP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
sham	sham	s050	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
33	33	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
beats	beat	b032	NNS	I-NP	O
per	per	p060	IN	B-PP	O
minute	minute	m05030	NN	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
postlesion	postlesion	p02340205	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
rostral	rostral	r023604	JJ	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
maintaining	maintain	m05305052	VBG	B-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Spinal	Spinal	s10504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
suprabulbar	suprabulbar	s0160104106	JJ	I-NP	O
structures	structure	s360230602	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesioned	lesione	l020503	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
multiagent	multiagent	m04302053	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
PEG	PEG	p020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
asparaginase	asparaginase	a21060205020	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
cytarabine	cytarabine	c030601050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
girl	girl	g064	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
induction	induction	i5302305	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
precursor	precursor	p60206206	NN	B-NP	O
B	B	b000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
ALL	ALL	a400	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
aphasia	aphasia	a1020	NN	B-NP	B-Disease
,	,	,000	,	O	O
incontinence	incontinence	i52053050520	NN	B-NP	B-Disease
,	,	,000	,	O	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
right	right	r0203	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sided	sided	s0303	JJ	I-NP	O
weakness	weakness	w02502	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
diffuse	diffuse	d01020	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
cytarabine	cytarabine	c030601050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Vincristine	Vincristine	v0526023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
polyethylene	polyethylene	p040304050	NN	B-NP	B-Chemical
glycol	glycol	g40204	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
asparaginase	asparaginase	a21060205020	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Neurologic	Neurologic	n06040202	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
within	within	w0305	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
4	4	4000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	I-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
320	320	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
adults	adult	a30432	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
third	third	t063	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
attain	attain	a305	NN	I-NP	O
adequate	adequate	a302030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
multidrug	multidrug	m04303602	JJ	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
lifelong	lifelong	l0104052	JJ	I-NP	O
nature	nature	n03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
therapies	therapy	t060102	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VAL	VAL	v040	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
monotherapy	monotherapy	m050306010	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
essential	essential	e205304	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
multicenter	multicenter	m0430205306	NN	B-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
parallel	parallel	p060404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
group	group	g601	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
essential	essential	e205304	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
sitting	sit	s03052	VBG	B-VP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
[	[	[000	(	O	O
MSDBP	MSDBP	m231	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
95	95	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
and	and	a530	CC	O	O
<	<	<000	SYM	B-NP	O
110	110	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
VAL	VAL	v040	NN	B-NP	B-Chemical
160	160	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
320	320	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
;	;	;000	:	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
12	12	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
;	;	;000	:	O	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
160	160	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
320	320	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
320	320	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
;	;	;000	:	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
MSDBP	MSDBP	m231	NN	B-NP	O
and	and	a530	CC	I-NP	O
mean	mean	m050	NN	I-NP	O
sitting	sit	s03052	VBG	B-VP	O
systolic	systolic	s0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
(	(	(000	(	O	O
MSSBP	MSSBP	m210	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
core	core	c060	NN	I-NP	O
study	study	s3030	NN	I-NP	O
end	end	e530	NN	I-NP	O
point	point	p053	NN	I-NP	O
.	.	.000	.	O	O

VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
320	320	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
320	320	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
further	further	f06306	RB	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
open	open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
extension	extension	e2305205	NN	I-NP	O
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
MSDBP	MSDBP	m231	NN	B-NP	O
<	<	<000	SYM	O	O
90	90	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
>	>	>000	SYM	I-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
MSDBP	MSDBP	m231	NN	B-NP	O
<	<	<000	SYM	O	O
90	90	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Tolerability	Tolerability	t04060104030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
monitoring	monitor	m050306052	VBG	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
randomization	randomization	r05305020305	NN	B-NP	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
visits	visit	v02032	NNS	I-NP	O
and	and	a530	CC	O	O
regular	regular	r020406	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hematology	hematology	h050304020	NN	B-NP	O
and	and	a530	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
chemistry	chemistry	c0502360	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
1346	1346	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
core	core	c060	NN	I-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
734	734	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
612	612	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
;	;	;000	:	O	O
924	924	0000	CD	B-NP	O
white	white	w030	JJ	I-NP	O
,	,	,000	,	O	O
291	291	0000	CD	B-NP	O
black	black	b402	JJ	I-NP	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
Asian	Asian	a205	NNP	I-NP	O
,	,	,000	,	O	O
108	108	0000	CD	B-NP	O
other	other	o306	JJ	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	NN	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
52	52	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
92	92	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
MSSBP	MSSBP	m210	NN	I-NP	O
and	and	a530	CC	I-NP	O
MSDBP	MSDBP	m231	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
core	core	c060	NN	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
each	each	e020	DT	B-NP	O
monotherapy	monotherapy	m050306010	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-VP	O
contributing	contribute	c05360103052	VBG	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
VAL	VAL	v040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-NP	O
greater	great	g60306	JJR	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
MSSBP	MSSBP	m210	NN	B-NP	O
and	and	a530	CC	I-NP	O
MSDBP	MSDBP	m231	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
monotherapies	monotherapy	m0503060102	NNS	I-NP	O
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
(	(	(000	(	O	O
all	all	a400	DT	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
MSSBP	MSSBP	m210	NN	B-NP	O
/	/	/000	SYM	B-NP	O
MSDBP	MSDBP	m231	NN	I-NP	O
with	with	w030	IN	B-PP	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
320	320	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
24	24	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
16	16	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
MSSBP	MSSBP	m210	NN	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
320	320	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
160	160	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Rates	Rate	r0302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
and	and	a530	CC	I-NP	O
BP	BP	b100	NN	I-NP	O
control	control	c053604	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
combination	combination	c051050305	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
HCTZ	HCTZ	h232	NN	I-NP	B-Chemical
combinations	combination	c0510503052	NNS	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
monotherapies	monotherapy	m0503060102	NNS	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
13	13	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
core	core	c060	NN	I-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
of	of	o100	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
HCTZ	HCTZ	h232	NN	I-NP	B-Chemical
combinations	combination	c0510503052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
extension	extension	e2305205	NN	I-NP	O
(	(	(000	(	O	O
797	797	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
combination	combination	c051050305	NN	B-NP	O
therapies	therapy	t060102	NNS	I-NP	O
with	with	w030	IN	B-PP	O
VAL	VAL	v040	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
HCTZ	HCTZ	h232	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-NP	O
greater	great	g60306	JJR	I-NP	O
BP	BP	b100	NN	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
less	less	l020	JJR	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Succimer	Succimer	s020506	NN	B-NP	B-Chemical
chelation	chelation	c040305	NN	I-NP	O
improves	improve	i5160102	VBZ	B-VP	O
learning	learning	l065052	NN	B-NP	O
,	,	,000	,	O	O
attention	attention	a305305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
arousal	arousal	a60204	JJ	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
but	but	b030	CC	O	O
produces	produce	p6030202	VBZ	B-VP	O
lasting	last	l023052	VBG	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
growing	grow	g6052	VBG	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
for	for	f060	IN	B-SBAR	O
clinicians	clinician	c40502052	NNS	B-NP	O
to	to	t000	TO	B-VP	O
prescribe	prescribe	p6026010	VB	I-VP	O
chelation	chelation	c040305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
at	at	a300	IN	B-PP	O
only	only	o540	RB	B-NP	O
slightly	slightly	s4020340	RB	I-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
lead	lead	l030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
very	very	v060	RB	B-NP	O
few	few	f000	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
chelation	chelation	c040305	NN	B-NP	O
improves	improve	i5160102	VBZ	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
children	child	c043605	NNS	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
whether	whether	w0306	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
affect	affect	a1023	VB	I-VP	O
brain	brain	b605	NN	B-NP	O
development	development	d0104015053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
answer	answer	a5206	VB	I-VP	O
these	these	t020	DT	B-NP	O
questions	question	q023052	NNS	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
rodent	rodent	r03053	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
childhood	childhood	c04303	NN	I-NP	O
Pb	Pb	p100	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
succimer	succimer	s020506	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
chelating	chelate	c0403052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Disease
poisoning	poisoning	p0205052	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Pb	Pb	p100	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
lasting	last	l023052	VBG	I-VP	O
impairments	impairment	i510650532	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
attention	attention	a305305	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
inhibitory	inhibitory	i50103060	JJ	B-NP	I-Disease
control	control	c053604	NN	I-NP	I-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
arousal	arousal	a60204	JJ	B-NP	I-Disease
regulation	regulation	r02040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
paralleling	parallel	p060404052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dysfunction	dysfunction	d021052305	NN	B-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Succimer	Succimer	s020506	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Pb	Pb	p100	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
learning	learning	l065052	NN	B-NP	O
,	,	,000	,	O	O
attention	attention	a305305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
arousal	arousal	a60204	JJ	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
varied	vary	v0603	VBD	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Pb	Pb	p100	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
level	level	l0104	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
deficit	deficit	d010203	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
succimer	succimer	s020506	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
not	not	n030	RB	B-VP	O
previously	previously	p6010240	RB	I-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
lasting	lasting	l023052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
pervasive	pervasive	p06102010	JJ	I-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
affective	affective	a1023010	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
comparable	comparable	c051060140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
magnitude	magnitude	m02503030	NN	B-NP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
Pb	Pb	p100	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
show	show	s000	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
any	any	a500	DT	B-NP	O
chelating	chelate	c0403052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
can	can	c050	MD	B-VP	O
alleviate	alleviate	a401030	VB	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
possible	possible	p020140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
a	a	a000	DT	B-NP	O
succimer	succimer	s020506	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
that	that	t030	WDT	B-NP	O
improves	improve	i5160102	VBZ	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
succimer	succimer	s020506	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
strongly	strongly	s3605240	RB	I-VP	O
discouraged	discourage	d02060203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
who	who	w000	WP	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
tissue	tissue	t020	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Pb	Pb	p100	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
heavy	heavy	h010	JJ	I-NP	O
metals	metal	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
challenge	challenge	c040520	NN	I-NP	O
test	test	t023	NN	I-NP	O
in	in	i500	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
and	and	a530	CC	O	O
depression	depression	d0160205	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
observe	observe	o120610	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
major	major	m0206	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
panic	panic	p0502	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
(	(	(000	(	O	O
MDP	MDP	m310	NN	B-NP	B-Disease
)	)	)000	)	O	O
(	(	(000	(	O	O
Diagnostic	Diagnostic	d02502302	NNP	B-NP	O
and	and	a530	CC	O	O
Statistical	Statistical	s3030230204	NNP	B-NP	O
Manual	Manual	m0504	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Mental	Mental	m05304	NNP	B-NP	B-Disease
Disorders	Disorders	d02063062	NNP	I-NP	I-Disease
,	,	,000	,	O	O
Fourth	Fourth	f0630	NNP	B-NP	O
Edition	Edition	e30305	NNP	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
)	)	)000	)	O	O
respond	respond	r021053	VBP	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
way	way	w000	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
challenge	challenge	c040520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
randomly	randomly	r0530540	RB	B-ADVP	O
selected	select	s0402303	VBD	B-VP	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
,	,	,000	,	O	O
27	27	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
MDP	MDP	m310	NN	B-NP	B-Disease
,	,	,000	,	O	O
25	25	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
major	major	m0206	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
panic	panic	p0502	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
(	(	(000	(	O	O
MD	MD	m300	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
28	28	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
psychotropic	psychotropic	p2020360102	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
occasions	occasion	o202052	NNS	I-NP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
apart	apart	a1063	RB	B-ADVP	O
,	,	,000	,	O	O
480	480	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
free	free	f600	JJ	O	O
(	(	(000	(	O	O
placebo	placebo	p402010	NN	B-NP	O
)	)	)000	)	O	O
solution	solution	s040305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
coffee	coffee	c010	NN	I-NP	O
form	form	f065	NN	I-NP	O
and	and	a530	CC	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
scales	scale	s20402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
each	each	e020	DT	B-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
58	58	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
,	,	,000	,	O	O
44	44	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
MDP	MDP	m310	NN	B-NP	B-Disease
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
MD	MD	m300	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
panic	panic	p0502	JJ	I-NP	B-Disease
attack	attack	a302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
480	480	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
challenge	challenge	c040520	NN	I-NP	O
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
chi	chi	c000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
22	22	0000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
MDP	MDP	m310	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
than	than	t050	IN	B-SBAR	O
were	be	w060	VBD	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
MD	MD	m300	NN	B-NP	B-Disease
and	and	a530	CC	O	O
healthy	healthy	h0430	JJ	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
panic	panic	p0502	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
solution	solution	s040305	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
MD	MD	m300	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
variance	variance	v060520	NN	B-NP	O
,	,	,000	,	O	O
group	group	g601	NN	B-NP	O
by	by	b000	IN	B-PP	O
time	time	t050	NN	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
Greenhouse	Greenhouse	g605020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
Geisser	Geisser	g0206	NN	I-NP	O
correction	correction	c0602305	NN	I-NP	O
:	:	:000	:	O	O
F	F	f000	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
762	762	0000	CD	I-NP	O
)	)	)000	)	O	O
=	=	=000	JJ	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
85	85	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
026	026	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
panic	panic	p0502	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
matter	matter	m0306	NN	I-NP	O
if	if	i100	IN	B-SBAR	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
MDP	MDP	m310	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hyperreactivity	hyperreactivity	h010602301030	NN	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
challenge	challenge	c040520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Mitral	Mitral	m03604	JJ	B-NP	O
annuloplasty	annuloplasty	a5040140230	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
restoration	restoration	r023060305	NN	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
failing	fail	f04052	VBG	I-NP	B-Disease
left	left	l013	JJ	I-NP	I-Disease
ventricle	ventricle	v05360240	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
AIM	AIM	a050	NN	I-NP	O
OF	OF	o100	IN	B-PP	O
THE	THE	t000	DT	B-NP	O
STUDY	STUDY	s3030	NN	I-NP	O
:	:	:000	:	O	O
Undersized	Undersized	u530620203	JJ	B-NP	O
mitral	mitral	m03604	JJ	I-NP	O
annuloplasty	annuloplasty	a5040140230	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
dilated	dilate	d040303	VBN	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
mitral	mitral	m03604	JJ	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MR	MR	m600	NN	B-NP	B-Disease
)	)	)000	)	O	O
since	since	s0520	IN	B-SBAR	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
addressing	address	a3602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
MR	MR	m600	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MAP	MAP	m010	NN	I-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
reshape	reshape	r02010	VB	I-VP	O
the	the	t000	DT	B-NP	O
dilated	dilated	d040303	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
(	(	(000	(	O	O
LV	LV	l100	NN	B-NP	O
)	)	)000	)	O	O
base	base	b020	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
reshaping	reshaping	r0201052	NN	I-NP	O
on	on	o500	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
MR	MR	m600	NN	B-NP	B-Disease
remain	remain	r0505	VBP	B-VP	O
incompletely	incompletely	i52051403040	RB	B-ADJP	O
understood	understand	u53062303	VBN	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
these	these	t020	DT	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
canine	canine	c05050	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
MAP	MAP	m010	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
prosthetic	prosthetic	p60230302	JJ	I-NP	O
band	band	b053	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
mitral	mitral	m03604	JJ	I-NP	O
annulus	annulus	a50402	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
four	four	f060	CD	B-NP	O
mattress	mattress	m03602	NN	I-NP	O
sutures	suture	s030602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
sutures	suture	s030602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
passed	pass	p0203	VBN	I-VP	O
individually	individually	i530103040	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
four	four	f060	CD	B-NP	O
tourniquets	tourniquet	t06502032	NNS	I-NP	O
and	and	a530	CC	O	O
exteriorized	exteriorize	e2306060203	VBN	B-VP	O
untied	untied	u5303	JJ	B-ADJP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
atriotomy	atriotomy	a3603050	NN	I-NP	O
.	.	.000	.	O	O

Sonomicrometry	Sonomicrometry	s0505026050360	NN	B-NP	O
crystals	crystal	c6023042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
implanted	implant	i51405303	VBN	I-VP	O
around	around	a6053	IN	B-PP	O
the	the	t000	DT	B-NP	O
mitral	mitral	m03604	JJ	I-NP	O
annulus	annulus	a50402	NN	I-NP	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
ventricle	ventricle	v05360240	NN	B-NP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
geometry	geometry	g050360	NN	B-NP	O
and	and	a530	CC	I-NP	O
regional	regional	r020504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
volume	volume	v04050	NN	I-NP	O
loading	loading	l03052	NN	I-NP	O
after	after	a1306	IN	B-PP	O
weaning	wean	w05052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
bypass	bypass	b0102	NN	I-NP	O
;	;	;000	:	O	O
an	an	a500	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MR	MR	m600	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
.	.	.000	.	O	O

MAP	MAP	m010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
accomplished	accomplish	a205140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cinching	cinch	c052052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
tourniquets	tourniquet	t06502032	NNS	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
acquired	acquire	a20603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
MAP	MAP	m010	NN	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
mitral	mitral	m03604	JJ	B-NP	O
annular	annular	a50406	JJ	I-NP	O
dimensions	dimension	d05052052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
commissure	commissure	c0502060	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
commissure	commissure	c0502060	NN	B-NP	O
and	and	a530	CC	O	O
septal	septal	s01304	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
directions	direction	d06023052	NNS	I-NP	O
.	.	.000	.	O	O

Concomitantly	Concomitantly	c052050305340	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
diameter	diameter	d050306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LV	LV	l100	NN	I-NP	O
base	base	b020	NN	I-NP	O
and	and	a530	CC	O	O
LV	LV	l100	NN	B-NP	O
sphericity	sphericity	s10602030	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
improved	improve	i5160103	VBD	B-VP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
37	37	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
to	to	t000	TO	B-PP	O
35	35	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
063	063	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
65	65	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
016	016	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Decreases	Decrease	d0260202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
LV	LV	l100	NN	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
17	17	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
15	15	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0480	0480	0000	CD	I-NP	O
and	and	a530	CC	O	O
Tau	Tau	t000	NNP	B-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
48	48	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
to	to	t000	TO	B-PP	O
45	45	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
ms	ms	m200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
fractional	fractional	f60230504	JJ	B-NP	O
shortening	shortening	s06305052	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
LV	LV	l100	NN	I-NP	O
base	base	b020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
045	045	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
,	,	,000	,	O	O
increases	increase	i5260202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
output	output	o03103	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
54	54	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
57	57	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
65	65	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
57	57	0000	CD	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Emax	Emax	e502	NN	B-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
86	86	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
41	41	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
31	31	0000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
acquired	acquire	a20603	VBN	B-VP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
isolated	isolate	i2040303	VBN	B-NP	O
MAP	MAP	m010	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
certain	certain	c06305	JJ	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
on	on	o500	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
dimension	dimension	d0505205	NN	I-NP	O
/	/	/000	SYM	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MR	MR	m600	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
further	further	f06306	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Piperacillin	Piperacillin	p0106020405	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	I-Chemical
tazobactam	tazobactam	t020102305	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
rapidly	rapidly	r010340	RB	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
flux	flux	f402	NN	I-NP	O
hemodialysis	hemodialysis	h0503040202	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
on	on	o500	IN	B-PP	O
peritoneal	peritoneal	p06030504	JJ	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
popular	popular	p010406	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dire	dire	d060	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
still	still	s304	RB	B-ADVP	O
goes	go	g020	VBZ	B-VP	O
unrecognized	unrecognized	u56020250203	JJ	B-ADJP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
delay	delay	d040	NN	I-NP	O
in	in	i500	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
receiving	receive	r0201052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
peritoneal	peritoneal	p06030504	JJ	I-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
(	(	(000	(	O	O
CAPD	CAPD	c013	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
slurred	slur	s40603	VBN	I-VP	O
speech	speech	s1020	NN	B-NP	O
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
,	,	,000	,	O	O
bizarre	bizarre	b02060	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
progressive	progressive	p602602010	JJ	B-NP	O
mental	mental	m05304	JJ	I-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
(	(	(000	(	O	O
GTCS	GTCS	g320	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	I-Chemical
tazobactam	tazobactam	t020102305	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
for	for	f060	IN	B-PP	O
bronchiectasis	bronchiectasis	b60520230202	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
electrolyte	electrolyte	e4023604030	NN	I-NP	O
and	and	a530	CC	I-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
but	but	b030	CC	O	O
leukocytosis	leukocytosis	l0202030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Neurologic	Neurologic	n06040202	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
dysarthria	dysarthria	d02063060	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
Babinski	Babinski	b010520	NNP	I-NP	O
sign	sign	s025	NN	I-NP	O
.	.	.000	.	O	O

Computed	Compute	c0510303	VBN	B-NP	O
tomography	tomography	t05026010	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
and	and	a530	CC	I-NP	O
electroencephalogram	electroencephalogram	e40236052010402605	NN	I-NP	O
were	be	w060	VBD	B-VP	O
unremarkable	unremarkable	u56050620140	JJ	B-ADJP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antiepileptic	antiepileptic	a53010401302	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
another	another	a50306	DT	B-NP	O
GTCS	GTCS	g320	NN	I-NP	B-Disease
episode	episode	e102030	NN	I-NP	O
recurred	recur	r020603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
sixth	sixth	s0230	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	I-Chemical
tazobactam	tazobactam	t020102305	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
and	and	a530	CC	O	O
organic	organic	o620502	JJ	B-NP	B-Disease
brain	brain	b605	NN	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Initiation	Initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
flux	flux	f402	NN	I-NP	O
hemodialysis	hemodialysis	h0503040202	NN	I-NP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
4	4	4000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Piperacillin	Piperacillin	p0106020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
uremic	uremic	u60502	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
unexplained	unexplained	u502140503	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
.	.	.000	.	O	O

CAPD	CAPD	c013	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
inefficient	inefficient	i50102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
removing	remove	r0501052	VBG	B-VP	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
can	can	c050	MD	B-VP	O
rapidly	rapidly	r010340	RB	I-VP	O
terminate	terminate	t06505030	VB	I-VP	O
the	the	t000	DT	B-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Frequency	Frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
carotid	carotid	c060303	NN	B-NP	O
endarterectomy	endarterectomy	e5306306023050	NN	I-NP	O
under	under	u5306	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Especially	Especially	e2102040	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
improvements	improvement	i51601050532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
,	,	,000	,	O	O
carotid	carotid	c060303	NN	B-NP	O
endarterectomy	endarterectomy	e5306306023050	NN	I-NP	O
done	do	d050	VBN	B-VP	O
under	under	u5306	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
become	become	b02050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
technique	technique	t0205020	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
centers	center	c053062	NNS	I-NP	O
.	.	.000	.	O	O

Temporary	Temporary	t05106060	JJ	B-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
palsies	palsy	p04202	NNS	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
most	most	m023	RBS	B-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
situations	situation	s0303052	NNS	B-NP	O
where	where	w060	WRB	B-ADVP	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
existing	exist	e2023052	VBG	I-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
on	on	o500	IN	B-PP	O
vocal	vocal	v0204	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
function	function	f052305	NN	I-NP	O
to	to	t000	TO	B-VP	O
better	well	b0306	RBR	I-VP	O
understand	understand	u530623053	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
possible	possible	p020140	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
28	28	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
carotid	carotid	c060303	NN	B-NP	O
endarterectomy	endarterectomy	e5306306023050	NN	I-NP	O
under	under	u5306	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Vocal	Vocal	v0204	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
before	before	b01060	IN	B-ADVP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
(	(	(000	(	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
day	day	d000	NN	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
using	use	u2052	VBG	B-VP	O
flexible	flexible	f4020140	JJ	B-NP	O
laryngoscopy	laryngoscopy	l0605202010	NN	I-NP	O
.	.	.000	.	O	O

Anesthesia	Anesthesia	a5023020	NNP	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
injecting	inject	i52023052	VBG	B-VP	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
40	40	0000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
mixture	mixture	m023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	O	O
-	-	-000	HYPH	O	O
acting	act	a23052	VBG	B-VP	O
(	(	(000	(	O	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
short	short	s063	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
acting	act	a23052	VBG	B-VP	O
(	(	(000	(	O	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
anesthetic	anesthetic	a50230302	JJ	B-ADJP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
vocal	vocal	v0204	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
function	function	f052305	NN	I-NP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
operating	operating	o10603052	NN	B-NP	O
time	time	t050	NN	I-NP	O
or	or	o600	CC	O	O
volume	volume	v04050	NN	B-NP	O
or	or	o600	CC	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
anesthetic	anesthetic	a50230302	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
temporary	temporary	t05106060	JJ	B-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
without	without	w0303	IN	B-PP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Local	Local	l0204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
temporary	temporary	t05106060	JJ	B-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
half	half	h041	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-PP	O
existing	exist	e2023052	VBG	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
preoperative	preoperative	p6010603010	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vocal	vocal	v0204	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
function	function	f052305	NN	I-NP	O
before	before	b01060	IN	B-PP	O
carotid	carotid	c060303	NN	B-NP	O
endarterectomy	endarterectomy	e5306306023050	NN	I-NP	O
under	under	u5306	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
avoid	avoid	a103	VB	I-VP	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
,	,	,000	,	O	O
surgery	surgery	s062060	NN	B-NP	O
under	under	u5306	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
.	.	.000	.	O	O

Impaired	Impaired	i510603	JJ	B-NP	B-Disease
fear	fear	f060	NN	I-NP	I-Disease
recognition	recognition	r020250305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
read	read	r030	VB	I-VP	O
facial	facial	f0204	JJ	B-NP	O
expressions	expression	e21602052	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
social	social	s0204	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
conduct	conduct	c053023	VB	I-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
expression	expression	e2160205	NN	I-NP	O
recognition	recognition	r020250305	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
in	in	i500	IN	B-PP	O
recreational	recreational	r026030504	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
comprised	comprise	c05160203	VBN	B-VP	O
of	of	o100	IN	B-PP	O
21	21	0000	CD	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
naive	naive	n010	JJ	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
(	(	(000	(	O	O
CN	CN	c500	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
occasional	occasional	o2020504	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
OC	OC	o200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
regular	regular	r020406	JJ	I-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
RC	RC	r200	NN	B-NP	O
)	)	)000	)	O	O
users	user	u2062	NNS	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
facial	facial	f0204	JJ	I-NP	O
expression	expression	e2160205	NN	I-NP	O
(	(	(000	(	O	O
EFE	EFE	e100	NN	B-NP	O
)	)	)000	)	O	O
task	task	t020	NN	B-NP	O
consisting	consist	c052023052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
face	face	f020	NN	I-NP	O
expressing	express	e21602052	VBG	B-VP	O
six	six	s020	CD	B-NP	O
basic	basic	b0202	JJ	I-NP	O
emotions	emotion	e503052	NNS	I-NP	O
(	(	(000	(	O	O
happiness	happiness	h010502	NN	B-NP	O
,	,	,000	,	O	O
surprise	surprise	s0616020	NN	B-NP	O
,	,	,000	,	O	O
sadness	sadness	s03502	NN	B-NP	O
,	,	,000	,	O	O
anger	anger	a5206	NN	B-NP	O
,	,	,000	,	O	O
fear	fear	f060	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
disgust	disgust	d02023	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
percent	percent	p062053	NN	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
and	and	a530	CC	O	O
latencies	latency	l0305202	NNS	B-NP	O
for	for	f060	IN	B-PP	O
correct	correct	c06023	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
across	across	a2602	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
presentations	presentation	p60205303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
emotion	emotion	e50305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
derived	derive	d060103	VBN	I-VP	O
.	.	.000	.	O	O

Participants	Participant	p06302010532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
Eyes	Eyes	e020	NNP	I-NP	O
task	task	t020	NN	I-NP	O
"	"	"000	''	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
recognize	recognize	r02025020	VB	I-VP	O
more	more	m060	RBR	B-NP	O
complex	complex	c051402	JJ	I-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
states	state	s30302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Symptom	Symptom	s051305	NNP	I-NP	O
CheckList	CheckList	c024023	NNP	I-NP	O
-	-	-000	HYPH	B-NP	O
90	90	0000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
Revised	Revise	r010203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
measure	measure	m02060	VB	I-VP	O
psychopathology	psychopathology	p202010304020	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
group	group	g601	NN	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
psychopathology	psychopathology	p202010304020	NN	B-NP	O
or	or	o600	CC	O	O
"	"	"000	``	O	O
eyes	eye	e020	NNS	B-NP	O
task	task	t020	NN	I-NP	O
"	"	"000	``	O	O
performance	performance	p0610650520	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
RC	RC	r200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
otherwise	otherwise	o306020	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
illicit	illicit	i40203	JJ	I-NP	O
substance	substance	s01230520	NN	I-NP	O
use	use	u200	NN	I-NP	O
histories	history	h0230602	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
OC	OC	o200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
exhibited	exhibit	e2010303	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
fear	fear	f060	NN	I-NP	I-Disease
recognition	recognition	r020250305	NN	I-NP	I-Disease
accuracy	accuracy	a206020	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
OC	OC	o200	NN	I-NP	O
and	and	a530	CC	I-NP	O
CN	CN	c500	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
RC	RC	r200	NNP	I-NP	O
group	group	g601	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
correctly	correctly	c0602340	RB	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
anger	anger	a5206	NN	B-NP	O
,	,	,000	,	O	O
fear	fear	f060	NN	B-NP	O
,	,	,000	,	O	O
happiness	happiness	h010502	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
surprise	surprise	s0616020	NN	B-NP	O
,	,	,000	,	O	O
more	more	m060	RBR	B-ADVP	O
slowly	slowly	s4040	RB	I-ADVP	O
than	than	t050	IN	B-PP	O
CN	CN	c500	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
OC	OC	o200	NN	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
OC	OC	o200	NNP	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
slower	slow	s406	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
CN	CN	c500	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
correctly	correctly	c0602340	RB	B-ADVP	O
identifying	identify	i305301052	VBG	B-VP	O
disgust	disgust	d02023	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
deficit	deficit	d010203	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
fear	fear	f060	NN	B-NP	I-Disease
recognition	recognition	r020250305	NN	I-NP	I-Disease
accuracy	accuracy	a206020	NN	I-NP	O
manifested	manifest	m050102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
RC	RC	r200	NN	I-NP	O
group	group	g601	NN	I-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
explained	explain	e2140503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
subacute	subacute	s0102030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
recent	recent	r02053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
less	less	l020	RBR	I-NP	O
recent	recent	r02053	JJ	I-NP	O
users	user	u2062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
similarly	similarly	s05040640	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
parallels	parallel	p0604042	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
RC	RC	r200	NN	B-NP	O
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	I-NP	O
psychopaths	psychopath	p202010302	NNS	I-NP	B-Disease
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
fear	fear	f060	NN	I-NP	I-Disease
recognition	recognition	r020250305	NN	I-NP	I-Disease
,	,	,000	,	O	O
amygdala	amygdala	a5023040	NN	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
etiology	etiology	e304020	NN	B-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Damage	Damage	d05020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
substantia	substantia	s01230530	NN	B-NP	I-Disease
nigra	nigra	n0260	NN	I-NP	I-Disease
pars	par	p062	NNS	I-NP	I-Disease
reticulata	reticulata	r030204030	VBP	B-VP	I-Disease
during	during	d06052	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
:	:	:000	:	O	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
,	,	,000	,	O	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
and	and	a530	CC	O	O
serum	serum	s0605	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
protein	protein	p60305	NN	I-NP	O
extravasation	extravasation	e23601020305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
gating	gate	g03052	VBG	I-NP	O
function	function	f052305	NN	I-NP	O
controlling	control	c053604052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
spread	spread	s1603	NN	I-NP	O
of	of	o100	IN	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
models	model	m03042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	B-Disease
status	status	s30302	NN	I-NP	I-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
the	the	t000	DT	B-NP	O
pars	par	p062	NNS	I-NP	O
reticulata	reticulata	r030204030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
substantia	substantia	s01230530	NN	B-NP	O
nigra	nigra	n0260	NN	I-NP	O
(	(	(000	(	O	O
SNR	SNR	s560	NN	B-NP	O
)	)	)000	)	O	O
suffers	suffer	s01062	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
massive	massive	m02010	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
arise	arise	a6020	VB	I-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
massive	massive	m02010	JJ	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
derangement	derangement	d0605205053	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hyperexcitation	hyperexcitation	h010602030305	NN	I-NP	O
developing	develop	d010401052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activated	activate	a23010303	VBN	I-NP	O
SNR	SNR	s560	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neuropathology	neuropathology	n06010304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
techniques	technique	t02050202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
emphasis	emphasis	e510202	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
astrocytes	astrocyte	a236020302	NNS	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
surviving	survive	s06101052	VBG	B-VP	O
20	20	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
40	40	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
perfusion	perfusion	p0610205	NN	B-NP	O
-	-	-000	HYPH	O	O
fixed	fix	f0203	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
brains	brain	b6052	NNS	B-NP	O
processed	process	p6020203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
.	.	.000	.	O	O

Nissl	Nissl	n024	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
staining	staining	s305052	NN	I-NP	O
and	and	a530	CC	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
neuron	neuron	n0605	NN	I-NP	O
-	-	-000	HYPH	O	O
specific	specific	s1020102	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
binding	bind	b053052	VBG	B-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
parvalbumin	parvalbumin	p0610410505	NN	B-NP	O
,	,	,000	,	O	O
served	serve	s06103	VBD	B-VP	O
to	to	t000	TO	I-VP	O
detect	detect	d03023	VB	I-VP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
.	.	.000	.	O	O

Antibodies	Antibody	a53010302	NNS	B-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
astroglia	astroglia	a2360240	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
cytoskeletal	cytoskeletal	c0302040304	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
glial	glial	g404	JJ	B-NP	O
fibrillary	fibrillary	f01604060	JJ	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
GFAP	GFAP	g101	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
glial	glial	g404	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
binding	bind	b053052	VBG	B-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
status	status	s30302	NN	I-NP	O
of	of	o100	IN	B-PP	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
for	for	f060	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
and	and	a530	CC	I-NP	O
immunoglobulins	immunoglobulin	i5050240104052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
as	as	a200	IN	B-PP	O
indicator	indicator	i53020306	NN	B-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	O
and	and	a530	CC	O	O
vasogenic	vasogenic	v02020502	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
formation	formation	f0650305	NN	I-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
loss	loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
GFAP	GFAP	g101	NN	B-NP	O
-	-	-000	HYPH	O	O
staining	stain	s305052	VBG	B-VP	O
already	already	a46030	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
oval	oval	o104	NN	I-NP	O
focus	focus	f0202	NN	I-NP	O
situated	situate	s030303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
center	center	c05306	NN	I-NP	O
of	of	o100	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
while	while	w040	IN	B-SBAR	O
sparing	spar	s106052	VBG	B-VP	O
medial	medial	m0304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
aspects	aspect	a210232	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
additional	additional	a3030504	JJ	B-NP	O
vacuolation	vacuolation	v02040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
100	100	0000	CD	I-NP	O
protein	protein	p60305	NN	I-NP	O
staining	staining	s305052	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
parvalbumin	parvalbumin	p0610410505	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
staining	staining	s305052	NN	I-NP	O
changed	change	c05203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
SNR	SNR	s560	NN	I-NP	O
indicating	indicate	i530203052	VBG	B-VP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
Nissl	Nissl	n024	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
staining	stain	s305052	VBG	I-VP	O
visualized	visualize	v02040203	VBN	I-VP	O
some	some	s050	DT	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
distortion	distortion	d02306305	NN	I-NP	O
.	.	.000	.	O	O

Staining	Stain	s305052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patchy	patchy	p0320	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
forebrain	forebrain	f0601605	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
6	6	6000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
vasogenic	vasogenic	v02020502	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
covered	cover	c010603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
lesioned	lesione	l020503	VBN	I-NP	B-Disease
SNR	SNR	s560	NN	I-NP	I-Disease
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
glial	glial	g404	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
massive	massive	m02010	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
center	center	c05306	NN	I-NP	O
of	of	o100	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
48	48	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
72	72	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
surrounding	surround	s06053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
size	size	s020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
polymorphic	polymorphic	p040506102	JJ	B-NP	O
phagocytotic	phagocytotic	p0202030302	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
invaded	invade	i510303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
damaged	damage	d050203	VBN	I-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
surviving	survive	s06101052	VBG	B-VP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
paraffin	paraffin	p060105	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
sections	section	s023052	NNS	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
glial	glial	g404	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
SNR	SNR	s560	NN	B-NP	I-Disease
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
pathology	pathology	p0304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
quality	quality	q04030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
always	always	a402	RB	I-VP	O
damaged	damage	d050203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
parallel	parallel	p060404	NN	B-NP	O
with	with	w030	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
anatomical	anatomical	a503050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
interrelationship	interrelationship	i5306040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
astrocytes	astrocyte	a236020302	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
particularly	particularly	p06302040640	RB	B-ADJP	O
tight	tight	t0203	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
SNR	SNR	s560	NN	B-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
cell	cell	c040	NN	I-NP	O
elements	element	e4050532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
suffer	suffer	s0106	VB	I-VP	O
in	in	i500	IN	B-PP	O
common	common	c0505	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
metabolic	metabolic	m03010402	JJ	B-NP	O
disturbance	disturbance	d0230610520	NN	I-NP	O
and	and	a530	CC	I-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
occur	occur	o206	NN	B-NP	O
during	during	d06052	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Neuroprotective	Neuroprotective	n0601603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cortical	cortical	c0630204	JJ	I-NP	B-Disease
dysplasia	dysplasia	d0214020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cortical	Cortical	c0630204	JJ	B-NP	B-Disease
dysplasia	dysplasia	d0214020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
malformation	malformation	m0410650305	NN	I-NP	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
defects	defect	d010232	NNS	B-NP	O
in	in	i500	IN	B-PP	O
proliferation	proliferation	p60401060305	NN	B-NP	O
,	,	,000	,	I-NP	O
migration	migration	m0260305	NN	I-NP	O
and	and	a530	CC	I-NP	O
maturation	maturation	m03060305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
offspring	offspre	o1216052	VBG	B-VP	O
rat	rat	r030	NN	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
carmustine	carmustine	c065023050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
[	[	[000	(	B-NP	O
1	1	1000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
bis	bis	b020	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroethyl	chloroethyl	c04060304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nitrosoure	nitrosoure	n03602060	NN	I-NP	I-Chemical
]	]	]000	)	O	O
(	(	(000	(	O	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exogenous	exogenous	e2020502	JJ	B-NP	O
melatonin	melatonin	m04030505	NN	I-NP	B-Chemical
upon	upon	u105	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
BCNU	BCNU	b250	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	B-Disease
dysplasia	dysplasia	d0214020	NN	I-NP	I-Disease
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
histological	histological	h02304020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
.	.	.000	.	O	O

Pregnant	Pregnant	p6025053	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
five	five	f010	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
intact	intact	i53023	JJ	B-ADJP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
,	,	,000	,	O	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
,	,	,000	,	O	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
exposed	expose	e210203	VBN	B-VP	O
and	and	a530	CC	O	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
exposed	expose	e210203	VBN	B-VP	O
plus	plus	p402	CC	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
embryonic	embryonic	e5160502	JJ	B-NP	O
day	day	d000	NN	I-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
until	until	u5304	IN	B-PP	O
delivery	delivery	d0401060	NN	B-NP	O
.	.	.000	.	O	O

Immuno	Immuno	i5050	NN	B-NP	O
/	/	/000	SYM	I-NP	O
histochemistry	histochemistry	h023020502360	NN	I-NP	O
and	and	a530	CC	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
malondialdehyde	malondialdehyde	m04053043030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Histopathologically	Histopathologically	h0230103040202040	RB	B-ADVP	O
,	,	,000	,	O	O
typical	typical	t010204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebella	cerebella	c0601040	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
embryonic	embryonic	e5160502	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
exposed	expose	e210203	VBN	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	B-Disease
dysplasia	dysplasia	d0214020	NN	I-NP	I-Disease
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
TUNEL	TUNEL	t0504	NN	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
nestin	nestin	n02305	NN	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
immunoreactivity	immunoreactivity	i5050602301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
glial	glial	g404	JJ	B-NP	O
fibrillary	fibrillary	f01604060	JJ	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
synaptophysin	synaptophysin	s05013010205	NN	B-NP	O
and	and	a530	CC	O	O
transforming	transform	t60521065052	VBG	B-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
beta1	beta1	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
maturation	maturation	m03060305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
these	these	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

Malondialdehyde	Malondialdehyde	m04053043030	NN	B-NP	B-Chemical
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
malondialdehyde	malondialdehyde	m04053043030	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
these	these	t020	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
exposure	exposure	e2102060	NN	B-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
to	to	t000	TO	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
maturation	maturation	m03060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
offspring	offspring	o1216052	NN	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
and	and	a530	CC	I-NP	O
melatonin	melatonin	m04030505	NN	I-NP	B-Chemical
protects	protect	p6030232	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Reduced	Reduce	r030203	VBN	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxypropyl	hydroxypropyl	h036020160104	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
methacrylamide	methacrylamide	m030260405030	NN	B-NP	I-Chemical
conjugates	conjugate	c052020302	NNS	I-NP	O
:	:	:000	:	O	O
and	and	a530	CC	O	O
experimental	experimental	e21060505304	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
late	late	l030	JJ	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
given	give	g0105	VBN	B-VP	O
either	either	e0306	CC	O	O
as	as	a200	IN	B-PP	O
free	free	f600	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxypropyl	hydroxypropyl	h036020160104	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
methacrylamide	methacrylamide	m030260405030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
HPMA	HPMA	h150	NN	B-NP	B-Chemical
)	)	)000	)	O	O
copolymer	copolymer	c01040506	NN	B-NP	O
conjugates	conjugate	c052020302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
HPMA	HPMA	h150	NN	I-NP	B-Chemical
copolymers	copolymer	c010405062	NNS	I-NP	O
,	,	,000	,	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
covalently	covalently	c010405340	RB	I-VP	O
bound	bind	b053	VBN	I-VP	O
via	via	v000	IN	B-PP	O
peptide	peptide	p013030	NN	B-NP	O
linkages	linkage	l0520202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
either	either	e0306	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
biodegradable	biodegradable	b03026030140	JJ	O	O
(	(	(000	(	O	O
Gly	Gly	g400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
Gly	Gly	g400	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
degradable	degradable	d026030140	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
lysosomal	lysosomal	l02020504	JJ	B-NP	O
proteinases	proteinas	p603050202	NNS	I-NP	O
(	(	(000	(	O	O
Gly	Gly	g400	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Phe	Phe	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Leu	Leu	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Gly	Gly	g400	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
biodegradable	biodegradable	b03026030140	JJ	I-NP	O
conjugate	conjugate	c05202030	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
galactosamine	galactosamine	g040230205050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
residue	residue	r02030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
targeted	target	t0620303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
free	free	f600	JJ	B-NP	O
and	and	a530	CC	I-NP	O
polymer	polymer	p040506	NN	I-NP	O
-	-	-000	HYPH	O	O
bound	bind	b053	VBN	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
polymer	polymer	p040506	NN	B-NP	O
-	-	-000	HYPH	O	O
bound	bind	b053	VBN	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
free	free	f600	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
mixture	mixture	m023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
unmodified	unmodified	u5030103	JJ	I-NP	O
parent	parent	p06053	NN	I-NP	O
HPMA	HPMA	h150	NN	I-NP	B-Chemical
copolymer	copolymer	c01040506	NN	I-NP	O
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Throughout	Throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
deaths	death	d0302	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
free	free	f600	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
mixture	mixture	m023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
HPMA	HPMA	h150	NN	B-NP	B-Chemical
copolymer	copolymer	c01040506	NN	I-NP	O
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
histological	histological	h02304020204	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Sequential	Sequential	s0205304	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
in	in	i500	IN	B-PP	O
surviving	survive	s06101052	VBG	B-VP	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
free	free	f600	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
mixture	mixture	m023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
HPMA	HPMA	h150	NN	B-NP	B-Chemical
copolymer	copolymer	c01040506	NN	I-NP	O
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
function	function	f052305	NN	B-NP	O
beginning	begin	b0205052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
4th	4th	4300	JJ	I-NP	O
week	week	w020	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
12	12	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
measured	measure	m020603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	O	O
matched	match	m03203	VBN	B-NP	O
control	control	c053604	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
the	the	t000	DT	B-NP	O
HPMA	HPMA	h150	NN	I-NP	B-Chemical
copolymer	copolymer	c01040506	NN	I-NP	O
conjugates	conjugate	c052020302	NNS	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
exhibited	exhibit	e2010303	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
histological	histological	h02304020204	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
HPMA	HPMA	h150	NN	B-NP	B-Chemical
copolymer	copolymer	c01040506	NN	I-NP	O
conjugates	conjugate	c052020302	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
beginning	begin	b0205052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
400	400	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Corneal	Corneal	c06504	JJ	B-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
aerosolized	aerosolize	a0602040203	VBN	B-NP	O
crack	crack	c602	NN	I-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
4	4	4000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
corneal	corneal	c06504	JJ	B-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
ulcers	ulcer	u42062	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Review	Review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
corneal	corneal	c06504	JJ	B-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
seen	see	s050	VBN	B-VP	O
at	at	a300	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
institution	institution	i523030305	NN	I-NP	O
from	from	f605	IN	B-PP	O
July	July	j040	NNP	B-NP	O
2006	2006	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
December	December	d0205106	NNP	B-NP	O
2006	2006	0000	CD	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
corneal	corneal	c06504	JJ	B-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
use	use	u200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
corneal	corneal	c06504	JJ	I-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
cultured	culture	c0430603	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
intensive	intensive	i53052010	JJ	B-NP	O
topical	topical	t010204	JJ	I-NP	O
antibiotic	antibiotic	a53010302	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
comprehensive	comprehensive	c0516052010	JJ	B-NP	O
health	health	h0430	NN	I-NP	O
care	care	c060	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
medical	medical	m030204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
substance	substance	s01230520	NN	I-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
consultations	consultation	c05204303052	NNS	I-NP	O
.	.	.000	.	O	O

Streptococcal	Streptococcal	s36013020204	JJ	B-NP	O
organisms	organism	o62050252	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
Capnocytophaga	Capnocytophaga	c015020301020	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Brevibacterium	Brevibacterium	b601010230605	NNP	I-NP	O
casei	casei	c020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
responded	respond	r02105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
antibiotic	antibiotic	a53010302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
needed	need	n0303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
tarsorrhaphy	tarsorrhaphy	t06206010	NN	I-NP	O
for	for	f060	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Aerosolized	Aerosolize	a0602040203	VBN	B-NP	O
crack	crack	c602	NN	I-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
use	use	u200	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
corneal	corneal	c06504	JJ	B-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
provides	provide	p6010302	VBZ	B-VP	O
additional	additional	a3030504	JJ	B-NP	O
challenges	challenge	c0405202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
management	management	m050205053	NN	B-NP	O
.	.	.000	.	O	O

Not	Not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
poor	poor	p060	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
noncompliance	noncompliance	n05205140520	NN	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
addressed	address	a360203	VBN	I-VP	O
.	.	.000	.	O	O

Comprehensive	Comprehensive	c0516052010	JJ	B-NP	O
care	care	c060	NN	I-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
the	the	t000	DT	B-NP	O
opportunity	opportunity	o106305030	NN	I-NP	O
to	to	t000	TO	B-VP	O
discontinue	discontinue	d02053050	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
substance	substance	s01230520	NN	I-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
,	,	,000	,	O	O
improve	improve	i516010	VB	B-VP	O
their	their	t060	PRP$	B-NP	O
overall	overall	o10604	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
prevent	prevent	p601053	VB	B-VP	O
future	future	f03060	JJ	B-NP	O
corneal	corneal	c06504	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Topical	Topical	t010204	JJ	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
025	025	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
post	post	p023	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
herpetic	herpetic	h0610302	JJ	I-NP	I-Disease
neuralgia	neuralgia	n060420	NN	I-NP	I-Disease
:	:	:000	:	O	O
efficacy	efficacy	e102020	NN	B-NP	O
,	,	,000	,	O	O
predictors	predictor	p603023062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
and	and	a530	CC	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
course	course	c0620	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
and	and	a530	CC	I-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
topical	topical	t010204	JJ	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
39	39	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
post	post	p023	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
herpetic	herpetic	h0610302	JJ	I-NP	I-Disease
neuralgia	neuralgia	n060420	NN	I-NP	I-Disease
(	(	(000	(	O	O
PHN	PHN	p050	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
median	median	m0305	JJ	B-NP	O
duration	duration	d060305	NN	I-NP	O
24	24	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
025	025	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
cream	cream	c605	NN	I-NP	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
rated	rat	r0303	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
(	(	(000	(	O	O
VAS	VAS	v020	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
verbal	verbal	v06104	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
investigation	investigation	i51023020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
study	study	s3030	NN	B-NP	O
onset	onset	o5203	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
.	.	.000	.	O	O

Nineteen	Nineteen	n050305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
substantially	substantially	s0123053040	RB	B-VP	O
improved	improve	i5160103	VBD	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
;	;	;000	:	O	O
5	5	5000	CD	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
discontinued	discontinue	d020530503	VBD	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
side	side	s030	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
intolerable	intolerable	i5304060140	JJ	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
burning	burning	b065052	NN	I-NP	O
sensations	sensation	s05203052	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
mastitis	mastitis	m0230302	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
15	15	0000	CD	B-NP	O
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
reported	report	r0106303	VBD	B-VP	O
no	no	n000	DT	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
VAS	VAS	v020	NN	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
application	application	a14020305	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
responders	responder	r021053062	NNS	I-NP	O
72	72	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
still	still	s304	RB	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
;	;	;000	:	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
third	third	t063	JJ	I-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
application	application	a14020305	NN	B-NP	O
irregularly	irregularly	i602040640	RB	B-ADVP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
or	or	o600	CC	O	O
localization	localization	l0204020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
PHN	PHN	p050	NN	B-NP	B-Disease
(	(	(000	(	O	O
trigeminal	trigeminal	t602050504	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
sensory	sensory	s052060	JJ	B-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
character	character	c0602306	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
course	course	c0620	NN	I-NP	O
or	or	o600	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
burning	burning	b065052	NN	I-NP	O
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
confirmed	confirm	c05106503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
controlled	controlled	c05360403	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
open	open	o105	JJ	I-NP	O
,	,	,000	,	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
randomized	randomize	r053050203	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
might	might	m0203	MD	B-VP	O
indicate	indicate	i5302030	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
PHN	PHN	p050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	O	O
interference	interference	i53061060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
neuropeptide	neuropeptide	n0601013030	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
and	and	a530	CC	O	O
morphological	morphological	m06104020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
(	(	(000	(	O	O
perhaps	perhaps	p06012	RB	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
afferents	afferent	a1060532	NNS	I-NP	O
.	.	.000	.	O	O

Myo	Myo	m000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
inositol	inositol	i5020304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MIP	MIP	m010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
synthase	synthase	s053020	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
:	:	:000	:	O	O
in	in	i500	FW	B-PP	O
-	-	-000	HYPH	B-NP	O
vivo	vivo	v010	FW	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
valproate	valproate	v0416030	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
prototypic	prototypic	p603030102	JJ	I-NP	O
mood	mood	m030	NN	I-NP	O
stabilizers	stabilizer	s3010402062	NNS	I-NP	O
and	and	a530	CC	O	O
have	have	h010	VBP	B-VP	O
diverse	diverse	d010620	JJ	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
targets	target	t062032	NNS	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
influence	influence	i5140520	VBP	B-VP	O
inositol	inositol	i5020304	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
IMPase	IMPase	i51020	NN	B-NP	O
and	and	a530	CC	I-NP	O
valproate	valproate	v0416030	NN	I-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
MIP	MIP	m010	NN	B-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
MIP	MIP	m010	NN	B-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
replicate	replicate	r01402030	VB	I-VP	O
or	or	o600	CC	I-VP	O
augment	augment	a025053	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inositol	inositol	i5020304	NN	I-NP	B-Chemical
sensitive	sensitive	s05203010	JJ	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
may	may	m000	MD	B-VP	O
stem	stem	s305	VB	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
de	de	d000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
novo	novo	n010	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
to	to	t000	TO	B-PP	O
cellular	cellular	c040406	JJ	B-NP	O
inositol	inositol	i5020304	NN	I-NP	B-Chemical
supply	supply	s0140	NN	I-NP	O
or	or	o600	CC	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
de	de	d000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
novo	novo	n010	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
by	by	b000	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
itself	itself	i32041	PRP	B-NP	O
.	.	.000	.	O	O

Non	Non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
acute	acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
granular	granular	g6050406	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
tubulo	tubulo	t01040	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
interstitial	interstitial	i5306230304	JJ	I-NP	I-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
(	(	(000	(	O	O
ATIN	ATIN	a305	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
insults	insult	i520432	NNS	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
immune	immune	i5050	JJ	B-NP	O
complex	complex	c051402	NN	I-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
tubulo	tubulo	t01040	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
interstitial	interstitial	i5306230304	JJ	B-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
drugs	drug	d602	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
a	a	a000	DT	O	O
far	far	f060	RB	B-ADVP	O
more	more	m060	RBR	I-ADVP	O
frequent	frequent	f602053	JJ	B-NP	O
cause	cause	c020	NN	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
entity	entity	e53030	NN	I-NP	O
,	,	,000	,	O	O
ATIN	ATIN	a305	NN	B-NP	B-Disease
remains	remain	r05052	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
symptoms	symptom	s0513052	NNS	B-NP	O
resolve	resolve	r020410	VBP	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
14	14	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
boy	boy	b000	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
valve	valve	v0410	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
put	put	p030	VBN	I-VP	O
on	on	o500	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
following	follow	f04052	VBG	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	O	O
took	take	t020	VBD	B-VP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
fever	fever	f0106	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
a	a	a000	DT	I-NP	O
week	week	w020	NN	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
presented	present	p60205303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
feeling	feel	f04052	VBG	B-VP	O
quite	quite	q030	RB	B-ADVP	O
ill	ill	i400	RB	I-ADVP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
blood	blood	b403	NN	I-NP	B-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BUN	BUN	b050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentration	concentration	c05205360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
of	of	o100	IN	B-PP	O
147	147	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
and	and	a530	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
.	.	.000	.	O	O

Dialysis	Dialysis	d040202	NN	B-NP	O
was	be	w020	VBD	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
infiltrate	infiltrate	i510436030	NN	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
ATIN	ATIN	a305	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
(	(	(000	(	O	O
TBM	TBM	t150	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
very	very	v060	RB	B-NP	O
intense	intense	i530520	JJ	I-NP	O
granular	granular	g6050406	JJ	I-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
polyclonal	polyclonal	p040240504	JJ	B-NP	O
IgG	IgG	i200	NN	I-NP	O
and	and	a530	CC	I-NP	O
C3	C3	0000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
needed	need	n0303	VBD	B-VP	O
dialysis	dialysis	d040202	NN	B-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
renal	renal	r0504	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
and	and	a530	CC	I-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
took	take	t020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
ATIN	ATIN	a305	NN	I-NP	B-Disease
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
deposits	deposit	d0102032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
granular	granular	g6050406	JJ	B-NP	O
immune	immune	i5050	JJ	I-NP	O
complex	complex	c051402	NN	I-NP	O
present	present	p602053	VBP	B-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
TBM	TBM	t150	NN	I-NP	O
and	and	a530	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
.	.	.000	.	O	O

Rifampicin	Rifampicin	r010510205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
necrotizing	necrotize	n0260302052	VBG	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
staphylococcal	staphylococcal	s30104020204	JJ	B-NP	B-Disease
endocarditis	endocarditis	e53020630302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Segmental	Segmental	s02505304	JJ	B-NP	O
necrotising	necrotising	n0260302052	NN	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
complication	complication	c0514020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
tuberculosis	tuberculosis	t01062040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Changing	Change	c052052	VBG	B-VP	O
epidemiology	epidemiology	e1030504020	NN	B-NP	O
of	of	o100	IN	B-PP	O
infections	infection	i51023052	NNS	B-NP	B-Disease
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
infective	infective	i51023010	JJ	B-NP	B-Disease
endocarditis	endocarditis	e53020630302	NN	I-NP	I-Disease
(	(	(000	(	O	O
IE	IE	i000	NN	B-NP	B-Disease
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
led	lead	l030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
Staphylococcal	Staphylococcal	s30104020204	JJ	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
Staphylococcal	Staphylococcal	s30104020204	JJ	B-NP	B-Disease
IE	IE	i000	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
necrotising	necrotise	n0260302052	VBG	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
review	review	r010	VB	B-VP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Rate	Rate	r030	NN	B-NP	O
of	of	o100	IN	B-PP	O
YMDD	YMDD	y530	NN	B-NP	O
motif	motif	m0301	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
Iranian	Iranian	i60505	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
YMDD	YMDD	y530	NN	I-NP	O
motif	motif	m0301	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
(	(	(000	(	O	O
resistant	resistant	r02023053	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
)	)	)000	)	O	O
occur	occur	o206	VBP	B-VP	O
as	as	a200	IN	B-PP	O
natural	natural	n030604	JJ	B-NP	O
genome	genome	g05050	NN	I-NP	O
variability	variability	v060104030	NN	I-NP	O
in	in	i500	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
YMDD	YMDD	y530	NN	B-NP	O
motif	motif	m0301	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Iran	Iran	i605	NNP	B-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
77	77	0000	CD	B-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
from	from	f605	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
polymerase	polymerase	p040506020	NN	B-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
restriction	restriction	r023602305	NN	I-NP	O
fragment	fragment	f6025053	NN	I-NP	O
length	length	l05230	NN	I-NP	O
polymorphism	polymorphism	p0405061025	NN	I-NP	O
(	(	(000	(	O	O
PCR	PCR	p260	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
RFLP	RFLP	r141	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
YMDD	YMDD	y530	NN	B-NP	O
motif	motif	m0301	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
,	,	,000	,	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HCV	HCV	h210	NN	B-NP	O
,	,	,000	,	O	O
HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HBe	HBe	h100	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
77	77	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
enrolled	enrol	e560403	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
73	73	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
male	male	m040	JJ	B-ADJP	O
and	and	a530	CC	O	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
female	female	f05040	JJ	B-ADJP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
ALT	ALT	a430	NN	I-NP	O
and	and	a530	CC	I-NP	O
AST	AST	a230	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
124	124	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
73	73	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	I-NP	O
103	103	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
81	81	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	O	O
l	l	l000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HBe	HBe	h100	NN	I-NP	O
in	in	i500	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Anti	Anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HCV	HCV	h210	NN	B-NP	O
was	be	w020	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
.	.	.000	.	O	O

YMDD	YMDD	y530	NN	B-NP	O
motif	motif	m0301	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
despite	despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HBe	HBe	h100	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
natural	natural	n030604	JJ	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
YMDD	YMDD	y530	NN	B-NP	O
motif	motif	m0301	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
untreated	untreated	u5360303	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
mutants	mutant	m030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Iranian	Iranian	i60505	JJ	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Branch	Branch	b60520	NN	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
branch	branch	b60520	NN	B-NP	O
retinal	retinal	r030504	NN	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
infrequent	infrequent	i51602053	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
ophthalmologists	ophthalmologist	o10304504020232	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
aware	aware	a060	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
because	because	b02020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
release	release	r04020	NN	I-NP	O
,	,	,000	,	O	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
pain	pain	p050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
blocking	block	b402052	VBG	B-VP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
input	input	i5103	NN	I-NP	O
from	from	f605	IN	B-PP	O
surgical	surgical	s0620204	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
,	,	,000	,	O	O
long	long	l052	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
acting	act	a23052	VBG	B-VP	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
directly	directly	d0602340	RB	I-VP	O
modulate	modulate	m0304030	VB	I-VP	O
inflammation	inflammation	i514050305	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
proinflammatory	proinflammatory	p605140503060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PGE2	PGE2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
production	production	p60302305	NN	B-NP	O
and	and	a530	CC	O	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	B-NP	O
(	(	(000	(	O	O
COX	COX	c020	NN	B-NP	O
)	)	)000	)	O	O
gene	gene	g050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
that	that	t030	WDT	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Subjects	Subject	s0120232	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
114	114	0000	CD	B-NP	O
)	)	)000	)	O	O
undergoing	undergo	u53062052	VBG	B-VP	O
extraction	extraction	e23602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
impacted	impacted	i5102303	JJ	B-NP	O
third	third	t063	JJ	I-NP	O
molars	molar	m04062	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	O	O
either	either	e0306	CC	O	O
rofecoxib	rofecoxib	r01020201	NN	B-NP	B-Chemical
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
orally	orally	o6040	RB	B-NP	O
90	90	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
48	48	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
mucosal	mucosal	m020204	JJ	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
extraction	extraction	e23602305	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
microdialysis	microdialysis	m02603040202	NN	I-NP	O
probe	probe	p6010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
placed	place	p40203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
site	site	s030	NN	I-NP	O
for	for	f060	IN	B-PP	O
PGE2	PGE2	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
thromboxane	thromboxane	t0605102050	NN	B-NP	B-Chemical
B2	B2	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TXB2	TXB2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
measurements	measurement	m0206050532	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
rofecoxib	rofecoxib	r01020201	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
less	less	l020	JJR	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analog	analog	a50402	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
three	three	t060	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
4	4	4000	CD	I-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
/	/	/000	SYM	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
and	and	a530	CC	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
4	4	4000	CD	I-NP	O
h	h	h000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
three	three	t060	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
COX	COX	c020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
at	at	a300	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
/	/	/000	SYM	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Thromboxane	Thromboxane	t0605102050	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
seen	see	s050	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
COX	COX	c020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
COX	COX	c020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
stimulates	stimulate	s305040302	VBZ	B-VP	O
COX	COX	c020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
after	after	a1306	IN	B-PP	O
tissue	tissue	t020	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
dissipates	dissipate	d02010302	NNS	I-NP	O
.	.	.000	.	O	O

p75NTR	p75NTR	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
sensory	sensory	s052060	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
and	and	a530	CC	O	O
spinal	spinal	s10504	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
nerve	nerve	n0610	NN	B-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
NGF	NGF	n210	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
contributing	contribute	c05360103052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
voiding	void	v03052	VBG	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	O	O
altered	altered	a430603	JJ	B-NP	O
sensation	sensation	s0520305	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	B-NP	O
and	and	a530	CC	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
tyrosine	tyrosine	t0602050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
Trks	Trk	t620	NNS	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
inflammation	inflammation	i514050305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
examine	examine	e205050	VBP	B-VP	O
the	the	t000	DT	O	O
expression	expression	e2160205	NN	B-NP	O
and	and	a530	CC	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
another	another	a50306	DT	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
bind	bind	b053	VB	I-VP	O
NGF	NGF	n210	NN	B-NP	O
,	,	,000	,	O	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
durations	duration	d0603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
inflammation	inflammation	i514050305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

CYP	CYP	c010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
superficial	superficial	s010610204	JJ	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
medial	medial	m0304	JJ	I-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
horn	horn	h065	NN	I-NP	O
in	in	i500	IN	B-PP	O
L1	L1	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
L2	L2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
L6	L6	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
S1	S1	0000	NN	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
immunoreactive	immunoreactive	i50506023010	JJ	B-ADJP	O
(	(	(000	(	O	O
-	-	-000	HYPH	B-NP	O
IR	IR	i600	NN	I-NP	O
)	)	)000	)	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lumbosacral	lumbosacral	l0510202604	JJ	I-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
root	root	r030	NN	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
(	(	(000	(	O	O
DRG	DRG	d620	NN	B-NP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
(	(	(000	(	O	O
acute	acute	a2030	JJ	B-ADJP	O
,	,	,000	,	O	O
intermediate	intermediate	i5306503030	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-ADJP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
,	,	,000	,	I-NP	O
real	real	r040	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
polymerase	polymerase	p040506020	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
mRNA	mRNA	m650	NN	B-NP	O
in	in	i500	IN	B-PP	O
DRG	DRG	d620	NN	B-NP	O
with	with	w030	IN	B-PP	O
intermediate	intermediate	i5306503030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
CYP	CYP	c010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Retrograde	Retrograde	r036026030	NN	B-NP	O
dye	dye	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
tracing	trace	t602052	VBG	B-VP	O
techniques	technique	t02050202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Fastblue	Fastblue	f023140	NN	B-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
presumptive	presumptive	p6020513010	JJ	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
afferent	afferent	a106053	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lumbosacral	lumbosacral	l0510202604	JJ	I-NP	O
DRG	DRG	d620	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
afferent	afferent	a106053	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
DRG	DRG	d620	NN	B-NP	O
,	,	,000	,	O	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
IR	IR	i600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
cystitis	cystitis	c0230302	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
IR	IR	i600	NN	I-NP	O
in	in	i500	IN	B-PP	O
DRG	DRG	d620	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
bodies	body	b0302	NNS	I-NP	O
,	,	,000	,	O	O
increases	increase	i5260202	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
pericellular	pericellular	p0602040406	JJ	B-ADJP	O
(	(	(000	(	O	O
encircling	encircle	e520624052	VBG	B-VP	O
DRG	DRG	d620	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
)	)	)000	)	O	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
IR	IR	i600	NN	I-NP	O
in	in	i500	IN	B-PP	O
DRG	DRG	d620	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
.	.	.000	.	O	O

Confocal	Confocal	c0510204	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
pericellular	pericellular	p0602040406	JJ	B-NP	O
p75	p75	0000	NN	I-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
IR	IR	i600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
colocalized	colocalize	c0402040203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
glial	glial	g404	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
,	,	,000	,	O	O
glial	glial	g404	JJ	B-NP	O
fibrillary	fibrillary	f01604060	JJ	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
GFAP	GFAP	g101	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
present	present	p602053	JJ	B-ADJP	O
constitutively	constitutively	c0523030301040	RB	B-ADVP	O
and	and	a530	CC	O	O
modified	modify	m030103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
inflammation	inflammation	i514050305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
p75	p75	0000	NN	B-NP	O
(	(	(000	(	O	O
NTR	NTR	n360	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Azathioprine	Azathioprine	a203016050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
suicidal	suicidal	s020304	JJ	I-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Azathioprine	Azathioprine	a203016050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
include	include	i524030	VBP	B-VP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
suppression	suppression	s0160205	NN	I-NP	O
.	.	.000	.	O	O

Alternatively	Alternatively	a430650301040	RB	B-ADVP	O
,	,	,000	,	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
could	could	c043	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
accelerated	accelerate	a204060303	VBN	B-NP	O
suicidal	suicidal	s020304	JJ	I-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
death	death	d030	NN	I-NP	O
or	or	o600	CC	I-NP	O
eryptosis	eryptosis	e60130202	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
of	of	o100	IN	B-PP	O
phosphatidylserine	phosphatidylserine	p021030304206050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PS	PS	p200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
shrinkage	shrinkage	s06052020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
explored	explore	e2140603	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
influences	influence	i51405202	VBZ	B-VP	O
eryptosis	eryptosis	e60130202	NN	B-NP	O
.	.	.000	.	O	O

According	Accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
annexin	annexin	a50205	NN	B-NP	O
V	V	v000	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
,	,	,000	,	O	O
erythrocytes	erythrocyte	e60306020302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
indeed	indeed	i5303	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
PS	PS	p200	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
series	series	s0602	NN	I-NP	O
,	,	,000	,	O	O
cytosolic	cytosolic	c03020402	JJ	B-NP	O
Ca2	Ca2	0000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
activity	activity	a2301030	NN	B-NP	O
(	(	(000	(	O	O
Fluo3	Fluo3	0000	NN	B-NP	B-Chemical
fluorescence	fluorescence	f406020520	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cell	cell	c040	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
(	(	(000	(	O	O
forward	forward	f06063	JJ	B-NP	O
scatter	scatter	s20306	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
PS	PS	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
exposure	exposure	e2102060	NN	B-NP	O
(	(	(000	(	O	O
annexin	annexin	a50205	NN	B-NP	O
V	V	v000	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
FACS	FACS	f020	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
in	in	i500	IN	B-PP	O
erythrocytes	erythrocyte	e60306020302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Exposure	Exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
48	48	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
cytosolic	cytosolic	c03020402	JJ	B-NP	O
Ca2	Ca2	0000	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
activity	activity	a2301030	NN	B-NP	O
and	and	a530	CC	I-NP	O
annexin	annexin	a50205	NN	I-NP	O
V	V	v000	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
forward	forward	f06063	RB	B-ADJP	O
scatter	scatt	s20306	JJR	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
both	both	b030	CC	O	O
annexin	annexin	a50205	NN	B-NP	O
V	V	v000	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
and	and	a530	CC	O	O
forward	forward	f06063	JJ	B-NP	O
scatter	scatter	s20306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
blunted	blunt	b405303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nominal	nominal	n050504	JJ	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
Ca2	Ca2	0000	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Azathioprine	Azathioprine	a203016050	NN	B-NP	B-Chemical
triggers	trigger	t602062	VBZ	B-VP	O
suicidal	suicidal	s020304	JJ	B-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
death	death	d030	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
presumably	presumably	p602050140	RB	B-VP	O
contributing	contribute	c05360103052	VBG	I-VP	O
to	to	t000	TO	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Levetiracetam	Levetiracetam	l010306020305	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
adjunct	adjunct	a320523	NN	I-NP	O
to	to	t000	TO	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	B-NP	O
,	,	,000	,	O	O
efficacy	efficacy	e102020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
tolerability	tolerability	t04060104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
levetiracetam	levetiracetam	l010306020305	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
adjunct	adjunct	a320523	NN	I-NP	O
to	to	t000	TO	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
poorly	poorly	p0640	RB	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
Open	Open	o105	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
,	,	,000	,	O	O
noncomparative	noncomparative	n0520510603010	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

ANIMALS	ANIMALS	a505042	NNS	B-NP	O
:	:	:000	:	O	O
12	12	0000	CD	B-NP	O
cats	cat	c032	NNS	I-NP	O
suspected	suspect	s02102303	VBN	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
poorly	poorly	p0640	RB	I-VP	O
controlled	control	c05360403	VBN	I-VP	O
with	with	w030	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
unacceptable	unacceptable	u5020130140	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

PROCEDURES	PROCEDURES	p602030602	NNS	B-NP	O
:	:	:000	:	O	O
Cats	Cat	c032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
[	[	[000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
lb	lb	l100	NN	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
PO	PO	p000	NN	B-NP	O
,	,	,000	,	O	O
q	q	q000	NN	B-NP	O
8	8	8000	CD	I-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
levetiracetam	levetiracetam	l010306020305	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
maximum	maximum	m020505	NN	B-NP	O
and	and	a530	CC	I-NP	O
minimum	minimum	m050505	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
elimination	elimination	e405050305	NN	B-NP	O
half	half	h041	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
life	life	l010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
frequencies	frequency	f60205202	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Median	Median	m0305	JJ	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
levetiracetam	levetiracetam	l010306020305	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
,	,	,000	,	O	O
median	median	m0305	JJ	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
levetiracetam	levetiracetam	l010306020305	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-NP	O
elimination	elimination	e405050305	NN	I-NP	O
half	half	h041	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
mo	mo	m000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
median	median	m0305	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
42	42	0000	CD	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
mo	mo	m000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
cats	cat	c032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
classified	classify	c4020103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
responded	respond	r02105303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	O	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cats	cat	c032	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
lethargy	lethargy	l030620	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
inappetence	inappetence	i501030520	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
AND	AND	a530	CC	O	O
CLINICAL	CLINICAL	c4050204	JJ	B-NP	O
RELEVANCE	RELEVANCE	r04010520	NN	I-NP	O
:	:	:000	:	O	O
Results	Result	r020432	NNS	B-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
adjunct	adjunct	a320523	NN	I-NP	O
to	to	t000	TO	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

Serotonin	Serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
,	,	,000	,	O	O
paranoia	paranoia	p06050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
.	.	.000	.	O	O

Antidepressants	Antidepressant	a5303016020532	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
paranoid	paranoid	p060503	JJ	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paranoid	paranoid	p060503	JJ	B-NP	B-Disease
exacerbation	exacerbation	e2020610305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
amitriptyline	amitriptyline	a503601304050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
here	here	h060	RB	B-ADVP	O
.	.	.000	.	O	O

Elements	Element	e4050532	NNS	B-NP	O
common	common	c0505	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
paranoid	paranoid	p060503	JJ	B-NP	B-Disease
symptomatology	symptomatology	s0513050304020	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
psychotic	psychotic	p2020302	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Complicated	Complicate	c0514020303	VBN	B-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
(	(	(000	(	O	O
including	include	i52403052	VBG	B-PP	O
atypicality	atypicality	a3010204030	NN	B-NP	O
of	of	o100	IN	B-PP	O
course	course	c0620	NN	B-NP	O
and	and	a530	CC	I-NP	O
symptomatology	symptomatology	s0513050304020	NN	I-NP	O
,	,	,000	,	O	O
chronicity	chronicity	c060502030	NN	B-NP	O
,	,	,000	,	O	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
,	,	,000	,	O	O
bipolarity	bipolarity	b010406030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
secondary	secondary	s02053060	JJ	B-NP	O
onset	onset	o5203	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
present	present	p602053	VB	I-VP	O
particular	particular	p063020406	JJ	B-NP	O
vulnerability	vulnerability	v045060104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
paranoid	paranoid	p060503	JJ	B-NP	B-Disease
exacerbations	exacerbation	e20206103052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
pharmacology	pharmacology	p0650204020	NN	I-NP	O
and	and	a530	CC	I-NP	O
neurobiology	neurobiology	n060104020	NN	I-NP	O
of	of	o100	IN	B-PP	O
paranoia	paranoia	p06050	NN	B-NP	B-Disease
remain	remain	r0505	VBP	B-VP	O
cryptic	cryptic	c601302	JJ	B-ADJP	O
,	,	,000	,	O	O
several	several	s010604	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
5HT3	5HT3	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
,	,	,000	,	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
noradrenergic	noradrenergic	n060360506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
downregulation	downregulation	d05602040305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
GABAB	GABAB	g0101	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
acting	act	a23052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vicinity	vicinity	v0205030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
(	(	(000	(	O	O
possibly	possibly	p020140	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
lateral	lateral	l030604	JJ	B-NP	O
orbitofrontal	orbitofrontal	o610301605304	JJ	I-NP	O
or	or	o600	CC	I-NP	O
anterior	anterior	a530606	JJ	I-NP	O
cingulate	cingulate	c05204030	JJ	I-NP	O
circuits	circuit	c062032	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
might	might	m0203	MD	B-VP	O
apply	apply	a140	VB	I-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
call	call	c040	VBP	B-VP	O
attention	attention	a305305	NN	B-NP	O
to	to	t000	TO	B-PP	O
possible	possible	p020140	JJ	B-NP	O
paranoid	paranoid	p060503	JJ	I-NP	B-Disease
exacerbations	exacerbation	e20206103052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
select	select	s04023	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
raise	raise	r020	VB	B-VP	O
neurobiological	neurobiological	n060104020204	JJ	B-NP	O
considerations	consideration	c052030603052	NNS	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
paranoia	paranoia	p06050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Spinal	Spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
employed	employ	e51403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
drawback	drawback	d60102	NN	I-NP	O
of	of	o100	IN	B-PP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
block	block	b402	NN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Efforts	Effort	e10632	NNS	B-NP	O
must	must	m023	MD	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
continue	continue	c053050	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
made	make	m030	VBN	I-VP	O
to	to	t000	TO	B-VP	O
obviate	obviate	o1030	VB	I-VP	O
this	this	t020	DT	B-NP	O
setback	setback	s03102	NN	I-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
With	With	w030	IN	B-PP	O
ethical	ethical	e30204	JJ	B-NP	O
approval	approval	a160104	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
74	74	0000	CD	B-NP	O
American	American	a5060205	NNP	I-NP	O
Society	Society	s02030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Anesthesiologists	Anesthesiologist	a50230204020232	NNS	B-NP	O
(	(	(000	(	O	O
ASA	ASA	a200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
class	class	c402	NN	I-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
scheduled	schedule	s2030403	VBN	B-VP	O
for	for	f060	IN	B-PP	O
elective	elective	e4023010	JJ	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
lower	low	l060	JJR	I-NP	O
limb	limb	l051	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
lateral	lateral	l030604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
position	position	p020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
operative	operative	o10603010	JJ	B-NP	O
side	side	s030	NN	I-NP	O
down	down	d050	RP	B-PRT	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
recived	recive	r020103	VBD	B-VP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
2mls	2ml	2542	NNS	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
hyperbaric	hyperbaric	h010610602	JJ	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
gauge	gauge	g020	NN	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
needle	needle	n0340	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
position	position	p020305	NN	I-NP	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
turned	turn	t06503	VBN	I-VP	O
supine	supine	s01050	NN	B-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
saturation	saturation	s03060305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
over	over	o106	IN	B-NP	O
1	1	1000	CD	I-NP	O
hour	hour	h060	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
group	group	g601	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
71	71	0000	CD	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
required	require	r020603	VBD	B-VP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
greater	great	g60306	JJR	I-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
at	at	a300	IN	B-PP	O
15	15	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
45	45	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
003	003	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
004	004	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
saturations	saturation	s030603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Compared	Compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
unilateral	unilateral	u504030604	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
fewer	few	f060	JJR	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
perturbations	perturbation	p06306103052	NNS	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
block	block	b402	NN	I-NP	O
instituted	institute	i523030303	VBN	B-VP	O
affected	affect	a102303	VBD	B-VP	O
neither	neither	n0306	CC	O	O
the	the	t000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
nor	nor	n060	CC	O	O
the	the	t000	DT	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
saturation	saturation	s03060305	NN	I-NP	O
.	.	.000	.	O	O

Spectrum	Spectrum	s1023605	NN	B-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
generic	generic	g050602	JJ	B-NP	O
HAART	HAART	h063	NN	I-NP	O
in	in	i500	IN	B-PP	O
southern	southern	s03065	JJ	B-NP	O
Indian	Indian	i5305	JJ	I-NP	O
HIV	HIV	h010	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
,	,	,000	,	O	O
fixed	fix	f0203	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
generic	generic	g050602	JJ	B-NP	O
highly	highly	h02040	RB	I-NP	O
active	active	a23010	JJ	I-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
HAART	HAART	h063	NN	B-NP	O
)	)	)000	)	O	O
use	use	u200	NN	B-NP	O
among	among	a5052	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
infected	infect	i5102303	VBN	B-VP	I-Disease
individuals	individual	i530103042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
South	South	s030	NNP	B-NP	O
India	India	i530	NNP	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
experiences	experience	e210605202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
3154	3154	0000	CD	B-NP	O
HIV	HIV	h010	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
individuals	individual	i530103042	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
generic	generic	g050602	JJ	B-NP	O
HAART	HAART	h063	NN	I-NP	O
between	between	b0305	IN	B-PP	O
February	February	f016060	NNP	B-NP	O
1996	1996	0000	CD	I-NP	O
and	and	a530	CC	O	O
December	December	d0205106	NNP	B-NP	O
2006	2006	0000	CD	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
tertiary	tertiary	t063060	JJ	I-NP	O
HIV	HIV	h010	NN	I-NP	O
care	care	c060	NN	I-NP	O
referral	referral	r010604	JJ	I-NP	O
center	center	c05306	NN	I-NP	O
in	in	i500	IN	B-PP	O
South	South	s030	NNP	B-NP	O
India	India	i530	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
3TC	3TC	3200	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
d4T	d4T	0000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
nevirapine	nevirapine	n010601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NVP	NVP	n100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
+	+	+000	SYM	B-NP	O
3TC	3TC	3200	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
NVP	NVP	n100	NN	I-NP	B-Chemical
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
3TC	3TC	3200	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
d4T	d4T	0000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
efavirenz	efavirenz	e10106052	NN	B-NP	B-Chemical
(	(	(000	(	O	O
EFV	EFV	e100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
3TC	3TC	3200	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
EFV	EFV	e100	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-NP	O
CD4	CD4	0000	NN	I-NP	O
at	at	a300	IN	B-PP	O
time	time	t050	NN	B-NP	O
of	of	o100	IN	B-PP	O
event	event	e1053	NN	B-NP	O
were	be	w060	VBD	B-VP	O
rash	rash	r020	NN	B-NP	B-Disease
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
CD4	CD4	0000	NN	B-NP	O
,	,	,000	,	O	O
285	285	0000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
microL	microL	m02604	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
348	348	0000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
microL	microL	m02604	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Clinically	Clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
(	(	(000	(	O	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
<	<	<000	SYM	O	O
7	7	7000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
CD4	CD4	0000	NN	B-NP	O
,	,	,000	,	O	O
165	165	0000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
microL	microL	m02604	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
(	(	(000	(	O	O
clinical	clinical	c4050204	JJ	B-NP	O
jaundice	jaundice	j053020	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
alanine	alanine	a405050	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
>	>	>000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
upper	upper	u106	JJ	I-NP	O
limits	limit	l05032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
CD4	CD4	0000	NN	B-NP	O
,	,	,000	,	O	O
260	260	0000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
microL	microL	m02604	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
experience	experience	e21060520	VB	I-VP	O
lactic	lactic	l02302	JJ	B-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
men	man	m050	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
experience	experience	e21060520	VB	I-VP	O
immune	immune	i5050	JJ	B-NP	B-Disease
reconstitution	reconstitution	r020523030305	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
NVP	NVP	n100	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
rash	rash	r020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
d4T	d4T	0000	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Anemia	Anemia	a5050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
often	often	o1305	RB	B-ADVP	O
occur	occur	o206	VBP	B-VP	O
within	within	w0305	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
initiating	initiate	i50303052	VBG	B-VP	O
generic	generic	g050602	JJ	B-NP	O
HAART	HAART	h063	NN	I-NP	O
.	.	.000	.	O	O

Frequent	Frequent	f602053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
early	early	e0640	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
developing	develop	d010401052	VBG	B-NP	O
countries	country	c053602	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
generic	generic	g050602	JJ	B-NP	O
HAART	HAART	h063	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
increasingly	increasingly	i5260205240	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
.	.	.000	.	O	O

Thalidomide	Thalidomide	t040305030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
sensory	sensory	s052060	JJ	B-NP	B-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
neurophysiological	neurophysiological	n06010204020204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Recent	Recent	r02053	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	B-Disease
axonal	axonal	a20504	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
aims	aim	a052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
measure	measure	m02060	VB	I-VP	O
variations	variation	v0603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
sural	sural	s0604	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
sensory	sensory	s052060	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
(	(	(000	(	O	O
SAP	SAP	s010	NN	B-NP	O
)	)	)000	)	O	O
amplitude	amplitude	a51403030	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	B-Disease
lupus	lupus	l0102	NN	I-NP	I-Disease
erythematosus	erythematosus	e60305030202	NN	I-NP	I-Disease
(	(	(000	(	O	O
CLE	CLE	c400	NN	B-NP	B-Disease
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
use	use	u200	VB	B-VP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	O
fibres	fibre	f01602	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Clinical	Clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CLE	CLE	c400	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
47	47	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Sural	Sural	s0604	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
SAP	SAP	s010	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
sural	sural	s0604	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
SAP	SAP	s010	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
<	<	<000	SYM	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
SAP	SAP	s010	NN	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
paresthesias	paresthesia	p060230202	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
leg	leg	l020	NN	B-NP	O
cramps	cramp	c60512	NNS	I-NP	B-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
sural	sural	s0604	JJ	B-NP	O
SAP	SAP	s010	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
sural	sural	s0604	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
SAP	SAP	s010	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
21	21	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
g	g	g000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
dosage	dosage	d02020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-SBAR	O
previously	previously	p6010240	RB	B-ADVP	O
reported	report	r0106303	VBN	B-VP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Sural	Sural	s0604	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
SAP	SAP	s010	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reliable	reliable	r040140	JJ	I-NP	O
and	and	a530	CC	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
degeneration	degeneration	d0205060305	NN	B-NP	O
and	and	a530	CC	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	O
fibres	fibre	f01602	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
parameter	parameter	p06050306	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
information	information	i510650305	NN	B-NP	O
about	about	a103	IN	B-PP	O
subclinical	subclinical	s0124050204	JJ	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
helpful	helpful	h04104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
predicting	predict	p603023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
encephalitis	encephalitis	e5201040302	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
loiasis	loiasis	l0202	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
diethylcarbamazine	diethylcarbamazine	d030420610502050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
encephalitis	encephalitis	e5201040302	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
diethylcarbamazine	diethylcarbamazine	d030420610502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DEC	DEC	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Congolese	Congolese	c05204020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Loa	Loa	l000	NN	B-NP	O
loa	loa	l000	NN	I-NP	O
filariasis	filariasis	f04060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fatal	fatal	f0304	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
notable	notable	n030140	JJ	I-NP	O
fact	fact	f023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
hospitalized	hospitalize	h02103040203	VBN	B-VP	O
before	before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
began	begin	b0205	VBD	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
particularly	particularly	p06302040640	RB	B-ADVP	O
strict	strict	s36023	VBP	B-VP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
precautions	precaution	p60203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
initial	initial	i50304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
DEC	DEC	d020	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
very	very	v060	RB	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
associated	associate	a2020303	VBN	B-VP	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	B-NP	O
allergic	allergic	a406202	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
that	that	t030	RB	B-ADJP	O
uncommon	uncommon	u520505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
highly	highly	h02040	RB	B-NP	O
endemic	endemic	e530502	JJ	I-NP	O
regions	region	r02052	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-ADVP	O
exclusively	exclusively	e240201040	RB	I-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
microfilarial	microfilarial	m02601040604	JJ	I-NP	O
load	load	l030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
encephalitis	encephalitis	e5201040302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
microfilaremia	microfilaremia	m026010406050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathophysiological	pathophysiological	p03010204020204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
light	light	l0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
other	other	o306	JJ	I-NP	O
comments	comment	c050532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
published	publish	p0140203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-VP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
mass	mass	m020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
unique	unique	u5020	JJ	B-NP	O
membranous	membranous	m05160502	JJ	I-NP	B-Disease
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
:	:	:000	:	O	O
Diagnostic	Diagnostic	d02502302	JJ	B-NP	O
pitfall	pitfall	p03104	NN	I-NP	O
and	and	a530	CC	O	O
new	new	n000	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
arrhythmic	arrhythmic	a6030502	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
various	various	v0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Reported	Report	r0106303	VBN	B-VP	O
herein	herein	h0605	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
autopsy	autopsy	a030120	NN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lung	lung	l052	NN	I-NP	B-Disease
mass	mass	m020	NN	I-NP	I-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
in	in	i500	IN	B-PP	O
diameter	diameter	d050306	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
76	76	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
time	time	t050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lung	lung	l052	NN	I-NP	B-Disease
mass	mass	m020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
highly	highly	h02040	RB	I-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
lung	lung	l052	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
and	and	a530	CC	I-NP	O
positron	positron	p0203605	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
histologically	histologically	h023040202040	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
composed	compose	c0510203	VBN	I-VP	O
of	of	o100	IN	B-PP	O
lymphoplasmacytic	lymphoplasmacytic	l051014025020302	JJ	B-NP	O
infiltrates	infiltrate	i5104360302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
alveolar	alveolar	a410406	JJ	B-NP	O
walls	wall	w042	NNS	I-NP	O
and	and	a530	CC	O	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
alveolar	alveolar	a410406	JJ	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
foamy	foamy	f050	JJ	B-NP	O
macrophages	macrophage	m026010202	NNS	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-NP	O
myelinoid	myelinoid	m040503	JJ	I-NP	O
bodies	body	b0302	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
lung	lung	l052	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
had	have	h030	VBD	B-VP	O
unevenly	unevenly	u5010540	RB	I-VP	O
distributed	distribute	d0236010303	VBN	I-VP	O
hemosiderin	hemosiderin	h0502030605	NN	B-NP	B-Disease
deposition	deposition	d01020305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
abnormally	abnormally	a15065040	RB	B-NP	O
tortuous	tortuous	t06302	JJ	I-NP	O
capillaries	capillary	c01040602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mass	mass	m020	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
heavily	heavily	h01040	RB	B-NP	O
hemosiderotic	hemosiderotic	h050203060302	JJ	I-NP	B-Disease
lung	lung	l052	NN	I-NP	O
portions	portion	p063052	NNS	I-NP	O
outside	outside	o032030	IN	B-PP	O
the	the	t000	DT	B-NP	O
mass	mass	m020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
,	,	,000	,	O	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
membrane	membrane	m0516050	NN	B-NP	O
spikes	spike	s10202	NNS	I-NP	O
,	,	,000	,	O	O
prominent	prominent	p60505053	JJ	B-NP	O
swelling	swelling	s04052	NN	I-NP	O
of	of	o100	IN	B-PP	O
podocytes	podocyte	p03020302	NNS	B-NP	O
and	and	a530	CC	O	O
subepithelial	subepithelial	s0101030404	JJ	B-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
sometimes	sometimes	s05030502	RB	B-ADJP	O
large	large	l0620	JJ	I-ADJP	O
and	and	a530	CC	I-ADJP	O
hump	hump	h051	JJ	I-ADJP	O
-	-	-000	HYPH	B-ADJP	O
like	like	l020	JJ	I-ADJP	O
.	.	.000	.	O	O

Autoimmune	Autoimmune	a0305050	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
viral	viral	v0604	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
malignant	malignant	m04025053	JJ	B-NP	O
neoplasms	neoplasm	n0140252	NNS	I-NP	B-Disease
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
diseases	disease	d020202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
known	know	k505	VBN	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
to	to	t000	TO	B-PP	O
membranous	membranous	m05160502	JJ	B-NP	B-Disease
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
highlights	highlight	h020402032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
differential	differential	d010605304	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
between	between	b0305	IN	B-PP	O
an	an	a500	DT	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-VP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
neoplasm	neoplasm	n014025	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
very	very	v060	RB	B-ADJP	O
difficult	difficult	d0102043	JJ	I-ADJP	O
radiologically	radiologically	r03040202040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
membranous	membranous	m05160502	JJ	B-NP	B-Disease
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
another	another	a50306	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
sulphonylurea	sulphonylurea	s0410504060	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
type	type	t010	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
matched	match	m03203	VBN	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

AIMS	AIMS	a052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
CAD	CAD	c030	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
type	type	t010	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
sulphonylureas	sulphonylurea	s04105040602	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
type	type	t010	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	I-Disease
diabetic	diabetic	d010302	JJ	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
cases	case	c0202	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
CAD	CAD	c030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CAD	CAD	c030	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
diabetes	diabete	d010302	NNS	B-NP	B-Disease
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
UKPDS	UKPDS	u2132	NN	I-NP	O
risk	risk	r020	NN	I-NP	O
engine	engine	e52050	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
match	match	m0320	VB	I-VP	O
cases	case	c0202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
76	76	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CAD	CAD	c030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
152	152	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hazard	hazard	h02063	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
CAD	CAD	c030	NN	B-NP	B-Disease
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
004	004	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
glibenclamide	glibenclamide	g401052405030	NN	B-NP	B-Chemical
;	;	;000	:	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
099	099	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
glipizide	glipizide	g40102030	NN	B-NP	B-Chemical
;	;	;000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
000	000	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hazard	hazard	h02063	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
385	385	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
glimepiride	glimepiride	g4050106030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
192	192	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
gliclazide	gliclazide	g402402030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
09	09	0000	CD	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
either	either	e0306	RB	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Initiating	Initiate	i50303052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
type	type	t010	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
glibenclamide	glibenclamide	g401052405030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
glipizide	glipizide	g40102030	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CAD	CAD	c030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
gliclazide	gliclazide	g402402030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
glimepiride	glimepiride	g4050106030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
confirmed	confirm	c05106503	VBN	B-VP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
important	important	i51063053	JJ	B-ADJP	O
because	because	b02020	IN	B-SBAR	O
most	most	m023	JJS	B-NP	O
Indian	Indian	i5305	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
receive	receive	r02010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
cheaper	cheap	c0106	JJR	I-NP	O
older	old	o4306	JJR	I-NP	O
sulphonylureas	sulphonylurea	s04105040602	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
present	present	p602053	JJ	B-NP	O
guidelines	guideline	g03040502	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
distinguish	distinguish	d023052020	VB	I-VP	O
between	between	b0305	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Reduced	Reduce	r030203	VBN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
type	type	t010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
potential	potential	p0305304	NN	I-NP	O
in	in	i500	IN	B-PP	O
slowing	slow	s4052	VBG	B-VP	O
down	down	d050	RP	B-PRT	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
progression	progression	p60260205	NN	I-NP	O
in	in	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
SHR	SHR	s060	NN	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
month	month	m0530	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
SHR	SHR	s060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
selected	select	s0402303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
SH	SH	s000	NN	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
SH	SH	s000	NN	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
vehicle	vehicle	v0240	NN	B-NP	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
LOS	LOS	l020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
LOS	LOS	l020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
w	w	w000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	LS	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
twice	twice	t020	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
LOS	LOS	l020	NN	I-NP	B-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	I-NP	O
w	w	w000	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
by	by	b000	IN	B-PP	O
gavages	gavage	g010202	NNS	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
group	group	g601	NN	I-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
LOS	LOS	l020	NN	I-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
or	or	o600	CC	I-NP	O
12	12	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Haemodynamic	Haemodynamic	h0503050502	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
anaesthetized	anaesthetize	a5023030203	VBN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
for	for	f060	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
was	be	w020	VBD	B-VP	O
processed	process	p6020203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
morphological	morphological	m06104020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Short	Short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
losartan	losartan	l0206305	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
besides	besides	b020302	IN	B-PP	O
antihypertensive	antihypertensive	a5301063052010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
improved	improve	i5160103	VBD	B-VP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
ameliorated	ameliorate	a504060303	VBN	B-NP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	B-Disease
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
further	further	f06306	JJ	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
and	and	a530	CC	O	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
fibrosis	fibrosis	f0160202	NN	I-NP	I-Disease
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
preventing	prevent	p601053052	VBG	B-VP	O
heavy	heavy	h010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Losartan	Losartan	l0206305	NNP	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
uraemia	uraemia	u6050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
urea	urea	u600	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
tubular	tubular	t010406	JJ	B-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
,	,	,000	,	O	O
interstitial	interstitial	i5306230304	JJ	B-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Losartan	Losartan	l0206305	NNP	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
focal	focal	f0204	JJ	I-NP	B-Disease
segmental	segmental	s02505304	JJ	I-NP	I-Disease
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	I-Disease
to	to	t000	TO	B-VP	O
end	end	e530	VB	I-VP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
and	and	a530	CC	O	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
1188	1188	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
unselected	unselected	u520402303	JJ	I-NP	O
,	,	,000	,	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Perioperative	Perioperative	p06010603010	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
consecutive	consecutive	c0520203010	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
prospectively	prospectively	p602102301040	RB	I-VP	O
collected	collect	c0402303	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
September	September	s01305106	NNP	B-NP	O
2005	2005	0000	CD	I-NP	O
and	and	a530	CC	O	O
June	June	j050	NNP	B-NP	O
2006	2006	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
university	university	u501062030	NN	I-NP	O
-	-	-000	HYPH	O	O
affiliated	affiliate	a1040303	VBN	B-VP	O
clinic	clinic	c40502	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1188	1188	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
5	5	5000	CD	I-NP	O
mo	mo	m000	NN	I-NP	O
,	,	,000	,	O	O
596	596	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
5	5	5000	CD	I-NP	O
mo	mo	m000	NN	I-NP	O
,	,	,000	,	O	O
592	592	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
T	T	t000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Except	Except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
antifibrinolytic	antifibrinolytic	a530101605040302	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
intraoperative	intraoperative	i536010603010	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Postoperatively	Postoperatively	p02301060301040	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
T	T	t000	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
significant	significant	s0250102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
valve	valve	v0410	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
subgroups	subgroup	s0126012	NNS	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
003	003	0000	CD	B-NP	O
;	;	;000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
035	035	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Persistent	Persistent	p062023053	JJ	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
fibrillation	fibrillation	f016040305	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
020	020	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
002	002	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NNP	B-NP	O
T	T	t000	NNP	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
valve	valve	v0410	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	NN	I-NP	O
,	,	,000	,	O	O
among	among	a5052	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
bypass	bypass	b0102	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
acute	acute	a2030	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarctions	infarction	i510623052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
027	027	0000	CD	B-NP	O
;	;	;000	:	O	O
22	22	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
036	036	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
after	after	a1306	IN	B-PP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
034	034	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
antifibrinolytic	antifibrinolytic	a530101605040302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
bear	bear	b060	VBP	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
depending	depend	d01053052	VBG	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
bypass	bypass	b0102	IN	B-PP	O
graft	graft	g6013	NN	B-NP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
valve	valve	v0410	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Delirium	Delirium	d040605	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
possibly	possibly	p020140	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Misoprostol	Misoprostol	m0201602304	NNP	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
gynecologic	gynecologic	g0502040202	JJ	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
headache	headache	h03020	NN	B-NP	B-Disease
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
an	an	a500	DT	B-NP	O
89	89	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
care	care	c060	NN	I-NP	O
facility	facility	f0204030	NN	I-NP	O
became	become	b02050	VBD	B-VP	O
confused	confuse	c0510203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
first	first	f0623	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
nine	nine	n050	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
significantly	significantly	s025010205340	RB	B-VP	O
improved	improve	i5160103	VBD	I-VP	O
after	after	a1306	IN	B-SBAR	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
her	her	h060	PRP$	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
changed	change	c05203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
experienced	experience	e210605203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
possibly	possibly	p020140	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
from	from	f605	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
biological	biological	b04020204	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
optical	optical	o130204	JJ	I-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
optical	optical	o130204	JJ	I-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
compared	compare	c0510603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocking	block	b402052	VBG	I-NP	O
and	and	a530	CC	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
blocking	block	b402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
inotropic	inotropic	i50360102	JJ	I-NP	O
and	and	a530	CC	I-NP	O
chronotropic	chronotropic	c06050360102	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
isoprenaline	isoprenaline	i20160504050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
hundredth	hundredth	h0536030	NN	I-NP	O
the	the	t000	DT	B-NP	O
potency	potency	p030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
which	which	w020	WDT	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
isoprenaline	isoprenaline	i20160504050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
PR	PR	p600	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
.	.	.000	.	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
isoprenaline	isoprenaline	i20160504050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
circulating	circulate	c0620403052	VBG	B-VP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
lactate	lactate	l023030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
fatty	fatty	f030	JJ	I-NP	B-Chemical
acids	acid	a2032	NNS	I-NP	I-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
all	all	a400	DT	O	O
blocked	block	b40203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
.	.	.000	.	O	O

(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
Propranolol	Propranolol	p6016050404	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
fatty	fatty	f030	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
mobilization	mobilization	m0104020305	NN	I-NP	O
but	but	b030	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
increments	increment	i526050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
lactate	lactate	l023030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
.	.	.000	.	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
possessed	possess	p020203	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
depressant	depressant	d01602053	NN	I-NP	O
potency	potency	p030520	NN	I-NP	O
on	on	o500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
taken	take	t0205	VBN	B-VP	O
from	from	f605	IN	B-PP	O
guinea	guinea	g050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
pigs	pig	p020	NNS	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
exhibited	exhibit	e2010303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
local	local	l0204	JJ	I-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
potencies	potency	p0305202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
frog	frog	f602	NN	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
preparation	preparation	p601060305	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
approximately	approximately	a16020503040	RB	B-NP	O
three	three	t060	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
that	that	t030	DT	I-NP	O
of	of	o100	IN	B-PP	O
procaine	procaine	p602050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
racemic	racemic	r020502	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
either	either	e0306	DT	B-NP	O
isomer	isomer	i20506	NN	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
anaesthetized	anaesthetize	a5023030203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
09	09	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
02	02	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
whereas	whereas	w0602	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
PR	PR	p600	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
.	.	.000	.	O	O

Blockade	Blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
arrhythmias	arrhythmia	a6030502	NNS	B-NP	B-Disease
with	with	w030	IN	B-PP	O
both	both	b030	DT	B-NP	O
isomers	isomer	i205062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
surmountable	surmountable	s0650530140	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
reversing	reverse	r01062052	VBG	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
anaesthetized	anaesthetize	a5023030203	VBN	B-NP	O
cats	cat	c032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
smaller	small	s50406	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
species	specie	s10202	NNS	B-NP	O
but	but	b030	CC	O	O
much	much	m020	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
required	require	r020603	VBN	B-VP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Topotecan	Topotecan	t01030205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
in	in	i500	IN	B-PP	O
unresectable	unresectable	u56020230140	JJ	B-NP	O
glioblastoma	glioblastoma	g4014023050	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
2	2	2000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Improving	Improve	i51601052	VBG	B-VP	O
glioblastoma	glioblastoma	g4014023050	NN	B-NP	B-Disease
multiforme	multiforme	m043010650	NN	I-NP	I-Disease
(	(	(000	(	O	O
GBM	GBM	g150	NN	B-NP	B-Disease
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
radio	radio	r030	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

Topotecan	Topotecan	t01030205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
attractive	attractive	a36023010	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
exhibits	exhibit	e201032	VBZ	B-VP	O
growth	growth	g6030	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
glioma	glioma	g4050	NN	I-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
brain	brain	b605	NN	B-NP	O
penetration	penetration	p050360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
Gy	Gy	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
30	30	0000	CD	B-NP	O
fractions	fraction	f6023052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
40	40	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
topotecan	topotecan	t01030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
on	on	o500	IN	B-PP	O
weeks	week	w020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
50	50	0000	CD	B-NP	O
adults	adult	a30432	NNS	I-NP	O
with	with	w030	IN	B-PP	O
histologically	histologically	h023040202040	RB	B-NP	O
proven	proven	p60105	JJ	I-NP	O
and	and	a530	CC	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
GBM	GBM	g150	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
hematological	hematological	h050304020204	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
and	and	a530	CC	O	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
hematological	hematological	h050304020204	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
mainly	mainly	m0540	RB	B-NP	O
lymphopenia	lymphopenia	l05101050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Partial	Partial	p06304	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	I-NP	O
stabilization	stabilization	s30104020305	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
32	32	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
overall	overall	o10604	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
(	(	(000	(	O	O
OS	OS	o200	NN	B-NP	O
)	)	)000	)	O	O
rate	rate	r030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
OS	OS	o200	NN	I-NP	O
of	of	o100	IN	B-PP	O
40	40	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Topotecan	Topotecan	t01030205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
response	response	r0210520	NN	B-NP	O
and	and	a530	CC	I-NP	O
stabilization	stabilization	s30104020305	NN	I-NP	O
concerned	concern	c05206503	VBN	B-VP	O
one	one	o500	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
third	third	t063	JJ	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
survival	survival	s0610104	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
unresectable	unresectable	u56020230140	JJ	B-NP	O
GBM	GBM	g150	NN	I-NP	B-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
hyperparathyroidism	hyperparathyroidism	h0106106030603025	NN	B-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
reviews	review	r0102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
and	and	a530	CC	O	O
parathyroid	parathyroid	p06030603	JJ	B-NP	O
glands	gland	g40532	NNS	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
options	option	o13052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
to	to	t000	TO	B-VP	O
better	well	b0306	RBR	I-VP	O
understand	understand	u530623053	VB	I-VP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Primary	Primary	p605060	JJ	B-NP	B-Disease
hyperparathyroidism	hyperparathyroidism	h0106106030603025	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	O	O
potentially	potentially	p03053040	RB	B-ADVP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
side	side	s030	NN	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
selection	selection	s0402305	NN	I-NP	O
and	and	a530	CC	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
can	can	c050	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
morbidity	morbidity	m06103030	NN	B-NP	O
.	.	.000	.	O	O

PRACTICAL	PRACTICAL	p60230204	JJ	B-NP	O
IMPLICATIONS	IMPLICATIONS	i5140203052	NNS	I-NP	O
:	:	:000	:	O	O
As	As	a200	RB	B-NP	O
much	much	m020	RB	I-NP	O
as	as	a200	IN	I-NP	O
15	15	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
become	become	b02050	VBP	B-VP	O
hypercalcemic	hypercalcemic	h010620420502	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
routinely	routinely	r0305040	RB	B-ADVP	O
monitoring	monitor	m050306052	VBG	B-VP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
healthcare	healthcare	h04302060	NN	B-NP	O
providers	provider	p60103062	NNS	I-NP	O
can	can	c050	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
laryngeal	laryngeal	l0605204	JJ	B-NP	O
mask	mask	m020	NN	I-NP	O
with	with	w030	IN	B-PP	O
endotracheal	endotracheal	e530360204	JJ	B-NP	O
tube	tube	t010	NN	I-NP	O
for	for	f060	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
in	in	i500	IN	B-PP	O
endoscopic	endoscopic	e53020102	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
surgical	surgical	s0620204	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
endoscopic	endoscopic	e53020102	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
(	(	(000	(	O	O
FESS	FESS	f020	NN	B-NP	O
)	)	)000	)	O	O
using	use	u2052	VBG	B-VP	O
flexible	flexible	f4020140	JJ	B-NP	O
reinforced	reinforced	r05106203	JJ	I-NP	O
laryngeal	laryngeal	l0605204	JJ	I-NP	O
mask	mask	m020	NN	I-NP	O
airway	airway	a060	NN	I-NP	O
(	(	(000	(	O	O
FRLMA	FRLMA	f6450	NN	B-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
endotracheal	endotracheal	e530360204	JJ	B-NP	O
tube	tube	t010	NN	I-NP	O
(	(	(000	(	O	O
ETT	ETT	e300	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
maintaining	maintain	m05305052	VBG	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
anesthesia	anesthesia	a5023020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
remifentanil	remifentanil	r05010530504	NN	I-NP	B-Chemical
total	total	t0304	JJ	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
(	(	(000	(	O	O
TIVA	TIVA	t010	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Sixty	Sixty	s0230	CD	B-NP	O
normotensive	normotensive	n06503052010	JJ	I-NP	O
American	American	a5060205	JJ	I-NP	O
Society	Society	s02030	NN	I-NP	O
of	of	o100	IN	B-PP	O
Anesthesiologists	Anesthesiologist	a50230204020232	NNS	B-NP	O
I	I	i000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
II	II	i000	CD	I-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
FESS	FESS	f020	NN	B-NP	O
under	under	u5306	IN	B-PP	O
controlled	control	c05360403	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
anesthesia	anesthesia	a5023020	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
remifentanil	remifentanil	r05010530504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
TIVA	TIVA	t010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
into	into	i530	IN	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
group	group	g601	NN	B-NP	O
I	I	i000	CD	I-NP	O
,	,	,000	,	O	O
FRLMA	FRLMA	f6450	NNP	B-NP	O
;	;	;000	:	O	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
ETT	ETT	e300	NNP	B-NP	O
.	.	.000	.	O	O

Hemorrhage	Hemorrhage	h0506020	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
visibility	visibility	v020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
operative	operative	o10603010	JJ	I-NP	O
field	field	f043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
six	six	s020	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
point	point	p053	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Controlled	Controlled	c05360403	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
shorter	short	s06306	JJR	I-NP	O
period	period	p0603	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
laryngeal	laryngeal	l0605204	JJ	B-NP	O
mask	mask	m020	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
lower	low	l060	JJR	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
summary	summary	s05060	NN	B-NP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
airway	airway	a060	NN	B-NP	O
management	management	m050205053	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
FRLMA	FRLMA	f6450	NN	B-NP	O
during	during	d06052	IN	B-PP	O
controlled	control	c05360403	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
anesthesia	anesthesia	a5023020	NN	I-NP	O
provided	provide	p6010303	VBD	B-VP	O
better	good	b0306	JJR	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
operative	operative	o10603010	JJ	B-NP	O
field	field	f043	NN	I-NP	O
and	and	a530	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
and	and	a530	CC	O	O
allowed	allow	a403	VBN	B-VP	O
for	for	f060	IN	B-PP	O
convenient	convenient	c05105053	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
TIVA	TIVA	t010	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
FESS	FESS	f020	NNS	B-NP	O
.	.	.000	.	O	O

Nonalcoholic	Nonalcoholic	n050420402	JJ	B-NP	B-Disease
fatty	fatty	f030	JJ	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Valproic	Valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
many	many	m050	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonalcoholic	nonalcoholic	n050420402	JJ	B-NP	B-Disease
fatty	fatty	f030	JJ	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
NAFLD	NAFLD	n0143	NN	B-NP	B-Disease
)	)	)000	)	O	O
arising	arise	a602052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
child	child	c043	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
obesity	obesity	o102030	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
data	datum	d030	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
hyperinsulinemia	hyperinsulinemia	h01060520405050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
index	index	i5302	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
metabolic	metabolic	m03010402	JJ	B-NP	O
and	and	a530	CC	I-NP	O
endocrine	endocrine	e53026050	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
;	;	;000	:	O	O
moreover	moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
ultrasound	ultrasound	u43602053	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
normalization	normalization	n06504020305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
obesity	obesity	o102030	NN	B-NP	B-Disease
,	,	,000	,	O	O
hyperinsulinemia	hyperinsulinemia	h01060520405050	NN	B-NP	B-Disease
,	,	,000	,	O	O
insulin	insulin	i520405	NN	B-NP	B-Disease
resistance	resistance	r020230520	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
all	all	a400	DT	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
NAFLD	NAFLD	n0143	NN	B-NP	B-Disease
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

Carbimazole	Carbimazole	c0610502040	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
ANCA	ANCA	a520	CC	B-NP	B-Disease
positive	positive	p0203010	JJ	I-NP	I-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Anti	Anti	a530	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
thyroid	thyroid	t0603	JJ	B-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PTU	PTU	p300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	B-Chemical
medications	medication	m030203052	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Antineutrophil	Antineutrophil	a53050360104	NN	B-NP	B-Disease
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	I-Disease
antibody	antibody	a5301030	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
ANCA	ANCA	a520	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
-	-	-000	HYPH	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
associated	associate	a2020303	VBN	I-NP	I-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
antithyroidmedications	antithyroidmedication	a530306035030203052	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
Graves	Graves	g60102	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
ANCA	ANCA	a520	NN	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
carbimazole	carbimazole	c0610502040	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
vasculitis	vasculitis	v02040302	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
vasculitic	vasculitic	v02040302	JJ	I-NP	B-Disease
skin	skin	s205	NN	I-NP	B-Disease
rash	rash	r020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
joint	joint	j053	JJ	I-NP	O
arthritis	arthritis	a63060302	NN	I-NP	B-Disease
,	,	,000	,	O	O
pyrexia	pyrexia	p06020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
parotiditis	parotiditis	p0603030302	NN	I-NP	B-Disease
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
or	or	o600	CC	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
us	us	u200	PRP	B-NP	O
for	for	f060	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
because	because	b02020	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
difficulty	difficulty	d01020430	NN	B-NP	O
in	in	i500	IN	B-PP	O
getting	get	g03052	VBG	B-VP	O
up	up	u100	RP	B-PRT	O
from	from	f605	IN	B-PP	O
squatting	squat	s203052	VBG	B-VP	O
position	position	p020305	NN	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
myositis	myositis	m020302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Carbimazole	Carbimazole	c0610502040	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
methimazole	methimazole	m030502040	NN	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
reported	report	r0106303	VBN	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
PUT	PUT	p030	NN	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
carbimazole	carbimazole	c0610502040	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
vasculitis	vasculitis	v02040302	NN	B-NP	B-Disease
case	case	c020	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
India	India	i530	NNP	B-NP	O
.	.	.000	.	O	O

Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
update	update	u13030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
U	U	u000	NNP	I-NP	O
.	.	.000	.	I-NP	O
S	S	s000	NNP	I-NP	O
.	.	.000	.	O	O

Preventive	Preventive	p601053010	JJ	B-NP	O
Services	Services	s0610202	NNP	I-NP	O
Task	Task	t020	NNP	I-NP	O
Force	Force	f0620	NNP	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Coronary	Coronary	c0605060	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
cerebrovascular	cerebrovascular	c0601601020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
leading	lead	l03052	VBG	I-VP	O
causes	cause	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
2002	2002	0000	CD	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
U	U	u000	NNP	I-NP	O
.	.	.000	.	I-NP	O
S	S	s000	NNP	I-NP	O
.	.	.000	.	O	O

Preventive	Preventive	p601053010	JJ	B-NP	O
Services	Services	s0610202	NNP	I-NP	O
Task	Task	t020	NNP	I-NP	O
Force	Force	f0620	NNP	I-NP	O
(	(	(000	(	O	O
USPSTF	USPSTF	u21231	NNP	B-NP	O
)	)	)000	)	O	O
strongly	strongly	s3605240	RB	B-VP	O
recommended	recommend	r020505303	VBD	I-VP	O
that	that	t030	IN	B-SBAR	O
clinicians	clinician	c40502052	NNS	B-NP	O
discuss	discuss	d0202	VBP	B-VP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
harms	harm	h0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
taking	take	t02052	VBG	B-VP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarctions	infarction	i510623052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
strokes	stroke	s360202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	O
.	.	.000	.	O	O

DATA	DATA	d030	NN	B-NP	O
SOURCES	SOURCES	s06202	NNS	I-NP	O
:	:	:000	:	O	O
MEDLINE	MEDLINE	m034050	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Cochrane	Cochrane	c0206050	NNP	I-NP	O
Library	Library	l016060	NNP	I-NP	O
(	(	(000	(	O	O
search	search	s0620	NN	B-NP	O
dates	date	d0302	NNS	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
January	January	j05060	NNP	I-NP	O
2001	2001	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
28	28	0000	CD	I-NP	O
August	August	a02023	NNP	I-NP	O
2008	2008	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
recent	recent	r02053	JJ	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
reviews	review	r0102	NNS	I-NP	O
,	,	,000	,	O	O
reference	reference	r01060520	NN	B-NP	O
lists	list	l0232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
retrieved	retrieved	r0360103	JJ	B-NP	O
articles	article	a6302402	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
suggestions	suggestion	s02023052	NNS	B-NP	O
from	from	f605	IN	B-PP	O
experts	expert	e210632	NNS	B-NP	O
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
SELECTION	SELECTION	s0402305	NN	I-NP	O
:	:	:000	:	O	O
English	English	e524020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
language	language	l052020	NN	I-NP	O
randomized	randomize	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
controlled	control	c05360403	VBN	B-NP	O
trials	trial	t6042	NNS	I-NP	O
(	(	(000	(	O	O
RCTs	RCT	r232	NNS	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
case	case	c020	NN	O	O
-	-	-000	HYPH	O	O
control	control	c053604	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
;	;	;000	:	O	O
meta	meta	m030	SYM	O	O
-	-	-000	HYPH	O	O
analyses	analysis	a5040202	NNS	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
systematic	systematic	s023050302	JJ	B-NP	O
reviews	review	r0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
versus	versus	v06202	CC	I-NP	O
control	control	c053604	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
CVD	CVD	c130	NN	B-NP	B-Disease
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
answer	answer	a5206	VB	I-VP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
questions	question	q023052	NNS	I-NP	O
:	:	:000	:	O	O
Does	Do	d020	VBZ	B-VP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
decrease	decrease	d026020	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
strokes	stroke	s360202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
death	death	d030	NN	B-NP	O
from	from	f605	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
events	event	e10532	NNS	I-NP	O
or	or	o600	CC	O	O
stroke	stroke	s36020	VB	B-VP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
all	all	a400	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
cause	cause	c020	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
known	known	k505	JJ	B-NP	O
CVD	CVD	c130	NN	I-NP	B-Disease
?	?	?000	.	O	O

Does	Do	d020	VBZ	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
increase	increase	i526020	NN	I-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	B-Disease
bleeding	bleeding	b403052	NN	I-NP	I-Disease
or	or	o600	CC	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
strokes	stroke	s360202	NNS	I-NP	I-Disease
?	?	?000	.	O	O

DATA	DATA	d030	NN	B-NP	O
EXTRACTION	EXTRACTION	e23602305	NN	I-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
,	,	,000	,	O	O
abstracted	abstract	a123602303	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
rated	rat	r0303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
quality	quality	q04030	NN	B-NP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
predefined	predefined	p603010503	JJ	B-NP	O
USPSTF	USPSTF	u21231	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
.	.	.000	.	O	O

DATA	DATA	d030	NN	B-NP	O
SYNTHESIS	SYNTHESIS	s0530202	NN	I-NP	O
:	:	:000	:	O	O
New	New	n000	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
good	good	g030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
quality	quality	q04030	NN	I-NP	O
RCT	RCT	r230	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
good	good	g030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
quality	quality	q04030	NN	I-NP	O
meta	meta	m030	SYM	O	O
-	-	-000	HYPH	O	O
analysis	analysis	a5040202	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
fair	fair	f060	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
quality	quality	q04030	NN	I-NP	O
subanalyses	subanalys	s0105040202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
RCTs	RCT	r232	NNS	B-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
CVD	CVD	c130	NN	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
known	known	k505	JJ	B-NP	O
CVD	CVD	c130	NN	I-NP	B-Disease
.	.	.000	.	O	O

Men	Men	m050	NN	B-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
fewer	few	f060	JJR	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarctions	infarction	i510623052	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
women	woman	w0505	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
fewer	few	f060	JJR	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	O
strokes	stroke	s360202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	I-VP	O
affect	affect	a1023	VB	I-VP	O
CVD	CVD	c130	NN	B-NP	B-Disease
mortality	mortality	m06304030	NN	I-NP	O
or	or	o600	CC	O	O
all	all	a400	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
cause	cause	c020	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
men	man	m050	NNS	B-NP	O
or	or	o600	CC	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
bleeding	bleed	b403052	VBG	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
primarily	primarily	p60506040	RB	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	B-Disease
bleeding	bleed	b403052	VBG	I-NP	I-Disease
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Men	Men	m050	NN	B-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
strokes	stroke	s360202	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
RCT	RCT	r230	NN	I-NP	O
and	and	a530	CC	I-NP	O
meta	meta	m030	NN	I-NP	O
-	-	-000	HYPH	O	O
analysis	analysis	a5040202	NN	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
strokes	stroke	s360202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
statistically	statistically	s30302302040	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
increased	increase	i5260203	VBN	I-ADJP	O
.	.	.000	.	O	O

LIMITATIONS	LIMITATIONS	l050303052	NNS	B-NP	O
:	:	:000	:	O	O
New	New	n000	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
on	on	o500	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CVD	CVD	c130	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
RCTs	RCT	r232	NNS	I-NP	O
varied	vary	v0603	VBD	B-VP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
estimation	estimation	e23050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
appropriate	appropriate	a16016030	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
for	for	f060	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
RCTs	RCT	r232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
populations	population	p010403052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
health	health	h0430	NN	B-NP	O
professionals	professional	p6010205042	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
potentially	potentially	p03053040	RB	B-ADVP	O
limits	limit	l05032	VBZ	B-VP	O
generalizability	generalizability	g050604020104030	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
and	and	a530	CC	I-NP	O
strokes	stroke	s360202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
.	.	.000	.	O	O

Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Reducing	Reduce	r0302052	VBG	B-NP	O
harm	harm	h065	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
:	:	:000	:	O	O
practical	practical	p60230204	JJ	B-NP	O
considerations	consideration	c052030603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
argatroban	argatroban	a620360105	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Argatroban	Argatroban	a620360105	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
hepatically	hepatically	h010302040	RB	I-NP	O
metabolized	metabolize	m0301040203	VBN	I-NP	O
,	,	,000	,	I-NP	O
direct	direct	d06023	JJ	I-NP	O
thrombin	thrombin	t0605105	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
used	use	u203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
prophylaxis	prophylaxis	p601040202	NN	B-NP	O
or	or	o600	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
undergoing	undergo	u53062052	VBG	B-VP	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
(	(	(000	(	O	O
PCI	PCI	p200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
review	review	r010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
summarize	summarize	s0506020	VB	I-VP	O
practical	practical	p60230204	JJ	B-NP	O
considerations	consideration	c052030603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
argatroban	argatroban	a620360105	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
US	US	u200	NNP	I-NP	O
FDA	FDA	f300	NNP	I-NP	O
-	-	-000	HYPH	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
argatroban	argatroban	a620360105	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
in	in	i500	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
reduced	reduce	r030203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
paediatric	paediatric	p0303602	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adjusted	adjust	a3202303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
activated	activate	a23010303	VBN	B-NP	O
partial	partial	p06304	JJ	I-NP	O
thromboplastin	thromboplastin	t0605101402305	NN	I-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
aPTTs	aPTT	a132	NNS	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
baseline	baseline	b0204050	NN	I-NP	O
(	(	(000	(	O	O
not	not	n030	RB	O	O
>	>	>000	SYM	O	O
100	100	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Contemporary	Contemporary	c05305106060	JJ	B-NP	O
experiences	experience	e210605202	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
reduced	reduce	r030203	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
needed	need	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
conditions	condition	c05303052	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
hypoperfusion	hypoperfusion	h01010610205	NN	I-NP	O
,	,	,000	,	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	.	O	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
yet	yet	y030	CC	O	O
are	be	a600	VBP	B-VP	O
unnecessary	unnecessary	u50202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
adult	adult	a3043	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
race	race	r020	NN	B-NP	O
/	/	/000	SYM	B-VP	O
ethnicity	ethnicity	e30502030	NN	B-NP	O
or	or	o600	CC	I-NP	O
obesity	obesity	o102030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Argatroban	Argatroban	a620360105	IN	B-PP	B-Chemical
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
typically	typically	t0102040	RB	B-VP	O
supports	support	s010632	VBZ	I-VP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
aPTTs	aPTT	a132	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
FDA	FDA	f300	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
during	during	d06052	IN	B-PP	O
PCI	PCI	p200	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
25	25	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
350	350	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
initial	initial	i50304	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adjusted	adjust	a3202303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
activated	activate	a23010303	VBN	B-NP	O
clotting	clotting	c403052	NN	I-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
ACTs	ACT	a232	NNS	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
300	300	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
450	450	0000	CD	I-NP	O
sec	sec	s020	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
PCI	PCI	p200	NN	B-NP	O
,	,	,000	,	O	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hepatically	hepatically	h010302040	RB	B-NP	O
impaired	impaired	i510603	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
dose	dose	d020	NN	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unnecessary	unnecessary	u50202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
race	race	r020	NN	B-NP	O
/	/	/000	SYM	B-VP	O
ethnicity	ethnicity	e30502030	NN	B-NP	O
or	or	o600	CC	I-NP	O
obesity	obesity	o102030	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
lesser	less	l0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
adequate	adequate	a302030	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
glycoprotein	glycoprotein	g4020160305	NN	I-NP	O
IIb	IIb	i010	NN	I-NP	O
/	/	/000	SYM	B-NP	O
IIIa	IIIa	i000	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
.	.	.000	.	O	O

Argatroban	Argatroban	a620360105	NNP	B-NP	B-Chemical
prolongs	prolong	p604052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
International	International	i53065030504	NNP	I-NP	O
Normalized	Normalized	n065040203	NNP	I-NP	O
Ratio	Ratio	r030	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
published	publish	p0140203	VBN	B-NP	O
approaches	approach	a160202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
monitoring	monitor	m050306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
argatroban	argatroban	a620360105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
transition	transition	t60520305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
followed	follow	f0403	VBN	I-VP	O
.	.	.000	.	O	O

Major	Major	m0206	JJ	B-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
interventional	interventional	i530610530504	JJ	I-NP	O
setting	setting	s03052	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
periprocedurally	periprocedurally	p06016020306040	RB	B-ADVP	O
.	.	.000	.	O	O

Argatroban	Argatroban	a620360105	NNP	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
antidote	antidote	a5303030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
if	if	i100	IN	B-SBAR	O
excessive	excessive	e202010	JJ	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
occurs	occur	o2062	VBZ	B-VP	O
,	,	,000	,	O	O
argatroban	argatroban	a620360105	JJ	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
stopped	stop	s30103	VBN	I-VP	O
or	or	o600	CC	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
.	.	.000	.	O	O

Improved	Improve	i5160103	VBN	B-NP	O
familiarity	familiarity	f050406030	NN	I-NP	O
of	of	o100	IN	B-PP	O
healthcare	healthcare	h04302060	NN	B-NP	O
professionals	professional	p6010205042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
argatroban	argatroban	a620360105	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
in	in	i500	IN	B-PP	O
special	special	s10204	JJ	B-NP	O
populations	population	p010403052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
PCI	PCI	p200	NN	B-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
harm	harm	h065	NN	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
(	(	(000	(	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	.	O	O
fewer	few	f060	JJR	B-NP	O
thromboses	thrombos	t060510202	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	.	O	O
fewer	few	f060	JJR	B-NP	O
argatroban	argatroban	a620360105	JJ	I-NP	B-Chemical
medication	medication	m03020305	NN	I-NP	O
errors	error	e6062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Rhabdomyolysis	Rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
heroin	heroin	h0605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
male	male	m040	NN	I-NP	O
under	under	u5306	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
several	several	s010604	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
heroin	heroin	h0605	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
,	,	,000	,	O	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
threatening	threatening	t060305052	NN	I-NP	O
.	.	.000	.	O	O

Methadone	Methadone	m0303050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
this	this	t020	DT	B-NP	O
problem	problem	p601405	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
case	case	c020	NN	I-NP	O
description	description	d02601305	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
33	33	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
presented	present	p60205303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
heroin	heroin	h0605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
since	since	s0520	IN	B-PP	O
age	age	a200	NN	B-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
methadone	methadone	m0303050	NN	I-NP	B-Chemical
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
unconsciousness	unconsciousness	u5205202502	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
home	home	h050	NN	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
sent	send	s053	VBN	I-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ER	ER	e600	NN	I-NP	O
,	,	,000	,	O	O
his	his	h020	PRP$	B-NP	O
opiate	opiate	o1030	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
4497	4497	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ICU	ICU	i200	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
transfer	transfer	t6052106	NN	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
internal	internal	i5306504	JJ	I-NP	O
ward	ward	w063	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
noted	note	n0303	VBD	B-VP	O
aphasia	aphasia	a1020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
weakness	weakness	w02502	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
left	left	l013	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
MRI	MRI	m600	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
ischemic	ischemic	i20502	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Those	Those	t020	DT	B-NP	O
using	use	u2052	VBG	I-NP	O
methadone	methadone	m0303050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
heroin	heroin	h0605	NN	I-NP	B-Chemical
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
warned	warn	w06503	VBN	I-VP	O
regarding	regard	r02063052	VBG	B-PP	O
these	these	t020	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Hypotheses	Hypothesis	h01030202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
abusers	abuser	a102062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
vulnerability	vulnerability	v045060104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxydopamine	hydroxydopamine	h03602030105050	NN	I-NP	I-Chemical
lesion	lesion	l0205	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
dyskinesias	dyskinesia	d02050202	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
lacking	lack	l02052	VBG	B-VP	O
CB1	CB1	0000	NN	B-NP	O
cannabinoid	cannabinoid	c05010503	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Motor	Motor	m0306	NNP	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
,	,	,000	,	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
neuronal	neuronal	n060504	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
proenkephalin	proenkephalin	p6052010405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PENK	PENK	p052	NN	B-NP	B-Chemical
)	)	)000	)	O	O
gene	gene	g050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
caudate	caudate	c03030	NN	I-NP	O
-	-	-000	HYPH	O	O
putamen	putaman	p030505	NNS	B-NP	O
(	(	(000	(	O	O
CPu	CPu	c100	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
lesioned	lesione	l020503	VBN	B-VP	O
and	and	a530	CC	I-VP	O
treated	treat	t60303	VBN	I-VP	O
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
+	+	+000	SYM	I-NP	I-Chemical
benserazide	benserazide	b0520602030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
CB1	CB1	0000	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
and	and	a530	CC	O	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
produced	produce	p6030203	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
severe	severe	s01060	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
CB1	CB1	0000	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
more	more	m060	JJR	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
PENK	PENK	p052	NN	I-NP	B-Chemical
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CPu	CPu	c100	NN	I-NP	O
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
nitrosative	nitrosative	n0360203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
neuroinflammatory	neuroinflammatory	n0605140503060	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CPu	CPu	c100	NN	I-NP	O
and	and	a530	CC	O	O
cingulate	cingulate	c05204030	VBP	B-VP	O
cortex	cortex	c06302	NN	B-NP	O
(	(	(000	(	O	O
Cg	Cg	c200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CB1	CB1	0000	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
MDA	MDA	m300	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
iNOS	iNOS	i502	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CPu	CPu	c100	NN	I-NP	O
and	and	a530	CC	I-NP	O
Cg	Cg	c200	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
+	+	+000	SYM	B-NP	I-Chemical
benserazide	benserazide	b0520602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
less	less	l020	RBR	B-NP	O
severe	severe	s01060	JJ	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
CB1	CB1	0000	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cannabinoid	cannabinoid	c05010503	NN	B-NP	O
CB1	CB1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
and	and	a530	CC	O	O
DA	DA	d000	NN	B-NP	B-Chemical
lesion	lesion	l0205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CB1	CB1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
offers	offer	o1062	VBZ	B-VP	O
neuroprotection	neuroprotection	n060160302305	NN	B-NP	O
against	against	a20523	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Hepatocellular	Hepatocellular	h010302040406	JJ	B-NP	O
oxidant	oxidant	o203053	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
intestinal	intestinal	i530230504	JJ	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
reperfusion	reperfusion	r010610205	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Reperfusion	Reperfusion	r010610205	NN	B-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
intestine	intestine	i53023050	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
release	release	r04020	NN	I-NP	O
into	into	i530	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
,	,	,000	,	O	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
neutrophil	neutrophil	n0360104	NN	B-NP	O
sequestration	sequestration	s0202360305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
oxidants	oxidant	o2030532	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
indirect	indirect	i5306023	JJ	I-NP	O
methods	method	m03032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
assessing	assess	a202052	VBG	B-VP	O
oxidant	oxidant	o203053	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
standardized	standardized	s30530630203	JJ	I-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
reperfusion	reperfusion	r010610205	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assayed	assay	a203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
and	and	a530	CC	O	O
oxidized	oxidize	o2030203	VBN	B-VP	B-Chemical
and	and	a530	CC	O	I-Chemical
reduced	reduce	r030203	VBN	B-NP	I-Chemical
glutathione	glutathione	g40303050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
following	follow	f04052	VBG	B-PP	O
intestinal	intestinal	i530230504	JJ	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
reperfusion	reperfusion	r010610205	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Oxidized	Oxidize	o2030203	VBN	B-NP	B-Chemical
glutathione	glutathione	g40303050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GSSG	GSSG	g200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
following	follow	f04052	VBG	I-VP	O
30	30	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
reperfusion	reperfusion	r010610205	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
products	product	p6030232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
injury	injury	i52060	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
GSSG	GSSG	g200	NN	B-NP	B-Chemical
within	within	w0305	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
during	during	d06052	IN	B-PP	O
intestinal	intestinal	i530230504	JJ	B-NP	O
reperfusion	reperfusion	r010610205	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
exposure	exposure	e2102060	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatocytes	hepatocyte	h0103020302	NNS	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
oxidant	oxidant	o203053	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
products	product	p6030232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
oxidant	oxidant	o203053	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
insufficient	insufficient	i520102053	JJ	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
to	to	t000	TO	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
irreversible	irreversible	i6010620140	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	O
to	to	t000	TO	B-PP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tissue	tissue	t020	NN	B-NP	O
GSSG	GSSG	g200	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
indicator	indicator	i53020306	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidant	oxidant	o203053	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
than	than	t050	IN	B-PP	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
products	product	p6030232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
.	.	.000	.	O	O

Animal	Animal	a50504	NN	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
mania	mania	m050	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
:	:	:000	:	O	O
Evidence	Evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
submitochondrial	submitochondrial	s0150302053604	JJ	B-NP	O
particles	particle	p06302402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
intracerebroventricular	intracerebroventricular	i5360206016010536020406	JJ	I-NP	O
(	(	(000	(	O	O
ICV	ICV	i210	NN	B-NP	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
mimic	mimic	m0502	VB	I-VP	O
some	some	s050	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Herein	Herein	h0605	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
ICV	ICV	i210	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
this	this	t020	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
and	and	a530	CC	O	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
ICV	ICV	i210	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
at	at	a300	IN	B-PP	O
concentrations	concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
locomotion	locomotion	l02050305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
field	field	f043	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
thiobarbituric	thiobarbituric	t01061030602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
reactive	reactive	r023010	JJ	I-NP	O
substances	substance	s012305202	NNS	I-NP	O
(	(	(000	(	O	O
TBARSs	TBARS	t1062	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
submitochondrial	submitochondrial	s0150302053604	JJ	B-NP	O
particles	particle	p06302402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	I-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
,	,	,000	,	I-NP	O
striatum	striatum	s360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
amygdala	amygdala	a5023040	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
hyperlocomotion	hyperlocomotion	h0106402050305	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
7	7	7000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
ICV	ICV	i210	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
persistent	persistent	p062023053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
locomotion	locomotion	l02050305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
TBARS	TBARS	t1062	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
generation	generation	g05060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
submitochondrial	submitochondrial	s0150302053604	JJ	B-NP	O
particles	particle	p06302402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	I-NP	O
striatum	striatum	s360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
amygdala	amygdala	a5023040	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
mania	mania	m050	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intraoperative	Intraoperative	i536010603010	JJ	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
during	during	d06052	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
with	with	w030	IN	B-PP	O
citrate	citrate	c036030	NN	B-NP	B-Chemical
dialysate	dialysate	d0402030	NN	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
acutely	acutely	a203040	RB	B-NP	O
ill	ill	i400	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
carries	carry	c0602	VBZ	B-VP	O
high	high	h020	JJ	B-NP	O
intraoperative	intraoperative	i536010603010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
immediate	immediate	i503030	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
risks	risk	r020	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
are	be	a600	VBP	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
AKI	AKI	a200	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
sometimes	sometimes	s05030502	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	B-VP	O
allow	allow	a400	VB	I-VP	O
the	the	t000	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
to	to	t000	TO	B-VP	O
proceed	proceed	p60203	VB	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
derangements	derangement	d06052050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
procoagulant	procoagulant	p6020204053	NN	I-NP	O
and	and	a530	CC	O	O
anticoagulant	anticoagulant	a53020204053	JJ	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
difficulties	difficulty	d010204302	NNS	B-NP	O
with	with	w030	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
continued	continue	c0530503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
operating	operating	o10603052	NN	I-NP	O
room	room	r050	NN	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unsafe	unsafe	u52010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
regional	regional	r020504	JJ	I-NP	O
citrate	citrate	c036030	NN	I-NP	B-Chemical
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	O
carries	carry	c0602	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
citrate	citrate	c036030	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Citrate	Citrate	c036030	JJ	B-NP	B-Chemical
dialysate	dialysate	d0402030	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
dialysate	dialysate	d0402030	NN	I-NP	O
with	with	w030	IN	B-PP	O
citric	citric	c03602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
regional	regional	r020504	JJ	B-NP	O
citrate	citrate	c036030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	NN	I-NP	O
with	with	w030	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
fulminant	fulminant	f04505053	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
AKI	AKI	a200	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
dialytic	dialytic	d040302	JJ	I-NP	O
support	support	s01063	NN	I-NP	O
during	during	d06052	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
anticoagulated	anticoagulate	a530202040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
citrate	citrate	c036030	NN	B-NP	B-Chemical
dialysate	dialysate	d0402030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
tolerated	tolerate	t04060303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
well	well	w040	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
citrate	citrate	c036030	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
maintained	maintain	m0530503	VBD	B-VP	O
adequate	adequate	a302030	JJ	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
for	for	f060	IN	B-PP	O
patency	patency	p030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
circuit	circuit	c06203	NN	I-NP	O
.	.	.000	.	O	O

Citrate	Citrate	c036030	JJ	B-NP	B-Chemical
dialysate	dialysate	d0402030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
for	for	f060	IN	B-PP	O
intradialytic	intradialytic	i53603040302	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Delirium	Delirium	d040605	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
flecainide	flecainide	f40205030	NN	I-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
69	69	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
white	white	w030	JJ	I-NP	O
female	female	f05040	JJ	I-NP	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
paranoia	paranoia	p06050	NN	I-NP	B-Disease
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
several	several	s010604	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
carvedilol	carvedilol	c061030404	NN	B-NP	B-Chemical
12	12	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
,	,	,000	,	O	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
levothyroxine	levothyroxine	l01030602050	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
pantoprazole	pantoprazole	p05301602040	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
.	.	.000	.	O	O

Flecainide	Flecainide	f40205030	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
started	start	s306303	VBN	I-VP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
test	test	t023	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
were	be	w060	VBD	B-VP	O
notable	notable	n030140	JJ	B-ADJP	O
only	only	o540	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
flecainide	flecainide	f40205030	NN	I-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1360	1360	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
reference	reference	r01060520	NN	B-NP	O
range	range	r0520	NN	I-NP	O
200	200	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1000	1000	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paroxetine	paroxetine	p060203050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
.	.	.000	.	O	O

Paroxetine	Paroxetine	p060203050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBD	B-VP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Flecainide	Flecainide	f40205030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
pharmacologically	pharmacologically	p06502040202040	RB	B-NP	O
similar	similar	s050406	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
interact	interact	i5306023	VBP	B-VP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
susceptible	susceptible	s020130140	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
MEDLINE	MEDLINE	m034050	NNP	I-NP	O
search	search	s0620	NN	I-NP	O
(	(	(000	(	O	O
1966	1966	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
January	January	j05060	NNP	B-NP	O
2009	2009	0000	CD	I-NP	O
)	)	)000	)	O	O
revealed	reveal	r010403	VBD	B-VP	O
one	one	o500	CD	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
CYP2D6	CYP2D6	0000	NN	I-NP	O
substrate	substrate	s01236030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
CYP2D6	CYP2D6	0000	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
3	3	3000	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
.	.	.000	.	O	O

According	Accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
,	,	,000	,	O	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
Horn	Horn	h065	NNP	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Interaction	Interaction	i530602305	NNP	I-NP	O
Probability	Probability	p6010104030	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paroxetine	paroxetine	p060203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Supratherapeutic	Supratherapeutic	s0160306010302	JJ	B-NP	O
flecainide	flecainide	f40205030	NN	I-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
when	when	w050	WRB	B-ADVP	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
potent	potent	p03053	JJ	I-NP	O
CYP2D6	CYP2D6	0000	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
,	,	,000	,	O	O
flecainide	flecainide	f40205030	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
closely	closely	c402040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
commencement	commencement	c0505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
CYP2D6	CYP2D6	0000	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
of	of	o100	IN	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
RAD001	RAD001	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
previously	previously	p6010240	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
with	with	w030	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	I-NP	O
EGFR	EGFR	e216	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Treatment	Treatment	t6035053	NN	B-NP	O
options	option	o13052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
scarce	scarce	s20620	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
advanced	advance	a3105203	VBN	I-VP	O
non	non	n050	AFX	O	B-Disease
-	-	-000	HYPH	O	I-Disease
small	small	s504	JJ	B-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

RAD001	RAD001	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mammalian	mammalian	m050405	JJ	I-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mTOR	mTOR	m306	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
shown	show	s050	VBN	I-VP	O
phase	phase	p020	NN	B-NP	O
I	I	i000	CD	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
in	in	i500	IN	B-PP	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Stage	Stage	s3020	NN	B-NP	O
IIIb	IIIb	i010	NN	I-NP	O
or	or	o600	CC	O	O
IV	IV	i100	CD	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
two	two	t000	CD	B-NP	O
or	or	o600	CC	I-NP	O
fewer	few	f060	JJR	I-NP	O
prior	prior	p606	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
platinum	platinum	p4030505	NN	I-NP	B-Chemical
based	base	b0203	VBN	B-VP	O
(	(	(000	(	O	O
stratum	stratum	s360305	NN	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
both	both	b030	CC	O	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	O	O
epidermal	epidermal	e10306504	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
tyrosine	tyrosine	t0602050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
(	(	(000	(	O	O
stratum	stratum	s360305	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
received	receive	r020103	VBD	B-VP	O
RAD001	RAD001	0000	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
until	until	u5304	IN	B-PP	O
progression	progression	p60260205	NN	B-NP	O
or	or	o600	CC	O	O
unacceptable	unacceptable	u5020130140	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Primary	Primary	p605060	JJ	B-NP	O
objective	objective	o12023010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
overall	overall	o10604	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
ORR	ORR	o600	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Analyses	Analysis	a5040202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
markers	marker	m062062	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
mTOR	mTOR	m306	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
on	on	o500	IN	B-PP	O
archival	archival	a620104	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
(	(	(000	(	O	O
IHC	IHC	i020	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
direct	direct	d06023	JJ	B-NP	O
mutation	mutation	m030305	NN	I-NP	O
sequencing	sequencing	s02052052	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
,	,	,000	,	O	O
42	42	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
stratum	stratum	s360305	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
43	43	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
stratum	stratum	s360305	NN	B-NP	O
.	.	.000	.	O	O

ORR	ORR	o600	NN	B-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
stratum	stratum	s360305	NN	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
stratum	stratum	s360305	NN	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Overall	Overall	o10604	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
control	control	c053604	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
47	47	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
progression	progression	p60260205	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survivals	survival	s06101042	NNS	I-NP	O
(	(	(000	(	O	O
PFSs	PFS	p120	NNS	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
(	(	(000	(	O	O
stratum	stratum	s360305	NN	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
stratum	stratum	s360305	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Common	Common	c0505	JJ	B-ADJP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	B-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
fatigue	fatigue	f03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
dyspnea	dyspnea	d02150	NN	B-NP	B-Disease
,	,	,000	,	O	O
stomatitis	stomatitis	s305030302	NN	B-NP	B-Disease
,	,	,000	,	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Pneumonitis	Pneumonitis	p505050302	NN	B-NP	B-Disease
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
or	or	o600	CC	I-ADVP	O
possibly	possibly	p020140	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
grade	grade	g6030	NN	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Cox	Cox	c020	NNP	B-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
IHC	IHC	i020	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
only	only	o540	RB	B-NP	O
phospho	phospho	p0210	JJ	I-NP	O
AKT	AKT	a230	NN	I-NP	O
(	(	(000	(	O	O
pAKT	pAKT	p023	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
independent	independent	i5301053053	JJ	I-NP	O
predictor	predictor	p60302306	NN	I-NP	O
of	of	o100	IN	B-PP	O
worse	worse	w0620	JJR	B-NP	O
PFS	PFS	p120	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
RAD001	RAD001	0000	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
modest	modest	m03023	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
pretreated	pretreate	p60360303	VBN	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
RAD001	RAD001	0000	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
standard	standard	s3053063	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
continues	continue	c0530502	VBZ	B-VP	O
.	.	.000	.	O	O

Posttransplant	Posttransplant	p023605214053	NN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Posttransplant	Posttransplant	p023605214053	NN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
problem	problem	p601405	NN	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
hinder	hinder	h05306	VB	I-VP	O
patients	patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
76	76	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
posttransplant	posttransplant	p023605214053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
increase	increase	i526020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
posttransplant	posttransplant	p023605214053	NN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	B-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
.	.	.000	.	O	O

Sirolimus	Sirolimus	s06040502	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
mammalian	mammalian	m050405	JJ	I-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
playing	play	p4052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
special	special	s10204	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
posttransplant	posttransplant	p023605214053	NN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
review	review	r010	NN	I-NP	O
considers	consider	c05203062	VBZ	B-VP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
its	its	i320	PRP$	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
,	,	,000	,	O	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
management	management	m050205053	NN	B-NP	O
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	O
computerized	computerized	c05103060203	JJ	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
for	for	f060	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
discharge	discharge	d020620	NN	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
presenting	present	p602053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
emergency	emergency	e50620520	NN	B-NP	O
departments	department	d0106350532	NNS	I-NP	O
(	(	(000	(	O	O
EDs	ED	e320	NNS	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
12	12	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
and	and	a530	CC	O	O
receive	receive	r02010	VB	B-VP	O
a	a	a000	DT	B-NP	O
"	"	"000	``	I-NP	O
rule	rule	r040	NN	I-NP	O
out	out	o030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
coronary	coronary	c0605060	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
"	"	"000	''	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
,	,	,000	,	O	O
often	often	o1305	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
noninvasive	noninvasive	n0505102010	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
discharge	discharge	d020620	VB	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	O
computerized	computerized	c05103060203	JJ	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
(	(	(000	(	O	O
CTA	CTA	c300	NN	B-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
safely	safely	s01040	RB	I-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
whether	whether	w0306	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
CTA	CTA	c300	NN	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
efficacious	efficacious	e1020202	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
account	account	a2053	VB	I-VP	O
for	for	f060	IN	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
CTA	CTA	c300	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
could	could	c043	MD	B-VP	O
identify	identify	i3053010	VB	I-VP	O
a	a	a000	DT	B-NP	O
subset	subset	s01203	NN	I-NP	O
safe	safe	s010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
discharge	discharge	d020620	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
CTA	CTA	c300	NN	I-NP	O
for	for	f060	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ED	ED	e300	NN	I-NP	O
with	with	w030	IN	B-PP	O
cocaineassociated	cocaineassociate	c020502020303	VBN	B-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
(	(	(000	(	O	O
self	self	s041	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
reported	report	r0106303	VBN	I-VP	O
or	or	o600	CC	O	O
positive	positive	p0203010	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
test	test	t023	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Consecutive	Consecutive	c0520203010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
immediate	immediate	i503030	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
CTA	CTA	c300	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ED	ED	e300	NN	I-NP	O
(	(	(000	(	O	O
without	without	w0303	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
underwent	undergo	u5306053	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	O
CTA	CTA	c300	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
with	with	w030	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
CTA	CTA	c300	NN	I-NP	O
(	(	(000	(	O	O
maximal	maximal	m020504	JJ	B-NP	O
stenosis	stenosis	s3050202	NN	I-NP	B-Disease
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
death	death	d030	NN	I-NP	O
or	or	o600	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
59	59	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
45	45	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
yrs	yr	y620	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
black	black	b402	JJ	B-ADJP	O
,	,	,000	,	O	O
66	66	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
male	male	m040	NN	I-NP	O
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
or	or	o600	CC	I-NP	O
nonspecific	nonspecific	n0521020102	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
and	and	a530	CC	O	O
85	85	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
TIMI	TIMI	t050	NN	I-NP	O
score	score	s2060	NN	I-NP	O
<	<	<000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	O
CTA	CTA	c300	NN	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ED	ED	e300	NN	I-NP	O
,	,	,000	,	O	O
18	18	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
were	be	w060	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
CTA	CTA	c300	NN	B-NP	O
(	(	(000	(	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
received	receive	r020103	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	O
CTA	CTA	c300	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
37	37	0000	CD	B-NP	O
discharged	discharged	d0206203	JJ	I-NP	O
home	home	h050	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
CTA	CTA	c300	NN	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
sustained	sustain	s0230503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
nonfatal	nonfatal	n0510304	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
can	can	c050	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	B-VP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
ECG	ECG	e200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
TIMI	TIMI	t050	NN	I-NP	O
risk	risk	r020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
<	<	<000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
safely	safely	s01040	RB	I-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
ED	ED	e300	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
CTA	CTA	c300	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
haemorrhagic	haemorrhagic	h05060202	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
globus	globus	g40102	NN	I-NP	I-Disease
pallidus	pallidus	p040302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
both	both	b030	CC	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
haemorrhagic	haemorrhagic	h05060202	JJ	I-NP	I-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
31	31	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
globus	globus	g40102	NN	I-NP	I-Disease
pallidus	pallidus	p040302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
excessive	excessive	e202010	JJ	B-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
intranasal	intranasal	i536050204	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
related	relate	r040303	VBN	I-NP	O
globus	globus	g40102	NN	I-NP	B-Disease
pallidus	pallidus	p040302	NN	I-NP	I-Disease
infarctions	infarction	i510623052	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
most	most	m023	RBS	I-VP	O
often	often	o1305	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
basal	basal	b0204	JJ	I-NP	B-Disease
ganglia	ganglia	g05240	NNS	I-NP	I-Disease
infarcts	infarct	i5106232	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
heroin	heroin	h0605	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
never	never	n0106	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
transient	transient	t6052053	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
or	or	o600	CC	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
likely	likely	l02040	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
hypoperfusion	hypoperfusion	h01010610205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Late	Late	l030	JJ	B-NP	O
fulminant	fulminant	f04505053	JJ	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	B-Disease
reversible	reversible	r010620140	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
Posterior	Posterior	p0230606	JJ	B-NP	B-Disease
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
severe	severe	s01060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
results	result	r020432	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
(	(	(000	(	O	O
primarily	primarily	p60506040	RB	B-NP	O
those	those	t020	DT	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
or	or	o600	CC	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathophysiologic	pathophysiologic	p030102040202	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
that	that	t030	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
remain	remain	r0505	VBP	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
46	46	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
center	center	c05306	NN	I-NP	O
as	as	a200	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
alcoholic	alcoholic	a420402	JJ	B-NP	B-Disease
cirrhosis	cirrhosis	c060202	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
either	either	e0306	CC	O	O
a	a	a000	DT	B-NP	O
fulminant	fulminant	f04505053	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
posterior	posterior	p0230606	JJ	B-NP	B-Disease
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	I-Disease
or	or	o600	CC	O	O
posterior	posterior	p0230606	JJ	B-NP	B-Disease
reversible	reversible	r010620140	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
110	110	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
initially	initially	i503040	RB	I-NP	O
uneventful	uneventful	u501053104	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
fell	fall	f040	VBD	B-VP	O
into	into	i530	IN	B-PP	O
deep	deep	d010	JJ	B-NP	O
coma	coma	c050	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Cerebral	Cerebral	c0601604	JJ	B-NP	O
MRI	MRI	m600	NN	I-NP	O
scan	scan	s205	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
typical	typical	t010204	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
enhancement	enhancement	e505205053	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pontine	pontine	p053050	NN	I-NP	O
and	and	a530	CC	O	O
posterior	posterior	p0230606	JJ	B-NP	O
regions	region	r02052	NNS	I-NP	O
.	.	.000	.	O	O

Switching	Switch	s032052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
from	from	f605	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
situation	situation	s030305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
termination	termination	t065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
any	any	a500	DT	B-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
that	that	t030	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Posterior	Posterior	p0230606	JJ	B-NP	B-Disease
reversible	reversible	r010620140	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recommend	recommend	r0205053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
cessation	cessation	c020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
bridge	bridge	b60320	NN	I-NP	O
to	to	t000	TO	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
for	for	f060	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
intracranial	intracranial	i5360260504	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
review	review	r010	VB	I-VP	O
evidence	evidence	e1030520	NN	B-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
options	option	o13052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
FHF	FHF	f010	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
applications	application	a140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypothermia	hypothermia	h01030650	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Case	Case	c020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
(	(	(000	(	O	O
MICU	MICU	m020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
tertiary	tertiary	t063060	JJ	I-NP	O
care	care	c060	NN	I-NP	O
facility	facility	f0204030	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	NN	I-NP	O
with	with	w030	IN	B-PP	O
FHF	FHF	f010	NN	B-NP	B-Disease
from	from	f605	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
resultant	resultant	r02043053	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
MICU	MICU	m020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
being	be	b052	VBG	B-VP	O
found	find	f053	VBN	I-VP	O
unresponsive	unresponsive	u56021052010	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
presumed	presume	p6020503	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
ingested	ingest	i5202303	VBN	I-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
depressed	depress	d0160203	VBN	I-VP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
lasting	last	l023052	VBG	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
admission	admission	a350205	NN	B-NP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
FHF	FHF	f010	NN	B-NP	B-Disease
from	from	f605	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hyperosmolar	hyperosmolar	h01060250406	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
hyperventilation	hyperventilation	h01061053040305	NN	B-NP	B-Disease
,	,	,000	,	O	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
chemical	chemical	c050204	NN	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
intracranial	intracranial	i5360260504	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-ADJP	O
despite	despite	d021030	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
initiated	initiate	i5030303	VBD	B-VP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
re	re	r000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
warming	warm	w065052	VBG	B-VP	O
,	,	,000	,	O	O
patient	patient	p03053	NN	B-NP	O
had	have	h030	VBD	B-VP	O
resolution	resolution	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
intracranial	intracranial	i5360260504	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
discharge	discharge	d020620	NN	B-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
functions	function	f0523052	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
FHF	FHF	f010	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
,	,	,000	,	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
could	could	c043	MD	B-VP	O
potentially	potentially	p03053040	RB	I-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
life	life	l010	NN	I-NP	O
saving	save	s01052	VBG	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
bridge	bridge	b60320	NN	I-NP	O
to	to	t000	TO	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypothermia	hypothermia	h01030650	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Binasal	Binasal	b050204	JJ	B-NP	B-Disease
visual	visual	v0204	JJ	I-NP	I-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
specific	specific	s1020102	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
vigabatrin	vigabatrin	v020103605	NN	I-NP	B-Chemical
(	(	(000	(	O	O
VGB	VGB	v210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
four	four	f060	CD	I-NP	O
people	people	p0140	NNS	I-NP	O
with	with	w030	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
grouped	group	g60103	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
antiepileptic	antiepileptic	a53010401302	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
current	current	c06053	JJ	B-ADJP	O
,	,	,000	,	O	O
previous	previous	p60102	JJ	B-ADJP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
no	no	n000	DT	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
VGB	VGB	v210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
matched	match	m03203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
gender	gender	g05306	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
objective	objective	o12023010	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
(	(	(000	(	O	O
wide	wide	w030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
field	field	f043	NN	I-NP	O
multifocal	multifocal	m043010204	JJ	I-NP	O
electroretinography	electroretinography	e40236060305026010	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
(	(	(000	(	O	O
static	static	s30302	JJ	B-NP	O
perimetry	perimetry	p06050360	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
constriction	constriction	c0523602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
59	59	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
currently	currently	c0605340	RB	B-VP	O
taking	take	t02052	VBG	I-VP	O
VGB	VGB	v210	NN	B-NP	B-Chemical
,	,	,000	,	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
previously	previously	p6010240	RB	B-ADVP	O
took	take	t020	VBD	B-VP	O
VGB	VGB	v210	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
VGB	VGB	v210	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
retinal	retinal	r030504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
48	48	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
VGB	VGB	v210	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
VGB	VGB	v210	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
VGB	VGB	v210	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	B-Disease
visual	visual	v0204	JJ	I-NP	I-Disease
field	field	f043	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
common	common	c0505	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treated	treat	t60303	VBN	I-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
history	history	h023060	NN	I-NP	O
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
by	by	b000	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
static	static	s30302	JJ	I-NP	O
perimetry	perimetry	p06050360	NN	I-NP	O
may	may	m000	MD	B-VP	O
neither	neither	n0306	CC	I-VP	O
be	be	b000	VB	I-VP	O
sufficiently	sufficiently	s010205340	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
nor	nor	n060	CC	I-ADJP	O
specific	specific	s1020102	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
reliably	reliably	r040140	RB	I-VP	O
identify	identify	i3053010	VB	I-VP	O
retinal	retinal	r030504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
VGB	VGB	v210	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Smoking	Smoking	s502052	NN	B-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
people	people	p0140	NNS	B-NP	O
who	who	w000	WP	B-NP	O
use	use	u200	VBP	B-VP	O
injection	injection	i5202305	NN	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Little	Little	l0340	JJ	B-ADJP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
role	role	r040	NN	I-NP	O
that	that	t030	WDT	B-NP	O
smoking	smoke	s502052	VBG	B-VP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
increasing	increase	i52602052	VBG	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
illicit	illicit	i40203	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
become	become	b02050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
included	include	i5240303	VBD	B-VP	O
data	datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
people	people	p0140	NNS	B-NP	O
participating	participate	p063020103052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Vancouver	Vancouver	v0520106	NNP	I-NP	O
Injection	Injection	i5202305	NNP	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Users	Users	u2062	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
who	who	w000	WP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
injecting	inject	i52023052	VBG	I-VP	O
illicit	illicit	i40203	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
once	once	o520	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
month	month	m0530	NN	I-NP	O
before	before	b01060	IN	B-PP	O
enrolment	enrolment	e56045053	NN	B-NP	O
,	,	,000	,	O	O
lived	live	l0103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
Vancouver	Vancouver	v0520106	NNP	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
HIV	HIV	h010	NN	B-NP	O
-	-	-000	HYPH	O	O
negative	negative	n0203010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
enrolment	enrolment	e56045053	NN	B-NP	O
and	and	a530	CC	O	O
completed	complete	c05140303	VBD	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
1	1	1000	CD	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
study	study	s3030	NN	B-NP	O
visit	visit	v0203	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
seroconversion	seroconversion	s060205106205	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
changed	change	c05203	VBD	B-VP	O
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
Cox	Cox	c020	NNP	B-NP	O
proportional	proportional	p6010630504	JJ	I-NP	O
hazards	hazard	h020632	NNS	I-NP	O
regression	regression	r0260205	NN	I-NP	O
and	and	a530	CC	O	O
divided	divide	d010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
into	into	i530	IN	B-PP	O
3	3	3000	CD	B-NP	O
periods	period	p06032	NNS	I-NP	O
:	:	:000	:	O	O
May	May	m000	NNP	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
1996	1996	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
Nov	Nov	n010	NNP	I-NP	O
.	.	.000	.	O	O

30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1999	1999	0000	CD	I-NP	O
(	(	(000	(	O	O
period	period	p0603	NN	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Dec	Dec	d020	NNP	B-NP	O
.	.	.000	.	O	O

1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
1999	1999	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
Nov	Nov	n010	NNP	I-NP	O
.	.	.000	.	O	O

30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
2002	2002	0000	CD	I-NP	O
(	(	(000	(	O	O
period	period	p0603	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Dec	Dec	d020	NNP	B-NP	O
.	.	.000	.	O	O

1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2002	2002	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
Dec	Dec	d020	NNP	I-NP	O
.	.	.000	.	O	O

30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
2005	2005	0000	CD	I-NP	O
(	(	(000	(	O	O
period	period	p0603	NN	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Overall	Overall	o10604	JJ	B-ADVP	O
,	,	,000	,	O	O
1048	1048	0000	CD	B-NP	O
eligible	eligible	e4020140	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
,	,	,000	,	O	O
137	137	0000	CD	B-NP	O
acquired	acquire	a20603	VBD	B-VP	O
HIV	HIV	h010	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
participants	participant	p06302010532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
daily	daily	d040	JJ	B-NP	O
smoking	smoking	s502052	NN	I-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
period	period	p0603	NN	B-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
39	39	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
period	period	p0603	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
adjusting	adjust	a32023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
confounders	confounder	c051053062	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
seroconversion	seroconversion	s060205106205	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
participants	participant	p06302010532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
daily	daily	d040	JJ	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
increased	increase	i5260203	VBD	B-VP	O
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
(	(	(000	(	O	O
period	period	p0603	NN	B-NP	O
1	1	1000	CD	I-NP	O
:	:	:000	:	O	O
hazard	hazard	h02063	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
[	[	[000	(	O	O
HR	HR	h600	NN	B-NP	O
]	]	]000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
57	57	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
85	85	0000	CD	I-NP	O
;	;	;000	:	O	O
period	period	p0603	NN	B-NP	O
2	2	2000	CD	I-NP	O
:	:	:000	:	O	O
HR	HR	h600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
68	68	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
80	80	0000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
period	period	p0603	NN	B-NP	O
3	3	3000	CD	I-NP	O
:	:	:000	:	O	O
HR	HR	h600	NN	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
74	74	0000	CD	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
06	06	0000	CD	I-NP	O
-	-	-000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
11	11	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

INTERPRETATION	INTERPRETATION	i530616030305	NN	B-NP	O
:	:	:000	:	O	O
Smoking	Smoking	s502052	NN	B-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
seroconversion	seroconversion	s060205106205	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
people	people	p0140	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
injection	injection	i5202305	NN	B-NP	O
drug	drug	d602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
points	point	p0532	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
urgent	urgent	u62053	JJ	I-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-VP	O
public	public	p01402	JJ	B-NP	O
health	health	h0430	NN	I-NP	O
initiatives	initiative	i503030102	NNS	I-NP	O
targeted	target	t0620303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
people	people	p0140	NNS	B-NP	O
who	who	w000	WP	B-NP	O
smoke	smoke	s5020	VBP	B-VP	O
crack	crack	c602	NN	B-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
improves	improve	i5160102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Cancer	Cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
adjuvant	adjuvant	a3201053	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
have	have	h010	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
experiencing	experience	e2106052052	VBG	I-VP	O
deteriorations	deterioration	d03060603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cognition	cognition	c0250305	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
readily	readily	r03040	RB	B-ADVP	O
crosses	cross	c60202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
and	and	a530	CC	O	O
so	so	s000	RB	B-VP	O
could	could	c043	MD	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-ADJP	O
this	this	t020	DT	B-NP	O
anti	anti	a530	JJ	I-NP	O
mitotic	mitotic	m030302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
could	could	c043	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
cell	cell	c040	NN	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neurogenic	neurogenic	n06020502	JJ	I-NP	O
regions	region	r02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
reports	report	r010632	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
neurogenesis	neurogenesis	n0602050202	NN	I-NP	O
and	and	a530	CC	I-NP	O
cognition	cognition	c0250305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
SSRI	SSRI	s260	NN	I-NP	B-Chemical
antidepressant	antidepressant	a530301602053	NN	I-NP	O
Fluoxetine	Fluoxetine	f40203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
the	the	t000	DT	B-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
(	(	(000	(	O	O
two	two	t000	CD	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
three	three	t060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
either	either	e0306	CC	O	O
separately	separately	s010603040	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
Lister	Lister	l02306	NNP	I-NP	O
hooded	hood	h0303	VBD	B-VP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Behavioural	Behavioural	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
context	context	c053023	NN	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
conditioned	condition	c053030503	VBN	I-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
CER	CER	c060	NN	B-NP	O
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
freezing	freeze	f602052	VBG	B-VP	O
time	time	t050	NN	B-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
spatial	spatial	s10304	JJ	I-NP	O
working	working	w062052	NN	I-NP	O
memory	memory	m05060	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
object	object	o12023	NN	I-NP	O
location	location	l020305	NN	I-NP	O
recognition	recognition	r020250305	NN	I-NP	O
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
OLR	OLR	o460	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
only	only	o540	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
carry	carry	c060	VB	I-VP	O
out	out	o030	RP	B-PRT	O
the	the	t000	DT	B-NP	O
OLR	OLR	o460	NN	I-NP	O
task	task	t020	NN	I-NP	O
but	but	b030	CC	O	O
co	co	c000	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
improved	improve	i5160103	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
proliferating	proliferate	p604010603052	VBG	B-VP	O
cells	cell	c042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sub	sub	s010	NN	I-NP	O
granular	granular	g6050406	JJ	I-NP	O
zone	zone	z050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
eliminated	eliminate	e405050303	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
co	co	c000	NN	B-NP	O
administered	administer	a35050230603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
own	own	o050	JJ	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
proliferating	proliferate	p604010603052	VBG	B-VP	O
cell	cell	c040	NN	B-NP	O
number	number	n05106	NN	I-NP	O
or	or	o600	CC	O	O
behaviour	behaviour	b0106	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
can	can	c050	MD	B-VP	O
negatively	negatively	n020301040	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
both	both	b030	CC	O	O
cell	cell	c040	NN	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
and	and	a530	CC	O	O
hippocampal	hippocampal	h010205104	NN	B-NP	O
dependent	dependent	d01053053	JJ	B-NP	O
working	work	w062052	VBG	I-NP	O
memory	memory	m05060	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
simultaneous	simultaneous	s050430502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
Fluoxetine	Fluoxetine	f40203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
ablation	ablation	a140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
integrin	integrin	i5302605	NN	B-NP	O
-	-	-000	HYPH	O	O
linked	link	l05203	VBN	B-NP	O
kinase	kinase	k05020	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
and	and	a530	CC	I-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
and	and	a530	CC	O	O
hepatomegaly	hepatomegaly	h01030502040	RB	B-ADVP	B-Disease
after	after	a1306	IN	B-SBAR	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
recently	recently	r0205340	RB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
matrix	matrix	m03602	NN	I-NP	O
(	(	(000	(	O	O
ECM	ECM	e250	NN	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
integrin	integrin	i5302605	NN	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
via	via	v000	IN	B-PP	O
elimination	elimination	e405050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
integrin	integrin	i5302605	NN	B-NP	O
-	-	-000	HYPH	O	O
linked	link	l05203	VBN	B-NP	O
kinase	kinase	k05020	NN	I-NP	O
(	(	(000	(	O	O
ILK	ILK	i420	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
hepatocytes	hepatocyte	h0103020302	NNS	B-NP	O
interferes	interfere	i530610602	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
signals	signal	s025042	NNS	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
termination	termination	t065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
regeneration	regeneration	r0205060305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigates	investigate	i51023020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
ILK	ILK	i420	NN	B-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
enlargement	enlargement	e5406205053	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PB	PB	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Wild	Wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
(	(	(000	(	O	O
WT	WT	w300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ILK	ILK	i420	NN	B-NP	O
:	:	:000	:	O	O
liver	liver	l0106	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
PB	PB	p100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
drinking	drinking	d6052052	NN	B-NP	O
water	water	w0306	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Livers	Liver	l01062	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
harvested	harvest	h06102303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatocyte	hepatocyte	h010302030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
ILK	ILK	i420	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liver	liver	l0106	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
:	:	:000	:	O	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	JJR	B-ADVP	O
than	than	t050	IN	I-ADVP	O
double	double	d0140	JJ	I-ADVP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
at	at	a300	IN	B-PP	O
days	day	d020	NNS	B-NP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
enlarged	enlarge	e5406203	VBN	I-VP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
WT	WT	w300	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
as	as	a200	RB	B-VP	O
expected	expect	e2102303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
literature	literature	l030603060	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
leveled	level	l010403	VBN	I-VP	O
off	off	o100	RP	B-PRT	O
after	after	a1306	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
slightly	slightly	s4020340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
proliferating	proliferate	p604010603052	VBG	B-VP	O
cell	cell	c040	NN	B-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ILK	ILK	i420	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liver	liver	l0106	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
animals	animal	a505042	NNS	B-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
WT	WT	w300	NN	B-NP	O
after	after	a1306	IN	B-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
WT	WT	w300	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
proliferative	proliferative	p604010603010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
had	have	h030	VBD	B-VP	O
come	come	c050	VBN	I-VP	O
back	back	b020	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
days	day	d020	NNS	B-NP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O

Hepatocytes	Hepatocyte	h0103020302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ILK	ILK	i420	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liver	liver	l0106	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
mice	mouse	m020	NNS	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
proliferate	proliferate	p6040106030	VB	I-VP	O
up	up	u100	RP	B-PRT	O
until	until	u5304	IN	B-PP	O
day	day	d000	NN	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O

ILK	ILK	i420	NN	B-NP	O
/	/	/000	SYM	B-NP	O
liver	liver	l0106	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
key	key	k000	JJ	B-NP	O
genes	gene	g0502	NNS	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
at	at	a300	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
time	time	t050	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
summary	summary	s05060	NN	B-NP	O
,	,	,000	,	O	O
ECM	ECM	e250	NN	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
communicate	communicate	c050502030	VBP	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
machinery	machinery	m0205060	NN	I-NP	O
of	of	o100	IN	B-PP	O
dividing	divide	d0103052	VBG	B-VP	O
cells	cell	c042	NNS	B-NP	O
via	via	v000	IN	B-PP	O
ILK	ILK	i420	NN	B-NP	O
to	to	t000	TO	B-VP	O
regulate	regulate	r0204030	VB	I-VP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
termination	termination	t065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
proliferative	proliferative	p604010603010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Lack	Lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
ILK	ILK	i420	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatocytes	hepatocyte	h0103020302	NNS	I-NP	O
imparts	impart	i510632	VBZ	B-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
proliferative	proliferative	p604010603010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
to	to	t000	TO	B-PP	O
stimuli	stimulus	s305040	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
liver	liver	l0106	NN	B-NP	O
regeneration	regeneration	r0205060305	NN	I-NP	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
to	to	t000	TO	B-PP	O
xenobiotic	xenobiotic	x05010302	JJ	B-NP	O
chemical	chemical	c050204	JJ	I-NP	O
mitogens	mitogen	m0302052	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Decreased	Decrease	d0260203	VBN	B-NP	O
Expression	Expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
,	,	,000	,	O	O
NHE3	NHE3	0000	NN	B-NP	O
,	,	,000	,	O	O
NBC1	NBC1	0000	NN	B-NP	O
,	,	,000	,	O	O
AQP1	AQP1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
OAT	OAT	o030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
Nephropathy	Nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
aimed	aim	a0503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
altered	altered	a430603	JJ	I-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
transporters	transporter	t60521063062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
~	~	~000	SYM	I-NP	O
250	250	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
subcutaneously	subcutaneously	s01203050240	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
transporters	transporter	t60521063062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
immunoblotting	immunoblotting	i50501403052	NN	B-NP	O
and	and	a530	CC	I-NP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
and	and	a530	CC	I-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
OAT	OAT	o030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Accordingly	Accordingly	a206305240	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
urine	urine	u6050	NN	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
water	water	w0306	NN	I-NP	O
reabsorption	reabsorption	r012061305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

Immunoblotting	Immunoblotting	i50501403052	NN	B-NP	O
and	and	a530	CC	I-NP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
decreased	decrease	d0260203	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
,	,	,000	,	O	O
NHE3	NHE3	0000	NN	B-NP	O
,	,	,000	,	O	O
NBC1	NBC1	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
AQP1	AQP1	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
OAT1	OAT1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
OAT3	OAT3	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
may	may	m000	MD	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
be	be	b000	VB	B-VP	O
causally	causally	c02040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
,	,	,000	,	I-NP	O
NHE3	NHE3	0000	NN	I-NP	O
,	,	,000	,	I-NP	O
NBC1	NBC1	0000	NN	I-NP	O
,	,	,000	,	I-NP	O
AQP1	AQP1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
OAT	OAT	o030	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
ileostomy	ileostomy	i4023050	NN	B-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
HD	HD	h300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
Burkitt	Burkitt	b06203	NN	B-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
its	its	i320	PRP$	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
delayed	delay	d0403	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
HD	HD	h300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
ileostomy	ileostomy	i4023050	NN	B-NP	O
,	,	,000	,	O	O
The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
boy	boy	b000	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
living	living	l01052	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
congenital	congenital	c052050304	JJ	B-NP	O
biliary	biliary	b04060	JJ	I-NP	B-Disease
atresia	atresia	a36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
833	833	0000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
PTLD	PTLD	p343	NN	B-NP	B-Disease
(	(	(000	(	O	O
post	post	p023	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
transplantation	transplantation	t6052140530305	NN	I-NP	I-Disease
lymphoproliferative	lymphoproliferative	l05101604010603010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
Burkitt	Burkitt	b06203	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
type	type	t010	NN	I-NP	I-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
ileal	ileal	i404	JJ	B-NP	O
perforation	perforation	p061060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
ileostomy	ileostomy	i4023050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
HD	HD	h300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
required	require	r020603	VBD	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
hemodialysis	hemodialysis	h0503040202	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
supposed	suppose	s010203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
intravascular	intravascular	i53601020406	JJ	B-NP	O
hypovolemia	hypovolemia	h010104050	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
substantial	substantial	s012305304	JJ	B-NP	O
drainage	drainage	d605020	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
ileostoma	ileostoma	i4023050	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
prerenal	prerenal	p6060504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
could	could	c043	MD	B-VP	O
safely	safely	s01040	RB	I-VP	O
treat	treat	t603	VB	I-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
HD	HD	h300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
by	by	b000	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
drainage	drainage	d605020	NN	B-NP	O
from	from	f605	IN	B-PP	O
ileostoma	ileostoma	i4023050	NN	B-NP	O
with	with	w030	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
parenteral	parenteral	p060530604	JJ	I-NP	O
nutrition	nutrition	n0360305	NN	I-NP	O
.	.	.000	.	O	O

Longitudinal	Longitudinal	l05203030504	JJ	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
progression	progression	p60260205	NN	I-NP	O
and	and	a530	CC	O	O
psychological	psychological	p20204020204	JJ	B-NP	O
health	health	h0430	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
and	and	a530	CC	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
progression	progression	p60260205	NN	I-NP	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
871	871	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
recruited	recruit	r0260303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
1993	1993	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1995	1995	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
US	US	u200	NNP	I-NP	O
cities	city	c0302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
medical	medical	m030204	JJ	B-NP	O
record	record	r02063	NN	I-NP	O
extraction	extraction	e23602305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
venipuncture	venipuncture	v05010523060	NN	B-NP	O
,	,	,000	,	O	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	I-NP	O
T	T	t000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
cell	cell	c040	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
,	,	,000	,	O	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
(	(	(000	(	O	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
self	self	s041	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
report	report	r01063	NN	I-NP	O
Center	Center	c05306	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Epidemiological	Epidemiological	e1030504020204	NNP	B-NP	O
Studies	Study	s30302	NNPS	I-NP	O
-	-	-000	HYPH	I-NP	O
Depression	Depression	d0160205	NN	I-NP	B-Disease
Scale	Scale	s2040	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	VBP	B-VP	O
assessment	assessment	a2025053	NN	B-NP	O
at	at	a300	IN	B-PP	O
enrollment	enrollment	e56045053	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
semiannually	semiannually	s0505040	RB	B-ADVP	O
until	until	u5304	IN	B-PP	O
March	March	m0620	NNP	B-NP	O
2000	2000	0000	CD	I-NP	O
.	.	.000	.	O	O

Multilevel	Multilevel	m043040104	JJ	B-NP	O
random	random	r05305	JJ	I-NP	O
coefficient	coefficient	c0102053	JJ	I-NP	O
ordinal	ordinal	o630504	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
multilevel	multilevel	m043040104	JJ	B-NP	O
models	model	m03042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
joint	joint	j053	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
level	level	l0104	NN	B-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	I-NP	O
CD4	CD4	0000	NN	I-NP	O
+	+	+000	SYM	I-NP	O
T	T	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
participants	participant	p06302010532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
stratified	stratify	s36030103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
antiretroviral	antiretroviral	a5306036010604	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
ART	ART	a630	NN	B-NP	O
)	)	)000	)	O	O
use	use	u200	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
CD4	CD4	0000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
T	T	t000	NN	I-NP	O
-	-	-000	HYPH	O	O
cell	cell	c040	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reach	reach	r020	VB	I-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
and	and	a530	CC	O	O
depression	depression	d0160205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Depression	Depression	d0160205	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	I-NP	O
T	T	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
ART	ART	a630	NNP	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
depression	depression	d0160205	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
progression	progression	p60260205	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
provision	provision	p6010205	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
and	and	a530	CC	O	O
psychological	psychological	p20204020204	JJ	B-NP	O
resources	resource	r0206202	NNS	I-NP	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
health	health	h0430	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
.	.	.000	.	O	O

Chemokine	Chemokine	c0502050	NN	B-NP	O
CCL2	CCL2	0000	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
CCR2	CCR2	0000	NN	I-NP	O
are	be	a600	VBP	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Neuroinflammation	Neuroinflammation	n060514050305	NN	B-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
after	after	a1306	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
.	.	.000	.	O	O

CCR2	CCR2	0000	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
chemokine	chemokine	c0502050	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
for	for	f060	IN	B-PP	O
CCL2	CCL2	0000	NN	B-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
mediates	mediate	m030302	VBZ	B-VP	O
monocyte	monocyte	m0502030	NN	B-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neuroinflammatory	neuroinflammatory	n0605140503060	JJ	I-NP	B-Disease
cascade	cascade	c02030	NN	I-NP	O
triggered	trigger	t6020603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
pathologies	pathology	p03040202	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
CCR2	CCR2	0000	NN	I-NP	O
and	and	a530	CC	O	O
CCL2	CCL2	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SE	SE	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
SE	SE	s000	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
instead	instead	i52303	RB	B-PP	O
of	of	o100	IN	I-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
,	,	,000	,	O	O
CCR2	CCR2	0000	NN	B-NP	O
staining	staining	s305052	NN	I-NP	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
and	and	a530	CC	O	O
glial	glial	g404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
imunohistochemical	imunohistochemical	i50502302050204	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
CCR2	CCR2	0000	NN	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
stereology	stereology	s30604020	NN	B-NP	O
probes	probe	p60102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

CCL2	CCL2	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
molecular	molecular	m04020406	JJ	B-NP	O
assay	assay	a200	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Increased	Increase	i5260203	VBN	B-NP	O
CCR2	CCR2	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
after	after	a1306	IN	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
also	also	a420	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
alterations	alteration	a430603052	NNS	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cell	cell	c040	NN	I-NP	O
types	type	t0102	NNS	I-NP	O
expressing	express	e21602052	VBG	B-VP	O
CCR2	CCR2	0000	NN	B-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
expressed	express	e2160203	VBD	B-VP	O
CCR2	CCR2	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
.	.	.000	.	O	O

Microglial	Microglial	m02602404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	I-VP	O
closely	closely	c402040	RB	I-VP	O
apposed	appose	a10203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
CCR2	CCR2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
labeled	label	l010403	VBN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
SE	SE	s000	NN	B-NP	B-Disease
exhibited	exhibit	e2010303	VBD	B-VP	O
CCR2	CCR2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
labeling	labeling	l0104052	NN	I-NP	O
in	in	i500	IN	B-PP	O
populations	population	p010403052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hypertrophied	hypertrophied	h0106360103	JJ	B-NP	B-Disease
astrocytes	astrocyte	a236020302	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
CA1	CA1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
CCR2	CCR2	0000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
astroctytes	astroctyte	a2360230302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Examination	Examination	e205050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CCL2	CCL2	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CCR2	CCR2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
CCL2	CCL2	0000	NN	I-NP	O
are	be	a600	VBP	B-VP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulated	regulate	r02040303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
after	after	a1306	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
SE	SE	s000	NN	I-NP	B-Disease
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
also	also	a420	RB	B-ADVP	O
result	result	r02043	VBP	B-VP	O
in	in	i500	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
CCR2	CCR2	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
astrocytes	astrocyte	a236020302	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
detrimental	detrimental	d0360505304	JJ	B-NP	O
neuroplasticity	neuroplasticity	n0601402302030	NN	I-NP	O
and	and	a530	CC	O	O
neuroinflammatory	neuroinflammatory	n0605140503060	JJ	B-NP	B-Disease
changes	change	c05202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
occur	occur	o206	VBP	B-VP	O
following	follow	f04052	VBG	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Metallothionein	Metallothionein	m0304030505	NN	B-NP	B-Chemical
induction	induction	i5302305	NN	I-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
caspase	caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	I-NP	O
TNFalpha	TNFalpha	t510410	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
preservation	preservation	p6020610305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
intact	intact	i53023	JJ	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
carmustine	carmustine	c065023050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Hippocampal	Hippocampal	h010205104	JJ	B-NP	O
integrity	integrity	i53026030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
metallothionein	metallothionein	m0304030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MT	MT	m300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
ZnSO	ZnSO	z520	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
neuroprotection	neuroprotection	n060160302305	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
documented	document	d020505303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
MT	MT	m300	NN	B-NP	B-Chemical
induction	induction	i5302305	NN	I-NP	O
on	on	o500	IN	B-PP	O
carmustine	carmustine	c065023050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
male	male	m040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
albino	albino	a41050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
)	)	)000	)	O	O
followed	follow	f0403	VBD	B-VP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
solvent	solvent	s041053	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	''	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
ZnSO	ZnSO	z520	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
,	,	,000	,	O	O
once	once	o520	RB	B-ADVP	O
)	)	)000	)	O	O
then	then	t050	RB	B-ADVP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
solvent	solvent	s041053	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	''	O	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Third	Third	t063	JJ	B-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
,	,	,000	,	O	O
once	once	o520	RB	B-ADVP	O
)	)	)000	)	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	''	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Fourth	Fourth	f0630	JJ	B-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ZnSO	ZnSO	z520	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
)	)	)000	)	O	O
then	then	t050	RB	B-NP	O
BCNU	BCNU	b250	NN	I-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
,	,	,000	,	O	O
once	once	o520	RB	B-ADVP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
obtained	obtain	o130503	VBN	I-NP	O
data	datum	d030	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
deterioration	deterioration	d0306060305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
and	and	a530	CC	O	I-Disease
short	short	s063	JJ	B-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
term	term	t065	NN	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
(	(	(000	(	O	O
STM	STM	s350	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
radial	radial	r0304	JJ	B-NP	O
arm	arm	a650	NN	I-NP	O
water	water	w0306	NN	I-NP	O
maze	maze	m020	NN	I-NP	O
,	,	,000	,	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
reductase	reductase	r03023020	NN	I-NP	O
(	(	(000	(	O	O
GR	GR	g600	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
GSH	GSH	g200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
content	content	c053053	NN	B-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
(	(	(000	(	O	O
TNFalpha	TNFalpha	t510410	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
MT	MT	m300	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
malondialdehyde	malondialdehyde	m04053043030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MDA	MDA	m300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
contents	content	c0530532	NNS	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
caspase	caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	O	O
3	3	3000	CD	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
.	.	.000	.	O	O

ZnSO	ZnSO	z520	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
pretreatment	pretreatment	p6036035053	NN	B-NP	O
counteracted	counteract	c0530602303	VBD	B-VP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GR	GR	g600	NN	B-NP	O
and	and	a530	CC	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GSH	GSH	g200	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MDA	MDA	m300	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
TNFalpha	TNFalpha	t510410	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
caspase	caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
histological	histological	h02304020204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ZnSO	ZnSO	z520	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
+	+	+000	SYM	B-NP	O
BCNU	BCNU	b250	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
only	only	o540	RB	B-NP	O
BCNU	BCNU	b250	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
MT	MT	m300	NN	B-NP	B-Chemical
induction	induction	i5302305	NN	I-NP	O
halts	halt	h0432	VBZ	B-VP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
as	as	a200	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
GR	GR	g600	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
and	and	a530	CC	O	O
GSH	GSH	g200	NN	B-NP	B-Chemical
depletion	depletion	d0140305	NN	I-NP	O
and	and	a530	CC	O	O
counteracted	counteract	c0530602303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TNFalpha	TNFalpha	t510410	NN	B-NP	O
,	,	,000	,	O	O
MDA	MDA	m300	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
caspase	caspase	c021020	NN	I-NP	O
-	-	-000	HYPH	O	O
3	3	3000	CD	B-NP	O
activity	activity	a2301030	NN	I-NP	O
with	with	w030	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
preservation	preservation	p6020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognition	cognition	c0250305	NN	B-NP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
eosinophilic	eosinophilic	e0205010402	JJ	I-NP	I-Disease
(	(	(000	(	O	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
)	)	)000	)	O	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
:	:	:000	:	O	O
emphasis	emphasis	e510202	NN	B-NP	O
on	on	o500	IN	B-PP	O
anatomical	anatomical	a503050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
histological	histological	h02304020204	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
,	,	,000	,	O	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
and	and	a530	CC	I-NP	O
genetics	genetic	g050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
differential	differential	d010605304	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
severe	severe	s01060	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
haemopoietic	haemopoietic	h05010302	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
exceptionally	exceptionally	e201305040	RB	B-NP	O
rare	rare	r060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
necrotizing	necrotize	n0260302052	VBG	I-VP	O
eosinophilic	eosinophilic	e0205010402	JJ	B-NP	O
(	(	(000	(	O	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
)	)	)000	)	O	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
mortem	mortem	m06305	NN	B-NP	O
.	.	.000	.	O	O

Histology	Histology	h02304020	NNP	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
diffuse	diffuse	d01020	JJ	B-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
by	by	b000	IN	B-PP	O
eosinophils	eosinophil	e020501042	NNS	B-NP	O
and	and	a530	CC	I-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
myocyte	myocyte	m02030	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Clinically	Clinically	c40502040	RB	B-ADVP	O
,	,	,000	,	O	O
death	death	d030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cardiogenic	cardiogenic	c063020502	JJ	B-NP	B-Disease
shock	shock	s020	NN	I-NP	I-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
best	good	b023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
English	English	e524020	JJ	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Neuropsychiatric	Neuropsychiatric	n060120203602	JJ	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
MPTP	MPTP	m131	NN	I-NP	B-Chemical
marmoset	marmoset	m0650203	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
Neuropsychiatric	Neuropsychiatric	n060120203602	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
increasingly	increasingly	i5260205240	RB	I-VP	O
recognised	recognise	r020250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
problem	problem	p601405	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
'	'	'000	``	B-NP	O
sensitisation	sensitisation	s05203020305	NN	I-NP	O
'	'	'000	''	O	O
following	follow	f04052	VBG	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
MPTP	MPTP	m131	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
lesioned	lesione	l020503	VBN	B-NP	O
marmoset	marmoset	m0650203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
compare	compare	c051060	VBP	B-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
motor	motor	m0306	NN	I-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
and	and	a530	CC	O	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	I-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Marmosets	Marmoset	m06502032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenyl	phenyl	p0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydropyridine	tetrahydropyridine	t036036010603050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
parkinsonism	parkinsonism	p06205205025	NN	I-NP	B-Disease
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	I-NP	O
benserazide	benserazide	b0520602030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O

b	b	b000	NN	B-NP	O
.	.	.000	.	O	O
i	i	i000	LS	B-LST	O
.	.	.000	.	B-NP	O
d	d	d000	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
,	,	,000	,	O	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
motor	motor	m0306	NN	B-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
on	on	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
0	0	0000	CD	I-NP	O
(	(	(000	(	O	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
13	13	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
27	27	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
using	use	u2052	VBG	B-VP	O
post	post	p023	NN	B-NP	O
hoc	hoc	h020	NN	I-NP	O
DVD	DVD	d130	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
trained	trained	t60503	JJ	I-NP	O
rater	rater	r0306	NN	I-NP	O
,	,	,000	,	O	O
blind	blind	b4053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
rating	rating	r03052	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
interrater	interrater	i53060306	NN	I-NP	O
reliability	reliability	r040104030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
three	three	t060	CD	B-NP	O
trained	train	t60503	VBN	I-NP	O
raters	rater	r03062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
differing	differ	d0106052	VBG	B-VP	O
professional	professional	p601020504	JJ	B-NP	O
backgrounds	background	b0260532	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
anticipated	anticipate	a5302010303	VBN	B-VP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
motor	motor	m0306	NN	I-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
,	,	,000	,	O	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
wearing	wearing	w06052	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
off	off	o100	RP	B-PRT	O
,	,	,000	,	O	O
that	that	t030	WDT	B-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
severity	severity	s0106030	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
an	an	a500	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
state	state	s3030	NN	I-NP	O
than	than	t050	IN	B-PP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensitisation	sensitisation	s05203020305	NN	B-NP	O
to	to	t000	TO	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Contrast	Contrast	c0536023	NN	B-NP	B-Chemical
medium	medium	m0305	NN	I-NP	I-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
and	and	a530	CC	O	O
coronary	coronary	c0605060	JJ	B-NP	O
angioplasty	angioplasty	a520140230	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Renal	Renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
iodinated	iodinate	i03050303	VBN	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
medium	medium	m0305	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CM	CM	c500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
can	can	c050	MD	B-VP	O
minimize	minimize	m0505020	VB	I-VP	O
the	the	t000	DT	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
interventional	interventional	i530610530504	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	O
angioplasty	angioplasty	a520140230	JJ	I-NP	O
(	(	(000	(	O	O
PTRA	PTRA	p360	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	B-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
PTRA	PTRA	p360	NN	B-NP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
submitted	submit	s0150303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
(	(	(000	(	O	O
PCI	PCI	p200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MATERIAL	MATERIAL	m030604	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
33	33	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
successfully	successfully	s02021040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
PTRA	PTRA	p360	NN	B-NP	O
(	(	(000	(	O	O
PTRA	PTRA	p360	NN	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
70	70	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
12	12	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
,	,	,000	,	I-NP	O
basal	basal	b0204	JJ	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
46	46	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
79	79	0000	CD	I-NP	O
,	,	,000	,	O	O
range	range	r0520	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
33	33	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
successful	successful	s0202104	JJ	B-NP	O
PCI	PCI	p200	NN	I-NP	O
(	(	(000	(	O	O
PCI	PCI	p200	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
matched	match	m03203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
basal	basal	b0204	JJ	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
44	44	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
range	range	r0520	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
gender	gender	g05306	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
postprocedural	postprocedural	p0231602030604	JJ	B-ADJP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Postprocedural	Postprocedural	p0231602030604	JJ	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
nonsignificantly	nonsignificantly	n052025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PTRA	PTRA	p360	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
46	46	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
34	34	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-VP	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
NS	NS	n200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PCI	PCI	p200	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
44	44	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
57	57	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
intervention	intervention	i5306105305	NN	B-NP	O
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
before	before	b01060	IN	B-SBAR	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
PTRA	PTRA	p360	NN	I-NP	O
and	and	a530	CC	I-NP	O
PCI	PCI	p200	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
13	13	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
014	014	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
a	a	a000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
or	or	o600	CC	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
submitted	submit	s0150303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
PTRA	PTRA	p360	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
than	than	t050	IN	B-PP	O
PCI	PCI	p200	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
PTRA	PTRA	p360	NN	B-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
barely	barely	b06040	RB	I-VP	O
influenced	influence	i51405203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Diphenhydramine	Diphenhydramine	d010503605050	NN	B-NP	B-Chemical
prevents	prevent	p6010532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
haemodynamic	haemodynamic	h0503050502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
ICU	ICU	i200	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Cimetidine	Cimetidine	c050303050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
H2	H2	0000	NN	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
,	,	,000	,	O	O
produces	produce	p6030202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
vasodilatation	vasodilatation	v020304030305	NN	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
critically	critically	c60302040	RB	B-NP	O
ill	ill	i400	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
because	because	b02020	IN	B-SBAR	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
acts	act	a232	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
H1	H1	0000	NN	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
diphenhydramine	diphenhydramine	d010503605050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
haemodynamic	haemodynamic	h0503050502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
ICU	ICU	i200	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
random	random	r05305	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
iv	iv	i100	NN	I-NP	O
on	on	o500	IN	B-PP	O
one	one	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
diphenhydramine	diphenhydramine	d010503605050	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
iv	iv	i100	NN	I-NP	O
with	with	w030	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
iv	iv	i100	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
107	107	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
to	to	t000	TO	B-PP	O
86	86	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
two	two	t000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
SVR	SVR	s160	NN	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
little	little	l0340	JJ	B-NP	O
haemodynamic	haemodynamic	h0503050502	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
H1	H1	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
iv	iv	i100	NN	B-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
vasodilating	vasodilate	v02030403052	VBG	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
H1	H1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Medical	Medical	m030204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
transplanted	transplant	t60521405303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Acetaminophen	Acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ALF	ALF	a410	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
UK	UK	u200	NNP	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
often	often	o1305	RB	B-ADVP	O
consume	consume	c052050	VBP	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
with	with	w030	IN	B-PP	O
suicidal	suicidal	s020304	JJ	B-NP	O
intent	intent	i53053	NN	I-NP	O
or	or	o600	CC	B-PP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
background	background	b026053	NN	I-NP	O
of	of	o100	IN	B-PP	O
substance	substance	s01230520	NN	B-NP	O
dependence	dependence	d010530520	NN	I-NP	O
.	.	.000	.	O	O

AIMS	AIMS	a052	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pretransplant	pretransplant	p603605214053	NN	B-NP	O
illness	illness	i4502	NN	I-NP	O
,	,	,000	,	O	O
psychiatric	psychiatric	p20203602	JJ	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
,	,	,000	,	O	O
medical	medical	m030204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
psychosocial	psychosocial	p202020204	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
(	(	(000	(	O	O
LT	LT	l300	NN	B-NP	O
)	)	)000	)	O	O
emergently	emergently	e506205340	RB	B-ADVP	O
between	between	b0305	IN	B-PP	O
1999	1999	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2004	2004	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
36	36	0000	CD	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
sex	sex	s020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
matched	match	m03203	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
emergent	emergent	e5062053	JJ	B-NP	O
LT	LT	l300	NN	I-NP	O
for	for	f060	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
35	35	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
elective	elective	e4023010	JJ	B-NP	O
LT	LT	l300	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
CLD	CLD	c430	NN	B-NP	B-Disease
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
34	34	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Acetaminophen	Acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
LT	LT	l300	NN	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
LT	LT	l300	NN	I-NP	O
illness	illness	i4502	NN	I-NP	O
reflected	reflect	r01402303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
Acute	Acute	a2030	NNP	I-NP	O
Physiology	Physiology	p0204020	NNP	I-NP	O
and	and	a530	CC	O	O
Chronic	Chronic	c060502	NNP	B-NP	O
Health	Health	h0430	NNP	I-NP	O
Evaluation	Evaluation	e1040305	NN	I-NP	O
II	II	i000	CD	B-NP	O
scores	score	s20602	NNS	I-NP	O
and	and	a530	CC	O	O
requirement	requirement	r020605053	NN	B-NP	O
for	for	f060	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
support	support	s01063	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
(	(	(000	(	O	O
56	56	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
formal	formal	f06504	JJ	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
before	before	b01060	IN	B-PP	O
LT	LT	l300	NN	B-NP	O
(	(	(000	(	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
35	35	0000	CD	I-NP	O
,	,	,000	,	O	O
CLD	CLD	c430	NN	B-NP	B-Disease
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	O	O
34	34	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
nine	nine	n050	CD	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
suicide	suicide	s02030	NN	I-NP	O
attempt	attempt	a30513	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rejection	rejection	r0202305	NN	B-NP	O
(	(	(000	(	O	O
acute	acute	a2030	JJ	B-ADJP	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-ADJP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
graft	graft	g6013	NN	B-NP	O
failure	failure	f04060	NN	I-NP	O
or	or	o600	CC	I-NP	O
survival	survival	s0610104	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
1	1	1000	CD	I-NP	O
year	year	y060	NN	I-NP	O
87	87	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
88	88	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
78	78	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
CLD	CLD	c430	NN	B-NP	B-Disease
93	93	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
82	82	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
:	:	:000	:	O	O
P	P	p000	NN	B-NP	O
>	>	>000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
log	log	l020	NN	I-NP	O
rank	rank	r052	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
reattempted	reattempte	r03051303	VBD	B-VP	O
suicide	suicide	s02030	NN	B-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
LT	LT	l300	NN	B-NP	O
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
died	die	d030	VBD	B-VP	O
8	8	8000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
LT	LT	l300	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Despite	Despite	d021030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	O
disturbance	disturbance	d0230610520	NN	I-NP	O
,	,	,000	,	O	O
outcomes	outcome	o0320502	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
transplanted	transplant	t60521405303	VBN	B-VP	O
emergently	emergently	e506205340	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
transplanted	transplant	t60521405303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
and	and	a530	CC	O	O
electively	electively	e402301040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
CLD	CLD	c430	NN	B-NP	B-Disease
.	.	.000	.	O	O

Multidisciplinary	Multidisciplinary	m043030201405060	JJ	B-NP	O
approaches	approach	a160202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
psychiatric	psychiatric	p20203602	JJ	B-ADJP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
low	low	l000	JJ	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
suicide	suicide	s02030	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
seen	see	s050	VBN	B-VP	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
graft	graft	g6013	NN	B-NP	O
loss	loss	l020	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
compliance	compliance	c05140520	NN	I-NP	O
.	.	.000	.	O	O

Antithrombotic	Antithrombotic	a5303060510302	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
microbleeds	microbleed	m026014032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
published	publish	p0140203	VBN	B-NP	O
and	and	a530	CC	I-NP	O
unpublished	unpublished	u510140203	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
PURPOSE	PURPOSE	p061020	NN	I-NP	O
:	:	:000	:	O	O
Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
microbleeds	microbleed	m026014032	NNS	I-NP	I-Disease
(	(	(000	(	O	O
MB	MB	m100	NN	B-NP	B-Disease
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
potential	potential	p0305304	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ICH	ICH	i200	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
if	if	i100	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
contraindication	contraindication	c0536053020305	NN	I-NP	O
to	to	t000	TO	B-PP	O
using	use	u2052	VBG	B-VP	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Insights	Insight	i5202032	NNS	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
gained	gain	g0503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pooling	pool	p04052	VBG	B-VP	O
data	datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
stratified	stratify	s36030103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
cohorts	cohort	c0632	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
and	and	a530	CC	O	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
(	(	(000	(	O	O
IS	IS	i200	NN	B-NP	B-Disease
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
transient	transient	t6052053	JJ	I-NP	B-Disease
ischemic	ischemic	i20502	JJ	I-NP	I-Disease
attack	attack	a302	NN	I-NP	I-Disease
(	(	(000	(	O	O
TIA	TIA	t000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
published	publish	p0140203	VBN	B-NP	O
and	and	a530	CC	I-NP	O
unpublished	unpublished	u510140203	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
cohorts	cohort	c0632	NNS	B-NP	O
with	with	w030	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
TIA	TIA	t000	NN	I-NP	B-Disease
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
vs	vs	v200	IN	B-PP	O
nonantithrombotic	nonantithrombotic	n0505303060510302	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
vs	vs	v200	IN	B-PP	O
nonusers	nonuser	n0502062	NNS	B-NP	O
with	with	w030	IN	B-PP	O
IS	IS	i200	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
TIA	TIA	t000	NN	I-NP	B-Disease
;	;	;000	:	O	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
ICH	ICH	i200	NN	B-NP	B-Disease
vs	vs	v200	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
stratified	stratify	s36030103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
analyzed	analyze	a5040203	VBD	B-VP	O
published	publish	p0140203	VBN	B-VP	O
and	and	a530	CC	O	O
unpublished	unpublished	u510140203	JJ	B-VP	O
follow	follow	f040	VB	I-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
data	datum	d030	NNS	B-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pooled	pooled	p0403	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
1460	1460	0000	CD	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
and	and	a530	CC	O	O
3817	3817	0000	CD	B-NP	O
IS	IS	i200	NN	I-NP	B-Disease
/	/	/000	SYM	O	O
TIA	TIA	t000	NN	B-NP	B-Disease
,	,	,000	,	O	O
MB	MB	m100	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
vs	vs	v200	IN	B-PP	O
IS	IS	i200	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
TIA	TIA	t000	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
excess	excess	e202	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
nonantithrombotic	nonantithrombotic	n0505303060510302	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
antiplatelet	antiplatelet	a53014030403	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
17	17	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
difference	difference	d01060520	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
an	an	a500	DT	B-NP	O
excess	excess	e202	NN	I-NP	O
of	of	o100	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
vs	vs	v200	IN	B-PP	O
nonusers	nonuser	n0502062	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
-	-	-000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
none	none	n050	NN	B-NP	O
in	in	i500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
IS	IS	i200	NN	B-NP	B-Disease
/	/	/000	SYM	O	O
TIA	TIA	t000	NN	B-NP	B-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
33	33	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
difference	difference	d01060520	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
smaller	small	s50406	JJR	I-NP	O
excess	excess	e202	NN	I-NP	O
of	of	o100	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
antiplatelet	antiplatelet	a53014030403	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
vs	vs	v200	IN	B-PP	O
nonusers	nonuser	n0502062	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
findings	finding	f053052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
antiplatelet	antiplatelet	a53014030403	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
IS	IS	i200	NN	B-NP	B-Disease
/	/	/000	SYM	O	O
TIA	TIA	t000	NN	B-NP	B-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
difference	difference	d01060520	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
pooled	pool	p0403	VBN	B-VP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
data	datum	d030	NNS	B-NP	O
for	for	f060	IN	B-PP	O
768	768	0000	CD	B-NP	O
antithrombotic	antithrombotic	a5303060510302	JJ	I-NP	O
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
substantially	substantially	s0123053040	RB	I-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
-	-	-000	:	O	O
42	42	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
excess	excess	e202	NN	I-NP	O
of	of	o100	IN	B-PP	O
MB	MB	m100	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
MB	MB	m100	NN	B-NP	B-Disease
increase	increase	i526020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
.	.	.000	.	O	O

Limited	Limit	l050303	VBN	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
corroborate	corroborate	c060106030	VBP	B-VP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
larger	large	l06206	JJR	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
urgently	urgently	u6205340	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
synergy	synergy	s050620	NN	B-NP	O
between	between	b0305	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neuropathic	neuropathic	n06010302	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
determined	determine	d030650503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
with	with	w030	IN	B-PP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
given	give	g0105	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
combinations	combination	c0510503052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neuropathic	neuropathic	n06010302	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Dose	Dose	d020	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
curves	curve	c06102	NNS	I-NP	O
for	for	f060	IN	B-PP	O
nonsedating	nonsedating	n0520303052	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
CNSB002	CNSB002	0000	NN	I-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
alone	alone	a4050	RB	I-ADVP	O
and	and	a530	CC	I-ADVP	O
together	together	t020306	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
combinations	combination	c0510503052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
constructed	construct	c0523602303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
paw	paw	p000	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
from	from	f605	IN	B-PP	O
noxious	noxious	n0202	JJ	B-NP	O
heat	heat	h030	NN	I-NP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
rat	rat	r030	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
:	:	:000	:	O	O
carrageenan	carrageenan	c06020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
paw	paw	p000	NN	I-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
and	and	a530	CC	O	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
nonsedating	nonsedating	n0520303052	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
CNSB002	CNSB002	0000	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
calculated	calculate	c042040303	VBN	B-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
(	(	(000	(	O	O
ED50	ED50	0000	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
54	54	0000	CD	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
81	81	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
83	83	0000	CD	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
54	54	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
carrageenan	carrageenan	c06020505	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
and	and	a530	CC	O	O
44	44	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
18	18	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
37	37	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
14	14	0000	CD	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
24	24	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
;	;	;000	:	O	O
mean	mean	m050	NN	B-NP	O
,	,	,000	,	I-NP	O
SEM	SEM	s050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
nonsedating	nonsedating	n0520303052	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ED50	ED50	0000	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
for	for	f060	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
nonsedating	nonsedating	n0520303052	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
56	56	0000	CD	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
55	55	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
carrageenan	carrageenan	c06020505	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
37	37	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
23	23	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
(	(	(000	(	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
;	;	;000	:	O	O
mean	mean	m050	NN	B-NP	O
,	,	,000	,	I-NP	O
SEM	SEM	s050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antinociception	antinociception	a5305020201305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
co	co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
with	with	w030	IN	B-PP	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
28	28	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
31	31	0000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
114	114	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
56	56	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
neuropathic	neuropathic	n06010302	JJ	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
;	;	;000	:	O	O
one	one	o500	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
variance	variance	v060520	NN	B-NP	O
-	-	-000	HYPH	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
either	either	e0306	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
achievable	achievable	a2010140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
nonsedating	nonsedating	n0520303052	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
CNSB002	CNSB002	0000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
practical	practical	p60230204	JJ	I-NP	O
review	review	r010	NN	I-NP	O
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
remains	remain	r05052	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
recognized	recognize	r020250203	VBN	B-VP	O
despite	despite	d021030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
devastating	devastate	d0102303052	VBG	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
begins	begin	b02052	VBZ	B-VP	O
when	when	w050	WRB	B-ADVP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
stimulates	stimulate	s305040302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
4	4	4000	CD	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
in	in	i500	IN	B-PP	O
turn	turn	t065	NN	B-NP	O
triggers	trigger	t602062	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
procoagulant	procoagulant	p6020204053	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
particles	particle	p06302402	NNS	I-NP	O
.	.	.000	.	O	O

Thrombosis	Thrombosis	t060510202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
follow	follow	f040	VBP	B-VP	O
comprise	comprise	c0516020	VB	I-VP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
hallmark	hallmark	h045062	NN	I-NP	O
traits	trait	t6032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
former	former	f06506	JJ	I-NP	O
largely	largely	l062040	RB	B-ADJP	O
responsible	responsible	r0210520140	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
varies	vary	v0602	VBZ	B-VP	O
among	among	a5052	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
subgroups	subgroup	s0126012	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
in	in	i500	IN	B-PP	O
surgical	surgical	s0620204	JJ	B-NP	O
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
populations	population	p010403052	NNS	I-NP	O
.	.	.000	.	O	O

HIT	HIT	h030	NN	B-NP	B-Disease
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
acknowledged	acknowledge	a250403203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
intense	intense	i530520	JJ	I-NP	O
predilection	predilection	p6030402305	NN	I-NP	O
for	for	f060	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
suspected	suspect	s02102303	VBN	B-VP	O
whenever	whenever	w050106	WRB	B-ADVP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
after	after	a1306	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	JJ	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
incorporates	incorporate	i52061060302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
serologic	serologic	s06040202	JJ	I-NP	O
clues	clue	c402	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
paramount	paramount	p0605053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
timely	timely	t05040	JJ	B-NP	O
institution	institution	i523030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
its	its	i320	PRP$	B-NP	O
delay	delay	d040	NN	I-NP	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
catastrophic	catastrophic	c0302360102	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
mandates	mandate	m0530302	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
cessation	cessation	c020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
institution	institution	i523030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
antithrombotic	antithrombotic	a5303060510302	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
most	most	m023	RBS	B-ADVP	O
commonly	commonly	c050540	RB	I-ADVP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	B-Chemical
thrombin	thrombin	t0605105	NN	I-NP	I-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Current	Current	c06053	JJ	B-NP	O
"	"	"000	``	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
"	"	"000	''	I-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
primarily	primarily	p60506040	RB	B-ADVP	O
include	include	i524030	VBP	B-VP	O
functional	functional	f05230504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
antigenic	antigenic	a53020502	JJ	I-NP	O
assays	assay	a202	NNS	I-NP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
more	more	m060	JJR	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
confirmatory	confirmatory	c05106503060	JJ	I-NP	O
than	than	t050	IN	B-PP	O
diagnostic	diagnostic	d02502302	JJ	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Special	Special	s10204	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
paid	pay	p030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	I-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
heparin	heparin	h010605	VB	I-VP	B-Chemical
multiple	multiple	m0430140	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Direct	Direct	d06023	JJ	B-NP	B-Chemical
thrombin	thrombin	t0605105	NN	I-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
appropriate	appropriate	a16016030	JJ	B-ADJP	O
,	,	,000	,	O	O
evidence	evidence	e1030520	NN	B-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-VP	O
alternatives	alternative	a43065030102	NNS	B-NP	O
to	to	t000	TO	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
undergo	undergo	u530620	VB	I-VP	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequently	frequently	f60205340	RB	I-NP	O
used	use	u203	VBN	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
today	today	t030	NN	B-NP	O
with	with	w030	IN	B-PP	O
potential	potential	p0305304	NN	B-NP	O
for	for	f060	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
every	every	e1060	DT	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
vigilance	vigilance	v02040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
counts	count	c0532	NNS	I-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
practiced	practice	p60230203	VBN	I-VP	O
whenever	whenever	w050106	WRB	B-ADVP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
.	.	.000	.	O	O

Abductor	Abductor	a1302306	NN	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
botox	botox	b0302	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
for	for	f060	IN	B-PP	O
adductor	adductor	a302306	NN	B-NP	B-Disease
spasmodic	spasmodic	s10250302	JJ	I-NP	I-Disease
dysphonia	dysphonia	d021050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NN	B-NP	O
/	/	/000	SYM	I-NP	O
HYPOTHESIS	HYPOTHESIS	h01030202	NN	I-NP	O
:	:	:000	SYM	O	O
Botulinum	Botulinum	b03040505	NN	B-NP	O
toxin	toxin	t0205	NN	I-NP	O
(	(	(000	(	O	O
Botox	Botox	b0302	NN	B-NP	B-Chemical
)	)	)000	)	O	O
injections	injection	i52023052	NNS	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
thyroarytenoid	thyroarytenoid	t0606030503	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
standard	standard	s3053063	NN	I-NP	O
of	of	o100	IN	B-PP	O
care	care	c060	NN	B-NP	O
for	for	f060	IN	B-PP	O
adductor	adductor	a302306	NN	B-NP	B-Disease
spasmodic	spasmodic	s10250302	JJ	I-NP	I-Disease
dysphonia	dysphonia	d021050	NN	I-NP	I-Disease
(	(	(000	(	O	O
ADSD	ADSD	a323	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Reported	Report	r0106303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
breathiness	breathiness	b6030502	NN	B-NP	O
,	,	,000	,	O	O
throat	throat	t0603	DT	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
difficulty	difficulty	d01020430	NN	B-NP	O
with	with	w030	IN	B-PP	O
swallowing	swallow	s04052	VBG	B-NP	O
liquids	liquid	l02032	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
abductor	abductor	a1302306	NN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
Botox	Botox	b0302	NN	B-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
ADSD	ADSD	a323	NN	B-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
previously	previously	p6010240	RB	B-ADJP	O
unreported	unreported	u560106303	JJ	I-ADJP	O
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
:	:	:000	:	O	O
Retrospective	Retrospective	r036021023010	JJ	B-NP	O
case	case	c020	NN	I-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
Botox	Botox	b0302	NN	B-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
spasmodic	spasmodic	s10250302	JJ	B-NP	B-Disease
dysphonia	dysphonia	d021050	NN	I-NP	I-Disease
between	between	b0305	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
2000	2000	0000	CD	I-NP	O
and	and	a530	CC	O	O
October	October	o230106	NNP	B-NP	O
2009	2009	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ADSD	ADSD	a323	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatments	treatment	t60350532	NNS	B-NP	O
received	receive	r020103	VBN	B-VP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
abductor	abductor	a1302306	NN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
paralytic	paralytic	p06040302	JJ	B-NP	O
Botox	Botox	b0302	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
prior	prior	p606	JJ	B-NP	O
Botox	Botox	b0302	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
course	course	c0620	NN	B-NP	O
following	follow	f04052	VBG	B-PP	O
paralysis	paralysis	p06040202	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
From	From	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
database	database	d0301020	NN	I-NP	O
of	of	o100	IN	B-PP	O
452	452	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
Botox	Botox	b0302	NN	B-NP	B-Chemical
,	,	,000	,	O	O
352	352	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ADSD	ADSD	a323	NN	B-NP	B-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
352	352	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffered	suffer	s010603	VBD	B-VP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
abductor	abductor	a1302306	NN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
affected	affect	a102303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
females	female	f050402	NNS	B-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
treatments	treatment	t60350532	NNS	B-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
abductor	abductor	a1302306	NN	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
continued	continue	c0530503	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
after	after	a1306	IN	B-PP	O
paralysis	paralysis	p06040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
restrictions	restriction	r0236023052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
tracheotomy	tracheotomy	t60203050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
abductor	abductor	a1302306	NN	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
Botox	Botox	b0302	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
for	for	f060	IN	B-PP	O
ADSD	ADSD	a323	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
34	34	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Bilateral	Bilateral	b04030604	JJ	B-NP	O
abductor	abductor	a1302306	NN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Botox	Botox	b0302	NN	B-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
ADSD	ADSD	a323	NN	B-NP	B-Disease
,	,	,000	,	O	O
causing	cause	c02052	VBG	B-VP	O
difficulty	difficulty	d01020430	NN	B-NP	O
with	with	w030	IN	B-PP	O
breathing	breathing	b603052	NN	B-NP	O
upon	upon	u105	IN	B-PP	O
exertion	exertion	e206305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
likely	likely	l02040	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
paralysis	paralysis	p06040202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
diffusion	diffusion	d010205	NN	B-NP	O
of	of	o100	IN	B-PP	O
Botox	Botox	b0302	NNP	B-NP	B-Chemical
around	around	a6053	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscular	muscular	m020406	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arytenoid	arytenoid	a6030503	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
cricoarytenoid	cricoarytenoid	c60206030503	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
temporary	temporary	t05106060	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
watchful	watchful	w0320104	JJ	B-NP	O
waiting	waiting	w03052	NN	I-NP	O
with	with	w030	IN	B-PP	O
restriction	restriction	r023602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
:	:	:000	:	O	O
Prevention	Prevention	p60105305	NN	B-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
targeted	target	t0620303	VBN	I-NP	O
antioxidant	antioxidant	a530203053	NN	I-NP	O
MitoQ	MitoQ	m0302	NNP	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
ROS	ROS	r020	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
altered	altered	a430603	JJ	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
that	that	t030	IN	B-NP	O
in	in	i500	IN	B-PP	O
turn	turn	t065	NN	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
left	left	l013	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
detected	detect	d0302303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
fibers	fiber	f01062	NNS	I-NP	O
,	,	,000	,	O	O
specifically	specifically	s1020102040	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
complex	complex	c051402	NN	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	O	O
complex	complex	c051402	NN	B-NP	O
III	III	i000	CD	I-NP	O
.	.	.000	.	O	O

ROS	ROS	r020	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
specifically	specifically	s1020102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
interfibrillar	interfibrillar	i530610160406	JJ	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
parallel	parallel	p060404	NN	B-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
ATP	ATP	a310	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
subsarcolemmal	subsarcolemmal	s012062040504	JJ	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
uncoupling	uncoupling	u52014052	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
phosphorylation	phosphorylation	p02106040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
detectable	detectable	d030230140	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
a	a	a000	DT	O	O
late	late	l030	JJ	O	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

MitoQ	MitoQ	m0302	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
targeted	target	t0620303	VBN	I-NP	O
antioxidant	antioxidant	a530203053	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
completely	completely	c051403040	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
these	these	t020	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
studied	study	s30303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
conductance	conductance	c0530230520	NN	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
to	to	t000	TO	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
pressure	pressure	p602060	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
volume	volume	v04050	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

Taken	Take	t0205	VBN	B-VP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
extend	extend	e23053	VBP	B-VP	O
previous	previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
and	and	a530	CC	O	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
defect	defect	d01023	NN	I-NP	I-Disease
.	.	.000	.	O	O

Trimethoprim	Trimethoprim	t6050301605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
oncology	oncology	o5204020	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
presenting	present	p602053052	VBG	B-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
red	red	r030	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hemoglobinuria	hemoglobinuria	h050240105060	NN	B-NP	B-Disease
.	.	.000	.	O	O

Transfusion	Transfusion	t605210205	NN	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
workup	workup	w06201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
positive	positive	p0203010	JJ	B-NP	O
direct	direct	d06023	JJ	I-NP	O
antiglobulin	antiglobulin	a53024010405	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
negative	negative	n0203010	JJ	B-NP	O
eluate	eluate	e4030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
microspherocytes	microspherocyte	m02602106020302	NNS	B-NP	O
on	on	o500	IN	B-PP	O
smear	smear	s506	NN	B-NP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
indirect	indirect	i5306023	JJ	I-NP	O
antiglobulin	antiglobulin	a53024010405	NN	I-NP	O
test	test	t023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
strongly	strongly	s3605240	RB	B-ADJP	O
positive	positive	p0203010	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
trimethoprim	trimethoprim	t6050301605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
trimethoprim	trimethoprim	t6050301605	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
sulfamethoxazole	sulfamethoxazole	s04105030202040	NN	B-NP	I-Chemical
but	but	b030	CC	O	O
negative	negative	n0203010	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
sulfamethoxazole	sulfamethoxazole	s04105030202040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
worse	worse	w0620	JJR	B-NP	O
-	-	-000	HYPH	I-NP	O
than	than	t050	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
expected	expect	e2102303	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
transfusion	transfusion	t605210205	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
always	always	a402	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
stimulation	stimulation	s305040305	NN	I-NP	O
test	test	t023	NN	I-NP	O
in	in	i500	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
:	:	:000	:	O	O
loss	loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
anatomic	anatomic	a5030502	JJ	B-NP	O
or	or	o600	CC	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
stalk	stalk	s3042	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
stimulation	stimulation	s305040305	NN	I-NP	O
test	test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
tool	tool	t040	NN	I-NP	O
for	for	f060	IN	B-PP	O
differential	differential	d010605304	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
with	with	w030	IN	B-PP	O
conflicting	conflict	c0514023052	VBG	B-VP	O
results	result	r020432	NNS	B-NP	O
.	.	.000	.	O	O

Macroprolactinemia	Macroprolactinemia	m0260160402305050	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
never	never	n0106	RB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
re	re	r000	VB	I-VP	O
-	-	-000	HYPH	O	O
investigate	investigate	i5102302030	VB	B-VP	O
the	the	t000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
all	all	a400	DT	O	O
screened	screen	s260503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
macroprolactinemia	macroprolactinemia	m0260160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Prolactin	Prolactin	p60402305	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-VP	O
verapamil	verapamil	v06010504	VB	I-VP	B-Chemical
in	in	i500	IN	B-PP	O
65	65	0000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
age	age	a200	NN	B-NP	O
:	:	:000	:	O	O
29	29	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
descriptive	descriptive	d026013010	JJ	I-NP	O
,	,	,000	,	I-NP	O
matched	match	m03203	VBN	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
80	80	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	O	O
PRL	PRL	p640	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
8th	8th	8300	JJ	B-NP	O
and	and	a530	CC	I-NP	O
16th	16th	0000	JJ	I-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
immunometric	immunometric	i5050503602	JJ	B-NP	O
chemiluminescence	chemiluminescence	c05040505020520	NN	I-NP	O
.	.	.000	.	O	O

Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
responsiveness	responsiveness	r021052010502	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
percent	percent	p062053	NN	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
basal	basal	b0204	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
(	(	(000	(	O	O
PRL	PRL	p640	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
PRL	PRL	p640	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
:	:	:000	:	O	O
183	183	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
macroprolactinoma	macroprolactinoma	m0260160402305050	NN	B-NP	B-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
:	:	:000	:	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
microprolactinoma	microprolactinoma	m0260160402305050	NN	B-NP	B-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
:	:	:000	:	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
macroprolactinemia	macroprolactinemia	m0260160402305050	NN	B-NP	B-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O
23	23	0000	CD	B-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
:	:	:000	:	O	O
126	126	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
pseudoprolactinoma	pseudoprolactinoma	p2030160402305050	NN	B-NP	B-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
:	:	:000	:	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

ROC	ROC	r020	NN	B-NP	O
curve	curve	c0610	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
unresponsiveness	unresponsiveness	u56021052010502	NN	B-NP	O
to	to	t000	TO	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
PRL	PRL	p640	NN	B-NP	O
<	<	<000	SYM	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
discriminated	discriminate	d02605050303	VBN	B-VP	O
anatomical	anatomical	a503050204	JJ	B-NP	O
or	or	o600	CC	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
stalk	stalk	s3042	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
(	(	(000	(	O	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
:	:	:000	:	O	O
74	74	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
specificity	specificity	s1020102030	NN	B-NP	O
:	:	:000	:	O	O
73	73	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
AUC	AUC	a020	NN	B-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
855	855	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
,	,	,000	,	O	O
CI	CI	c000	NNP	B-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
768	768	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
942	942	0000	CD	I-NP	O
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pseudoprolactinoma	pseudoprolactinoma	p2030160402305050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
responsiveness	responsiveness	r021052010502	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
reliable	reliable	r040140	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
unresponsiveness	unresponsiveness	u56021052010502	NN	I-NP	O
discriminates	discriminate	d02605050302	VBZ	B-VP	O
stalk	stalk	s3042	NN	B-NP	O
effect	effect	e1023	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
anatomically	anatomically	a5030502040	RB	B-ADVP	O
or	or	o600	CC	I-ADVP	O
functionally	functionally	f052305040	RB	I-VP	O
inhibited	inhibit	i5010303	VBD	I-VP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
tonus	tonus	t0502	NN	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
other	other	o306	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
varying	vary	v06052	VBG	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
responsiveness	responsiveness	r021052010502	NN	B-NP	O
.	.	.000	.	O	O

Blockade	Blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
mesenchymal	mesenchymal	m020520504	JJ	I-NP	O
transition	transition	t60520305	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
Smad3	Smad3	0000	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
delays	delay	d0402	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
early	early	e0640	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
type	type	t010	NN	B-NP	B-Disease
1	1	1000	CD	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
normoalbuminuria	normoalbuminuria	n0650410505060	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
retard	retard	r03063	VB	I-VP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
other	other	o306	JJ	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
(	(	(000	(	O	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
previously	previously	p6010240	RB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
endothelial	endothelial	e53030404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
mesenchymal	mesenchymal	m020520504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
transition	transition	t60520305	NN	I-NP	O
(	(	(000	(	O	O
EndoMT	EndoMT	e53053	NN	B-NP	O
)	)	)000	)	O	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
independently	independently	i530105305340	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
microalbuminuria	microalbuminuria	m0260410505060	NN	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabete	d010302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
blocking	block	b402052	VBG	B-VP	O
EndoMT	EndoMT	e53053	NNP	B-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESEARCH	RESEARCH	r020620	NN	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
EndoMT	EndoMT	e53053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
pancreatic	pancreatic	p05260302	JJ	I-NP	O
microvascular	microvascular	m02601020406	JJ	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
line	line	l050	NN	I-NP	O
(	(	(000	(	O	O
MMEC	MMEC	m502	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
glycation	glycation	g4020305	NN	I-NP	O
end	end	e530	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
(	(	(000	(	O	O
AGEs	AGE	a202	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
lineage	lineage	l05020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
traceble	traceble	t6020140	JJ	I-NP	O
mouse	mouse	m020	NN	I-NP	O
line	line	l050	NN	I-NP	O
Tie2	Tie2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
Cre	Cre	c600	NN	I-NP	O
;	;	;000	:	O	O
Loxp	Loxp	l021	NN	B-NP	O
-	-	-000	HYPH	O	O
EGFP	EGFP	e210	NN	B-NP	O
by	by	b000	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
AGEs	AGE	a202	NNS	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
nonglycated	nonglycated	n0524020303	JJ	B-NP	O
mouse	mouse	m020	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
serving	serve	s061052	VBG	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Phosphorylated	Phosphorylate	p02106040303	VBN	B-NP	O
Smad3	Smad3	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
immunoprecipitation	immunoprecipitation	i5050160201030305	NN	B-NP	O
/	/	/000	SYM	O	O
Western	Western	w023065	NN	B-NP	O
blotting	blotting	b403052	NN	I-NP	O
and	and	a530	CC	O	O
confocal	confocal	c0510204	JJ	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

Blocking	Blocking	b402052	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
receptor	receptor	r0201306	NN	B-NP	O
for	for	f060	IN	B-PP	O
AGE	AGE	a200	NN	B-NP	O
siRNA	siRNA	s0650	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
Smad3	Smad3	0000	NN	B-NP	O
(	(	(000	(	O	O
SIS3	SIS3	0000	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
MMECs	MMEC	m502	NNS	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Tie2	Tie2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
Cre	Cre	c600	NN	I-NP	O
;	;	;000	:	O	O
Loxp	Loxp	l021	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
EGFP	EGFP	e210	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Confocal	Confocal	c0510204	JJ	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
and	and	a530	CC	O	O
real	real	r040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
PCR	PCR	p260	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
AGEs	AGE	a202	NNS	B-NP	O
induced	induce	i530203	VBD	B-VP	O
EndoMT	EndoMT	e53053	NN	B-NP	O
in	in	i500	IN	B-PP	O
MMECs	MMEC	m502	NNS	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
Tie2	Tie2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
Cre	Cre	c600	NN	I-NP	O
;	;	;000	:	O	O
Loxp	Loxp	l021	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
EGFP	EGFP	e210	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Immunoprecipitation	Immunoprecipitation	i5050160201030305	NN	B-NP	O
/	/	/000	SYM	I-NP	O
Western	Western	w023065	NN	I-NP	O
blotting	blotting	b403052	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
Smad3	Smad3	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
activated	activate	a23010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
AGEs	AGE	a202	NNS	B-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
SIS3	SIS3	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
MMECs	MMEC	m502	NNS	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Confocal	Confocal	c0510204	JJ	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
and	and	a530	CC	O	O
real	real	r040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
PCR	PCR	p260	NN	I-NP	O
further	further	f06306	RBR	B-ADVP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
SIS3	SIS3	0000	NN	B-NP	O
abrogated	abrogate	a16020303	VBD	B-VP	O
EndoMT	EndoMT	e53053	NNP	B-NP	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
retarded	retard	r0306303	VBN	B-VP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
EndoMT	EndoMT	e53053	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
early	early	e0640	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Blockade	Blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
EndoMT	EndoMT	e53053	NN	B-NP	O
by	by	b000	IN	B-PP	O
SIS3	SIS3	0000	NN	B-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
to	to	t000	TO	B-VP	O
retard	retard	r03063	VB	I-VP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Cytostatic	Cytostatic	c030230302	JJ	B-ADJP	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	O	O
angiogenic	angiogenic	a52020502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
mantle	mantle	m05340	NN	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Mantle	Mantle	m05340	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MCL	MCL	m240	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
B	B	b000	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
non	non	n050	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
Hodgkin	Hodgkin	h03205	NN	I-NP	I-Disease
'	'	'000	''	I-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
become	become	b02050	VBP	B-VP	O
progressively	progressively	p60260201040	RB	B-ADJP	O
refractory	refractory	r016023060	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
poor	poor	p060	JJ	B-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
38	38	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
remission	remission	r050205	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
recently	recently	r0205340	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
MCL	MCL	m240	NN	I-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
mTOR	mTOR	m306	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O
Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
opportunity	opportunity	o106305030	NN	I-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
MCL	MCL	m240	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
regression	regression	r0260205	NN	I-NP	O
two	two	t000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
lymph	lymph	l0510	NN	B-NP	O
node	node	n030	NN	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
arrest	arrest	a6023	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
any	any	a500	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Apart	Apart	a1063	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
cytostatic	cytostatic	c030230302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
antiangiogenic	antiangiogenic	a53052020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
with	with	w030	IN	B-PP	O
decrease	decrease	d026020	NN	B-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
microvessel	microvessel	m026010204	NN	I-NP	O
density	density	d052030	NN	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
VEGF	VEGF	v021	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
numerous	numerous	n050602	JJ	B-NP	O
patchy	patchy	p0320	NN	I-NP	O
,	,	,000	,	O	O
well	well	w040	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
limited	limited	l050303	JJ	I-NP	O
fibrotic	fibrotic	f0160302	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
,	,	,000	,	O	O
compatible	compatible	c051030140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
necrotic	necrotic	n0260302	JJ	I-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
repair	repair	r0106	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
temsirolimus	temsirolimus	t05206040502	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
burden	burden	b06305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
cytostatic	cytostatic	c030230302	JJ	I-NP	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
angiogenic	angiogenic	a52020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O
This	This	t020	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
temsirolimus	temsirolimus	t05206040502	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
could	could	c043	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
recently	recently	r0205340	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
efficiency	efficiency	e1020520	NN	I-NP	O
in	in	i500	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
MCL	MCL	m240	NN	I-NP	B-Disease
resistant	resistant	r02023053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
23	23	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
bacteriologically	bacteriologically	b02306040202040	RB	B-NP	O
proven	prove	p60105	VBN	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
tuberculosis	tuberculosis	t01062040202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
various	various	v0602	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antituberculosis	antituberculosis	a530301062040202	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
15	15	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Rifampicin	Rifampicin	r010510205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
thrice	thrice	t06020	NN	B-NP	O
as	as	a200	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
drug	drug	d602	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
and	and	a530	CC	O	O
each	each	e020	DT	B-NP	O
time	time	t050	NN	I-NP	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
untoward	untoward	u53063	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
like	like	l020	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
and	and	a530	CC	O	O
fever	fever	f0106	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
chills	chill	c042	NNS	B-NP	O
and	and	a530	CC	I-NP	O
rigors	rigor	r02062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
such	such	s020	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
failure	failure	f04060	NN	I-NP	O
at	at	a300	IN	B-PP	O
which	which	w020	WDT	B-NP	O
stage	stage	s3020	NN	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
made	make	m030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
full	full	f040	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

Syncope	Syncope	s052010	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
and	and	a530	CC	I-NP	O
spironolactone	spironolactone	s1060504023050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
76	76	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
bypass	bypass	b0102	IN	B-PP	O
grafting	graft	g6013052	VBG	B-VP	O
and	and	a530	CC	O	O
prior	prior	p606	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
room	room	r050	NN	I-NP	O
with	with	w030	IN	B-PP	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
consciousness	consciousness	c05202502	NN	B-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
marked	marked	m06203	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
normal	normal	n06504	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
restored	restore	r0230603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
correction	correction	c0602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
several	several	s010604	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
spiranolactone	spiranolactone	s1060504023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ramipril	ramipril	r0501604	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
ACE	ACE	a200	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
example	example	e205140	NN	I-NP	O
of	of	o100	IN	B-PP	O
electrolyte	electrolyte	e4023604030	NN	B-NP	O
imbalance	imbalance	i51040520	NN	I-NP	O
causing	cause	c02052	VBG	B-VP	O
acute	acute	a2030	JJ	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
alert	alert	a4063	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
ACE	ACE	a200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
ARB	ARB	a610	NN	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
sparing	spar	s106052	VBG	I-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
mild	mild	m043	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
.	.	.000	.	O	O

Diffuse	Diffuse	d01020	NN	B-NP	O
skeletal	skeletal	s2040304	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
alendronate	alendronate	a4053605030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Osteoporosis	Osteoporosis	o2301060202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
resorption	resorption	r02061305	NN	I-NP	O
in	in	i500	IN	B-PP	O
excess	excess	e202	NN	B-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
bisphosphonates	bisphosphonate	b021021050302	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
bone	bone	b050	NN	B-NP	O
resorption	resorption	r02061305	NN	I-NP	O
.	.	.000	.	O	O

Alendronate	Alendronate	a4053605030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
biphosphonate	biphosphonate	b0102105030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
few	few	f000	JJ	I-ADJP	O
and	and	a530	CC	O	O
prominently	prominently	p6050505340	RB	B-ADJP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-ADJP	O
.	.	.000	.	O	O

Musculoskeletal	Musculoskeletal	m020402040304	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
out	out	o030	RP	I-NP	O
-	-	-000	HYPH	I-NP	O
patient	patient	p03053	NN	I-NP	O
clinic	clinic	c40502	NN	I-NP	O
with	with	w030	IN	B-PP	O
diffuse	diffuse	d01020	JJ	B-NP	O
skeletal	skeletal	s2040304	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
three	three	t060	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alendronate	alendronate	a4053605030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
report	report	r01063	VB	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
bisphosphonate	bisphosphonate	b02102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
should	should	s043	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
ascribing	ascribe	a2601052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
complaint	complaint	c0514053	NN	I-NP	O
to	to	t000	TO	B-PP	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Cerebrospinal	Cerebrospinal	c060160210504	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
penetration	penetration	p050360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
daptomycin	daptomycin	d013050205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
Staphylococcus	Staphylococcus	s30104020202	FW	I-NP	O
aureus	aureus	a0602	FW	I-NP	O
meningitis	meningitis	m050520302	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
methicillin	methicillin	m03020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
sensitive	sensitive	s05203010	JJ	B-NP	O
Staphylococcus	Staphylococcus	s30104020202	FW	I-NP	O
aureus	aureus	a0602	FW	I-NP	O
(	(	(000	(	O	O
MSSA	MSSA	m200	NN	B-NP	O
)	)	)000	)	O	O
bacteremia	bacteremia	b02306050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
MSSA	MSSA	m200	NN	I-NP	O
meningitis	meningitis	m050520302	NN	I-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
daptomycin	daptomycin	d013050205	NN	I-NP	B-Chemical
assessed	assess	a20203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
and	and	a530	CC	O	O
cerebrospinal	cerebrospinal	c060160210504	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
(	(	(000	(	O	O
CSF	CSF	c210	NN	B-NP	O
)	)	)000	)	O	O
concentrations	concentration	c052053603052	NNS	B-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
with	with	w030	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
weakness	weakness	w02502	NN	I-NP	B-Disease
and	and	a530	CC	O	O
presumed	presume	p6020503	VBN	B-NP	O
health	health	h0430	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
care	care	c060	NN	I-NP	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
pneumonia	pneumonia	p505050	NN	I-NP	B-Disease
shown	show	s050	VBN	B-VP	O
on	on	o500	IN	B-PP	O
chest	chest	c023	NN	B-NP	O
radiograph	radiograph	r03026010	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
empirically	empirically	e510602040	RB	I-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
tazobactam	tazobactam	t020102305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
cultures	culture	c0430602	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
S	S	s000	NN	B-NP	O
.	.	.000	.	B-NP	O
aureus	aureus	a0602	NN	I-NP	O
susceptible	susceptible	s020130140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
oxacillin	oxacillin	o2020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Empiric	Empiric	e510602	JJ	B-NP	O
antibiotic	antibiotic	a53010302	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
narrowed	narrow	n0603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
nafcillin	nafcillin	n0120405	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
the	the	t000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
day	day	d000	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
on	on	o500	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Glasgow	Glasgow	g4020	NNP	I-NP	O
Coma	Coma	c050	NNP	I-NP	O
Score	Score	s2060	NNP	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
shown	show	s050	VBN	B-VP	O
on	on	o500	IN	B-PP	O
computed	compute	c0510303	VBN	B-NP	O
tomography	tomography	t05026010	NN	I-NP	O
scan	scan	s205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
head	head	h030	NN	I-NP	O
72	72	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
an	an	a500	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
relapsing	relapse	r04012052	VBG	I-VP	O
MSSA	MSSA	m200	NN	B-NP	O
bacteremia	bacteremia	b02306050	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
suspicion	suspicion	s0210205	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
infection	infection	i5102305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Nafcillin	Nafcillin	n0120405	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
daptomycin	daptomycin	d013050205	NN	B-NP	B-Chemical
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
meningitis	meningitis	m050520302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
until	until	u5304	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
death	death	d030	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
16	16	0000	CD	I-NP	O
.	.	.000	.	O	O

Daptomycin	Daptomycin	d013050205	NN	B-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
and	and	a530	CC	O	O
CSF	CSF	c210	NN	B-NP	O
trough	trough	t6020	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
21	21	0000	CD	B-NP	O
ug	ug	u200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
52	52	0000	CD	B-NP	O
ug	ug	u200	NN	I-NP	O
/	/	/000	SYM	O	O
mL	mL	m400	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Lumbar	Lumbar	l05106	JJ	B-NP	O
puncture	puncture	p0523060	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
inconclusive	inconclusive	i52052402010	JJ	B-ADJP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
MSSA	MSSA	m200	NN	B-NP	O
.	.	.000	.	O	O

Creatine	Creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
daptomycin	daptomycin	d013050205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reassessed	reassess	r020203	VBN	I-VP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Daptomycin	Daptomycin	d013050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
possible	possible	p020140	JJ	B-NP	O
nafcillin	nafcillin	n0120405	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
relapsing	relapse	r04012052	VBG	B-VP	O
bacteremia	bacteremia	b02306050	NN	B-NP	B-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
9	9	9000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
resultant	resultant	r02043053	JJ	B-NP	O
penetration	penetration	p050360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
,	,	,000	,	O	O
more	more	m060	RBR	B-ADJP	O
consistent	consistent	c052023053	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
inflamed	inflamed	i5140503	JJ	B-NP	O
meninges	meninge	m0505202	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
daptomycin	daptomycin	d013050205	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
for	for	f060	IN	B-PP	O
MSSA	MSSA	m200	NN	B-NP	O
bacteremia	bacteremia	b02306050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
source	source	s0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
failed	fail	f0403	VBN	I-VP	O
or	or	o600	CC	O	O
cannot	cannot	c0503	MD	B-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
standard	standard	s3053063	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
confirmed	confirm	c05106503	VBN	B-NP	O
meningitis	meningitis	m050520302	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Lindane	Lindane	l053050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
organochloride	organochloride	o6205020406030	NN	I-NP	O
pesticide	pesticide	p02302030	NN	I-NP	O
and	and	a530	CC	I-NP	O
scabicide	scabicide	s20102030	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
evokes	evoke	e10202	VBZ	B-VP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
mainly	mainly	m0540	RB	B-ADVP	O
trough	trough	t6020	IN	B-PP	O
the	the	t000	DT	B-NP	O
blockage	blockage	b402020	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
receptors	receptor	r02013062	NNS	B-NP	O
.	.	.000	.	O	O

Nitric	Nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
gaseous	gaseous	g0202	JJ	B-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
contradictor	contradictor	c05360302306	NN	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
opposite	opposite	o102030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
,	,	,000	,	O	O
precursor	precursor	p60206206	NN	B-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
syntheses	synthesis	s0530202	NNS	I-NP	O
(	(	(000	(	O	O
NOS	NOS	n020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NOS	NOS	n020	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
)	)	)000	)	O	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	NN	I-NP	O
and	and	a530	CC	I-NP	O
EEG	EEG	e020	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
albino	albino	a41050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
600	600	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
800	800	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
1000	1000	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
convulsion	convulsion	c05104205	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
and	and	a530	CC	O	O
shortened	shorten	s0630503	VBD	B-VP	O
latency	latency	l030520	NN	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
convulsion	convulsion	c05104205	NN	I-NP	B-Disease
elicited	elicit	e4020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
lindane	lindane	l053050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	NN	I-NP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
700	700	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
900	900	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
convulsion	convulsion	c05104205	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
and	and	a530	CC	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
latency	latency	l030520	NN	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
convulsion	convulsion	c05104205	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
injection	injection	i5202305	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

EEG	EEG	e020	NN	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
increase	increase	i526020	NN	B-NP	O
of	of	o100	IN	B-PP	O
number	number	n05106	NN	B-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ictal	ictal	i2304	JJ	B-NP	O
periods	period	p06032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
EEG	EEG	e020	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
l	l	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
number	number	n05106	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
conclusion	conclusion	c05240205	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
NO	NO	n000	NN	B-NP	B-Chemical
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
endogenous	endogenous	e53020502	JJ	B-NP	O
convulsant	convulsant	c051042053	NN	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
polyneuropathy	polyneuropathy	p04050601030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
motor	motor	m0306	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
thiotepa	thiotepa	t03010	NN	I-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
:	:	:000	:	O	O
description	description	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	O	O
(	(	(000	(	O	O
IT	IT	i300	JJ	B-ADJP	O
)	)	)000	)	O	O
combination	combination	c051050305	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
thiotepa	thiotepa	t03010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TSPA	TSPA	t210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
predominance	predominance	p60305050520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Neurologic	Neurologic	n06040202	JJ	B-NP	B-Disease
toxicities	toxicity	t02020302	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
IT	IT	i300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
cytosine	cytosine	c0302050	NN	I-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
IT	IT	i300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
TSPA	TSPA	t210	NN	I-NP	B-Chemical
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
three	three	t060	CD	I-NP	O
agents	agent	a20532	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
spite	spite	s1030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
TSPA	TSPA	t210	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
IT	IT	i300	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
combination	combination	c051050305	NN	I-NP	O
with	with	w030	IN	B-PP	O
MTX	MTX	m320	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ara	ara	a600	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
C	C	c000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
could	could	c043	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
severe	severe	s01060	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
unexpected	unexpected	u502102303	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
toxicology	toxicology	t020204020	NN	I-NP	O
research	research	r020620	NN	I-NP	O
on	on	o500	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
TSPA	TSPA	t210	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cromakalim	cromakalim	c605020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pinacidil	pinacidil	p05020304	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
epicardial	epicardial	e10206304	JJ	I-NP	O
and	and	a530	CC	I-NP	O
small	small	s504	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
bolus	bolus	b0402	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cromakalim	cromakalim	c605020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pinacidil	pinacidil	p05020304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
(	(	(000	(	I-NP	O
circumflex	circumflex	c062051402	NN	I-NP	O
artery	artery	a63060	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
small	small	s504	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
chronically	chronically	c060502040	RB	B-NP	O
instrumented	instrument	i52360505303	VBN	I-NP	O
conscious	conscious	c05202	JJ	I-NP	O
dogs	dog	d020	NNS	I-NP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nitroglycerin	Nitroglycerin	n036024020605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
up	up	u100	IN	B-ADVP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
selectively	selectively	s0402301040	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
circumflex	circumflex	c062051402	NN	B-NP	O
artery	artery	a63060	NN	I-NP	O
diameter	diameter	d050306	NN	I-NP	O
(	(	(000	(	O	O
CxAD	CxAD	c203	NN	B-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
affecting	affect	a1023052	VBG	B-VP	O
any	any	a500	DT	B-NP	O
other	other	o306	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
or	or	o600	CC	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
parameter	parameter	p06050306	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
cromakalim	cromakalim	c605020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pinacidil	pinacidil	p05020304	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
all	all	a400	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
and	and	a530	CC	I-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
dependently	dependently	d0105305340	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
CxAD	CxAD	c203	NN	I-NP	O
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	O	O
aortic	aortic	a06302	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Cromakalim	Cromakalim	c605020405	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
pinacidil	pinacidil	p05020304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
CxAD	CxAD	c203	NN	B-NP	O
.	.	.000	.	O	O

Vasodilation	Vasodilation	v0203040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
and	and	a530	CC	I-NP	O
small	small	s504	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cromakalim	cromakalim	c605020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pinacidil	pinacidil	p05020304	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
beta	beta	b030	NN	I-NP	B-Chemical
adrenergic	adrenergic	a360506202	JJ	I-NP	I-Chemical
and	and	a530	CC	I-NP	I-Chemical
muscarinic	muscarinic	m02060502	JJ	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	I-Chemical
blockade	blockade	b402030	NN	I-NP	I-Chemical
but	but	b030	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
circumflex	circumflex	c062051402	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
constant	constant	c0523053	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
CxAD	CxAD	c203	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cromakalim	cromakalim	c605020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
pinacidil	pinacidil	p05020304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
68	68	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
54	54	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-ADJP	O
9	9	9000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
preferentially	preferentially	p60106053040	RB	B-ADVP	O
and	and	a530	CC	O	O
flow	flow	f400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
independently	independently	i530105305340	RB	B-ADVP	O
dilates	dilate	d040302	VBZ	B-VP	O
large	large	l0620	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
,	,	,000	,	O	O
cromakalim	cromakalim	c605020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pinacidil	pinacidil	p05020304	NN	I-NP	B-Chemical
dilate	dilate	d04030	VBP	B-VP	O
both	both	b030	CC	O	O
large	large	l0620	JJ	B-NP	O
and	and	a530	CC	I-NP	O
small	small	s504	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
dependent	dependent	d01053053	JJ	B-ADJP	O
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
simultaneous	simultaneous	s050430502	JJ	I-NP	O
beta	beta	b030	NN	I-NP	O
adrenoceptors	adrenoceptor	a360502013062	NNS	I-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
demand	demand	d05053	NN	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
,	,	,000	,	O	O
direct	direct	d06023	JJ	B-NP	O
vasodilation	vasodilation	v0203040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
flow	flow	f400	NN	I-NP	O
dependency	dependency	d010530520	NN	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cromakalim	cromakalim	c605020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
pinacidil	pinacidil	p05020304	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CxAD	CxAD	c203	NN	B-NP	O
.	.	.000	.	O	O

Mefenamic	Mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
females	female	f050402	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hypothyroidism	hypothyroidism	h01030603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
mefenamic	mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
non	non	n050	AFX	B-ADVP	O
-	-	-000	HYPH	B-NP	O
oliguric	oliguric	o4020602	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
occurring	occur	o206052	VBG	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
females	female	f050402	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
maturation	maturation	m03060305	NN	B-NP	O
arrest	arrest	a6023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myeloid	myeloid	m0403	JJ	I-NP	O
series	series	s0602	NN	I-NP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
hypothyroid	hypothyroid	h01030603	JJ	B-ADJP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
clear	clear	c406	JJ	B-ADJP	O
whether	whether	w0306	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
predisposing	predispose	p60302102052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
would	would	w043	MD	B-VP	O
seem	seem	s050	VB	I-VP	O
prudent	prudent	p603053	JJ	B-ADJP	O
not	not	n030	RB	O	O
to	to	t000	TO	B-VP	O
use	use	u200	VB	I-VP	O
mefenamic	mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
hypothyroid	hypothyroid	h01030603	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
until	until	u5304	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothyroidism	hypothyroidism	h01030603025	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
corrected	correct	c0602303	VBN	I-VP	O
.	.	.000	.	O	O

Etiology	Etiology	e304020	NN	B-NP	O
of	of	o100	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Fourteen	Fourteen	f06305	CD	B-NP	O
of	of	o100	IN	B-PP	O
39	39	0000	CD	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
became	become	b02050	VBD	B-VP	O
hypercalcemic	hypercalcemic	h010620420502	JJ	B-ADJP	B-Disease
after	after	a1306	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
principal	principal	p60520104	JJ	I-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
binder	binder	b05306	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
,	,	,000	,	O	O
indirect	indirect	i5306023	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intestinal	intestinal	i530230504	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
reabsorption	reabsorption	r012061305	NN	I-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
turnover	turnover	t0650106	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
14	14	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
results	result	r020432	NNS	B-NP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
eucalcemic	eucalcemic	e020420502	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
matched	match	m03203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
length	length	l05230	NN	B-NP	O
of	of	o100	IN	B-PP	O
time	time	t050	NN	B-NP	O
on	on	o500	IN	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
etiology	etiology	e304020	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
experiencing	experience	e2106052052	VBG	B-VP	O
hypercalcemic	hypercalcemic	h010620420502	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
peak	peak	p020	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypercalcemic	hypercalcemic	h010620420502	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
before	before	b01060	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
switch	switch	s0320	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
value	value	v040	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
7	7	7000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
observation	observation	o120610305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
switch	switch	s0320	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
[	[	[000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
006	006	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
eucalcemic	eucalcemic	e020420502	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
values	value	v0402	NNS	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
[	[	[000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CaCO3	CaCO3	0000	NN	B-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
,	,	,000	,	O	O
calculated	calculate	c042040303	VBN	B-VP	O
dietary	dietary	d03060	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
circulating	circulate	c0620403052	VBG	B-VP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Physical	Physical	p020204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
index	index	i5302	NN	I-NP	O
and	and	a530	CC	O	O
predialysis	predialysis	p603040202	NN	B-NP	O
serum	serum	s0605	NN	I-NP	O
bicarbonate	bicarbonate	b0206105030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
parameters	parameter	p060503062	NNS	B-NP	O
reflecting	reflect	r014023052	VBG	B-VP	O
bone	bone	b050	NN	B-NP	O
turnover	turnover	t0650106	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Late	Late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
scleroderma	scleroderma	s2406030650	NN	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
crisis	crisis	c60202	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
prednisolone	prednisolone	p60350204050	NN	I-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Scleroderma	Scleroderma	s2406030650	NN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
crisis	crisis	c60202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SRC	SRC	s620	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SSc	SSc	s200	NN	B-NP	B-Disease
)	)	)000	)	O	O
but	but	b030	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
severe	severe	s01060	JJ	B-ADJP	O
enough	enough	e5020	RB	I-ADJP	O
to	to	t000	TO	B-VP	O
require	require	r02060	VB	I-VP	O
temporary	temporary	t05106060	JJ	B-NP	O
or	or	o600	CC	I-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Moderate	Moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
SRC	SRC	s620	NN	B-NP	B-Disease
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reports	report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
precipitated	precipitate	p60201030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SSc	SSc	s200	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
SRC	SRC	s620	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
call	call	c040	VB	I-VP	O
attention	attention	a305305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SSc	SSc	s200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Methyldopa	Methyldopa	m03043010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
presenting	presenting	p602053052	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
near	near	n060	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
syncope	syncope	s052010	NN	I-NP	B-Disease
.	.	.000	.	O	O

Methyldopa	Methyldopa	m03043010	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
generically	generically	g050602040	RB	B-ADVP	O
and	and	a530	CC	O	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
trade	trade	t6030	NN	I-NP	O
name	name	n050	NN	I-NP	O
Aldomet	Aldomet	a430503	NN	I-NP	B-Chemical
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
and	and	a530	CC	O	O
infrequently	infrequently	i5160205340	RB	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

Methyldopa	Methyldopa	m03043010	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
take	take	t020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
boy	boy	b000	NN	I-NP	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	B-Disease
department	department	d010635053	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
near	near	n060	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
syncope	syncope	s052010	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
boy	boy	b000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
methyldopa	methyldopa	m03043010	NN	I-NP	B-Chemical
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
trauma	trauma	t6050	NN	I-NP	B-Disease
admission	admission	a350205	NN	I-NP	O
seven	seven	s0105	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
grams	gram	g6052	NNS	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
Coombs	Coombs	c0512	NNP	I-NP	O
'	'	'000	POS	B-NP	O
test	test	t023	NN	I-NP	O
with	with	w030	IN	B-PP	O
polyspecific	polyspecific	p04021020102	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
human	human	h0505	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
and	and	a530	CC	I-NP	O
monospecific	monospecific	m05021020102	JJ	I-NP	O
IgG	IgG	i200	NN	I-NP	O
reagents	reagent	r020532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
warm	warm	w065	JJ	I-NP	O
reacting	react	r023052	VBG	I-NP	O
autoantibody	autoantibody	a0305301030	NN	I-NP	O
.	.	.000	.	O	O

Transfusion	Transfusion	t605210205	NN	B-NP	O
and	and	a530	CC	I-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Emergency	Emergency	e50620520	NN	B-NP	O
physicians	physician	p0202052	NNS	I-NP	O
treating	treat	t603052	VBG	B-VP	O
children	child	c043605	NNS	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
diagnose	diagnose	d025020	VB	I-VP	O
and	and	a530	CC	I-VP	O
treat	treat	t603	VB	I-VP	O
it	it	i300	PRP	B-NP	O
correctly	correctly	c0602340	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
autoimmune	autoimmune	a0305050	JJ	B-NP	O
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemias	anemia	a50502	NNS	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
provided	provide	p6010303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
and	and	a530	CC	O	O
associated	associate	a2020303	VBN	B-VP	O
factors	factor	f023062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Malaysia	Malaysia	m04020	NNP	B-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lifetime	lifetime	l0103050	NN	B-NP	O
and	and	a530	CC	O	O
current	current	c06053	JJ	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
dependence	dependence	d010530520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
conducted	conduct	c05302303	VBN	B-VP	O
concurrently	concurrently	c0520605340	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
teaching	teaching	t02052	NN	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
rehabilitation	rehabilitation	r0104030305	NN	I-NP	O
center	center	c05306	NN	I-NP	O
in	in	i500	IN	B-PP	O
Malaysia	Malaysia	m04020	NNP	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
based	base	b0203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
DSM	DSM	d250	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IV	IV	i100	CD	I-NP	O
were	be	w060	VBD	B-VP	O
interviewed	interview	i5306103	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Mini	Mini	m050	NNP	I-NP	O
International	International	i53065030504	NNP	I-NP	O
Neuropsychiatric	Neuropsychiatric	n060120203602	NNP	I-NP	O
Interview	Interview	i530610	NNP	I-NP	O
(	(	(000	(	O	O
M	M	m000	NNP	B-NP	O
.	.	.000	.	I-NP	O
I	I	i000	NNP	I-NP	O
.	.	.000	.	I-NP	O
N	N	n000	NNP	I-NP	O
.	.	.000	.	I-NP	O
I	I	i000	NNP	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
Axis	Axis	a202	NN	I-NP	O
I	I	i000	CD	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
information	information	i510650305	NN	I-NP	O
on	on	o500	IN	B-PP	O
sociodemographic	sociodemographic	s0203050260102	JJ	B-NP	O
background	background	b026053	NN	I-NP	O
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
history	history	h023060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
interview	interview	i530610	NN	B-NP	O
or	or	o600	CC	O	O
medical	medical	m030204	JJ	B-NP	O
records	record	r020632	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-NP	O
292	292	0000	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
47	47	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
having	have	h01052	VBG	I-VP	O
current	current	c06053	JJ	B-NP	O
psychotic	psychotic	p2020302	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Co	Co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
morbid	morbid	m06103	JJ	I-NP	O
major	major	m0206	JJ	I-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
18	18	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
612	612	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
19	19	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
708	708	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
13	13	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
807	807	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
194	194	0000	CD	B-NP	O
-	-	-000	:	O	O
36	36	0000	CD	B-NP	O
.	.	.000	.	O	O
706	706	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
antisocial	antisocial	a53020204	JJ	B-NP	B-Disease
personality	personality	p0620504030	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
619	619	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
702	702	0000	CD	B-NP	O
-	-	-000	:	O	O
23	23	0000	CD	B-NP	O
.	.	.000	.	O	O
759	759	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
heavy	heavy	h010	JJ	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
uses	use	u202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lifetime	lifetime	l0103050	NN	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
adjusted	adjust	a3202303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
other	other	o306	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Major	Major	m0206	JJ	B-NP	B-Disease
depressive	depressive	d01602010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
870	870	0000	CD	I-NP	O
,	,	,000	,	O	O
CI	CI	c000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
154	154	0000	CD	B-NP	O
-	-	-000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
142	142	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
antisocial	antisocial	a53020204	JJ	B-NP	B-Disease
personality	personality	p0620504030	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
299	299	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
375	375	0000	CD	B-NP	O
-	-	-000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
914	914	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
dependence	dependence	d010530520	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
co	co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
morbid	morbid	m06103	NN	I-NP	O
affective	affective	a1023010	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
antisocial	antisocial	a53020204	JJ	B-NP	B-Disease
personality	personality	p0620504030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
heavy	heavy	h010	JJ	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
dependence	dependence	d010530520	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
screened	screen	s260503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Cerebellar	Cerebellar	c06010406	JJ	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
processing	processing	p60202052	NN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
impact	impact	i51023	VBP	B-VP	O
motor	motor	m0306	NN	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
:	:	:000	:	O	O
clues	clue	c402	NNS	B-NP	O
from	from	f605	IN	B-PP	O
dyskinetic	dyskinetic	d02050302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
(	(	(000	(	O	O
M1	M1	0000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
(	(	(000	(	O	O
LIDs	LID	l032	NNS	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
severely	severely	s0106040	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recently	recently	r0205340	RB	B-ADVP	O
reported	report	r0106303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
that	that	t030	IN	B-NP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
of	of	o100	IN	B-PP	O
M1	M1	0000	NN	B-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
paired	paired	p0603	JJ	B-NP	O
associative	associative	a20203010	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
(	(	(000	(	O	O
PAS	PAS	p020	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
M1	M1	0000	NN	I-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reinstated	reinstate	r05230303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
session	session	s0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
real	real	r040	JJ	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
sham	sham	s050	NN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
only	only	o540	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasticity	plasticity	p402302030	NN	B-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
processing	processing	p60202052	NN	I-NP	O
function	function	f052305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
resurgence	resurgence	r020620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
M1	M1	0000	NN	B-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
of	of	o100	IN	B-PP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
linked	link	l05203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensorimotor	sensorimotor	s05206050306	NN	B-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
of	of	o100	IN	B-PP	O
M1	M1	0000	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
looking	look	l02052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
PAS	PAS	p020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
sessions	session	s02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
,	,	,000	,	I-NP	O
real	real	r040	JJ	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
or	or	o600	CC	I-NP	O
sham	sham	s050	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
real	real	r040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
not	not	n030	RB	I-NP	O
sham	sham	s050	NN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
antidyskinetic	antidyskinetic	a530302050302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
paralleled	parallel	p06040403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
resurgence	resurgence	r020620520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
of	of	o100	IN	B-PP	O
M1	M1	0000	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
processing	processing	p60202052	NN	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
occurring	occur	o206052	VBG	B-VP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
signals	signal	s025042	NNS	I-NP	O
reaching	reach	r02052	VBG	B-VP	O
it	it	i300	PRP	B-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
element	element	e405053	NN	I-NP	O
contributing	contribute	c05360103052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
maladaptive	maladaptive	m0403013010	JJ	I-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
plasticity	plasticity	p402302030	NN	I-NP	O
of	of	o100	IN	B-PP	O
M1	M1	0000	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
emergence	emergence	e50620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
involuntary	involuntary	i5104053060	JJ	I-NP	I-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
danazol	danazol	d050204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hereditary	hereditary	h060303060	JJ	B-NP	B-Disease
angioedema	angioedema	a5203050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
safety	safety	s01030	NN	I-NP	O
(	(	(000	(	O	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
danazol	danazol	d050204	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
established	establish	e230140203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
settings	setting	s03052	NNS	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
information	information	i510650305	NN	I-NP	O
exists	exist	e20232	VBZ	B-VP	O
as	as	a200	IN	B-SBAR	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
safety	safety	s01030	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
danazol	danazol	d050204	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
performing	perform	p061065052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
chart	chart	c063	NN	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hereditary	hereditary	h060303060	JJ	B-NP	B-Disease
angioedema	angioedema	a5203050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
danazol	danazol	d050204	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
or	or	o600	CC	O	O
longer	long	l05206	JJR	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
35	35	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
59	59	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Virtually	Virtually	v063040	RB	B-ADVP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

Menstrual	Menstrual	m0523604	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
(	(	(000	(	O	O
79	79	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
muscle	muscle	m0240	NN	B-NP	B-Disease
cramps	cramp	c60512	NNS	I-NP	I-Disease
/	/	/000	SYM	O	O
myalgias	myalgia	m04202	NNS	B-NP	B-Disease
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
transaminase	transaminase	t60520505020	NN	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
died	die	d030	VBN	I-VP	O
or	or	o600	CC	I-VP	O
suffered	suffer	s010603	VBN	I-VP	O
any	any	a500	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
directly	directly	d0602340	RB	B-ADJP	O
attributable	attributable	a3601030140	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
,	,	,000	,	O	O
danazol	danazol	d050204	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
proven	prove	p60105	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
remarkably	remarkably	r050620140	RB	B-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
and	and	a530	CC	I-NP	O
NK1	NK1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK1	NK1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Sixty	Sixty	s0230	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NNP	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
subsequently	subsequently	s0120205340	RB	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
with	with	w030	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK1	NK1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
'	'	'000	POS	B-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
Suramin	Suramin	s060505	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
GR	GR	g600	NN	B-NP	B-Chemical
82334	82334	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

Spontaneous	Spontaneous	s10530502	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Urodynamic	Urodynamic	u603050502	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
,	,	,000	,	O	O
bladder	bladder	b40306	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
volume	volume	v04050	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
,	,	,000	,	O	O
maximum	maximum	m020505	JJ	B-NP	O
voiding	voiding	v03052	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MVP	MVP	m100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
maximum	maximum	m020505	JJ	B-NP	O
cystometric	cystometric	c0230503602	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
(	(	(000	(	O	O
MCC	MCC	m200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Pathological	Pathological	p0304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Immunofluorescence	Immunofluorescence	i50501406020520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK1	NK1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
behaviors	behaviors	b01062	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
instability	instability	i5230104030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
storage	storage	s306020	NN	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
model	model	m0304	NN	B-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
intervention	intervention	i5306105305	NN	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
X	X	x000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
619	619	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
007	007	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
X	X	x000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
13	13	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
755	755	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
000	000	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MCC	MCC	m200	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
evident	evident	e103053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
model	model	m0304	NN	B-NP	O
and	and	a530	CC	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
rats	rat	r032	NNS	I-NP	O
'	'	'000	POS	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
edema	edema	e3050	NN	B-NP	B-Disease
,	,	,000	,	O	O
vasodilation	vasodilation	v0203040305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
infiltration	infiltration	i5104360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
model	model	m0304	NN	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
urothelium	urothelium	u6030405	NN	B-NP	O
and	and	a530	CC	I-NP	O
suburothelium	suburothelium	s0106030405	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
NK1	NK1	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
suburothelium	suburothelium	s0106030405	NN	B-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
in	in	i500	IN	B-PP	O
intervention	intervention	i5306105305	NN	B-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK1	NK1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
urothelium	urothelium	u6030405	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
suburothelium	suburothelium	s0106030405	NN	B-NP	O
.	.	.000	.	O	O

Perfusion	Perfusion	p0610205	NN	B-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
with	with	w030	IN	B-PP	O
P2X3	P2X3	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK1	NK1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
ameliorated	ameliorate	a504060303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Patient	Patient	p03053	NN	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
chlorhexidine	chlorhexidine	c04060203050	NN	I-NP	B-Chemical
diphosphanilate	diphosphanilate	d010210504030	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
topical	topical	t010204	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
burns	burn	b0652	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Effective	Effective	e1023010	JJ	B-NP	O
topical	topical	t010204	JJ	I-NP	O
antimicrobial	antimicrobial	a53050260104	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
decrease	decrease	d026020	VBP	B-VP	O
infection	infection	i5102305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
burn	burn	b065	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Chlorhexidine	Chlorhexidine	c04060203050	NN	B-NP	B-Chemical
phosphanilate	phosphanilate	p0210504030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CHP	CHP	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
broad	broad	b603	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
antimicrobial	antimicrobial	a53050260104	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
topical	topical	t010204	JJ	I-NP	O
burn	burn	b065	NN	I-NP	B-Disease
wound	wound	w053	NN	I-NP	O
dressing	dress	d602052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
cream	cream	c605	NN	B-NP	O
form	form	f065	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
painful	painful	p05104	JJ	B-ADJP	O
upon	upon	u105	IN	B-PP	O
application	application	a14020305	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
compared	compare	c0510603	VBD	B-VP	O
various	various	v0602	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CHP	CHP	c010	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
tolerable	tolerable	t04060140	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
retention	retention	r0305305	NN	B-NP	O
of	of	o100	IN	B-PP	O
antimicrobial	antimicrobial	a53050260104	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
burn	burn	b065	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
each	each	e020	DT	B-NP	O
with	with	w030	IN	B-PP	O
two	two	t000	CD	B-NP	O
similar	similar	s050406	JJ	I-NP	O
burns	burn	b0652	NNS	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
separately	separately	s010603040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
pairs	pair	p062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
treatments	treatment	t60350532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
successive	successive	s0202010	JJ	B-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
burn	burn	b065	NN	I-NP	B-Disease
site	site	s030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
CHP	CHP	c010	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
silver	silver	s04106	NN	I-NP	B-Chemical
sulphadiazine	sulphadiazine	s0410302050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AgSD	AgSD	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
cream	cream	c605	NN	B-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
antimicrobial	antimicrobial	a53050260104	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
frequently	frequently	f60205340	RB	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
burn	burn	b065	NN	B-NP	B-Disease
wounds	wound	w0532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
site	site	s030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
always	always	a402	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
AgSD	AgSD	a230	NN	B-NP	B-Chemical
cream	cream	c605	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
CHP	CHP	c010	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
analogue	analogue	a504020	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
CHP	CHP	c010	NN	I-NP	B-Chemical
cream	cream	c605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
closest	closest	c402023	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
AgSD	AgSD	a230	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
tolerance	tolerance	t04060520	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
differed	differ	d010603	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
AgSD	AgSD	a230	NN	B-NP	B-Chemical
or	or	o600	CC	B-PP	O
from	from	f605	IN	B-PP	O
each	each	e020	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
ease	ease	e020	NN	B-NP	O
of	of	o100	IN	B-PP	O
application	application	a14020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CHP	CHP	c010	NN	B-NP	B-Chemical
creams	cream	c6052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
satisfactory	satisfactory	s03021023060	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
AgSD	AgSD	a230	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
formulations	formulation	f0650403052	NNS	B-NP	O
at	at	a300	IN	B-PP	O
or	or	o600	CC	I-PP	O
below	below	b040	IN	I-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
CHP	CHP	c010	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
prove	prove	p6010	VB	I-VP	O
acceptable	acceptable	a20130140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
wound	wound	w053	NN	B-NP	O
care	care	c060	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
system	system	s02305	NN	I-NP	O
needs	need	n032	VBZ	B-VP	O
pharmaceutical	pharmaceutical	p06502030204	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
to	to	t000	TO	B-VP	O
render	render	r05306	VB	I-VP	O
it	it	i300	PRP	B-NP	O
more	more	m060	RBR	B-ADJP	O
tolerable	tolerable	t04060140	JJ	I-ADJP	O
and	and	a530	CC	O	O
easier	easy	e0206	JJR	B-ADJP	O
to	to	t000	TO	B-VP	O
use	use	u200	VB	I-VP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clopidogrel	clopidogrel	c4010302604	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
responsible	responsible	r0210520140	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clopidogrel	clopidogrel	c4010302604	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
strongly	strongly	s3605240	RB	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
accurate	accurate	a206030	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
.	.	.000	.	O	O

Reports	Report	r010632	NNS	B-NP	O
about	about	a103	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
clopidogrel	clopidogrel	c4010302604	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
few	few	f000	JJ	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
physicians	physician	p0202052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
carefully	carefully	c0601040	RB	I-VP	O
consider	consider	c0520306	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
clopidogrel	clopidogrel	c4010302604	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
.	.	.000	.	O	O

Bortezomib	Bortezomib	b063020501	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
salvage	salvage	s041020	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
/	/	/000	SYM	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
:	:	:000	:	O	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

Bortezomib	Bortezomib	b063020501	NN	B-NP	B-Chemical
(	(	(000	(	O	O
bort	bort	b063	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
dex	dex	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
/	/	/000	SYM	I-NP	O
refractory	refractory	r016023060	NN	I-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
R	R	r000	NN	I-NP	O
)	)	)000	)	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MM	MM	m500	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bort	bort	b063	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dex	dex	d020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
bort	bort	b063	NN	B-NP	B-Chemical
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
salvage	salvage	s041020	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
85	85	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
R	R	r000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
R	R	r000	NN	I-NP	O
MM	MM	m500	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
autologous	autologous	a03040202	JJ	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
or	or	o600	CC	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
lines	line	l0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
immunomodulatory	immunomodulatory	i50505030403060	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
included	include	i5240303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
line	line	l050	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
before	before	b01060	IN	B-PP	O
bort	bort	b063	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
bort	bort	b063	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
cycles	cycle	c02402	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
6	6	6000	CD	B-NP	O
,	,	,000	,	O	O
up	up	u100	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
intention	intention	i5305305	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
treat	treat	t603	NN	I-NP	O
basis	basis	b0202	NN	I-NP	O
,	,	,000	,	O	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CR	CR	c600	NN	I-NP	O
and	and	a530	CC	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
very	very	v060	RB	I-NP	O
good	good	g030	JJ	I-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
durations	duration	d0603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
next	next	n023	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
interval	interval	i5306104	NN	I-NP	O
were	be	w060	VBD	B-VP	O
8	8	8000	CD	B-NP	O
,	,	,000	,	I-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
78	78	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
grade	grade	g6030	NN	B-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
grade	grade	g6030	NN	B-NP	O
III	III	i000	CD	I-NP	O
,	,	,000	,	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
22	22	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
median	median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
progression	progression	p60260205	NN	B-NP	O
,	,	,000	,	O	O
progression	progression	p60260205	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
(	(	(000	(	O	O
PFS	PFS	p120	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
overall	overall	o10604	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
(	(	(000	(	O	O
OS	OS	o200	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
22	22	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
PFS	PFS	p120	NN	I-NP	O
and	and	a530	CC	I-NP	O
OS	OS	o200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
achieving	achieve	a201052	VBG	B-VP	O
CR	CR	c600	NN	B-NP	O
and	and	a530	CC	O	O
receiving	receive	r0201052	VBG	B-VP	O
bort	bort	b063	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
line	line	l050	NN	I-NP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Bort	Bort	b063	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
salvage	salvage	s041020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
MM	MM	m500	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
relapse	relapse	r040120	NN	I-NP	O
.	.	.000	.	O	O

Pubertal	Pubertal	p0106304	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
Bisphenol	Bisphenol	b0210504	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
increases	increase	i5260202	VBZ	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
and	and	a530	CC	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Bisphenol	Bisphenol	b0210504	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BPA	BPA	b100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
neurodevelopment	neurodevelopment	n06030104015053	NN	B-NP	O
and	and	a530	CC	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
well	well	w040	RB	I-VP	O
established	establish	e230140203	VBN	I-VP	O
.	.	.000	.	O	O

Acetylcholinesterase	Acetylcholinesterase	a203042040502306020	NN	B-NP	O
(	(	(000	(	O	O
AChE	AChE	a200	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
regulatory	regulatory	r020403060	JJ	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
phenotypes	phenotype	p05030102	NNS	I-NP	O
and	and	a530	CC	O	O
AChE	AChE	a200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
BPA	BPA	b100	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
puberty	puberty	p010630	NN	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
postnatal	postnatal	p02350304	JJ	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
PND	PND	p530	NN	B-NP	O
)	)	)000	)	O	O
35	35	0000	CD	B-NP	O
,	,	,000	,	O	O
male	male	m040	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
50mg	50mg	0000	CD	B-NP	O
BPA	BPA	b100	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
diet	diet	d030	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
35	35	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
PND71	PND71	0000	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
assay	assay	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
(	(	(000	(	O	O
EPM	EPM	e150	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
light	light	l0203	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dark	dark	d062	JJ	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
AChE	AChE	a200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	I-NP	O
hypothalamus	hypothalamus	h0103040502	NN	I-NP	O
,	,	,000	,	I-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
and	and	a530	CC	I-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
from	from	f605	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
phenotyping	phenotyping	p050301052	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
-	-	-000	HYPH	B-VP	O
like	like	l020	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
BPA	BPA	b100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

AChE	AChE	a200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
BPA	BPA	b100	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	I-NP	O
hypothalamus	hypothalamus	h0103040502	NN	I-NP	O
and	and	a530	CC	I-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
pubertal	pubertal	p0106304	JJ	B-NP	O
BPA	BPA	b100	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
AChE	AChE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
in	in	i500	IN	B-PP	O
PBE	PBE	p100	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
.	.	.000	.	O	O

Biochemical	Biochemical	b02050204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Solidago	Solidago	s0403020	NNP	B-NP	O
virgaurea	virgaurea	v062060	NNP	I-NP	O
extract	extract	e236023	NN	I-NP	O
on	on	o500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cardiovascular	Cardiovascular	c06301020406	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
(	(	(000	(	O	O
CVDs	CVD	c132	NNS	B-NP	B-Disease
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
problem	problem	p601405	NN	I-NP	O
of	of	o100	IN	B-PP	O
advanced	advance	a3105203	VBN	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
developing	develop	d010401052	VBG	B-NP	O
countries	country	c053602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
world	world	w0643	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Solidago	Solidago	s0403020	NNP	I-NP	O
virgaurea	virgaurea	v062060	NNP	I-NP	O
extract	extract	e236023	NN	I-NP	O
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
into	into	i530	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
twice	twice	t020	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
,	,	,000	,	O	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
,	,	,000	,	O	O
alanine	alanine	a405050	NN	B-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
,	,	,000	,	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
,	,	,000	,	O	O
triglycerides	triglyceride	t602402060302	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
free	free	f600	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
fatty	fatty	f030	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MDA	MDA	m300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
S	S	s000	NN	B-NP	O
.	.	.000	.	O	O
virgaurea	virgaurea	v062060	NN	B-NP	O
extract	extract	e236023	NN	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
.	.	.000	.	O	O

Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
used	use	u203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
S	S	s000	NN	B-NP	O
.	.	.000	.	O	O
virgaurea	virgaurea	v062060	NN	B-NP	O
extract	extract	e236023	NN	I-NP	O
exerts	exert	e20632	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
by	by	b000	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
MDA	MDA	m300	NN	B-NP	B-Chemical
level	level	l0104	NN	I-NP	O
and	and	a530	CC	O	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
emphasizes	emphasize	e51020202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
S	S	s000	NN	B-NP	O
.	.	.000	.	O	O
virgaurea	virgaurea	v062060	NN	B-NP	O
extract	extract	e236023	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

"	"	"000	``	O	O
Real	Real	r040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
world	world	w0643	NN	I-NP	O
"	"	"000	''	B-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lenalidomide	lenalidomide	l05040305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
/	/	/000	SYM	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
practice	practice	p6023020	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Greek	Greek	g602	NNP	I-NP	O
Myeloma	Myeloma	m04050	NNP	I-NP	B-Disease
Study	Study	s3030	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
.	.	.000	.	O	O

Lenalidomide	Lenalidomide	l05040305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
RD	RD	r300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
standard	standard	s3053063	NN	I-NP	O
of	of	o100	IN	B-PP	O
care	care	c060	NN	B-NP	O
for	for	f060	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
/	/	/000	SYM	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
(	(	(000	(	O	O
RRMM	RRMM	r650	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
published	publish	p0140203	VBN	B-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
real	real	r040	JJ	I-NP	O
world	world	w0643	NN	I-NP	O
"	"	"000	''	O	O
(	(	(000	(	O	O
RW	RW	r000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
International	International	i53065030504	NNP	I-NP	O
Society	Society	s02030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Pharmacoeconomics	Pharmacoeconomics	p0650202050502	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Outcomes	Outcomes	o0320502	NNP	I-NP	O
Research	Research	r020620	NNP	I-NP	O
definition	definition	d01050305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
212	212	0000	CD	B-NP	O
RRMM	RRMM	r650	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
RD	RD	r300	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
RW	RW	r000	NN	B-NP	O
.	.	.000	.	O	O

Objective	Objective	o12023010	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
PR	PR	p600	NN	I-NP	O
(	(	(000	(	O	O
partial	partial	p06304	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
rate	rate	r030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
77	77	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
complete	complete	c0514030	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
CR	CR	c600	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
and	and	a530	CC	I-NP	O
best	good	b023	JJS	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
CR	CR	c600	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
RD	RD	r300	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
as	as	a200	IN	B-PP	O
2nd	2nd	2530	CD	B-NP	O
or	or	o600	CC	O	O
>	>	>000	JJR	B-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
nd	nd	n300	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
line	line	l050	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	I-NP	O
11	11	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Quality	Quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
independent	independent	i5301053053	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
lines	line	l0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapies	therapy	t060102	NNS	B-NP	O
or	or	o600	CC	O	O
previous	previous	p60102	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
bortezomib	bortezomib	b063020501	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
34	34	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
RD	RD	r300	NN	B-NP	B-Chemical
until	until	u5304	IN	B-PP	O
progression	progression	p60260205	NN	B-NP	O
(	(	(000	(	O	O
not	not	n030	RB	B-VP	O
reached	reach	r0203	VBN	I-VP	O
versus	versus	v06202	IN	B-PP	O
19	19	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
humoral	humoral	h050604	JJ	B-NP	O
immunity	immunity	i505030	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
responders	responder	r021053062	NNS	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
achieved	achieve	a20103	VBD	B-VP	O
stable	stable	s30140	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
68	68	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
49	49	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
needed	need	n0303	VBD	B-VP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
deep	deep	d010	JJ	B-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
needed	need	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
permanent	permanent	p06505053	JJ	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Performance	Performance	p0610650520	NN	B-NP	O
status	status	s30302	NN	I-NP	O
(	(	(000	(	O	O
PS	PS	p200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
initial	initial	i50304	JJ	B-NP	O
lenalidomide	lenalidomide	l05040305030	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
predicted	predict	p60302303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
.	.	.000	.	O	O

Extra	Extra	e2360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
relapses	relapse	r0401202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
confirms	confirm	c0510652	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
RD	RD	r300	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
RRMM	RRMM	r650	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
RW	RW	r000	NN	I-NP	O
;	;	;000	:	O	O
it	it	i300	PRP	B-NP	O
produces	produce	p6030202	VBZ	B-VP	O
durable	durable	d060140	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
continue	continue	c053050	VBP	B-VP	O
on	on	o500	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
till	till	t040	NN	I-NP	O
progression	progression	p60260205	NN	I-NP	O
and	and	a530	CC	O	O
improves	improve	i5160102	VBZ	B-VP	O
humoral	humoral	h050604	JJ	B-NP	O
immunity	immunity	i505030	NN	I-NP	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cytogenetic	cytogenetic	c0302050302	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
combination	combination	c051050305	NN	I-NP	O
on	on	o500	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
rabbit	rabbit	r0103	NN	I-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
/	/	/000	SYM	O	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
cytogenetic	cytogenetic	c0302050302	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Ifosfamide	Ifosfamide	i102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
IFO	IFO	i100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
alkylating	alkylate	a420403052	VBG	I-NP	O
nitrogen	nitrogen	n0360205	NN	I-NP	B-Chemical
mustard	mustard	m023063	NN	I-NP	O
,	,	,000	,	O	O
administrated	administrate	a350502360303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
antineoplasmic	antineoplasmic	a530501402502	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
intense	intense	i530520	JJ	I-NP	O
urotoxic	urotoxic	u6030202	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
IFO	IFO	i100	NN	B-NP	B-Chemical
raises	raise	r0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
requirement	requirement	r020605053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
sulfanylethanesulfonate	sulfanylethanesulfonate	s041050403050204105030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
Mesna	Mesna	m0250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
aiming	aim	a05052	VBG	B-VP	O
to	to	t000	TO	I-VP	O
avoid	avoid	a103	VB	I-VP	O
or	or	o600	CC	I-VP	O
minimize	minimize	m0505020	VB	I-VP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

IFO	IFO	i100	NNP	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Mesna	Mesna	m0250	NNP	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
administrated	administrate	a350502360303	VBN	I-VP	O
separately	separately	s010603040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
rabbit	rabbit	r0103	NN	B-NP	O
'	'	'000	''	O	O
s	s	s000	JJ	B-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
later	later	l0306	RB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

Cytogenetic	Cytogenetic	c0302050302	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
sister	sister	s02306	NN	B-NP	O
chromatid	chromatid	c06050303	NN	I-NP	O
exchanges	exchange	e205202	NNS	I-NP	O
(	(	(000	(	O	O
SCEs	SCE	s202	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
proliferation	proliferation	p60401060305	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
index	index	i5302	NN	I-NP	O
(	(	(000	(	O	O
PRI	PRI	p600	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Mitotic	Mitotic	m030302	JJ	B-NP	O
Index	Index	i5302	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
action	action	a2305	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
IFO	IFO	i100	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
SCEs	SCE	s202	NNS	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
SCEs	SCE	s202	NNS	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
when	when	w050	WRB	B-ADVP	O
IFO	IFO	i100	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
high	high	h020	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
alone	alone	a4050	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
PRI	PRI	p600	NN	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
,	,	,000	,	O	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
IFO	IFO	i100	NN	B-NP	B-Chemical
acting	act	a23052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
.	.	.000	.	O	O

Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduces	reduce	r030202	VBZ	B-VP	O
IFO	IFO	i100	NN	B-NP	B-Chemical
'	'	'000	''	I-NP	O
s	s	s000	NNS	I-NP	O
genotoxicity	genotoxicity	g05030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
it	it	i300	PRP	B-NP	O
acts	act	a232	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytostatic	cytostatic	c030230302	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
and	and	a530	CC	O	O
predictors	predictor	p603023062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
among	among	a5052	IN	B-PP	O
multiethnic	multiethnic	m043030502	JJ	B-NP	O
Malaysians	Malaysian	m0402052	NNPS	I-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
pulsatile	pulsatile	p04203040	JJ	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
and	and	a530	CC	O	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
and	and	a530	CC	I-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
among	among	a5052	IN	B-PP	O
multiethnic	multiethnic	m043030502	JJ	B-NP	O
Malaysian	Malaysian	m040205	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
95	95	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
uninterrupted	uninterrupted	u50530601303	JJ	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
instrument	instrument	i523605053	NN	I-NP	O
used	use	u203	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
UPDRS	UPDRS	u1362	NNP	I-NP	O
questionnaires	questionnaire	q023050602	VBZ	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
65	65	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
age	age	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
58	58	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
6	6	6000	CD	B-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
years	year	y062	NNS	B-NP	O
.	.	.000	.	O	O

Dyskinesia	Dyskinesia	d0205020	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
42	42	0000	CD	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
median	median	m0305	JJ	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
64	64	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
Chinese	Chinese	c05020	JJ	B-ADJP	O
,	,	,000	,	O	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
Malays	Malay	m0402	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
Indians	Indian	i53052	NNPS	B-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
ethnic	ethnic	e30502	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
lower	low	l060	JJR	B-NP	O
onset	onset	o5203	NN	I-NP	O
age	age	a200	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
longer	long	l05206	JJR	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
longer	long	l05206	JJR	B-NP	O
disease	disease	d02020	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
higher	high	h0206	JJR	B-NP	O
total	total	t0304	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
total	total	t0304	JJ	I-NP	O
UPDRS	UPDRS	u1362	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
onset	onset	o5203	NN	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
onset	onset	o5203	NN	B-NP	O
age	age	a200	NN	I-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Busulfan	Busulfan	b0204105	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
neurotoxic	neurotoxic	n06030202	JJ	B-ADJP	B-Disease
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
and	and	a530	CC	I-NP	O
humans	human	h05052	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
acute	acute	a2030	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
remains	remain	r05052	VBZ	B-VP	O
poorly	poorly	p0640	RB	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
here	here	h060	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
123	123	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
receiving	receive	r0201052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
before	before	b01060	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	O
solid	solid	s0403	JJ	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
,	,	,000	,	O	O
brain	brain	b605	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
excluded	exclude	e240303	VBD	B-VP	O
.	.	.000	.	O	O

Busulfan	Busulfan	b0204105	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
o	o	o000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
6	6	6000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
16	16	0000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
over	over	o106	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
total	total	t0304	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
consecutively	consecutively	c052020301040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
:	:	:000	:	O	O
16	16	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
then	then	t050	RB	O	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
calculation	calculation	c042040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
28	28	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ninety	Ninety	n05030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
given	give	g0105	VBN	I-VP	O
anticonvulsive	anticonvulsive	a5302051042010	JJ	B-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
;	;	;000	:	O	O
7	7	7000	CD	B-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
course	course	c0620	NN	I-NP	O
or	or	o600	CC	B-PP	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
into	into	i530	IN	B-PP	O
account	account	a2053	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
16	16	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
57	57	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
of	of	o100	IN	B-PP	O
39	39	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
a	a	a000	DT	B-NP	O
600	600	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
m2	m2	0000	NN	I-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
with	with	w030	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
;	;	;000	:	O	O
none	none	n050	NN	B-NP	O
had	have	h030	VBD	B-VP	O
any	any	a500	DT	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Busulfan	Busulfan	b0204105	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
gas	gas	g020	NN	I-NP	O
chromatographic	chromatographic	c0605030260102	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
mass	mass	m020	NN	I-NP	O
spectrometry	spectrometry	s10236050360	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
and	and	a530	CC	I-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
of	of	o100	IN	B-PP	O
9	9	9000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
central	central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
under	under	u5306	IN	B-PP	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
:	:	:000	:	O	O
busulfan	busulfan	b0204105	NN	B-NP	B-Chemical
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
:	:	:000	:	O	O
plasma	plasma	p40250	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
39	39	0000	CD	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
:	:	:000	:	O	O
plasma	plasma	p40250	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
previously	previously	p6010240	RB	B-VP	O
defined	define	d010503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
16	16	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
busulfan	busulfan	b0204105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
busulfan	busulfan	b0204105	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
dependent	dependent	d01053053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
and	and	a530	CC	O	O
efficiently	efficiently	e10205340	RB	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
busulfan	busulfan	b0204105	JJ	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
calculated	calculate	c042040303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
close	close	c4020	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
plasma	plasma	p40250	NN	B-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
faster	fast	f02306	JJR	I-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
may	may	m000	MD	B-VP	O
approximate	approximate	a160205030	VB	I-VP	O
more	more	m060	RBR	B-ADVP	O
closely	closely	c402040	RB	I-ADVP	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
usual	usual	u204	JJ	I-NP	O
16	16	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
inferences	inference	i510605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
anticancer	anticancer	a530205206	JJ	B-NP	O
or	or	o600	CC	I-NP	O
myeloablative	myeloablative	m0401403010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
and	and	a530	CC	I-NP	O
infants	infant	i510532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reconsidered	reconsider	r02052030603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
unexpected	unexpected	u502102303	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
:	:	:000	:	O	O
AL	AL	a400	JJ	B-NP	B-Disease
amyloidosis	amyloidosis	a504030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
expected	expected	e2102303	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
mammalian	mammalian	m050405	JJ	B-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	O
(	(	(000	(	O	O
mTOR	mTOR	m306	NN	B-NP	O
-	-	-000	HYPH	O	O
i	i	i000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
suspicion	suspicion	s0210205	NN	I-NP	O
should	should	s043	MD	B-VP	O
always	always	a402	RB	I-VP	O
be	be	b000	VB	I-VP	O
supported	support	s0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
potential	potential	p0305304	JJ	B-NP	O
alternate	alternate	a43065030	JJ	I-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
acute	acute	a2030	JJ	B-NP	O
or	or	o600	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
rejection	rejection	r0202305	NN	I-NP	O
,	,	,000	,	O	O
interstitial	interstitial	i5306230304	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
tubular	tubular	t010406	JJ	B-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
recurrent	recurrent	r0206053	JJ	B-NP	O
or	or	o600	CC	I-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
glomerulopathy	glomerulopathy	g405060401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
unexpected	unexpected	u502102303	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
amyloidosis	amyloidosis	a504030202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
monoclonal	monoclonal	m050240504	JJ	I-NP	O
gammapathy	gammapathy	g0501030	NN	I-NP	O
of	of	o100	IN	B-PP	O
undetermined	undetermined	u53030650503	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
from	from	f605	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
oral	oral	o604	JJ	I-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
prevents	prevent	p6010532	VBZ	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
intracerebroventricularly	intracerebroventricularly	i536020601601053602040640	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Basic	Basic	b0202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
research	research	r020620	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
dementia	dementia	d050530	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
sporadic	sporadic	s1060302	JJ	B-NP	O
Alzheimer	Alzheimer	a420506	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
sAD	sAD	s030	NN	B-NP	O
)	)	)000	)	O	O
type	type	t010	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
dysfunction	dysfunction	d021052305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
-	-	-000	HYPH	O	O
receptor	receptor	r0201306	NN	B-NP	O
(	(	(000	(	O	O
IR	IR	i600	NN	B-NP	O
)	)	)000	)	O	O
system	system	s02305	NN	B-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
transport	transport	t60521063	NN	I-NP	O
via	via	v000	IN	B-PP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
GLUT4	GLUT4	0000	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
source	source	s0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
energy	energy	e50620	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
d	d	d000	VBN	I-VP	B-Chemical
-	-	-000	:	O	I-Chemical
galactose	galactose	g04023020	NN	B-NP	I-Chemical
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
epimer	epimer	e10506	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glucose	glucose	g402020	NN	I-NP	I-Chemical
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
transported	transport	t6052106303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
by	by	b000	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
GLUT3	GLUT3	0000	NN	I-NP	O
transporter	transporter	t6052106306	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
metabolized	metabolize	m0301040203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Leloir	Leloir	l0406	NNP	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

Exclusively	Exclusively	e240201040	RB	B-NP	O
parenteral	parenteral	p060530604	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
galactose	galactose	g04023020	NN	B-NP	B-Chemical
induce	induce	i53020	VBP	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
generate	generate	g0506030	VB	I-VP	O
animal	animal	a50504	NN	B-NP	O
aging	aging	a2052	NN	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
never	never	n0106	RB	I-VP	O
been	be	b050	VBN	I-VP	O
tested	test	t02303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
(	(	(000	(	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
icv	icv	i210	NN	I-NP	O
)	)	)000	)	O	O
rat	rat	r030	NN	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
sAD	sAD	s030	NN	B-NP	O
,	,	,000	,	O	O
tested	test	t02303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Morris	Morris	m0602	NNP	B-NP	O
Water	Water	w0306	NNP	I-NP	O
Maze	Maze	m020	NNP	I-NP	O
and	and	a530	CC	O	O
Passive	Passive	p02010	NNP	B-NP	O
Avoidance	Avoidance	a1030520	NNP	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
initiated	initiate	i5030303	VBN	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
icv	icv	i210	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
successfully	successfully	s02021040	RB	B-VP	O
prevented	prevent	p60105303	VBD	I-VP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
icv	icv	i210	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Beneficial	Beneficial	b05010204	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
independent	independent	i5301053053	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
100	100	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
galactose	galactose	g04023020	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
galactose	galactose	g04023020	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
was	be	w020	VBD	B-VP	O
several	several	s010604	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
lower	low	l060	JJR	I-NP	O
after	after	a1306	IN	B-PP	O
oral	oral	o604	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
after	after	a1306	IN	B-SBAR	O
parenteral	parenteral	p060530604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
galactose	galactose	g04023020	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
beneficial	beneficial	b05010204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
ability	ability	a104030	NN	I-NP	O
and	and	a530	CC	O	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
worth	worth	w0630	JJ	B-PP	O
investigating	investigate	i510230203052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
improvement	improvement	i5160105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
glucose	glucose	g402020	NN	B-NP	B-Disease
hypometabolism	hypometabolism	h0105030104025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
AD	AD	a300	NN	B-NP	B-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
persons	person	p062052	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
tenofovir	tenofovir	t05010106	VB	I-VP	B-Chemical
disoproxil	disoproxil	d020160204	NN	B-NP	I-Chemical
fumarate	fumarate	f0506030	NN	I-NP	I-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
database	database	d0301020	NN	I-NP	O
(	(	(000	(	O	O
MHRA	MHRA	m060	NN	B-NP	O
database	database	d0301020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
tenofovir	tenofovir	t05010106	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
syndromes	syndrome	s05360502	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
established	establish	e230140203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
mechanistic	mechanistic	m020502302	JJ	O	O
and	and	a530	CC	O	O
randomised	randomise	r053050203	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
exact	exact	e2023	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
uncertain	uncertain	u5206305	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
undertook	undertake	u5306302	VBD	B-VP	O
a	a	a000	DT	B-NP	O
descriptive	descriptive	d026013010	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
Yellow	Yellow	y040	NNP	B-NP	O
Card	Card	c063	NNP	I-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
407	407	0000	CD	B-NP	O
HIV	HIV	h010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
persons	person	p062052	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
tenofovir	tenofovir	t05010106	NN	B-NP	B-Chemical
disoproxil	disoproxil	d020160204	NN	I-NP	I-Chemical
fumarate	fumarate	f0506030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TDF	TDF	t310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
and	and	a530	CC	O	O
submitted	submit	s0150303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Medicines	Medicines	m03020502	NNP	I-NP	O
and	and	a530	CC	O	O
Healthcare	Healthcare	h04302060	NNP	B-NP	O
Products	Products	p6030232	NNP	I-NP	O
Regulatory	Regulatory	r020403060	NNP	I-NP	O
Agency	Agency	a20520	NNP	I-NP	O
(	(	(000	(	O	O
MHRA	MHRA	m060	NN	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Reports	Report	r010632	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
satisfy	satisfy	s030210	VBP	B-VP	O
defined	define	d010503	VBN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
classified	classify	c4020103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
kidney	kidney	k0350	NN	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
407	407	0000	CD	I-NP	O
Yellow	Yellow	y040	NNP	I-NP	O
Card	Card	c063	NNP	I-NP	O
records	record	r020632	NNS	I-NP	O
analysed	analyse	a5040203	VBD	B-VP	O
,	,	,000	,	O	O
106	106	0000	CD	B-NP	O
satisfied	satisfied	s0302103	JJ	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
TDF	TDF	t310	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
kidney	kidney	k0350	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
53	53	0000	CD	B-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
35	35	0000	CD	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
18	18	0000	CD	B-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
TDF	TDF	t310	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
316	316	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
interquartile	interquartile	i53062063040	JJ	B-NP	O
range	range	r0520	NN	I-NP	O
120	120	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
740	740	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hospitalisation	hospitalisation	h0210304020305	NN	B-NP	O
for	for	f060	IN	B-PP	O
TDF	TDF	t310	NN	B-NP	B-Chemical
kidney	kidney	k0350	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
amongst	amongst	a50523	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
syndromes	syndrome	s05360502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
series	series	s0602	NN	I-NP	O
mirrors	mirror	m06062	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
reported	report	r0106303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
randomised	randomise	r053050203	VBN	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Cessation	Cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
TDF	TDF	t310	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
up	up	u100	RP	B-PRT	O
half	half	h041	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
high	high	h020	JJ	B-ADJP	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
known	known	k505	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Postoperative	Postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
populations	population	p010403052	NNS	B-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
known	known	k505	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ICU	ICU	i200	NN	I-NP	O
for	for	f060	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
after	after	a1306	IN	B-PP	O
elective	elective	e4023010	JJ	B-NP	O
major	major	m0206	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
investigated	investigate	i51023020303	VBN	B-VP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
eventual	eventual	e105304	JJ	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
demographic	demographic	d050260102	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
and	and	a530	CC	O	O
anesthetic	anesthetic	a50230302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
observational	observational	o12061030504	JJ	I-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
ICU	ICU	i200	NN	I-NP	O
within	within	w0305	IN	B-PP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Exclusion	Exclusion	e240205	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
any	any	a500	DT	B-NP	O
preexisting	preexisting	p602023052	JJ	I-NP	O
predisposing	predispose	p60302102052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
or	or	o600	CC	O	O
other	other	o306	JJ	B-ADJP	O
potentially	potentially	p03053040	RB	B-VP	O
confounding	confound	c051053052	VBG	I-VP	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
daily	daily	d040	RB	B-ADVP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
assessment	assessment	a2025053	NN	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
ICU	ICU	i200	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	RB	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
incidence	incidence	i52030520	NN	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
three	three	t060	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
According	Accord	a2063052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
confusion	confusion	c0510205	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
ICU	ICU	i200	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
,	,	,000	,	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
thiopentone	thiopentone	t01053050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
higher	high	h0206	JJR	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
(	(	(000	(	O	O
57	57	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
RR	RR	r600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
X2	X2	0000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
256	256	0000	CD	B-NP	O
;	;	;000	:	O	O
df	df	d100	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
;	;	;000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
<	<	<000	SYM	I-NP	O
p	p	p000	NN	I-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
early	early	e0640	JJ	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
common	common	c0505	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
known	known	k505	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Thiopentone	Thiopentone	t01053050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
independently	independently	i530105305340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
long	long	l052	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
lasting	last	l023052	VBG	B-VP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
METH	METH	m030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
triggers	trigger	t602062	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
monoaminergic	monoaminergic	m05050506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
and	and	a530	CC	I-NP	O
METH	METH	m030	NN	I-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
states	state	s30302	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
currently	currently	c0605340	RB	B-ADJP	O
unknown	unknown	u52505	JJ	I-ADJP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
causes	cause	c0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
long	long	l052	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
lasting	last	l023052	VBG	B-VP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
phenotype	phenotype	p0503010	NN	I-NP	O
and	and	a530	CC	O	O
persistent	persistent	p062023053	JJ	B-NP	O
monoaminergic	monoaminergic	m05050506202	JJ	I-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
now	now	n000	RB	B-ADVP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
at	at	a300	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
and	and	a530	CC	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
periods	period	p06032	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
METH	METH	m030	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

METH	METH	m030	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
procedural	procedural	p602030604	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
as	as	a200	IN	B-SBAR	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
swimming	swim	s05052	VBG	B-VP	O
speed	speed	s103	NN	B-NP	O
and	and	a530	CC	I-NP	O
escape	escape	e2010	NN	I-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-VP	O
find	find	f053	VB	I-VP	O
the	the	t000	DT	B-NP	O
platform	platform	p4031065	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
cued	cue	c030	VBN	I-NP	O
version	version	v06205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
water	water	w0306	NN	I-NP	O
maze	maze	m020	NN	I-NP	O
task	task	t020	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
METH	METH	m030	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
immobility	immobility	i50104030	NN	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tail	tail	t040	NN	I-NP	O
suspension	suspension	s02105205	NN	I-NP	O
test	test	t023	NN	I-NP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
49	49	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
frontostriatal	frontostriatal	f605302360304	JJ	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
,	,	,000	,	O	O
indicated	indicate	i53020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
DOPAC	DOPAC	d0102	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
HVA	HVA	h100	NN	I-NP	B-Chemical
,	,	,000	,	O	O
tyrosine	tyrosine	t0602050	NN	B-NP	B-Chemical
hydroxylase	hydroxylase	h0360204020	NN	I-NP	O
and	and	a530	CC	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
,	,	,000	,	O	O
observed	observe	o1206103	VBN	B-VP	O
at	at	a300	IN	B-PP	O
both	both	b030	CC	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
49	49	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
parallel	parallel	p060404	NN	B-NP	O
,	,	,000	,	O	O
another	another	a50306	DT	B-NP	O
neurochemical	neurochemical	n0602050204	JJ	I-NP	O
feature	feature	f03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
-	-	-000	HYPH	O	O
astroglial	astroglial	a23602404	JJ	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	SYM	B-NP	O
was	be	w020	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
striatal	striatal	s360304	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
astrocytic	astrocytic	a236020302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
marker	marker	m06206	NN	I-NP	O
,	,	,000	,	O	O
glial	glial	g404	JJ	B-NP	O
fibrillary	fibrillary	f01604060	JJ	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
only	only	o540	RB	I-VP	O
transiently	transiently	t605205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
that	that	t030	IN	B-ADVP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
long	long	l052	RB	B-ADVP	O
-	-	-000	HYPH	O	O
lasting	last	l023052	VBG	B-VP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
persistent	persistent	p062023053	JJ	I-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
frontostriatal	frontostriatal	f605302360304	JJ	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
homoeostasis	homoeostasis	h050230202	NN	I-NP	O
.	.	.000	.	O	O

Linezolid	Linezolid	l05020403	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
antimicrobials	antimicrobial	a530502601042	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
ocular	ocular	o20406	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
especially	especially	e2102040	RB	B-ADJP	O
relevant	relevant	r0401053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
multidrug	multidrug	m04303602	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
drug	drug	d602	NN	I-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
ocular	ocular	o20406	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
loss	loss	l020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
linezolid	linezolid	l05020403	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
second	second	s02053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	O	O
tuberculous	tuberculous	t010620402	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
linezolid	linezolid	l05020403	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ethambutol	ethambutol	e30510304	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
extensively	extensively	e2305201040	RB	B-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
resistant	resistant	r02023053	JJ	I-NP	I-Disease
tuberculosis	tuberculosis	t01062040202	NN	I-NP	I-Disease
(	(	(000	(	O	O
XDR	XDR	x360	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
TB	TB	t100	NN	I-NP	I-Disease
)	)	)000	)	O	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
us	us	u200	PRP	B-NP	O
with	with	w030	IN	B-PP	O
painless	painless	p05402	JJ	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
loss	loss	l020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

Color	Color	c0406	NN	B-NP	O
vision	vision	v0205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
defective	defective	d01023010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
fundus	fundus	f05302	NN	I-NP	O
examination	examination	e205050305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
optic	optic	o1302	JJ	B-NP	B-Disease
disc	disc	d020	NN	I-NP	I-Disease
edema	edema	e3050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
toxic	toxic	t0202	JJ	I-NP	B-Disease
optic	optic	o1302	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
and	and	a530	CC	O	O
tablet	tablet	t01403	NN	B-NP	O
ethambutol	ethambutol	e30510304	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
.	.	.000	.	O	O

Deterioration	Deterioration	d0306060305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
despite	despite	d021030	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Discontinuation	Discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
linezolid	linezolid	l05020403	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
vision	vision	v0205	NN	B-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
report	report	r01063	NN	I-NP	O
emphasizes	emphasize	e51020202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
monitoring	monitoring	m050306052	NN	B-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
linezolid	linezolid	l05020403	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Resuscitation	Resuscitation	r0202030305	NN	B-NP	O
with	with	w030	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
,	,	,000	,	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	CC	O	O
in	in	i500	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
newborn	newborn	n01065	JJ	B-NP	O
piglets	piglet	p024032	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
emulsion	emulsion	e504205	NN	I-NP	O
,	,	,000	,	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	O	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
yet	yet	y030	RB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
neonates	neonate	n050302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
LAST	LAST	l023	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Newborn	Newborn	n01065	JJ	B-NP	O
piglets	piglet	p024032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
until	until	u5304	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
collapse	collapse	c040120	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Standard	Standard	s3053063	JJ	B-NP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	I-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
and	and	a530	CC	O	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
,	,	,000	,	O	O
fibrillation	fibrillation	f016040305	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
QRS	QRS	q620	NN	B-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
.	.	.000	.	O	O

Piglets	Piglet	p024032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
saline	saline	s04050	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Intralipid	Intralipid	i536040103	NN	B-NP	O
(	(	(000	(	O	O
)	)	)000	)	O	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Intralipd	Intralipd	i53604013	NNP	B-NP	O
plus	plus	p402	CC	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Resuscitation	Resuscitation	r0202030305	NN	B-NP	O
continued	continue	c0530503	VBD	B-VP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
or	or	o600	CC	B-PP	O
until	until	u5304	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
return	return	r03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
circulation	circulation	c062040305	NN	I-NP	O
(	(	(000	(	O	O
ROSC	ROSC	r020	NN	B-NP	O
)	)	)000	)	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
at	at	a300	IN	B-PP	O
or	or	o600	CC	O	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
normal	normal	n06504	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
ROSC	ROSC	r020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
piglets	piglet	p024032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treated	treat	t60303	VBN	I-NP	O
piglets	piglet	p024032	NNS	I-NP	O
.	.	.000	.	O	O

Mortality	Mortality	m06304030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
zero	zero	z060	CD	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Intralipid	Intralipid	i536040103	NN	I-NP	O
only	only	o540	RB	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
14	14	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
17	17	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Lipid	Lipid	l0103	NN	B-NP	O
emulsion	emulsion	e504205	NN	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
equally	equally	e2040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
achieving	achieve	a201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
return	return	r03065	NN	I-NP	O
to	to	t000	TO	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
circulation	circulation	c062040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
LAST	LAST	l023	NN	B-NP	O
.	.	.000	.	O	O

Epinephrine	Epinephrine	e1050106050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
emulsion	emulsion	e504205	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
and	and	a530	CC	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
count	count	c053	NN	I-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
graft	graft	g6013	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Thrombocytopenia	Thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
disorder	disorder	d0206306	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
portal	portal	p06304	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thrombopoetin	thrombopoetin	t06051010305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
endotoxemia	endotoxemia	e530302050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
immune	immune	i5050	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
mediated	mediate	m030303	VBN	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
yet	yet	y030	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-SBAR	O
few	few	f000	JJ	B-NP	O
literature	literature	l030603060	NN	I-NP	O
citations	citation	c0303052	NNS	I-NP	O
reporting	report	r01063052	VBG	B-VP	O
contradictory	contradictory	c053603023060	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
the	the	t000	DT	B-NP	O
perioperative	perioperative	p06010603010	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
and	and	a530	CC	O	O
determine	determine	d03065050	VB	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
205	205	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
full	full	f040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
size	size	s020	NN	I-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
2006	2006	0000	CD	I-NP	O
and	and	a530	CC	O	O
December	December	d0205106	NNP	B-NP	O
2010	2010	0000	CD	I-NP	O
due	due	d000	IN	B-ADVP	O
to	to	t000	TO	B-VP	O
end	end	e530	VB	I-VP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
or	or	o600	CC	O	I-Disease
malignant	malignant	m04025053	JJ	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Preoperative	Preoperative	p6010603010	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
count	count	c053	NN	I-NP	O
,	,	,000	,	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
platelets	platelet	p40304032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
155	155	0000	CD	B-NP	O
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
205	205	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
before	before	b01060	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
influenced	influence	i51405203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Model	Model	m0304	NN	B-NP	O
of	of	o100	IN	B-PP	O
End	End	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
Stage	Stage	s3020	NN	I-NP	I-Disease
Liver	Liver	l0106	NN	I-NP	I-Disease
Disease	Disease	d02020	NN	I-NP	I-Disease
score	score	s2060	NN	I-NP	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	B-Disease
cirrhosis	cirrhosis	c060202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
count	count	c053	NN	I-NP	O
exceeded	exceed	e20303	VBD	B-VP	O
100	100	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
uL	uL	u400	NN	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
193	193	0000	CD	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
medium	medium	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Regarding	Regard	r02063052	VBG	B-VP	O
HIT	HIT	h030	NN	B-NP	B-Disease
II	II	i000	CD	I-NP	I-Disease
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
four	four	f060	CD	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
background	background	b026053	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
about	about	a103	IN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
further	far	f06306	JJR	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
II	II	i000	CD	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
weight	weight	w0203	NN	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
count	count	c053	NN	I-NP	O
.	.	.000	.	O	O

Takotsubo	Takotsubo	t02032010	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
or	or	o600	CC	O	O
apical	apical	a10204	JJ	B-NP	B-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
)	)	)000	)	O	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
Zolmitriptan	Zolmitriptan	z04503601305	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

Takotsubo	Takotsubo	t02032010	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
TS	TS	t200	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
also	also	a420	RB	B-VP	O
known	know	k505	VBN	I-VP	O
as	as	a200	IN	B-PP	O
broken	broken	b60205	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricle	ventricle	v05360240	NN	I-NP	O
apical	apical	a10204	JJ	I-NP	O
ballooning	ballooning	b0405052	NN	I-NP	O
with	with	w030	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
biomarkers	biomarker	b05062062	NNS	I-NP	O
and	and	a530	CC	O	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
coronary	coronary	c0605060	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	O	O
ST	ST	s300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
,	,	,000	,	O	O
T	T	t000	NN	B-NP	O
wave	wave	w010	NN	I-NP	O
inversions	inversion	i51062052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pathologic	pathologic	p03040202	JJ	B-NP	O
Q	Q	q000	NN	I-NP	O
waves	wave	w0102	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
54	54	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitral	mitral	m03604	JJ	B-NP	B-Disease
valve	valve	v0410	NN	I-NP	I-Disease
prolapse	prolapse	p6040120	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
migraines	migraine	m0260502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
substernal	substernal	s012306504	JJ	B-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
segment	segment	s025053	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
leads	lead	l032	NNS	B-NP	O
II	II	i000	CD	B-NP	O
,	,	,000	,	I-NP	O
III	III	i000	CD	I-NP	O
,	,	,000	,	O	O
aVF	aVF	a100	NN	B-NP	O
,	,	,000	,	O	O
V5	V5	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
V6	V6	0000	NN	B-NP	O
and	and	a530	CC	O	O
positive	positive	p0203010	JJ	B-NP	O
troponin	troponin	t6010505	NN	I-NP	O
I	I	i000	CD	I-NP	O
.	.	.000	.	O	O

Emergent	Emergent	e5062053	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
angiogram	angiogram	a5202605	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
with	with	w030	IN	B-PP	O
moderately	moderately	m030603040	RB	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
wall	wall	w040	NN	B-NP	O
motion	motion	m0305	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
TS	TS	t200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Detailed	Detailed	d030403	JJ	B-NP	O
history	history	h023060	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
took	take	t020	VBD	B-VP	O
zolmitriptan	zolmitriptan	z04503601305	NN	B-NP	B-Chemical
sparingly	sparingly	s10605240	RB	B-ADVP	O
only	only	o540	RB	O	O
when	when	w050	WRB	B-ADVP	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
migraines	migraine	m0260502	NNS	B-NP	B-Disease
.	.	.000	.	O	O

But	But	b030	CC	O	O
before	before	b01060	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
event	event	e1053	NN	I-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
zolmitriptan	zolmitriptan	z04503601305	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
daily	daily	d040	RB	I-NP	O
for	for	f060	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
persistent	persistent	p062023053	JJ	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
otherwise	otherwise	o306020	RB	B-ADVP	O
reported	report	r0106303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
quite	quite	q030	RB	B-ADJP	O
active	active	a23010	JJ	I-ADJP	O
,	,	,000	,	O	O
rides	ride	r0302	NNS	B-NP	O
horses	horse	h06202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
does	do	d020	VBZ	B-VP	O
show	show	s000	VB	I-VP	O
jumping	jump	j051052	VBG	B-VP	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
limitations	limitation	l050303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
physical	physical	p020204	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
or	or	o600	CC	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
migrainosus	migrainosus	m026050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Extensive	Extensive	e23052010	JJ	B-NP	O
literature	literature	l030603060	NN	I-NP	O
search	search	s0620	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
zolmitriptan	zolmitriptan	z04503601305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
TS	TS	t200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Depression	Depression	d0160205	NN	B-NP	B-Disease
,	,	,000	,	O	O
impulsiveness	impulsiveness	i51042010502	NN	B-NP	B-Disease
,	,	,000	,	O	O
sleep	sleep	s401	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
memory	memory	m05060	NN	B-NP	O
in	in	i500	IN	B-PP	O
past	past	p023	JJ	B-NP	O
and	and	a530	CC	I-NP	O
present	present	p602053	JJ	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	m030405030205030510305050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ecstasy	ecstasy	e23020	JJ	B-ADJP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
Ecstasy	Ecstasy	e23020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	m030405030205030510305050	NN	I-NP	I-Chemical
,	,	,000	,	I-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
worldwide	worldwide	w0643030	RB	I-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
of	of	o100	IN	B-PP	O
abuse	abuse	a1020	NN	B-NP	O
.	.	.000	.	O	O

Unfortunately	Unfortunately	u510630503040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
from	from	f605	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
investigating	investigate	i510230203052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
psychological	psychological	p20204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
inconsistent	inconsistent	i52052023053	JJ	B-ADJP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
largest	large	l062023	JJS	I-NP	O
to	to	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
in	in	i500	IN	B-PP	O
sample	sample	s05140	NN	B-NP	O
size	size	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
5HT	5HT	5030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
present	present	p602053	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
past	past	p023	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
to	to	t000	TO	B-VP	O
include	include	i524030	VB	I-VP	O
robust	robust	r01023	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
other	other	o306	JJ	B-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
substances	substance	s012305202	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
sample	sample	s05140	NN	I-NP	O
of	of	o100	IN	B-PP	O
997	997	0000	CD	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
(	(	(000	(	O	O
52	52	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
male	male	m040	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
recruited	recruit	r0260303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
four	four	f060	CD	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
drug	drug	d602	NN	B-NP	O
(	(	(000	(	O	O
ND	ND	n300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AN	AN	a500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
cannabis	cannabis	c050102	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
/	/	/000	SYM	O	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CAN	CAN	c050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
polydrug	polydrug	p0403602	NN	I-NP	O
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
polydrug	polydrug	p0403602	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
present	present	p602053	JJ	B-ADJP	O
(	(	(000	(	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
past	past	p023	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
EX	EX	e200	NN	B-NP	O
-	-	-000	HYPH	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Participants	Participant	p06302010532	NNS	B-NP	O
completed	complete	c05140303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
history	history	h023060	NN	I-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
,	,	,000	,	O	O
Beck	Beck	b020	NNP	B-NP	O
Depression	Depression	d0160205	NNP	I-NP	B-Disease
Inventory	Inventory	i51053060	NNP	I-NP	O
,	,	,000	,	O	O
Barratt	Barratt	b0603	NNP	B-NP	O
Impulsiveness	Impulsiveness	i51042010502	NNP	I-NP	B-Disease
Scale	Scale	s2040	NNP	I-NP	O
,	,	,000	,	O	O
Pittsburgh	Pittsburgh	p03210620	NNP	B-NP	O
Sleep	Sleep	s401	NNP	I-NP	O
Quality	Quality	q04030	NNP	I-NP	O
Index	Index	i5302	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Wechsler	Wechsler	w0202406	NNP	B-NP	O
Memory	Memory	m05060	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
-	-	-000	HYPH	O	O
Revised	Revise	r010203	VBN	B-VP	O
which	which	w020	WDT	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
total	total	t0304	NN	B-NP	O
,	,	,000	,	O	O
provided	provide	p6010303	VBN	B-PP	O
13	13	0000	CD	B-NP	O
psychometric	psychometric	p2020503602	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
CAN	CAN	c050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
PD	PD	p300	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
record	record	r02063	VB	I-VP	O
greater	great	g60306	JJR	B-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
EX	EX	e200	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
recorded	record	r0206303	VBD	B-VP	O
greater	great	g60306	JJR	B-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
than	than	t050	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
on	on	o500	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
13	13	0000	CD	I-NP	O
psychometric	psychometric	p2020503602	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
.	.	.000	.	O	O

Strikingly	Strikingly	s360205240	RB	B-ADVP	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
98	98	0000	CD	B-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
9	9	9000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
past	past	p023	IN	B-PP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
few	few	f000	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
present	present	p602053	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
users	user	u2062	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
for	for	f060	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
measures	measure	m020602	NNS	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
measures	measure	m020602	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
improvement	improvement	i5160105053	NN	B-NP	O
on	on	o500	IN	B-PP	O
just	just	j023	RB	B-NP	O
one	one	o500	CD	I-NP	O
measure	measure	m02060	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Given	Give	g0105	VBN	B-VP	O
this	this	t020	DT	B-NP	O
record	record	r02063	NN	I-NP	O
of	of	o100	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
memory	memory	m05060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
,	,	,000	,	O	O
impulsiveness	impulsiveness	i51042010502	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
sleep	sleep	s401	NN	B-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
generation	generation	g05060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
concern	concern	c052065	NN	B-NP	O
.	.	.000	.	O	O

Association	Association	a2020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
variants	variant	v060532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HOMER1	HOMER1	0000	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
with	with	w030	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
symptomatic	symptomatic	s0513050302	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
use	use	u200	NN	I-NP	O
could	could	c043	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
motor	motor	m0306	NN	B-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
,	,	,000	,	O	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

HOMER1	HOMER1	0000	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
with	with	w030	IN	B-PP	O
pivotal	pivotal	p010304	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
transmission	transmission	t605250205	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigates	investigate	i51023020302	VBZ	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
polymorphisms	polymorphism	p04050610252	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
HOMER1	HOMER1	0000	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
promoter	promoter	p6050306	NN	I-NP	O
region	region	r0205	NN	I-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
205	205	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
genotyped	genotype	g05030103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
rs4704559	rs4704559	0000	NN	B-NP	O
,	,	,000	,	I-NP	O
rs10942891	rs10942891	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
rs4704560	rs4704560	0000	NN	I-NP	O
by	by	b000	IN	B-PP	O
allelic	allelic	a40402	JJ	B-NP	O
discrimination	discrimination	d02605050305	NN	I-NP	O
with	with	w030	IN	B-PP	O
Taqman	Taqman	t02505	NN	B-NP	O
assays	assay	a202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rs4704559	rs4704559	0000	NN	I-NP	O
G	G	g000	NN	I-NP	O
allele	allele	a4040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
(	(	(000	(	O	O
prevalence	prevalence	p601040520	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
(	(	(000	(	O	O
PR	PR	p600	NN	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
615	615	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
CI	CI	c000	NN	B-NP	O
)	)	)000	)	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
426	426	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
887	887	0000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
009	009	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
PR	PR	p600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
515	515	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
295	295	0000	CD	I-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
899	899	0000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
020	020	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
HOMER1	HOMER1	0000	NN	B-NP	O
rs4704559	rs4704559	0000	NN	I-NP	O
G	G	g000	NN	I-NP	O
allele	allele	a4040	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Crocin	Crocin	c60205	NN	B-NP	B-Chemical
improves	improve	i5160102	VBZ	B-VP	O
lipid	lipid	l0103	NN	B-NP	O
dysregulation	dysregulation	d02602040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
subacute	subacute	s0102030	JJ	B-NP	O
diazinon	diazinon	d020505	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
through	through	t06020	IN	B-PP	O
ERK1	ERK1	0000	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
pathway	pathway	p030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Diazinon	Diazinon	d020505	NNP	B-NP	B-Chemical
Yis	Yis	y020	NNP	I-NP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
broadly	broadly	b60340	RB	I-NP	O
used	use	u203	VBN	I-NP	O
organophosphorus	organophosphorus	o6205010210602	NN	I-NP	B-Chemical
insecticides	insecticide	i52023020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
agriculture	agriculture	a2602043060	NN	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
interfere	interfere	i53061060	VB	I-VP	O
with	with	w030	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hypolipidemic	hypolipidemic	h010401030502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
established	establish	e230140203	VBN	I-VP	O
.	.	.000	.	O	O

Earlier	Early	e06406	JJR	B-NP	O
studies	study	s30302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
Extracellular	Extracellular	e23602040406	JJ	B-NP	O
signal	signal	s02504	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
regulated	regulate	r02040303	VBN	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
(	(	(000	(	O	O
ERK	ERK	e620	NN	B-NP	O
)	)	)000	)	O	O
pathways	pathway	p0302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
density	density	d052030	NN	I-NP	O
lipoprotein	lipoprotein	l010160305	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
LDLr	LDLr	l346	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
,	,	,000	,	O	O
ERK	ERK	e620	NN	B-NP	O
and	and	a530	CC	O	O
LDLr	LDLr	l346	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
subacute	subacute	s0102030	JJ	B-NP	O
diazinon	diazinon	d020505	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
ameliorating	ameliorate	a5040603052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
disturbed	disturbed	d02306103	JJ	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
homeostasis	homeostasis	h050230202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
24	24	0000	CD	B-NP	O
Rats	Rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
4	4	4000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	O	O
received	receive	r020103	VBD	B-VP	O
following	follow	f04052	VBG	B-PP	O
treatments	treatment	t60350532	NNS	B-NP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
;	;	;000	:	O	O
Corn	Corn	c065	NN	B-NP	O
oil	oil	o040	NN	I-NP	O
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15mg	15mg	0000	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
orally	orally	o6040	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	O	O
25mg	25mg	0000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
,	,	,000	,	O	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
LDL	LDL	l340	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
mRNA	mRNA	m650	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
LDLr	LDLr	l346	NN	B-NP	O
and	and	a530	CC	I-NP	O
ERK1	ERK1	0000	NN	I-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
protein	protein	p60305	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
activated	activated	a23010303	JJ	I-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ERK1	ERK1	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
liver	liver	l0106	NN	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Western	Western	w023065	JJ	B-NP	O
blotting	blotting	b403052	NN	I-NP	O
and	and	a530	CC	O	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
real	real	r040	JJ	I-NP	O
time	time	t050	NN	I-NP	O
polymerase	polymerase	p040506020	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
subacute	subacute	s0102030	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-VP	O
diazinon	diazinon	d020505	VB	I-VP	B-Chemical
significantly	significantly	s025010205340	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
,	,	,000	,	O	O
triglyceride	triglyceride	t60240206030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
LDL	LDL	l340	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-NP	O
diazinon	diazinon	d020505	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
ERK1	ERK1	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
protein	protein	p60305	NN	I-NP	O
phosphorylation	phosphorylation	p02106040305	NN	I-NP	O
and	and	a530	CC	O	O
LDLr	LDLr	l346	NN	B-NP	O
transcript	transcript	t60526013	NN	I-NP	O
.	.	.000	.	O	O

Crocin	Crocin	c60205	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ERK	ERK	e620	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	O	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperlipemia	hyperlipemia	h0106401050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
LDLr	LDLr	l346	NN	B-NP	O
transcript	transcript	t60526013	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Crocin	Crocin	c60205	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperlipemia	hyperlipemia	h0106401050	NN	I-NP	B-Disease
through	through	t06020	IN	B-PP	O
modulating	modulating	m030403052	NN	B-NP	O
of	of	o100	IN	B-PP	O
ERK	ERK	e620	NN	B-NP	O
pathway	pathway	p030	NN	I-NP	O
and	and	a530	CC	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
LDLr	LDLr	l346	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
P	P	p000	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
active	active	a23010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
Hodgkin	Hodgkin	h03205	NN	I-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hodgkin	Hodgkin	h03205	NN	B-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
(	(	(000	(	O	O
HL	HL	h400	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
chemosensitive	chemosensitive	c050205203010	JJ	I-NP	O
malignancy	malignancy	m040250520	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
relapse	relapse	r040120	NN	B-NP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
with	with	w030	IN	B-PP	O
autologous	autologous	a03040202	JJ	B-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
which	which	w020	WDT	B-NP	O
relies	rely	r0402	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
control	control	c053604	NN	I-NP	O
with	with	w030	IN	B-PP	O
salvage	salvage	s041020	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Regimens	Regimen	r0205052	NNS	B-NP	O
commonly	commonly	c050540	RB	B-VP	O
used	use	u203	VBN	I-VP	O
often	often	o1305	RB	B-ADVP	O
require	require	r02060	VBP	B-VP	O
inpatient	inpatient	i5103053	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
deliver	deliver	d040106	VB	I-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Gemcitabine	Gemcitabine	g0520301050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
activity	activity	a2301030	NN	B-NP	O
in	in	i500	IN	B-PP	O
HL	HL	h400	NN	B-NP	B-Disease
,	,	,000	,	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
overlapping	overlap	o106401052	VBG	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
chemotherapeutics	chemotherapeutic	c050306010302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
delivered	deliver	d04010603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
centre	centre	c05360	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
relapsed	relapsed	r0401203	JJ	B-NP	O
or	or	o600	CC	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
HL	HL	h400	NN	I-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
day	day	d000	NN	B-NP	O
(	(	(000	(	O	O
D	D	d000	NN	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
D8	D8	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
D15	D15	0000	NN	I-NP	O
;	;	;000	:	O	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
D1	D1	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
5	5	5000	CD	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
D15	D15	0000	NN	B-NP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
28	28	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
P	P	p000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

Demographic	Demographic	d050260102	JJ	B-NP	O
,	,	,000	,	I-NP	O
survival	survival	s0610104	NN	I-NP	O
,	,	,000	,	I-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
data	datum	d030	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
eligible	eligible	e4020140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
:	:	:000	:	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
27	27	0000	CD	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	I-NP	O
twenty	twenty	t0530	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
total	total	t0304	NN	B-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
3	3	3000	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
of	of	o100	IN	B-PP	O
41	41	0000	CD	B-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
as	as	a200	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
41	41	0000	CD	I-NP	O
(	(	(000	(	O	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
ORR	ORR	o600	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
complete	complete	c0514030	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
CR	CR	c600	NN	B-NP	O
)	)	)000	)	O	O
37	37	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
partial	partial	p06304	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
14	14	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
15	15	0000	CD	I-NP	O
CR	CR	c600	NN	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
CR	CR	c600	NN	I-NP	O
on	on	o500	IN	B-PP	O
PET	PET	p030	NN	B-NP	O
and	and	a530	CC	I-NP	O
ORR	ORR	o600	NN	I-NP	O
of	of	o100	IN	B-PP	O
85	85	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
second	second	s02053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
3	3	3000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
4	4	4000	CD	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
haematological	haematological	h050304020204	JJ	B-ADJP	O
:	:	:000	:	O	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
54	54	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
51	51	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
P	P	p000	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
progression	progression	p60260205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
46	46	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
CI	CI	c000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
62	62	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
overall	overall	o10604	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
59	59	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
43	43	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
74	74	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Fourteen	Fourteen	f06305	CD	B-NP	O
of	of	o100	IN	B-PP	O
41	41	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
proceeded	proceed	p6020303	VBD	B-VP	O
directly	directly	d0602340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
autologous	autologous	a03040202	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
.	.	.000	.	O	O

GEM	GEM	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
P	P	p000	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
salvage	salvage	s041020	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
with	with	w030	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
high	high	h020	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
successful	successful	s0202104	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
relapsed	relapsed	r0401203	JJ	B-NP	O
or	or	o600	CC	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
HL	HL	h400	NN	I-NP	B-Disease
.	.	.000	.	O	O

Basal	Basal	b0204	JJ	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothalamic	hypothalamic	h0103040502	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenal	adrenal	a360504	JJ	I-NP	O
(	(	(000	(	O	O
HPA	HPA	h100	JJ	B-ADJP	O
)	)	)000	)	O	O
axis	axis	a202	NN	B-NP	O
and	and	a530	CC	O	O
psychological	psychological	p20204020204	JJ	B-NP	O
distress	distress	d023602	NN	I-NP	O
in	in	i500	IN	B-PP	O
recreational	recreational	r026030504	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
Ecstasy	Ecstasy	e23020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
psychostimulant	psychostimulant	p2020230504053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
increasingly	increasingly	i5260205240	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
psychobiological	psychobiological	p2020104020204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
acute	acute	a2030	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
neuroendocrine	neuroendocrine	n06053026050	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
less	less	l020	JJR	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
about	about	a103	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
HPA	HPA	h100	NN	B-NP	O
functionality	functionality	f05230504030	NN	I-NP	O
in	in	i500	IN	B-PP	O
recreational	recreational	r026030504	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
use	use	u200	NN	I-NP	O
on	on	o500	IN	B-PP	O
psychological	psychological	p20204020204	JJ	B-NP	O
distress	distress	d023602	NN	I-NP	O
and	and	a530	CC	O	O
basal	basal	b0204	JJ	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
HPA	HPA	h100	JJ	I-NP	O
axis	axis	a202	NN	I-NP	O
through	through	t06020	IN	B-PP	O
assessing	assess	a202052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
across	across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
diurnal	diurnal	d06504	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
nonusers	nonuser	n0502062	NNS	I-NP	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
light	light	l0203	JJ	I-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
heavy	heavy	h010	JJ	I-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
)	)	)000	)	O	O
completed	complete	c05140303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
substance	substance	s01230520	NN	I-NP	O
use	use	u200	NN	I-NP	O
inventory	inventory	i51053060	NN	I-NP	O
and	and	a530	CC	I-NP	O
measures	measure	m020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
psychological	psychological	p20204020204	JJ	B-NP	O
distress	distress	d023602	NN	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
then	then	t050	RB	O	O
two	two	t000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
sampling	sampling	s0514052	NN	I-NP	O
(	(	(000	(	O	O
on	on	o500	IN	B-PP	O
awakening	awaken	a0205052	VBG	B-VP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
post	post	p023	NN	I-NP	O
awakening	awakening	a0205052	NN	I-NP	O
,	,	,000	,	O	O
between	between	b0305	IN	B-PP	O
1400	1400	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1600	1600	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
and	and	a530	CC	O	O
pre	pre	p600	JJ	B-NP	O
bedtime	bedtime	b03050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
participants	participant	p06302010532	NNS	B-NP	O
also	also	a420	RB	B-ADVP	O
attended	attend	a305303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
to	to	t000	TO	B-VP	O
complete	complete	c0514030	VB	I-VP	O
a	a	a000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
multitasking	multitasking	m0430302052	JJ	I-NP	O
stressor	stressor	s360206	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
user	us	u206	JJR	B-NP	O
groups	group	g6012	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
greater	great	g60306	JJR	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
nonusers	nonuser	n0502062	NNS	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
profile	profile	p601040	NN	I-NP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
light	light	l0203	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
bed	bed	b030	NN	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
heavy	heavy	h010	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
upon	upon	u105	IN	B-PP	O
awakening	awaken	a0205052	VBG	B-VP	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
bed	bed	b030	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
group	group	g601	NN	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
afternoon	afternoon	a1306505	NN	B-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
overall	overall	o10604	JJ	B-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
secretion	secretion	s0260305	NN	I-NP	O
across	across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
in	in	i500	IN	B-PP	O
line	line	l050	NN	B-NP	O
with	with	w030	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
recreational	recreational	r026030504	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

Dysregulated	Dysregulate	d02602040303	VBN	B-NP	O
diurnal	diurnal	d06504	JJ	I-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
inappropriate	inappropriate	i5016016030	JJ	B-NP	O
anticipation	anticipation	a5302010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
forthcoming	forthcoming	f0630205052	JJ	B-NP	O
demands	demand	d050532	NNS	I-NP	O
and	and	a530	CC	I-NP	O
hypersecretion	hypersecretion	h010620260305	NN	I-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
psychological	psychological	p20204020204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
physical	physical	p020204	JJ	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
heavy	heavy	h010	JJ	B-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Ifosfamide	Ifosfamide	i102105030	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
timely	timely	t05040	JJ	I-NP	O
EEG	EEG	e020	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Ifosfamide	Ifosfamide	i102105030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
alkylating	alkylate	a420403052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cancers	cancer	c052062	NNS	B-NP	B-Disease
including	include	i52403052	VBG	B-PP	O
sarcomas	sarcoma	s0620502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
lymphoma	lymphoma	l051050	NN	B-NP	B-Disease
,	,	,000	,	O	O
gynecologic	gynecologic	g0502040202	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
testicular	testicular	t023020406	JJ	I-NP	I-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Encephalopathy	Encephalopathy	e52010401030	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
IV	IV	i100	CD	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
highlight	highlight	h02040203	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
electroencephalogram	electroencephalogram	e40236052010402605	NN	B-NP	O
(	(	(000	(	O	O
EEG	EEG	e020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
detection	detection	d0302305	NN	I-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Retrospective	Retrospective	r036021023010	JJ	B-NP	O
chart	chart	c063	NN	I-NP	O
review	review	r010	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
and	and	a530	CC	I-NP	O
EEG	EEG	e020	NN	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
on	on	o500	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
MD	MD	m300	NNP	B-NP	O
Anderson	Anderson	a5306205	NNP	I-NP	O
Cancer	Cancer	c05206	NNP	I-NP	B-Disease
Center	Center	c05306	NNP	I-NP	O
between	between	b0305	IN	B-PP	O
years	year	y062	NNS	B-NP	O
2009	2009	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2012	2012	0000	CD	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
five	five	f010	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
(	(	(000	(	O	O
within	within	w0305	IN	B-PP	O
12	12	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
receiving	receive	r0201052	VBG	B-VP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
generalized	generalize	g0506040203	VBN	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
non	non	n050	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
convulsive	convulsive	c051042010	JJ	I-NP	I-Disease
status	status	s30302	NN	I-NP	I-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
NCSE	NCSE	n200	NN	B-NP	B-Disease
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
required	require	r020603	VBD	B-VP	O
ICU	ICU	i200	NN	B-NP	O
admission	admission	a350205	NN	I-NP	O
and	and	a530	CC	I-NP	O
intubation	intubation	i53010305	NN	I-NP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
EEG	EEG	e020	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
epileptiform	epileptiform	e10401301065	NN	B-NP	O
discharges	discharge	d0206202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
run	run	r050	NN	B-NP	O
of	of	o100	IN	B-PP	O
triphasic	triphasic	t6010202	JJ	B-NP	O
waves	wave	w0102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
moderate	moderate	m0306030	JJ	B-NP	O
degree	degree	d0260	NN	I-NP	O
diffuse	diffuse	d01020	JJ	B-ADJP	O
generalized	generalize	g0506040203	VBN	B-VP	O
slowing	slow	s4052	VBG	B-VP	O
.	.	.000	.	O	O

Mixed	Mix	m0203	VBN	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
sharps	sharp	s0612	NNS	I-NP	O
and	and	a530	CC	O	O
triphasic	triphasic	t6010202	JJ	B-NP	O
waves	wave	w0102	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

Repeat	Repeat	r0103	NN	B-NP	O
EEGs	EEG	e020	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
_	_	_000	NN	I-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptom	symptom	s051305	NN	B-NP	O
onset	onset	o5203	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Severity	Severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
EEG	EEG	e020	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
timely	timely	t05040	JJ	I-NP	O
EEG	EEG	e020	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
develop	develop	d010401	VBP	B-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
hospitalised	hospitalised	h02103040203	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
contrast	contrast	c0536023	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
CIN	CIN	c050	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
hospitalised	hospitalised	h02103040203	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Ninety	Ninety	n05030	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
enhanced	enhance	e505203	VBN	B-VP	O
computed	compute	c0510303	VBN	B-NP	O
tomography	tomography	t05026010	NN	I-NP	O
(	(	(000	(	O	O
CT	CT	c300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
serially	serially	s06040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
.	.	.000	.	O	O

CIN	CIN	c050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Cr	Cr	c600	NN	B-NP	B-Chemical
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Cr	Cr	c600	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
over	over	o106	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Relationships	Relationship	r0403052012	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
CIN	CIN	c050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
90	90	0000	CD	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

CIN	CIN	c050	NN	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CIN	CIN	c050	NN	B-NP	O
more	more	m060	RBR	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
CT	CT	c300	NN	B-NP	O
within	within	w0305	IN	B-PP	O
45	45	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
an	an	a500	DT	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
017	017	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CIN	CIN	c050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	JJR	I-ADJP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
bevacizumab	bevacizumab	b0102020501	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
irinotecan	irinotecan	i605030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
021	021	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
044	044	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
in	in	i500	IN	B-PP	O
hospitalised	hospitalised	h02103040203	JJ	B-NP	O
oncological	oncological	o5204020204	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

CIN	CIN	c050	NN	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
times	time	t0502	NNS	I-NP	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
recent	recent	r02053	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bevacizumab	bevacizumab	b0102020501	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
irinotecan	irinotecan	i605030205	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
additional	additional	a3030504	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	O
development	development	d0104015053	NN	I-NP	O
.	.	.000	.	O	O

KEY	KEY	k000	NN	B-NP	O
POINTS	POINTS	p0532	NNS	I-NP	O
:	:	:000	:	O	O
.	.	.000	.	O	O

Contrast	Contrast	c0536023	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
CIN	CIN	c050	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
concern	concern	c052065	NN	I-NP	O
for	for	f060	IN	B-PP	O
oncological	oncological	o5204020204	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
CT	CT	c300	NN	B-NP	O
.	.	.000	.	O	O

.	.	.000	.	O	O
CIN	CIN	c050	NN	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
more	more	m060	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
when	when	w050	WRB	B-ADVP	O
CT	CT	c300	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
<	<	<000	SYM	B-NP	O
45	45	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

.	.	.000	.	O	O
Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
bevacizumab	bevacizumab	b0102020501	NN	B-NP	B-Chemical
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
additional	additional	a3030504	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Syndrome	Syndrome	s0536050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
antidiuretic	antidiuretic	a5303060302	JJ	I-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
desvenlafaxine	desvenlafaxine	d0210540102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
syndrome	syndrome	s0536050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
anti	anti	a530	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
diuretic	diuretic	d060302	JJ	I-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
(	(	(000	(	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
)	)	)000	)	O	O
secretion	secretion	s0260305	NN	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
desvenlafaxine	desvenlafaxine	d0210540102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
with	with	w030	IN	B-PP	O
hyponatraemia	hyponatraemia	h0105036050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
desvenlafaxine	desvenlafaxine	d0210540102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
time	time	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
120	120	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	O	O
L	L	l000	NN	B-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
263	263	0000	CD	B-NP	O
mosmol	mosmol	m02504	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
410	410	0000	CD	I-NP	O
mosmol	mosmol	m02504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
63	63	0000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Desvenlafaxine	Desvenlafaxine	d0210540102050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
ceased	cease	c0203	VBN	I-VP	O
and	and	a530	CC	O	O
fluid	fluid	f403	NN	B-NP	O
restriction	restriction	r023602305	NN	I-NP	O
implemented	implement	i5140505303	VBD	B-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
the	the	t000	DT	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
128	128	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
and	and	a530	CC	I-NP	O
fluid	fluid	f403	NN	I-NP	O
restriction	restriction	r023602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
relaxed	relax	r040203	VBN	I-VP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
further	further	f06306	JJ	I-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
inpatient	inpatient	i5103053	JJ	I-NP	O
admission	admission	a350205	NN	I-NP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
134	134	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
137	137	0000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	O	O
L	L	l000	NN	B-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
mirtazapine	mirtazapine	m0630201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
widely	widely	w03040	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
desvenlafaxine	desvenlafaxine	d0210540102050	NN	B-NP	B-Chemical
might	might	m0203	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
hyponatremia	hyponatremia	h0105036050	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
take	take	t020	VB	B-VP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
corrective	corrective	c06023010	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
on	on	o500	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
and	and	a530	CC	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
remains	remain	r05052	VBZ	B-VP	O
controversial	controversial	c05360106204	JJ	B-ADJP	O
.	.	.000	.	O	O

Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
66	66	0000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
acute	acute	a2030	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
58	58	0000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
4	4	4000	CD	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
(	(	(000	(	O	O
M0	M0	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
(	(	(000	(	O	O
M1	M1	0000	NN	B-NP	O
,	,	,000	,	O	O
M2	M2	0000	NN	B-NP	O
,	,	,000	,	O	O
M3	M3	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
M4	M4	0000	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
chronological	chronological	c060504020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
used	use	u203	VBN	B-VP	O
at	at	a300	IN	B-PP	O
M0	M0	0000	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
used	use	u203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
moment	moment	m05053	NN	B-NP	O
-	-	-000	HYPH	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
total	total	t0304	JJ	I-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
(	(	(000	(	O	O
TAP	TAP	t010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
DNA	DNA	d500	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
morphology	morphology	m06104020	NN	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
at	at	a300	IN	B-PP	O
each	each	e020	DT	B-NP	O
time	time	t050	NN	I-NP	O
point	point	p053	NN	I-NP	O
.	.	.000	.	O	O

Single	Single	s05240	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
disarrangement	disarrangement	d020605205053	NN	I-NP	I-Disease
,	,	,000	,	O	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
DNA	DNA	d500	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
(	(	(000	(	O	O
strand	strand	s36053	NN	B-NP	O
breaks	break	b602	NNS	I-NP	O
(	(	(000	(	O	O
SBs	SB	s120	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
oxidized	oxidize	o2030203	VBN	B-NP	O
pyrimidines	pyrimidine	p0605030502	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBN	B-NP	O
TAP	TAP	t010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
chronological	chronological	c060504020204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
on	on	o500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
011	011	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
004	004	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
TAP	TAP	t010	NN	B-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
95	95	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
049	049	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
DNA	DNA	d500	NN	B-NP	O
SBs	SB	s120	NNS	I-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
95	95	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
049	049	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

DNA	DNA	d500	NN	B-NP	O
SBs	SB	s120	NNS	I-NP	O
damage	damage	d05020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negatively	negatively	n020301040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
TAP	TAP	t010	NN	B-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
98	98	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
018	018	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
97	97	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
027	027	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
oxidative	oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
plausible	plausible	p4020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
different	different	d0106053	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
versus	versus	v06202	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Tacrolimus	Tacrolimus	t026040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
related	relate	r040303	VBN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
center	center	c05306	NN	I-NP	O
experience	experience	e21060520	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
new	new	n000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
LT	LT	l300	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
implications	implication	i5140203052	NNS	I-NP	O
and	and	a530	CC	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
27	27	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
children	child	c043605	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
LT	LT	l300	NNP	B-NP	O
from	from	f605	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
December	December	d0205106	NNP	B-NP	O
2010	2010	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
center	center	c05306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Pre	Pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	B-ADJP	O
,	,	,000	,	O	O
intra	intra	i5360	AFX	O	O
-	-	-000	HYPH	O	O
operative	operative	o10603010	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
generalized	generalize	g0506040203	VBN	I-VP	O
tonic	tonic	t0502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
two	two	t000	CD	I-NP	O
wk	wk	w200	NN	I-NP	O
after	after	a1306	IN	B-PP	O
LT	LT	l300	NN	B-NP	O
.	.	.000	.	O	O

Univariate	Univariate	u50106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
LT	LT	l300	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
gender	gender	g05306	NN	B-NP	O
,	,	,000	,	O	O
pediatric	pediatric	p0303602	JJ	B-NP	O
end	end	e530	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
stage	stage	s3020	NN	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
score	score	s2060	NN	I-NP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
Child	Child	c043	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Pugh	Pugh	p020	NNP	I-NP	O
score	score	s2060	NN	I-NP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
total	total	t0304	JJ	I-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
trough	trough	t6020	NN	B-NP	O
TAC	TAC	t020	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
trough	trough	t6020	NN	B-NP	O
TAC	TAC	t020	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
independent	independent	i5301053053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
survived	survive	s0610103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
good	good	g030	JJ	B-NP	O
graft	graft	g6013	NN	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
remained	remain	r050503	VBD	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-ADJP	O
free	free	f600	JJ	I-ADJP	O
without	without	w0303	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
drugs	drug	d602	NNS	I-NP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
of	of	o100	IN	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
trough	trough	t6020	NN	I-NP	O
TAC	TAC	t020	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
contributed	contribute	c0536010303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
LT	LT	l300	NN	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
PELD	PELD	p043	NN	I-NP	O
and	and	a530	CC	O	O
Child	Child	c043	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Pugh	Pugh	p020	NNP	I-NP	O
scores	score	s20602	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
LT	LT	l300	NN	B-NP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
Tbil	Tbil	t104	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
contributory	contributory	c05360103060	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
TAC	TAC	t020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
flavonoid	flavonoid	f4010503	JJ	I-NP	B-Chemical
apigenin	apigenin	a1020505	NN	I-NP	B-Chemical
delays	delay	d0402	VBZ	B-VP	O
forgetting	forgetting	f06203052	NN	B-NP	O
of	of	o100	IN	B-PP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
conditioning	conditioning	c0530305052	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
flavonoid	flavonoid	f4010503	NN	I-NP	B-Chemical
apigenin	apigenin	a1020505	NN	I-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
acquisition	acquisition	a2020305	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
and	and	a530	CC	O	O
forgetting	forgetting	f06203052	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
step	step	s301	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
through	through	t06020	IN	B-PP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
apigenin	apigenin	a1020505	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
apigenin	apigenin	a1020505	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1mg	1mg	1520	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
acquisition	acquisition	a2020305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
-	-	-000	HYPH	B-ADVP	O
and	and	a530	CC	I-ADVP	O
apigenin	apigenin	a1020505	NN	I-ADVP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
step	step	s301	VB	I-VP	O
through	through	t06020	RP	B-PRT	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
dark	dark	d062	JJ	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
cut	cut	c030	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
off	off	o100	RP	B-PRT	O
time	time	t050	NN	B-NP	O
(	(	(000	(	O	O
540	540	0000	CD	B-NP	O
s	s	s000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
retested	reteste	r0302303	VBN	I-VP	O
weekly	weekly	w0240	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
eight	eight	e0203	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
treated	treated	t60303	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
five	five	f010	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
acquisition	acquisition	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
apigenin	apigenin	a1020505	NN	B-NP	B-Chemical
still	still	s304	RB	B-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
step	step	s301	VB	I-VP	O
through	through	t06020	IN	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
apigenin	apigenin	a1020505	NN	B-NP	B-Chemical
delays	delay	d0402	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
forgetting	forgetting	f06203052	NN	I-NP	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
modulate	modulate	m0304030	VB	I-VP	O
the	the	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fear	fear	f060	NN	B-NP	O
memory	memory	m05060	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
obtained	obtain	o130503	VBN	I-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
apigenin	apigenin	a1020505	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
conditioning	conditioning	c0530305052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
implicate	implicate	i51402030	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
action	action	a2305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Histamine	Histamine	h02305050	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
and	and	a530	CC	O	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Hemodynamic	Hemodynamic	h0503050502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
by	by	b000	IN	B-PP	O
bolus	bolus	b0402	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

H1	H1	0000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
H2	H2	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
dosing	dosing	d02052	NN	B-NP	O
with	with	w030	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
to	to	t000	TO	B-PP	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	HYPH	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
;	;	;000	:	O	O
group	group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	HYPH	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
plus	plus	p402	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
;	;	;000	:	O	O
group	group	g601	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	HYPH	I-NP	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
plus	plus	p402	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	HYPH	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Histamine	Histamine	h02305050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
level	level	l0104	NN	I-NP	O
2	2	2000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
dosing	dosing	d02052	NN	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
change	change	c0520	NN	I-NP	O
and	and	a530	CC	O	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
58	58	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
not	not	n030	RB	O	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

Prior	Prior	p606	JJ	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
with	with	w030	IN	B-PP	O
antagonists	antagonist	a5302050232	NNS	B-NP	O
partially	partially	p063040	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
dosing	dosing	d02052	NN	I-NP	O
are	be	a600	VBP	B-VP	O
only	only	o540	RB	I-VP	O
partially	partially	p063040	RB	I-VP	O
explained	explain	e2140503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-NP	O
prior	prior	p606	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
with	with	w030	IN	B-PP	O
H1	H1	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
H2	H2	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
only	only	o540	RB	B-NP	O
partial	partial	p06304	JJ	I-NP	O
protection	protection	p60302305	NN	I-NP	O
.	.	.000	.	O	O

Cholecystokinin	Cholecystokinin	c0402023020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
octapeptide	octapeptide	o2301013030	NN	I-NP	I-Chemical
restored	restore	r0230603	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
impairment	impairment	i51065053	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Cholecystokinin	Cholecystokinin	c0402023020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
octapeptide	octapeptide	o2301013030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
8	8	8000	CD	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
gut	gut	g030	NN	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
,	,	,000	,	O	O
exerts	exert	e20632	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
biological	biological	b04020204	JJ	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
previously	previously	p6010240	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
significantly	significantly	s025010205340	RB	I-NP	O
alleviated	alleviate	a4010303	VBN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBD	B-VP	O
spine	spine	s1050	NN	B-NP	O
density	density	d052030	NN	I-NP	O
decreases	decrease	d0260202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CA1	CA1	0000	NN	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
in	in	i500	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
(	(	(000	(	O	O
LTP	LTP	l310	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
perforant	perforant	p06106053	JJ	I-NP	O
path	path	p030	NN	I-NP	O
(	(	(000	(	O	O
LPP	LPP	l100	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
synapse	synapse	s050120	NN	I-NP	O
of	of	o100	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
(	(	(000	(	O	O
DG	DG	d200	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
or	or	o600	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Population	Population	p01040305	NN	B-NP	O
spikes	spike	s10202	NNS	I-NP	O
(	(	(000	(	O	O
PS	PS	p200	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
evoked	evoke	e10203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
stimulation	stimulation	s305040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LPP	LPP	l100	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DG	DG	d200	NN	I-NP	O
region	region	r0205	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
30mg	30mg	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
LTP	LTP	l310	NN	I-NP	O
and	and	a530	CC	I-NP	O
CCK	CCK	c200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
8	8	8000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
1ug	1ug	1020	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
restored	restore	r0230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
of	of	o100	IN	B-PP	O
PS	PS	p200	NNP	B-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
8	8	8000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1ug	1ug	1020	CD	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
augmented	augment	a02505303	VBD	B-VP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
LTP	LTP	l310	NN	I-NP	O
in	in	i500	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
(	(	(000	(	O	O
1ml	1ml	1540	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Pre	Pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
CCK2	CCK2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
365	365	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
260	260	0000	CD	I-NP	O
(	(	(000	(	O	O
10ug	10ug	0000	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
)	)	)000	)	O	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
CCK1	CCK1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
364	364	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
718	718	0000	CD	I-NP	O
(	(	(000	(	O	O
10ug	10ug	0000	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
attenuates	attenuate	a3050302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
LTP	LTP	l310	NN	I-NP	O
through	through	t06020	IN	B-PP	O
CCK2	CCK2	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
an	an	a500	DT	B-NP	O
ameliorative	ameliorative	a5040603010	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
8	8	8000	CD	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

Glial	Glial	g404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	O	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
synaptic	synaptic	s0501302	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
key	key	k000	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Streptozotocin	Streptozotocin	s3601302030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ICV	ICV	i210	NN	B-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
glial	glial	g404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	O	O
post	post	p023	NN	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
ICV	ICV	i210	NN	B-NP	O
Streptozotocin	Streptozotocin	s3601302030205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
impaired	impaired	i510603	JJ	I-NP	I-Disease
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
explored	explore	e2140603	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
experiment	experiment	e210605053	NN	B-NP	O
set	set	s030	VBN	B-VP	O
up	up	u100	RP	B-PRT	O
1	1	1000	CD	B-NP	O
:	:	:000	SYM	I-NP	O
Memory	Memory	m05060	NN	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Morris	Morris	m0602	NNP	B-NP	O
water	water	w0306	NN	I-NP	O
maze	maze	m020	NN	I-NP	O
test	test	t023	NN	I-NP	O
on	on	o500	IN	B-PP	O
14	14	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
16	16	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ICV	ICV	i210	NN	B-NP	O
;	;	;000	:	O	O
3mg	3mg	3520	NN	B-NP	O
/	/	/000	SYM	I-NP	O
Kg	Kg	k200	NN	I-NP	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

STZ	STZ	s320	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
GFAP	GFAP	g101	NN	B-NP	O
,	,	,000	,	I-NP	O
CD11b	CD11b	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
TNF	TNF	t510	NN	I-NP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
indicating	indicate	i530203052	VBG	I-NP	O
glial	glial	g404	JJ	I-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	I-NP	O
neuroinflammation	neuroinflammation	n060514050305	NN	I-NP	B-Disease
.	.	.000	.	O	O

STZ	STZ	s320	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-VP	O
increased	increase	i5260203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
ROS	ROS	r020	NN	B-NP	O
,	,	,000	,	O	O
nitrite	nitrite	n036030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
synaptosomal	synaptosomal	s05013020504	JJ	B-NP	O
preparation	preparation	p601060305	NN	I-NP	O
illustrating	illustrate	i4023603052	VBG	B-VP	O
free	free	f600	JJ	B-NP	O
radical	radical	r030204	NN	I-NP	O
generation	generation	g05060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
excitotoxicity	excitotoxicity	e203030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-VP	O
expression	expression	e2160205	NN	B-NP	O
and	and	a530	CC	O	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
Caspase	Caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
treated	treated	t60303	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
which	which	w020	WDT	B-NP	O
specify	specify	s102010	VBP	B-VP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
and	and	a530	CC	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

STZ	STZ	s320	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
decrease	decrease	d026020	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
post	post	p023	JJ	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
CaMKIIa	CaMKIIa	c0520	NN	I-NP	O
and	and	a530	CC	I-NP	O
PSD	PSD	p230	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
95	95	0000	CD	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
,	,	,000	,	O	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
pre	pre	p600	JJ	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
(	(	(000	(	O	O
synaptophysin	synaptophysin	s05013010205	NN	B-NP	O
and	and	a530	CC	I-NP	O
SNAP	SNAP	s501	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
25	25	0000	CD	I-NP	O
)	)	)000	)	O	O
remains	remain	r05052	VBZ	B-VP	O
unaltered	unaltered	u50430603	JJ	B-NP	O
indicating	indicate	i530203052	VBG	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
post	post	p023	NN	I-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
Memantine	Memantine	m05053050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10mg	10mg	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Ibuprofen	Ibuprofen	i10160105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
13	13	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
glial	glial	g404	JJ	I-NP	O
activation	activation	a23010305	NN	I-NP	O
,	,	,000	,	O	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
and	and	a530	CC	O	O
post	post	p023	NN	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
experiment	experiment	e210605053	NN	B-NP	O
set	set	s030	VBN	B-VP	O
up	up	u100	RP	B-PRT	O
2	2	2000	CD	B-NP	O
:	:	:000	:	O	O
where	where	w060	WRB	B-ADVP	O
memory	memory	m05060	NN	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	O	O
9	9	9000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
GFAP	GFAP	g101	NN	B-NP	O
,	,	,000	,	O	O
CD11b	CD11b	0000	NN	B-NP	O
,	,	,000	,	O	O
TNF	TNF	t510	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
a	a	a000	NN	I-NP	O
,	,	,000	,	I-NP	O
ROS	ROS	r020	NN	I-NP	O
and	and	a530	CC	I-NP	O
nitrite	nitrite	n036030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
marker	marker	m06206	NN	I-NP	O
,	,	,000	,	O	O
synaptic	synaptic	s0501302	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
,	,	,000	,	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
remained	remain	r050503	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
.	.	.000	.	O	O

Collective	Collective	c04023010	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
neuroinflammatory	neuroinflammatory	n0605140503060	JJ	B-NP	B-Disease
process	process	p60202	NN	I-NP	O
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
occurs	occur	o2062	VBZ	B-VP	O
earlier	early	e06406	JJR	B-ADVP	O
to	to	t000	TO	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
and	and	a530	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
memory	memory	m05060	NN	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Present	Present	p602053	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
clearly	clearly	c40640	RB	B-ADVP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
glial	glial	g404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	O	O
post	post	p023	NN	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
key	key	k000	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
neuronal	neuronal	n060504	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
Contrast	Contrast	c0536023	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
CIN	CIN	c050	NN	B-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-VP	O
increases	increase	i5260202	VBZ	I-VP	O
the	the	t000	DT	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
and	and	a530	CC	I-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
CIN	CIN	c050	NN	B-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
iodinated	iodinate	i03050303	VBN	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
(	(	(000	(	O	O
PCAG	PCAG	p202	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
with	with	w030	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
values	value	v0402	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	O	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
solution	solution	s040305	NN	I-NP	O
that	that	t030	IN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
dextrose	dextrose	d0236020	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
the	the	t000	DT	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
'	'	'000	POS	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
blood	blood	b403	NN	I-NP	B-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BUN	BUN	b050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
seventh	seventh	s010530	JJ	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
material	material	m030604	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
included	include	i5240303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ARF	ARF	a610	NN	B-NP	B-Disease
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	B-Chemical
material	material	m030604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
ARF	ARF	a610	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
five	five	f010	CD	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
six	six	s020	CD	B-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
five	five	f010	CD	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
isotonic	isotonic	i2030502	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
application	application	a14020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	O
.	.	.000	.	O	O

Neurocognitive	Neurocognitive	n060202503010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neuroradiologic	neuroradiologic	n060603040202	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
late	late	l030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
Pediatric	Pediatric	p0303602	NNP	B-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
(	(	(000	(	O	O
POG	POG	p020	NN	B-NP	O
)	)	)000	)	O	O
P9605	P9605	0000	NN	B-NP	O
(	(	(000	(	O	O
standard	standard	s3053063	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
P9201	P9201	0000	NN	B-NP	O
(	(	(000	(	O	O
lesser	less	l0206	JJR	B-NP	O
risk	risk	r020	NN	I-NP	O
)	)	)000	)	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
protocols	protocol	p60302042	NNS	I-NP	O
(	(	(000	(	O	O
ACCL0131	ACCL0131	0000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
consequence	consequence	c052020520	NN	I-NP	O
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
.	.	.000	.	O	O

Concerns	Concern	c0520652	NNS	B-NP	O
about	about	a103	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MTX	MTX	m320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
1990s	1990	0000	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
modifications	modification	m03010203052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	O	O
(	(	(000	(	O	O
IT	IT	i300	JJ	B-ADJP	O
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
leucovorin	leucovorin	l02010605	NN	B-NP	O
rescue	rescue	r020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
frequency	frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
neurocognitive	neurocognitive	n060202503010	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
and	and	a530	CC	O	O
neuroradiologic	neuroradiologic	n060603040202	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intense	intense	i530520	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
directed	direct	d0602303	VBN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
P9605	P9605	0000	NN	B-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
those	those	t020	DT	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
fewer	few	f060	JJR	B-NP	O
CNS	CNS	c520	NN	I-NP	O
-	-	-000	HYPH	O	O
directed	direct	d0602303	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
days	day	d020	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
intensive	intensive	i53052010	JJ	B-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
(	(	(000	(	O	O
P9201	P9201	0000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
66	66	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
from	from	f605	IN	B-PP	O
16	16	0000	CD	B-NP	O
Pediatric	Pediatric	p0303602	NNP	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
institutions	institution	i5230303052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
"	"	"000	``	O	O
standard	standard	s3053063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
"	"	"000	''	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
00	00	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
99	99	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
at	at	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
CNS	CNS	c520	NN	B-NP	O
leukemia	leukemia	l02050	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
on	on	o500	IN	B-PP	O
ACCL0131	ACCL0131	0000	NN	B-NP	O
:	:	:000	:	O	O
28	28	0000	CD	B-NP	O
from	from	f605	IN	B-PP	O
P9201	P9201	0000	NN	B-NP	O
and	and	a530	CC	O	O
38	38	0000	CD	B-NP	O
from	from	f605	IN	B-PP	O
P9605	P9605	0000	NN	B-NP	O
.	.	.000	.	O	O

Magnetic	Magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
scans	scan	s2052	NNS	I-NP	O
and	and	a530	CC	O	O
standard	standard	s3053063	JJ	B-NP	O
neuropsychological	neuropsychological	n060120204020204	JJ	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
>	>	>000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Significantly	Significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
P9605	P9605	0000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
P9201	P9201	0000	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	O	O
83	83	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	O	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
identified	identify	i30530103	VBN	B-VP	O
as	as	a200	IN	B-PP	O
late	late	l030	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
scored	score	s20603	VBD	B-VP	O
<	<	<000	SYM	B-NP	O
85	85	0000	CD	I-NP	O
on	on	o500	IN	B-PP	O
either	either	e0306	DT	B-NP	O
Verbal	Verbal	v06104	NNP	I-NP	O
or	or	o600	CC	I-NP	O
Performance	Performance	p0610650520	NNP	I-NP	O
IQ	IQ	i200	NNP	I-NP	O
.	.	.000	.	O	O

Children	Child	c043605	NNS	B-NP	O
on	on	o500	IN	B-PP	O
both	both	b030	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	B-Disease
problems	problem	p6014052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
P9605	P9605	0000	NN	B-NP	O
children	child	c043605	NNS	I-NP	O
scored	score	s20603	VBN	B-VP	O
below	below	b040	IN	B-PP	O
average	average	a106020	NN	B-NP	O
on	on	o500	IN	B-PP	O
more	more	m060	RBR	B-NP	O
neurocognitive	neurocognitive	n060202503010	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
treated	treat	t60303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
P9201	P9201	0000	NN	B-NP	O
(	(	(000	(	O	O
82	82	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
measures	measure	m020602	NNS	I-NP	O
vs	vs	v200	CC	O	O
.	.	.000	.	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
measures	measure	m020602	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
supports	support	s010632	VBZ	B-VP	O
ongoing	ongoing	o52052	JJ	B-NP	O
concerns	concern	c0520652	NNS	I-NP	O
about	about	a103	IN	B-PP	O
intensive	intensive	i53052010	JJ	B-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
contributor	contributor	c0536010306	NN	I-NP	O
to	to	t000	TO	B-PP	O
CNS	CNS	c520	NN	B-NP	O
late	late	l030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Tranexamic	Tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
overdosage	overdosage	o106302020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
lady	lady	l030	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	O
4	4	4000	CD	I-NP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
tubulointerstial	tubulointerstial	t0104053062304	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
center	center	c05306	NN	I-NP	O
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
menorrhagia	menorrhagia	m0506020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
three	three	t060	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
packed	packed	p0203	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
session	session	s0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
.	.	.000	.	O	O

Tranexamic	Tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TNA	TNA	t500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hourly	hourly	h0640	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
her	her	h060	PRP	B-NP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
bleeding	bleed	b403052	VBG	I-VP	B-Disease
per	per	p060	IN	B-PP	O
vaginum	vaginum	v020505	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
sixth	sixth	s0230	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
TNA	TNA	t500	NN	B-NP	B-Chemical
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
convulsions	convulsion	c051042052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

TNA	TNA	t500	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Investigations	Investigation	i510230203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
or	or	o600	CC	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	B-Disease
system	system	s02305	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
provoked	provoke	p6010203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
require	require	r02060	VB	I-VP	O
any	any	a500	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
dialytic	dialytic	d040302	JJ	I-NP	O
support	support	s01063	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
convulsion	convulsion	c05104205	NN	B-NP	B-Disease
till	till	t040	IN	B-PP	O
dis	dis	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
charge	charge	c0620	NN	I-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
precipitating	precipitate	p602010303052	VBG	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
believed	believe	b040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
TNA	TNA	t500	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pre	Pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
using	use	u2052	VBG	B-VP	O
different	different	d0106053	JJ	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
formulations	formulation	f0650403052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Pre	Pre	p600	NN	B-NP	O
-	-	-000	HYPH	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
emulsions	emulsion	e5042052	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
lethal	lethal	l0304	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
alleviate	alleviate	a401030	VB	I-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
intralipid	intralipid	i536040103	NN	B-NP	O
or	or	o600	CC	I-NP	O
medialipid	medialipid	m03040103	NN	I-NP	O
emulsions	emulsion	e5042052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
anaesthetised	anaesthetise	a5023030203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
intralipid	intralipid	i536040103	NN	B-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
P	P	p000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
medialipid	medialipid	m03040103	NN	B-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Thereafter	Thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recorded	record	r0206303	VBD	B-VP	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
dysrhythmia	dysrhythmia	d02603050	NN	I-NP	B-Disease
occurrence	occurrence	o2060520	NN	I-NP	O
,	,	,000	,	O	O
respective	respective	r021023010	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
and	and	a530	CC	I-NP	O
tissue	tissue	t020	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
dysrhythmia	dysrhythmia	d02603050	NN	I-NP	B-Disease
occurrence	occurrence	o2060520	NN	I-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
HR	HR	h600	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
longer	long	l05206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
P	P	p000	NN	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
at	at	a300	IN	B-PP	O
those	those	t020	DT	B-NP	O
time	time	t050	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
P	P	p000	NN	I-NP	O
.	.	.000	.	O	O
Plasma	Plasma	p40250	NN	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
P	P	p000	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
.	.	.000	.	O	O
Bupivacaine	Bupivacaine	b010102050	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
P	P	p000	NN	I-NP	O
and	and	a530	CC	I-NP	O
Group	Group	g601	NN	I-NP	O
L	L	l000	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
intralipid	intralipid	i536040103	NN	B-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
medialipid	medialipid	m03040103	NN	B-NP	O
or	or	o600	CC	I-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	O	O
delayed	delay	d0403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
reduced	reduce	r030203	VBN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
tissue	tissue	t020	NN	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
medialipid	medialipid	m03040103	NN	B-NP	O
and	and	a530	CC	O	O
adapt	adapt	a3013	VB	B-VP	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
to	to	t000	TO	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	B-VP	I-Disease
Induced	Induce	i530203	VBN	B-NP	I-Disease
Acute	Acute	a2030	JJ	I-NP	I-Disease
Liver	Liver	l0106	NN	I-NP	I-Disease
Injury	Injury	i52060	NN	I-NP	I-Disease
Within	Within	w0305	IN	B-PP	O
12	12	0000	CD	B-NP	O
Hours	Hour	h062	NNS	I-NP	O
After	After	a1306	IN	B-PP	O
Fluvastatin	Fluvastatin	f4010230305	NN	B-NP	B-Chemical
Therapy	Therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
statins	statin	s303052	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
generally	generally	g0506040	RB	B-ADVP	O
well	well	w040	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
recent	recent	r02053	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
induced	induce	i530203	VBN	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
52	52	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
man	man	m050	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
12	12	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
beginning	begin	b0205052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
fluvastatin	fluvastatin	f4010230305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Patient	Patient	p03053	NN	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
complaints	complaint	c05140532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
anorexia	anorexia	a506020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
upper	upper	u106	JJ	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
and	and	a530	CC	I-NP	O
transaminases	transaminase	t605205050202	NNS	I-NP	O
.	.	.000	.	O	O

Testing	Test	t023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
autoantibodies	autoantibody	a03053010302	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
negative	negative	n0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
biochemistries	biochemistry	b0205023602	NNS	I-NP	O
eventually	eventually	e1053040	RB	B-ADVP	O
normalized	normalize	n065040203	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
fluvastatin	fluvastatin	f4010230305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-NP	O
statins	statin	s303052	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
taken	take	t0205	VBN	I-VP	O
into	into	i530	IN	B-PP	O
account	account	a2053	NN	B-NP	O
.	.	.000	.	O	O

Fluconazole	Fluconazole	f4020502040	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	I-NP	O
agranulocytosis	agranulocytosis	a26050402030202	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	I-NP	O
agranulocytosis	agranulocytosis	a26050402030202	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
upon	upon	u105	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
began	begin	b0205	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
white	white	w030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
platelets	platelet	p40304032	NNS	B-NP	O
within	within	w0305	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
began	begin	b0205	VBD	B-VP	O
to	to	t000	TO	I-VP	O
recover	recover	r020106	VB	I-VP	O
with	with	w030	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
highlights	highlight	h020402032	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
blood	blood	b403	NN	I-NP	B-Disease
dyscrasias	dyscrasia	d0260202	NNS	I-NP	I-Disease
can	can	c050	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
unexpectedly	unexpectedly	u50210230340	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
drug	drug	d602	NN	I-NP	O
thought	think	t0203	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
"	"	"000	``	B-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
"	"	"000	''	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
According	Accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
Naranjo	Naranjo	n060520	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
algorithm	algorithm	a42060305	VBP	B-VP	O
the	the	t000	DT	B-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
agranulocytosis	agranulocytosis	a26050402030202	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
probable	probable	p6010140	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
points	point	p0532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
feel	feel	f040	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
weight	weight	w0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
strong	strong	s36052	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-ADJP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
suppression	suppression	s0160205	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
abatement	abatement	a10305053	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
following	follow	f04052	VBG	I-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
dimensional	dimensional	d050520504	JJ	I-NP	O
speckle	speckle	s10240	NN	I-NP	O
tracking	track	t602052	VBG	B-VP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
troponin	troponin	t6010505	NN	I-NP	O
T	T	t000	NN	I-NP	O
in	in	i500	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
detection	detection	d0302305	NN	I-NP	O
and	and	a530	CC	O	O
prediction	prediction	p60302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
epirubicine	epirubicine	e1060102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

AIMS	AIMS	a052	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
alterations	alteration	a430603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
strain	strain	s3605	NN	I-NP	I-Disease
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
troponin	troponin	t6010505	NN	I-NP	O
T	T	t000	NN	I-NP	O
(	(	(000	(	O	O
cTnT	cTnT	c353	NN	B-NP	O
)	)	)000	)	O	O
could	could	c043	MD	B-VP	O
predict	predict	p603023	VB	I-VP	O
future	future	f03060	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
epirubicin	epirubicin	e106010205	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	O	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
non	non	n050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Hodgkin	Hodgkin	h03205	NN	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
epirubicin	epirubicin	e106010205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
collection	collection	c0402305	NN	I-NP	O
and	and	a530	CC	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
completion	completion	c05140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
during	during	d06052	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

Global	Global	g40104	JJ	B-NP	O
longitudinal	longitudinal	l05203030504	JJ	I-NP	O
(	(	(000	(	O	O
GLS	GLS	g420	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
circumferential	circumferential	c0620510605304	JJ	B-ADJP	O
(	(	(000	(	O	O
GCS	GCS	g200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
radial	radial	r0304	JJ	B-NP	O
strain	strain	s3605	NN	I-NP	O
(	(	(000	(	O	O
GRS	GRS	g620	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
speckle	speckle	s10240	NN	B-NP	O
tracking	tracking	t602052	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
real	real	r040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
3D	3D	3000	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Cardiotoxicity	Cardiotoxicity	c063030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LVEF	LVEF	l101	NN	I-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	JJR	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
<	<	<000	SYM	B-NP	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
or	or	o600	CC	O	O
an	an	a500	DT	B-NP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LVEF	LVEF	l101	NN	I-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	JJR	B-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
<	<	<000	SYM	B-NP	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Fourteen	Fourteen	f06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

GLS	GLS	g420	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
48	48	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
72	72	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-ADVP	O
.	.	.000	.	O	O
-	-	-000	HYPH	B-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
96	96	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
GCS	GCS	g200	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
93	93	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
86	86	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
-	-	-000	SYM	O	O
19	19	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
21	21	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
GRS	GRS	g620	NN	B-NP	O
(	(	(000	(	O	O
39	39	0000	CD	B-NP	O
.	.	.000	.	O	O
23	23	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
44	44	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
34	34	0000	CD	B-NP	O
.	.	.000	.	O	O
98	98	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
markedly	markedly	m0620340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
and	and	a530	CC	O	O
cTnT	cTnT	c353	NN	B-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
0010	0010	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0020	0020	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
0073	0073	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0038	0038	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
all	all	a400	DT	B-NP	O
<	<	<000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
>	>	>000	SYM	I-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
GLS	GLS	g420	NN	B-NP	O
[	[	[000	(	O	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
,	,	,000	,	O	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
specificity	specificity	s1020102030	NN	B-NP	O
,	,	,000	,	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
area	area	a600	NN	B-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
curve	curve	c0610	NN	I-NP	O
(	(	(000	(	O	O
AUC	AUC	a020	NN	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
815	815	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
]	]	]000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
>	>	>000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
004	004	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
cTnT	cTnT	c353	NN	B-NP	O
(	(	(000	(	O	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
,	,	,000	,	O	O
79	79	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
specificity	specificity	s1020102030	NN	B-NP	O
,	,	,000	,	O	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
AUC	AUC	a020	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
757	757	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
predicted	predict	p60302303	VBD	B-VP	O
later	later	l0306	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
GLS	GLS	g420	NN	B-NP	O
remained	remain	r050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
independent	independent	i5301053053	JJ	I-NP	O
predictor	predictor	p60302306	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
000	000	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
GLS	GLS	g420	NN	B-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cTnT	cTnT	c353	NN	B-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
a	a	a000	DT	B-NP	O
reliable	reliable	r040140	JJ	I-NP	O
and	and	a530	CC	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
to	to	t000	TO	B-VP	O
predict	predict	p603023	VB	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
anthracycline	anthracycline	a530602024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Prevention	Prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
:	:	:000	:	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
:	:	:000	:	O	O
Fentanyl	Fentanyl	f0530504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
Retrospective	Retrospective	r036021023010	JJ	I-NP	O
comparative	comparative	c0510603010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
comparative	comparative	c0510603010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
.	.	.000	.	O	O

MATERIAL	MATERIAL	m030604	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
records	record	r020632	NNS	I-NP	O
.	.	.000	.	O	O

Depending	Depend	d01053052	VBG	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
with	with	w030	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
separated	separate	s01060303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
4	4	4000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
no	no	n000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
NP	NP	n100	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
ug	ug	u200	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
F	F	f000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
M	M	m000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
015	015	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
ug	ug	u200	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
FM	FM	f500	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
induced	induce	i530203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
etomidate	etomidate	e30503030	NN	I-NP	B-Chemical
injected	inject	i5202303	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
seconds	second	s020532	NNS	I-NP	O
.	.	.000	.	O	O

Myoclonic	Myoclonic	m0240502	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
and	and	a530	CC	I-VP	O
graded	grade	g60303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
severity	severity	s0106030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
etomidate	etomidate	e30503030	VB	I-VP	B-Chemical
injection	injection	i5202305	NN	B-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Study	Study	s3030	NN	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
85	85	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NNP	B-NP	O
NP	NP	n100	NNP	I-NP	O
,	,	,000	,	O	O
Group	Group	g601	NNP	B-NP	O
F	F	f000	NNP	I-NP	O
,	,	,000	,	O	O
Group	Group	g601	NNP	B-NP	O
M	M	m000	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Group	Group	g601	NNP	B-NP	O
FM	FM	f500	NNP	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
F	F	f000	NN	I-NP	O
and	and	a530	CC	O	O
Group	Group	g601	NN	B-NP	O
FM	FM	f500	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
.	.	.000	.	O	O

Convulsant	Convulsant	c051042053	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
regional	regional	r020504	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Lindane	Lindane	l053050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	h020204060202402050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
organochlorine	organochlorine	o6205020406050	NN	I-NP	O
insecticide	insecticide	i5202302030	NN	I-NP	O
with	with	w030	IN	B-PP	O
known	known	k505	JJ	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
well	well	w040	RB	B-VP	O
understood	understand	u53062303	VBN	I-VP	O
although	although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
acts	act	a232	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
A	A	a000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
GABAergic	GABAergic	g0106202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
brain	brain	b605	NN	I-NP	O
areas	area	a602	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
suffered	suffer	s010603	VBD	B-VP	O
tonic	tonic	t0502	JJ	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
at	at	a300	IN	B-PP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
only	only	o540	RB	I-VP	O
slightly	slightly	s4020340	RB	I-VP	O
but	but	b030	CC	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBD	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
colliculi	colliculi	c0402040	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
modifications	modification	m03010203052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mesencephalon	mesencephalon	m02052010405	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
DOPAC	DOPAC	d0102	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mesencephalon	mesencephalon	m02052010405	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

Cholestatic	Cholestatic	c040230302	JJ	B-NP	B-Disease
presentation	presentation	p6020530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
yellow	yellow	y040	JJ	B-NP	O
phosphorus	phosphorus	p0210602	NN	I-NP	B-Chemical
poisoning	poisoning	p0205052	NN	I-NP	B-Disease
.	.	.000	.	O	O

Yellow	Yellow	y040	JJ	B-NP	O
phosphorus	phosphorus	p0210602	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
pesticide	pesticide	p02302030	NN	I-NP	O
pastes	paste	p02302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
fireworks	firework	f06062	NNS	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Poisoning	Poison	p0205052	VBG	B-VP	B-Disease
with	with	w030	IN	B-PP	O
yellow	yellow	y040	JJ	B-NP	O
phosphorus	phosphorus	p0210602	NN	I-NP	B-Chemical
classically	classically	c40202040	RB	B-ADVP	O
manifests	manifest	m05010232	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
need	need	n030	VB	I-VP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
yellow	yellow	y040	JJ	B-NP	O
phosphorus	phosphorus	p0210602	NN	I-NP	B-Chemical
poisoning	poisoning	p0205052	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
florid	florid	f40603	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cholestasis	cholestasis	c040230202	NN	B-NP	B-Disease
highlighting	highlight	h02040203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
cholestasis	cholestasis	c040230202	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
rarely	rarely	r06040	RB	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
presenting	present	p602053052	VBG	I-NP	O
feature	feature	f03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
yellow	yellow	y040	JJ	B-NP	O
phosphorus	phosphorus	p0210602	NN	I-NP	B-Chemical
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Vasovagal	Vasovagal	v02010204	JJ	B-NP	B-Disease
syncope	syncope	s052010	NN	I-NP	I-Disease
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
intranasal	intranasal	i536050204	JJ	B-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
procedural	procedural	p602030604	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
syncope	syncope	s052010	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
11	11	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
girl	girl	g064	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intranasal	intranasal	i536050204	JJ	B-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
voiding	void	v03052	VBG	I-NP	O
cystourethrogram	cystourethrogram	c02306030602605	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
successful	successful	s0202104	JJ	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
VCUG	VCUG	v202	NN	B-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
60	60	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
consciousness	consciousness	c05202502	NN	B-NP	O
and	and	a530	CC	O	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
presedation	presedation	p602030305	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Upon	Upon	u105	IN	B-PP	O
leaving	leave	l01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
collapsed	collapse	c0401203	VBD	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
inciting	incite	i5203052	VBG	I-NP	O
event	event	e1053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
quickly	quickly	q0240	RB	B-ADVP	O
regained	regain	r020503	VBD	B-VP	O
consciousness	consciousness	c05202502	NN	B-NP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
injury	injury	i52060	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
found	find	f053	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
persistent	persistent	p062023053	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
telemetric	telemetric	t040503602	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
lasted	last	l02303	VBD	B-VP	O
~	~	~000	RB	B-NP	O
2	2	2000	CD	I-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
further	further	f06306	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
workup	workup	w06201	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
.	.	.000	.	O	O

Unanticipated	Unanticipated	u505302010303	JJ	B-ADJP	O
and	and	a530	CC	O	O
previously	previously	p6010240	RB	B-NP	O
unreported	unreported	u560106303	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
witnessed	witness	w0350203	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
we	we	w000	PRP	B-NP	O
expand	expand	e21053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
sedatives	sedative	s03030102	NNS	I-NP	O
to	to	t000	TO	B-PP	O
alternative	alternative	a4306503010	JJ	B-NP	O
routes	route	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

Paradoxical	Paradoxical	p0603020204	JJ	B-NP	O
severe	severe	s01060	JJ	I-NP	O
agitation	agitation	a2030305	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
add	add	a300	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
on	on	o500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
doses	dose	d0202	NNS	I-NP	O
quetiapine	quetiapine	q0301050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
schizo	schizo	s2020	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
affective	affective	a1023010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
35	35	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
schizo	schizo	s2020	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
affective	affective	a1023010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
since	since	s0520	IN	B-PP	O
the	the	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
19	19	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
treated	treat	t60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
,	,	,000	,	O	O
zuclopenthixol	zuclopenthixol	z024010530204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1200	1200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
serum	serum	s0605	NN	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
85	85	0000	CD	I-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	I-NP	O
l	l	l000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
personality	personality	p0620504030	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
particularly	particularly	p06302040640	RB	B-NP	O
no	no	n000	DT	I-NP	O
antisocial	antisocial	a53020204	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
substance	substance	s01230520	NN	I-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
48	48	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
600	600	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
agitation	agitation	a2030305	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
an	an	a500	DT	B-NP	O
environmental	environmental	e51060505304	JJ	I-NP	O
explanation	explanation	e214050305	NN	I-NP	O
,	,	,000	,	O	O
contrasting	contrast	c0536023052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
aggressiveness	aggressiveness	a2602010502	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
personality	personality	p0620504030	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
manic	manic	m0502	JJ	B-NP	B-Disease
shift	shift	s013	NN	I-NP	O
and	and	a530	CC	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
dismissed	dismiss	d0250203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
reintroduction	reintroduction	r05360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
another	another	a50306	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
agitation	agitation	a2030305	NN	I-NP	B-Disease
,	,	,000	,	O	O
enabled	enable	e501403	VBD	B-VP	O
us	us	u200	PRP	B-NP	O
to	to	t000	TO	B-VP	O
attribute	attribute	a3601030	VB	I-VP	O
the	the	t000	DT	B-NP	O
agitation	agitation	a2030305	NN	I-NP	B-Disease
specifically	specifically	s1020102040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Antioxidant	Antioxidant	a530203053	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bovine	bovine	b01050	JJ	B-NP	O
lactoferrin	lactoferrin	l023010605	NN	I-NP	O
on	on	o500	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
Dex	Dex	d020	NN	B-NP	B-Chemical
-	-	-000	SYM	O	O
)	)	)000	)	O	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Lactoferrin	Lactoferrin	l023010605	NN	B-NP	O
(	(	(000	(	O	O
LF	LF	l100	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
binding	bind	b053052	VBG	B-VP	O
glycoprotein	glycoprotein	g4020160305	NN	B-NP	O
with	with	w030	IN	B-PP	O
antihypertensive	antihypertensive	a5301063052010	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LF	LF	l100	NN	B-NP	O
on	on	o500	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
upon	upon	u105	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
u	u	u000	SYM	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
bovine	bovine	b01050	JJ	I-NP	O
LF	LF	l100	NN	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
8	8	8000	CD	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
reversal	reversal	r0106204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
LF	LF	l100	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
continued	continue	c0530503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Systolic	Systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
tail	tail	t040	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
cuff	cuff	c010	NN	I-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

Thymus	Thymus	t0502	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
hydrogen	hydrogen	h0360205	NN	I-NP	B-Chemical
peroxide	peroxide	p0602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
H2O2	H2O2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentration	concentration	c05205360305	NN	B-NP	O
and	and	a530	CC	O	O
ferric	ferric	f0602	JJ	B-ADJP	O
reducing	reduce	r0302052	VBG	B-VP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
power	power	p060	NN	I-NP	O
(	(	(000	(	O	O
FRAP	FRAP	f601	NN	B-NP	O
)	)	)000	)	O	O
value	value	v040	NN	B-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
SBP	SBP	s100	NN	B-NP	O
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
H2O2	H2O2	0000	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
thymus	thymus	t0502	NN	B-NP	O
and	and	a530	CC	I-NP	O
body	body	b030	NN	I-NP	O
weights	weight	w02032	NNS	I-NP	O
.	.	.000	.	O	O

LF	LF	l100	NN	B-NP	O
lowered	lower	l0603	VBD	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
001	001	0000	CD	O	O
)	)	)000	)	O	O
Dex	Dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

LF	LF	l100	NN	B-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
elevated	elevate	e4010303	VBN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
H2O2	H2O2	0000	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
FRAP	FRAP	f601	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LF	LF	l100	NN	B-NP	O
strongly	strongly	s3605240	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ROS	ROS	r020	NN	B-NP	O
and	and	a530	CC	O	O
improved	improve	i5160103	VBN	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
as	as	a200	IN	B-PP	O
another	another	a50306	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
antihypertensive	antihypertensive	a5301063052010	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LF	LF	l100	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
convulsive	convulsive	c051042010	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
multivariate	multivariate	m0430106030	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
529	529	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
contemporary	contemporary	c05305106060	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
undertook	undertake	u5306302	VBD	B-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
prospectively	prospectively	p602102301040	RB	B-NP	O
collected	collect	c0402303	VBN	I-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
11	11	0000	CD	B-NP	O
529	529	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
bypass	bypass	b0102	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
December	December	d0205106	NNP	B-NP	O
2010	2010	0000	CD	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
seizure	seizure	s02060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
disturbed	disturbed	d02306103	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
function	function	f052305	NN	I-NP	O
characterised	characterise	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
involuntary	involuntary	i5104053060	JJ	I-NP	I-Disease
motor	motor	m0306	NN	I-NP	I-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
identify	identify	i3053010	VB	I-VP	O
independent	independent	i5301053053	JJ	B-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Generalised	Generalise	g0506040203	VBN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
focal	focal	f0204	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
68	68	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
32	32	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
(	(	(000	(	O	O
IQR	IQR	i260	NN	B-NP	O
[	[	[000	(	O	O
range	range	r0520	NN	B-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
time	time	t050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
was	be	w020	VBD	B-VP	O
7	7	7000	CD	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
[	[	[000	(	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
216	216	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
h	h	h000	NN	B-NP	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
11	11	0000	CD	I-NP	O
[	[	[000	(	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
18	18	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
h	h	h000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Epileptiform	Epileptiform	e10401301065	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
electroencephalography	electroencephalography	e402360520104026010	NN	B-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
19	19	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Independent	Independent	i5301053053	JJ	B-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
included	include	i5240303	VBD	B-VP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
female	female	f05040	JJ	B-NP	O
sex	sex	s020	NN	I-NP	O
,	,	,000	,	O	O
redo	redo	r030	VBP	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
calcification	calcification	c04201020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ascending	ascend	a2053052	VBG	B-VP	O
aorta	aorta	a0630	NN	B-NP	O
,	,	,000	,	O	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
deep	deep	d010	JJ	B-NP	O
hypothermic	hypothermic	h010306502	JJ	I-NP	B-Disease
circulatory	circulatory	c0620403060	JJ	I-NP	O
arrest	arrest	a6023	NN	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
clamp	clamp	c4051	NN	I-NP	O
and	and	a530	CC	O	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
tested	test	t02303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
multivariate	multivariate	m0430106030	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
independent	independent	i5301053053	JJ	I-NP	O
predictor	predictor	p60302306	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
36	36	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
convulsive	convulsive	c051042010	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
had	have	h030	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-ADJP	O
times	time	t0502	NNS	I-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
and	and	a530	CC	O	O
twice	twice	t020	RB	B-NP	O
the	the	t000	DT	I-NP	O
length	length	l05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
stay	stay	s300	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
convulsive	convulsive	c051042010	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Mean	Mean	m050	NN	B-NP	O
(	(	(000	(	O	O
IQR	IQR	i260	NN	B-NP	O
[	[	[000	(	O	O
range	range	r0520	NN	B-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
length	length	l05230	NN	B-NP	O
of	of	o100	IN	B-PP	O
stay	stay	s300	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
was	be	w020	VBD	B-VP	O
115	115	0000	CD	B-NP	O
(	(	(000	(	O	O
49	49	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
228	228	0000	CD	B-NP	O
[	[	[000	(	O	O
32	32	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
481	481	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
h	h	h000	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
convulsive	convulsive	c051042010	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
26	26	0000	CD	B-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
69	69	0000	CD	I-NP	O
[	[	[000	(	O	O
14	14	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1080	1080	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
h	h	h000	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Convulsive	Convulsive	c051042010	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
complication	complication	c0514020305	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
modifiable	modifiable	m03010140	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
exceeding	exceed	e203052	VBG	B-VP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
weighed	weigh	w0203	VBN	I-VP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Dysfunctional	Dysfunctional	d02105230504	JJ	B-NP	B-Disease
overnight	overnight	o10650203	JJ	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
consolidation	consolidation	c05204030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

Sleep	Sleep	s401	NN	B-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
integration	integration	i530260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
process	process	p60202	NN	I-NP	O
called	call	c0403	VBN	B-VP	O
overnight	overnight	o10650203	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
marked	mark	m06203	VBN	I-VP	O
and	and	a530	CC	O	O
persistent	persistent	p062023053	JJ	B-NP	O
neurocognitive	neurocognitive	n060202503010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
sleep	sleep	s401	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
related	relate	r040303	VBN	I-NP	I-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
extend	extend	e23053	VBP	B-VP	O
past	past	p023	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
by	by	b000	IN	B-PP	O
examining	examine	e20505052	VBG	B-VP	O
overnight	overnight	o10650203	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
among	among	a5052	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
drug	drug	d602	NN	B-NP	O
naive	naive	n010	JJ	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
26	26	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Memory	Memory	m05060	NN	B-NP	O
recall	recall	r0204	NN	I-NP	O
of	of	o100	IN	B-PP	O
word	word	w063	NN	B-NP	O
pairs	pair	p062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
interference	interference	i53061060520	NN	B-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
testing	testing	t023052	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
neurocognitive	neurocognitive	n060202503010	JJ	B-NP	O
performances	performance	p06106505202	NNS	I-NP	O
across	across	a2602	IN	B-PP	O
tasks	task	t020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
,	,	,000	,	O	O
memory	memory	m05060	NN	B-NP	O
and	and	a530	CC	O	O
executive	executive	e20203010	NN	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
.	.	.000	.	O	O

Ecstasy	Ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
overnight	overnight	o10650203	JJ	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
consolidation	consolidation	c05204030305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
following	follow	f04052	VBG	B-PP	O
associative	associative	a20203010	JJ	B-NP	O
interference	interference	i53061060520	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
impairments	impairment	i510650532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
tasks	task	t020	NNS	B-NP	O
recruiting	recruit	r02603052	VBG	B-VP	O
frontostriatal	frontostriatal	f605302360304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
neural	neural	n0604	JJ	I-NP	O
circuitry	circuitry	c0620360	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
domains	domain	d05052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
proactive	proactive	p6023010	JJ	B-NP	O
interference	interference	i53061060520	NN	I-NP	O
memory	memory	m05060	NN	I-NP	O
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
memory	memory	m05060	NN	I-NP	O
,	,	,000	,	O	O
encoding	encode	e5203052	VBG	B-VP	O
,	,	,000	,	O	O
working	work	w062052	VBG	B-VP	O
memory	memory	m05060	NN	B-NP	O
and	and	a530	CC	O	O
complex	complex	c051402	JJ	B-NP	O
planning	planning	p405052	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
fronto	fronto	f60530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
circuitry	circuitry	c0620360	NN	I-NP	O
may	may	m000	MD	B-VP	O
underlie	underlie	u530640	VB	I-VP	O
overnight	overnight	o10650203	JJ	B-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

Normoammonemic	Normoammonemic	n06505050502	JJ	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
:	:	:000	:	O	O
solely	solely	s04040	RB	B-NP	O
valproate	valproate	v0416030	NN	I-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
or	or	o600	CC	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
77	77	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
subacute	subacute	s0102030	JJ	B-NP	O
onset	onset	o5203	NN	I-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
,	,	,000	,	O	O
aggression	aggression	a260205	NN	B-NP	B-Disease
,	,	,000	,	O	O
auditory	auditory	a0303060	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
delusions	delusion	d0402052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
preceding	precede	p60203052	VBG	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
admissions	admission	a3502052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
hemiparesis	hemiparesis	h0501060202	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
droop	droop	d601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
started	start	s306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
presumed	presume	p6020503	VBN	B-NP	O
hemiplegic	hemiplegic	h050140202	JJ	I-NP	B-Disease
migraine	migraine	m026050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
and	and	a530	CC	O	O
her	her	h060	PRP$	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
abilities	ability	a1040302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
gradually	gradually	g603040	RB	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
over	over	o106	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
taken	take	t0205	VBN	B-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
were	be	w060	VBD	B-VP	O
subtherapeutic	subtherapeutic	s01306010302	JJ	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normoammonaemic	normoammonaemic	n06505050502	JJ	B-ADJP	O
.	.	.000	.	O	O

EEG	EEG	e020	NN	B-NP	O
undertaken	undertake	u530630205	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
inpatient	inpatient	i5103053	NN	B-NP	O
stay	stay	s300	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
titre	titre	t0360	NN	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartate	aspartate	a21063030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
aetiologies	aetiology	a03040202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
encephalitis	encephalitis	e5201040302	NN	I-NP	B-Disease
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
dilemma	dilemma	d04050	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
putative	putative	p0303010	JJ	I-NP	O
combinatorial	combinatorial	c05105030604	JJ	I-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
to	to	t000	TO	B-VP	O
explain	explain	e21405	VB	I-VP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Cerebellar	Cerebellar	c06010406	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
oculomotor	oculomotor	o204050306	NN	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pethidine	Pethidine	p0303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
opioid	opioid	o103	NN	I-NP	O
that	that	t030	WDT	B-NP	O
gains	gain	g052	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
popularity	popularity	p010406030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
control	control	c053604	NN	I-NP	O
through	through	t06020	IN	B-PP	O
acting	act	a23052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
rapid	rapid	r0103	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
relief	relief	r0401	NN	I-NP	O
sometimes	sometimes	s05030502	RB	B-ADVP	O
brings	bring	b6052	VBZ	B-VP	O
about	about	a103	IN	B-PP	O
unfavourable	unfavourable	u5101060140	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
largely	largely	l062040	RB	B-ADVP	O
limit	limit	l0503	VBP	B-VP	O
its	its	i320	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
utility	utility	u304030	NN	I-NP	O
.	.	.000	.	O	O

Common	Common	c0505	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
need	need	n030	VBP	B-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
control	control	c053604	NN	I-NP	O
,	,	,000	,	O	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
excitatory	excitatory	e20303060	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
effects	effect	e10232	NNS	B-NP	O
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
metabolite	metabolite	m030104030	NN	I-NP	O
,	,	,000	,	O	O
norpethidine	norpethidine	n0610303050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
irritability	irritability	i6030104030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	NN	I-NP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
not	not	n030	RB	O	O
clinically	clinically	c40502040	RB	B-ADJP	O
apparent	apparent	a106053	JJ	I-ADJP	O
,	,	,000	,	O	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
potentially	potentially	p03053040	RB	B-ADVP	O
causes	cause	c0202	VBZ	B-VP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
impacts	impact	i510232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
and	and	a530	CC	O	O
impairs	impair	i51062	VBZ	B-VP	O
normal	normal	n06504	JJ	B-NP	O
cerebellar	cerebellar	c06010406	NN	I-NP	O
and	and	a530	CC	I-NP	O
oculomotor	oculomotor	o204050306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
term	term	t065	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
highlight	highlight	h02040203	VBP	B-VP	O
opioid	opioid	o103	JJ	B-NP	O
'	'	'000	''	I-NP	O
s	s	s000	JJ	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
structure	structure	s36023060	NN	I-NP	O
that	that	t030	WDT	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
dysmetria	dysmetria	d0250360	NN	B-NP	B-Disease
,	,	,000	,	O	O
dysarthria	dysarthria	d02063060	NN	B-NP	B-Disease
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
smooth	smooth	s5030	JJ	B-NP	O
pursuit	pursuit	p06203	NN	I-NP	O
gain	gain	g050	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
saccadic	saccadic	s020302	JJ	B-NP	O
velocity	velocity	v0402030	NN	I-NP	O
.	.	.000	.	O	O

Baboon	Baboon	b0105	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
maculopapular	maculopapular	m020401010406	JJ	I-NP	B-Disease
eruption	eruption	e601305	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
flexural	flexural	f4020604	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
buttocks	buttock	b0302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	O
ketoconazole	ketoconazole	k03020502040	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
baboon	baboon	b0105	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
based	base	b0203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
prior	prior	p606	JJ	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
topical	topical	t010204	JJ	B-NP	O
ketoconazole	ketoconazole	k03020502040	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
physical	physical	p020204	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Baboon	Baboon	b0105	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
or	or	o600	CC	O	O
contact	contact	c053023	NN	B-NP	O
allergen	allergen	a406205	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
maculopapular	maculopapular	m020401010406	JJ	I-NP	B-Disease
eruption	eruption	e601305	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
typically	typically	t0102040	RB	B-ADVP	O
involves	involve	i5104102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
flexural	flexural	f4020604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
gluteal	gluteal	g40304	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
baboon	baboon	b0105	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
English	English	e524020	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
Case	Case	c020	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Sudden	Sudden	s0305	NNP	B-NP	B-Disease
Cardiac	Cardiac	c06302	NNP	I-NP	I-Disease
Death	Death	d030	NNP	I-NP	I-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
Pilsicainide	Pilsicainide	p0420205030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
Induced	Induce	i530203	VBN	B-VP	O
Torsades	Torsades	t0620302	NNP	B-NP	B-Disease
de	de	d000	IN	I-NP	I-Disease
Pointes	Pointes	p05302	NNP	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
84	84	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
received	receive	r020103	VBN	I-NP	O
oral	oral	o604	JJ	I-NP	O
pilsicainide	pilsicainide	p0420205030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pure	pure	p060	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
with	with	w030	IN	B-PP	O
slow	slow	s400	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
kinetics	kinetic	k050302	NNS	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
convert	convert	c051063	VB	I-VP	O
his	his	h020	PRP$	B-NP	O
paroxysmal	paroxysmal	p060202504	JJ	I-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	I-Disease
death	death	d030	NN	I-NP	I-Disease
two	two	t000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Holter	Holter	h04306	NNP	I-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
worn	wear	w065	VBN	I-VP	O
by	by	b000	IN	B-PP	O
chance	chance	c0520	NN	B-NP	O
,	,	,000	,	O	O
revealed	reveal	r010403	VBD	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
with	with	w030	IN	B-PP	O
gradually	gradually	g603040	RB	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
QT	QT	q300	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
rapidly	rapidly	r010340	RB	I-VP	O
absorbed	absorb	a1206103	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	O
tract	tract	t6023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
excreted	excrete	e260303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
highly	highly	h02040	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilsicainide	pilsicainide	p0420205030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilsicainide	pilsicainide	p0420205030	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
high	high	h020	JJ	B-ADJP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	I-NP	I-Disease
pointes	pointe	p05302	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
octogenarian	octogenarian	o2302050605	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
class	class	c402	NN	B-NP	O
IC	IC	i200	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
pilsicainide	pilsicainide	p0420205030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
terminate	terminate	t06505030	VB	I-VP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
careful	careful	c060104	JJ	B-NP	O
consideration	consideration	c05203060305	NN	I-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
taken	take	t0205	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
giving	give	g01052	VBG	B-VP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
to	to	t000	TO	B-PP	O
octogenarians	octogenarian	o23020506052	NNS	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	NN	I-NP	I-Chemical
retinoic	retinoic	r030502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
myositis	myositis	m020302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
promyelocytic	promyelocytic	p60504020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	NN	I-NP	I-Chemical
retinoic	retinoic	r030502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
promyelocytic	promyelocytic	p60504020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
APL	APL	a140	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
potentially	potentially	p03053040	RB	B-NP	O
serious	serious	s0602	JJ	I-NP	O
but	but	b030	CC	I-NP	O
treatable	treatable	t6030140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
numerous	numerous	n050602	JJ	B-NP	O
organ	organ	o6205	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
rare	rare	r060	JJ	B-NP	O
skeletal	skeletal	s2040304	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
handful	handful	h053104	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myositis	myositis	m020302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
none	none	n050	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
radiology	radiology	r0304020	NN	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
such	such	s020	PDT	B-NP	O
a	a	a000	DT	I-NP	O
case	case	c020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
with	with	w030	IN	B-PP	O
APL	APL	a140	NN	B-NP	B-Disease
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
recognition	recognition	r020250305	NN	B-NP	O
of	of	o100	IN	B-PP	O
imaging	image	i502052	VBG	B-NP	O
findings	finding	f053052	NNS	I-NP	O
played	play	p403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
crucial	crucial	c60204	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
making	make	m02052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
and	and	a530	CC	O	O
facilitated	facilitate	f0204030303	VBD	B-VP	O
prompt	prompt	p60513	JJ	B-NP	O
,	,	,000	,	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Tolerability	Tolerability	t04060104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
lomustine	lomustine	l05023050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lymphoma	lymphoma	l051050	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
of	of	o100	IN	B-PP	O
lomustine	lomustine	l05023050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CTX	CTX	c320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lymphoma	lymphoma	l051050	NN	B-NP	B-Disease
.	.	.000	.	O	O

CCNU	CCNU	c250	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
per	per	p060	IN	B-PP	O
os	o	o200	NNS	B-NP	O
(	(	(000	(	O	O
PO	PO	p000	NN	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
targeted	target	t0620303	VBN	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
CTX	CTX	c320	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
PO	PO	p000	NN	B-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
targeted	target	t0620303	VBN	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
divided	divide	d010303	VBN	B-VP	O
over	over	o106	IN	B-PP	O
days	day	d020	NNS	B-NP	O
0	0	0000	CD	B-NP	O
through	through	t06020	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
dogs	dog	d020	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
.	.	.000	.	O	O

Ninety	Ninety	n05030	CD	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
57	57	0000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
included	include	i5240303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Neutropenia	Neutropenia	n03601050	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
principal	principal	p60520104	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
grade	grade	g6030	NN	B-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
CTX	CTX	c320	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
19	19	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
43	43	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
grade	grade	g6030	NN	B-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
(	(	(000	(	O	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
kg	kg	k200	NN	I-NP	O
+	+	+000	SYM	B-NP	O
13	13	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
develop	develop	d010401	VB	I-VP	O
grade	grade	g6030	NN	B-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
(	(	(000	(	O	O
31	31	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
kg	kg	k200	NN	I-NP	O
+	+	+000	SYM	B-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
dog	dog	d020	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
dogs	dog	d020	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
or	or	o600	CC	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
reported	report	r0106303	VBN	B-VP	O
herein	herein	h0605	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
CTX	CTX	c320	NN	B-NP	B-Chemical
(	(	(000	(	O	O
divided	divide	d010303	VBN	B-VP	O
over	over	o106	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
q	q	q000	NN	B-NP	O
4	4	4000	CD	I-NP	O
wk	wk	w200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
tolerable	tolerable	t04060140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
bearing	bear	b06052	VBG	B-VP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

Nelarabine	Nelarabine	n040601050	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
:	:	:000	:	O	O
Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
literature	literature	l030603060	NN	B-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
nelarabine	nelarabine	n040601050	NN	I-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
(	(	(000	(	O	O
IT	IT	i300	JJ	B-ADJP	O
)	)	)000	)	O	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
T	T	t000	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
relapsed	relapsed	r0401203	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
originally	originally	o60205040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
autologous	autologous	a03040202	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
relapsed	relapse	r0401203	VBN	B-NP	O
disease	disease	d02020	NN	I-NP	O
10	10	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
leukemic	leukemic	l020502	JJ	B-NP	B-Disease
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
re	re	r000	AFX	B-ADJP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nelarabine	nelarabine	n040601050	NN	B-NP	B-Chemical
1500	1500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
cytarabine	cytarabine	c030601050	NN	I-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
as	as	a200	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
prophylaxis	prophylaxis	p601040202	NN	B-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
sequelae	sequelae	s02040	VB	I-VP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
lysis	lysis	l0202	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
TLS	TLS	t420	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
tolerated	tolerate	t04060303	VBD	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
well	well	w040	RB	B-ADVP	O
,	,	,000	,	O	O
entered	enter	e530603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
remission	remission	r050205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
recovered	recover	r02010603	VBD	B-VP	O
her	her	h060	PRP$	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
of	of	o100	IN	B-PP	O
nelarabine	nelarabine	n040601050	NN	B-NP	B-Chemical
without	without	w0303	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
IT	IT	i300	NN	I-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
this	this	t020	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
noted	note	n0303	VBD	B-VP	O
numbness	numbness	n051502	NN	B-NP	O
in	in	i500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
lower	low	l060	JJR	I-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
.	.	.000	.	O	O

Predominantly	Predominantly	p603050505340	RB	B-ADJP	O
sensory	sensory	s052060	JJ	I-ADJP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
also	also	a420	RB	B-ADVP	O
motor	motor	m0306	NN	B-NP	O
and	and	a530	CC	O	O
autonomic	autonomic	a03050502	JJ	B-NP	O
,	,	,000	,	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
started	start	s306303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
feet	foot	f030	NNS	I-NP	O
,	,	,000	,	O	O
ascended	ascend	a205303	VBD	B-VP	O
proximally	proximally	p60205040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
mid	mid	m030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
thoracic	thoracic	t060202	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
eventually	eventually	e1053040	RB	B-VP	O
included	include	i5240303	VBD	I-VP	O
her	her	h060	PRP	B-NP	O
distal	distal	d02304	JJ	I-NP	O
upper	upper	u106	JJ	I-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
spine	spine	s1050	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
from	from	f605	IN	B-PP	O
C2	C2	0000	NN	B-NP	O
to	to	t000	TO	B-PP	O
C6	C6	0000	NN	B-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
subacute	subacute	s0102030	JJ	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
.	.	.000	.	O	O

Nelarabine	Nelarabine	n040601050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
felt	feel	f043	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
stabilized	stabilize	s301040203	VBD	B-VP	O
and	and	a530	CC	I-VP	O
showed	show	s030	VBD	I-VP	O
slight	slight	s40203	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
and	and	a530	CC	O	O
ultimately	ultimately	u430503040	RB	B-VP	O
received	receive	r020103	VBD	I-VP	O
an	an	a500	DT	B-NP	O
unrelated	unrelated	u56040303	JJ	I-NP	O
,	,	,000	,	I-NP	O
reduced	reduce	r030203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
allogeneic	allogeneic	a4020502	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
relapsed	relapse	r0401203	VBD	B-VP	O
disease	disease	d02020	NN	B-NP	O
10	10	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
currently	currently	c0605340	RB	I-VP	O
being	be	b052	VBG	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
best	good	b023	JJS	B-NP	O
supportive	supportive	s01063010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
published	publish	p0140203	VBN	I-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nelarabine	nelarabine	n040601050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
IT	IT	i300	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperammonemic	hyperammonemic	h010605050502	JJ	I-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
transplanted	transplant	t60521405303	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Neurological	Neurological	n0604020204	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
constitute	constitute	c052303030	VBP	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morbidity	morbidity	m06103030	NN	B-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
essential	essential	e205304	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperammonemic	hyperammonemic	h010605050502	JJ	I-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
uncommon	uncommon	u520505	JJ	I-NP	O
but	but	b030	CC	I-NP	O
serious	serious	s0602	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
girl	girl	g064	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
revealed	reveal	r010403	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
consciousness	consciousness	c05202502	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
12	12	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
withdraw	withdraw	w030360	NN	B-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
awareness	awareness	a060502	NN	I-NP	O
for	for	f060	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
transplanted	transplant	t60521405303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Necrotising	Necrotise	n0260302052	VBG	B-VP	B-Disease
fasciitis	fasciitis	f020302	NN	B-NP	I-Disease
after	after	a1306	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
regimen	regimen	r020505	NN	B-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Waldenstrom	Waldenstrom	w0430523605	NNP	B-NP	B-Disease
macroglobulinaemia	macroglobulinaemia	m026024010405050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Bortezomib	Bortezomib	b063020501	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
regimens	regimen	r0205052	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
generally	generally	g0506040	RB	B-ADJP	O
tolerable	tolerable	t04060140	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
few	few	f000	JJ	B-NP	O
severe	severe	s01060	JJ	I-NP	O
bacterial	bacterial	b0230604	JJ	I-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
B	B	b000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
malignancies	malignancy	m0402505202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
information	information	i510650305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
concerning	concern	c052065052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
76	76	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
Waldenstrom	Waldenstrom	w0430523605	NNP	B-NP	B-Disease
macroglobulinaemia	macroglobulinaemia	m026024010405050	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
necrotising	necrotise	n0260302052	VBG	I-VP	B-Disease
fasciitis	fasciitis	f020302	NN	B-NP	I-Disease
without	without	w0303	IN	B-PP	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
rituximab	rituximab	r03020501	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
antimicrobial	antimicrobial	a53050260104	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
succumbed	succumb	s0205103	VBD	B-VP	O
23	23	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
recognise	recognise	r02025020	VB	I-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
bacterial	bacterial	b0230604	JJ	I-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
bortezomib	bortezomib	b063020501	VB	I-VP	B-Chemical
plus	plus	p402	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
we	we	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
warrants	warrant	w060532	VBZ	B-VP	O
further	further	f06306	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
integrated	integrate	i530260303	VBN	I-NP	O
characterization	characterization	c0602306020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serological	serological	s0604020204	JJ	B-NP	O
,	,	,000	,	I-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
efficacious	efficacious	e1020202	JJ	I-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
treatments	treatment	t60350532	NNS	I-NP	O
cause	cause	c020	VBP	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
,	,	,000	,	O	O
yet	yet	y030	CC	O	O
biomarkers	biomarker	b05062062	NNS	B-NP	O
or	or	o600	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
indices	index	i530202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
would	would	w043	MD	B-VP	O
allow	allow	a400	VB	I-VP	O
monitoring	monitoring	m050306052	NN	B-NP	O
and	and	a530	CC	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
lacking	lack	l02052	VBG	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
utilized	utilize	u3040203	VBN	I-VP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
,	,	,000	,	O	O
applying	apply	a14052	VBG	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
approaches	approach	a160202	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
provide	provide	p601030	VB	I-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
comprehensive	comprehensive	c0516052010	JJ	I-NP	O
characterization	characterization	c0602306020305	NN	I-NP	O
to	to	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
timecourse	timecourse	t05020620	NN	I-NP	O
of	of	o100	IN	B-PP	O
serological	serological	s0604020204	JJ	B-NP	O
,	,	,000	,	I-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Hannover	Hannover	h050106	NNP	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
dosed	dose	d0203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
weekly	weekly	w0240	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
week	week	w020	NN	I-NP	O
off	off	o100	RB	B-ADVP	O
-	-	-000	HYPH	O	O
dosing	dose	d02052	VBG	B-VP	O
"	"	"000	``	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
"	"	"000	''	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
subcellular	subcellular	s012040406	JJ	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
marked	marked	m06203	JJ	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	I-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
,	,	,000	,	O	O
hypertrophy	hypertrophy	h010636010	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
cytomegaly	cytomegaly	c030502040	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
extensive	extensive	e23052010	JJ	B-NP	O
vacuolation	vacuolation	v02040305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
two	two	t000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Extensive	Extensive	e23052010	JJ	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
(	(	(000	(	O	O
quantified	quantify	q0530103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Sirius	Sirius	s0602	NNP	B-NP	O
red	red	r030	JJ	I-NP	O
staining	staining	s305052	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
off	off	o100	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Functional	Functional	f05230504	JJ	B-NP	O
indices	index	i530202	NNS	I-NP	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
MRI	MRI	m600	NN	I-NP	O
(	(	(000	(	O	O
including	include	i52403052	VBG	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
(	(	(000	(	O	O
LVEF	LVEF	l101	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
E	E	e000	NN	B-NP	O
/	/	/000	SYM	O	O
A	A	a000	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
)	)	)000	)	O	O
declined	decline	d0240503	VBD	B-VP	O
progressively	progressively	p60260201040	RB	B-ADVP	O
,	,	,000	,	O	O
reaching	reach	r02052	VBG	B-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
after	after	a1306	IN	B-PP	O
two	two	t000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
and	and	a530	CC	O	O
culminating	culminate	c0450503052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
"	"	"000	``	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
"	"	"000	''	I-NP	O
LV	LV	l100	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
and	and	a530	CC	O	O
serological	serological	s0604020204	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
troponin	troponin	t6010505	NN	I-NP	O
I	I	i000	CD	I-NP	O
(	(	(000	(	O	O
cTnI	cTnI	c350	NN	B-NP	O
)	)	)000	)	O	O
emerged	emerge	e506203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
importantly	importantly	i5106305340	RB	B-VP	O
preceding	precede	p60203052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
LVEF	LVEF	l101	NN	I-NP	O
decline	decline	d024050	NN	I-NP	O
to	to	t000	TO	B-PP	O
<	<	<000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Troponin	Troponin	t6010505	NN	B-NP	O
I	I	i000	CD	I-NP	O
levels	level	l01042	NNS	I-NP	O
positively	positively	p020301040	RB	B-ADVP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
and	and	a530	CC	I-NP	O
peak	peak	p020	JJ	I-NP	O
gadolinium	gadolinium	g03040505	NN	I-NP	B-Chemical
contrast	contrast	c0536023	NN	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
,	,	,000	,	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
grading	grading	g603052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
diastolic	diastolic	d0230402	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
summary	summary	s05060	NN	B-NP	O
,	,	,000	,	O	O
subcellular	subcellular	s012040406	JJ	B-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	I-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
earliest	early	e064023	JJS	I-NP	O
marker	marker	m06206	NN	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
decline	decline	d024050	NN	I-NP	O
and	and	a530	CC	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
and	and	a530	CC	O	O
elevations	elevation	e40103052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cTnI	cTnI	c350	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
indices	index	i530202	NNS	I-NP	O
predated	predate	p6030303	VBD	B-VP	O
"	"	"000	``	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
"	"	"000	''	I-NP	O
LV	LV	l100	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
thus	thus	t020	RB	B-NP	O
warrant	warrant	w06053	JJ	I-NP	O
further	further	f06306	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
as	as	a200	IN	B-PP	O
predictive	predictive	p603023010	JJ	B-NP	O
biomarkers	biomarker	b05062062	NNS	I-NP	O
.	.	.000	.	O	O

Intradermal	Intradermal	i5360306504	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
:	:	:000	:	O	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
interindividual	interindividual	i5306053010304	JJ	I-NP	O
variability	variability	v060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
provoked	provoked	p6010203	JJ	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Intradermal	Intradermal	i5360306504	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
attractive	attractive	a36023010	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
use	use	u200	VB	I-VP	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
because	because	b02020	IN	B-SBAR	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
mimic	mimic	m0502	VBP	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
aspects	aspect	a210232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
reproducibility	reproducibility	r01603020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
24	24	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
18	18	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
38	38	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
intradermal	intradermal	i5360306504	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
volar	volar	v0406	JJ	I-NP	O
forearm	forearm	f06065	NN	I-NP	O
.	.	.000	.	O	O

Magnitudes	Magnitude	m025030302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	O
pinprick	pinprick	p051602	NN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
brush	brush	b6020	NN	I-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
von	von	v050	NNP	B-NP	O
Frey	Frey	f600	NNP	I-NP	O
filaments	filament	f04050532	NNS	I-NP	O
(	(	(000	(	O	O
gauges	gauge	g0202	NNS	B-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
60	60	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
100	100	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
brush	brush	b6020	JJ	B-NP	O
strokes	stroke	s360202	NNS	I-NP	O
.	.	.000	.	O	O

Areas	Area	a602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
quantified	quantify	q0530103	VBN	I-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
15	15	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
identical	identical	i30530204	JJ	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
separated	separate	s01060303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
7	7	7000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

Reproducibility	Reproducibility	r01603020104030	NN	B-NP	O
across	across	a2602	IN	B-PP	O
and	and	a530	CC	I-PP	O
within	within	w0305	IN	I-PP	O
volunteers	volunteer	v04053062	NNS	B-NP	O
(	(	(000	(	O	O
inter	inter	i5306	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
and	and	a530	CC	O	O
intra	intra	i5360	AFX	O	O
-	-	-000	HYPH	O	O
individual	individual	i53010304	JJ	B-NP	O
variation	variation	v060305	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
intraclass	intraclass	i53602402	JJ	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
coefficient	coefficient	c0102053	NN	I-NP	O
(	(	(000	(	O	O
ICC	ICC	i200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
coefficient	coefficient	c0102053	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
variation	variation	v060305	NN	B-NP	O
(	(	(000	(	O	O
CV	CV	c100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Secondary	Secondary	s02053060	JJ	B-NP	O
pinprick	pinprick	p051602	NN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
(	(	(000	(	O	O
VAS	VAS	v020	NN	B-NP	O
)	)	)000	)	O	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
von	von	v050	NNP	B-NP	O
Frey	Frey	f600	NNP	I-NP	O
gauges	gauge	g0202	VBZ	B-VP	O
60	60	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
100	100	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
secondary	secondary	s02053060	JJ	B-NP	O
pinprick	pinprick	p051602	NN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
all	all	a400	DT	B-NP	O
von	von	v050	NNP	I-NP	O
Frey	Frey	f600	NNP	I-NP	O
gauges	gauge	g0202	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Glutamate	Glutamate	g40305030	NN	B-NP	B-Chemical
evoked	evoke	e10203	VBD	B-VP	O
reproducible	reproducible	r01603020140	JJ	B-NP	O
VAS	VAS	v020	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
all	all	a400	DT	B-NP	O
von	von	v050	NNP	I-NP	O
Frey	Frey	f600	NNP	I-NP	O
gauges	gauge	g0202	NNS	I-NP	O
(	(	(000	(	O	O
ICC	ICC	i200	NN	B-NP	O
>	>	>000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
60	60	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
brush	brush	b6020	JJ	B-NP	O
strokes	stroke	s360202	NNS	I-NP	O
(	(	(000	(	O	O
ICC	ICC	i200	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
83	83	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Capsaicin	Capsaicin	c0120205	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reproducible	reproducible	r01603020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ICC	ICC	i200	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
70	70	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
allodynia	allodynia	a403050	NN	B-NP	B-Disease
(	(	(000	(	O	O
ICC	ICC	i200	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
71	71	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Intra	Intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
individual	individual	i53010304	JJ	I-NP	O
variability	variability	v060104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
generally	generally	g0506040	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
VAS	VAS	v020	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
von	von	v050	NNP	B-NP	O
Frey	Frey	f600	NNP	I-NP	O
and	and	a530	CC	O	O
brush	brush	b6020	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
areas	area	a602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
yield	yield	y043	NN	I-NP	O
reproducible	reproducible	r01603020140	JJ	B-NP	O
hyperalgesic	hyperalgesic	h01060420202	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	O
allodynic	allodynic	a4030502	JJ	I-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
suited	suit	s0303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
basic	basic	b0202	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
for	for	f060	IN	B-PP	O
assessing	assess	a202052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
phenomena	phenomenon	p0505050	NNS	I-NP	O
.	.	.000	.	O	O

Ocular	Ocular	o20406	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
ER	ER	e600	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
rescues	rescue	r0202	VBZ	B-VP	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
murine	murine	m06050	JJ	B-NP	O
glucocorticoid	glucocorticoid	g402020630203	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
glucocorticoids	glucocorticoid	g4020206302032	NNS	B-NP	O
induces	induce	i530202	VBZ	B-VP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
untreated	untreated	u5360303	JJ	B-ADJP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
can	can	c050	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
a	a	a000	DT	B-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
resembles	resemble	r02051402	VBZ	B-VP	O
primary	primary	p605060	JJ	B-NP	B-Disease
open	open	o105	JJ	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
angle	angle	a5240	NN	I-NP	I-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
(	(	(000	(	O	O
POAG	POAG	p020	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
fully	fully	f040	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
,	,	,000	,	O	O
due	due	d000	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
to	to	t000	TO	B-PP	O
lack	lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
appropriate	appropriate	a16016030	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
exhibits	exhibit	e201032	VBZ	B-VP	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
features	feature	f030602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
ocular	ocular	o20406	JJ	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intraocular	intraocular	i536020406	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
IOP	IOP	i010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
functional	functional	f05230504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
retinal	retinal	r030504	JJ	B-NP	B-Disease
ganglion	ganglion	g052405	NN	I-NP	I-Disease
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
,	,	,000	,	O	O
resembling	resemble	r020514052	VBG	B-VP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
ER	ER	e600	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
trabecular	trabecular	t601020406	JJ	I-NP	O
meshwork	meshwork	m02062	NN	I-NP	O
(	(	(000	(	O	O
TM	TM	t500	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
IOP	IOP	i010	NN	I-NP	O
and	and	a530	CC	I-NP	O
ER	ER	e600	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
transcriptional	transcriptional	t605260130504	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
CHOP	CHOP	c010	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
ER	ER	e600	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
segment	segment	s025053	NN	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Chop	Chop	c010	NN	B-NP	O
deletion	deletion	d040305	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
ER	ER	e600	NN	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
and	and	a530	CC	O	O
prevented	prevent	p60105303	VBD	B-VP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ER	ER	e600	NN	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
TM	TM	t500	NN	I-NP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenylbutyrate	phenylbutyrate	p050410306030	NN	I-NP	I-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ER	ER	e600	NN	B-NP	O
stress	stress	s3602	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
reducing	reduce	r0302052	VBG	B-VP	O
ER	ER	e600	NN	B-NP	O
stress	stress	s3602	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
potential	potential	p0305304	NN	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
for	for	f060	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ginsenosides	ginsenoside	g05205020302	NNS	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
opioid	opioid	o103	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Opioid	Opioid	o103	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
(	(	(000	(	O	O
OIH	OIH	o000	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
cessation	cessation	c020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

OIH	OIH	o000	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
limit	limit	l0503	VB	I-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
opioid	opioid	o103	JJ	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
and	and	a530	CC	O	O
complicate	complicate	c051402030	VBP	B-VP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
from	from	f605	IN	B-PP	O
opioid	opioid	o103	JJ	B-NP	B-Disease
addiction	addiction	a302305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Re	Re	r000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
Rg1	Rg1	0000	NN	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
and	and	a530	CC	O	I-Chemical
Rb1	Rb1	0000	NN	B-NP	I-Chemical
ginsenosides	ginsenoside	g05205020302	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
bioactive	bioactive	b023010	JJ	I-NP	O
components	component	c051050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ginseng	ginseng	g052052	NN	B-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
OIH	OIH	o000	NN	B-NP	B-Disease
.	.	.000	.	O	O

OIH	OIH	o000	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
(	(	(000	(	O	O
days	day	d020	NNS	B-NP	O
8	8	8000	CD	B-NP	O
and	and	a530	CC	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
Re	Re	r000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
Rb1	Rb1	0000	NN	B-NP	B-Chemical
intragastrically	intragastrically	i53602023602040	RB	B-ADVP	O
two	two	t000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
10	10	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
thermal	thermal	t06504	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
acetic	acetic	a20302	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
writhing	writhing	w603052	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Re	Re	r000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
inhibited	inhibit	i5010303	VBD	B-VP	O
OIH	OIH	o000	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
thermal	thermal	t06504	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
acetic	acetic	a20302	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
writhing	writhing	w603052	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Rg1	Rg1	0000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	I-Chemical
Rb1	Rb1	0000	NN	I-NP	I-Chemical
ginsenosides	ginsenoside	g05205020302	NNS	I-NP	I-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
OIH	OIH	o000	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
either	either	e0306	DT	B-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
tendency	tendency	t0530520	NN	I-NP	O
to	to	t000	TO	B-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
OIH	OIH	o000	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acetic	acetic	a20302	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
writhing	writhing	w603052	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
ginsenoside	ginsenoside	g0520502030	NN	I-NP	B-Chemical
Re	Re	r000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
Rb1	Rb1	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
toward	toward	t063	IN	B-PP	O
reversal	reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
OIH	OIH	o000	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
in	in	i500	IN	B-PP	O
neurocritical	neurocritical	n06026030204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
used	use	u203	VBN	I-VP	O
sedatives	sedative	s03030102	NNS	B-NP	O
in	in	i500	IN	B-PP	O
neurocritical	neurocritical	n06026030204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
allow	allow	a400	VBP	B-VP	O
for	for	f060	IN	B-PP	O
frequent	frequent	f602053	JJ	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
neurocritical	neurocritical	n06026030204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Multicenter	Multicenter	m0430205306	NNP	B-NP	O
,	,	,000	,	O	O
retrospective	retrospective	r036021023010	JJ	B-NP	O
,	,	,000	,	I-NP	O
propensity	propensity	p601052030	NN	I-NP	O
-	-	-000	HYPH	O	O
matched	match	m03203	VBN	B-VP	O
cohort	cohort	c063	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Neurocritical	Neurocritical	n06026030204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
units	unit	u5032	NNS	I-NP	O
at	at	a300	IN	B-PP	O
two	two	t000	CD	B-NP	O
academic	academic	a2030502	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
centers	center	c053062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
dedicated	dedicate	d03020303	VBN	B-NP	O
neurocritical	neurocritical	n06026030204	JJ	I-NP	O
care	care	c060	NN	I-NP	O
teams	team	t052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
board	board	b063	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
certified	certify	c0630103	VBN	I-NP	O
neurointensivists	neurointensivist	n06053052010232	NNS	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
Neurocritical	Neurocritical	n06026030204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
admitted	admit	a350303	VBN	B-VP	O
between	between	b0305	IN	B-PP	O
July	July	j040	NNP	B-NP	O
2009	2009	0000	CD	I-NP	O
and	and	a530	CC	O	O
September	September	s01305106	NNP	B-NP	O
2012	2012	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
and	and	a530	CC	O	O
then	then	t050	RB	O	O
matched	match	m03203	VBD	B-VP	O
1	1	1000	CD	B-NP	O
:	:	:000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
propensity	propensity	p601052030	NN	B-NP	O
scoring	scoring	s206052	NN	I-NP	O
of	of	o100	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
.	.	.000	.	O	O

INTERVENTIONS	INTERVENTIONS	i53061053052	NNS	B-NP	O
:	:	:000	:	O	O
Continuous	Continuous	c0530502	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
with	with	w030	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
MAIN	MAIN	m050	NN	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
342	342	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
105	105	0000	CD	B-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
237	237	0000	CD	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
190	190	0000	CD	B-NP	O
matched	match	m03203	VBN	B-VP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
propensity	propensity	p601052030	NN	B-NP	O
score	score	s2060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
composite	composite	c05102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
<	<	<000	SYM	B-NP	O
60	60	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
(	(	(000	(	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
<	<	<000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
sedative	sedative	s0303010	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
composite	composite	c05102030	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
unmatched	unmatched	u503203	JJ	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
94	94	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
matched	match	m03203	VBN	B-NP	O
cohorts	cohort	c0632	NNS	I-NP	O
(	(	(000	(	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
34	34	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
35	35	0000	CD	I-NP	O
)	)	)000	)	O	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
analyzed	analyze	a5040203	VBN	B-VP	O
separately	separately	s010603040	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
the	the	t000	DT	B-NP	O
unmatched	unmatched	u503203	JJ	I-NP	O
or	or	o600	CC	I-NP	O
matched	matched	m03203	JJ	I-NP	O
cohorts	cohort	c0632	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Severe	Severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
occur	occur	o206	VBP	B-VP	O
at	at	a300	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
neurocritical	neurocritical	n06026030204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
receive	receive	r02010	VBP	B-VP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Providers	Provider	p60103062	NNS	B-NP	O
should	should	s043	MD	B-VP	O
similarly	similarly	s05040640	RB	I-VP	O
consider	consider	c0520306	VB	I-VP	O
the	the	t000	DT	B-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
before	before	b01060	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
either	either	e0306	CC	O	O
sedative	sedative	s0303010	JJ	B-ADJP	O
.	.	.000	.	O	O

Hydroxytyrosol	Hydroxytyrosol	h0360203060204	NN	B-NP	B-Chemical
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
aging	aging	a2052	NN	I-NP	O
and	and	a530	CC	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Herein	Herein	h0605	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigate	investigate	i5102302030	VBP	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
chronic	chronic	c060502	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
hydroxytyrosol	hydroxytyrosol	h0360203060204	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
bearing	bear	b06052	VBG	B-VP	O
breast	breast	b6023	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
chemically	chemically	c0502040	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
4	4	4000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
hydroxytyrosol	hydroxytyrosol	h0360203060204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5mg	5mg	5200	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
5days	5day	5302	NNS	B-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1mg	1mg	1520	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
hydroxytyrosol	hydroxytyrosol	h0360203060204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
electron	electron	e4023605	NN	I-NP	O
transport	transport	t60521063	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
complexes	complex	c05140202	NNS	I-NP	O
I	I	i000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
IV	IV	i100	CD	I-NP	O
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
-	-	-000	HYPH	O	O
inducing	induce	i5302052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
markers	marker	m062062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Hydroxytyrosol	Hydroxytyrosol	h0360203060204	NN	B-NP	B-Chemical
improved	improve	i5160103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
enhanced	enhance	e505203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
altered	alter	a430603	VBN	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hydroxytyrosol	hydroxytyrosol	h0360203060204	NN	B-NP	B-Chemical
improve	improve	i516010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
electron	electron	e4023605	NN	I-NP	O
transport	transport	t60521063	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
hydroxytyrosol	hydroxytyrosol	h0360203060204	NN	B-NP	B-Chemical
protect	protect	p603023	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
provoked	provoke	p6010203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
decreasing	decrease	d02602052	VBG	B-VP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
and	and	a530	CC	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myxoedema	myxoedema	m0203050	NN	I-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
62	62	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thyroid	Thyroid	t0603	NN	B-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
168	168	0000	CD	B-NP	O
uIU	uIU	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	B-NP	O
(	(	(000	(	O	O
nl	nl	n400	NN	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
uIU	uIU	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
thyroxine	thyroxine	t0602050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
FT4	FT4	0000	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
(	(	(000	(	O	O
nl	nl	n400	NN	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluids	fluid	f4032	NNS	I-NP	O
,	,	,000	,	O	O
vasopressor	vasopressor	v020160206	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
stress	stress	s3602	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
;	;	;000	:	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
intubated	intubate	i53010303	VBN	I-VP	O
and	and	a530	CC	O	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
500	500	0000	CD	B-NP	O
ug	ug	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
levothyroxine	levothyroxine	l01030602050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
18	18	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
150	150	0000	CD	B-NP	O
ug	ug	u200	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	B-ADJP	O
daily	daily	d040	RB	B-ADVP	O
thereafter	thereafter	t0601306	RB	I-ADVP	O
.	.	.000	.	O	O

Haemodynamic	Haemodynamic	h0503050502	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
,	,	,000	,	O	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
FT4	FT4	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
96	96	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
levothyroxine	levothyroxine	l01030602050	NN	B-NP	B-Chemical
175	175	0000	CD	I-NP	O
(	(	(000	(	O	O
g	g	g000	NN	B-NP	O
POorally	POorally	p06040	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
thyroid	thyroid	t0603	JJ	I-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
diffuse	diffuse	d01020	JJ	B-NP	O
heterogeneity	heterogeneity	h03060205030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
hour	hour	h060	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
iodine	iodine	i03050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
3657	3657	0000	CD	B-NP	O
(	(	(000	(	O	O
mcg	mcg	m200	NN	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
756	756	0000	CD	B-NP	O
(	(	(000	(	O	O
mcg	mcg	m200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
two	two	t000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myxoedema	myxoedema	m0203050	NN	I-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
report	report	r01063	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
death	death	d030	NN	I-NP	O
despite	despite	d021030	IN	B-PP	O
supportive	supportive	s01063010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	I-NP	O
thyroid	thyroid	t0603	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
represents	represent	r016020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
thoroughly	thoroughly	t0602040	RB	I-NP	O
investigated	investigate	i51023020303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myxoedema	myxoedema	m0203050	NN	I-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
significant	significant	s0250102053	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
subclinical	subclinical	s0124050204	JJ	B-NP	O
thyroid	thyroid	t0603	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
-	-	-000	HYPH	O	O
directed	direct	d0602303	VBN	B-NP	O
thrombolysis	thrombolysis	t06051040202	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
alteplase	alteplase	a43014020	NN	B-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
(	(	(000	(	O	O
HITT	HITT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
-	-	-000	HYPH	O	O
directed	direct	d0602303	VBN	B-VP	O
thrombolysis	thrombolysis	t06051040202	NN	B-NP	B-Disease
(	(	(000	(	O	O
CDT	CDT	c300	NN	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
alteplase	alteplase	a43014020	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

SUMMARY	SUMMARY	s05060	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
63	63	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
amyloidosis	amyloidosis	a504030202	NN	I-NP	B-Disease
undergoing	undergo	u53062052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
collection	collection	c0402305	NN	I-NP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
autologous	autologous	a03040202	JJ	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
upper	upper	u106	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
extremity	extremity	e23605030	NN	I-NP	I-Disease
deep	deep	d010	JJ	I-NP	I-Disease
venous	venous	v0502	JJ	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
(	(	(000	(	O	O
DVT	DVT	d130	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
embolism	embolism	e5104025	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
managed	manage	m050203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
floor	floor	f406	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
with	with	w030	IN	B-PP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
compromise	compromise	c051605020	NN	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
superior	superior	s010606	JJ	B-NP	B-Disease
vena	vena	v050	NN	I-NP	I-Disease
cava	cava	c010	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
SVC	SVC	s120	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
syndrome	syndrome	s0536050	NN	B-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
percutaneous	percutaneous	p062030502	JJ	I-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
thrombectomy	thrombectomy	t06051023050	NN	I-NP	O
and	and	a530	CC	I-NP	O
CDT	CDT	c300	NN	I-NP	O
with	with	w030	IN	B-PP	O
alteplase	alteplase	a43014020	NN	B-NP	O
were	be	w060	VBD	B-VP	O
attempted	attempt	a3051303	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
aborted	abort	a106303	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
epistaxis	epistaxis	e10230202	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
epistaxis	epistaxis	e10230202	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
restarted	restart	r02306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
percutaneous	percutaneous	p062030502	JJ	I-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
thrombectomy	thrombectomy	t06051023050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
six	six	s020	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
and	and	a530	CC	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
revascularization	revascularization	r01020406020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
SVC	SVC	s120	NN	I-NP	O
and	and	a530	CC	I-NP	O
central	central	c053604	JJ	I-NP	O
veins	vein	v052	NNS	I-NP	O
.	.	.000	.	O	O

Postthrombectomy	Postthrombectomy	p02306051023050	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
CDT	CDT	c300	NN	I-NP	O
with	with	w030	IN	B-PP	O
alteplase	alteplase	a43014020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
commenced	commence	c0505203	VBN	I-VP	O
while	while	w040	IN	B-SBAR	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
withheld	withhold	w03043	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
patency	patency	p030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
SVC	SVC	s120	NN	I-NP	O
and	and	a530	CC	I-NP	O
central	central	c053604	JJ	I-NP	O
veins	vein	v052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
three	three	t060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Alteplase	Alteplase	a43014020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reinitiated	reinitiate	r05030303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
;	;	;000	:	O	O
ultimately	ultimately	u430503040	RB	B-ADVP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
transitioned	transitione	t6052030503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
vision	vision	v0205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
63	63	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
amyloidosis	amyloidosis	a504030202	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
SVC	SVC	s120	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
HITT	HITT	h030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
CDT	CDT	c300	NN	I-NP	O
with	with	w030	IN	B-PP	O
alteplase	alteplase	a43014020	NN	B-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
dehydroepiandrosterone	dehydroepiandrosterone	d03601053602306050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
schizophrenia	schizophrenia	s2020106050	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dehydroepiandrosterone	dehydroepiandrosterone	d03601053602306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DHEA	DHEA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Seventy	Seventy	s010530	CD	B-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
albino	albino	a41050	NN	I-NP	O
female	female	f05040	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
35	35	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
4	4	4000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
free	free	f600	JJ	O	O
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
50	50	0000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
DHEA	DHEA	d000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
DHEA	DHEA	d000	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
(	(	(000	(	O	O
ip	ip	i100	RB	B-ADVP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Amphetamine	Amphetamine	a510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
hyper	hyper	h0106	NN	B-NP	B-Disease
locomotion	locomotion	l02050305	NN	I-NP	O
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
[	[	[000	(	O	O
sc	sc	s200	NN	B-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
induced	induce	i530203	VBN	B-NP	O
climbing	climbing	c4051052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
Animal	Animal	a50504	NNP	I-NP	O
Experiment	Experiment	e210605053	NNP	I-NP	O
Laboratories	Laboratories	l0106030602	NNP	I-NP	O
,	,	,000	,	O	O
Department	Department	d010635053	NNP	B-NP	O
of	of	o100	IN	B-PP	O
Pharmacology	Pharmacology	p0650204020	NNP	B-NP	O
,	,	,000	,	O	O
Medical	Medical	m030204	NNP	B-NP	O
School	School	s204	NNP	I-NP	O
,	,	,000	,	O	O
Eskisehir	Eskisehir	e20206	NNP	B-NP	O
Osmangazi	Osmangazi	o25052020	NNP	I-NP	O
University	University	u501062030	NNP	I-NP	O
,	,	,000	,	O	O
Eskisehir	Eskisehir	e20206	NNP	B-NP	O
,	,	,000	,	O	O
Turkey	Turkey	t0620	NNP	B-NP	O
between	between	b0305	IN	B-PP	O
March	March	m0620	NNP	B-NP	O
and	and	a530	CC	O	O
May	May	m000	NNP	B-NP	O
2012	2012	0000	CD	I-NP	O
.	.	.000	.	O	O

Statistical	Statistical	s3030230204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
using	use	u2052	VBG	B-VP	O
Kruskal	Kruskal	k60204	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Wallis	Wallis	w0402	NNP	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
hyper	hyper	h0106	NN	B-NP	B-Disease
locomotion	locomotion	l02050305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
ANOVA	ANOVA	a5010	NN	I-NP	O
for	for	f060	IN	B-PP	O
climbing	climbing	c4051052	NN	B-NP	O
and	and	a530	CC	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotion	locomotion	l02050305	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
DHEA	DHEA	d000	NN	B-NP	B-Chemical
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-VP	O
decreased	decrease	d0260203	VBD	I-VP	O
all	all	a400	DT	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotion	locomotion	l02050305	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
climbing	climbing	c4051052	NN	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	I-VP	O
climbing	climb	c4051052	VBG	B-VP	O
test	test	t023	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
DHEA	DHEA	d000	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
both	both	b030	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
climbing	climb	c4051052	VBG	B-VP	O
behavior	behavior	b0106	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
DHEA	DHEA	d000	NN	B-NP	B-Chemical
displays	display	d021402	VBZ	B-VP	O
typical	typical	t010204	JJ	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Availability	Availability	a1040104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pluripotent	pluripotent	p4060103053	JJ	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
derived	derive	d060103	VBN	I-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
assessment	assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Field	Field	f043	JJ	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
(	(	(000	(	O	O
FPD	FPD	f130	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
pluripotent	pluripotent	p4060103053	JJ	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
derived	derive	d060103	VBN	I-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
(	(	(000	(	O	O
hiPS	hiPS	h012	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
CMs	CM	c520	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
can	can	c050	MD	B-VP	O
express	express	e21602	VB	I-VP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
tool	tool	t040	NN	I-NP	O
to	to	t000	TO	B-VP	O
predict	predict	p603023	VB	I-VP	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
and	and	a530	CC	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
blocker	blocker	b40206	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
showing	show	s052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
technique	technique	t0205020	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
predict	predict	p603023	VB	I-VP	O
multichannel	multichannel	m043020504	JJ	B-NP	O
blocker	blocker	b40206	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
show	show	s000	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
FPD	FPD	f130	NN	B-NP	O
from	from	f605	IN	B-PP	O
MEA	MEA	m000	NN	B-NP	O
(	(	(000	(	O	O
Multielectrode	Multielectrode	m043040236030	NN	B-NP	O
array	array	a600	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
hiPS	hiPS	h012	NN	B-NP	O
-	-	-000	HYPH	O	O
CMs	CM	c520	NNS	B-NP	O
can	can	c050	MD	B-VP	O
detect	detect	d03023	VB	I-VP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
multichannel	multichannel	m043020504	JJ	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

hiPS	hiPS	h012	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
CMs	CM	c520	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seeded	seed	s0303	VBN	I-VP	O
onto	onto	o530	IN	B-PP	O
MEA	MEA	m000	NN	B-NP	O
and	and	a530	CC	I-NP	O
FPD	FPD	f130	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
2min	2min	2505	NN	B-NP	O
every	every	e1060	DT	B-NP	O
10min	10min	0000	NN	I-NP	O
for	for	f060	IN	B-PP	O
30min	30min	0000	NN	B-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
and	and	a530	CC	O	O
each	each	e020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

IKr	IKr	i260	NN	B-NP	O
and	and	a530	CC	I-NP	O
IKs	IKs	i200	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-ADVP	O
prolonged	prolong	p60405203	VBD	B-VP	O
corrected	correct	c0602303	VBN	I-VP	O
FPD	FPD	f130	NN	B-NP	O
(	(	(000	(	O	O
FPDc	FPDc	f132	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-ADVP	O
shortened	shorten	s0630503	VBD	B-VP	O
FPDc	FPDc	f132	NN	B-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
multichannel	multichannel	m043020504	JJ	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
Amiodarone	Amiodarone	a50306050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
Paroxetine	Paroxetine	p060203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Terfenadine	Terfenadine	t0610503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Citalopram	Citalopram	c030401605	NN	I-NP	B-Chemical
prolonged	prolong	p60405203	VBD	B-VP	O
FPDc	FPDc	f132	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
IKr	IKr	i260	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
Terfenadine	Terfenadine	t0610503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Citalopram	Citalopram	c030401605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
Torsade	Torsade	t062030	NNP	B-NP	B-Disease
de	de	d000	IN	I-NP	I-Disease
Pointes	Pointes	p05302	NNP	I-NP	I-Disease
(	(	(000	(	O	O
TdP	TdP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
,	,	,000	,	O	O
produced	produce	p6030203	VBD	B-VP	O
early	early	e0640	JJ	B-NP	O
afterdepolarization	afterdepolarization	a13063010406020305	NN	I-NP	O
(	(	(000	(	O	O
EAD	EAD	e030	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

hiPS	hiPS	h012	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
CMs	CM	c520	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
MEA	MEA	m000	NN	B-NP	O
system	system	s02305	NN	I-NP	O
and	and	a530	CC	I-NP	O
FPDc	FPDc	f132	NN	I-NP	O
can	can	c050	MD	B-VP	O
predict	predict	p603023	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
candidates	candidate	c053030302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
assay	assay	a200	NN	I-NP	O
can	can	c050	MD	B-VP	O
help	help	h041	VB	I-VP	O
detect	detect	d03023	VB	I-VP	O
EAD	EAD	e030	NN	B-NP	O
for	for	f060	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
with	with	w030	IN	B-PP	O
TdP	TdP	t310	NN	B-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
.	.	.000	.	O	O

Dermal	Dermal	d06504	JJ	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
phenylimide	phenylimide	p050405030	NN	I-NP	O
herbicides	herbicide	h061020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
53482	53482	0000	CD	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
S	S	s000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
23121	23121	0000	CD	B-NP	I-Chemical
are	be	a600	VBP	B-VP	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
phenylimide	phenylimide	p050405030	NN	I-NP	O
herbicides	herbicide	h061020302	NNS	I-NP	O
and	and	a530	CC	O	O
produced	produce	p6030203	VBD	B-VP	O
embryolethality	embryolethality	e516040304030	NN	B-NP	B-Disease
,	,	,000	,	O	O
teratogenicity	teratogenicity	t0603020502030	NN	B-NP	B-Disease
(	(	(000	(	O	O
mainly	mainly	m0540	RB	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
wavy	wavy	w010	NN	B-NP	O
ribs	rib	r012	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
growth	growth	g6030	NN	B-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
objective	objective	o12023010	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
induce	induce	i53020	VBP	B-VP	O
developmental	developmental	d010401505304	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
dermal	dermal	d06504	JJ	I-NP	O
route	route	r030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
relevant	relevant	r0401053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
occupational	occupational	o201030504	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
hence	hence	h0520	RB	B-ADJP	O
better	good	b0306	JJR	I-ADJP	O
addressing	address	a3602052	VBG	B-VP	O
human	human	h0505	JJ	B-NP	O
health	health	h0430	NN	I-NP	O
risks	risk	r020	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
53482	53482	0000	CD	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
dermally	dermally	d065040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
during	during	d06052	IN	B-PP	O
organogenesis	organogenesis	o620502050202	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
23121	23121	0000	CD	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
200	200	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
400	400	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
applicable	applicable	a14020140	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Fetuses	Fetus	f030202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
Cesarean	Cesarean	c020605	JJ	I-NP	O
section	section	s02305	NN	I-NP	O
and	and	a530	CC	O	O
examined	examine	e2050503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
external	external	e2306504	JJ	B-NP	O
,	,	,000	,	I-NP	O
visceral	visceral	v020604	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
skeletal	skeletal	s2040304	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Dermal	Dermal	d06504	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
to	to	t000	TO	B-PP	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
53482	53482	0000	CD	B-NP	I-Chemical
at	at	a300	IN	B-PP	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
patterns	pattern	p030652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
developmental	developmental	d010401505304	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

Toxicity	Toxicity	t0202030	NN	B-NP	B-Disease
included	include	i5240303	VBD	B-VP	O
embryolethality	embryolethality	e516040304030	NN	B-NP	B-Disease
,	,	,000	,	O	O
teratogenicity	teratogenicity	t0603020502030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
growth	growth	g6030	NN	B-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Dermal	Dermal	d06504	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
23121	23121	0000	CD	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
embryonic	embryonic	e5160502	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
defect	defect	d01023	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
retarded	retard	r0306303	VBD	B-VP	O
fetal	fetal	f0304	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
following	follow	f04052	VBG	I-VP	O
oral	oral	o604	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
23121	23121	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Based	Base	b0203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
,	,	,000	,	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
53482	53482	0000	CD	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
S	S	s000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
23121	23121	0000	CD	B-NP	I-Chemical
were	be	w060	VBD	B-VP	O
teratogenic	teratogenic	t0603020502	JJ	B-ADJP	B-Disease
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
dermally	dermally	d065040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
investigation	investigation	i51023020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
human	human	h0505	JJ	I-NP	O
relevancy	relevancy	r04010520	NN	I-NP	O
become	become	b02050	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
.	.	.000	.	O	O

Rates	Rate	r0302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
Renal	Renal	r0504	JJ	B-NP	B-Disease
Toxicity	Toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Cancer	Cancer	c05206	NNP	B-NP	B-Disease
Patients	Patients	p030532	NNP	I-NP	O
Receiving	Receiving	r0201052	NNP	I-NP	O
Cisplatin	Cisplatin	c02140305	NNP	I-NP	B-Chemical
With	With	w030	IN	B-PP	O
and	and	a530	CC	I-PP	O
Without	Without	w0303	IN	I-PP	O
Mannitol	Mannitol	m050304	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cisplatin	Cisplatin	c02140305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	B-ADJP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
many	many	m050	JJ	B-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
this	this	t020	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
nephroprotectant	nephroprotectant	n010601603023053	NN	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
hydration	hydration	h0360305	NN	B-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
agent	agent	a2053	NN	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
and	and	a530	CC	I-PP	O
without	without	w0303	IN	I-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
center	center	c05306	NN	I-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
quasi	quasi	q020	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
created	create	c60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
national	national	n030504	JJ	I-NP	O
mannitol	mannitol	m050304	NN	I-NP	B-Chemical
shortage	shortage	s063020	NN	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
agent	agent	a2053	NN	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
from	from	f605	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
2011	2011	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
September	September	s01305106	NNP	B-NP	O
2012	2012	0000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
AKI	AKI	a200	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
143	143	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
agent	agent	a2053	NN	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
;	;	;000	:	O	O
97	97	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
head	head	h030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
primary	primary	p605060	JJ	I-NP	O
malignancy	malignancy	m040250520	NN	I-NP	B-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
receive	receive	r02010	VB	I-VP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
:	:	:000	:	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
[	[	[000	(	O	O
OR	OR	o600	NN	B-NP	O
]	]	]000	)	O	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
646	646	0000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
008	008	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	I-NP	O
944	944	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
048	048	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
dosing	dosing	d02052	NN	B-NP	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
also	also	a420	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
:	:	:000	:	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
494	494	0000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
149	149	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
32	32	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
258	258	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
219	219	0000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
228	228	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
439	439	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
017	017	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
When	When	w050	WRB	B-ADVP	O
limited	limited	l050303	JJ	B-NP	O
quantities	quantity	q0530302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
should	should	s043	MD	B-VP	O
preferentially	preferentially	p60106053040	RB	I-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
particularly	particularly	p06302040640	RB	B-NP	O
high	high	h020	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
would	would	w043	MD	B-VP	O
benefit	benefit	b050103	VB	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
learning	learning	l065052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
kindling	kindling	k0534052	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Cognitive	Cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
and	and	a530	CC	I-NP	O
severe	severe	s01060	JJ	I-NP	O
comorbidity	comorbidity	c0506103030	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
,	,	,000	,	O	O
greatly	greatly	g60340	RB	B-VP	O
diminishes	diminish	d05050202	VBZ	I-VP	O
the	the	t000	DT	B-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
current	current	c06053	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
also	also	a420	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
untoward	untoward	u53063	JJ	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
urgent	urgent	u62053	JJ	I-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
new	new	n000	JJ	B-NP	O
kinds	kind	k0532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
agents	agent	a20532	NNS	B-NP	O
targeting	target	t06203052	VBG	B-VP	O
both	both	b030	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
cognition	cognition	c0250305	NN	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
play	play	p400	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
and	and	a530	CC	O	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
antioxidants	antioxidant	a5302030532	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
putative	putative	p0303010	JJ	I-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
commonly	commonly	c050540	RB	I-NP	O
prescribed	prescribe	p60260103	VBN	I-NP	O
antidiabetic	antidiabetic	a5303010302	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
ameliorative	ameliorative	a5040603010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
brain	brain	b605	NN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
markers	marker	m062062	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
kindling	kindling	k0534052	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
C57BL	C57BL	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
subconvulsive	subconvulsive	s012051042010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
37	37	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
every	every	e1060	DT	B-NP	O
other	other	o306	JJ	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
200mg	200mg	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
alternate	alternate	a43065030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
PTZ	PTZ	p320	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
kindling	kindling	k0534052	NN	B-NP	O
,	,	,000	,	O	O
ameliorated	ameliorate	a504060303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
brain	brain	b605	NN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
concluded	conclude	c05240303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
medicine	medicine	m0302050	NN	I-NP	O
against	against	a20523	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

P53	P53	0000	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
exacerbates	exacerbate	e2020610302	VBZ	B-VP	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
stage	stage	s3020	NN	I-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

AIMS	AIMS	a052	NNS	B-NP	O
:	:	:000	:	O	O
Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
therapeutic	therapeutic	t06010302	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	B-NP	O
acute	acute	a2030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
late	late	l030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
stage	stage	s3020	NN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Children	Child	c043605	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
particularly	particularly	p06302040640	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
p53	p53	0000	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
stage	stage	s3020	NN	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
juvenile	juvenile	j0105040	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
MHC	MHC	m020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
CB7	CB7	0000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
which	which	w020	WDT	B-NP	O
express	express	e21602	VBP	B-VP	O
dominant	dominant	d0505053	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
interfering	interfere	i5306106052	VBG	B-VP	O
p53	p53	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
transgenic	transgenic	t60520502	JJ	I-NP	O
(	(	(000	(	O	O
NON	NON	n050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
TXG	TXG	t200	NN	I-NP	O
)	)	)000	)	O	O
littermates	littermate	l030650302	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
weekly	weekly	w0240	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
acute	acute	a2030	JJ	B-NP	O
stage	stage	s3020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
MHC	MHC	m020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
CB7	CB7	0000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
improved	improved	i5160103	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
NON	NON	n050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
TXG	TXG	t200	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Surprisingly	Surprisingly	s06160205240	RB	B-ADVP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
13	13	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
late	late	l030	JJ	B-NP	O
stage	stage	s3020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
MHC	MHC	m020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
CB7	CB7	0000	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
NON	NON	n050	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
TXG	TXG	t200	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

p53	p53	0000	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
blocked	block	b40203	VBD	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
STAT3	STAT3	0000	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
MHC	MHC	m020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
CB7	CB7	0000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DNA	DNA	d500	NN	I-NP	O
repair	repair	r0106	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
Ku70	Ku70	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
Ku80	Ku80	0000	NN	I-NP	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
restricted	restrict	r023602303	VBN	I-NP	O
deletion	deletion	d040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
STAT3	STAT3	0000	NN	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
worse	worse	w0620	JJR	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
higher	high	h0206	JJR	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ku70	Ku70	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
Ku80	Ku80	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	I-PP	O
to	to	t000	TO	I-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
wherein	wherein	w0605	IN	B-PP	O
a	a	a000	DT	B-NP	O
p53	p53	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
,	,	,000	,	O	O
mediated	mediate	m030303	VBN	B-VP	O
via	via	v000	IN	B-PP	O
STAT3	STAT3	0000	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
,	,	,000	,	O	O
mitigates	mitigate	m03020302	VBZ	B-VP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
during	during	d06052	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
an	an	a500	DT	B-NP	O
explanation	explanation	e214050305	NN	I-NP	O
as	as	a200	IN	B-PP	O
to	to	t000	TO	B-PP	O
how	how	h000	WRB	B-ADVP	O
p53	p53	0000	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
can	can	c050	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
cardioprotection	cardioprotection	c0630160302305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
paradoxically	paradoxically	p06030202040	RB	B-ADVP	O
,	,	,000	,	O	O
enhanced	enhance	e505203	VBN	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
long	long	l052	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
cessation	cessation	c020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Metronidazole	Metronidazole	m036050302040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
uncommon	uncommon	u520505	JJ	I-NP	O
scenario	scenario	s205060	NN	I-NP	O
.	.	.000	.	O	O

Metronidazole	Metronidazole	m036050302040	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
neurological	neurological	n0604020204	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
although	although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
scenario	scenario	s205060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
metronidazole	metronidazole	m036050302040	NN	I-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

Magnetic	Magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
brain	brain	b605	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
signal	signal	s02504	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
both	both	b030	CC	O	O
dentate	dentate	d053030	VBP	B-VP	O
nuclei	nucleus	n0240	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cerebellum	cerebellum	c06010405	NN	B-NP	O
and	and	a530	CC	I-NP	O
splenium	splenium	s140505	NN	I-NP	O
of	of	o100	IN	B-PP	O
corpus	corpus	c06102	NN	B-NP	O
callosum	callosum	c040205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
MRI	MRI	m600	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
and	and	a530	CC	O	O
supported	support	s0106303	VBN	B-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
.	.	.000	.	O	O

Aconitine	Aconitine	a20503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
Ca2	Ca2	0000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
overload	overload	o106403	NN	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
triggers	trigger	t602062	VBZ	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
through	through	t06020	IN	B-PP	O
p38	p38	0000	NN	B-NP	O
MAPK	MAPK	m012	NN	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Aconitine	Aconitine	a20503050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
bioactive	bioactive	b023010	JJ	I-NP	O
diterpenoid	diterpenoid	d030610503	NN	I-NP	O
alkaloid	alkaloid	a420403	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
content	content	c053053	NN	I-NP	O
derived	derive	d060103	VBN	B-VP	O
from	from	f605	IN	B-PP	O
herbal	herbal	h06104	JJ	B-NP	O
aconitum	aconitum	a2050305	NN	I-NP	O
plants	plant	p40532	NNS	I-NP	O
.	.	.000	.	O	O

Emerging	Emerge	e5062052	VBG	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
voltage	voltage	v043020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channels	channel	c05042	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
pivotal	pivotal	p010304	JJ	B-NP	O
roles	role	r0402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
reports	report	r010632	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
poisoning	poisoning	p0205052	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
explored	explore	e2140603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pathological	pathological	p0304020204	JJ	B-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
signaling	signaling	s02504052	NN	B-NP	O
in	in	i500	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
poisoning	poisoning	p0205052	NN	I-NP	B-Disease
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
overload	overload	o106403	NN	B-NP	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
accelerated	accelerate	a204060303	VBN	B-NP	O
beating	beat	b03052	VBG	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
rat	rat	r030	NN	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
and	and	a530	CC	O	O
caused	cause	c0203	VBD	B-VP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-ADJP	O
freely	freely	f6040	RB	B-VP	O
moving	move	m01052	VBG	I-VP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
cytotoxicity	cytotoxicity	c03030202030	NN	B-NP	B-Disease
assay	assay	a200	NN	I-NP	O
in	in	i500	IN	B-PP	O
neonatal	neonatal	n050304	JJ	B-NP	O
rat	rat	r030	NN	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
(	(	(000	(	O	O
NRVMs	NRVM	n6152	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
measured	measure	m020603	VBN	B-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
culture	culture	c043060	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NRVMs	NRVM	n6152	NNS	B-NP	O
and	and	a530	CC	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
NRVMs	NRVM	n6152	NNS	I-NP	O
viability	viability	v0104030	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
confirm	confirm	c051065	VB	I-VP	O
the	the	t000	DT	B-NP	O
pro	pro	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
apoptotic	apoptotic	a10130302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
flow	flow	f400	NN	B-NP	O
cytometric	cytometric	c030503602	JJ	I-NP	O
detection	detection	d0302305	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
histology	histology	h02304020	NN	I-NP	O
,	,	,000	,	O	O
transmission	transmission	t605250205	NN	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
and	and	a530	CC	O	O
terminal	terminal	t0650504	JJ	B-NP	O
deoxynucleotidyl	deoxynucleotidyl	d0205024030304	NN	I-NP	O
transferase	transferase	t6052106020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
dUTP	dUTP	d031	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
biotin	biotin	b0305	NN	I-NP	B-Chemical
nick	nick	n020	NN	I-NP	O
end	end	e530	NN	I-NP	O
labeling	labeling	l0104052	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
stimulated	stimulate	s305040303	VBD	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
handling	handle	h0534052	VBG	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
promoted	promote	p6050303	VBD	B-VP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
overload	overload	o106403	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
handling	handle	h0534052	VBG	B-VP	O
proteins	protein	p603052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
pro	pro	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
apoptotic	apoptotic	a10130302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
upregulated	upregulate	u1602040303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
apoptotic	apoptotic	a10130302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
BCL	BCL	b240	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
downregulated	downregulate	d05602040303	VBN	I-VP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
phosphorylation	phosphorylation	p02106040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
MAPK	MAPK	m012	NN	B-NP	O
family	family	f05040	NN	I-NP	O
members	member	m051062	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P38	P38	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
P38	P38	0000	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
.	.	.000	.	O	O

Hence	Hence	h0520	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
aggravates	aggravate	a26010302	VBZ	B-VP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
overload	overload	o106403	NN	B-NP	O
and	and	a530	CC	O	O
causes	cause	c0202	VBZ	B-VP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
finally	finally	f05040	RB	B-VP	O
promotes	promote	p6050302	VBZ	I-VP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
via	via	v000	IN	B-PP	O
phosphorylation	phosphorylation	p02106040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
P38	P38	0000	NN	B-NP	O
mitogen	mitogen	m030205	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
activated	activate	a23010303	VBN	B-NP	O
protein	protein	p60305	NN	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
suppresses	suppress	s0160202	VBZ	B-VP	O
toll	toll	t040	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
4	4	4000	CD	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
and	and	a530	CC	O	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
left	left	l013	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
AMP	AMP	a510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
activated	activate	a23010303	VBN	I-NP	O
protein	protein	p60305	NN	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
(	(	(000	(	O	O
AMPK	AMPK	a512	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
toll	toll	t040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
TLR4	TLR4	0000	NN	B-NP	O
)	)	)000	)	O	O
activities	activity	a23010302	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
relation	relation	r040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
AMPK	AMPK	a512	NN	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
normal	normal	n06504	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
25	25	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
50	50	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
100mg	100mg	0000	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100mg	100mg	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
13th	13th	0000	JJ	I-NP	O
and	and	a530	CC	I-NP	O
14th	14th	0000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
indexed	index	i530203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
LVdp	LVdp	l131	NN	B-NP	O
/	/	/000	SYM	B-VP	O
dtmax	dtmax	d3502	NN	B-NP	O
and	and	a530	CC	I-NP	O
LVdp	LVdp	l131	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dtmin	dtmin	d3505	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
25	25	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
50mg	50mg	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Metfromin	Metfromin	m03160505	NN	B-NP	O
markedly	markedly	m0620340	RB	B-ADVP	O
lowered	lower	l0603	VBD	B-VP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TLR4	TLR4	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
,	,	,000	,	O	O
myeloid	myeloid	m0403	JJ	B-NP	O
differentiation	differentiation	d01060530305	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
88	88	0000	CD	I-NP	O
(	(	(000	(	O	O
MyD88	MyD88	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
tumor	tumor	t0506	NN	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
(	(	(000	(	O	O
TNF	TNF	t510	NN	B-NP	O
-	-	-000	HYPH	O	O
a	a	a000	DT	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
interleukin	interleukin	i530640205	NN	B-NP	O
6	6	6000	CD	I-NP	O
(	(	(000	(	O	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TNF	TNF	t510	NN	B-NP	O
-	-	-000	HYPH	O	O
a	a	a000	DT	B-NP	O
and	and	a530	CC	I-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
50mg	50mg	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
100mg	100mg	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Phosphorylated	Phosphorylate	p02106040303	VBN	B-NP	O
AMPKa	AMPKa	a5120	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
AMPK	AMPK	a512	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
25mg	25mg	0000	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
slightly	slightly	s4020340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
50mg	50mg	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	I-PP	O
by	by	b000	IN	B-PP	O
100mg	100mg	0000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	O	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
cardiac	cardiac	c06302	JJ	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
and	and	a530	CC	O	O
suppresses	suppress	s0160202	VBZ	B-VP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
TLR4	TLR4	0000	NN	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
to	to	t000	TO	B-VP	O
protect	protect	p603023	VB	I-VP	O
infarcted	infarcted	i51062303	JJ	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
.	.	.000	.	O	O

Unusual	Unusual	u50204	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
four	four	f060	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
literature	literature	l030603060	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
methimazole	methimazole	m030502040	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
lupus	lupus	l0102	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thyroidectomy	thyroidectomy	t0603023050	NN	B-NP	O
and	and	a530	CC	I-NP	O
radioiodine	radioiodine	r0303050	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
circumstances	circumstance	c062052305202	NNS	I-NP	O
131I	131I	0000	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
for	for	f060	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
tetrabenazine	tetrabenazine	t036010502050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
Huntington	Huntington	h053052305	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
herein	herein	h0605	RB	B-ADVP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
81	81	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
36	36	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
tiapride	tiapride	t016030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
tetrabenazine	tetrabenazine	t036010502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
Huntington	Huntington	h053052305	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
tiapride	tiapride	t016030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
tetrabenazine	tetrabenazine	t036010502050	NN	I-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
advanced	advance	a3105203	VBN	I-VP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
tetrabenazine	tetrabenazine	t036010502050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Tetrabenazine	Tetrabenazine	t036010502050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
very	very	v060	RB	B-ADVP	O
carefully	carefully	c0601040	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	B-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
worsening	worsen	w06205052	VBG	I-NP	O
general	general	g050604	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
terbinafine	terbinafine	t0610501050	NN	I-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
sinus	sinus	s0502	NN	I-NP	B-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
terbinafine	terbinafine	t0610501050	NN	I-NP	B-Chemical
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
63	63	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
man	man	m050	NN	I-NP	O
on	on	o500	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
90	90	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
terbinafine	terbinafine	t0610501050	NN	I-NP	B-Chemical
250	250	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
onychomycosis	onychomycosis	o50205020202	NN	B-NP	B-Disease
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
49th	49th	0000	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
terbinafine	terbinafine	t0610501050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
brought	bring	b60203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
room	room	r050	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
global	global	g40104	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
falls	fall	f042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
sinus	sinus	s0502	NN	I-NP	B-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
adverse	adverse	a310620	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
sinus	sinus	s0502	NN	I-NP	B-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
terbinafine	terbinafine	t0610501050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
ameliorated	ameliorate	a504060303	VBN	B-VP	O
first	first	f0623	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
subsequently	subsequently	s0120205340	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
bisoprolol	bisoprolol	b020160404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
inhibiting	inhibit	i50103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
P450	P450	0000	NN	I-NP	O
2D6	2D6	0000	NN	I-NP	O
,	,	,000	,	O	O
terbinafine	terbinafine	t0610501050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
resulted	result	r0204303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	B-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Optochiasmatic	Optochiasmatic	o13020250302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
overtreatment	overtreatment	o10636035053	NN	I-NP	O
.	.	.000	.	O	O

Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
,	,	,000	,	O	O
more	more	m060	RBR	B-ADVP	O
rarely	rarely	r06040	RB	I-ADVP	O
,	,	,000	,	O	O
axonal	axonal	a20504	JJ	B-NP	O
polyneuropathy	polyneuropathy	p04050601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
characterize	characterize	c0602306020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
,	,	,000	,	I-NP	O
neurophysiological	neurophysiological	n06010204020204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
neuroimaging	neuroimaging	n060502052	NN	B-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
72	72	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
visual	visual	v0204	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
paresthesias	paresthesia	p060230202	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
11	11	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
supratherapeutic	supratherapeutic	s0160306010302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
vulnerability	vulnerability	v045060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
and	and	a530	CC	O	O
peripheral	peripheral	p06010604	JJ	B-NP	O
nerves	nerve	n06102	NNS	I-NP	O
to	to	t000	TO	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Adult	Adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
intracerebroventricularly	intracerebroventricularly	i536020601601053602040640	RB	B-ADVP	O
(	(	(000	(	O	O
icv	icv	i210	NN	B-NP	O
)	)	)000	)	O	O
infused	infuse	i510203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
(	(	(000	(	O	O
750	750	0000	CD	B-NP	O
ug	ug	u200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
d	d	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
d	d	d000	NN	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Castration	Castration	c02360305	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
another	another	a50306	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
operation	operation	o1060305	NN	I-NP	O
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
sc	sc	s200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
androgen	androgen	a5360205	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
flutamide	flutamide	f40305030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ip	ip	i100	JJ	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
tamoxifen	tamoxifen	t05020105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ip	ip	i100	JJ	B-ADJP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
aromatase	aromatase	a60503020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
letrozole	letrozole	l03602040	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ip	ip	i100	JJ	B-ADJP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
d	d	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
castration	castration	c02360305	NN	B-NP	O
markedly	markedly	m0620340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
both	both	b030	CC	O	O
STL1	STL1	0000	NN	B-NP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
STL2	STL2	0000	NN	B-NP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
replacement	replacement	r0140205053	NN	I-NP	O
almost	almost	a45023	RB	B-ADVP	O
restored	restore	r0230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
STL1	STL1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
STL2	STL2	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
castrated	castrate	c02360303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
prolonged	prolong	p60405203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
STL1	STL1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
STL2	STL2	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
flutamide	flutamide	f40305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
letrozole	letrozole	l03602040	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
impaired	impair	i510603	VBD	B-VP	B-Disease
the	the	t000	DT	B-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
attenuated	attenuate	a3050303	VBD	I-VP	O
the	the	t000	DT	B-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
replacement	replacement	r0140205053	NN	I-NP	O
in	in	i500	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
castration	castration	c02360305	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
castration	castration	c02360305	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
neurochemical	neurochemical	n0602050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
garcinielliptone	garcinielliptone	g0620504013050	NN	B-NP	B-Chemical
FC	FC	f200	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Garcinielliptone	Garcinielliptone	g0620504013050	NN	B-NP	B-Chemical
FC	FC	f200	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GFC	GFC	g120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
hexanic	hexanic	h020502	JJ	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
seed	seed	s030	NN	I-NP	O
extract	extract	e236023	NN	I-NP	O
of	of	o100	IN	B-PP	O
species	specie	s10202	NNS	B-NP	O
Platonia	Platonia	p403050	NNP	B-NP	O
insignis	insigni	i5202502	VBZ	B-VP	O
Mart	Mart	m063	NNP	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
folk	folk	f042	NN	B-NP	O
medicine	medicine	m0302050	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
skin	skin	s205	NN	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
humans	human	h05052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
animals	animal	a505042	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
seed	seed	s030	NN	I-NP	O
decoction	decoction	d0202305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
treat	treat	t603	VB	I-VP	O
diarrheas	diarrhea	d0602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
research	research	r020620	NN	I-NP	O
on	on	o500	IN	B-PP	O
GFC	GFC	g120	NN	B-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
GFC	GFC	g120	NN	I-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
50	50	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
75	75	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
on	on	o500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
parameters	parameter	p060503062	NNS	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
amino	amino	a5050	NN	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
r	r	r000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
glutamine	glutamine	g40305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
on	on	o500	IN	B-PP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	B-NP	O
(	(	(000	(	O	O
AChE	AChE	a200	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
after	after	a1306	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

GFC	GFC	g120	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
25mg	25mg	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
12	12	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
50mg	50mg	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
95	95	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
21	21	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
23	23	0000	CD	B-NP	O
.	.	.000	.	O	O
43	43	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
seized	seize	s0203	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
GFC75	GFC75	0000	NN	B-NP	O
plus	plus	p402	CC	I-NP	O
P400	P400	0000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
46	46	0000	CD	B-NP	O
.	.	.000	.	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
seized	seize	s0203	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
glutamine	glutamine	g40305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
detected	detect	d0302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
.	.	.000	.	O	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
GFC75	GFC75	0000	NN	B-NP	O
plus	plus	p402	CC	I-NP	O
P400	P400	0000	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
seized	seize	s0203	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Hippocampus	Hippocampus	h010205102	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
GFC75	GFC75	0000	NN	B-NP	O
plus	plus	p402	CC	I-NP	O
P400	P400	0000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
AChE	AChE	a200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
63	63	0000	CD	B-NP	O
.	.	.000	.	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
seized	seize	s0203	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
GFC	GFC	g120	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
exert	exert	e2063	VB	I-VP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
reduce	reduce	r03020	VB	B-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
installation	installation	i523040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
demonstrated	demonstrate	d05052360303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
increase	increase	i526020	NN	B-NP	O
in	in	i500	IN	B-PP	O
latency	latency	l030520	NN	B-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
GFC	GFC	g120	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
influence	influence	i5140520	VB	I-VP	O
in	in	i500	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
and	and	a530	CC	O	O
promote	promote	p605030	VB	B-VP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
actions	action	a23052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
model	model	m0304	NN	I-NP	O
by	by	b000	IN	B-PP	O
modulating	modulate	m030403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
contents	content	c0530532	NNS	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
AChE	AChE	a200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
seized	seize	s0203	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
neuronal	neuronal	n060504	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Standard	Standard	s3053063	JJ	B-NP	O
operating	operating	o10603052	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
antibiotic	antibiotic	a53010302	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
,	,	,000	,	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
interventional	interventional	i530610530504	JJ	I-NP	O
,	,	,000	,	I-NP	O
observational	observational	o12061030504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Acute	Acute	a2030	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
AKI	AKI	a200	NN	B-NP	B-Disease
)	)	)000	)	O	O
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
hospitalized	hospitalize	h02103040203	VBN	B-NP	O
and	and	a530	CC	I-NP	O
66	66	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Intensive	Intensive	i53052010	JJ	B-NP	O
Care	Care	c060	NNP	I-NP	O
Unit	Unit	u503	NNP	I-NP	O
(	(	(000	(	O	O
ICU	ICU	i200	NN	B-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
,	,	,000	,	O	O
hospital	hospital	h0210304	NN	B-NP	O
length	length	l05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
stay	stay	s300	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
costs	cost	c0232	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
,	,	,000	,	O	O
whether	whether	w0306	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
adherence	adherence	a3060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
guidelines	guideline	g03040502	NNS	B-NP	O
(	(	(000	(	O	O
standard	standard	s3053063	JJ	B-NP	O
operating	operating	o10603052	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
(	(	(000	(	O	O
SOP	SOP	s010	NN	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
potentially	potentially	p03053040	RB	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
antibiotics	antibiotic	a53010302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
AKI	AKI	a200	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
,	,	,000	,	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
interventional	interventional	i530610530504	JJ	I-NP	O
,	,	,000	,	I-NP	O
observational	observational	o12061030504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Data	Data	d030	NN	B-NP	O
collection	collection	c0402305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
170	170	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
ICUs	ICU	i202	NNS	I-NP	O
at	at	a300	IN	B-PP	O
Charite	Charite	c06030	NNP	B-NP	O
-	-	-000	HYPH	O	O
Universitaetsmedizin	Universitaetsmedizin	u501062030325030205	NNP	B-NP	O
Berlin	Berlin	b06405	NNP	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
675	675	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
;	;	;000	:	O	O
163	163	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
had	have	h030	VBD	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
;	;	;000	:	O	O
were	be	w060	VBD	B-VP	O
>	>	>000	JJR	B-NP	O
18	18	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
treated	treat	t60303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ICU	ICU	i200	NN	I-NP	O
for	for	f060	IN	B-PP	O
>	>	>000	JJR	B-NP	O
24	24	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
adherence	adherence	a3060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
SOP	SOP	s010	NN	B-NP	O
>	>	>000	SYM	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
classified	classify	c4020103	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
adherence	adherence	a3060520	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
HAG	HAG	h020	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
adherence	adherence	a3060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
<	<	<000	SYM	B-NP	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
adherence	adherence	a3060520	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
LAG	LAG	l020	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

AKI	AKI	a200	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
RIFLE	RIFLE	r0140	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
.	.	.000	.	O	O

Adherence	Adherence	a3060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
SOPs	SOP	s012	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
retrospective	retrospective	r036021023010	JJ	B-NP	O
expert	expert	e21063	NN	I-NP	O
audit	audit	a0303	NN	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
AKI	AKI	a200	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
with	with	w030	IN	B-PP	O
exact	exact	e2023	JJ	B-NP	O
Chi2	Chi2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
(	(	(000	(	O	O
two	two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
sided	sided	s0303	JJ	I-NP	O
P	P	p000	NN	I-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
LAG	LAG	l020	NN	B-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
75	75	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
46	46	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
88	88	0000	CD	B-NP	O
HAG	HAG	h020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

AKI	AKI	a200	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
more	more	m060	RBR	I-ADVP	O
often	often	o1305	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
LAG	LAG	l020	NN	B-NP	O
with	with	w030	IN	B-PP	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
HAG	HAG	h020	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
035	035	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Basic	Basic	b0202	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
soft	soft	s013	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
LAG	LAG	l020	NN	B-NP	O
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
an	an	a500	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
LAG	LAG	l020	NN	B-NP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
AKI	AKI	a200	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
HAG	HAG	h020	NN	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
195	195	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
124	124	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
039	039	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Low	Low	l000	JJ	B-NP	O
adherence	adherence	a3060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
SOPs	SOP	s012	NNS	B-NP	O
for	for	f060	IN	B-PP	O
potentially	potentially	p03053040	RB	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
antibiotics	antibiotic	a53010302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
AKI	AKI	a200	NN	B-NP	B-Disease
.	.	.000	.	O	O

TRIAL	TRIAL	t604	NN	B-NP	O
REGISTRATION	REGISTRATION	r0202360305	NN	I-NP	O
:	:	:000	:	O	O
Current	Current	c06053	NNP	B-NP	O
Controlled	Controlled	c05360403	NNP	I-NP	O
Trials	Trial	t6042	NNPS	I-NP	O
ISRCTN54598675	ISRCTN54598675	0000	NNP	I-NP	O
.	.	.000	.	O	O

Registered	Register	r020230603	VBN	B-NP	O
17	17	0000	CD	I-NP	O
August	August	a02023	NNP	I-NP	O
2007	2007	0000	CD	I-NP	O
.	.	.000	.	O	O

Rhabdomyolysis	Rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
C	C	c000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
infected	infected	i5102303	JJ	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
telaprevir	telaprevir	t040160106	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
46	46	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
C	C	c000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
received	receive	r020103	VBD	B-VP	O
triple	triple	t60140	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
telaprevir	telaprevir	t040160106	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
because	because	b02020	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
because	because	b02020	IN	B-SBAR	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
peaked	peak	p0203	VBD	B-VP	O
at	at	a300	IN	B-PP	O
62	62	0000	CD	B-NP	O
,	,	,000	,	O	O
246	246	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
.	.	.000	.	O	O

Fourteen	Fourteen	f06305	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
,	,	,000	,	O	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
had	have	h030	VBD	B-VP	O
returned	return	r0306503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
230	230	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
.	.	.000	.	O	O

Telaprevir	Telaprevir	t040160106	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
the	the	t000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
causative	causative	c0203010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Drug	Drug	d602	NNP	I-NP	O
Interaction	Interaction	i530602305	NNP	I-NP	O
Probability	Probability	p6010104030	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
.	.	.000	.	O	O

Simvastatin	Simvastatin	s0510230305	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
30	30	0000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	I-NP	O
statin	statin	s30305	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
statin	statin	s30305	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
we	we	w000	PRP	B-NP	O
illustrate	illustrate	i40236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
telaprevir	telaprevir	t040160106	NN	B-NP	B-Chemical
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
statins	statin	s303052	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
susceptible	susceptible	s020130140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
.	.	.000	.	O	O

Combination	Combination	c051050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
,	,	,000	,	O	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VTD	VTD	v300	NN	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
after	after	a1306	IN	B-PP	O
autologous	autologous	a03040202	JJ	B-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Japanese	Japanese	j0105020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Consolidation	Consolidation	c05204030305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MM	MM	m500	NN	B-NP	B-Disease
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
widely	widely	w03040	RB	I-VP	O
adopted	adopt	a301303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
improve	improve	i516010	VB	I-VP	O
treatment	treatment	t6035053	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
autologous	autologous	a03040202	JJ	B-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
analyzed	analyze	a5040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
,	,	,000	,	O	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VTD	VTD	v300	NN	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
newly	newly	n040	RB	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
MM	MM	m500	NN	I-NP	B-Disease
.	.	.000	.	O	O

VTD	VTD	v300	NN	B-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	I-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
22	22	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
35	35	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
and	and	a530	CC	I-NP	O
three	three	t060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
13	13	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
drug	drug	d602	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
cytopenia	cytopenia	c0301050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
case	case	c020	NN	I-NP	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
(	(	(000	(	O	O
63	63	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
severe	severe	s01060	JJ	B-NP	O
grade	grade	g6030	NN	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Very	Very	v060	RB	B-NP	O
good	good	g030	JJ	I-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
or	or	o600	CC	O	O
better	good	b0306	JJR	B-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
VGPR	VGPR	v216	NN	I-NP	O
)	)	)000	)	O	O
rates	rate	r0302	NNS	B-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
54	54	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
79	79	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
probability	probability	p6010104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
<	<	<000	JJR	B-NP	O
VGPR	VGPR	v216	NN	I-NP	O
before	before	b01060	IN	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
to	to	t000	TO	B-PP	O
>	>	>000	JJR	B-NP	O
VGPR	VGPR	v216	NN	I-NP	O
after	after	a1306	IN	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
041	041	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
VTD	VTD	v300	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
safe	safe	s010	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
MM	MM	m500	NN	B-NP	O
in	in	i500	IN	B-PP	O
Japanese	Japanese	j0105020	JJ	B-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Conversion	Conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
:	:	:000	:	O	O
focus	focus	f0202	NN	B-NP	O
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
,	,	,000	,	O	O
gene	gene	g050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	O
expression	expression	e2160205	NN	I-NP	O
biomarkers	biomarker	b05062062	NNS	I-NP	O
.	.	.000	.	O	O

Protocols	Protocol	p60302042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
from	from	f605	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
immunotherapy	immunotherapy	i5050306010	NN	B-NP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
these	these	t020	DT	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
remain	remain	r0505	VBP	B-VP	O
nuclear	nuclear	n02406	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
and	and	a530	CC	O	O
putative	putative	p0303010	JJ	B-NP	O
biomarkers	biomarker	b05062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
SRL	SRL	s640	NN	I-NP	B-Chemical
conversion	conversion	c05106205	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
animal	animal	a50504	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
9	9	9000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
:	:	:000	:	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
conversion	conversion	c05106205	NN	B-NP	O
(	(	(000	(	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Classical	Classical	c4020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
emergent	emergent	e5062053	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
kidney	kidney	k0350	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
(	(	(000	(	O	O
gene	gene	g050	NN	B-NP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
)	)	)000	)	O	O
markers	marker	m062062	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hematoxylin	hematoxylin	h0503020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eosin	eosin	e0205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
periodic	periodic	p060302	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
-	-	-000	HYPH	O	O
Schiff	Schiff	s201	NNP	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Masson	Masson	m0205	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
trichrome	trichrome	t60206050	NN	I-NP	O
stains	stain	s3052	NNS	I-NP	O
.	.	.000	.	O	O

SRL	SRL	s640	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
presented	present	p60205303	VBD	B-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
NGAL	NGAL	n204	NN	I-NP	O
(	(	(000	(	O	O
serum	serum	s0605	NN	B-NP	O
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-ADJP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

Short	Short	s063	JJ	B-NP	O
CsA	CsA	c200	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
slight	slight	s40203	JJ	B-NP	O
or	or	o600	CC	I-NP	O
even	even	e105	RB	I-NP	O
absent	absent	a12053	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
b	b	b000	NN	B-NP	O
,	,	,000	,	O	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	O	O
kb	kb	k100	NN	B-NP	O
,	,	,000	,	O	O
mTOR	mTOR	m306	NN	B-NP	O
,	,	,000	,	O	O
PCNA	PCNA	p250	NN	B-NP	O
,	,	,000	,	O	O
TP53	TP53	0000	NN	B-NP	O
,	,	,000	,	O	O
KIM	KIM	k050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
CTGF	CTGF	c321	NN	B-NP	O
as	as	a200	IN	B-PP	O
relevant	relevant	r0401053	JJ	B-NP	O
gene	gene	g050	NN	I-NP	O
and	and	a530	CC	I-NP	O
protein	protein	p60305	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

Prolonged	Prolong	p60405203	VBN	B-NP	O
CsA	CsA	c200	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
aggravated	aggravate	a26010303	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
clear	clear	c406	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
traditional	traditional	t603030504	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
with	with	w030	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
serums	serum	s06052	NNS	B-NP	O
TGF	TGF	t210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
b	b	b000	NN	I-NP	O
and	and	a530	CC	I-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	O	O
TBARs	TBARs	t1062	NNP	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
kidney	kidney	k0350	NN	B-NP	O
TGF	TGF	t210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
b	b	b000	NN	I-NP	O
and	and	a530	CC	I-NP	O
mTOR	mTOR	m306	NN	I-NP	O
.	.	.000	.	O	O

Conversion	Conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
evolution	evolution	e1040305	NN	I-NP	O
(	(	(000	(	O	O
absent	absent	a12053	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
mild	mild	m043	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
NGAL	NGAL	n204	NN	B-NP	O
(	(	(000	(	O	O
serum	serum	s0605	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
)	)	)000	)	O	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
feasible	feasible	f020140	JJ	I-NP	O
biomarker	biomarker	b0506206	NN	I-NP	O
of	of	o100	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
replacement	replacement	r0140205053	NN	I-NP	O
to	to	t000	TO	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Kinin	Kinin	k0505	NN	B-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
deletion	deletion	d040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
blockage	blockage	b402020	NN	I-NP	O
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cisplatin	Cisplatin	c02140305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
adopted	adopt	a301303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
chemotherapies	chemotherapy	c0503060102	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	O	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
due	due	d000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
negatively	negatively	n020301040	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
augment	augment	a025053	NN	B-NP	O
serum	serum	s0605	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
,	,	,000	,	O	O
increase	increase	i526020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
score	score	s2060	NN	I-NP	O
and	and	a530	CC	O	O
up	up	u100	RB	B-VP	O
-	-	-000	HYPH	I-VP	O
regulate	regulate	r0204030	VB	I-VP	O
cytokines	cytokine	c03020502	NNS	B-NP	O
(	(	(000	(	O	O
e	e	e000	JJ	B-NP	O
.	.	.000	.	I-NP	O
g	g	g000	NN	I-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1b	1b	1000	NN	I-NP	O
and	and	a530	CC	I-NP	O
TNF	TNF	t510	NN	I-NP	O
-	-	-000	HYPH	O	O
a	a	a000	DT	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
process	process	p60202	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytokine	cytokine	c0302050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
deletion	deletion	d040305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
status	status	s30302	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
in	in	i500	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
kinin	kinin	k0505	NN	B-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
knockout	knockout	k50203	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
challenged	challenge	c0405203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
after	after	a1306	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

B2	B2	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
WT	WT	w300	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
shown	show	s050	VBN	B-VP	O
by	by	b000	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
better	good	b0306	JJR	B-NP	O
preservation	preservation	p6020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
down	down	d050	RB	B-ADVP	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
cytokines	cytokine	c03020502	NNS	I-NP	O
and	and	a530	CC	O	O
less	less	l020	RBR	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
effectively	effectively	e102301040	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
mediating	mediate	m0303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
necrotic	necrotic	n0260302	JJ	I-NP	B-Disease
process	process	p60202	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
cytokines	cytokine	c03020502	NNS	I-NP	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
declined	decline	d0240503	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
highlight	highlight	h02040203	VBP	B-VP	O
the	the	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B2	B2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
amelioration	amelioration	a504060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluocinolone	fluocinolone	f4020504050	NN	B-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
intravitreal	intravitreal	i5360103604	JJ	I-NP	O
implant	implant	i514053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
59	59	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
birdshot	birdshot	b063203	NN	B-NP	B-Disease
retinochoroidopathy	retinochoroidopathy	r030502060301030	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fluocinolone	fluocinolone	f4020504050	NN	I-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
intravitreal	intravitreal	i5360103604	JJ	I-NP	O
implant	implant	i514053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
59	59	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
birdshot	birdshot	b063203	NN	B-NP	B-Disease
retinochoroidopathy	retinochoroidopathy	r030502060301030	NN	I-NP	I-Disease
whose	whose	w020	WP$	B-NP	O
disease	disease	d02020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
refractory	refractory	r016023060	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
intolerant	intolerant	i530406053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
immunomodulatory	immunomodulatory	i50505030403060	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
case	case	c020	NN	I-NP	O
series	series	s0602	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
11	11	0000	CD	B-NP	O
birdshot	birdshot	b063203	NN	I-NP	B-Disease
retinochoroidopathy	retinochoroidopathy	r030502060301030	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
eyes	eye	e020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
eyes	eye	e020	NNS	I-NP	O
)	)	)000	)	O	O
underwent	undergo	u5306053	VBD	B-VP	O
surgery	surgery	s062060	NN	B-NP	O
for	for	f060	IN	B-PP	O
fluocinolone	fluocinolone	f4020504050	NN	B-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
implant	implant	i514053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
59	59	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
interest	interest	i5306023	NN	B-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
before	before	b01060	IN	B-PP	O
fluocinolone	fluocinolone	f4020504050	NN	B-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
implant	implant	i514053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
beyond	beyond	b053	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Disease	Disease	d02020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
markers	marker	m062062	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
,	,	,000	,	O	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
retinal	retinal	r030504	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
Swedish	Swedish	s03020	JJ	B-NP	O
interactive	interactive	i5306023010	JJ	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
algorithm	algorithm	a42060305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
short	short	s063	JJ	I-NP	O
wavelength	wavelength	w010405230	NN	I-NP	O
automated	automate	a03050303	VBD	B-VP	O
perimetry	perimetry	p06050360	NN	B-NP	O
Humphrey	Humphrey	h051060	NNP	I-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
electroretinographic	electroretinographic	e402360603050260102	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
optical	optical	o130204	JJ	B-NP	O
coherence	coherence	c060520	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
occurrence	occurrence	o2060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
cataract	cataract	c0306023	NN	B-NP	B-Disease
and	and	a530	CC	O	O
raised	raise	r0203	VBD	B-VP	B-Disease
intraocular	intraocular	i536020406	JJ	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Intraocular	Intraocular	i536020406	JJ	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	I-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
beyond	beyond	b053	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
implant	implant	i514053	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Active	Active	a23010	JJ	B-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
36	36	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

More	More	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
20	20	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
47	47	0000	CD	B-NP	O
.	.	.000	.	O	O
61	61	0000	CD	B-NP	O
-	-	-000	:	O	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cystoid	cystoid	c02303	JJ	B-NP	B-Disease
macular	macular	m020406	JJ	I-NP	I-Disease
edema	edema	e3050	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
postimplant	postimplant	p0230514053	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
on	on	o500	IN	B-PP	O
immunomodulatory	immunomodulatory	i50505030403060	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
45	45	0000	CD	B-NP	O
.	.	.000	.	O	O
45	45	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
44	44	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
postimplant	postimplant	p0230514053	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	B-Disease
intraocular	intraocular	i536020406	JJ	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
cataract	cataract	c0306023	NN	B-NP	B-Disease
formation	formation	f0650305	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
fluocinolone	fluocinolone	f4020504050	NN	B-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
implant	implant	i514053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
59	59	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
helps	help	h0412	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
control	control	c053604	VB	I-VP	O
inflammation	inflammation	i514050305	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
otherwise	otherwise	o306020	RB	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
birdshot	birdshot	b063203	NN	B-NP	B-Disease
retinochoroidopathy	retinochoroidopathy	r030502060301030	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cataract	cataract	c0306023	NN	B-NP	B-Disease
and	and	a530	CC	O	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
requiring	require	r0206052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Optimal	Optimal	o130504	JJ	B-NP	O
precurarizing	precurarize	p602060602052	VBG	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
fasciculation	fasciculation	f0202040305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Succinylcholine	Succinylcholine	s020504204050	NN	B-NP	B-Chemical
commonly	commonly	c050540	RB	B-ADVP	O
produces	produce	p6030202	VBZ	B-VP	O
frequent	frequent	f602053	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculation	fasciculation	f0202040305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
fasciculation	fasciculation	f0202040305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
and	and	a530	CC	O	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
speed	speed	s103	NN	I-NP	O
of	of	o100	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blinded	blind	b405303	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
100	100	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
randomly	randomly	r0530540	RB	B-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
five	five	f010	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
each	each	e020	DT	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
06	06	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
rocuronium	rocuronium	r02060505	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
precurarizing	precurarize	p602060602052	VBG	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Neuromuscular	Neuromuscular	n0605020406	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
each	each	e020	DT	B-NP	O
precurarizing	precurarize	p602060602052	VBG	I-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
adductor	adductor	a302306	NN	I-NP	O
pollicis	pollicis	p040202	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
acceleromyography	acceleromyography	a2040605026010	NN	B-NP	O
with	with	w030	IN	B-PP	O
train	train	t605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	SYM	B-NP	O
four	four	f060	CD	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ulnar	ulnar	u4506	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
precurarization	precurarization	p6020606020305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fasciculations	fasciculation	f02020403052	NNS	B-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
visible	visible	v020140	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
fasciculation	fasciculation	f0202040305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
precurarizing	precurarize	p602060602052	VBG	B-VP	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Those	Those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
tend	tend	t053	VBP	B-VP	O
to	to	t000	TO	I-VP	O
decrease	decrease	d026020	VB	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
precurarizing	precurarize	p602060602052	VBG	B-VP	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
072	072	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
longer	longer	l05206	RBR	I-ADJP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
precurarizing	precurarize	p602060602052	VBG	B-VP	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Precurarization	Precurarization	p6020606020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
04	04	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
rocuronium	rocuronium	r02060505	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
considering	consider	c0520306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fasciculation	fasciculation	f0202040305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
acceptable	acceptable	a20130140	JJ	B-NP	O
onset	onset	o5203	NN	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
precurarization	precurarization	p6020606020305	NN	I-NP	O
.	.	.000	.	O	O

Absence	Absence	a120520	NN	B-NP	O
of	of	o100	IN	B-PP	O
PKC	PKC	p200	NN	B-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
,	,	,000	,	O	O
induces	induce	i530202	VBZ	B-VP	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
(	(	(000	(	O	O
NDI	NDI	n300	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
to	to	t000	TO	B-VP	O
concentrate	concentrate	c0520536030	VB	I-VP	O
urine	urine	u6050	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
acutely	acutely	a203040	RB	B-VP	O
disrupting	disrupt	d026013052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
cAMP	cAMP	c051	NN	I-NP	B-Chemical
pathway	pathway	p030	NN	I-NP	O
and	and	a530	CC	O	O
chronically	chronically	c060502040	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
urea	urea	u600	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
(	(	(000	(	O	O
UT	UT	u300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
A1	A1	0000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
water	water	w0306	NN	B-NP	O
channel	channel	c0504	NN	I-NP	O
(	(	(000	(	O	O
AQP2	AQP2	0000	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
.	.	.000	.	O	O

Targeting	Target	t06203052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
PKC	PKC	p200	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
.	.	.000	.	O	O

PKC	PKC	p200	NN	B-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
null	null	n040	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
PKCa	PKCa	p200	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
strain	strain	s3605	NN	B-NP	O
-	-	-000	HYPH	O	O
matched	match	m03203	VBN	B-VP	O
wild	wild	w043	JJ	B-NP	O
type	type	t010	NN	I-NP	O
(	(	(000	(	O	O
WT	WT	w300	NN	B-NP	O
)	)	)000	)	O	O
controls	control	c0536042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
or	or	o600	CC	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
urine	urine	u6050	NN	B-NP	O
output	output	o03103	NN	I-NP	O
and	and	a530	CC	O	O
lowered	lower	l0603	VBD	B-VP	O
urine	urine	u6050	NN	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
whereas	whereas	w0602	IN	B-PP	O
PKCa	PKCa	p200	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
output	output	o03103	NN	I-NP	O
or	or	o600	CC	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

Western	Western	w023065	NN	B-NP	O
blot	blot	b403	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
AQP2	AQP2	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
medullary	medullary	m0304060	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
lowered	lower	l0603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
AQP2	AQP2	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
PKCa	PKCa	p200	NN	B-NP	O
KO	KO	k000	NN	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
UT	UT	u300	NN	B-NP	O
-	-	-000	HYPH	O	O
A1	A1	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
WT	WT	w300	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
19	19	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
fold	fold	f043	RB	I-NP	O
increased	increase	i5260203	VBN	I-NP	O
urine	urine	u6050	NN	I-NP	O
output	output	o03103	NN	I-NP	O
whereas	whereas	w0602	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
PKCa	PKCa	p200	NN	I-NP	O
KO	KO	k000	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
output	output	o03103	NN	B-NP	O
.	.	.000	.	O	O

AQP2	AQP2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
UT	UT	u300	NN	I-NP	O
-	-	-000	HYPH	O	O
A1	A1	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lowered	lower	l0603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
week	week	w020	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
WT	WT	w300	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
whereas	whereas	w0602	IN	B-ADVP	O
in	in	i500	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
PKCa	PKCa	p200	NN	I-NP	O
KO	KO	k000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
AQP2	AQP2	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
and	and	a530	CC	O	O
UT	UT	u300	NN	B-NP	O
-	-	-000	HYPH	O	O
A1	A1	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
fed	feed	f030	VBN	B-NP	O
WT	WT	w300	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
fed	feed	f030	VBN	I-NP	O
PKCa	PKCa	p200	NN	I-NP	O
KO	KO	k000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ablation	ablation	a140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
PKCa	PKCa	p200	NN	B-NP	O
preserves	preserve	p60206102	VBZ	B-VP	O
AQP2	AQP2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
UT	UT	u300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
A1	A1	0000	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
localization	localization	l0204020305	NN	B-NP	O
in	in	i500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
NDI	NDI	n300	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
prevents	prevent	p6010532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Is	Be	i200	VBZ	O	O
Dysguesia	Dysguesia	d02020	NNP	B-NP	B-Disease
Going	Going	g052	NNP	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
Rare	Rare	r060	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
Common	Common	c0505	JJ	I-NP	O
Side	Side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
Amlodipine	Amlodipine	a540301050	NN	B-NP	B-Chemical
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
rare	rare	r060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	O	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
dysguesia	dysguesia	d02020	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
case	case	c020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
about	about	a103	IN	B-PP	O
a	a	a000	DT	B-NP	O
female	female	f05040	NN	I-NP	O
with	with	w030	IN	B-PP	O
essential	essential	e205304	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
taste	taste	t0230	NN	B-NP	I-Disease
sensation	sensation	s0520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Condition	Condition	c0530305	NN	B-NP	O
moderately	moderately	m030603040	RB	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
on	on	o500	IN	B-PP	O
stoppage	stoppage	s301020	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
25	25	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
dysguesia	dysguesia	d02020	NN	B-NP	B-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
and	and	a530	CC	O	O
review	review	r010	VB	B-VP	O
the	the	t000	DT	B-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dysguesia	dysguesia	d02020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Rhabdomyolysis	Rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
increment	increment	i52605053	NN	I-NP	O
in	in	i500	IN	B-PP	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Clarithromycin	Clarithromycin	c4060306050205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
documented	document	d020505303	VBN	I-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
P450	P450	0000	NN	I-NP	O
3A4	3A4	0000	NN	I-NP	O
(	(	(000	(	O	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
)	)	)000	)	O	O
inhibitor	inhibitor	i5010306	NN	B-NP	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
particular	particular	p063020406	JJ	I-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
interest	interest	i5306023	NN	B-NP	O
as	as	a200	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
only	only	o540	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
raised	raise	r0203	VBN	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
biomarkers	biomarker	b05062062	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
obvious	obvious	o102	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
issues	issue	i202	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
linked	link	l05203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
no	no	n000	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
structure	structure	s36023060	NN	I-NP	O
and	and	a530	CC	I-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
increase	increase	i526020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myopathy	myopathy	m01030	NN	B-NP	B-Disease
or	or	o600	CC	O	O
inhibit	inhibit	i50103	VB	B-VP	O
the	the	t000	DT	B-NP	O
CYP3A4	CYP3A4	0000	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
troponin	troponin	t6010505	NN	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
statin	statin	s30305	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
warrant	warrant	w06053	VB	I-VP	O
further	further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Characterization	Characterization	c0602306020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
BCHE	BCHE	b200	NN	I-NP	O
"	"	"000	``	B-NP	O
silent	silent	s04053	JJ	I-NP	O
"	"	"000	''	I-NP	O
allele	allele	a4040	NN	I-NP	O
:	:	:000	:	O	O
point	point	p053	NN	B-NP	O
mutation	mutation	m030305	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
Val204Asp	Val204Asp	0000	NN	I-NP	O
)	)	)000	)	O	O
causes	cause	c0202	VBZ	B-VP	O
loss	loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
and	and	a530	CC	O	O
prolonged	prolonged	p60405203	JJ	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Butyrylcholinesterase	Butyrylcholinesterase	b0306042040502306020	NN	B-NP	B-Disease
deficiency	deficiency	d01020520	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
relaxants	relaxant	r04020532	NNS	I-NP	O
(	(	(000	(	O	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
mivacurium	mivacurium	m01020605	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
mutations	mutation	m0303052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BCHE	BCHE	b200	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	O
block	block	b402	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
discovery	discovery	d0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
BCHE	BCHE	b200	NN	I-NP	O
variant	variant	v06053	NN	I-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
695T	695T	0000	NN	B-NP	O
>	>	>000	SYM	I-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
Val204Asp	Val204Asp	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
kinetic	kinetic	k050302	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
and	and	a530	CC	O	O
molecular	molecular	m04020406	JJ	B-NP	O
dynamics	dynamic	d050502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
understand	understand	u530623053	VB	I-VP	O
how	how	h000	WRB	B-ADVP	O
this	this	t020	DT	B-NP	O
mutation	mutation	m030305	NN	I-NP	O
disrupts	disrupt	d0260132	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
catalytic	catalytic	c03040302	JJ	I-NP	O
triad	triad	t603	NN	I-NP	O
and	and	a530	CC	O	O
determines	determine	d030650502	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
"	"	"000	``	I-NP	O
silent	silent	s04053	JJ	I-NP	O
"	"	"000	''	I-NP	O
phenotype	phenotype	p0503010	NN	I-NP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
butyrylcholinesterase	butyrylcholinesterase	b0306042040502306020	NN	I-NP	O
with	with	w030	IN	B-PP	O
butyrylthiocholine	butyrylthiocholine	b03060430204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
BTC	BTC	b320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
benzoylcholine	benzoylcholine	b05204204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
values	value	v0402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
dibucaine	dibucaine	d0102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
fluoride	fluoride	f406030	NN	I-NP	B-Chemical
numbers	number	n051062	NNS	I-NP	O
fit	fit	f030	VBP	B-VP	O
with	with	w030	IN	B-PP	O
heterozygous	heterozygous	h0306020202	JJ	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
silent	silent	s04053	JJ	I-NP	O
genotype	genotype	g0503010	NN	I-NP	O
.	.	.000	.	O	O

Electrophoretic	Electrophoretic	e4023601060302	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
BChE	BChE	b200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
proband	proband	p601053	NN	I-NP	O
and	and	a530	CC	O	O
his	his	h020	PRP$	B-NP	O
mother	mother	m0306	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
patient	patient	p03053	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tetrameric	tetrameric	t036050602	JJ	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
minor	minor	m0506	JJ	B-NP	O
fast	fast	f023	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
moving	move	m01052	VBG	I-NP	O
BChE	BChE	b200	NN	I-NP	O
components	component	c051050532	NNS	I-NP	O
:	:	:000	:	O	O
monomer	monomer	m050506	NN	B-NP	O
,	,	,000	,	O	O
dimer	dimer	d0506	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
monomer	monomer	m050506	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
conjugate	conjugate	c05202030	NN	I-NP	O
are	be	a600	VBP	B-VP	O
missing	miss	m02052	VBG	I-VP	O
.	.	.000	.	O	O

Kinetic	Kinetic	k050302	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
Val204Asp	Val204Asp	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
Asp70Gly	Asp70Gly	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
Ala539Thr	Ala539Thr	0000	NN	I-NP	O
BChE	BChE	b200	NN	I-NP	O
displays	display	d021402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
pure	pure	p060	JJ	I-NP	O
Michaelian	Michaelian	m020405	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
with	with	w030	IN	B-PP	O
BTC	BTC	b320	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
substrate	substrate	s01236030	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
catalytic	catalytic	c03040302	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
Km	Km	k500	NN	I-NP	O
=	=	=000	SYM	B-VP	O
265	265	0000	CD	B-NP	O
uM	uM	u500	NN	I-NP	O
for	for	f060	IN	B-PP	O
BTC	BTC	b320	NN	B-NP	B-Chemical
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
higher	high	h0206	JJR	B-ADVP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
Vmax	Vmax	v502	NN	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
against	against	a20523	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Molecular	Molecular	m04020406	JJ	B-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
(	(	(000	(	O	O
MD	MD	m300	NN	B-NP	O
)	)	)000	)	O	O
simulations	simulation	s050403052	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mutation	mutation	m030305	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
Val204Asp	Val204Asp	0000	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hydrogen	hydrogen	h0360205	NN	B-NP	B-Chemical
bonding	bonding	b053052	NN	I-NP	O
between	between	b0305	IN	B-PP	O
Gln223	Gln223	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
Glu441	Glu441	0000	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-NP	O
Ser198	Ser198	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
His438	His438	0000	NN	I-NP	O
to	to	t000	TO	B-VP	O
move	move	m010	VB	I-VP	O
away	away	a000	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
each	each	e020	DT	B-NP	O
other	other	o306	JJ	I-NP	O
with	with	w030	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
catalytic	catalytic	c03040302	JJ	I-NP	O
triad	triad	t603	NN	I-NP	O
functionality	functionality	f05230504030	NN	I-NP	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
substrate	substrate	s01236030	NN	B-NP	O
.	.	.000	.	O	O

MD	MD	m300	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
denaturation	denaturation	d0503060305	NN	I-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
fits	fit	f032	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
Ala204Asp	Ala204Asp	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
Asp70Gly	Asp70Gly	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
Ala539Thr	Ala539Thr	0000	NN	I-NP	O
tetrameric	tetrameric	t036050602	JJ	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
detectable	detectable	d030230140	JJ	B-ADJP	O
fast	fast	f023	RB	B-VP	O
moving	move	m01052	VBG	I-VP	O
-	-	-000	HYPH	B-NP	O
bands	band	b0532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
electrophoresis	electrophoresis	e4023601060202	NN	B-NP	O
gels	gel	g042	NNS	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
injectable	injectable	i520230140	JJ	B-NP	O
artesunate	artesunate	a630205030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Democratic	Democratic	d050260302	JJ	I-NP	O
Republic	Republic	r0101402	NNP	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Congo	Congo	c0520	NNP	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
manageable	manageable	m05020140	JJ	I-NP	O
issue	issue	i200	NN	I-NP	O
.	.	.000	.	O	O

Cases	Case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
injectable	injectable	i520230140	JJ	B-NP	O
artesunate	artesunate	a630205030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
World	World	w0643	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
(	(	(000	(	O	O
WHO	WHO	w000	WP	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
recommended	recommend	r020505303	VBN	B-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
malaria	malaria	m04060	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
350	350	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
215	215	0000	CD	B-NP	O
[	[	[000	(	O	O
61	61	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
<	<	<000	SYM	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	O	O
135	135	0000	CD	B-NP	O
[	[	[000	(	O	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
>	>	>000	SYM	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
injectable	injectable	i520230140	JJ	B-NP	O
artesunate	artesunate	a630205030	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
malaria	malaria	m04060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
hospitals	hospital	h02103042	NNS	B-NP	O
and	and	a530	CC	I-NP	O
health	health	h0430	NN	I-NP	O
centers	center	c053062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Democratic	Democratic	d050260302	JJ	I-NP	O
Republic	Republic	r0101402	NNP	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Congo	Congo	c0520	NNP	I-NP	O
.	.	.000	.	O	O

Complete	Complete	c0514030	JJ	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
(	(	(000	(	O	O
Hb	Hb	h100	NN	B-NP	O
)	)	)000	)	O	O
measurements	measurement	m0206050532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
201	201	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
Hb	Hb	h100	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
Hb	Hb	h100	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
below	below	b040	IN	B-PP	O
5	5	5000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
during	during	d06052	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
visit	visit	v0203	NN	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-ADJP	O
manageable	manageable	m05020140	JJ	I-ADJP	O
and	and	a530	CC	O	O
resolved	resolve	r0204103	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
.	.	.000	.	O	O

Regulation	Regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
signal	signal	s02504	NN	B-NP	O
transducer	transducer	t605230206	NN	I-NP	O
and	and	a530	CC	I-NP	O
activator	activator	a23010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
transcription	transcription	t6052601305	NN	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
by	by	b000	IN	B-PP	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
attenuates	attenuate	a3050302	VBZ	B-VP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
experimentally	experimentally	e210605053040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
focusing	focus	f0202052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
signal	signal	s02504	NN	B-NP	O
transducer	transducer	t605230206	NN	I-NP	O
and	and	a530	CC	I-NP	O
activator	activator	a23010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
transcription	transcription	t6052601305	NN	B-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
STAT3	STAT3	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	NNP	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
200	200	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
orally	orally	o6040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
40	40	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemic	ischemic	i20502	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
85	85	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
,	,	,000	,	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
and	and	a530	CC	O	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
protein	protein	p60305	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
400	400	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
marker	marker	m06206	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
and	and	a530	CC	O	O
prevented	prevent	p60105303	VBD	B-VP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
remodeling	remodeling	r050304052	NN	I-NP	I-Disease
.	.	.000	.	O	O

Western	Western	w023065	NN	B-NP	O
blot	blot	b403	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
phosphorylation	phosphorylation	p02106040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
STAT3	STAT3	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
or	or	o600	CC	O	O
further	further	f06306	RBR	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
myocardium	myocardium	m0206305	NN	B-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
400	400	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Bcl	Bcl	b240	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
Bax	Bax	b020	NN	B-NP	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
causing	cause	c02052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
Bcl	Bcl	b240	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
Bax	Bax	b020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
further	further	f06306	RBR	I-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
summary	summary	s05060	NN	B-NP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
betaine	betaine	b03050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
STAT3	STAT3	0000	NN	B-NP	O
and	and	a530	CC	O	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
.	.	.000	.	O	O

Quetiapine	Quetiapine	q0301050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Quetiapine	Quetiapine	q0301050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
dibenzothiazepine	dibenzothiazepine	d01052030201050	NN	I-NP	O
derivative	derivative	d060103010	NN	I-NP	O
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
causing	cause	c02052	VBG	B-VP	O
blood	blood	b403	NN	B-NP	B-Disease
dyscrasias	dyscrasia	d0260202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
some	some	s050	DT	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	VBZ	B-VP	O
about	about	a103	IN	B-PP	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
possible	possible	p020140	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
seldom	seldom	s04305	RB	I-VP	O
discussed	discuss	d020203	VBN	I-VP	O
and	and	a530	CC	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
here	here	h060	RB	B-ADVP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
REPORT	REPORT	r01063	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
62	62	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Taiwanese	Taiwanese	t05020	JJ	I-NP	O
widow	widow	w030	NN	I-NP	O
with	with	w030	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
age	age	a200	NN	B-NP	O
60	60	0000	CD	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
leucopenia	leucopenia	l0201050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
her	her	h060	PRP$	B-NP	O
white	white	w030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
count	count	c053	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
physicians	physician	p0202052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
cautious	cautious	c0302	JJ	B-ADJP	O
about	about	a103	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
and	and	a530	CC	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
for	for	f060	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Lateral	Lateral	l030604	JJ	B-NP	O
antebrachial	antebrachial	a530160204	JJ	I-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
at	at	a300	IN	B-PP	O
lateral	lateral	l030604	JJ	B-NP	O
epicondyle	epicondyle	e102053040	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
OBJECTIVES	OBJECTIVES	o120230102	NNS	I-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
aimed	aim	a0503	VBN	B-VP	O
to	to	t000	TO	B-VP	O
present	present	p602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lateral	lateral	l030604	JJ	B-NP	O
antebrachial	antebrachial	a530160204	JJ	I-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
LACNP	LACNP	l0251	NN	B-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
epicondyle	epicondyle	e102053040	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
lateral	lateral	l030604	JJ	B-NP	B-Disease
epicondylitis	epicondylitis	e102053040302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

MATERIAL	MATERIAL	m030604	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
METHOD	METHOD	m0303	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
sensation	sensation	s0520305	NN	I-NP	O
and	and	a530	CC	I-NP	O
paresthesia	paresthesia	p06023020	NN	I-NP	B-Disease
over	over	o106	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
right	right	r0203	JJ	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
forearm	forearm	f06065	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
paresthesia	paresthesia	p06023020	NN	I-NP	B-Disease
had	have	h030	VBD	B-VP	O
occurred	occur	o20603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
epicondyle	epicondyle	e102053040	NN	I-NP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
before	before	b01060	RB	B-ADVP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
sensation	sensation	s0520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
light	light	l0203	JJ	B-NP	O
touch	touch	t020	NN	I-NP	O
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
diminished	diminish	d05050203	VBN	I-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
side	side	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
forearm	forearm	f06065	NN	I-NP	O
and	and	a530	CC	I-NP	O
wrist	wrist	w6023	NN	I-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
antebrachial	antebrachial	a530160204	JJ	I-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
(	(	(000	(	O	O
LACN	LACN	l025	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
uV	uV	u100	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
uV	uV	u100	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
amplitude	amplitude	a51403030	NN	B-NP	O
between	between	b0305	IN	B-PP	O
both	both	b030	DT	B-NP	O
sides	side	s0302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
because	because	b02020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	B-PP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
LACNP	LACNP	l0251	NN	I-NP	O
(	(	(000	(	O	O
mainly	mainly	m0540	RB	B-NP	O
axonal	axonal	a20504	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
electrodiagnostic	electrodiagnostic	e402360302502302	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
improved	improve	i5160103	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
physical	physical	p020204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
but	but	b030	CC	O	O
persisted	persist	p06202303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
some	some	s050	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
LACNP	LACNP	l0251	NN	B-NP	O
that	that	t030	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
lateral	lateral	l030604	JJ	B-NP	B-Disease
epicondylitis	epicondylitis	e102053040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
electrodiagnostic	electrodiagnostic	e402360302502302	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LACN	LACN	l025	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
helpful	helpful	h04104	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
diagnose	diagnose	d025020	VB	I-VP	O
right	right	r0203	JJ	B-NP	O
LACNP	LACNP	l0251	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
find	find	f053	VB	I-VP	O
the	the	t000	DT	B-NP	O
passage	passage	p02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LACN	LACN	l025	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
epicondyle	epicondyle	e102053040	NN	I-NP	O
.	.	.000	.	O	O

Curcumin	Curcumin	c0620505	NN	B-NP	B-Chemical
prevents	prevent	p6010532	VBZ	B-VP	O
maleate	maleate	m04030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
hemodynamic	hemodynamic	h0503050502	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
,	,	,000	,	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
and	and	a530	CC	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
complex	complex	c051402	NN	I-NP	O
I	I	i000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dietary	dietary	d03060	JJ	I-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
curcumin	curcumin	c0620505	NN	I-NP	B-Chemical
(	(	(000	(	O	O
120	120	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
Kg	Kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
maleate	maleate	m04030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Tubular	Tubular	t010406	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
maleate	maleate	m04030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Maleate	Maleate	m04030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
included	include	i5240303	VBD	B-VP	O
increase	increase	i526020	NN	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
neutrophil	neutrophil	n0360104	NN	B-NP	O
gelatinase	gelatinase	g040305020	NN	I-NP	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
lipocalin	lipocalin	l01020405	NN	B-NP	O
(	(	(000	(	O	O
NGAL	NGAL	n204	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	O	O
acetyl	acetyl	a20304	NN	B-NP	O
b	b	b000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
(	(	(000	(	O	O
NAG	NAG	n020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
upregulation	upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
molecule	molecule	m0402040	NN	I-NP	O
(	(	(000	(	O	O
KIM	KIM	k050	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
and	and	a530	CC	I-NP	O
claudin	claudin	c40305	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
expression	expression	e2160205	NN	I-NP	O
besides	besides	b020302	IN	B-PP	O
of	of	o100	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
on	on	o500	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
oxidation	oxidation	o2030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipids	lipid	l01032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
and	and	a530	CC	O	O
diminution	diminution	d05050305	NN	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
Nrf2	Nrf2	0000	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
LLC	LLC	l420	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
PK1	PK1	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
kidneys	kidney	k03502	NNS	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Maleate	Maleate	m04030	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
cell	cell	c040	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
and	and	a530	CC	O	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
(	(	(000	(	O	O
ROS	ROS	r020	NN	B-NP	O
)	)	)000	)	O	O
production	production	p60302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
LLC	LLC	l420	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
PK1	PK1	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
culture	culture	c043060	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
maleate	maleate	m04030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
in	in	i500	IN	B-PP	O
ADP	ADP	a310	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
stimulated	stimulate	s305040303	VBN	I-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
and	and	a530	CC	O	O
diminished	diminish	d05050203	VBN	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
index	index	i5302	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
using	use	u2052	VBG	B-VP	O
malate	malate	m04030	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
substrate	substrate	s01236030	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
complex	complex	c051402	NN	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	O	O
aconitase	aconitase	a20503020	NN	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
diminished	diminish	d05050203	VBN	I-VP	O
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
above	above	a1010	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
described	describe	d0260103	VBN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
curcumin	curcumin	c0620505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
curcumin	curcumin	c0620505	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
maleate	maleate	m04030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
cell	cell	c040	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
protection	protection	p60302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	I-NP	O
preservation	preservation	p6020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
and	and	a530	CC	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
complex	complex	c051402	NN	I-NP	O
I	I	i000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
protection	protection	p60302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ROS	ROS	r020	NN	B-NP	O
production	production	p60302305	NN	I-NP	O
.	.	.000	.	O	O

Anticonvulsant	Anticonvulsant	a5302051042053	JJ	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
noncompetitive	noncompetitive	n0520510303010	JJ	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
two	two	t000	CD	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
,	,	,000	,	O	O
coadministration	coadministration	c0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
major	major	m0206	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

First	First	f0623	RB	B-ADVP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
produced	produce	p6030203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
with	with	w030	IN	I-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
different	different	d0106053	JJ	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
control	control	c053604	VBP	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Second	Second	s02053	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
periods	period	p06032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
demonstration	demonstration	d05052360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
conclusion	conclusion	c05240205	NN	I-NP	O
derived	derive	d060103	VBN	B-VP	O
from	from	f605	IN	B-PP	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
that	that	t030	IN	B-SBAR	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
requires	require	r020602	VBZ	B-VP	O
agonist	agonist	a205023	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
opening	opening	o105052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
channel	channel	c0504	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Third	Third	t063	RB	B-ADVP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
easy	easy	e020	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
block	block	b402	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anticonvulsants	anticonvulsant	a53020510420532	NNS	B-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
difficult	difficult	d0102043	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
terminate	terminate	t06505030	VB	I-VP	O
ongoing	ongoing	o52052	JJ	B-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
block	block	b402	VB	B-VP	O
the	the	t000	DT	B-NP	O
lethality	lethality	l0304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
30	30	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
,	,	,000	,	O	O
gradually	gradually	g603040	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
electrical	electrical	e402360204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
greatly	greatly	g60340	RB	B-VP	O
enhanced	enhance	e505203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
survival	survival	s0610104	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
further	further	f06306	RB	I-VP	O
supported	support	s0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
results	result	r020432	NNS	B-NP	O
showing	show	s052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
nonconvulsive	nonconvulsive	n052051042010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
synergistic	synergistic	s0506202302	JJ	B-ADJP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

Continuous	Continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carbenicillin	carbenicillin	c06105020405	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
infections	infection	i51023052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cure	cure	c060	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
infections	infection	i51023052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
adversely	adversely	a31062040	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
(	(	(000	(	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
mm3	mm3	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
(	(	(000	(	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
100	100	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
mm3	mm3	0000	NN	I-NP	O
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
antibiotics	antibiotic	a53010302	NNS	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
overcome	overcome	o1062050	VB	I-VP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
,	,	,000	,	O	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
by	by	b000	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
carbenicillin	carbenicillin	c06105020405	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Tobramycin	Tobramycin	t016050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
carbenicillin	carbenicillin	c06105020405	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
gm	gm	g500	NN	I-NP	O
every	every	e1060	DT	B-NP	O
four	four	f060	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
125	125	0000	CD	B-NP	O
infectious	infectious	i5102302	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
116	116	0000	CD	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
myelosuppressive	myelosuppressive	m040201602010	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
cure	cure	c060	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Pneumonia	Pneumonia	p505050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
and	and	a530	CC	O	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
59	59	0000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
cured	cure	c0603	VBN	I-VP	O
.	.	.000	.	O	O

Gram	Gram	g605	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
bacilli	bacilli	b02040	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
causative	causative	c0203010	JJ	I-NP	O
organisms	organism	o62050252	NNS	I-NP	O
and	and	a530	CC	O	O
69	69	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
cured	cure	c0603	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
pathogen	pathogen	p030205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
Klebsiella	Klebsiella	k4012040	NNP	B-NP	O
pneumoniae	pneumoniae	p505050	NNP	I-NP	B-Disease
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
Escherichia	Escherichia	e206020	FW	B-NP	O
coli	coli	c040	FW	I-NP	O
and	and	a530	CC	O	O
Pseudomonas	Pseudomonas	p203050502	NNP	B-NP	O
aeruginosa	aeruginosa	a060205020	NN	I-NP	O
,	,	,000	,	O	O
accounted	account	a205303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
74	74	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
gram	gram	g605	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
negative	negative	n0203010	JJ	I-NP	I-Disease
bacillary	bacillary	b0204060	JJ	I-NP	I-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influenced	influence	i51405203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
neutrophil	neutrophil	n0360104	NN	I-NP	O
count	count	c053	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
62	62	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
cure	cure	c060	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
for	for	f060	IN	B-PP	O
39	39	0000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
failure	failure	f04060	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neutrophil	neutrophil	n0360104	NN	I-NP	O
count	count	c053	NN	I-NP	O
to	to	t000	TO	B-VP	O
increase	increase	i526020	VB	I-VP	O
during	during	d06052	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
adversely	adversely	a31062040	RB	B-VP	O
affected	affect	a102303	VBD	I-VP	O
response	response	r0210520	NN	B-NP	O
.	.	.000	.	O	O

Azotemia	Azotemia	a203050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
recognized	recognize	r020250203	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
episodes	episode	e1020302	NNS	B-NP	O
.	.	.000	.	O	O

Major	Major	m0206	JJ	B-NP	O
azotemia	azotemia	a203050	NN	I-NP	B-Disease
(	(	(000	(	O	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
or	or	o600	CC	I-NP	O
BUN	BUN	b050	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Azotemia	Azotemia	a203050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
or	or	o600	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
antibiotic	antibiotic	a53010302	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
both	both	b030	CC	O	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	O	O
acceptable	acceptable	a20130140	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
solid	solid	s0403	JJ	B-NP	O
tumours	tumour	t05062	NNS	I-NP	B-Disease
among	among	a5052	IN	B-PP	O
pesticide	pesticide	p02302030	NN	B-NP	O
applicators	applicator	a140203062	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
organophosphate	organophosphate	o620501021030	NN	I-NP	B-Chemical
insecticide	insecticide	i5202302030	NN	I-NP	O
diazinon	diazinon	d020505	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Agricultural	Agricultural	a26020430604	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
updated	update	u130303	VBN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Diazinon	Diazinon	d020505	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
organophosphate	organophosphate	o620501021030	NN	I-NP	B-Chemical
insecticide	insecticide	i5202302030	NN	I-NP	O
with	with	w030	IN	B-PP	O
genotoxic	genotoxic	g05030202	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lung	lung	l052	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Agricultural	Agricultural	a26020430604	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
(	(	(000	(	O	O
AHS	AHS	a020	NNP	B-NP	O
)	)	)000	)	O	O
cohort	cohort	c063	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
few	few	f000	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
epidemiological	epidemiological	e1030504020204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
updated	update	u130303	VBN	B-NP	O
diazinon	diazinon	d020505	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
cancer	cancer	c05206	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
information	information	i510650305	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
solid	solid	s0403	JJ	B-NP	O
tumour	tumour	t0506	NN	I-NP	B-Disease
risk	risk	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
AHS	AHS	a020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	JJ	B-NP	O
pesticide	pesticide	p02302030	NN	I-NP	O
applicators	applicator	a140203062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Iowa	Iowa	i000	NNP	B-NP	O
and	and	a530	CC	O	O
North	North	n0630	NNP	B-NP	O
Carolina	Carolina	c0604050	NNP	I-NP	O
reported	report	r0106303	VBD	B-VP	O
lifetime	lifetime	l0103050	NN	B-NP	O
diazinon	diazinon	d020505	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
at	at	a300	IN	B-PP	O
enrolment	enrolment	e56045053	NN	B-NP	O
(	(	(000	(	O	O
1993	1993	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
1997	1997	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
1998	1998	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2005	2005	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
cancer	cancer	c05206	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
2010	2010	0000	CD	B-NP	O
(	(	(000	(	O	O
North	North	n0630	NNP	B-NP	O
Carolina	Carolina	c0604050	NNP	I-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
2011	2011	0000	CD	I-NP	O
(	(	(000	(	O	O
Iowa	Iowa	i000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
applicators	applicator	a140203062	NNS	B-NP	O
with	with	w030	IN	B-PP	O
usage	usage	u2020	NN	B-NP	O
information	information	i510650305	NN	I-NP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
exposure	exposure	e2102060	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
Poisson	Poisson	p0205	NN	B-NP	O
regression	regression	r0260205	NN	I-NP	O
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
adjusted	adjust	a3202303	VBN	B-NP	O
rate	rate	r030	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
(	(	(000	(	O	O
RRs	RR	r620	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
for	for	f060	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
sites	site	s0302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
>	>	>000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
exposed	expose	e210203	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
both	both	b030	CC	O	O
lifetime	lifetime	l0103050	NN	B-NP	O
(	(	(000	(	O	O
LT	LT	l300	NN	B-NP	O
)	)	)000	)	O	O
exposure	exposure	e2102060	NN	B-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-VP	O
(	(	(000	(	O	O
IW	IW	i000	NN	B-NP	O
)	)	)000	)	O	O
lifetime	lifetime	l0103050	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
accounting	accounting	a2053052	NN	B-NP	O
for	for	f060	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
impacting	impact	i51023052	VBG	B-VP	O
exposure	exposure	e2102060	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
lung	lung	l052	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
risks	risk	r020	NNS	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
283	283	0000	CD	B-NP	O
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
applicators	applicator	a140203062	NNS	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
LT	LT	l300	NN	B-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
60	60	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
11	11	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
31	31	0000	CD	I-NP	O
;	;	;000	:	O	O
Ptrend	Ptrend	p36053	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
IW	IW	i000	NN	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
41	41	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
98	98	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
;	;	;000	:	O	O
Ptrend	Ptrend	p36053	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Kidney	Kidney	k0350	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
94	94	0000	CD	B-NP	O
)	)	)000	)	O	O
risks	risk	r020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
elevated	elevated	e4010303	JJ	I-ADJP	O
(	(	(000	(	O	O
RRLT	RRLT	r643	NN	B-NP	O
days	day	d020	NNS	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
77	77	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
90	90	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
51	51	0000	CD	I-NP	O
;	;	;000	:	O	O
Ptrend	Ptrend	p36053	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
09	09	0000	CD	B-NP	O
;	;	;000	:	O	O
RRIW	RRIW	r600	NN	B-NP	O
days	day	d020	NNS	I-NP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
37	37	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
64	64	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
92	92	0000	CD	I-NP	O
;	;	;000	:	O	O
Ptrend	Ptrend	p36053	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
50	50	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
were	be	w060	VBD	B-VP	O
risks	risk	r020	NNS	B-NP	O
for	for	f060	IN	B-PP	O
aggressive	aggressive	a2602010	JJ	B-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
656	656	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
updated	update	u130303	VBN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diazinon	diazinon	d020505	NN	B-NP	B-Chemical
provides	provide	p6010302	VBZ	B-VP	O
additional	additional	a3030504	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
lung	lung	l052	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

Newly	Newly	n040	RB	B-NP	O
identified	identify	i30530103	VBN	I-NP	O
links	link	l052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
kidney	kidney	k0350	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
associations	association	a20203052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
aggressive	aggressive	a2602010	JJ	B-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
require	require	r02060	VBP	B-VP	O
further	far	f06306	JJR	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

Associations	Association	a20203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
Ozone	Ozone	o2050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
PM2	PM2	0000	NN	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
Concentrations	Concentration	c052053603052	NNPS	I-NP	O
With	With	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
Disease	Disease	d02020	NN	I-NP	I-Disease
Among	Among	a5052	IN	B-PP	O
Participants	Participant	p06302010532	NNPS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Agricultural	Agricultural	a26020430604	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
associations	association	a20203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ozone	ozone	o2050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
fine	fine	f050	JJ	B-NP	O
particulate	particulate	p0630204030	JJ	I-NP	B-Chemical
matter	matter	m0306	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
observed	observe	o1206103	VBN	B-VP	O
among	among	a5052	IN	B-PP	O
farmers	farmer	f065062	NNS	B-NP	O
in	in	i500	IN	B-PP	O
North	North	n0630	NNP	B-NP	O
Carolina	Carolina	c0604050	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Iowa	Iowa	i000	NNP	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
logistic	logistic	l0202302	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
associations	association	a20203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
pollutants	pollutant	p04030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
self	self	s041	NN	B-NP	O
-	-	-000	HYPH	O	O
reported	report	r0106303	VBN	B-VP	O
,	,	,000	,	O	O
doctor	doctor	d02306	NN	B-NP	O
-	-	-000	HYPH	O	O
diagnosed	diagnose	d0250203	VBN	B-VP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Daily	Daily	d040	NNP	B-NP	O
predicted	predict	p60302303	VBD	B-VP	O
pollutant	pollutant	p0403053	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
derive	derive	d06010	VB	I-VP	O
surrogates	surrogate	s06020302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
link	link	l052	VB	B-VP	O
them	them	t050	PRP	B-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
participants	participant	p06302010532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
geocoded	geocode	g020303	VBN	I-NP	O
addresses	address	a360202	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
positive	positive	p0203010	JJ	B-NP	O
associations	association	a20203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
ozone	ozone	o2050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
39	39	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
98	98	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
98	98	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
fine	fine	f050	JJ	B-NP	O
particulate	particulate	p0630204030	JJ	I-NP	B-Chemical
matter	matter	m0306	NN	I-NP	I-Chemical
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
34	34	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
93	93	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
93	93	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
North	North	n0630	NNP	B-NP	O
Carolina	Carolina	c0604050	NNP	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
Iowa	Iowa	i000	NNP	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
plausibility	plausibility	p4020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ambient	ambient	a51053	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
pollutants	pollutant	p04030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
risk	risk	r020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
supported	support	s0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
damage	damage	d05020	NN	B-NP	O
to	to	t000	TO	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
relevant	relevant	r0401053	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
address	address	a3602	VB	I-VP	O
uncertainties	uncertainty	u5206305302	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
confounding	confound	c051053052	VBG	B-VP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
temporal	temporal	t0510604	JJ	B-NP	O
aspects	aspect	a210232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
associations	association	a20203052	NNS	I-NP	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
programming	programming	p602605052	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
AT2R	AT2R	0000	NN	I-NP	O
mediates	mediate	m030302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
origin	origin	o60205	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
prenatal	prenatal	p6050304	JJ	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

UNASSIGNED	UNASSIGNED	u50202503	VBN	B-VP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
previous	previous	p60102	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
prenatal	prenatal	p6050304	JJ	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
(	(	(000	(	O	O
PCE	PCE	p200	NN	B-NP	O
)	)	)000	)	O	O
could	could	c043	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
intrauterine	intrauterine	i5360306050	JJ	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	I-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
(	(	(000	(	O	O
IUGR	IUGR	i026	NN	B-NP	B-Disease
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
offspring	offspring	o1216052	NN	B-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
IUGR	IUGR	i026	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
whether	whether	w0306	IN	B-SBAR	O
PCE	PCE	p200	NN	B-NP	O
could	could	c043	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
underlying	underlying	u53064052	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
remain	remain	r0505	VBP	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
to	to	t000	TO	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
by	by	b000	IN	B-PP	O
PCE	PCE	p200	NN	B-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
intrauterine	intrauterine	i5360306050	JJ	I-NP	O
programming	programming	p602605052	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
IUGR	IUGR	i026	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
established	establish	e230140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
PCE	PCE	p200	NN	B-NP	O
,	,	,000	,	O	O
male	male	m040	JJ	B-NP	O
fetuses	fetus	f030202	NNS	I-NP	O
and	and	a530	CC	O	O
adult	adult	a3043	JJ	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
postnatal	postnatal	p02350304	JJ	B-NP	O
week	week	w020	NN	I-NP	O
24	24	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
euthanized	euthanize	e03050203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
offspring	offspring	o1216052	NN	I-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PCE	PCE	p200	NN	I-NP	O
group	group	g601	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
fibrosis	fibrosis	f0160202	NN	I-NP	I-Disease
,	,	,000	,	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
elevated	elevate	e4010303	VBN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
urine	urine	u6050	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
type	type	t010	NN	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
AT2R	AT2R	0000	NN	B-NP	O
)	)	)000	)	O	O
gene	gene	g050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
PCE	PCE	p200	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
type	type	t010	NN	I-NP	O
1a	1a	1000	NN	I-NP	O
(	(	(000	(	O	O
AT1aR	AT1aR	0000	NN	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	O	O
AT2R	AT2R	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fetal	fetal	f0304	JJ	I-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PCE	PCE	p200	NN	I-NP	O
group	group	g601	NN	I-NP	O
displayed	display	d021403	VBD	B-VP	O
an	an	a500	DT	B-NP	O
enlarged	enlarged	e5406203	JJ	I-NP	O
Bowman	Bowman	b0505	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
space	space	s1020	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
shrunken	shrunken	s0605205	JJ	I-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
tuft	tuft	t013	NN	I-NP	O
,	,	,000	,	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
width	width	w030	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	O
zone	zone	z050	NN	I-NP	O
/	/	/000	SYM	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
zone	zone	z050	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
.	.	.000	.	O	O

Observation	Observation	o120610305	NN	B-NP	O
by	by	b000	IN	B-PP	O
electronic	electronic	e402360502	JJ	B-NP	O
microscope	microscope	m02602010	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
structural	structural	s360230604	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
of	of	o100	IN	B-PP	O
podocytes	podocyte	p03020302	NNS	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
podocyte	podocyte	p0302030	NN	B-NP	O
marker	marker	m06206	NN	I-NP	O
genes	gene	g0502	NNS	I-NP	O
,	,	,000	,	O	O
nephrin	nephrin	n010605	NN	B-NP	O
and	and	a530	CC	O	O
podocin	podocin	p030205	NN	B-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
q	q	q000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
PCR	PCR	p260	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
AT2R	AT2R	0000	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
expressions	expression	e21602052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
PCE	PCE	p200	NN	B-NP	O
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
repression	repression	r0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
glial	glial	g404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
-	-	-000	HYPH	O	O
derived	derive	d060103	VBN	B-VP	O
neurotrophic	neurotrophic	n060360102	JJ	B-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
GDNF	GDNF	g351	NN	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
tyrosine	tyrosine	t0602050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
Ret	Ret	r030	NN	I-NP	O
)	)	)000	)	O	O
signaling	signaling	s02504052	NN	B-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
PCE	PCE	p200	NN	B-NP	O
could	could	c043	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
dysplasia	dysplasia	d0214020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
fetal	fetal	f0304	JJ	B-NP	I-Disease
kidneys	kidney	k03502	NNS	I-NP	I-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
programming	programming	p602605052	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
AT2R	AT2R	0000	NN	I-NP	O
might	might	m0203	MD	B-VP	O
mediate	mediate	m03030	VB	I-VP	O
the	the	t000	DT	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
origin	origin	o60205	NN	I-NP	O
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Butadiene	Butadiene	b0303050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
CML	CML	c540	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
t	t	t000	NN	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
:	:	:000	SYM	O	O
22	22	0000	CD	O	O
)	)	)000	)	O	O
translocation	translocation	t60524020305	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
reality	reality	r04030	NN	I-NP	O
check	check	c020	NN	I-NP	O
.	.	.000	.	O	O

UNASSIGNED	UNASSIGNED	u50202503	VBN	B-VP	O
:	:	:000	:	O	O
Epidemiological	Epidemiological	e1030504020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
butadiene	butadiene	b0303050	NN	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
suggest	suggest	s02023	VBP	I-VP	O
that	that	t030	IN	B-SBAR	O
exposures	exposure	e21020602	NNS	B-NP	O
to	to	t000	TO	B-PP	O
humans	human	h05052	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
myeloid	myeloid	m0403	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
CML	CML	c540	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

CML	CML	c540	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
documented	document	d020505303	VBN	I-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
ionizing	ionize	i0502052	VBG	B-VP	O
radiation	radiation	r030305	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
reports	report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
associations	association	a20203052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chemical	chemical	c050204	JJ	B-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
questioned	question	q0230503	VBN	I-VP	O
.	.	.000	.	O	O

Ionizing	Ionize	i0502052	VBG	B-VP	O
radiation	radiation	r030305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
requisite	requisite	r0202030	JJ	I-NP	O
CML	CML	c540	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
t	t	t000	NN	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
:	:	:000	SYM	O	O
22	22	0000	CD	O	O
)	)	)000	)	O	O
translocation	translocation	t60524020305	NN	B-NP	O
(	(	(000	(	O	O
Philadelphia	Philadelphia	p04030410	NN	B-NP	B-Disease
chromosome	chromosome	c060502050	NN	I-NP	I-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	FW	B-PP	O
vitro	vitro	v0360	FW	B-NP	O
but	but	b030	CC	O	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
,	,	,000	,	O	O
chemicals	chemical	c0502042	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
this	this	t020	DT	B-NP	O
capacity	capacity	c0102030	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-NP	O
1	1	1000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
butadiene	butadiene	b0303050	NN	I-NP	I-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
be	be	b000	VB	B-VP	O
so	so	s000	RB	I-VP	O
tested	test	t02303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
reality	reality	r04030	NN	I-NP	O
check	check	c020	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
epidemiological	epidemiological	e1030504020204	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
conduct	conduct	c053023	VB	I-VP	O
reliable	reliable	r040140	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
regard	regard	r02063	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
for	for	f060	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
be	be	b000	VB	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
ionizing	ionize	i0502052	VBG	I-VP	O
radiation	radiation	r030305	NN	B-NP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
such	such	s020	PDT	B-NP	O
a	a	a000	DT	I-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
described	describe	d0260103	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
fact	fact	f023	NN	B-NP	O
induce	induce	i53020	VBP	B-VP	O
pathogenic	pathogenic	p03020502	JJ	B-NP	O
t	t	t000	NN	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
:	:	:000	SYM	O	O
22	22	0000	CD	O	O
)	)	)000	)	O	O
translocations	translocation	t605240203052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
myeloid	myeloid	m0403	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
line	line	l050	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
does	do	d020	VBZ	B-VP	O
so	so	s000	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
.	.	.000	.	O	O

Conditions	Condition	c05303052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
butadiene	butadiene	b0303050	NN	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Cancer	Cancer	c05206	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
metolachlor	metolachlor	m0304020406	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Agricultural	Agricultural	a26020430604	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
update	update	u13030	NN	I-NP	O
.	.	.000	.	O	O

UNASSIGNED	UNASSIGNED	u50202503	VBN	B-VP	O
:	:	:000	:	O	O
Metolachlor	Metolachlor	m0304020406	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
herbicide	herbicide	h06102030	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
classified	classify	c4020103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
Group	Group	g601	NN	I-NP	O
C	C	c000	NN	I-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
U	U	u000	NNP	I-NP	O
.	.	.000	.	I-NP	O
S	S	s000	NNP	I-NP	O
.	.	.000	.	O	O

Environmental	Environmental	e51060505304	NNP	B-NP	O
Protection	Protection	p60302305	NNP	I-NP	O
Agency	Agency	a20520	NNP	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
neoplasms	neoplasm	n0140252	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Epidemiologic	Epidemiologic	e10305040202	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
health	health	h0430	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
limited	limit	l050303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Agricultural	Agricultural	a26020430604	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
(	(	(000	(	O	O
AHS	AHS	a020	NNP	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
licensed	license	l0205203	VBN	B-NP	O
private	private	p601030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
commercial	commercial	c0506204	JJ	I-NP	O
pesticide	pesticide	p02302030	NN	I-NP	O
applicators	applicator	a140203062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Iowa	Iowa	i000	NNP	B-NP	O
and	and	a530	CC	O	O
North	North	n0630	NNP	B-NP	O
Carolina	Carolina	c0604050	NNP	I-NP	O
enrolled	enrol	e560403	VBD	B-VP	O
1993	1993	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1997	1997	0000	CD	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
through	through	t06020	IN	B-PP	O
2010	2010	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
2011	2011	0000	CD	I-NP	O
(	(	(000	(	O	O
NC	NC	n200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
IA	IA	i000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
49	49	0000	CD	B-NP	O
,	,	,000	,	O	O
616	616	0000	CD	B-NP	O
applicators	applicator	a140203062	NNS	I-NP	O
,	,	,000	,	O	O
53	53	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
ever	ever	e106	RB	I-VP	O
using	use	u2052	VBG	I-VP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
Poisson	Poisson	p0205	NN	B-NP	O
regression	regression	r0260205	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
relations	relation	r0403052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
two	two	t000	CD	B-NP	O
metrics	metric	m03602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
(	(	(000	(	O	O
lifetime	lifetime	l0103050	NN	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
intensity	intensity	i53052030	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
weighted	weight	w020303	VBN	B-NP	O
lifetime	lifetime	l0103050	NN	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
cancer	cancer	c05206	NN	B-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
saw	see	s000	VBD	B-VP	O
no	no	n000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
combined	combine	c0510503	VBN	B-VP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
701	701	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
lag	lag	l020	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
most	most	m023	JJS	B-NP	O
site	site	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
analyses	analysis	a5040202	NNS	B-NP	O
restricted	restrict	r023602303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
exposed	expose	e210203	VBN	B-NP	O
workers	worker	w062062	NNS	I-NP	O
,	,	,000	,	O	O
elevations	elevation	e40103052	NNS	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
categories	category	c03020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
trends	trend	t60532	NNS	B-NP	O
for	for	f060	IN	B-PP	O
both	both	b030	CC	O	O
lifetime	lifetime	l0103050	NN	B-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-NP	O
lifetime	lifetime	l0103050	NN	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metolachor	metolachor	m03040206	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
and	and	a530	CC	O	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
unexposed	unexposed	u50210203	JJ	I-NP	O
reference	reference	r01060520	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
follicular	follicular	f04020406	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
lymphoma	lymphoma	l051050	NN	I-NP	B-Disease
subtypes	subtype	s0130102	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
earlier	early	e06406	JJR	I-NP	O
suggestion	suggestion	s0202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
lung	lung	l052	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
risk	risk	r020	NN	I-NP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
update	update	u13030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
suggestion	suggestion	s0202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
pesticide	pesticide	p02302030	NN	B-NP	O
applicators	applicator	a140203062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
and	and	a530	CC	O	O
echoes	echo	e202	VBZ	B-VP	O
observation	observation	o120610305	NN	B-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
neoplasms	neoplasm	n0140252	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
animal	animal	a50504	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
both	both	b030	CC	O	O
liver	liver	l0106	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
follicular	follicular	f04020406	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
lymphoma	lymphoma	l051050	NN	I-NP	B-Disease
warrant	warrant	w06053	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
to	to	t000	TO	B-VP	O
better	well	b0306	RBR	I-VP	O
differentiate	differentiate	d0106053030	VB	I-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
metolachlor	metolachlor	m0304020406	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
from	from	f605	IN	B-PP	O
other	other	o306	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Mechanisms	Mechanism	m02050252	NNS	B-NP	O
Underlying	Underlie	u53064052	VBG	B-VP	O
Latent	Latent	l03053	JJ	B-NP	O
Disease	Disease	d02020	NN	I-NP	O
Risk	Risk	r020	NN	I-NP	O
Associated	Associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Early	Early	e0640	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
Life	Life	l010	NN	I-NP	O
Arsenic	Arsenic	a620502	JJ	I-NP	B-Chemical
Exposure	Exposure	e2102060	NN	I-NP	O
:	:	:000	:	O	O
Current	Current	c06053	NNP	B-NP	O
Research	Research	r020620	NNP	I-NP	O
Trends	Trends	t60532	NNP	I-NP	O
and	and	a530	CC	O	O
Scientific	Scientific	s20530102	NNP	B-NP	O
Gaps	Gaps	g012	NNP	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Millions	Million	m04052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
individuals	individual	i530103042	NNS	B-NP	O
worldwide	worldwide	w0643030	RB	B-ADVP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
those	those	t020	DT	B-NP	O
living	live	l01052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
rural	rural	r0604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
developing	develop	d010401052	VBG	I-NP	O
areas	area	a602	NNS	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
harmful	harmful	h065104	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inorganic	inorganic	i50620502	JJ	B-NP	B-Chemical
arsenic	arsenic	a620502	JJ	I-NP	I-Chemical
(	(	(000	(	O	O
iAs	iA	i020	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
water	water	w0306	NN	I-NP	O
.	.	.000	.	O	O

Inorganic	Inorganic	i50620502	JJ	B-ADJP	B-Chemical
As	As	a200	IN	B-PP	I-Chemical
exposure	exposure	e2102060	NN	B-NP	O
during	during	d06052	IN	B-PP	O
key	key	k000	JJ	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
periods	period	p06032	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
health	health	h0430	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
those	those	t020	DT	B-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
adulthood	adulthood	a304303	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
considerable	considerable	c05203060140	JJ	B-NP	O
interest	interest	i5306023	NN	I-NP	O
in	in	i500	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
relate	relate	r04030	VBP	B-VP	O
early	early	e0640	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
iAs	iA	i020	NNS	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
latent	latent	l03053	JJ	I-NP	O
diseases	disease	d020202	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
relationship	relationship	r040305201	NN	B-NP	O
to	to	t000	TO	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
summarizes	summarize	s05060202	VBZ	B-VP	O
research	research	r020620	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
underlie	underlie	u530640	VBP	B-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
in	in	i500	IN	B-PP	O
adulthood	adulthood	a304303	NN	B-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
iAs	iA	i020	NNS	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Epigenetic	Epigenetic	e102050302	JJ	B-NP	O
reprogramming	reprogramming	r01602605052	NN	I-NP	O
that	that	t030	WDT	B-NP	O
imparts	impart	i510632	VBZ	B-VP	O
functional	functional	f05230504	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
gene	gene	g050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
stem	stem	s305	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
immunomodulation	immunomodulation	i5050503040305	NN	B-NP	O
are	be	a600	VBP	B-VP	O
plausible	plausible	p4020140	JJ	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
early	early	e0640	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
iAs	iA	i020	NNS	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
elicits	elicit	e402032	VBZ	B-VP	O
latent	latent	l03053	JJ	B-NP	O
carcinogenic	carcinogenic	c06205020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Evidence	Evidence	e1030520	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
mounting	mount	m053052	VBG	I-VP	O
that	that	t030	DT	B-NP	O
relates	relate	r040302	VBZ	B-VP	O
early	early	e0640	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
iAs	iA	i020	NNS	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	I-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

Future	Future	f03060	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
should	should	s043	MD	B-VP	O
include	include	i524030	VB	I-VP	O
animal	animal	a50504	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
address	address	a3602	VBP	B-VP	O
mechanistic	mechanistic	m020502302	JJ	B-NP	O
hypotheses	hypothesis	h01030202	NNS	I-NP	O
and	and	a530	CC	I-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
populations	population	p010403052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
integrate	integrate	i53026030	VBP	B-VP	O
early	early	e0640	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
molecular	molecular	m04020406	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
latent	latent	l03053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

Nifedipine	Nifedipine	n010301050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
80	80	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
male	male	m040	NN	I-NP	O
with	with	w030	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
autonomic	autonomic	a03050502	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
70	70	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
which	which	w020	WDT	B-NP	O
slowed	slow	s403	VBD	B-VP	O
down	down	d050	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
divided	divide	d010303	VBN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
which	which	w020	WDT	B-NP	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
paced	pace	p0203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
70	70	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
inconsistent	inconsistent	i52052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
established	establish	e230140203	VBN	I-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
normally	normally	n065040	RB	B-NP	O
innervated	innervate	i50610303	VBN	I-NP	O
hearts	heart	h0632	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
hearts	heart	h0632	NNS	B-NP	O
deprived	deprive	d0160103	VBN	B-VP	O
of	of	o100	IN	B-PP	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
drive	drive	d6010	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
toxic	toxic	t0202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	O	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
75	75	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
death	death	d030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
70	70	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
82	82	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
death	death	d030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
lower	low	l060	JJR	B-ADVP	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
at	at	a300	IN	B-PP	O
most	most	m023	JJS	B-NP	O
doses	dose	d0202	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
highest	high	h02023	JJS	I-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
lowering	lowering	l06052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reach	reach	r020	VB	I-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
blocker	blocker	b40206	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
against	against	a20523	IN	B-PP	O
death	death	d030	NN	B-NP	O
from	from	f605	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
without	without	w0303	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
mortality	mortality	m06304030	NN	B-NP	O
.	.	.000	.	O	O

Autoradiographic	Autoradiographic	a0306030260102	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
nuclei	nucleus	n0240	NNS	B-NP	O
of	of	o100	IN	B-PP	O
diethylstilbesterol	diethylstilbesterol	d0304230410230604	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hamster	hamster	h052306	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Estrogen	Estrogen	e2360205	NN	B-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
autoradiography	autoradiography	a030603026010	NN	B-NP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
transplantable	transplantable	t6052140530140	JJ	I-NP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
primary	primary	p605060	JJ	I-NP	O
diethylstilbesterol	diethylstilbesterol	d0304230410230604	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
hamsters	hamster	h0523062	NNS	I-NP	O
.	.	.000	.	O	O

Radiolabelling	Radiolabelling	r03040104052	NN	B-NP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
3H	3H	3000	NN	B-NP	O
-	-	-000	HYPH	O	O
17	17	0000	CD	B-NP	O
beta	beta	b030	SYM	I-NP	O
estradiol	estradiol	e2360304	NN	I-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
;	;	;000	:	O	O
stereologic	stereologic	s306040202	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
times	time	t0502	NNS	I-NP	O
higher	high	h0206	JJR	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
silver	silver	s04106	NN	I-NP	B-Chemical
grains	grain	g6052	NNS	I-NP	O
over	over	o106	IN	B-PP	O
nuclei	nucleus	n0240	NNS	B-NP	O
than	than	t050	IN	B-PP	O
cytoplasm	cytoplasm	c03014025	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
which	which	w020	WDT	B-NP	O
peaked	peak	p0203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
bind	bind	b053	VB	I-VP	O
the	the	t000	DT	B-NP	O
ligand	ligand	l02053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
published	publish	p0140203	VBN	I-NP	O
report	report	r01063	NN	I-NP	O
documenting	document	d0205053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
preferential	preferential	p6010605304	JJ	I-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
binding	binding	b053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
nuclei	nucleus	n0240	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hamster	hamster	h052306	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NNP	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
biperiden	biperiden	b01060305	VB	I-VP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
38	38	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
postzosteric	postzosteric	p02320230602	JJ	I-NP	B-Disease
trigeminal	trigeminal	t602050504	JJ	I-NP	B-Disease
neuralgia	neuralgia	n060420	NN	I-NP	I-Disease
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
biperiden	biperiden	b01060305	JJ	I-NP	B-Chemical
lactate	lactate	l023030	NN	I-NP	I-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
lasting	last	l023052	VBG	B-VP	O
paradoxical	paradoxical	p0603020204	JJ	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
considerable	considerable	c05203060140	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
dysarthria	dysarthria	d02063060	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
dysphagia	dysphagia	d021020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
back	back	b020	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
within	within	w0305	IN	B-PP	O
12	12	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
upon	upon	u105	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
orciprenaline	orciprenaline	o620160504050	NN	B-NP	B-Chemical
under	under	u5306	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
biperiden	biperiden	b01060305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
speed	speed	s103	NN	I-NP	O
of	of	o100	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
dual	dual	d040	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
muscarine	muscarine	m0206050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Deliberate	Deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
enflurane	enflurane	e51406050	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
middle	middle	m0340	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
ear	ear	e060	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
feasibility	feasibility	f020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
inhalation	inhalation	i5040305	NN	B-NP	O
anaesthetics	anaesthetic	a50230302	NNS	I-NP	O
(	(	(000	(	O	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
middle	middle	m0340	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
ear	ear	e060	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
86	86	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	I-NP	O
mean	mean	m050	NN	I-NP	O
)	)	)000	)	O	O
mmHg	mmHg	m502	NN	B-NP	O
to	to	t000	TO	B-PP	O
52	52	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
98	98	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
halothane	halothane	h0403050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
H	H	h000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
79	79	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	B-PP	O
53	53	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
to	to	t000	TO	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
129	129	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
11	11	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
enflurane	enflurane	e51406050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
E	E	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
from	from	f605	IN	B-PP	O
80	80	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	B-PP	O
49	49	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
to	to	t000	TO	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
135	135	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
I	I	i000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
H	H	h000	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inspiratory	inspiratory	i5210603060	JJ	I-NP	O
gas	gas	g020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
vol	vol	v040	NN	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
E	E	e000	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
vol	vol	v040	NN	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
I	I	i000	CD	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
vol	vol	v040	NN	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
d	d	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
52	52	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
59	59	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
without	without	w0303	IN	B-PP	O
tachy	tachy	t020	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
operating	operating	o10603052	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
bleeding	bleeding	b403052	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
rose	rise	r020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
values	value	v0402	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
returned	return	r0306503	VBD	B-VP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
the	the	t000	DT	B-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
rebound	rebound	r01053	NN	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
or	or	o600	CC	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
easily	easily	e02040	RB	B-NP	O
adjustable	adjustable	a320230140	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
rebound	rebound	r01053	VB	B-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Convulsion	Convulsion	c05104205	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluorescein	fluorescein	f4060205	NN	I-NP	B-Chemical
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

Tonic	Tonic	t0502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
followed	follow	f0403	VBD	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluorescein	fluorescein	f4060205	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
for	for	f060	IN	B-PP	O
fundus	fundus	f05302	NN	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
precautions	precaution	p60203052	NNS	B-NP	O
this	this	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
recurred	recur	r020603	VBD	B-VP	O
on	on	o500	IN	B-PP	O
re	re	r000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluorescein	fluorescein	f4060205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Pharmacology	Pharmacology	p0650204020	NN	B-NP	O
of	of	o100	IN	B-PP	O
ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
prodrug	prodrug	p603602	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9653	9653	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
disodium	disodium	d020305	NN	I-NP	B-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxymethyl	hydroxymethyl	h03602050304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	I-NP	I-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
prodrug	prodrug	p603602	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
advantageous	advantageous	a310530202	JJ	B-NP	O
physicochemical	physicochemical	p020202050204	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9653	9653	0000	CD	B-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
rapidly	rapidly	r010340	RB	I-VP	O
converted	convert	c05106303	VBN	I-VP	O
enzymatically	enzymatically	e52050302040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
phenytoin	phenytoin	p050305	NN	I-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
equivalent	equivalent	e20104053	JJ	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
electroshock	electroshock	e402360202	NN	I-NP	O
(	(	(000	(	O	O
MES	MES	m020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	O
,	,	,000	,	I-NP	O
or	or	o600	CC	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ED50	ED50	0000	NN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
16	16	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	B-NP	O
ACC	ACC	a200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
8	8	8000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
.	.	.000	.	O	O

ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
phenytoin	phenytoin	p050305	NN	I-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
similar	similar	s050406	JJ	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
or	or	o600	CC	O	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
convert	convert	c051063	VB	I-VP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
24	24	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
14	14	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
phenytoin	phenytoin	p050305	NN	I-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
displayed	display	d021403	VBD	B-VP	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
strophanthidin	strophanthidin	s36010530305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
guinea	guinea	g050	NN	B-NP	O
pig	pig	p020	NN	I-NP	O
right	right	r0203	JJ	I-NP	O
atria	atria	a360	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9653	9653	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
31	31	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
over	over	o106	IN	B-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
equimolar	equimolar	e2050406	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ACC	ACC	a200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9653	9653	0000	CD	B-NP	I-Chemical
and	and	a530	CC	O	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
treatments	treatment	t60350532	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
marked	marked	m06203	JJ	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
contractile	contractile	c0536023040	JJ	B-NP	O
force	force	f0620	NN	I-NP	O
(	(	(000	(	O	O
LVdP	LVdP	l131	NN	B-NP	O
/	/	/000	SYM	O	O
dt	dt	d300	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
maximum	maximum	m020505	NN	B-NP	O
phenytoin	phenytoin	p050305	NN	I-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
rabbits	rabbit	r01032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
dogs	dog	d020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
m	m	m000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
routes	route	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
and	and	a530	CC	O	O
occurred	occur	o20603	VBD	B-VP	O
at	at	a300	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
equivalent	equivalent	e20104053	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Importantly	Importantly	i5106305340	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
irritation	irritation	i6030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9653	9653	0000	CD	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
following	follow	f04052	VBG	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
m	m	m000	NN	B-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Tachyphylaxis	Tachyphylaxis	t0201040202	NN	B-NP	O
to	to	t000	TO	B-PP	O
systemic	systemic	s0230502	JJ	B-ADJP	O
but	but	b030	CC	I-ADJP	O
not	not	n030	RB	I-ADJP	O
to	to	t000	TO	B-PP	O
airway	airway	a060	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
inhaled	inhale	i50403	VBD	B-VP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
asthmatics	asthmatic	a23050302	NNS	B-NP	B-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inhaled	inhale	i50403	VBN	B-NP	O
salbutamol	salbutamol	s041030504	NN	I-NP	B-Chemical
produce	produce	p603020	VBP	B-VP	O
substantial	substantial	s012305304	JJ	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
airway	airway	a060	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
asthma	asthma	a23050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
tachyphylaxis	tachyphylaxis	t0201040202	NN	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
during	during	d06052	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
inhaled	inhale	i50403	VBD	B-VP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
asthmatic	asthmatic	a23050302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
FEV1	FEV1	0000	NN	B-NP	O
,	,	,000	,	O	O
81	81	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
predicted	predict	p60302303	VBN	B-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
requiring	require	r0206052	VBG	B-VP	O
only	only	o540	RB	B-NP	O
occasional	occasional	o2020504	JJ	I-NP	O
inhaled	inhale	i50403	VBD	B-VP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
agonists	agonist	a2050232	NNS	B-NP	O
as	as	a200	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
sole	sole	s040	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
a	a	a000	DT	B-NP	O
14	14	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
inhaled	inhale	i50403	VBD	B-VP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HDS	HDS	h320	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
daily	daily	d040	JJ	I-NP	O
,	,	,000	,	I-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
inhaled	inhale	i50403	VBD	B-VP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
LDS	LDS	l320	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
800	800	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
daily	daily	d040	RB	B-ADVP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
PI	PI	p000	NN	B-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
metered	meter	m030603	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
inhaler	inhaler	i50406	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
crossover	crossover	c6020106	NN	I-NP	O
design	design	d02025	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
14	14	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
run	run	r050	VB	B-VP	O
-	-	-000	HYPH	B-NP	O
in	in	i500	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
washout	washout	w0203	NN	B-NP	O
periods	period	p06032	NNS	I-NP	O
,	,	,000	,	O	O
inhaled	inhale	i50403	VBD	B-VP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
agonists	agonist	a2050232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
withheld	withhold	w03043	VBN	I-VP	O
and	and	a530	CC	O	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
bromide	bromide	b605030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
substituted	substitute	s0123030303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
rescue	rescue	r020	NN	B-NP	O
purposes	purpose	p0610202	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
14	14	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
response	response	r0210520	NN	B-NP	O
curve	curve	c0610	NN	I-NP	O
(	(	(000	(	O	O
DRC	DRC	d620	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
airway	airway	a060	NN	B-NP	O
(	(	(000	(	O	O
FEV1	FEV1	0000	NN	B-NP	O
,	,	,000	,	O	O
FEF25	FEF25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
75	75	0000	CD	I-NP	O
)	)	)000	)	O	O
chronotropic	chronotropic	c06050360102	JJ	O	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
metabolic	metabolic	m03010402	JJ	B-ADJP	O
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Glu	Glu	g400	NN	B-NP	B-Chemical
)	)	)000	)	O	O
responses	response	r02105202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
each	each	e020	DT	B-NP	O
step	step	s301	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
100	100	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
FEV1	FEV1	0000	NN	B-NP	O
and	and	a530	CC	O	O
FEF25	FEF25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
75	75	0000	CD	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
HDS	HDS	h320	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
displace	displace	d0214020	VB	I-VP	O
the	the	t000	DT	B-NP	O
DRC	DRC	d620	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	NN	I-NP	O
.	.	.000	.	O	O

DRC	DRC	d620	NN	B-NP	O
for	for	f060	IN	B-PP	O
HR	HR	h600	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Glu	Glu	g400	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
HDS	HDS	h320	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
PI	PI	p000	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
differences	difference	d010605202	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
HDS	HDS	h320	NN	B-NP	O
and	and	a530	CC	I-NP	O
LDS	LDS	l320	NN	I-NP	O
for	for	f060	IN	B-PP	O
HR	HR	h600	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Glu	Glu	g400	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
responses	response	r02105202	NNS	B-NP	O
.	.	.000	.	O	O

Frequency	Frequency	f6020520	NN	B-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
subjective	subjective	s012023010	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
HDS	HDS	h320	NN	B-NP	O
:	:	:000	:	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
palpitations	palpitation	p0410303052	NNS	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Phenytoin	Phenytoin	p050305	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
fatal	fatal	f0304	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
61	61	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
fatal	fatal	f0304	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
multisystem	multisystem	m0430202305	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
precedes	precede	p6020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	O
,	,	,000	,	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pathologic	pathologic	p03040202	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
mixed	mixed	m0203	JJ	I-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
presents	present	p6020532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
viral	viral	v0604	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
illness	illness	i4502	NN	I-NP	O
,	,	,000	,	O	O
early	early	e0640	JJ	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
and	and	a530	CC	O	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
are	be	a600	VBP	B-VP	O
mandatory	mandatory	m05303060	JJ	B-ADJP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
lethal	lethal	l0304	JJ	B-NP	O
pertussis	pertussis	p0630202	NN	I-NP	B-Chemical
vaccine	vaccine	v02050	NN	I-NP	I-Chemical
reaction	reaction	r02305	NN	I-NP	O
with	with	w030	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
H1	H1	0000	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
after	after	a1306	IN	B-PP	O
pertussis	pertussis	p0630202	NN	B-NP	B-Disease
immunization	immunization	i505020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
.	.	.000	.	O	O

Without	Without	w0303	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
73	73	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
92	92	0000	CD	B-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
died	die	d030	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bovine	bovine	b01050	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
(	(	(000	(	O	O
BSA	BSA	b200	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
+	+	+000	SYM	O	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
pertussis	pertussis	p0630202	NN	B-NP	B-Disease
immunization	immunization	i505020305	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyproheptadine	cyproheptadine	c01601303050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
mianserin	mianserin	m0520605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
5	5	5000	CD	I-NP	O
of	of	o100	IN	B-PP	O
105	105	0000	CD	B-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
died	die	d030	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
BSA	BSA	b200	NN	B-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
+	+	+000	SYM	O	O
7	7	7000	CD	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Blockade	Blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
H1	H1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
mortality	mortality	m06304030	NN	B-NP	O
in	in	i500	IN	B-PP	O
pertussis	pertussis	p0630202	NN	B-NP	B-Disease
immunization	immunization	i505020305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Support	Support	s01063	NN	B-NP	O
for	for	f060	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
hypothesis	hypothesis	h01030202	NN	I-NP	O
:	:	:000	:	O	O
18	18	0000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
crossover	crossover	c6020106	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
6	6	6000	CD	I-NP	O
h	h	h000	NN	I-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
458	458	0000	CD	I-NP	O
pmol	pmol	p504	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
911	911	0000	CD	I-NP	O
pmol	pmol	p504	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
dextrose	dextrose	d0236020	NN	I-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
ten	ten	t050	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
random	random	r05305	JJ	B-NP	O
order	order	o6306	NN	I-NP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
apart	apart	a1063	RB	B-ADVP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
the	the	t000	DT	B-NP	O
haemodynamic	haemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Adrenaline	Adrenaline	a360504050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
and	and	a530	CC	O	O
protracted	protract	p603602303	VBD	B-VP	O
pressor	pressor	p60206	NN	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
postinfusion	postinfusion	p0230510205	NN	I-NP	O
period	period	p0603	NN	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
6	6	6000	CD	B-NP	O
(	(	(000	(	O	O
SEM	SEM	s050	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
(	(	(000	NN	I-NP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
%	%	%000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
after	after	a1306	IN	B-PP	O
dextrose	dextrose	d0236020	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
ANOVA	ANOVA	a5010	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
"	"	"000	``	B-NP	O
stress	stress	s3602	NN	I-NP	O
"	"	"000	''	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
230	230	0000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
h	h	h000	NN	I-NP	O
cause	cause	c020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
and	and	a530	CC	I-NP	O
protracted	protract	p603602303	VBN	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
strong	strong	s36052	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
hypothesis	hypothesis	h01030202	NN	I-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
alkylxanthines	alkylxanthine	a420420530502	NNS	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Adenosine	Adenosine	a30502050	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
benefit	benefit	b050103	NN	B-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
ischaemic	ischaemic	i20502	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ARF	ARF	a610	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
alkylxanthines	alkylxanthine	a420420530502	NNS	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
potencies	potency	p0305202	NNS	I-NP	O
as	as	a200	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
8	8	8000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenyltheophylline	phenyltheophylline	p050430104050	NN	I-NP	I-Chemical
,	,	,000	,	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
enprofylline	enprofylline	e5160104050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
developing	develop	d010401052	VBG	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
daily	daily	d040	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
(	(	(000	(	O	O
plasma	plasma	p40250	NN	B-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
functional	functional	f05230504	JJ	B-ADJP	O
(	(	(000	(	O	O
urine	urine	u6050	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
and	and	a530	CC	O	O
[	[	[000	(	B-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
inulin	inulin	i50405	NN	I-NP	O
and	and	a530	CC	O	O
[	[	[000	(	B-NP	O
14C	14C	0000	NN	I-NP	O
]	]	]000	)	I-NP	O
p	p	p000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminohippuric	aminohippuric	a505010602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
clearances	clearance	c40605202	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
morphological	morphological	m06104020204	JJ	B-NP	O
(	(	(000	(	O	O
degree	degree	d0260	NN	B-NP	O
of	of	o100	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
)	)	)000	)	O	O
indices	index	i530202	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
various	various	v0602	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
improvements	improvement	i51601050532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-NP	O
all	all	a400	DT	I-NP	O
,	,	,000	,	O	O
measurements	measurement	m0206050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
any	any	a500	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
largely	largely	l062040	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
exerted	exert	e206303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
(	(	(000	(	O	O
polyethylene	polyethylene	p040304050	NN	B-NP	B-Chemical
glycol	glycol	g40204	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
NaOH	NaOH	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
consistent	consistent	c052023053	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
noted	note	n0303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
alkylxanthines	alkylxanthine	a420420530502	NNS	I-NP	B-Chemical
tested	test	t02303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
plays	play	p402	VBZ	B-VP	O
little	little	l0340	JJ	O	O
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
any	any	a500	DT	B-NP	O
,	,	,000	,	O	O
pathophysiological	pathophysiological	p03010204020204	JJ	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ARF	ARF	a610	NN	I-NP	B-Disease
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
ocular	ocular	o20406	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
possibly	possibly	p020140	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
isotretinoin	isotretinoin	i2036030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
261	261	0000	CD	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
ocular	ocular	o20406	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
237	237	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
isotretinoin	isotretinoin	i2036030505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
cystic	cystic	c02302	JJ	I-NP	O
acne	acne	a250	NN	I-NP	B-Disease
.	.	.000	.	O	O

Blepharoconjunctivitis	Blepharoconjunctivitis	b40106020520523010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
subjective	subjective	s012023010	JJ	B-NP	O
complaints	complaint	c05140532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dry	dry	d600	JJ	B-NP	B-Disease
eyes	eye	e020	NNS	I-NP	I-Disease
,	,	,000	,	O	O
blurred	blur	b40603	VBD	B-VP	B-Disease
vision	vision	v0205	NN	B-NP	I-Disease
,	,	,000	,	O	O
contact	contact	c053023	NN	B-NP	O
lens	lens	l052	NN	I-NP	O
intolerance	intolerance	i5304060520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
photodermatitis	photodermatitis	p0303065030302	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

More	More	m060	RBR	B-NP	O
serious	serious	s0602	JJ	I-NP	O
ocular	ocular	o20406	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
papilledema	papilledema	p010403050	NN	B-NP	B-Disease
,	,	,000	,	O	O
pseudotumor	pseudotumor	p203030506	NN	B-NP	B-Disease
cerebri	cerebri	c060160	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
white	white	w030	JJ	B-NP	O
or	or	o600	CC	I-NP	O
gray	gray	g600	JJ	I-NP	O
subepithelial	subepithelial	s0101030404	JJ	I-NP	O
corneal	corneal	c06504	JJ	I-NP	B-Disease
opacities	opacity	o1020302	NNS	I-NP	I-Disease
;	;	;000	:	O	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
are	be	a600	VBP	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Reported	Report	r0106303	VBN	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
dark	dark	d062	JJ	I-NP	O
adaptation	adaptation	a30130305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
under	under	u5306	IN	B-PP	O
investigation	investigation	i51023020305	NN	B-NP	O
.	.	.000	.	O	O

Isotretinoin	Isotretinoin	i2036030505	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
contraindicated	contraindicate	c0536053020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
many	many	m050	JJ	I-NP	O
reported	report	r0106303	VBD	B-VP	O
congenital	congenital	c052050304	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
use	use	u200	NN	I-NP	O
(	(	(000	(	O	O
including	include	i52403052	VBG	B-PP	O
microphthalmos	microphthalmo	m026010304502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
orbital	orbital	o610304	JJ	B-NP	O
hypertelorism	hypertelorism	h010630406025	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
optic	optic	o1302	JJ	B-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
hypoplasia	hypoplasia	h01014020	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Procaterol	Procaterol	p602030604	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
terbutaline	terbutaline	t0610304050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
bronchial	bronchial	b605204	JJ	B-NP	B-Disease
asthma	asthma	a23050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
over	over	o106	IN	B-PP	O
study	study	s3030	NN	B-NP	O
.	.	.000	.	O	O

Procaterol	Procaterol	p602030604	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
stimulant	stimulant	s30504053	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
over	over	o106	IN	B-PP	O
trial	trial	t604	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
bronchial	bronchial	b605204	JJ	B-NP	B-Disease
asthma	asthma	a23050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
procaterol	procaterol	p602030604	NN	I-NP	B-Chemical
50	50	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
procaterol	procaterol	p602030604	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
t	t	t000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
randomly	randomly	r0530540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
periods	period	p06032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
best	well	b023	RBS	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
with	with	w030	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	B-NP	O
asthmatic	asthmatic	a23050302	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	O
tremorgenic	tremorgenic	t6050620502	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
procaterol	procaterol	p602030604	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
related	relate	r040303	VBN	I-ADJP	O
.	.	.000	.	O	O

Procaterol	Procaterol	p602030604	NNP	B-NP	B-Chemical
appeared	appear	a10603	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
twice	twice	t020	RB	I-NP	O
daily	daily	d040	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
would	would	w043	MD	B-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
suitable	suitable	s030140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Subacute	Subacute	s0102030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
B	B	b000	NN	B-NP	O
24	24	0000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
76	76	0000	CD	B-NP	O
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
correlation	correlation	c06040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
B	B	b000	NN	B-NP	O
24	24	0000	CD	I-NP	O
/	/	/000	SYM	O	O
76	76	0000	CD	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
dichlorophenoxy	dichlorophenoxy	d0204060105020	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
[	[	[000	(	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
dimethoxyphenyl	dimethoxyphenyl	d050302010504	NN	I-NP	O
)	)	)000	)	O	O
ethanolamino	ethanolamino	e3050405050	NN	B-NP	O
]	]	]000	)	O	O
-	-	-000	HYPH	B-NP	O
prop	prop	p601	NN	I-NP	O
an	an	a500	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
ol	ol	o400	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
blocking	blocking	b402052	NN	I-NP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
properties	property	p60106302	NNS	B-NP	O
with	with	w030	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
neither	neither	n0306	DT	B-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
nor	nor	n060	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
suppress	suppress	s01602	VB	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
blockers	blocker	b402062	NNS	B-NP	O
influenced	influence	i51405203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertrophy	hypertrophy	h010636010	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
reproducible	reproducible	r01603020140	JJ	B-NP	O
extent	extent	e23053	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
possible	possible	p020140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
suppress	suppress	s01602	VB	I-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
ornithine	ornithine	o6503050	NN	I-NP	B-Chemical
decarboxylase	decarboxylase	d020610204020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
hypertrophied	hypertrophied	h0106360103	JJ	B-NP	B-Disease
hearts	heart	h0632	NNS	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
mass	mass	m020	NN	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
nor	nor	n060	CC	O	O
B	B	b000	NN	B-NP	O
24	24	0000	CD	I-NP	O
/	/	/000	SYM	O	O
76	76	0000	CD	B-NP	O
could	could	c043	MD	B-VP	O
stop	stop	s301	VB	I-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
characteristic	characteristic	c060230602302	JJ	I-NP	O
myosin	myosin	m0205	NN	I-NP	O
isoenzyme	isoenzyme	i2052050	NN	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertrophied	hypertrophied	h0106360103	JJ	I-NP	B-Disease
rat	rat	r030	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
provide	provide	p601030	VB	I-VP	O
any	any	a500	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
B	B	b000	NN	I-NP	O
24	24	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
76	76	0000	CD	I-NP	O
have	have	h010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
potency	potency	p030520	NN	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
producing	produce	p60302052	VBG	B-VP	O
heart	heart	h063	NN	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
,	,	,000	,	O	O
somatic	somatic	s050302	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methoxy	methoxy	m03020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxyphenethyleneglycol	hydroxyphenethyleneglycol	h0360201050304050240204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MHPG	MHPG	m012	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
17	17	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
meeting	meet	m03052	VBG	B-VP	O
DSM	DSM	d250	NN	B-NP	O
-	-	-000	HYPH	O	O
III	III	i000	CD	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
agoraphobia	agoraphobia	a20601010	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
panic	panic	p0502	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
or	or	o600	CC	O	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
greater	great	g60306	JJR	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
subject	subject	s012023	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
rated	rat	r0303	VBN	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
,	,	,000	,	O	O
nervousness	nervousness	n06102502	NN	B-NP	O
,	,	,000	,	O	O
fear	fear	f060	NN	B-NP	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
palpitations	palpitation	p0410303052	NNS	B-NP	B-Disease
,	,	,000	,	O	O
restlessness	restlessness	r023402502	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
tremors	tremor	t605062	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
experienced	experience	e210605203	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
plasma	plasma	p40250	NN	B-NP	O
MHPG	MHPG	m012	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
the	the	t000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
or	or	o600	CC	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
equally	equally	e2040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
healthy	healthy	h0430	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
panic	panic	p0502	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
neuronal	neuronal	n060504	JJ	B-NP	I-Disease
systems	system	s023052	NNS	I-NP	I-Disease
involving	involve	i51041052	VBG	B-VP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
may	may	m000	MD	B-VP	O
benefit	benefit	b050103	VB	I-VP	O
by	by	b000	IN	B-PP	O
avoiding	avoid	a103052	VBG	B-VP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
foods	food	f032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
beverages	beverage	b01060202	NNS	I-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxitropium	oxitropium	o20360105	NN	B-NP	B-Chemical
bromide	bromide	b605030	NN	I-NP	I-Chemical
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
slow	slow	s400	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
nocturnal	nocturnal	n02306504	JJ	B-NP	O
asthma	asthma	a23050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
inhaled	inhaled	i50403	JJ	I-NP	O
antimuscarinic	antimuscarinic	a530502060502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
oxitropium	oxitropium	o20360105	NN	B-NP	B-Chemical
bromide	bromide	b605030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
slow	slow	s400	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
preparation	preparation	p601060305	NN	I-NP	O
upon	upon	u105	IN	B-PP	O
nocturnal	nocturnal	n02306504	JJ	B-NP	O
asthma	asthma	a23050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
:	:	:000	:	O	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
oxitropium	oxitropium	o20360105	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
600	600	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
at	at	a300	IN	B-PP	O
400	400	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
t	t	t000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	LS	O	O
.	.	.000	.	O	O
d	d	d000	VB	B-VP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
whereas	whereas	w0602	IN	O	O
11	11	0000	CD	B-NP	O
received	receive	r020103	VBD	B-VP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	LS	O	O
.	.	.000	.	O	O
d	d	d000	VB	B-VP	O
.	.	.000	.	O	O

Morning	Morne	m065052	VBG	B-NP	O
dipping	dipping	d01052	NN	I-NP	O
,	,	,000	,	O	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
overnight	overnight	o10650203	RB	B-ADVP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
periods	period	p06032	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
either	either	e0306	CC	O	O
active	active	a23010	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noticed	notice	n030203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noticed	notice	n030203	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
results	result	r020432	NNS	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	B-NP	O
active	active	a23010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
dosage	dosage	d02020	NN	B-NP	O
of	of	o100	IN	B-PP	O
oxitropium	oxitropium	o20360105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oxitropium	oxitropium	o20360105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
three	three	t060	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
reporting	report	r01063052	VBG	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
tremors	tremor	t605062	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Oxitropium	Oxitropium	o20360105	NN	B-NP	B-Chemical
proves	prove	p60102	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
valuable	valuable	v040140	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
nocturnal	nocturnal	n02306504	JJ	B-NP	O
asthma	asthma	a23050	NN	I-NP	B-Disease
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
equally	equally	e2040	RB	B-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
,	,	,000	,	O	O
safer	safe	s0106	JJR	B-ADJP	O
and	and	a530	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
require	require	r02060	VB	I-VP	O
the	the	t000	DT	B-NP	O
titration	titration	t0360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dosage	dosage	d02020	NN	B-NP	O
.	.	.000	.	O	O

Penicillin	Penicillin	p05020405	NN	B-NP	B-Chemical
anaphylaxis	anaphylaxis	a501040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
penicillin	penicillin	p05020405	NN	I-NP	B-Chemical
anaphylaxis	anaphylaxis	a501040202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
terminology	terminology	t0650504020	NN	I-NP	O
,	,	,000	,	O	O
occurrence	occurrence	o2060520	NN	B-NP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
,	,	,000	,	O	O
pathogenesis	pathogenesis	p0302050202	NN	B-NP	O
,	,	,000	,	O	O
prevention	prevention	p60105305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
anaphylaxis	anaphylaxis	a501040202	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

Emergency	Emergency	e50620520	NN	B-NP	O
physicians	physician	p0202052	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
penicillin	penicillin	p05020405	NN	I-NP	B-Chemical
anaphylaxis	anaphylaxis	a501040202	NN	I-NP	B-Disease
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
by	by	b000	IN	B-PP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
antibiotic	antibiotic	a53010302	JJ	I-NP	O
judiciously	judiciously	j03020240	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
knowledgeably	knowledgeably	k5040320140	RB	I-ADVP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
offer	offer	o106	VB	I-VP	O
optimal	optimal	o130504	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
once	once	o520	RB	O	O
this	this	t020	DT	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
threatening	threaten	t060305052	VBG	I-VP	O
reaction	reaction	r02305	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
begun	begin	b0205	VBN	I-VP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
valproic	valproic	v041602	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
valproic	valproic	v041602	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
21	21	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
insidious	insidious	i520302	JJ	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
global	global	g40104	JJ	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
abilities	ability	a1040302	NNS	I-NP	O
documented	document	d020505303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
neuropsychological	neuropsychological	n060120204020204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Repeat	Repeat	r0103	NN	B-NP	O
neuropsychological	neuropsychological	n060120204020204	JJ	I-NP	O
testing	testing	t023052	NN	I-NP	O
7	7	7000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
dramatic	dramatic	d6050302	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
IQ	IQ	i200	NN	B-NP	O
,	,	,000	,	O	O
memory	memory	m05060	NN	B-NP	O
,	,	,000	,	O	O
naming	naming	n05052	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
tasks	task	t020	NNS	I-NP	O
commensurate	commensurate	c0505206030	VBP	B-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
in	in	i500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
intellectual	intellectual	i530402304	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
pathophysiological	pathophysiological	p03010204020204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
operative	operative	o10603010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
include	include	i524030	VBP	B-VP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
toxic	toxic	t0202	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
paradoxical	paradoxical	p0603020204	JJ	I-NP	O
epileptogenic	epileptogenic	e104013020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
indirect	indirect	i5306023	JJ	I-NP	O
CNS	CNS	c520	NN	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperammonemia	hyperammonemia	h01060505050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Reversal	Reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
by	by	b000	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
training	training	t605052	NN	I-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
five	five	f010	CD	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
modulating	modulate	m030403052	VBG	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
retention	retention	r0305305	NN	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Scopolamine	Scopolamine	s2010405050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
methyl	methyl	m0304	NN	B-NP	B-Chemical
scopolamine	scopolamine	s2010405050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
latency	latency	l030520	NN	B-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

Naloxone	Naloxone	n0402050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
injected	inject	i5202303	VBN	B-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
training	training	t605052	NN	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
retention	retention	r0305305	NN	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
peak	peak	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
specificity	specificity	s1020102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Post	Post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
training	training	t605052	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
or	or	o600	CC	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
split	split	s1403	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
neither	neither	n0306	CC	B-NP	O
an	an	a500	DT	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
sensitivity	sensitivity	s0520301030	NN	I-NP	O
(	(	(000	(	O	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
training	training	t605052	NN	B-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
nor	nor	n060	CC	O	O
an	an	a500	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aversive	aversive	a1062010	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
(	(	(000	(	O	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
training	training	t605052	NN	B-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
retention	retention	r0305305	NN	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
extend	extend	e23053	VBP	B-VP	O
previous	previous	p60102	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
implicating	implicate	i5140203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
in	in	i500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
septo	septo	s0130	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
urinary	urinary	u605060	JJ	I-NP	I-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
by	by	b000	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Fully	Fully	f040	RB	B-NP	O
developed	develop	d01040103	VBN	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
detachment	detachment	d030205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
urothelium	urothelium	u6030405	NN	I-NP	O
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
submucosal	submucosal	s015020204	JJ	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
owing	owe	o052	VBG	B-VP	O
to	to	t000	TO	I-VP	O
damage	damage	d05020	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
microvascular	microvascular	m02601020406	JJ	I-NP	O
bed	bed	b030	NN	I-NP	O
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
necroses	necros	n0260202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
attack	attack	a302	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
fragmentation	fragmentation	f60250530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
luminal	luminal	l050504	JJ	I-NP	B-Chemical
membrane	membrane	m0516050	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
damages	damage	d050202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertonic	hypertonic	h010630502	JJ	I-NP	O
urine	urine	u6050	NN	I-NP	O
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
breaks	break	b602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
superficial	superficial	s010610204	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
intermediate	intermediate	i5306503030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
basal	basal	b0204	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
intercellular	intercellular	i53062040406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
intracellular	intracellular	i53602040406	JJ	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
disintegration	disintegration	d020530260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
desmosomes	desmosome	d025020502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
hemidesmosomes	hemidesmosome	h0503025020502	NNS	I-NP	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
detachment	detachment	d030205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
and	and	a530	CC	I-NP	O
splitting	splitting	s1403052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
become	become	b02050	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
location	location	l020305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
damage	damage	d05020	NN	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
mediator	mediator	m030306	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
permeability	permeability	p0650104030	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
correlate	correlate	c0604030	NN	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
gaps	gap	g012	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interendothelial	interendothelial	i5306053030404	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
connections	connection	c05023052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
venules	venule	v050402	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
effectively	effectively	e102301040	RB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
sign	sign	s025	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
granules	granule	g6050402	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
presumed	presumed	p6020503	JJ	I-NP	O
lysosomal	lysosomal	l02020504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
superficial	superficial	s010610204	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Increase	Increase	i526020	NN	B-NP	O
in	in	i500	IN	B-PP	O
intragastric	intragastric	i53602023602	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
fasciculations	fasciculation	f02020403052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
:	:	:000	:	O	O
inhibition	inhibition	i5010305	NN	B-NP	O
by	by	b000	IN	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
intragastric	intragastric	i53602023602	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
32	32	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
yr	yr	y600	NN	I-NP	O
)	)	)000	)	O	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
or	or	o600	CC	I-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
50	50	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

Anaesthesia	Anaesthesia	a5023020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
thiopentone	thiopentone	t01053050	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculations	fasciculation	f02020403052	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
intragastric	intragastric	i53602023602	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculations	fasciculation	f02020403052	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
(	(	(000	(	O	O
SEM	SEM	s050	NN	B-NP	O
)	)	)000	)	O	O
cm	cm	c500	NN	B-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
SEM	SEM	s050	NN	B-NP	O
)	)	)000	)	O	O
cm	cm	c500	NN	B-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
intragastric	intragastric	i53602023602	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
directly	directly	d0602340	RB	B-ADJP	O
related	relate	r040303	VBN	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculations	fasciculation	f02020403052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
regression	regression	r0260205	NN	B-NP	O
line	line	l050	NN	I-NP	O
:	:	:000	:	O	O
y	y	y000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
78x	78x	0000	CD	I-NP	O
with	with	w030	IN	B-PP	O
r	r	r000	NN	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
78	78	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
intragastric	intragastric	i53602023602	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculations	fasciculation	f02020403052	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Alfentanil	Alfentanil	a410530504	NNP	B-NP	B-Chemical
50	50	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
effectively	effectively	e102301040	RB	B-ADVP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
fasciculations	fasciculation	f02020403052	NNS	I-NP	I-Disease
;	;	;000	:	O	O
moreover	moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
intragastric	intragastric	i53602023602	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
at	at	a300	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
control	control	c053604	NN	I-NP	O
value	value	v040	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
normalizes	normalize	n065040202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
morphometric	morphometric	m0610503602	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
earlier	early	e06406	JJR	I-NP	O
reported	report	r0106303	VBD	B-VP	O
protective	protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
diabetes	diabete	d010302	NNS	I-NP	B-Disease
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ISO	ISO	i200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
to	to	t000	TO	I-NP	O
135	135	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
crystalline	crystalline	c602304050	NN	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
,	,	,000	,	O	O
ISO	ISO	i200	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
and	and	a530	CC	O	O
when	when	w050	WRB	B-ADVP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
morphometrically	morphometrically	m0610503602040	RB	I-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
highly	highly	h02040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
83	83	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
p	p	p000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
006	006	0000	CD	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
slope	slope	s4010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
8	8	8000	CD	I-NP	O
day	day	d000	NN	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
while	while	w040	IN	B-SBAR	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
consequent	consequent	c05202053	JJ	I-NP	O
down	down	d050	JJ	I-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
could	could	c043	MD	B-VP	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
explain	explain	e21405	VB	B-VP	O
this	this	t020	DT	B-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
resistance	resistance	r020230520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
reversion	reversion	r0106205	NN	I-NP	O
after	after	a1306	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
excludes	exclude	e240302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
itself	itself	i32041	PRP	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
ISO	ISO	i200	NN	I-NP	B-Chemical
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	O	O
points	point	p0532	NNS	B-NP	O
towards	towards	t0632	IN	B-PP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
insulin	insulin	i520405	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
sensitivity	sensitivity	s0520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
might	might	m0203	MD	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
pathogenetic	pathogenetic	p0302050302	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
behind	behind	b053	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
possibly	possibly	p020140	RB	I-VP	O
have	have	h010	VB	I-VP	O
relevance	relevance	r04010520	NN	B-NP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
widespread	widespread	w03021603	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
forebrain	forebrain	f0601605	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
salicylate	salicylate	s040204030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
phenylbutazone	phenylbutazone	p050410302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
mefenamic	mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
salicylate	salicylate	s040204030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
ED50	ED50	0000	NN	B-NP	O
103	103	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
174	174	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
phenylbutazone	phenylbutazone	p050410302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
59	59	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
70	70	0000	CD	I-NP	O
)	)	)000	)	O	O
converted	convert	c05106303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
one	one	o500	CD	I-NP	O
.	.	.000	.	O	O

Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
modulate	modulate	m0304030	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Mefenamic	Mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
30	30	0000	CD	O	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
prevented	prevent	p60105303	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
protected	protected	p60302303	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
from	from	f605	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-PP	O
related	relate	r040303	VBN	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
380	380	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
differentially	differentially	d0106053040	RB	B-ADVP	O
modulate	modulate	m0304030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
neurologic	neurologic	n06040202	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
glioma	glioma	g4050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Etoposide	Etoposide	e30102030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VP	VP	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
16	16	0000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
213	213	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
many	many	m050	JJ	B-NP	O
solid	solid	s0403	JJ	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
hematologic	hematologic	h0503040202	JJ	B-NP	B-Disease
malignancies	malignancy	m0402505202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
autologous	autologous	a03040202	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
activity	activity	a2301030	NN	B-NP	O
against	against	a20523	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
including	include	i52403052	VBG	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
glioma	glioma	g4050	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
we	we	w000	PRP	B-NP	O
treated	treat	t60303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
or	or	o600	CC	I-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
glioma	glioma	g4050	NN	I-NP	B-Disease
,	,	,000	,	O	O
sudden	sudden	s0305	JJ	B-NP	O
severe	severe	s01060	JJ	I-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
9	9	9000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
included	include	i5240303	VBN	I-VP	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
,	,	,000	,	O	O
papilledema	papilledema	p010403050	NN	B-NP	B-Disease
,	,	,000	,	O	O
somnolence	somnolence	s05040520	NN	B-NP	B-Disease
,	,	,000	,	O	O
exacerbation	exacerbation	e2020610305	NN	B-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
sharp	sharp	s061	JJ	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
computerized	computerize	c05103060203	VBD	B-VP	O
tomographic	tomographic	t050260102	JJ	B-NP	O
(	(	(000	(	O	O
CT	CT	c300	NN	B-NP	O
)	)	)000	)	O	O
brain	brain	b605	NN	B-NP	O
scans	scan	s2052	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
stability	stability	s30104030	NN	B-NP	O
in	in	i500	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
size	size	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
peritumor	peritumor	p06030506	NN	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
pretransplant	pretransplant	p603605214053	NN	B-NP	O
scans	scan	s2052	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
represent	represent	r01602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
new	new	n000	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
glioma	glioma	g4050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Progressive	Progressive	p602602010	JJ	B-NP	O
bile	bile	b040	NN	I-NP	B-Disease
duct	duct	d023	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
thiabendazole	thiabendazole	t0105302040	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	O
wk	wk	w200	NN	I-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
thiabendazole	thiabendazole	t0105302040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cholestasis	Cholestasis	c040230202	NN	B-NP	B-Disease
persisted	persist	p06202303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
yr	yr	y600	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
which	which	w020	WDT	B-NP	O
time	time	t050	NN	I-NP	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
hepatectomy	hepatectomy	h0103023050	NN	I-NP	O
specimen	specimen	s1020505	NN	I-NP	O
were	be	w060	VBD	B-VP	O
remarkable	remarkable	r050620140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
interlobular	interlobular	i53064010406	JJ	B-NP	O
bile	bile	b040	NN	I-NP	O
ducts	duct	d0232	NNS	I-NP	O
.	.	.000	.	O	O

Prominent	Prominent	p60505053	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	O
regeneration	regeneration	r0205060305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
present	present	p602053	JJ	B-ADJP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
lobular	lobular	l010406	JJ	I-NP	O
architecture	architecture	a6203023060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
represents	represent	r016020532	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
example	example	e205140	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	B-NP	O
idiosyncratic	idiosyncratic	i30205260302	JJ	I-NP	O
"	"	"000	''	I-NP	O
drug	drug	d602	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
induced	induce	i530203	VBN	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
injury	injury	i52060	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
bile	bile	b040	NN	I-NP	O
duct	duct	d023	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bile	bile	b040	NN	I-NP	B-Disease
duct	duct	d023	NN	I-NP	I-Disease
destruction	destruction	d023602305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydropyridine	dihydropyridine	d036010603050	NN	I-NP	I-Chemical
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	I-Chemical
blockers	blocker	b402062	NNS	I-NP	I-Chemical
:	:	:000	:	O	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
.	.	.000	.	O	O

Increasing	Increase	i52602052	VBG	B-VP	O
recognition	recognition	r020250305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
stimulated	stimulate	s305040303	VBN	I-VP	O
research	research	r020620	NN	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	I-Chemical
blocking	block	b402052	VBG	B-VP	I-Chemical
agents	agent	a20532	NNS	B-NP	I-Chemical
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
favorable	favorable	f01060140	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
make	make	m020	VBP	B-VP	O
them	them	t050	PRP	B-NP	O
attractive	attractive	a36023010	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
modalities	modality	m03040302	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
applications	application	a140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	I-Chemical
blockers	blocker	b402062	NNS	I-NP	I-Chemical
parallel	parallel	p060404	VBP	B-VP	O
their	their	t060	PRP$	B-NP	O
tissue	tissue	t020	NN	I-NP	O
selectivity	selectivity	s0402301030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
roughly	roughly	r02040	RB	B-ADJP	O
equipotent	equipotent	e20103053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
actions	action	a23052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	O	O
vascular	vascular	v020406	JJ	B-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dihydropyridine	dihydropyridine	d036010603050	NN	I-NP	B-Chemical
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	I-Chemical
blockers	blocker	b402062	NNS	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
potent	potent	p03053	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
vasodilator	vasodilator	v0203040306	NN	I-NP	O
agents	agent	a20532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
exert	exert	e2063	VBP	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
electrophysiologic	electrophysiologic	e402360102040202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
nodal	nodal	n0304	NN	I-NP	O
or	or	o600	CC	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
dihydropyridine	dihydropyridine	d036010603050	NN	I-NP	B-Chemical
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
,	,	,000	,	O	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
controls	control	c0536042	VBZ	B-VP	O
angina	angina	a52050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
minimal	minimal	m050504	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
members	member	m051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	I-Chemical
blockers	blocker	b402062	NNS	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
studied	study	s30303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
indications	indication	i530203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
which	which	w020	WDT	B-NP	O
they	they	t000	PRP	B-NP	O
may	may	m000	MD	B-VP	O
offer	offer	o106	VB	I-VP	O
advantages	advantage	a310530202	NNS	B-NP	O
over	over	o106	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Once	Once	o520	RB	B-ADVP	O
or	or	o600	CC	O	O
twice	twice	t020	RB	B-NP	O
daily	daily	d040	RB	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
possible	possible	p020140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
nitrendipine	nitrendipine	n03605301050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nisoldipine	nisoldipine	n0204301050	NN	I-NP	B-Chemical
offers	offer	o1062	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
convenient	convenient	c05105053	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
encourages	encourage	e52060202	VBZ	B-VP	O
patient	patient	p03053	NN	B-NP	O
compliance	compliance	c05140520	NN	I-NP	O
in	in	i500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
vasodilating	vasodilate	v02030403052	VBG	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nisoldipine	nisoldipine	n0204301050	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
led	lead	l030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
angina	angina	a52050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Selectivity	Selectivity	s0402301030	NN	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebrovascular	cerebrovascular	c0601601020406	JJ	I-NP	O
bed	bed	b030	NN	I-NP	O
makes	make	m0202	VBZ	B-VP	O
nimodipine	nimodipine	n050301050	NN	B-NP	B-Chemical
potentially	potentially	p03053040	RB	B-ADJP	O
useful	useful	u20104	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
migraine	migraine	m026050	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
,	,	,000	,	O	O
dementia	dementia	d050530	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
general	general	g050604	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dihydropyridine	dihydropyridine	d036010603050	NN	I-NP	B-Chemical
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	I-Chemical
blockers	blocker	b402062	NNS	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
usually	usually	u2040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
facial	facial	f0204	JJ	B-NP	O
flushing	flushing	f402052	NN	I-NP	B-Disease
,	,	,000	,	O	O
palpitations	palpitation	p0410303052	NNS	B-NP	B-Disease
,	,	,000	,	O	O
edema	edema	e3050	NN	B-NP	B-Disease
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
anorexia	anorexia	a506020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminonucleoside	aminonucleoside	a5050502402030	NN	B-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
protamine	protamine	p60305050	NN	B-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	B-Disease
segmental	segmental	s02505304	JJ	I-NP	I-Disease
glomerular	glomerular	g405060406	JJ	I-NP	I-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
(	(	(000	(	O	O
FSGS	FSGS	f200	NN	B-NP	B-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
AMNS	AMNS	a520	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
protamine	protamine	p60305050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PS	PS	p200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
uninephrectomized	uninephrectomized	u5050106023050203	JJ	B-VP	O
three	three	t060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
before	before	b01060	RB	B-ADVP	O
,	,	,000	,	O	O
received	receive	r020103	VBD	B-VP	O
daily	daily	d040	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
AMNS	AMNS	a520	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
PS	PS	p200	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
separated	separate	s01060303	VBN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
injections	injection	i52023052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
another	another	a50306	DT	B-NP	O
three	three	t060	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
day	day	d000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
24	24	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
52	52	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
80	80	0000	CD	B-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
finally	finally	f05040	RB	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
course	course	c0620	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
of	of	o100	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
dropped	drop	d60103	VBD	B-VP	O
and	and	a530	CC	I-VP	O
showed	show	s030	VBD	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
difference	difference	d01060520	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
,	,	,000	,	O	O
AMNS	AMNS	a520	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
PS	PS	p200	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
injected	inject	i5202303	VBN	B-VP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
FSGS	FSGS	f200	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
particles	particle	p06302402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
perfused	perfuse	p0610203	VBN	B-NP	O
ruthenium	ruthenium	r030505	NN	I-NP	B-Chemical
red	red	r030	VBD	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lamina	lamina	l05050	NN	I-NP	O
rara	rara	r060	NN	I-NP	O
externa	externa	e230650	NN	I-NP	O
and	and	a530	CC	O	O
marked	marked	m06203	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
epithelial	epithelial	e1030404	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
cytoplasm	cytoplasm	c03014025	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PS	PS	p200	NNP	B-NP	B-Chemical
enhances	enhance	e505202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
AMNS	AMNS	a520	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerulus	glomerulus	g405060402	NN	I-NP	O
and	and	a530	CC	O	O
readily	readily	r03040	RB	B-VP	O
produces	produce	p6030202	VBZ	I-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
FSGS	FSGS	f200	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Theophylline	Theophylline	t0104050	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
altered	alter	a430603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
.	.	.000	.	O	O

Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
20	20	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
nonpregnant	nonpregnant	n0516025053	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	I-NP	O
strain	strain	s3605	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
infusions	infusion	i5102052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
until	until	u5304	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
28	28	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Theophylline	Theophylline	t0104050	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
endpoint	endpoint	e531053	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
(	(	(000	(	O	O
total	total	t0304	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
CSF	CSF	c210	NN	B-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
but	but	b030	CC	O	O
serum	serum	s0605	NN	B-NP	O
(	(	(000	(	O	O
free	free	f600	JJ	B-ADJP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
brain	brain	b605	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
slightly	slightly	s4020340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Theophylline	Theophylline	t0104050	NN	B-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
equilibrium	equilibrium	e20401605	NN	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Fetal	Fetal	f0304	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mother	mother	m0306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
and	and	a530	CC	I-NP	O
CSF	CSF	c210	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
correlated	correlate	c06040303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
former	former	f06506	JJ	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
advanced	advance	a3105203	VBN	B-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
negligible	negligible	n024020140	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Hyperkalemia	Hyperkalemia	h0106204050	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
naproxen	naproxen	n0160205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
fludrocortisone	fludrocortisone	f40360206302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
rheumatoid	rheumatoid	r050303	JJ	I-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
mefenamic	mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
inappropriate	inappropriate	i5016016030	JJ	B-NP	O
hypoaldosteronism	hypoaldosteronism	h010430230605025	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	O	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
naproxen	naproxen	n0160205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
preexisting	preexist	p602023052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
predisposed	predispose	p6030210203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
to	to	t000	TO	B-PP	O
type	type	t010	NN	B-NP	B-Disease
IV	IV	i100	CD	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
synthetase	synthetase	s05303020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
discontinue	discontinue	d02053050	VB	I-VP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
fludrocortisone	fludrocortisone	f40360206302050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
added	add	a303	VBN	I-VP	O
,	,	,000	,	O	O
correcting	correct	c06023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
allowing	allow	a4052	VBG	B-VP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
continued	continue	c0530503	VBN	I-VP	O
safely	safely	s01040	RB	B-ADVP	O
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
colorectal	colorectal	c040602304	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CDDP	CDDP	c310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
required	require	r020603	VBD	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
despite	despite	d021030	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
(	(	(000	(	O	O
EKG	EKG	e200	NN	B-NP	O
)	)	)000	)	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
(	(	(000	(	O	O
hemodynamic	hemodynamic	h0503050502	JJ	B-ADJP	O
,	,	,000	,	O	O
echocardiographic	echocardiographic	e2020630260102	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
scintigraphic	scintigraphic	s20530260102	JJ	B-ADJP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
new	new	n000	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
influenced	influence	i51405203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
CDDP	CDDP	c310	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
pathophysiologic	pathophysiologic	p030102040202	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
woman	woman	w0505	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
concerns	concern	c0520652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
bone	bone	b050	NN	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
only	only	o540	RB	B-NP	O
the	the	t000	DT	I-NP	O
fourth	fourth	f0630	JJ	I-NP	O
documented	document	d020505303	VBN	I-NP	O
and	and	a530	CC	I-NP	O
published	publish	p0140203	VBN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Carbamazepine	Carbamazepine	c061050201050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
physicians	physician	p0202052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
exceedingly	exceedingly	e20305240	RB	I-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
potentially	potentially	p03053040	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
better	well	b0306	RBR	B-ADJP	O
prevented	prevent	p60105303	VBN	I-ADJP	O
by	by	b000	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
by	by	b000	IN	B-PP	O
laboratory	laboratory	l010603060	NN	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
.	.	.000	.	O	O

Participation	Participation	p06302010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
bulbospinal	bulbospinal	b0410210504	JJ	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
brain	brain	b605	NN	I-NP	O
in	in	i500	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
microliter	microliter	m026040306	NN	I-NP	O
)	)	)000	)	O	O
into	into	i530	IN	B-PP	O
a	a	a000	DT	B-NP	O
region	region	r0205	NN	I-NP	O
adjacent	adjacent	a3202053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
surface	surface	s061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
oblongata	oblongata	o14052030	NN	I-NP	O
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
urethane	urethane	u603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Intramedullary	Intramedullary	i536050304060	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
saline	saline	s04050	NN	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
transection	transection	t605202305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
bilateral	bilateral	b04030604	JJ	B-NP	O
vagotomy	vagotomy	v0203050	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
vagotomy	vagotomy	v0203050	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
spinal	spinal	s10504	JJ	B-NP	O
transection	transection	t605202305	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
selective	selective	s04023010	JJ	B-NP	O
destruction	destruction	d023602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
nerves	nerve	n06102	NNS	I-NP	O
,	,	,000	,	O	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dihydroxytryptamine	dihydroxytryptamine	d0360203601305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasodepressor	vasodepressor	v02030160206	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
bradycardiac	bradycardiac	b6030206302	JJ	I-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
microinjected	microinjecte	m02605202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
near	near	n060	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
surface	surface	s061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
oblongata	oblongata	o14052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
bulbospinal	bulbospinal	b0410210504	JJ	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
brought	bring	b60203	VBN	I-VP	O
about	about	a103	RP	B-PRT	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
efferent	efferent	e106053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
vagal	vagal	v0204	JJ	B-NP	O
efferent	efferent	e106053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
imipramine	imipramine	i501605050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
finding	finding	f053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
Imipramine	Imipramine	i501605050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
190	190	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
160	160	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
girl	girl	g064	NN	I-NP	O
with	with	w030	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
Imipramine	Imipramine	i501605050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
a	a	a000	DT	B-NP	O
behavior	behavior	b0106	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
later	later	l0306	RB	B-ADVP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
recurring	recur	r0206052	VBG	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
episode	episode	e102030	NN	I-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
at	at	a300	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
and	and	a530	CC	O	O
none	none	n050	NN	B-NP	O
following	follow	f04052	VBG	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Imipramine	Imipramine	i501605050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
when	when	w050	WRB	B-ADVP	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
florid	florid	f40603	JJ	B-NP	O
relapse	relapse	r040120	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
her	her	h060	PRP$	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
disease	disease	d02020	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
caused	cause	c0203	VBD	B-VP	O
her	her	h060	PRP$	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
believed	believe	b040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vasoactive	vasoactive	v02023010	JJ	B-NP	O
catecholamines	catecholamine	c030204050502	NNS	I-NP	B-Chemical
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
interference	interference	i53061060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
physiologic	physiologic	p02040202	JJ	I-NP	O
inactivation	inactivation	i5023010305	NN	I-NP	O
by	by	b000	IN	B-PP	O
Imipramine	Imipramine	i501605050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
experience	experience	e21060520	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
urge	urge	u620	VBP	B-VP	O
extreme	extreme	e236050	JJ	B-NP	O
caution	caution	c0305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
neuroblastoma	neuroblastoma	n06014023050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Rechallenge	Rechallenge	r02040520	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
oral	oral	o604	JJ	B-NP	B-Disease
candidiasis	candidiasis	c053030202	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
hoarseness	hoarseness	h0620502	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
beclomethasone	beclomethasone	b024050302050	NN	B-NP	B-Chemical
dipropionate	dipropionate	d0160105030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
158	158	0000	CD	B-NP	O
asthmatic	asthmatic	a23050302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
placed	place	p40203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
inhaled	inhale	i50403	VBN	B-NP	O
beclomethasone	beclomethasone	b024050302050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
either	either	e0306	CC	O	O
hoarseness	hoarseness	h0620502	NN	B-NP	B-Disease
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	O
thrush	thrush	t06020	NN	I-NP	B-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
their	their	t060	PRP$	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
subsided	subside	s0120303	VBD	B-VP	O
,	,	,000	,	O	O
seven	seven	s0105	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
15	15	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
rechallenged	rechallenge	r020405203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
inhaled	inhale	i50403	VBN	B-NP	O
beclomethasone	beclomethasone	b024050302050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
included	include	i5240303	VBD	B-VP	O
five	five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hoarseness	hoarseness	h0620502	NN	B-NP	B-Disease
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
Candidiasis	Candidiasis	c053030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
both	both	b030	DT	B-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
thrush	thrush	t06020	NN	I-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
recur	recur	r0206	VB	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hoarseness	hoarseness	h0620502	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
recurrence	recurrence	r02060520	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
restarted	restart	r02306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
inhaled	inhale	i50403	VBN	B-NP	O
beclomethasone	beclomethasone	b024050302050	NN	I-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
clinically	clinically	c40502040	RB	B-ADVP	O
indicated	indicate	i53020303	VBN	B-VP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
develop	develop	d010401	VBP	B-VP	O
hoarseness	hoarseness	h0620502	NN	B-NP	B-Disease
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
re	re	r000	AFX	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
challenged	challenge	c0405203	VBN	B-VP	O
.	.	.000	.	O	O

Concomitant	Concomitant	c0520503053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
prednisone	prednisone	p603502050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
topical	topical	t010204	JJ	B-NP	O
beclomethasone	beclomethasone	b024050302050	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
hoarseness	hoarseness	h0620502	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
candidiasis	candidiasis	c053030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
dosing	dosing	d02052	NN	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
undergo	undergo	u530620	VBP	B-VP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
generally	generally	g0506040	RB	I-VP	O
immunosuppressed	immunosuppresse	i505020160203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CYA	CYA	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	I-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
weight	weight	w0203	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
these	these	t020	DT	B-NP	O
high	high	h020	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
serious	serious	s0602	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
definitive	definitive	d010503010	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	B-NP	O
agent	agent	a2053	NN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
generally	generally	g0506040	RB	B-ADVP	O
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
per	per	p060	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
calculated	calculate	c042040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
transplanted	transplant	t60521405303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
institution	institution	i523030305	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
per	per	p060	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
as	as	a200	IN	B-PP	O
preparation	preparation	p601060305	NN	B-NP	O
for	for	f060	IN	B-PP	O
marrow	marrow	m060	NN	B-NP	O
grafting	grafting	g6013052	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
84	84	0000	CD	B-NP	O
transplants	transplant	t6052140532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
Wiskott	Wiskott	w0203	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	a436020	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
severe	severe	s01060	JJ	B-NP	B-Disease
combined	combined	c0510503	JJ	I-NP	I-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Fourteen	Fourteen	f06305	CD	B-NP	O
of	of	o100	IN	B-PP	O
84	84	0000	CD	B-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
signs	sign	s0252	NNS	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
within	within	w0305	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
14	14	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
with	with	w030	IN	B-PP	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
per	per	p060	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
CYA	CYA	c000	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
:	:	:000	:	O	O
Group	Group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
CYA	CYA	c000	NN	B-NP	B-Chemical
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
;	;	;000	:	O	O
Group	Group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
CYA	CYA	c000	NN	B-NP	B-Chemical
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Cardiotoxicity	Cardiotoxicity	c063030202030	NN	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
32	32	0000	CD	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
/	/	/000	SYM	O	O
52	52	0000	CD	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
025	025	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Congestive	Congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
caused	cause	c0203	VBD	B-VP	O
or	or	o600	CC	I-VP	O
contributed	contribute	c0536010303	VBD	I-VP	O
to	to	t000	TO	B-PP	O
death	death	d030	NN	B-NP	O
in	in	i500	IN	B-PP	O
0	0	0000	CD	B-NP	O
/	/	/000	SYM	O	O
32	32	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
v	v	v000	NN	I-NP	O
6	6	6000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
52	52	0000	CD	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
engraftment	engraftment	e5260135053	NN	B-NP	O
of	of	o100	IN	B-PP	O
evaluable	evaluable	e1040140	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
CYA	CYA	c000	NN	I-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
CYA	CYA	c000	NN	B-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
calculated	calculate	c042040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
immunodeficiencies	immunodeficiency	i50503010205202	NNS	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
effectively	effectively	e102301040	RB	I-VP	O
prepared	prepare	p6010603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
grafting	graft	g6013052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
CYA	CYA	c000	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
whose	whose	w020	WP$	B-NP	O
CYA	CYA	c000	NN	I-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
reaffirms	reaffirm	r010652	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
principle	principle	p60520140	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
per	per	p060	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
epidemiology	epidemiology	e1030504020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
fully	fully	f040	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
aminoglycosides	aminoglycoside	a50502402020302	NNS	B-NP	B-Chemical
cause	cause	c020	VBP	B-VP	O
proximal	proximal	p6020504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
rarely	rarely	r06040	RB	B-ADVP	O
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
ever	ever	e106	RB	B-ADVP	O
,	,	,000	,	O	O
cause	cause	c020	VBP	B-VP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycosides	aminoglycoside	a50502402020302	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
seriously	seriously	s060240	RB	B-NP	O
ill	ill	i400	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
ranges	range	r05202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
8	8	8000	CD	B-NP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
attributable	attributable	a3601030140	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
80	80	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
advanced	advanced	a3105203	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
initial	initial	i50304	JJ	I-NP	O
estimated	estimate	e23050303	VBN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
,	,	,000	,	O	O
female	female	f05040	JJ	B-NP	O
gender	gender	g05306	NN	I-NP	O
all	all	a400	DT	O	O
increase	increase	i526020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
shock	shock	s020	NN	B-NP	B-Disease
,	,	,000	,	O	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
an	an	a500	DT	B-NP	O
additive	additive	a303010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Predictive	Predictive	p603023010	JJ	B-NP	O
models	model	m03042	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
from	from	f605	IN	B-PP	O
these	these	t020	DT	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
models	model	m03042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
insights	insight	i5202032	NNS	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
narcotic	narcotic	n0620302	JJ	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
.	.	.000	.	O	O

Part	Part	p063	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
.	.	.000	.	O	O

Noradrenergic	Noradrenergic	n060360506202	JJ	B-NP	O
influences	influence	i51405202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
analgesics	analgesic	a50420202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
naphazoline	naphazoline	n010204050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
xylometazoline	xylometazoline	x0405030204050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
analgesia	analgesia	a5042020	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
codeine	codeine	c03050	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
pentazocine	pentazocine	p0530202050	NN	I-NP	B-Chemical
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
on	on	o500	IN	B-PP	O
cataleptic	cataleptic	c030401302	JJ	B-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
codine	codine	c03050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
assays	assay	a202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
turnover	turnover	t0650106	NN	I-NP	O
of	of	o100	IN	B-PP	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NA	NA	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
three	three	t060	CD	B-NP	O
drugs	drug	d602	NNS	I-NP	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
central	central	c053604	JJ	B-NP	O
NA	NA	n000	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
ED50	ED50	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
they	they	t000	PRP	B-NP	O
enhanced	enhance	e505203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Codeine	Codeine	c03050	NN	B-NP	B-Chemical
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
naphazoline	naphazoline	n010204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
xylometazoline	xylometazoline	x0405030204050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NA	NA	n000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
codeine	codeine	c03050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
45	45	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
slightly	slightly	s4020340	RB	B-ADVP	O
enhanced	enhance	e505203	VBD	B-VP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

Pentazocine	Pentazocine	p0530202050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
NA	NA	n000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NA	NA	n000	NN	B-NP	B-Chemical
turnover	turnover	t0650106	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
altered	alter	a430603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
analgesics	analgesic	a50420202	NNS	B-NP	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
NA	NA	n000	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
diminished	diminish	d05050203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
light	light	l0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
uniform	uniform	u501065	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
NA	NA	n000	NN	I-NP	B-Chemical
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
less	less	l020	RBR	I-NP	O
important	important	i51063053	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
monoamines	monoamine	m05050502	NNS	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
potent	potent	p03053	JJ	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
.	.	.000	.	O	O

Flurothyl	Flurothyl	f4060304	NN	B-NP	B-Chemical
seizure	seizure	s02060	NN	I-NP	B-Disease
thresholds	threshold	t06020432	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
neonatally	neonatally	n0503040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
monosodium	monosodium	m05020305	NN	B-NP	B-Chemical
glutamate	glutamate	g40305030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MSG	MSG	m200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
:	:	:000	:	O	O
evaluation	evaluation	e1040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
flurothyl	flurothyl	f4060304	NN	B-NP	B-Chemical
seizure	seizure	s02060	NN	I-NP	B-Disease
testing	testing	t023052	NN	I-NP	O
.	.	.000	.	O	O

Monosodium	Monosodium	m05020305	NN	B-NP	B-Chemical
glutamate	glutamate	g40305030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MSG	MSG	m200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
to	to	t000	TO	B-PP	O
neonatal	neonatal	n050304	JJ	B-NP	O
rodents	rodent	r030532	NNS	I-NP	O
produces	produce	p6030202	VBZ	B-VP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
numerous	numerous	n050602	JJ	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
neonatal	neonatal	n050304	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
MSG	MSG	m200	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
previous	previous	p60102	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
inconclusive	inconclusive	i52052402010	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
flurothyl	flurothyl	f4060304	NN	I-NP	B-Chemical
ether	ether	e306	NN	I-NP	B-Chemical
seizure	seizure	s02060	NN	I-NP	B-Disease
screening	screening	s2605052	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
neonatal	neonatal	n050304	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MSG	MSG	m200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
g	g	g000	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MSG	MSG	m200	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whole	whole	w040	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
challenge	challenge	c040520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
altering	alter	a4306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
thresholds	threshold	t06020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
MSG	MSG	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Flurothyl	Flurothyl	f4060304	NN	B-NP	B-Chemical
ether	ether	e306	NN	I-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
hypothermia	hypothermia	h01030650	NN	B-NP	B-Disease
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
flurothyl	flurothyl	f4060304	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypothermia	hypothermia	h01030650	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
induction	induction	i5302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

Flurothyl	Flurothyl	f4060304	NN	B-NP	B-Chemical
seizure	seizure	s02060	NN	I-NP	B-Disease
testing	testing	t023052	NN	I-NP	O
proved	prove	p60103	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
and	and	a530	CC	I-NP	O
reliable	reliable	r040140	JJ	I-NP	O
technique	technique	t0205020	NN	I-NP	O
with	with	w030	IN	B-PP	O
which	which	w020	WDT	B-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
.	.	.000	.	O	O

Susceptibility	Susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
vinyl	vinyl	v0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
GABA	GABA	g010	NN	I-NP	I-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
.	.	.000	.	O	O

Pilocarpine	Pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
given	give	g0105	VBN	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
reproduces	reproduce	r016030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
neuropathological	neuropathological	n06010304020204	JJ	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
of	of	o100	IN	B-PP	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
and	and	a530	CC	O	O
provides	provide	p6010302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
studying	study	s303052	VBG	B-VP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
buildup	buildup	b04301	NN	B-NP	O
of	of	o100	IN	B-PP	O
convulsive	convulsive	c051042010	JJ	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
pathways	pathway	p0302	NNS	B-NP	O
operative	operative	o10603010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
generalization	generalization	g050604020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
propagation	propagation	p601020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
forebrain	forebrain	f0601605	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
manipulating	manipulate	m05010403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
on	on	o500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
microinjections	microinjection	m026052023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
,	,	,000	,	O	O
150	150	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
synthesizing	synthesize	s0530202052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glutamic	glutamic	g4030502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
decarboxylase	decarboxylase	d020610204020	NN	I-NP	O
,	,	,000	,	O	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
pars	par	p062	NNS	I-NP	O
reticulata	reticulata	r030204030	NN	I-NP	O
(	(	(000	(	O	O
SNR	SNR	s560	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
,	,	,000	,	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
convulsant	convulsant	c051042053	NN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
limbic	limbic	l05102	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Electroencephalographic	Electroencephalographic	e4023605201040260102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
profound	profound	p601053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Morphological	Morphological	m06104020204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
frontal	frontal	f605304	JJ	B-NP	O
forebrain	forebrain	f0601605	NN	I-NP	O
sections	section	s023052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
light	light	l0203	JJ	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
,	,	,000	,	O	O
thalamus	thalamus	t040502	NN	B-NP	O
,	,	,000	,	O	O
amygdala	amygdala	a5023040	NN	B-NP	O
,	,	,000	,	O	O
olfactory	olfactory	o41023060	JJ	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
substantia	substantia	s01230530	NN	B-NP	O
nigra	nigra	n0260	NN	I-NP	O
and	and	a530	CC	I-NP	O
neocortex	neocortex	n0206302	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
typically	typically	t0102040	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
exceeding	exceed	e203052	VBG	B-VP	O
350	350	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
intrastriatal	intrastriatal	i53602360304	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
augment	augment	a025053	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Application	Application	a14020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
,	,	,000	,	O	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
vinyl	vinyl	v0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
GABA	GABA	g010	NN	B-NP	I-Chemical
(	(	(000	(	O	O
D	D	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
L	L	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
amino	amino	a5050	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hex	hex	h020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
enoic	enoic	e502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
,	,	,000	,	O	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
SNR	SNR	s560	NN	I-NP	O
,	,	,000	,	O	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
,	,	,000	,	O	O
suppressed	suppress	s0160203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
electrographic	electrographic	e402360260102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
380	380	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
protect	protect	p603023	VB	I-VP	O
animals	animal	a505042	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Microinjections	Microinjection	m026052023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
vinyl	vinyl	v0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
GABA	GABA	g010	NN	I-NP	I-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
,	,	,000	,	O	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
,	,	,000	,	O	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
380	380	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
synaptic	synaptic	s0501302	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
.	.	.000	.	O	O

Human	Human	h0505	JJ	B-NP	O
and	and	a530	CC	I-NP	O
canine	canine	c05050	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
vasoactive	vasoactive	v02023010	JJ	I-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
polypeptide	polypeptide	p0401013030	NN	I-NP	O
:	:	:000	:	O	O
decrease	decrease	d026020	NN	B-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Vasoactive	Vasoactive	v02023010	JJ	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
polypeptide	polypeptide	p0401013030	NN	I-NP	O
(	(	(000	(	O	O
VIP	VIP	v010	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
vasodilator	vasodilator	v0203040306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
positive	positive	p0203010	JJ	B-NP	O
inotropic	inotropic	i50360102	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VIP	VIP	v010	NN	B-NP	O
were	be	w060	VBD	B-VP	O
assayed	assay	a203	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
canine	canine	c05050	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
,	,	,000	,	I-NP	O
cobalt	cobalt	c01043	NN	I-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
;	;	;000	:	O	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
radioimmunoassay	radioimmunoassay	r030505020	NN	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
35	35	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
11	11	0000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	O	O
mg	mg	m200	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SD	SD	s300	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	O	O
mg	mg	m200	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
VIP	VIP	v010	NN	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
31	31	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
11	11	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	O	O
mg	mg	m200	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
VIP	VIP	v010	NN	B-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
of	of	o100	IN	B-PP	O
resected	resecte	r0202303	VBN	B-NP	O
failing	fail	f04052	VBG	I-NP	O
hearts	heart	h0632	NNS	I-NP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
papillary	papillary	p0104060	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
five	five	f010	CD	B-NP	O
with	with	w030	IN	B-PP	O
rheumatic	rheumatic	r050302	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
nine	nine	n050	CD	B-NP	O
with	with	w030	IN	B-PP	O
myxomatous	myxomatous	m02050302	JJ	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
)	)	)000	)	O	O
receiving	receive	r0201052	VBG	B-VP	O
mitral	mitral	m03604	JJ	B-NP	O
valve	valve	v0410	NN	I-NP	O
prostheses	prosthesis	p60230202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lowest	low	l023	JJS	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
VIP	VIP	v010	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
receiving	receive	r0201052	VBG	I-NP	O
mitral	mitral	m03604	JJ	I-NP	O
prostheses	prosthesis	p60230202	NNS	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mg	mg	m200	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
VIP	VIP	v010	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	O	O
mg	mg	m200	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
average	average	a106020	JJ	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
62	62	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
VIP	VIP	v010	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-ADVP	O
-	-	-000	SYM	B-NP	O
7	7	7000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mg	mg	m200	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
hearts	heart	h0632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
catecholamines	catecholamine	c030204050502	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
weak	weak	w020	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
57	57	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
tissue	tissue	t020	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VIP	VIP	v010	NN	B-NP	O
and	and	a530	CC	I-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Non	Non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
mapping	mapping	m01052	NN	I-NP	O
after	after	a1306	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Electrocardiographic	Electrocardiographic	e40236020630260102	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
568	568	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
41	41	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
after	after	a1306	IN	B-PP	O
submaximal	submaximal	s015020504	JJ	B-NP	O
treadmill	treadmill	t603504	NN	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
by	by	b000	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
body	body	b030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
mapping	mapping	m01052	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
;	;	;000	:	O	O
19	19	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
anterior	anterior	a530606	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
ANT	ANT	a530	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
MI	MI	m000	NN	I-NP	I-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
eight	eight	e0203	CD	B-NP	O
with	with	w030	IN	B-PP	O
inferior	inferior	i510606	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
INF	INF	i510	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
MI	MI	m000	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
unipolar	unipolar	u5010406	JJ	I-NP	O
electrocardiograms	electrocardiogram	e4023602063026052	NNS	I-NP	O
(	(	(000	(	O	O
ECGs	ECG	e200	NNS	B-NP	O
)	)	)000	)	O	O
distributed	distribute	d0236010303	VBN	B-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
thoracic	thoracic	t060202	JJ	I-NP	O
surface	surface	s061020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
simultaneously	simultaneously	s05043050240	RB	I-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
segment	segment	s025053	NN	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
mV	mV	m100	NN	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
84	84	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ANT	ANT	a530	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
MI	MI	m000	NN	I-NP	I-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
63	63	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
INF	INF	i510	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
MI	MI	m000	NN	I-NP	I-Disease
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Exercise	Exercise	e2062020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ST	ST	s300	NN	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
84	84	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ANT	ANT	a530	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
MI	MI	m000	NN	I-NP	I-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
INF	INF	i510	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
MI	MI	m000	NN	I-NP	I-Disease
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
obvious	obvious	o102	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
body	body	b030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ST	ST	s300	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
pressure	pressure	p602060	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
product	product	p603023	NN	I-NP	O
after	after	a1306	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
treadmill	treadmill	t603504	NN	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
inhomogenous	inhomogenous	i505020502	JJ	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
ECG	ECG	e200	NN	I-NP	O
test	test	t023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
as	as	a200	RB	B-ADJP	O
useful	useful	u20104	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
ECG	ECG	e200	NN	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NNP	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MP	MP	m100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
or	or	o600	CC	I-NP	O
3	3	3000	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
pulse	pulse	p0420	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
,	,	,000	,	O	O
most	most	m023	RBS	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
complaints	complaint	c05140532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
substernal	substernal	s012306504	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Reversal	Reversal	r0106204	NN	B-NP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O

Electrocardiographic	Electrocardiographic	e40236020630260102	JJ	B-NP	O
registrations	registration	r02023603052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
sinus	sinus	s0502	NN	B-NP	B-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
electrolytes	electrolyte	e40236040302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
MP	MP	m100	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
MP	MP	m100	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
contraindicated	contraindicate	c0536053020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
known	know	k505	VBN	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
downbeat	downbeat	d05103	JJ	B-NP	B-Disease
nystagmus	nystagmus	n02302502	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
oscillopsia	oscillopsia	o2040120	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Downbeat	Downbeat	d05103	NN	B-NP	B-Disease
nystagmus	nystagmus	n02302502	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
craniocervical	craniocervical	c605020610204	JJ	I-NP	O
junction	junction	j052305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
occasionally	occasionally	o20205040	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metabolic	metabolic	m03010402	JJ	B-NP	O
imbalance	imbalance	i51040520	NN	I-NP	O
or	or	o600	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recorded	record	r0206303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
eye	eye	e000	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
reversible	reversible	r010620140	JJ	B-NP	O
downbeat	downbeat	d05103	JJ	I-NP	B-Disease
nystagmus	nystagmus	n02302502	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nystagmus	nystagmus	n02302502	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
resolved	resolve	r0204103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Neuroradiologic	Neuroradiologic	n060603040202	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
scans	scan	s2052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
intracranial	intracranial	i5360260504	JJ	B-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
downbeat	downbeat	d05103	JJ	B-NP	B-Disease
nystagmus	nystagmus	n02302502	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
taking	take	t02052	VBG	I-VP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
,	,	,000	,	O	O
consideration	consideration	c05203060305	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
before	before	b01060	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
by	by	b000	IN	B-PP	O
denopamine	denopamine	d050105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TA	TA	t000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
064	064	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
lung	lung	l052	NN	I-NP	O
preparation	preparation	p601060305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
denopamine	denopamine	d050105050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
orally	orally	o6040	RB	I-NP	O
active	active	a23010	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
dog	dog	d020	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
lung	lung	l052	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
depressed	depress	d0160203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
118	118	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
28	28	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	NN	B-NP	O
value	value	v040	NN	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SD	SD	s300	NN	B-NP	O
)	)	)000	)	O	O
such	such	s020	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
and	and	a530	CC	O	O
maximum	maximum	m020505	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
rise	rise	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
LV	LV	l100	NN	B-NP	O
dP	dP	d100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dt	dt	d300	NN	I-NP	O
max	max	m020	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
about	about	a103	RB	B-NP	O
35	35	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
respective	respective	r021023010	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
denopamine	denopamine	d050105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
300	300	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
100	100	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
denopamine	denopamine	d050105050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
almost	almost	a45023	RB	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
attained	attain	a30503	VBN	I-VP	O
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
slight	slight	s40203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
these	these	t020	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
denopamine	denopamine	d050105050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
warrant	warrant	w06053	VBP	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
denopamine	denopamine	d050105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Clonazepam	Clonazepam	c405020105	NN	B-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
range	range	r0520	NN	I-NP	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
infantile	infantile	i51053040	JJ	B-NP	B-Disease
spasms	spasm	s10252	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Disappearance	Disappearance	d0201060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
EEG	EEG	e020	NN	I-NP	O
with	with	w030	IN	B-PP	O
disappearance	disappearance	d0201060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
77	77	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
71	71	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
89	89	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
EEG	EEG	e020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noticed	notice	n030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
76	76	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
diffuse	diffuse	d01020	JJ	B-NP	O
paroxysms	paroxysm	p06020252	NNS	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	O
paroxysms	paroxysm	p06020252	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
excellent	excellent	e204053	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
dosages	dosage	d020202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
086	086	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
021	021	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
in	in	i500	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
057	057	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
022	022	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
in	in	i500	IN	B-PP	O
schoolchildren	schoolchildren	s2042043605	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
drowsiness	drowsiness	d6020502	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
ataxia	ataxia	a3020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
only	only	o540	RB	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Postmarketing	Postmarkete	p023506203052	VBG	B-VP	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	I-NP	B-Chemical
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
postmarketing	postmarkete	p023506203052	VBG	I-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
ratio	ratio	r030	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
maleate	maleate	m04030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
to	to	t000	TO	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
9	9	9000	CD	B-NP	O
,	,	,000	,	O	O
037	037	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
455	455	0000	CD	I-NP	O
participating	participate	p063020103052	VBG	I-NP	O
physicians	physician	p0202052	NNS	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
25	25	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
and	and	a530	CC	O	O
mean	mean	m050	JJ	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
declined	decline	d0240503	VBD	B-VP	O
15	15	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
of	of	o100	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
,	,	,000	,	O	O
race	race	r020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sex	sex	s020	NN	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
no	no	n000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
more	more	m060	RBR	B-NP	O
severe	severe	s01060	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
453	453	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
658	658	0000	CD	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
being	be	b052	VBG	I-NP	O
fatigue	fatigue	f03020	NN	I-NP	B-Disease
,	,	,000	,	O	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
weakness	weakness	w02502	NN	B-NP	B-Disease
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
in	in	i500	IN	B-PP	O
590	590	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Salicylate	Salicylate	s040204030	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Gunn	Gunn	g050	NNP	I-NP	O
rat	rat	r030	NN	I-NP	O
:	:	:000	:	O	O
potential	potential	p0305304	JJ	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandins	prostaglandin	p6023024053052	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandins	prostaglandin	p6023024053052	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
analgesic	analgesic	a50420202	JJ	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Gunn	Gunn	g050	NNP	I-NP	O
strain	strain	s3605	NN	I-NP	O
of	of	o100	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
homozygous	homozygous	h05020202	JJ	I-NP	O
Gunn	Gunn	g050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
unconjugated	unconjugate	u52052020303	VBN	I-VP	O
hyperbilirubinemia	hyperbilirubinemia	h0106104060105050	NN	B-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucuronyl	glucuronyl	g402060504	NN	B-NP	B-Chemical
transferase	transferase	t6052106020	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
marked	marked	m06203	JJ	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
deposition	deposition	d01020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
and	and	a530	CC	I-NP	O
papilla	papilla	p01040	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	B-ADVP	O
highly	highly	h02040	RB	B-ADJP	O
susceptible	susceptible	s020130140	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
papillary	papillary	p0104060	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
analgesic	analgesic	a50420202	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
homozygous	homozygous	h05020202	JJ	B-ADJP	O
(	(	(000	(	O	O
jj	jj	j200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
phenotypically	phenotypically	p05030102040	RB	B-NP	O
normal	normal	n06504	JJ	I-NP	O
heterozygous	heterozygous	h0306020202	JJ	I-NP	O
(	(	(000	(	O	O
jJ	jJ	j200	NN	B-NP	O
)	)	)000	)	O	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
:	:	:000	:	O	O
jj	jj	j200	NN	B-NP	O
and	and	a530	CC	I-NP	O
jJ	jJ	j200	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
either	either	e0306	CC	B-PP	O
with	with	w030	IN	I-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
every	every	e1060	DT	B-NP	O
other	other	o306	JJ	I-NP	O
day	day	d000	NN	I-NP	O
or	or	o600	CC	I-NP	O
sham	sham	s050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
slices	slice	s40202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cortex	cortex	c06302	NN	B-NP	O
,	,	,000	,	O	O
outer	outer	o0306	JJ	B-NP	O
and	and	a530	CC	I-NP	O
inner	inner	i506	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
from	from	f605	IN	B-PP	O
one	one	o500	CD	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
were	be	w060	VBD	B-VP	O
incubated	incubate	i52010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
buffer	buffer	b0106	NN	B-NP	O
and	and	a530	CC	I-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
radioimmunoassay	radioimmunoassay	r030505020	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
histologically	histologically	h023040202040	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
corticomedullary	corticomedullary	c06302050304060	JJ	I-NP	O
gradient	gradient	g603053	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

PGE2	PGE2	0000	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
outer	outer	o0306	JJ	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
cortex	cortex	c06302	NN	B-NP	O
or	or	o600	CC	O	O
inner	inner	i506	JJ	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
jj	jj	j200	NN	B-NP	O
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
mg	mg	m200	NN	I-NP	O
prot	prot	p603	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
jJ	jJ	j200	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
PGE2	PGE2	0000	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
regions	region	r02052	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
outer	outer	o0306	JJ	B-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
remained	remain	r050503	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
jj	jj	j200	NN	B-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
jJ	jJ	j200	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

PGF2	PGF2	0000	NN	B-NP	B-Chemical
alpha	alpha	a410	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
outer	outer	o0306	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
of	of	o100	IN	B-PP	O
jj	jj	j200	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	I-PP	O
without	without	w0303	IN	I-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
were	be	w060	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
jj	jj	j200	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
jJ	jJ	j200	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
:	:	:000	:	O	O
increased	increase	i5260203	VBN	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hematuria	hematuria	h0503060	NN	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
increased	increase	i5260203	VBN	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
increase	increase	i526020	VB	B-VP	O
in	in	i500	IN	B-PP	O
outer	outer	o0306	JJ	B-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
histopathologic	histopathologic	h0230103040202	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
sham	sham	s050	NN	B-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
jj	jj	j200	NN	I-NP	O
or	or	o600	CC	I-NP	O
aspirin	aspirin	a210605	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
jJ	jJ	j200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
enhanced	enhance	e505203	VBN	B-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
maintenance	maintenance	m053050520	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
morphological	morphological	m06104020204	JJ	B-NP	O
integrity	integrity	i53026030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
pathological	pathological	p0304020204	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
medullary	medullary	m0304060	JJ	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
deterioration	deterioration	d0306060305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Prophylactic	Prophylactic	p6010402302	JJ	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
seen	see	s050	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
entered	enter	e530603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
vs	vs	v200	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
hour	hour	h060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
or	or	o600	CC	O	O
sustained	sustained	s0230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
204	204	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Lidocaine	Lidocaine	l0302050	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
intramuscularly	intramuscularly	i5360502040640	RB	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
warning	warn	w065052	VBG	B-VP	O
arrhythmias	arrhythmia	a6030502	NNS	B-NP	B-Disease
between	between	b0305	IN	B-PP	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
45	45	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
10	10	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-PP	O
blocking	block	b402052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
not	not	n030	RB	O	O
on	on	o500	IN	B-PP	O
beta	beta	b030	NN	B-NP	O
blocking	block	b402052	VBG	I-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
study	study	s3030	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
nine	nine	n050	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
from	from	f605	IN	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
had	have	h030	VBN	I-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
advocate	advocate	a3102030	VB	I-VP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
prophylactically	prophylactically	p6010402302040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Experiments	Experiment	e2106050532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
tested	test	t02303	VBN	B-VP	O
previous	previous	p60102	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
systems	system	s023052	NNS	I-NP	O
promotes	promote	p6050302	VBZ	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
intact	intact	i53023	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
full	full	f040	JJ	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Large	Large	l0620	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cholinomimetic	cholinomimetic	c040505050302	JJ	I-NP	O
,	,	,000	,	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
could	could	c043	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
disrupted	disrupt	d02601303	VBD	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Intracranial	Intracranial	i5360260504	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
hemicholinium	hemicholinium	h0502040505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
neuroleptics	neuroleptic	n060401302	NNS	B-NP	B-Chemical
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
actually	actually	a23040	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intrinsic	intrinsic	i53605202	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
.	.	.000	.	O	O

Alternatively	Alternatively	a430650301040	RB	B-ADVP	O
,	,	,000	,	O	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
could	could	c043	MD	B-VP	O
promote	promote	p605030	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
systems	system	s023052	NNS	I-NP	O
.	.	.000	.	O	O

Cardiovascular	Cardiovascular	c06301020406	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
pentobarbital	pentobarbital	p053010610304	NN	I-NP	I-Chemical
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Barium	Barium	b0605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
supplemented	supplement	s0140505303	VBN	B-VP	O
Long	Long	l052	NNP	B-NP	O
-	-	-000	HYPH	O	O
Evans	Evans	e1052	NNP	B-NP	O
hooded	hood	h0303	VBD	B-VP	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
persistent	persistent	p062023053	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
of	of	o100	IN	B-PP	O
barium	barium	b0605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
mineral	mineral	m050604	NN	I-NP	O
fortified	fortify	f0630103	VBN	B-VP	O
water	water	w0306	NN	B-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
,	,	,000	,	O	O
contractility	contractility	c053602304030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
metabolic	metabolic	m03010402	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
16	16	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
other	other	o306	JJ	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	B-Disease
within	within	w0305	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
distinctive	distinctive	d0230523010	JJ	I-NP	O
aspect	aspect	a21023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
demonstrated	demonstrate	d05052360303	VBN	I-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
pentobarbital	pentobarbital	p053010610304	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
barbiturate	barbiturate	b0610306030	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
virtually	virtually	v063040	RB	B-NP	O
all	all	a400	DT	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
indices	index	i530202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
depressed	depress	d0160203	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
barium	barium	b0605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
relative	relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
control	control	c053604	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
fed	feed	f030	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
xylazine	xylazine	x0402050	NN	I-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
pentobarbital	pentobarbital	p053010610304	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
barium	barium	b0605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
linked	link	l05203	VBN	I-VP	O
specifically	specifically	s1020102040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
representative	representative	r0160205303010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
pathophysiologic	pathophysiologic	p030102040202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
barium	barium	b0605	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
manifest	manifest	m0501023	JJ	B-ADJP	O
,	,	,000	,	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
employed	employ	e51403	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
element	element	e405053	NN	I-NP	O
shortening	shorten	s06305052	VBG	B-VP	O
velocity	velocity	v0402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
fibers	fiber	f01062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
slower	slow	s406	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
barium	barium	b0605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
relative	relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
energy	energy	e50620	NN	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
element	element	e405053	NN	I-NP	O
shortening	shorten	s06305052	VBG	B-VP	O
velocity	velocity	v0402030	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
system	system	s02305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
depressed	depress	d0160203	VBN	I-VP	O
preferentially	preferentially	p60106053040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	O
nodal	nodal	n0304	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearts	heart	h0632	NNS	B-NP	O
from	from	f605	IN	B-PP	O
barium	barium	b0605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
altered	alter	a430603	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
and	and	a530	CC	I-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
pentobarbital	pentobarbital	p053010610304	NN	I-NP	I-Chemical
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
existence	existence	e20230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
heretofore	heretofore	h060301060	RB	I-NP	O
undescribed	undescribed	u530260103	JJ	I-NP	O
cardiomyopathic	cardiomyopathic	c06305010302	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
represent	represent	r01602053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
indication	indication	i53020305	NN	I-NP	O
that	that	t030	IN	B-NP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
long	long	l052	JJ	I-NP	O
barium	barium	b0605	NN	I-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mammalian	mammalian	m050405	JJ	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Propranolol	Propranolol	p6016050404	NN	B-NP	B-Chemical
antagonism	antagonism	a530205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylpropanolamine	phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Phenylpropanolamine	Phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PPA	PPA	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
overdose	overdose	o1063020	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
severe	severe	s01060	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
either	either	e0306	CC	B-PP	O
by	by	b000	IN	B-PP	O
mouth	mouth	m030	NN	B-NP	O
for	for	f060	IN	B-PP	O
48	48	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
or	or	o600	CC	B-PP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
after	after	a1306	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

PPA	PPA	p100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
31	31	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
14	14	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
systolic	systolic	s0230402	JJ	B-ADJP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
diastolic	diastolic	d0230402	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
10	10	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
systolic	systolic	s0230402	JJ	B-ADJP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
diastolic	diastolic	d0230402	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
(	(	(000	(	O	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
PPA	PPA	p100	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
62	62	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
20	20	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
to	to	t000	TO	B-PP	O
80	80	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
22	22	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
70	70	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-ADVP	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
L	L	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
1710	1710	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
200	200	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
2190	2190	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
700	700	0000	CD	B-NP	O
dyne	dyne	d050	NN	I-NP	O
X	X	x000	SYM	B-NP	O
sec	sec	s020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
cm5	cm5	0000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
further	further	f06306	RBR	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
to	to	t000	TO	B-PP	O
2660	2660	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1200	1200	0000	CD	B-NP	O
dyne	dyne	d050	NN	I-NP	O
X	X	x000	SYM	B-NP	O
sec	sec	s020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
cm5	cm5	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
PPA	PPA	p100	NN	B-NP	B-Chemical
increases	increase	i5260202	VBZ	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
antagonizes	antagonize	a5302050202	VBZ	B-VP	O
this	this	t020	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
by	by	b000	IN	B-PP	O
reversing	reverse	r01062052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
.	.	.000	.	O	O

That	That	t030	DT	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
antagonizes	antagonize	a5302050202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
enhances	enhance	e505202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
probably	probably	p6010140	RB	B-ADVP	O
because	because	b02020	IN	B-SBAR	O
PPA	PPA	p100	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
less	less	l020	JJR	B-NP	O
beta	beta	b030	SYM	I-NP	O
2	2	2000	CD	I-NP	O
activity	activity	a2301030	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
does	do	d020	VBZ	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Mesangial	Mesangial	m0205204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
aminonucleoside	aminonucleoside	a5050502402030	NN	B-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
mesangial	mesangial	m0205204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
model	model	m0304	NN	B-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
male	male	m040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
;	;	;000	:	O	O
five	five	f010	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
saline	saline	s04050	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
severely	severely	s0106040	RB	B-ADJP	O
proteinuric	proteinuric	p603050602	JJ	I-ADJP	B-Disease
(	(	(000	(	O	O
190	190	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
colloidal	colloidal	c040304	JJ	B-NP	O
carbon	carbon	c06105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
CC	CC	c200	NN	B-NP	O
)	)	)000	)	O	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomeruli	glomeruli	g40506040	NN	I-NP	O
of	of	o100	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
;	;	;000	:	O	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

Glomeruli	Glomerulus	g40506040	NNS	B-NP	O
of	of	o100	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
contained	contain	c0530503	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
CC	CC	c200	NN	I-NP	O
than	than	t050	IN	B-PP	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
of	of	o100	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Glomeruli	Glomerulus	g40506040	NNS	B-NP	O
with	with	w030	IN	B-PP	O
sclerosis	sclerosis	s24060202	NN	B-NP	B-Disease
contained	contain	c0530503	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
CC	CC	c200	NN	I-NP	O
than	than	t050	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
sclerotic	sclerotic	s24060302	JJ	I-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
.	.	.000	.	O	O

CC	CC	c200	NN	B-NP	O
was	be	w020	VBD	B-VP	O
preferentially	preferentially	p60106053040	RB	I-VP	O
localized	localize	l02040203	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
sclerotic	sclerotic	s24060302	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
affected	affect	a102303	VBN	I-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
mesangial	mesangial	m0205204	JJ	B-NP	O
CC	CC	c200	NN	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
mesangium	mesangium	m0205205	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
during	during	d06052	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
preferential	preferential	p6010605304	JJ	I-NP	O
CC	CC	c200	NN	I-NP	O
localization	localization	l0204020305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
CC	CC	c200	NN	I-NP	O
uptake	uptake	u13020	NN	I-NP	O
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
in	in	i500	IN	B-PP	O
apparent	apparent	a106053	JJ	B-NP	O
vulnerable	vulnerable	v045060140	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
sclerosis	sclerosis	s24060202	NN	B-NP	B-Disease
will	will	w040	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
subsequently	subsequently	s0120205340	RB	B-ADVP	O
.	.	.000	.	O	O

Cluster	Cluster	c402306	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
random	random	r05305	JJ	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lesions	lesion	l02052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
glomeruli	glomeruli	g40506040	NN	I-NP	O
in	in	i500	IN	B-PP	O
concordance	concordance	c0520630520	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
random	random	r05305	JJ	I-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mesangial	mesangial	m0205204	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
with	with	w030	IN	B-PP	O
dysfunction	dysfunction	d021052305	NN	B-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
remnant	remnant	r05053	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
"	"	"000	``	O	O
mesangial	mesangial	m0205204	JJ	B-NP	O
overloading	overloading	o106403052	NN	I-NP	O
.	.	.000	.	O	O
"	"	"000	''	O	O

Relationship	Relationship	r040305201	NN	B-NP	O
between	between	b0305	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
controversy	controversy	c0536010620	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
existed	exist	e202303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
relevance	relevance	r04010520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
bungarotoxin	bungarotoxin	b05206030205	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
mice	mouse	m020	NNS	B-NP	O
derived	derive	d060103	VBN	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
classical	classical	c4020204	JJ	I-NP	O
F2	F2	0000	NN	I-NP	O
and	and	a530	CC	O	O
backcross	backcross	b02602	RB	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
design	design	d02025	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
bungarotoxin	bungarotoxin	b05206030205	NN	I-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
sensitive	sensitive	s05203010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
greater	great	g60306	JJR	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
bungarotoxin	bungarotoxin	b05206030205	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
than	than	t050	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
insensitive	insensitive	i5205203010	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
binding	bind	b053052	VBG	I-NP	O
sites	site	s0302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
sensitive	sensitive	s05203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
equally	equally	e2040	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
dithiothreitol	dithiothreitol	d0303060304	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
trypsin	trypsin	t601205	NN	I-NP	O
or	or	o600	CC	I-NP	O
heat	heat	h030	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
it	it	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
sensitive	sensitive	s05203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
insensitive	insensitive	i5205203010	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
bungarotoxin	bungarotoxin	b05206030205	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
p	p	p000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminophenol	aminophenol	a505010504	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
bis	bis	b020	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
p	p	p000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitrophenyl	nitrophenyl	n036010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
phosphate	phosphate	p021030	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
p	p	p000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminophenol	aminophenol	a505010504	NN	I-NP	I-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
Fischer	Fischer	f0206	NNP	B-NP	O
344	344	0000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Acetaminophen	Acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
APAP	APAP	a101	NN	B-NP	B-Chemical
)	)	)000	)	O	O
produces	produce	p6030202	VBZ	B-VP	O
proximal	proximal	p6020504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Fischer	Fischer	f0206	NNP	B-NP	O
344	344	0000	CD	I-NP	O
(	(	(000	(	O	O
F344	F344	0000	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminophenol	aminophenol	a505010504	NN	B-NP	I-Chemical
(	(	(000	(	O	O
PAP	PAP	p010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
potent	potent	p03053	JJ	I-NP	O
nephrotoxicant	nephrotoxicant	n0106030202053	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
F344	F344	0000	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
PAP	PAP	p010	NN	B-NP	B-Chemical
formation	formation	f0650305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
requisite	requisite	r0202030	JJ	I-NP	O
step	step	s301	NN	I-NP	O
in	in	i500	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
bis	bis	b020	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
p	p	p000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitrophenyl	nitrophenyl	n036010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
phosphate	phosphate	p021030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
BNPP	BNPP	b510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
acylamidase	acylamidase	a2040503020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
PAP	PAP	p010	NN	I-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

BNPP	BNPP	b510	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
mM	mM	m500	NN	I-NP	O
)	)	)000	)	O	O
reduced	reduce	r030203	VBD	B-VP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
deacetylation	deacetylation	d0203040305	NN	I-NP	O
and	and	a530	CC	O	O
covalent	covalent	c0104053	JJ	B-NP	O
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
F344	F344	0000	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
homogenates	homogenate	h0502050302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
BNPP	BNPP	b510	NN	B-NP	B-Chemical
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
PAP	PAP	p010	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
(	(	(000	(	O	O
900	900	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
PAP	PAP	p010	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
result	result	r02043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
altered	altered	a430603	JJ	B-NP	O
disposition	disposition	d021020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
APAP	APAP	a101	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
acetylated	acetylate	a203040303	VBN	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
or	or	o600	CC	O	O
renal	renal	r0504	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

Rather	Rather	r0306	RB	B-ADVP	O
,	,	,000	,	O	O
BNPP	BNPP	b510	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
excreted	excrete	e260303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
PAP	PAP	p010	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
64	64	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
75	75	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
750	750	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
900	900	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

BNPP	BNPP	b510	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
deacetylated	deacetylate	d0203040303	VBN	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
nor	nor	n060	CC	O	O
did	do	d030	VBD	B-VP	O
BNPP	BNPP	b510	NN	B-NP	B-Chemical
alter	alter	a4306	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PAP	PAP	p010	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
PAP	PAP	p010	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
150	150	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
BNPP	BNPP	b510	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
deacetylation	deacetylation	d0203040305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
PAP	PAP	p010	NN	B-NP	B-Chemical
formation	formation	f0650305	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
accounts	account	a20532	NNS	B-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
APAP	APAP	a101	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Morphine	Morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
newborn	newborn	n01065	JJ	B-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
suffered	suffer	s010603	VBN	B-VP	O
from	from	f605	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
32	32	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
hr	hr	h600	NN	I-NP	O
and	and	a530	CC	I-NP	O
40	40	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-VP	O
hr	hr	h600	NN	B-NP	O
larger	large	l06206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
24	24	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
hr	hr	h600	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
excessive	excessive	e202010	JJ	B-ADJP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
90	90	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
known	known	k505	JJ	I-NP	O
reasons	reason	r02052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
ruled	rule	r0403	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
stopped	stop	s30103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reoccur	reoccur	r0206	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
8	8	8000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
exceed	exceed	e203	VB	I-VP	O
20	20	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
in	in	i500	IN	B-PP	O
neonates	neonate	n050302	NNS	B-NP	O
.	.	.000	.	O	O

Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
volume	volume	v04050	NN	I-NP	O
depleted	deplete	d0140303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
indomethacin	indomethacin	i5305030205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
IDM	IDM	i350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
volume	volume	v04050	NN	I-NP	O
depleted	deplete	d0140303	VBD	B-VP	O
rats	rat	r032	NNS	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
renin	renin	r0505	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
PRA	PRA	p600	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
fell	fall	f040	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
four	four	f060	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
repleted	replete	r0140303	VBN	B-VP	O
animals	animal	a505042	NNS	B-NP	O
indomethacin	indomethacin	i5305030205	NN	I-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
although	although	a43020	IN	B-SBAR	O
plasma	plasma	p40250	NN	B-NP	O
renin	renin	r0505	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
may	may	m000	MD	B-VP	O
diminish	diminish	d0505020	VB	I-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
maintaining	maintain	m05305052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
stimulated	stimulate	s305040303	VBN	I-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
volume	volume	v04050	NN	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
substituted	substitute	s0123030303	VBN	I-NP	O
piperazine	piperazine	p010602050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
of	of	o100	IN	B-PP	O
trans	trans	t6052	AFX	O	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
amino	amino	a5050	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydroanaphthalene	tetrahydroanaphthalene	t03603605010304050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
trans	trans	t6052	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydro	tetrahydro	t0360360	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
naphthyl	naphthyl	n010304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-ADJP	I-Chemical
(	(	(000	(	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
oxo	oxo	o200	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenyl	phenyl	p0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylpropyl	methylpropyl	m0304160104	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
piperazine	piperazine	p010602050	NN	I-NP	I-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
referred	refer	r010603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
as	as	a200	IN	B-PP	O
P11	P11	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
studied	study	s30303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
anaesthesized	anaesthesize	a5023020203	VBN	B-NP	O
cats	cat	c032	NNS	I-NP	O
and	and	a530	CC	O	O
Wistar	Wistar	w02306	NNP	B-NP	O
albino	albino	a41050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
on	on	o500	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
anaesthesized	anaesthesize	a5023020203	VBN	I-NP	O
rabbits	rabbit	r01032	NNS	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
-	-	-000	SYM	B-NP	O
-	-	-000	HYPH	B-ADJP	O
with	with	w030	IN	B-PP	O
BaCl2	BaCl2	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
chloroform	chloroform	c040601065	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
strophantine	strophantine	s3601053050	JJ	B-NP	B-Chemical
G	G	g000	NN	I-NP	I-Chemical
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
P11	P11	0000	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
introduced	introduce	i536030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
orally	orally	o6040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
manifests	manifest	m05010232	VBZ	B-VP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
used	use	u203	VBN	B-VP	O
,	,	,000	,	O	O
causing	cause	c02052	VBG	B-VP	O
greatest	great	g603023	JJS	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chloroform	chloroform	c040601065	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
90	90	0000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
BaCl2	BaCl2	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
84	84	0000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoblocking	adrenoblocke	a360501402052	VBG	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
membrane	membrane	m0516050	NN	I-NP	O
-	-	-000	HYPH	O	O
stabilizing	stabilize	s3010402052	VBG	B-VP	O
action	action	a2305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
aminocaproic	aminocaproic	a5050201602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Epsilon	Epsilon	e120405	NN	B-NP	B-Chemical
aminocaproic	aminocaproic	a5050201602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
EACA	EACA	e020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
rebleeding	rebleede	r01403052	VBG	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
SAH	SAH	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
rebleeding	rebleede	r01403052	VBG	B-VP	O
,	,	,000	,	O	O
several	several	s010604	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
EACA	EACA	e020	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
included	include	i5240303	VBN	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
and	and	a530	CC	O	O
intracranial	intracranial	i5360260504	JJ	B-NP	B-Disease
vascular	vascular	v020406	JJ	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SAH	SAH	s000	NN	B-NP	B-Disease
,	,	,000	,	O	O
arteriolar	arteriolar	a63060406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
fibrin	fibrin	f01605	NN	I-NP	O
thrombi	thrombi	t060510	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
fibrinolytic	fibrinolytic	f01605040302	JJ	B-NP	O
syndromes	syndrome	s05360502	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
EACA	EACA	e020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
thromboembolic	thromboembolic	t060510510402	JJ	I-NP	B-Disease
phenomena	phenomenon	p0505050	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
intravascular	intravascular	i53601020406	JJ	B-NP	O
fibrin	fibrin	f01605	NN	I-NP	O
thrombi	thrombi	t060510	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
fibrinolytic	fibrinolytic	f01605040302	JJ	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
,	,	,000	,	O	O
EACA	EACA	e020	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrin	fibrin	f01605	NN	B-NP	O
thrombi	thrombi	t060510	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
disseminated	disseminate	d0205050303	VBN	B-NP	B-Disease
intravascular	intravascular	i53601020406	JJ	I-NP	I-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
other	other	o306	JJ	I-NP	O
"	"	"000	''	I-NP	O
consumption	consumption	c052051305	NN	I-NP	B-Disease
coagulopathies	coagulopathy	c0204010302	NNS	I-NP	I-Disease
.	.	.000	.	O	O
"	"	"000	''	O	O
This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
subtotal	subtotal	s0130304	JJ	B-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
a	a	a000	DT	B-NP	I-Disease
normal	normal	n06504	JJ	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
occlusion	occlusion	o240205	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
EACA	EACA	e020	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
SAH	SAH	s000	NN	B-NP	B-Disease
and	and	a530	CC	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
documentation	documentation	d02050530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
SAH	SAH	s000	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
abrupt	abrupt	a16013	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
Pseudomonas	Pseudomonas	p203050502	NNP	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
monkeys	monkey	m05202	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rhesus	rhesus	r0202	NN	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
Pseudomonas	Pseudomonas	p203050502	NNP	B-NP	O
aeruginosa	aeruginosa	a060205020	NN	I-NP	O
organisms	organism	o62050252	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
illness	illness	i4502	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
'	'	'000	POS	B-NP	O
duration	duration	d060305	NN	I-NP	O
with	with	w030	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
;	;	;000	:	O	O
blood	blood	b403	NN	B-NP	O
cultures	culture	c0430602	NNS	I-NP	O
became	become	b02050	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
challenge	challenge	c040520	NN	B-NP	O
.	.	.000	.	O	O

Leukocytosis	Leukocytosis	l0202030202	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
or	or	o600	CC	I-NP	O
intratracheal	intratracheal	i5360360204	JJ	I-NP	O
inoculation	inoculation	i502040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
leukopenia	leukopenia	l0201050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
inoculation	inoculation	i502040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
pyocin	pyocin	p0205	NN	B-NP	O
type	type	t010	NN	I-NP	O
6	6	6000	CD	I-NP	O
Pseudomonas	Pseudomonas	p203050502	NN	I-NP	O
organisms	organism	o62050252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
monkeys	monkey	m05202	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
previously	previously	p6010240	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
Pseudomonas	Pseudomonas	p203050502	NNP	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
died	die	d030	VBD	B-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
antimetabolite	antimetabolite	a5305030104030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
leukopenia	leukopenia	l0201050	NN	I-NP	B-Disease
predisposes	predispose	p6030210202	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
Pseudomonas	Pseudomonas	p203050502	NN	I-NP	O
sepsis	sepsis	s01202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
such	such	s020	JJ	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
may	may	m000	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
biological	biological	b04020204	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
comparative	comparative	c0510603010	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
antimicrobial	antimicrobial	a53050260104	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Modification	Modification	m0301020305	NN	B-NP	O
by	by	b000	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypoglycaemia	hypoglycaemia	h0102402050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypoglycaemia	hypoglycaemia	h0102402050	NN	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
blockade	blockade	b402030	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
fourteen	fourteen	f06305	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
men	man	m050	NNS	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
received	receive	r020103	VBD	B-VP	O
insulin	insulin	i520405	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
eight	eight	e0203	CD	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
original	original	o6020504	JJ	I-NP	O
insulin	insulin	i520405	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
only	only	o540	RB	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
insulin	insulin	i520405	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
group	group	g601	NN	I-NP	O
the	the	t000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypoglycaemia	hypoglycaemia	h0102402050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
group	group	g601	NN	I-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Typical	Typical	t010204	JJ	B-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
T	T	t000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
T	T	t000	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
insulin	insulin	i520405	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
group	group	g601	NN	I-NP	O
but	but	b030	CC	B-PP	O
in	in	i500	IN	B-PP	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
insulin	insulin	i520405	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
diabetics	diabetic	d010302	NNS	B-NP	B-Disease
prone	prone	p6050	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
hypoglycaemia	hypoglycaemia	h0102402050	NN	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	O
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
blockers	blocker	b402062	NNS	B-NP	O
because	because	b02020	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
a	a	a000	DT	B-NP	O
sharp	sharp	s061	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
:	:	:000	:	O	O
maternal	maternal	m0306504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
fetal	fetal	f0304	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

Propranolol	Propranolol	p6016050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
found	find	f053	VBN	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
position	position	p020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
practice	practice	p6023020	NN	I-NP	O
of	of	o100	IN	B-PP	O
medicine	medicine	m0302050	NN	B-NP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
question	question	q02305	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
detrimental	detrimental	d0360505304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fetus	fetus	f0302	NN	I-NP	O
and	and	a530	CC	I-NP	O
neonate	neonate	n05030	NN	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
where	where	w060	WRB	B-ADVP	O
chronic	chronic	c060502	JJ	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

Maternal	Maternal	m0306504	JJ	B-NP	O
,	,	,000	,	I-NP	O
fetal	fetal	f0304	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
neonatal	neonatal	n050304	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
made	make	m030	VBN	I-VP	O
to	to	t000	TO	I-VP	O
differentiate	differentiate	d0106053030	VB	I-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	HYPH	I-NP	O
related	relate	r040303	VBN	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
previously	previously	p6010240	RB	B-NP	O
reported	report	r0106303	VBN	I-NP	O
hypoglycemia	hypoglycemia	h0102402050	NN	I-NP	B-Disease
,	,	,000	,	O	O
hyperbilirubinemia	hyperbilirubinemia	h0106104060105050	NN	B-NP	B-Disease
,	,	,000	,	O	O
polycythemia	polycythemia	p040203050	NN	B-NP	B-Disease
,	,	,000	,	O	O
neonatal	neonatal	n050304	JJ	B-NP	B-Disease
apnea	apnea	a150	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
invariable	invariable	i51060140	JJ	B-ADJP	O
and	and	a530	CC	O	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
statistically	statistically	s30302302040	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Growth	Growth	g6030	NN	B-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	O
excitatory	excitatory	e20303060	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
flurazepam	flurazepam	f406020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Toxic	Toxic	t0202	JJ	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
flurazepam	flurazepam	f406020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FZP	FZP	f210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
,	,	,000	,	I-NP	O
mice	mouse	m020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
excitation	excitation	e2030305	NN	I-NP	O
,	,	,000	,	O	O
most	most	m023	RBS	B-VP	O
clearly	clearly	c40640	RB	I-VP	O
seen	see	s050	VBN	I-VP	O
as	as	a200	IN	B-PP	O
clonic	clonic	c40502	JJ	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
superimposed	superimpose	s01060510203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
lethal	lethal	l0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
death	death	d030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
always	always	a402	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Comparing	Compare	c05106052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
central	central	c053604	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
excitation	excitation	e2030305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
least	least	l023	RBS	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	B-NP	O
first	first	f0623	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
loss	loss	l020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
consciousness	consciousness	c05202502	NN	B-NP	I-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
cats	cat	c032	NNS	B-NP	O
most	most	m023	RBS	B-ADVP	O
clearly	clearly	c40640	RB	I-ADVP	O
showed	show	s030	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
excitatory	excitatory	e20303060	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
.	.	.000	.	O	O

Signs	Sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
FZP	FZP	f210	NN	B-NP	B-Chemical
toxocity	toxocity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
excessive	excessive	e202010	JJ	B-NP	O
salivation	salivation	s04010305	NN	I-NP	B-Disease
,	,	,000	,	O	O
extreme	extreme	e236050	JJ	B-NP	O
apprehensive	apprehensive	a16052010	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
retching	retching	r032052	NN	B-NP	O
,	,	,000	,	O	O
muscle	muscle	m0240	NN	B-NP	B-Disease
tremors	tremor	t605062	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
FZP	FZP	f210	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
pentylenetetrazol	pentylenetetrazol	p0530405030360204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pretreating	pretreate	p603603052	VBG	B-VP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
FZP	FZP	f210	NN	B-NP	B-Chemical
before	before	b01060	IN	B-PP	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
,	,	,000	,	O	O
FZP	FZP	f210	NN	B-NP	B-Chemical
first	first	f0623	RB	B-ADVP	O
protected	protect	p60302303	VBD	B-VP	O
against	against	a20523	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
again	again	a205	RB	B-ADVP	O
emerged	emerge	e506203	VBD	B-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
FZP	FZP	f210	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
that	that	t030	WDT	B-NP	O
would	would	w043	MD	B-VP	O
alone	alone	a4050	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
relevant	relevant	r0401053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
FZP	FZP	f210	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
situations	situation	s0303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
neural	neural	n0604	JJ	B-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
or	or	o600	CC	O	O
sedative	sedative	s0303010	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
hypnotic	hypnotic	h0150302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
orthostatic	orthostatic	o630230302	JJ	I-NP	I-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
orthostatic	orthostatic	o630230302	JJ	I-NP	I-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
physiologic	physiologic	p02040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
autonomic	autonomic	a03050502	JJ	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
all	all	a400	DT	O	O
exhibited	exhibit	e2010303	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
catecholamines	catecholamine	c030204050502	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
renin	renin	r0505	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
recumbent	recumbent	r02051053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
upright	upright	u160203	JJ	I-NP	O
positions	position	p0203052	NNS	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
marked	mark	m06203	VBN	I-VP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
infused	infuse	i510203	VBN	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
propanolol	propanolol	p601050404	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
produced	produce	p6030203	VBD	B-VP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
supine	supine	s01050	NN	B-NP	O
and	and	a530	CC	O	O
upright	upright	u160203	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
individuals	individual	i530103042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rises	rise	r0202	NNS	B-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
11	11	0000	CD	B-NP	O
/	/	/000	SYM	B-ADJP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
22	22	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
11	11	0000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
160	160	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
elevated	elevate	e4010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
order	order	o6306	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
35	35	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
mmg	mmg	m520	NN	I-NP	O
being	be	b052	VBG	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
marked	marked	m06203	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
had	have	h030	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
otherwise	otherwise	o306020	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
continued	continue	c0530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
persistence	persistence	p0620230520	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
some	some	s050	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
with	with	w030	IN	B-PP	O
time	time	t050	NN	B-NP	O
.	.	.000	.	O	O

Hemodynamic	Hemodynamic	h0503050502	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	O	O
essentially	essentially	e2053040	RB	B-NP	O
no	no	n000	DT	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	B-Disease
orthostatic	orthostatic	o630230302	JJ	I-NP	I-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

III	III	i000	CD	B-NP	O
.	.	.000	.	O	O

Some	Some	s050	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
required	require	r020603	VBN	B-VP	O
to	to	t000	TO	I-VP	O
maintain	maintain	m05305	VB	I-VP	O
sleep	sleep	s401	NN	B-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
surgery	surgery	s062060	NN	B-NP	O
under	under	u5306	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
local	local	l0204	JJ	I-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Premedication	Premedication	p60503020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sleep	sleep	s401	NN	B-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
and	and	a530	CC	I-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
whenever	whenever	w050106	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
would	would	w043	MD	B-VP	O
open	open	o105	VB	I-VP	O
his	his	h020	PRP$	B-NP	O
eyes	eye	e020	NNS	I-NP	O
on	on	o500	IN	B-PP	O
request	request	r02023	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
overall	overall	o10604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
17	17	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O
was	be	w020	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
maintain	maintain	m05305	VB	I-VP	O
sleep	sleep	s401	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
great	great	g603	JJ	B-NP	O
individual	individual	i53010304	JJ	I-NP	O
variation	variation	v060305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
requiring	require	r0206052	VBG	B-VP	O
less	less	l020	JJR	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
myoclonia	myoclonia	m024050	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
caused	cause	c0203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
technique	technique	t0205020	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
abandoned	abandon	a10530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
will	will	w040	MD	B-VP	O
prove	prove	p6010	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypnotic	hypnotic	h0150302	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
totally	totally	t03040	RB	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
technique	technique	t0205020	NN	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myoclonia	myoclonia	m024050	NN	B-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
prolonged	prolonged	p60405203	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
uncontrollable	uncontrollable	u520536040140	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
many	many	m050	JJ	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
consciousness	consciousness	c05202502	NN	B-NP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptors	adrenoceptor	a360502013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
atenolol	atenolol	a3050404	NN	I-NP	B-Chemical
(	(	(000	(	O	O
cardioselective	cardioselective	c0630204023010	JJ	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
(	(	(000	(	O	O
nonselective	nonselective	n05204023010	JJ	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
on	on	o500	IN	B-PP	O
both	both	b030	CC	O	O
exercise	exercise	e2062020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
nine	nine	n050	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Maximal	Maximal	m020504	JJ	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
187	187	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
(	(	(000	(	O	O
SEM	SEM	s050	NN	B-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
to	to	t000	TO	B-PP	O
146	146	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
bpm	bpm	b150	NN	I-NP	O
after	after	a1306	IN	B-PP	O
atenolol	atenolol	a3050404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
138	138	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
bpm	bpm	b150	NN	I-NP	O
after	after	a1306	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
04	04	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
sensitivity	sensitivity	s0520301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
that	that	t030	WDT	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
by	by	b000	IN	B-PP	O
25	25	0000	CD	B-NP	O
bpm	bpm	b150	NN	I-NP	O
(	(	(000	(	O	O
CD25	CD25	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
to	to	t000	TO	B-PP	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
atenolol	atenolol	a3050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
the	the	t000	DT	B-NP	O
CD25	CD25	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
atenolol	atenolol	a3050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
remained	remain	r050503	VBD	B-VP	O
different	different	d0106053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
atenolol	atenolol	a3050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
change	change	c0520	NN	I-NP	O
with	with	w030	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
sensitivity	sensitivity	s0520301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
Ka	Ka	k000	NNP	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ng	ng	n200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
exercise	exercise	e2062020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
results	result	r020432	NNS	I-NP	O
largely	largely	l062040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	B-NP	O
cardioselective	cardioselective	c0630204023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
nonselective	nonselective	n05204023010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
activates	activate	a23010302	VBZ	B-VP	O
both	both	b030	CC	O	O
beta	beta	b030	SYM	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-ADJP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
so	so	s000	IN	B-SBAR	O
that	that	t030	IN	I-SBAR	O
after	after	a1306	IN	B-PP	O
cardioselective	cardioselective	c0630204023010	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
there	there	t060	EX	B-NP	O
remains	remain	r05052	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
component	component	c05105053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
nonselective	nonselective	n05204023010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
beta	beta	b030	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
physiologic	physiologic	p02040202	JJ	I-NP	O
or	or	o600	CC	I-NP	O
pathologic	pathologic	p03040202	JJ	I-NP	O
roles	role	r0402	NNS	I-NP	O
remain	remain	r0505	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
defined	define	d010503	VBN	I-VP	O
.	.	.000	.	O	O

Hormones	Hormone	h0650502	NNS	B-NP	O
and	and	a530	CC	O	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
reports	report	r010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
menopausal	menopausal	m05010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
hormonal	hormonal	h0650504	JJ	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
(	(	(000	(	O	O
29	29	0000	CD	B-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
surgical	surgical	s0620204	JJ	B-NP	O
menopause	menopause	m0501020	NN	I-NP	O
;	;	;000	:	O	O
their	their	t060	PRP$	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
45	45	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
hypothesized	hypothesize	h0103020203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
progestins	progestin	p602023052	NNS	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
equilibrate	equilibrate	e204016030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
estrogenic	estrogenic	e236020502	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mammary	mammary	m05060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
endometrial	endometrial	e530503604	JJ	I-NP	O
target	target	t06203	NN	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
on	on	o500	IN	B-PP	O
hormonal	hormonal	h0650504	JJ	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
conjugated	conjugate	c052020303	VBN	B-NP	B-Chemical
estrogens	estrogen	e23602052	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
Premarin	Premarin	p6050605	NN	B-NP	B-Chemical
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
21	21	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
Medroxyprogesterone	Medroxyprogesterone	m036020160202306050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
month	month	m0530	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
was	be	w020	VBD	B-VP	O
18	18	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
,	,	,000	,	O	O
attention	attention	a305305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
paid	pay	p030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
breast	breast	b6023	NN	B-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
symptomatology	symptomatology	s0513050304020	NN	B-NP	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
plate	plate	p4030	NN	B-NP	O
thermography	thermography	t065026010	NN	I-NP	O
.	.	.000	.	O	O

Mastodynia	Mastodynia	m02303050	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
light	light	l0203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
breast	breast	b6023	NN	B-NP	O
firmness	firmness	f06502	NN	I-NP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
breast	breast	b6023	NN	B-NP	O
nodularity	nodularity	n030406030	NN	I-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Themography	Themography	t05026010	NN	B-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
existence	existence	e20230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
excessive	excessive	e202010	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
mastodynia	mastodynia	m02303050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
7	7	7000	CD	I-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
mastodynia	mastodynia	m02303050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Normalization	Normalization	n06504020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
halving	halve	h041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hormonal	hormonal	h0650504	JJ	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
safely	safely	s01040	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
satisfied	satisfy	s0302103	VBN	I-VP	O
:	:	:000	:	O	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
,	,	,000	,	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
,	,	,000	,	I-NP	O
cytologic	cytologic	c03040202	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
mammographic	mammographic	m050260102	JJ	B-NP	O
perspective	perspective	p0621023010	NN	I-NP	O
;	;	;000	:	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
cyclic	cyclic	c02402	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
progestative	progestative	p60202303010	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
3	3	3000	LS	B-LST	O
)	)	)000	)	O	O
periodic	periodic	p060302	JJ	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
accurate	accurate	a206030	JJ	B-NP	O
thermographic	thermographic	t0650260102	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
breast	breast	b6023	NN	I-NP	O
target	target	t06203	NN	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	JJ	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
renal	renal	r0504	JJ	I-NP	O
,	,	,000	,	I-NP	O
seventeen	seventeen	s0105305	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
twenty	twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
liver	liver	l0106	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
infection	infection	i5102305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Seventeen	Seventeen	s0105305	CD	B-NP	O
renal	renal	r0504	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Aza	Aza	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
prednisone	prednisone	p603502050	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunosuppression	immunosuppression	i505020160205	NN	B-NP	O
with	with	w030	IN	B-PP	O
21	21	0000	CD	B-NP	O
cyclosporine	cyclosporine	c02402106050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
prednisone	prednisone	p603502050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
others	other	o3062	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
prednisone	prednisone	p603502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
Aza	Aza	a200	NN	I-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
overall	overall	o10604	JJ	I-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-NP	O
nonviral	nonviral	n0510604	JJ	I-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
cyclosporine	cyclosporine	c02402106050	NN	I-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
than	than	t050	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
renal	renal	r0504	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
but	but	b030	CC	O	O
fewer	few	f060	JJR	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
Aza	Aza	a200	NNP	I-NP	B-Chemical
renal	renal	r0504	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
infectious	infectious	i5102302	JJ	I-NP	O
deaths	death	d0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
Aza	Aza	a200	NN	I-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
infection	infection	i5102305	NN	B-NP	B-Disease
played	play	p403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
6	6	6000	CD	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
deaths	death	d0302	NNS	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
9	9	9000	CD	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
deaths	death	d0302	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
fewest	few	f023	JJS	I-NP	O
bacteremias	bacteremia	b023060502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
site	site	s030	NN	B-NP	O
of	of	o100	IN	B-PP	O
infection	infection	i5102305	NN	B-NP	B-Disease
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
preponderance	preponderance	p601053060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
intrathoracic	intrathoracic	i53603060202	JJ	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
tract	tract	t6023	NN	I-NP	I-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Pulmonary	Pulmonary	p04505060	JJ	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
renal	renal	r0504	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Aza	Aza	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Aza	Aza	a200	NN	B-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
staphylococcal	staphylococcal	s30104020204	JJ	I-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
than	than	t050	IN	B-PP	O
all	all	a400	DT	B-NP	O
other	other	o306	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
systemic	systemic	s0230502	JJ	B-NP	O
fungal	fungal	f05204	JJ	I-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Cytomegalovirus	Cytomegalovirus	c03050204010602	NN	B-NP	O
(	(	(000	(	O	O
CMV	CMV	c510	NN	B-NP	O
)	)	)000	)	O	O
shedding	shedding	s03052	NN	B-NP	O
or	or	o600	CC	O	O
serological	serological	s0604020204	JJ	B-NP	O
rises	rise	r0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
antibody	antibody	a5301030	NN	B-NP	O
titer	titer	t0306	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
78	78	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
76	76	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Aza	Aza	a200	NN	B-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cyclosporine	cyclosporine	c02402106050	NN	I-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
CMV	CMV	c510	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Serological	Serological	s0604020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
Epstein	Epstein	e12305	NNP	B-NP	B-Disease
Barr	Barr	b060	NNP	I-NP	I-Disease
Virus	Virus	v0602	NNP	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
65	65	0000	CD	B-NP	O
cyclosporine	cyclosporine	c02402106050	NN	I-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
had	have	h030	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lymphoma	lymphoma	l051050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Structure	Structure	s36023060	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
relationships	relationship	r0403052012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
by	by	b000	IN	B-PP	O
cholecystokinin	cholecystokinin	c0402023020505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
fragments	fragment	f60250532	NNS	B-NP	O
and	and	a530	CC	I-NP	O
analogues	analogue	a5040202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cholecystokinin	cholecystokinin	c0402023020505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Intraperitoneal	Intraperitoneal	i5360106030504	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cholecystokinin	cholecystokinin	c0402023020505	NN	B-NP	B-Chemical
octapeptide	octapeptide	o2301013030	NN	I-NP	I-Chemical
sulphate	sulphate	s041030	NN	I-NP	O
ester	ester	e2306	NN	I-NP	O
(	(	(000	(	O	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
8	8	8000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
nonsulphated	nonsulphated	n0520410303	JJ	B-NP	O
cholecystokinin	cholecystokinin	c0402023020505	NN	I-NP	B-Chemical
octapeptide	octapeptide	o2301013030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
8	8	8000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
NS	NS	n200	NN	I-NP	O
)	)	)000	)	O	O
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Experiments	Experiment	e2106050532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
C	C	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
fragments	fragment	f60250532	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
tetrapeptide	tetrapeptide	t03601013030	NN	I-NP	O
(	(	(000	(	O	O
CCK	CCK	c200	NN	B-NP	O
-	-	-000	HYPH	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
centre	centre	c05360	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
CCK	CCK	c200	NN	I-NP	O
octapeptide	octapeptide	o2301013030	NN	I-NP	O
molecule	molecule	m0402040	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
analogues	analogue	a5040202	NNS	I-NP	O
CCK	CCK	c200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
and	and	a530	CC	I-NP	O
CCK	CCK	c200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
NS	NS	n200	NN	I-NP	O
(	(	(000	(	O	O
dose	dose	d020	NN	B-NP	O
range	range	r0520	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	:	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
caerulein	caerulein	c060405	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
range	range	r0520	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
bell	bell	b040	NN	B-NP	O
-	-	-000	HYPH	O	O
shaped	shape	s0103	VBN	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
curves	curve	c06102	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
maximum	maximum	m020505	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
for	for	f060	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
NS	NS	n200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
peptide	peptide	p013030	NN	I-NP	O
CCK	CCK	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
weak	weak	w020	JJ	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
octapeptides	octapeptide	o23010130302	NNS	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	O	O
larger	large	l06206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
totally	totally	t03040	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
peptides	peptide	p0130302	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Experiments	Experiment	e2106050532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
analogues	analogue	a5040202	NNS	B-NP	O
and	and	a530	CC	I-NP	O
derivatives	derivative	d0601030102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
alanyl	alanyl	a40504	NN	I-NP	O
derivatives	derivative	d0601030102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
equipotent	equipotent	e20103053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
CCK	CCK	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
analogues	analogue	a5040202	NNS	I-NP	O
,	,	,000	,	O	O
Ser	Ser	s060	NN	B-NP	O
(	(	(000	(	O	O
SO3H	SO3H	0000	NN	B-NP	O
)	)	)000	)	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
Ac	Ac	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
CCK	CCK	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
and	and	a530	CC	I-NP	O
Thr	Thr	t060	NN	I-NP	O
(	(	(000	(	O	O
SO3H	SO3H	0000	NN	B-NP	O
)	)	)000	)	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
Ac	Ac	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
CCK	CCK	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
and	and	a530	CC	I-NP	O
Hyp	Hyp	h010	NN	I-NP	O
(	(	(000	(	O	O
SO3H	SO3H	0000	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
Ac	Ac	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
CCK	CCK	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
slightly	slightly	s4020340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
active	active	a23010	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
CCK	CCK	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
SE	SE	s000	NN	I-NP	O
.	.	.000	.	O	O

Vasopressin	Vasopressin	v020160205	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
contributor	contributor	c0536010306	NN	I-NP	O
to	to	t000	TO	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
process	process	p60202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

Vasopressin	Vasopressin	v020160205	NN	B-NP	B-Chemical
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOCA	DOCA	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
salt	salt	s043	NN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
substantial	substantial	s012305304	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
DOCA	DOCA	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
salt	salt	s043	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
DDAVP	DDAVP	d301	NN	B-NP	B-Chemical
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
antidiuretic	antidiuretic	a5303060302	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
but	but	b030	CC	O	O
minimal	minimal	m050504	JJ	B-NP	O
vasopressor	vasopressor	v020160206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
neurohypophysis	neurohypophysis	n0601010202	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
promotes	promote	p6050302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
pathogenetic	pathogenetic	p0302050302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
unproportional	unproportional	u516010630504	JJ	I-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
adjusting	adjust	a32023052	VBG	I-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	O
forming	form	f065052	VBG	I-NP	O
and	and	a530	CC	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
for	for	f060	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
balance	balance	b040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
essential	essential	e205304	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Toxic	Toxic	t0202	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
alcoholic	alcoholic	a420402	JJ	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
alcoholic	alcoholic	a420402	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
causative	causative	c0203010	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
proven	prove	p60105	VBN	I-VP	O
by	by	b000	IN	B-PP	O
challenge	challenge	c040520	NN	B-NP	O
.	.	.000	.	O	O

Atrial	Atrial	a3604	JJ	B-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
of	of	o100	IN	B-PP	O
F	F	f000	NN	B-NP	O
-	-	-000	HYPH	O	O
344	344	0000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
ingesting	ingest	i52023052	VBG	B-VP	O
quinacrine	quinacrine	q05026050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Quinacrine	Quinacrine	q05026050	JJ	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
toxic	toxic	t0202	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
of	of	o100	IN	B-PP	O
F	F	f000	NN	B-NP	O
-	-	-000	HYPH	O	O
344	344	0000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
500	500	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
quinacrine	quinacrine	q05026050	NN	I-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
all	all	a400	DT	O	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
dilatation	dilatation	d04030305	NN	I-NP	O
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
died	die	d030	VBD	B-VP	O
from	from	f605	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
congestion	congestion	c05202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lungs	lung	l052	NNS	I-NP	O
,	,	,000	,	O	O
liver	liver	l0106	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
organs	organ	o62052	NNS	I-NP	O
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
250	250	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
quinacrine	quinacrine	q05026050	NN	I-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
ppm	ppm	p150	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
nitrite	nitrite	n036030	NN	I-NP	I-Chemical
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
had	have	h030	VBD	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
atria	atria	a360	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
untreated	untreated	u5360303	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
nitrite	nitrite	n036030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
quinacrine	quinacrine	q05026050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
no	no	n000	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Alternating	Alternate	a4306503052	VBG	B-VP	B-Disease
sinus	sinus	s0502	NN	B-NP	I-Disease
rhythm	rhythm	r0305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Alternating	Alternate	a4306503052	VBG	B-VP	B-Disease
sinus	sinus	s0502	NN	B-NP	I-Disease
rhythm	rhythm	r0305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	B-Disease
(	(	(000	(	O	I-Disease
S	S	s000	NN	B-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
A	A	a000	NN	I-NP	I-Disease
)	)	)000	)	O	I-Disease
block	block	b402	NN	B-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
,	,	,000	,	O	O
under	under	u5306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
angina	angina	a52050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
daily	daily	d040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
alternation	alternation	a430650305	NN	B-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
short	short	s063	JJ	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
and	and	a530	CC	O	O
occasional	occasional	o2020504	JJ	B-NP	O
pauses	pause	p0202	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
pauses	pause	p0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
always	always	a402	RB	I-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
usually	usually	u2040	RB	I-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
two	two	t000	CD	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
P	P	p000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
92	92	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
95	95	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
representing	represent	r01602053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
these	these	t020	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
,	,	,000	,	O	O
alternating	alternate	a4306503052	VBG	B-VP	B-Disease
rhythm	rhythm	r0305	NN	B-NP	I-Disease
started	start	s306303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
longer	long	l05206	JJR	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
ranged	range	r05203	VBD	B-VP	O
between	between	b0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
04	04	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
12	12	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
80	80	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
84	84	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pauses	pause	p0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
equal	equal	e204	JJ	B-ADJP	O
or	or	o600	CC	O	O
almost	almost	a45023	RB	B-ADJP	O
equal	equal	e204	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
short	short	s063	JJ	I-NP	O
plus	plus	p402	CC	O	O
one	one	o500	CD	B-NP	O
long	long	l052	JJ	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
or	or	o600	CC	O	O
to	to	t000	TO	B-VP	O
twice	twice	t020	VB	I-VP	O
the	the	t000	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
recording	record	r02063052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
with	with	w030	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
S	S	s000	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
A	A	a000	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
short	short	s063	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
interrupted	interrupt	i530601303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
sudden	sudden	s0305	JJ	B-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
starting	start	s3063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
small	small	s504	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
shape	shape	s010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
P	P	p000	NN	I-NP	O
waves	wave	w0102	NNS	I-NP	O
and	and	a530	CC	O	O
P	P	p000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
R	R	r000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

S	S	s000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
A	A	a000	NN	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
two	two	t000	CD	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
with	with	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
block	block	b402	NN	I-NP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
having	have	h01052	VBG	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
14	14	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
longer	long	l05206	JJR	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
time	time	t050	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
occasional	occasional	o2020504	JJ	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
block	block	b402	NN	I-NP	O
was	be	w020	VBD	B-VP	O
proposed	propose	p6010203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
explanation	explanation	e214050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
alternating	alternate	a4306503052	VBG	I-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P	P	p000	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
seen	see	s050	VBN	B-VP	O
.	.	.000	.	O	O

Atropine	Atropine	a3601050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
shortening	shortening	s06305052	NN	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
P	P	p000	NN	I-NP	O
-	-	-000	HYPH	O	O
P	P	p000	NN	B-NP	O
intervals	interval	i53061042	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
changing	change	c052052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
restarted	restart	r02306303	VBN	I-VP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
S	S	s000	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
A	A	a000	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
accepted	accept	a201303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
conduction	conduction	c05302305	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Antitumor	Antitumor	a53030506	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IgM	IgM	i250	NN	I-NP	O
solid	solid	s0403	JJ	I-NP	O
immunocytoma	immunocytoma	i5050203050	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
bearing	bear	b06052	VBG	B-VP	O
LOU	LOU	l000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
M	M	m000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
WSL	WSL	w240	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Antitumor	Antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
LOU	LOU	l000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
M	M	m000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
WSL	WSL	w240	NN	I-NP	O
inbred	inbred	i51603	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
each	each	e020	DT	B-NP	O
bearing	bear	b06052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
transplantable	transplantable	t6052140530140	JJ	I-NP	O
solid	solid	s0403	JJ	I-NP	O
IgM	IgM	i250	NN	I-NP	O
immunocytoma	immunocytoma	i5050203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
(	(	(000	(	O	O
diameter	diameter	d050306	NN	B-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
iv	iv	i100	NN	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
5	5	5000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	O
weekly	weekly	w0240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
dose	dose	d020	NN	B-NP	O
range	range	r0520	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
015	015	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Tumor	Tumor	t0506	NN	B-NP	B-Disease
regression	regression	r0260205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Complete	Complete	c0514030	JJ	B-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Histologic	Histologic	h023040202	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
scored	score	s20603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
grade	grade	g6030	NN	B-NP	O
III	III	i000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
above	above	a1010	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
albuminuria	albuminuria	a410505060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
very	very	v060	RB	B-NP	O
low	low	l000	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
level	level	l0104	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liter	liter	l0306	NN	I-NP	O
.	.	.000	.	O	O

Ascites	Ascites	a20302	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hydrothorax	hydrothorax	h036030602	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
bearing	bear	b06052	VBG	B-VP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
no	no	n000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
LOU	LOU	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
M	M	m000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
WSL	WSL	w240	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Albuminuria	Albuminuria	a410505060	NNP	B-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
extremely	extremely	e23605040	RB	B-NP	O
low	low	l000	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
so	so	s000	IN	O	O
ascites	ascite	a20302	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hydrothorax	hydrothorax	h036030602	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
necessarily	necessarily	n020206040	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Intraoperative	Intraoperative	i536010603010	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
eye	eye	e000	NN	I-NP	O
drops	drop	d6012	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
69	69	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
concurrently	concurrently	c0520605340	RB	I-VP	O
being	be	b052	VBG	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
nitrate	nitrate	n036030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
maleate	maleate	m04030	NN	I-NP	I-Chemical
eye	eye	e000	NN	I-NP	O
drops	drop	d6012	NNS	I-NP	O
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
became	become	b02050	VBD	B-VP	O
hypotensive	hypotensive	h0103052010	JJ	B-ADJP	B-Disease
during	during	d06052	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
subsequently	subsequently	s0120205340	RB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
collection	collection	c0402305	NN	I-NP	O
of	of	o100	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
.	.	.000	.	O	O

Timolol	Timolol	t050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
sample	sample	s05140	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
removed	remove	r050103	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
ml	ml	m400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
postulated	postulate	p023040303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
action	action	a2305	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
resultant	resultant	r02043053	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Pilocarpine	Pilocarpine	p0402061050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
had	have	h030	VBD	I-VP	O
a	a	a000	DT	B-NP	O
contributory	contributory	c05360103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Succinylcholine	Succinylcholine	s020504204050	NN	B-NP	B-Chemical
apnoea	apnoea	a150	NN	I-NP	B-Disease
:	:	:000	:	O	O
attempted	attempt	a3051303	VBN	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
with	with	w030	IN	B-PP	O
anticholinesterases	anticholinesteras	a53020405023060202	NNS	B-NP	O
.	.	.000	.	O	O

Anticholinesterases	Anticholinesteras	a53020405023060202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	B-Disease
blockade	blockade	b402030	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
found	find	f053	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
homozygous	homozygous	h05020202	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
.	.	.000	.	O	O

Edrophonium	Edrophonium	e36010505	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
74	74	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
train	train	t605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	SYM	B-NP	O
four	four	f060	CD	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
block	block	b402	NN	I-NP	O
,	,	,000	,	O	O
produced	produce	p6030203	VBD	B-VP	O
partial	partial	p06304	JJ	B-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
sustained	sustain	s0230503	VBN	I-VP	O
.	.	.000	.	O	O

Repeated	Repeat	r010303	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
edrophonium	edrophonium	e36010505	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
70	70	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	I-NP	O
neostigmine	neostigmine	n023025050	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
or	or	o600	CC	I-VP	O
augment	augment	a025053	VB	I-VP	O
the	the	t000	DT	B-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

Spontaneous	Spontaneous	s10530502	JJ	B-NP	O
respiration	respiration	r021060305	NN	I-NP	O
recommenced	recommence	r020505203	VBD	B-VP	O
200	200	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
anticholinesterases	anticholinesteras	a53020405023060202	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
only	only	o540	RB	B-ADVP	O
partially	partially	p063040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
restoring	restore	r02306052	VBG	B-VP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
apnoea	apnoea	a150	NN	I-NP	B-Disease
despite	despite	d021030	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
twitch	twitch	t0320	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
typical	typical	t010204	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
[	[	[000	(	O	B-Chemical
omega	omega	o5020	SYM	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
I	I	i000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
131	131	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
heptadecanoic	heptadecanoic	h01303020502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
myocardial	myocardial	m0206304	JJ	I-NP	O
scintigraphy	scintigraphy	s2053026010	NN	I-NP	O
and	and	a530	CC	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
dynamic	dynamic	d050502	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
scintigraphy	scintigraphy	s2053026010	NN	I-NP	O
with	with	w030	IN	B-PP	O
[	[	[000	(	O	B-Chemical
omega	omega	o5020	SYM	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
I	I	i000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
131	131	0000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
heptadecanoic	heptadecanoic	h01303020502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
I	I	i000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
131	131	0000	CD	B-NP	I-Chemical
HA	HA	h000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
on	on	o500	IN	B-PP	O
global	global	g40104	JJ	B-NP	O
left	left	l013	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
determined	determine	d030650503	VBN	B-VP	O
echocardiographically	echocardiographically	e2020630260102040	RB	B-ADVP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
mongrel	mongrel	m052604	NN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
extractable	extractable	e2360230140	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
postmortem	postmortem	p023506305	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
progressive	progressive	p602602010	JJ	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
global	global	g40104	JJ	B-NP	O
LV	LV	l100	NN	I-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
t1	t1	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
I	I	i000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
131	131	0000	CD	I-NP	I-Chemical
HA	HA	h000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
extractable	extractable	e2360230140	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
lipids	lipid	l01032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
control	control	c053604	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
with	with	w030	IN	B-PP	O
I	I	i000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
131	131	0000	CD	I-NP	I-Chemical
HA	HA	h000	NN	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
initiating	initiate	i50303052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Hemodynamics	Hemodynamic	h0503050502	NNS	B-NP	O
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
under	under	u5306	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
work	work	w062	NN	I-NP	O
and	and	a530	CC	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SNP	SNP	s510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
trimetaphan	trimetaphan	t605030105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TMP	TMP	t510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
deliberate	deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
mean	mean	m050	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Regarding	Regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
,	,	,000	,	O	O
aortic	aortic	a06302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
,	,	,000	,	O	O
pO2	pO2	0000	NN	B-NP	O
,	,	,000	,	O	O
pCO2	pCO2	0000	NN	B-NP	O
)	)	)000	)	O	O
we	we	w000	PRP	B-NP	O
could	could	c043	MD	B-VP	O
confirm	confirm	c051065	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
safely	safely	s01040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
mean	mean	m050	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
trimetaphan	trimetaphan	t605030105	NN	B-NP	B-Chemical
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
mean	mean	m050	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
work	work	w062	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
SNP	SNP	s510	NN	B-NP	B-Chemical
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
O2	O2	0000	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
and	and	a530	CC	O	O
O2	O2	0000	NN	B-NP	B-Chemical
availability	availability	a1040104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
directly	directly	d0602340	RB	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
gases	gas	g0202	NNS	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
T	T	t000	NN	I-NP	O
segment	segment	s025053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
mandatory	mandatory	m05303060	JJ	B-ADJP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
noradrenergic	noradrenergic	n060360506202	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
stimulant	stimulant	s30504053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
neurotoxin	neurotoxin	n06030205	NN	I-NP	O
DSP4	DSP4	0000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
amphetamine	amphetamine	a510305050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
40	40	0000	CD	I-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
amphetamine	amphetamine	a510305050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
DSP4	DSP4	0000	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
rearings	rearing	r06052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
stereotypies	stereotypy	s306030102	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
DSP4	DSP4	0000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
DSP4	DSP4	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
uptake	uptake	u13020	NN	B-NP	O
blocking	block	b402052	VBG	B-VP	O
agent	agent	a2053	NN	B-NP	O
,	,	,000	,	O	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
prevents	prevent	p6010532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
DSP4	DSP4	0000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
noradrenergic	noradrenergic	n060360506202	JJ	I-NP	O
neurones	neurone	n060502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
stimulant	stimulant	s30504053	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Accelerated	Accelerate	a204060303	VBN	B-NP	B-Disease
junctional	junctional	j05230504	JJ	I-NP	I-Disease
rhythms	rhythm	r03052	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
atrioventricular	atrioventricular	a36010536020406	JJ	B-NP	O
(	(	(000	(	O	O
AV	AV	a100	NN	B-NP	O
)	)	)000	)	O	O
dissociation	dissociation	d02020305	NN	B-NP	O
and	and	a530	CC	O	O
accelerated	accelerate	a204060303	VBD	B-VP	B-Disease
junctional	junctional	j05230504	JJ	B-NP	I-Disease
rhythms	rhythm	r03052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
59	59	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Accelerated	Accelerate	a204060303	VBN	B-NP	B-Disease
junctional	junctional	j05230504	JJ	I-NP	I-Disease
rhythms	rhythm	r03052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
AV	AV	a100	NN	B-NP	O
dissociation	dissociation	d02020305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
frequent	frequent	f602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
supraventricular	supraventricular	s016010536020406	JJ	B-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
AV	AV	a100	NN	B-NP	O
nodal	nodal	n0304	JJ	I-NP	O
reentry	reentry	r05360	NN	I-NP	O
.	.	.000	.	O	O

Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
junctional	junctional	j05230504	JJ	I-NP	O
pacemakers	pacemaker	p020502062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
syndromes	syndrome	s05360502	NNS	I-NP	O
,	,	,000	,	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
neither	neither	n0306	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
junctional	junctional	j05230504	JJ	B-NP	O
rhythms	rhythm	r03052	NNS	I-NP	O
nor	nor	n060	CC	O	O
suppressed	suppress	s0160203	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
role	role	r040	NN	I-NP	O
as	as	a200	IN	B-PP	O
escape	escape	e2010	NN	B-NP	O
rhythms	rhythm	r03052	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
physiologically	physiologically	p02040202040	RB	B-NP	O
appropriate	appropriate	a16016030	JJ	I-NP	O
circumstances	circumstance	c062052305202	NNS	I-NP	O
.	.	.000	.	O	O

Interstrain	Interstrain	i530623605	NN	B-NP	O
variation	variation	v060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
among	among	a5052	IN	B-PP	O
inbred	inbred	i51603	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
males	male	m0402	NNS	I-NP	O
from	from	f605	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
inbred	inbred	i51603	JJ	I-NP	O
mouse	mouse	m020	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
J	J	j000	NN	I-NP	O
,	,	,000	,	O	O
BALB	BALB	b041	NN	B-NP	O
/	/	/000	SYM	I-NP	O
cJ	cJ	c200	NN	I-NP	O
,	,	,000	,	O	O
CBA	CBA	c100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
J	J	j000	NN	I-NP	O
,	,	,000	,	O	O
C3H	C3H	0000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
HeJ	HeJ	h020	NN	I-NP	O
,	,	,000	,	O	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
6J	6J	6200	NN	I-NP	O
,	,	,000	,	O	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
2J	2J	2000	NN	I-NP	O
,	,	,000	,	O	O
SWR	SWR	s060	NN	B-NP	O
/	/	/000	SYM	I-NP	O
J	J	j000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
6J	6J	6200	NN	I-NP	O
,	,	,000	,	O	O
chosen	choose	c0205	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
"	"	"000	``	I-NP	O
prototypic	prototypic	p603030102	JJ	I-NP	O
"	"	"000	''	I-NP	O
mouse	mouse	m020	NN	I-NP	O
strain	strain	s3605	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
broad	broad	b603	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
phenotypic	phenotypic	p05030102	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
righting	righting	r0203052	NN	B-NP	O
ability	ability	a104030	NN	I-NP	O
,	,	,000	,	O	O
clonic	clonic	c40502	JJ	B-NP	B-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
induction	induction	i5302305	NN	I-NP	O
,	,	,000	,	O	O
stress	stress	s3602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lethality	lethality	l0304030	NN	I-NP	O
,	,	,000	,	O	O
death	death	d030	NN	B-NP	O
without	without	w0303	IN	B-PP	O
external	external	e2306504	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	SYM	B-NP	O
were	be	w060	VBD	B-VP	O
scored	score	s20603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
naive	naive	n010	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
empirically	empirically	e510602040	RB	B-NP	O
optimized	optimize	o13050203	VBN	B-VP	O
,	,	,000	,	O	O
rigidly	rigidly	r020340	RB	B-NP	O
constant	constant	c0523053	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
point	point	p053	NN	I-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
single	single	s05240	JJ	B-NP	O
IP	IP	i100	NN	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
volume	volume	v04050	NN	I-NP	O
/	/	/000	SYM	I-NP	O
g	g	g000	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
physiological	physiological	p0204020204	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
carrier	carrier	c0606	NN	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
125	125	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Loss	Loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
righting	righting	r0203052	NN	B-NP	O
ability	ability	a104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
scored	score	s20603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
min	min	m050	NN	I-NP	O
post	post	p023	NN	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonic	clonic	c40502	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
scored	score	s20603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
to	to	t000	TO	B-PP	O
time	time	t050	NN	B-NP	O
of	of	o100	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
for	for	f060	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
these	these	t020	DT	B-NP	O
proceeded	proceed	p6020303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
tonic	tonic	t0502	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
,	,	,000	,	O	O
death	death	d030	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
20	20	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
surviving	survive	s06101052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
stressed	stress	s360203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
swim	swim	s050	NN	I-NP	O
test	test	t023	NN	I-NP	O
in	in	i500	IN	B-PP	O
25	25	0000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
C	C	c000	NN	I-NP	O
water	water	w0306	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	O
-	-	-000	HYPH	O	O
producing	produce	p60302052	VBG	B-VP	O
tonic	tonic	t0502	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
scored	score	s20603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
15	15	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
any	any	a500	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
criterion	criterion	c6030605	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
,	,	,000	,	O	O
marked	marked	m06203	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
strains	strain	s36052	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
behavioral	behavioral	b010604	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
testing	testing	t023052	NN	I-NP	O
of	of	o100	IN	B-PP	O
alkylxanthines	alkylxanthine	a420420530502	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
mouse	mouse	m020	NN	I-NP	O
strain	strain	s3605	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
misleading	misleading	m02403052	JJ	B-ADJP	O
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
toxic	toxic	t0202	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
compounds	compound	c0510532	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
genetically	genetically	g050302040	RB	I-VP	O
influenced	influence	i51405203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mammals	mammal	m05042	NNS	B-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
platinum	platinum	p4030505	NN	I-NP	I-Chemical
,	,	,000	,	I-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
hexamethylmelamine	hexamethylmelamine	h0205030450405050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
2	2	2000	CD	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
38	38	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatinum	cisplatinum	c0214030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CPDD	CPDD	c130	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	B-NP	O
,	,	,000	,	O	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
m2	m2	0000	NN	B-NP	O
,	,	,000	,	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
m2	m2	0000	NN	B-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
hexamethylmelamine	hexamethylmelamine	h0205030450405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HMM	HMM	h500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
course	course	c0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
monthly	monthly	m053040	RB	B-ADVP	O
.	.	.000	.	O	O

2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
stage	stage	s3020	NN	B-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
stage	stage	s3020	NN	I-NP	O
III	III	i000	CD	B-NP	O
and	and	a530	CC	I-NP	O
22	22	0000	CD	I-NP	O
stage	stage	s3020	NN	I-NP	O
IV	IV	i100	CD	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

14	14	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
38	38	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
with	with	w030	IN	B-PP	O
radiation	radiation	r030305	NN	B-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	O	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	I-NP	O
radiation	radiation	r030305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
17	17	0000	CD	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
any	any	a500	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
before	before	b01060	IN	B-PP	O
CPDD	CPDD	c130	NN	B-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
.	.	.000	.	O	O

31	31	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
38	38	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
81	81	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
objective	objective	o12023010	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
lasting	last	l023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
partial	partial	p06304	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
19	19	0000	CD	B-NP	O
and	and	a530	CC	O	O
complete	complete	c0514030	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Hematologic	Hematologic	h0503040202	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
reversible	reversible	r010620140	JJ	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
developing	develop	d010401052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
71	71	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Gastrointestinal	Gastrointestinal	g02360530230504	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
from	from	f605	IN	B-PP	O
CPDD	CPDD	c130	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
universal	universal	u50106204	JJ	B-ADJP	O
.	.	.000	.	O	O

HMM	HMM	h500	NN	B-NP	B-Chemical
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
necessitated	necessitate	n0202030303	VBD	B-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
deaths	death	d0302	NNS	I-NP	O
.	.	.000	.	O	O

Nontraumatic	Nontraumatic	n0536050302	JJ	B-NP	O
dissecting	dissect	d02023052	VBG	I-NP	B-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
basilar	basilar	b020406	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
nontraumatic	nontraumatic	n0536050302	JJ	B-NP	O
dissecting	dissect	d02023052	VBG	I-NP	B-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
basilar	basilar	b020406	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
smoke	smoke	s5020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
female	female	f05040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
locked	lock	l0203	VBN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
in	in	i500	IN	B-PP	I-Disease
syndrome	syndrome	s0536050	NN	B-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tocolytic	tocolytic	t02040302	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
mimetics	mimetic	m050302	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
method	method	m0303	NN	I-NP	O
permitting	permit	p06503052	VBG	B-VP	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
finger	finger	f05206	NN	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
displacement	displacement	d02140205053	NN	I-NP	O
-	-	-000	HYPH	O	O
time	time	t050	NN	B-NP	O
curve	curve	c0610	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
test	test	t023	NN	I-NP	O
system	system	s02305	NN	I-NP	O
with	with	w030	IN	B-PP	O
simple	simple	s05140	JJ	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
calibration	calibration	c040160305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
coordinates	coordinate	c063050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
inversion	inversion	i5106205	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
displacement	displacement	d02140205053	NN	I-NP	O
-	-	-000	HYPH	O	O
time	time	t050	NN	B-NP	O
curves	curve	c06102	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
graphical	graphical	g6010204	JJ	B-NP	O
input	input	i5103	NN	I-NP	O
equipment	equipment	e2015053	NN	I-NP	O
to	to	t000	TO	B-PP	O
punched	punch	p05203	VBN	B-NP	O
tape	tape	t010	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
computer	computer	c0510306	NN	I-NP	O
program	program	p602605	NN	I-NP	O
,	,	,000	,	O	O
periods	period	p06032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
amplitudes	amplitude	a514030302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
oscillations	oscillation	o20403052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
and	and	a530	CC	O	O
classified	classify	c4020103	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
event	event	e1053	NN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
periods	period	p06032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
amplitudes	amplitude	a514030302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fenoterol	fenoterol	f05030604	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hydrobromide	hydrobromide	h03601605030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
ritodrin	ritodrin	r0303605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
given	give	g0105	VBN	B-PP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
crossover	crossover	c6020106	NN	I-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
this	this	t020	DT	B-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
both	both	b030	DT	B-NP	O
substances	substance	s012305202	NNS	I-NP	O
raised	raise	r0203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
amplitude	amplitude	a51403030	NN	I-NP	O
to	to	t000	TO	B-PP	O
about	about	a103	IN	B-NP	O
three	three	t060	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
control	control	c053604	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
within	within	w0305	IN	B-PP	O
each	each	e020	DT	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
amplitudes	amplitude	a514030302	NNS	B-NP	O
shortened	shorten	s0630503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
ms	m	m200	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
periods	period	p06032	NNS	I-NP	O
calculated	calculate	c042040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
all	all	a400	DT	B-NP	O
oscillations	oscillation	o20403052	NNS	I-NP	O
together	together	t020306	RB	B-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
fenoterol	fenoterol	f05030604	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hydrobromide	hydrobromide	h03601605030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
amplitudes	amplitude	a514030302	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
faster	fast	f02306	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
ritodrin	ritodrin	r0303605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Propylthiouracil	Propylthiouracil	p601043060204	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
,	,	,000	,	O	O
proven	prove	p60105	VBN	B-VP	O
by	by	b000	IN	B-PP	O
rechallenge	rechallenge	r02040520	NN	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
presents	present	p6020532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
picture	picture	p023060	NN	I-NP	O
resembling	resemble	r020514052	VBG	B-VP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
active	active	a23010	JJ	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Bepridil	Bepridil	b0160304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
active	active	a23010	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
for	for	f060	IN	B-PP	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
anginal	anginal	a520504	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
persistent	persistent	p062023053	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
tachycardial	tachycardial	t020206304	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
of	of	o100	IN	B-PP	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
support	support	s01063	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
for	for	f060	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
sino	sino	s050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
atrial	atrial	a3604	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
from	from	f605	IN	B-PP	O
rabbit	rabbit	r0103	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
action	action	a2305	NN	B-NP	O
potential	potential	p0305304	NN	I-NP	O
(	(	(000	(	O	O
AP	AP	a100	NN	B-NP	O
)	)	)000	)	O	O
spike	spike	s1020	NN	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
(	(	(000	(	O	O
recorded	record	r0206303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
KCl	KCl	k240	NN	B-NP	B-Chemical
microelectrodes	microelectrode	m0260402360302	NNS	I-NP	O
)	)	)000	)	O	O
starting	start	s3063052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
X	X	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
up	up	u100	IN	B-PP	O
to	to	t000	TO	B-PP	O
concentrations	concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
X	X	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
,	,	,000	,	O	O
whereupon	whereupon	w060105	IN	B-PP	O
blockade	blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
set	set	s030	VBN	B-VP	O
in	in	i500	IN	B-PP	O
.	.	.000	.	O	O

Bepridil	Bepridil	b0160304	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
X	X	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
AP	AP	a100	NN	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
(	(	(000	(	O	O
falling	fall	f04052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
71	71	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
mV	mV	m100	NN	I-NP	O
to	to	t000	TO	B-PP	O
47	47	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
mV	mV	m100	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
maximum	maximum	m020505	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
depolarization	depolarization	d010406020305	NN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
(	(	(000	(	O	O
phase	phase	p020	NN	B-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
fell	fall	f040	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
85	85	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
35	35	0000	CD	I-NP	O
V	V	v000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
84	84	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
28	28	0000	CD	I-NP	O
V	V	v000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
maximum	maximum	m020505	NN	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
depolarization	depolarization	d010406020305	NN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
(	(	(000	(	O	O
phase	phase	p020	NN	B-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
fell	fall	f040	VBD	B-VP	O
from	from	f605	IN	B-PP	O
38	38	0000	CD	B-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
mV	mV	m100	NN	I-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
to	to	t000	TO	B-PP	O
24	24	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	I-NP	O
mV	mV	m100	NN	I-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	LS	O	O
.	.	.000	.	O	O
)	)	)000	)	O	O
into	into	i530	IN	B-PP	O
6	6	6000	CD	B-NP	O
anaesthetized	anaesthetize	a5023030203	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
ablation	ablation	a140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
extrinsic	extrinsic	e23605202	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
afferent	afferent	a106053	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
supply	supply	s0140	NN	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
medullo	medullo	m03040	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenalectomy	adrenalectomy	a360504023050	NN	I-NP	O
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
which	which	w020	WDT	B-NP	O
fell	fall	f040	VBD	B-VP	O
from	from	f605	IN	B-PP	O
98	98	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
to	to	t000	TO	B-PP	O
76	76	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
sustained	sustain	s0230503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
45	45	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
by	by	b000	IN	B-PP	O
acting	act	a23052	VBG	B-VP	O
directly	directly	d0602340	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
node	node	n030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
flattening	flattening	f40305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
0	0	0000	CD	I-NP	O
and	and	a530	CC	O	O
phase	phase	p020	NN	B-NP	O
4	4	4000	CD	I-NP	O
slope	slope	s4010	NN	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
longer	long	l05206	JJR	I-NP	O
AP	AP	a100	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
constants	constant	c05230532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
slow	slow	s400	JJ	B-NP	O
inward	inward	i5063	JJ	I-NP	O
ionic	ionic	i0502	JJ	I-NP	O
currents	current	c060532	NNS	I-NP	O
(	(	(000	(	O	O
already	already	a46030	RB	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
elsewhere	elsewhere	e42060	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
time	time	t050	NN	I-NP	O
constant	constant	c0523053	NN	I-NP	O
for	for	f060	IN	B-PP	O
deactivation	deactivation	d023010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
outward	outward	o03063	JJ	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
current	current	c06053	NN	I-NP	O
(	(	(000	(	O	O
Ip	Ip	i100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
with	with	w030	IN	B-PP	O
methoxyflurane	methoxyflurane	m030201406050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
69	69	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
operated	operate	o1060303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
cholecystitis	cholecystitis	c04020230302	NN	I-NP	I-Disease
under	under	u5306	IN	B-PP	O
methoxyflurane	methoxyflurane	m030201406050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Massive	Massive	m02010	JJ	B-NP	O
bleeding	bleeding	b403052	NN	I-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
which	which	w020	WDT	B-NP	O
lasted	last	l02303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
six	six	s020	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Postoperative	Postoperative	p023010603010	JJ	B-NP	O
evolution	evolution	e1040305	NN	I-NP	O
under	under	u5306	IN	B-PP	O
supportive	supportive	s01063010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
favourable	favourable	f01060140	JJ	B-ADJP	O
.	.	.000	.	O	O

Complete	Complete	c0514030	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
controls	control	c0536042	NNS	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

Pituitary	Pituitary	p0303060	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
luteinizing	luteinize	l030502052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
during	during	d06052	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
and	and	a530	CC	O	O
luteinizing	luteinize	l030502052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
(	(	(000	(	O	O
LH	LH	l000	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
male	male	m040	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
LH	LH	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
(	(	(000	(	O	O
LH	LH	l000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
RH	RH	r000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
infusions	infusion	i5102052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
NaCl	NaCl	n024	NN	I-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
infusions	infusion	i5102052	NNS	I-NP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
abolished	abolish	a1040203	VBN	I-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
LH	LH	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
RH	RH	r000	NN	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
responses	response	r02105202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Antirifampicin	Antirifampicin	a5306010510205	NN	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
rifampicin	rifampicin	r010510205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
with	with	w030	IN	B-PP	O
thrombopenia	thrombopenia	t0605101050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
)	)	)000	)	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
reintroduction	reintroduction	r05360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
taken	take	t0205	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
but	but	b030	CC	I-NP	O
1	1	1000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
antirifampicin	antirifampicin	a5306010510205	NN	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

Antibodies	Antibody	a53010302	NNS	B-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
IgM	IgM	i250	NN	I-NP	O
class	class	c402	NN	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hematological	hematological	h050304020204	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
biopsied	biopsie	b01203	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
indistinguishable	indistinguishable	i53023052020140	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
,	,	,000	,	O	O
raised	raise	r0203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
mediated	mediate	m030303	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
triggering	trigger	t60206052	VBG	I-NP	O
immunoallergic	immunoallergic	i5050406202	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Cardiovascular	Cardiovascular	c06301020406	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
triphosphate	triphosphate	t601021030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
denervated	denervate	d050610303	VBN	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
.	.	.000	.	O	O

Adenosine	Adenosine	a30502050	NN	B-NP	B-Chemical
triphosphate	triphosphate	t601021030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SNP	SNP	s510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
and	and	a530	CC	I-VP	O
control	control	c053604	VB	I-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

SNP	SNP	s510	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
authorized	authorize	a03060203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
USA	USA	u200	NNP	B-NP	O
and	and	a530	CC	I-NP	O
UK	UK	u200	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
clinically	clinically	c40502040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
countries	country	c053602	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
Japan	Japan	j0105	NNP	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
how	how	h000	WRB	B-ADVP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
act	act	a230	VBP	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
denervated	denervate	d050610303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
we	we	w000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
devised	devise	d010203	VBN	I-VP	O
.	.	.000	.	O	O

ATP	ATP	a310	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
SNP	SNP	s510	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
by	by	b000	IN	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
70	70	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-ADVP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
major	major	m0206	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ATP	ATP	a310	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
central	central	c053604	JJ	B-NP	O
venous	venous	v0502	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
rate	rate	r030	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
product	product	p603023	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
body	body	b030	NN	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
001	001	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
all	all	a400	PDT	B-NP	O
these	these	t020	DT	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
within	within	w0305	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ATP	ATP	a310	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
SNP	SNP	s510	NN	B-NP	B-Chemical
similar	similar	s050406	JJ	I-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
central	central	c053604	JJ	B-NP	O
venous	venous	v0502	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
rate	rate	r030	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
product	product	p603023	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
content	content	c053053	NN	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
mixed	mixed	m0203	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

Recoveries	Recovery	r02010602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
SNP	SNP	s510	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
act	act	a230	VB	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

Comparative	Comparative	c0510603010	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
:	:	:000	:	O	O
Endografine	Endografine	e5302601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
diatrizoate	diatrizoate	d03602030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
Vasurix	Vasurix	v020602	NN	B-NP	B-Chemical
polyvidone	polyvidone	p040103050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
acetrizoate	acetrizoate	a203602030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
Dimer	Dimer	d0506	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
X	X	x000	NN	B-NP	I-Chemical
(	(	(000	(	O	O
iocarmate	iocarmate	i02065030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
Hexabrix	Hexabrix	h0201602	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ioxaglate	ioxaglate	i02024030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
hysterosalpingography	hysterosalpingography	h0230602041052026010	NN	B-NP	O
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hysterosalpingography	hysterosalpingography	h0230602041052026010	NN	B-NP	O
with	with	w030	IN	B-PP	O
Dimer	Dimer	d0506	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
X	X	x000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
Hexabrix	Hexabrix	h0201602	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
Vasurix	Vasurix	v020602	NNP	B-NP	B-Chemical
polyvidone	polyvidone	p040103050	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
Endografine	Endografine	e5302601050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
142	142	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
receiving	receive	r0201052	VBG	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
tested	test	t02303	VBN	I-NP	O
media	medium	m030	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
replies	reply	r01402	NNS	B-NP	O
to	to	t000	TO	B-PP	O
postal	postal	p02304	JJ	B-NP	O
questionnaires	questionnaire	q023050602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Dimer	Dimer	d0506	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
X	X	x000	NN	I-NP	I-Chemical
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
dizziness	dizziness	d020502	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Endografine	Endografine	e5302601050	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
occur	occur	o206	VBP	B-VP	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
30	30	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Hexabrix	Hexabrix	h0201602	NNP	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Vasurix	Vasurix	v020602	NNP	I-NP	B-Chemical
polyvidone	polyvidone	p040103050	NN	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
media	medium	m030	NNS	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
hysterosalpingography	hysterosalpingography	h0230602041052026010	NN	B-NP	O
and	and	a530	CC	O	O
perhaps	perhaps	p06012	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
low	low	l000	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
Hexabrix	Hexabrix	h0201602	NNP	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
preferred	prefer	p6010603	VBN	I-VP	O
.	.	.000	.	O	O

Post	Post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
suxamethonium	suxamethonium	s0205030505	NN	I-NP	B-Chemical
pains	pain	p052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Nigerian	Nigerian	n020605	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Contrary	Contrary	c0536060	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
earlier	early	e06406	JJR	I-NP	O
report	report	r01063	NN	I-NP	O
by	by	b000	IN	B-PP	O
Coxon	Coxon	c0205	NNP	B-NP	O
,	,	,000	,	O	O
scoline	scoline	s204050	NN	B-NP	B-Chemical
pain	pain	p050	NN	I-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
African	African	a160205	JJ	B-NP	O
negroes	negro	n02602	NNS	I-NP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
Nigerian	Nigerian	n020605	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
out	out	o030	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

About	About	a103	RB	B-NP	O
62	62	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
out	out	o030	RB	I-NP	O
-	-	-000	HYPH	O	O
patients	patient	p030532	NNS	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
scoline	scoline	s204050	NN	B-NP	B-Chemical
pain	pain	p050	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
about	about	a103	RB	B-NP	O
26	26	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
abolition	abolition	a1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
fasciculations	fasciculation	f02020403052	NNS	I-NP	B-Disease
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
075mg	075mg	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fazadinium	Fazadinium	f02030505	NN	B-NP	B-Chemical
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
scoline	scoline	s204050	NN	B-NP	B-Chemical
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
agent	agent	a2053	NN	I-NP	O
(	(	(000	(	O	O
Althesin	Althesin	a430205	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
Thiopentone	Thiopentone	t01053050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
nor	nor	n060	CC	O	O
the	the	t000	DT	B-NP	O
salt	salt	s043	NN	I-NP	O
preparation	preparation	p601060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
used	use	u203	VBN	B-VP	O
(	(	(000	(	O	O
chloride	chloride	c0406030	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
bromide	bromide	b605030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
affected	affect	a102303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
scoline	scoline	s204050	NN	B-NP	B-Chemical
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Invasive	Invasive	i5102010	JJ	B-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
pelvis	pelvis	p04102	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
nonmalignant	nonmalignant	n0504025053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
hydroureteronephrosis	hydroureteronephrosis	h0360603060501060202	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
ureterovesical	ureterovesical	u6030601020204	JJ	B-NP	O
junction	junction	j052305	NN	I-NP	O
obstruction	obstruction	o123602305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
gross	gross	g602	JJ	B-NP	O
hematuria	hematuria	h0503060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
years	year	y062	NNS	I-NP	O
wtih	wtih	w300	VBP	B-VP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
nephroureterectomy	nephroureterectomy	n0106060306023050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
bleeding	bleed	b403052	VBG	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathology	pathology	p0304020	NN	I-NP	O
specimen	specimen	s1020505	NN	I-NP	O
contained	contain	c0530503	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-NP	O
occult	occult	o2043	JJ	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
pelvis	pelvis	p04102	NN	I-NP	I-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
urine	urine	u6050	NN	B-NP	O
cytologic	cytologic	c03040202	JJ	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
indistinguishable	indistinguishable	i53023052020140	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
high	high	h020	JJ	B-NP	O
grade	grade	g6030	NN	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
less	less	l020	RBR	I-VP	O
widely	widely	w03040	RB	I-VP	O
appreciated	appreciate	a16020303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
urinary	urinary	u605060	JJ	I-NP	I-Disease
tract	tract	t6023	NN	I-NP	I-Disease
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
carcinomas	carcinoma	c062050502	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
urinary	urinary	u605060	JJ	I-NP	I-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
prostate	prostate	p6023030	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
pelvis	pelvis	p04102	NN	I-NP	I-Disease
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
urinary	urinary	u605060	JJ	I-NP	B-Disease
tract	tract	t6023	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
nonmalignant	nonmalignant	n0504025053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
preexisting	preexist	p602023052	VBG	B-VP	O
hydroureteronephrosis	hydroureteronephrosis	h0360603060501060202	NN	B-NP	B-Disease
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
stasis	stasis	s30202	NN	B-NP	O
prolonged	prolong	p60405203	VBD	B-VP	O
and	and	a530	CC	I-VP	O
intensified	intensify	i530520103	VBD	I-VP	O
exposure	exposure	e2102060	NN	B-NP	O
of	of	o100	IN	B-PP	O
upper	upper	u106	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
tract	tract	t6023	NN	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
to	to	t000	TO	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
candidates	candidate	c053030302	NNS	B-NP	O
for	for	f060	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
routinely	routinely	r0305040	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
obstructive	obstructive	o1236023010	JJ	B-NP	B-Disease
uropathy	uropathy	u601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Medial	Medial	m0304	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
spasm	spasm	s1025	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
media	medium	m030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
small	small	s504	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
in	in	i500	IN	B-PP	O
diameter	diameter	d050306	NN	B-NP	O
)	)	)000	)	O	O
previously	previously	p6010240	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
contain	contain	c05305	VB	I-VP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
vacuoles	vacuole	v020402	NNS	I-NP	O
,	,	,000	,	O	O
identified	identify	i30530103	VBN	B-VP	O
ultrastructurally	ultrastructurally	u436023602306040	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
herniations	herniation	h06503052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
into	into	i530	IN	B-PP	O
another	another	a50306	DT	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
intense	intense	i530520	JJ	B-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
would	would	w043	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
vacuoles	vacuole	v020402	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
tested	test	t02303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
media	medium	m030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
saphenous	saphenous	s010502	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
distal	distal	d02304	JJ	I-NP	O
branch	branch	b60520	NN	I-NP	O
,	,	,000	,	O	O
vasoconstriction	vasoconstriction	v02020523602305	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	I-Chemical
produced	produce	p6030203	VBD	B-VP	O
many	many	m050	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
hernias	hernia	h06502	NNS	I-NP	B-Disease
within	within	w0305	IN	B-PP	O
15	15	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
their	their	t060	PRP$	B-NP	O
number	number	n05106	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
about	about	a103	IN	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
original	original	o6020504	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
the	the	t000	DT	B-NP	O
vessel	vessel	v0204	NN	I-NP	O
was	be	w020	VBD	B-VP	O
almost	almost	a45023	RB	I-VP	O
restored	restore	r0230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

Triple	Triple	t60140	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
over	over	o106	IN	B-PP	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
severe	severe	s01060	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
media	medium	m030	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
smooth	smooth	s5030	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
susceptible	susceptible	s020130140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
damage	damage	d05020	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
medial	medial	m0304	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
instances	instance	i52305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
spasm	spasm	s1025	NN	I-NP	B-Disease
.	.	.000	.	O	O

Endothelial	Endothelial	e53030404	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
were	be	w060	VBD	B-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
paper	paper	p0106	NN	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
choriocapillaris	choriocapillaris	c060201040602	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
suspensions	suspension	s021052052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
:	:	:000	:	O	O
I	I	i000	LS	B-LST	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
documented	document	d020505303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
choriocapillaris	choriocapillaris	c060201040602	NN	I-NP	I-Disease
occlusions	occlusion	o2402052	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
blindness	blindness	b4053502	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
head	head	h030	NN	B-NP	O
and	and	a530	CC	O	O
neck	neck	n020	NN	B-NP	O
soft	soft	s013	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
tissue	tissue	t020	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
with	with	w030	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
had	have	h030	VBD	B-VP	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
hazy	hazy	h020	JJ	B-NP	O
sensorium	sensorium	s0520605	NN	I-NP	O
,	,	,000	,	O	O
superior	superior	s010606	JJ	B-NP	O
gaze	gaze	g020	NN	I-NP	O
palsy	palsy	p0420	NN	I-NP	B-Disease
,	,	,000	,	O	O
pupillary	pupillary	p0104060	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
conjunctival	conjunctival	c05205230104	JJ	B-NP	O
hemorrhages	hemorrhage	h05060202	NNS	I-NP	B-Disease
with	with	w030	IN	B-PP	O
edema	edema	e3050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Follow	Follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
changes	change	c05202	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
constricted	constrict	c0523602303	VBN	B-VP	O
visual	visual	v0204	JJ	B-NP	O
fields	field	f0432	NNS	I-NP	O
,	,	,000	,	O	O
optic	optic	o1302	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
pallor	pallor	p0406	NN	I-NP	O
,	,	,000	,	O	O
vascular	vascular	v020406	JJ	B-NP	O
attenuation	attenuation	a3050305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
chorioretinal	chorioretinal	c0606030504	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Abnormalities	Abnormality	a15065040302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pupil	pupil	p0104	NN	I-NP	O
and	and	a530	CC	I-NP	O
visual	visual	v0204	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
evoked	evoked	e10203	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
in	in	i500	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
amblyopia	amblyopia	a514010	NN	I-NP	B-Disease
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
blindness	blindness	b4053502	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
pupillary	pupillary	p0104060	JJ	I-NP	I-Disease
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
denervation	denervation	d050610305	NN	B-NP	O
supersensitivity	supersensitivity	s010620520301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
evoked	evoke	e10203	VBN	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
leg	leg	l020	NN	B-NP	B-Disease
cramps	cramp	c60512	NNS	I-NP	I-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
later	later	l0306	RB	B-ADVP	O
recovered	recover	r02010603	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
acuity	acuity	a2030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
pupillary	pupillary	p0104060	JJ	I-NP	I-Disease
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
denervation	denervation	d050610305	NN	B-NP	O
supersensitivity	supersensitivity	s010620520301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
evoked	evoke	e10203	VBN	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Suxamethonium	Suxamethonium	s0205030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
jaw	jaw	j000	NN	I-NP	B-Disease
stiffness	stiffness	s301502	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
11	11	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
nitrous	nitrous	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
pancuronium	pancuronium	p052060505	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
for	for	f060	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
a	a	a000	DT	I-NP	O
marked	marked	m06203	JJ	I-NP	O
jaw	jaw	j000	NN	I-NP	B-Disease
stiffness	stiffness	s301502	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
which	which	w020	WDT	B-NP	O
lasted	last	l02303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
apnoea	apnoea	a150	NN	B-NP	B-Disease
ensued	ensue	e5203	VBD	B-VP	O
and	and	a530	CC	O	O
he	he	h000	PRP	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
generalized	generalize	g0506040203	VBN	I-VP	O
severe	severe	s01060	JJ	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
lasting	last	l023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
atypical	atypical	a3010204	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
dibucaine	dibucaine	d0102050	NN	I-NP	B-Chemical
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
homozygocity	homozygocity	h05020202030	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
verified	verify	v060103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
family	family	f05040	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
prolonged	prolonged	p60405203	JJ	B-NP	B-Disease
jaw	jaw	j000	NN	I-NP	I-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
after	after	a1306	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
despite	despite	d021030	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
pancuronium	pancuronium	p052060505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
gouty	gouty	g030	NN	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
severe	severe	s01060	JJ	B-NP	O
,	,	,000	,	I-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
threatening	threaten	t060305052	VBG	B-VP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
developed	develop	d01040103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
gouty	gouty	g030	NN	I-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
and	and	a530	CC	O	O
consequent	consequent	c05202053	JJ	B-NP	O
hyporeninemic	hyporeninemic	h010605050502	JJ	I-NP	B-Disease
hypoaidosteronism	hypoaidosteronism	h01030230605025	NN	I-NP	I-Disease
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
balance	balance	b040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	I-NP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
or	or	o600	CC	O	O
preexisting	preexisting	p602023052	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
will	will	w040	MD	B-VP	O
help	help	h041	VB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
this	this	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
serious	serious	s0602	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Etomidate	Etomidate	e30503030	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
foreshortened	foreshorten	f06020630503	VBN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
outpatient	outpatient	o03103053	NN	B-NP	O
cystoscopy	cystoscopy	c02302010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
embarked	embark	e5106203	VBN	I-VP	O
upon	upon	u105	IN	B-PP	O
.	.	.000	.	O	O

Unpremedicated	Unpremedicated	u5160503020303	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Anaesthesia	Anaesthesia	a5023020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
etomidate	etomidate	e30503030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
interviewed	interview	i5306103	VBN	I-VP	O
personally	personally	p06205040	RB	B-ADVP	O
later	later	l0306	RB	B-NP	O
the	the	t000	DT	I-NP	O
same	same	s050	JJ	I-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
questionnaire	questionnaire	q02305060	NN	B-NP	O
three	three	t060	CD	I-NP	O
to	to	t000	TO	I-NP	O
four	four	f060	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
20	20	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
an	an	a500	DT	B-NP	O
unacceptable	unacceptable	u5020130140	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Venous	Venous	v0502	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
redness	redness	r03502	NN	B-NP	O
,	,	,000	,	O	O
pain	pain	p050	NN	B-NP	B-Disease
or	or	o600	CC	O	O
swelling	swell	s04052	VBG	B-VP	B-Disease
related	relate	r040303	VBN	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
site	site	s030	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
lasting	last	l023052	VBG	B-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
three	three	t060	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

Skeletal	Skeletal	s2040304	JJ	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
;	;	;000	:	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
experienced	experienced	e210605203	JJ	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
upset	upset	u1203	NN	I-NP	I-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
sufficiently	sufficiently	s010205340	RB	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
necessitate	necessitate	n020203030	VB	I-VP	O
abandoning	abandon	a105305052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
technique	technique	t0205020	NN	I-NP	O
.	.	.000	.	O	O

Nausea	Nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
25	25	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
disturbing	disturbing	d023061052	JJ	B-NP	O
emergence	emergence	e50620520	NN	I-NP	O
psychoses	psychos	p2020202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
responsive	responsive	r021052010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
mixed	mixed	m0203	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
11	11	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
47	47	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
modification	modification	m0301020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
motor	motor	m0306	NN	I-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
predominantly	predominantly	p603050505340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	I-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
dystonic	dystonic	d0230502	JJ	B-NP	B-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
(	(	(000	(	O	O
onset	onset	o5203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
upper	upper	u106	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
choreic	choreic	c0602	JJ	B-NP	B-Disease
mid	mid	m030	JJ	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
dose	dose	d020	NN	I-NP	I-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
increased	increase	i5260203	VBN	B-NP	O
brain	brain	b605	NN	I-NP	O
serotoninergic	serotoninergic	s0603050506202	JJ	I-NP	O
transmission	transmission	t605250205	NN	I-NP	O
with	with	w030	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
aggravating	aggravate	a260103052	VBG	B-VP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
motor	motor	m0306	NN	I-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
based	base	b0203	VBN	I-VP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
trimethoprim	trimethoprim	t6050301605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
sulfamethoxazole	sulfamethoxazole	s04105030202040	NN	B-NP	I-Chemical
,	,	,000	,	O	O
trimethoprim	trimethoprim	t6050301605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
cephalexin	cephalexin	c01040205	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
uncommon	uncommon	u520505	JJ	B-NP	O
serious	serious	s0602	JJ	I-NP	O
drug	drug	d602	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-VP	O
45	45	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
232	232	0000	CD	B-NP	O
,	,	,000	,	O	O
390	390	0000	CD	B-NP	O
people	people	p0140	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
trimethoprim	trimethoprim	t6050301605	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
sulfamethoxazole	sulfamethoxazole	s04105030202040	NN	B-NP	I-Chemical
(	(	(000	(	O	O
TMP	TMP	t510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
SMZ	SMZ	s520	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
266	266	0000	CD	B-NP	O
,	,	,000	,	O	O
951	951	0000	CD	B-NP	O
prescribed	prescribe	p60260103	VBN	I-NP	O
trimethoprim	trimethoprim	t6050301605	NN	I-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
196	196	0000	CD	B-NP	O
,	,	,000	,	O	O
397	397	0000	CD	B-NP	O
prescribed	prescribed	p60260103	JJ	I-NP	O
cephalexin	cephalexin	c01040205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
,	,	,000	,	O	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
skin	skin	s205	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
referral	referral	r010604	NN	B-NP	O
or	or	o600	CC	I-NP	O
hospitalization	hospitalization	h0210304020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
based	base	b0203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
information	information	i510650305	NN	B-NP	O
recorded	record	r0206303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
office	office	o1020	NN	B-NP	O
computers	computer	c05103062	NNS	I-NP	O
by	by	b000	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
general	general	g050604	JJ	I-NP	O
practitioners	practitioner	p60230305062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
Kingdom	Kingdom	k052305	NNP	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
records	record	r020632	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinically	clinically	c40502040	RB	B-NP	O
important	important	i51063053	JJ	I-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-SBAR	O
persons	person	p062052	NNS	B-NP	O
prescribed	prescribe	p60260103	VBD	B-VP	O
TMP	TMP	t510	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
SMZ	SMZ	s520	NN	B-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
prescribed	prescribe	p60260103	VBN	I-NP	O
trimethoprim	trimethoprim	t6050301605	NN	I-NP	B-Chemical
alone	alone	a4050	RB	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
those	those	t020	DT	B-NP	O
prescribed	prescribe	p60260103	VBN	I-NP	O
cephalexin	cephalexin	c01040205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
somewhat	somewhat	s0503	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
five	five	f010	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
was	be	w020	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
TMP	TMP	t510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
SMZ	SMZ	s520	NN	I-NP	I-Chemical
;	;	;000	:	O	O
of	of	o100	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
with	with	w030	IN	B-PP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
multiforme	multiforme	m043010650	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	O
Stevens	Stevens	s301052	NNP	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Johnson	Johnson	j05205	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
were	be	w060	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
TMP	TMP	t510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
SMZ	SMZ	s520	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
one	one	o500	CD	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	B-Disease
epidermal	epidermal	e10306504	JJ	I-NP	I-Disease
necrolysis	necrolysis	n026040202	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
took	take	t020	VBD	B-VP	O
cephalexin	cephalexin	c01040205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
five	five	f010	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
parenchymal	parenchymal	p060520504	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
,	,	,000	,	O	O
none	none	n050	NN	B-NP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
diseases	disease	d020202	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
is	be	i200	VBZ	B-VP	O
small	small	s504	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
compares	compare	c0510602	VBZ	B-VP	O
reasonably	reasonably	r02050140	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
many	many	m050	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MI	MI	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
university	university	u501062030	NN	I-NP	O
,	,	,000	,	O	O
university	university	u501062030	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
affiliated	affiliate	a1040303	VBN	I-VP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
community	community	c0505030	NN	B-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
total	total	t0304	NN	B-NP	O
of	of	o100	IN	B-PP	O
117	117	0000	CD	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

PARTICIPANTS	PARTICIPANTS	p06302010532	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-NP	O
29	29	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
died	die	d030	VBD	B-VP	O
;	;	;000	:	O	O
exhibited	exhibit	e2010303	VBN	B-NP	O
bradydysrhythmias	bradydysrhythmia	b60303026030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
;	;	;000	:	O	O
or	or	o600	CC	O	O
experienced	experienced	e210605203	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Despite	Despite	d021030	IN	B-PP	O
theoretical	theoretical	t06030204	JJ	B-NP	O
concerns	concern	c0520652	NNS	I-NP	O
that	that	t030	IN	B-NP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
enhance	enhance	e50520	VB	I-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
central	central	c053604	JJ	I-NP	I-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
anabolizing	anabolize	a5010402052	VBG	B-VP	O
agents	agent	a20532	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
still	still	s304	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
way	way	w000	NN	I-NP	O
from	from	f605	IN	B-PP	O
discovering	discover	d020106052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
unequivocal	unequivocal	u502010204	JJ	I-NP	O
pathogenetic	pathogenetic	p0302050302	JJ	I-NP	O
interpretation	interpretation	i530616030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Noteworthy	Noteworthy	n030630	JJ	B-NP	O
efforts	effort	e10632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
made	make	m030	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
field	field	f043	NN	I-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
recessive	recessive	r0202010	JJ	I-NP	O
autosomic	autosomic	a03020502	JJ	I-NP	O
form	form	f065	NN	I-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
bear	bear	b060	VB	I-VP	O
the	the	t000	DT	B-NP	O
closest	close	c402023	JJS	I-NP	O
resemblance	resemblance	r0205140520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
form	form	f065	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
point	point	p053	NN	I-NP	O
of	of	o100	IN	B-PP	O
view	view	v000	NN	B-NP	O
.	.	.000	.	O	O

Myopathy	Myopathy	m01030	NN	B-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
lack	lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
viruses	virus	v060202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
much	much	m020	JJ	B-NP	O
in	in	i500	IN	B-PP	O
common	common	c0505	JJ	B-ADJP	O
anatomically	anatomically	a5030502040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
pathologically	pathologically	p03040202040	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
form	form	f065	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
induced	induce	i530203	VBD	B-VP	O
myodystrophy	myodystrophy	m030236010	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
by	by	b000	IN	B-PP	O
giving	give	g01052	VBG	B-VP	O
it	it	i300	PRP	B-NP	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
lacking	lack	l02052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
degenerative	degenerative	d02050603010	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
brought	bring	b60203	VBD	B-VP	O
about	about	a103	RP	B-PRT	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
deficiency	deficiency	d01020520	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscles	muscle	m02402	NNS	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
illustrated	illustrate	i402360303	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
thus	thus	t020	RB	I-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
histological	histological	h02304020204	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myopathic	myopathic	m010302	JJ	B-NP	B-Disease
rat	rat	r030	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
experimentally	experimentally	e210605053040	RB	B-ADVP	O
are	be	a600	VBP	B-VP	O
extraordinarily	extraordinarily	e2360630506040	RB	B-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
as	as	a200	IN	B-SBAR	O
confirmed	confirm	c05106503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
biopsies	biopsy	b01202	NNS	B-NP	O
performed	perform	p06106503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
Orthopaedic	Orthopaedic	o63010302	NNP	I-NP	O
Traumatological	Traumatological	t6050304020204	NNP	I-NP	O
Centre	Centre	c05360	NNP	I-NP	O
,	,	,000	,	O	O
Florence	Florence	f4060520	NNP	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
encouraging	encouraging	e520602052	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
authoratative	authoratative	a03060303010	JJ	I-NP	O
departments	department	d0106350532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
myopathic	myopathic	m010302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
anabolizing	anabolize	a5010402052	VBG	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
encouraged	encourage	e52060203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
anabolizing	anabolize	a5010402052	VBG	B-VP	O
agent	agent	a2053	NN	B-NP	O
(	(	(000	(	O	O
Dianabol	Dianabol	d050104	NN	B-NP	B-Chemical
,	,	,000	,	O	O
CIBA	CIBA	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
rendered	render	r0530603	VBN	B-VP	O
myopathic	myopathic	m010302	JJ	B-ADJP	B-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
deficient	deficient	d0102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
way	way	w000	NN	I-NP	O
they	they	t000	PRP	B-NP	O
obtained	obtain	o130503	VBD	B-VP	O
appreciable	appreciable	a16020140	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
(	(	(000	(	O	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
50	50	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
70	70	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
forty	forty	f0630	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
of	of	o100	IN	B-PP	O
anabolizing	anabolize	a5010402052	VBG	B-VP	O
agent	agent	a2053	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
they	they	t000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
histological	histological	h02304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
"	"	"000	``	B-NP	O
regenerative	regenerative	r02050603010	JJ	I-NP	O
"	"	"000	''	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
however	however	h0106	RB	B-ADVP	O
maintained	maintain	m0530503	VBD	B-VP	O
its	its	i320	PRP$	B-NP	O
myopathic	myopathic	m010302	JJ	I-NP	B-Disease
characteristics	characteristic	c060230602302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anabolizing	anabolize	a5010402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
by	by	b000	IN	B-PP	O
affirming	affirm	a1065052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
undoubted	undoubted	u5301303	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anabolizing	anabolize	a5010402052	VBG	I-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
myopathic	myopathic	m010302	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
they	they	t000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
reservations	reservation	r0206103052	NNS	B-NP	O
as	as	a200	IN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
transfer	transfer	t6052106	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
field	field	f043	NN	I-NP	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
high	high	h020	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
continuously	continuously	c053050240	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
on	on	o500	IN	B-PP	O
virility	virility	v0604030	NN	B-NP	O
;	;	;000	:	O	O
because	because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
tissue	tissue	t020	NN	I-NP	O
injury	injury	i52060	NN	I-NP	O
too	too	t000	RB	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
occurs	occur	o2062	VBZ	B-VP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
vis	vi	v020	NNS	I-NP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
-	-	-000	:	O	O
vis	vi	v020	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
regeneration	regeneration	r0205060305	NN	I-NP	O
"	"	"000	''	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
finally	finally	f05040	RB	B-ADVP	O
because	because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dystrophic	dystrophic	d02360102	JJ	I-NP	O
injurious	injurious	i520602	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
certainly	certainly	c0630540	RB	B-ADVP	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
but	but	b030	CC	O	O
something	something	s0503052	NN	B-NP	O
as	as	a200	RB	B-ADJP	O
yet	yet	y030	RB	I-ADJP	O
unknown	unknown	u52505	JJ	I-ADJP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
:	:	:000	:	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
escalation	escalation	e2040305	NN	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Taxol	Taxol	t0204	NN	B-NP	B-Chemical
;	;	;000	:	O	O
Bristol	Bristol	b602304	NNP	B-NP	O
-	-	-000	:	O	O
Myers	Myers	m062	NNP	B-NP	O
Squibb	Squibb	s201	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
Princeton	Princeton	p60520305	NNP	B-NP	O
,	,	,000	,	O	O
NJ	NJ	n200	NNP	B-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
combined	combine	c0510503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
directed	direct	d0602303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
non	non	n050	AFX	O	B-Disease
-	-	-000	HYPH	O	I-Disease
small	small	s504	JJ	B-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Carboplatin	Carboplatin	c0610140305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
target	target	t06203	NN	I-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
time	time	t050	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Calvert	Calvert	c041063	NNP	I-NP	O
formula	formula	f065040	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
escalated	escalate	e2040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
cohorts	cohort	c0632	NNS	I-NP	O
from	from	f605	IN	B-PP	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
(	(	(000	(	I-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
I	I	i000	CD	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
175	175	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
200	200	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
225	225	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
225	225	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
m2	m2	0000	NN	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
expanded	expand	e2105303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
since	since	s0520	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
level	level	l0104	NN	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
(	(	(000	(	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
required	require	r020603	VBD	B-VP	O
modification	modification	m0301020305	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
nonhematologic	nonhematologic	n050503040202	JJ	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
(	(	(000	(	O	O
arthralgia	arthralgia	a63060420	NN	B-NP	B-Disease
and	and	a530	CC	O	O
sensory	sensory	s052060	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Therapeutic	Therapeutic	t06010302	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
all	all	a400	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
objective	objective	o12023010	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
17	17	0000	CD	B-NP	O
(	(	(000	(	O	O
two	two	t000	CD	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
partial	partial	p06304	JJ	I-NP	O
regressions	regression	r02602052	NNS	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
41	41	0000	CD	B-NP	O
previously	previously	p6010240	RB	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Toxicities	Toxicity	t02020302	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
identical	identical	i30530204	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Carboplatin	Carboplatin	c0610140305	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
add	add	a300	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	B-Disease
toxicities	toxicity	t02020302	NNS	I-NP	I-Disease
observed	observe	o1206103	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
/	/	/000	SYM	B-VP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
dosed	dose	d0203	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
well	well	w040	RB	B-NP	O
compensated	compensate	c0510520303	VBN	I-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Misoprostol	Misoprostol	m0201602304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
acutely	acutely	a203040	RB	I-VP	O
counteract	counteract	c05306023	VB	I-VP	O
the	the	t000	DT	B-NP	O
indomethacin	indomethacin	i5305030205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
well	well	w040	RB	B-NP	O
compensated	compensate	c0510520303	VBN	I-NP	O
cirrhotic	cirrhotic	c060302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
.	.	.000	.	O	O

Parameters	Parameter	p060503062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
and	and	a530	CC	O	O
tubular	tubular	t010406	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
water	water	w0306	NN	B-NP	O
handling	handling	h0534052	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
clearance	clearance	c4060520	NN	B-NP	O
techniques	technique	t02050202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
26	26	0000	CD	B-NP	O
well	well	w040	RB	I-NP	O
compensated	compensate	c0510520303	VBN	I-NP	O
cirrhotic	cirrhotic	c060302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
various	various	v0602	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
200	200	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
totally	totally	t03040	RB	I-VP	O
abolish	abolish	a104020	VB	I-VP	O
the	the	t000	DT	B-NP	O
deleterious	deleterious	d04030602	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
800	800	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
dose	dose	d020	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
worsening	worsening	w06205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
and	and	a530	CC	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
maximal	maximal	m020504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hour	hour	h060	NN	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
medications	medication	m030203052	NNS	B-NP	O
and	and	a530	CC	O	O
slowly	slowly	s4040	RB	B-VP	O
returned	return	r0306503	VBD	I-VP	O
toward	toward	t063	IN	B-PP	O
base	base	b020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
line	line	l050	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
until	until	u5304	IN	B-PP	O
this	this	t020	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
prudent	prudent	p603053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cirrhosis	cirrhosis	c060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
angio	angio	a520	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
oedema	oedema	o03050	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
drugs	drug	d602	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
well	well	w040	RB	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
or	or	o600	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
angio	angio	a520	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
oedema	oedema	o03050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Angiotensin	Angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
(	(	(000	(	O	I-Chemical
ACE	ACE	a200	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
inhibitors	inhibitor	i50103062	NNS	B-NP	I-Chemical
,	,	,000	,	O	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
introduced	introduce	i536030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Europe	Europe	e06010	NNP	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
middle	middle	m0340	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
eighties	eighty	e020302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
progressively	progressively	p60260201040	RB	B-ADVP	O
.	.	.000	.	O	O

Soon	Soon	s050	RB	B-PP	O
after	after	a1306	IN	I-PP	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ACE	ACE	a200	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
bouts	bout	b032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
angio	angio	a520	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
oedema	oedema	o03050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
wish	wish	w020	VBP	B-VP	O
to	to	t000	TO	I-VP	O
draw	draw	d600	VB	I-VP	O
attention	attention	a305305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-VP	O
ACE	ACE	a200	VB	I-VP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	B-NP	I-Chemical
after	after	a1306	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-PP	O
existing	exist	e2023052	VBG	B-NP	O
angio	angio	a520	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
oedema	oedema	o03050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Myoclonus	Myoclonus	m0240502	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lorazepam	lorazepam	l06020105	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
very	very	v060	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
birth	birth	b0630	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
weight	weight	w0203	NN	I-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

Lorazepam	Lorazepam	l06020105	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
being	be	b052	VBG	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
sedative	sedative	s0303010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
newborn	newborn	n01065	JJ	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
infant	infant	i51053	NN	I-NP	O
.	.	.000	.	O	O

Concern	Concern	c052065	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
raised	raise	r0203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lorazepam	lorazepam	l06020105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
age	age	a200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
very	very	v060	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
birth	birth	b0630	NN	I-NP	O
-	-	-000	HYPH	O	O
weight	weight	w0203	NN	B-NP	O
(	(	(000	(	O	O
VLBW	VLBW	v410	NN	B-NP	O
;	;	;000	:	O	O
<	<	<000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
500	500	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
infants	infant	i510532	NNS	B-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
young	young	y052	JJ	I-NP	O
infants	infant	i510532	NNS	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
birth	birth	b0630	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
<	<	<000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
500	500	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
,	,	,000	,	O	O
experienced	experience	e210605203	VBD	B-VP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lorazepam	lorazepam	l06020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
(	(	(000	(	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Injectable	Injectable	i520230140	JJ	B-NP	O
lorazepam	lorazepam	l06020105	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
in	in	i500	IN	B-PP	O
VLBW	VLBW	v410	NN	B-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

Transvenous	Transvenous	t605210502	JJ	B-NP	O
right	right	r0203	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pacing	pacing	p02052	NN	I-NP	O
during	during	d06052	IN	B-PP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	I-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
efforts	effort	e10632	NNS	I-NP	O
on	on	o500	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
circulatory	circulatory	c0620403060	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
viral	viral	v0604	JJ	I-NP	O
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
eosinophilic	eosinophilic	e0205010402	JJ	I-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
had	have	h030	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
hemosiderosis	hemosiderosis	h050203060202	NN	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cardiogenic	cardiogenic	c063020502	JJ	I-NP	B-Disease
shock	shock	s020	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
continuously	continuously	c053050240	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
venous	venous	v0502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
catheters	catheter	c0303062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
routine	routine	r03050	JJ	B-NP	O
noninvasive	noninvasive	n0505102010	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
introducer	introducer	i536030206	NN	I-NP	O
sheath	sheath	s030	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sterile	sterile	s306040	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
wires	wire	w0602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
readily	readily	r03040	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
should	should	s043	MD	O	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
arise	arise	a6020	VBP	B-VP	O
to	to	t000	TO	I-VP	O
terminate	terminate	t06505030	VB	I-VP	O
resistant	resistant	r02023053	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
cardiocirculatory	cardiocirculatory	c063020620403060	JJ	B-NP	O
arrest	arrest	a6023	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
extreme	extreme	e236050	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	B-Disease
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
48	48	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
admission	admission	a350205	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
(	(	(000	(	O	O
PICU	PICU	p020	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Right	Right	r0203	RB	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
wires	wire	w0602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
inserted	insert	i5206303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
during	during	d06052	IN	B-PP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
(	(	(000	(	O	O
CPR	CPR	c160	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
temporary	temporary	t05106060	JJ	I-NP	O
captured	captured	c0130603	JJ	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
and	and	a530	CC	I-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
output	output	o03103	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
death	death	d030	NN	B-NP	O
,	,	,000	,	O	O
within	within	w0305	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
60	60	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
used	use	u203	VBN	I-VP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
converted	convert	c05106303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
by	by	b000	IN	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
defibrillation	defibrillation	d01016040305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
three	three	t060	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
initiating	initiate	i50303052	VBG	B-VP	O
CPR	CPR	c160	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
cardiac	cardiac	c06302	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
during	during	d06052	IN	B-PP	O
resuscitative	resuscitative	r02020303010	JJ	B-NP	O
efforts	effort	e10632	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
value	value	v040	NN	I-NP	O
in	in	i500	IN	B-PP	O
and	and	a530	CC	I-PP	O
of	of	o100	IN	I-PP	O
itself	itself	i32041	PRP	B-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	O	O
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
temporary	temporary	t05106060	JJ	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
stability	stability	s30104030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
this	this	t020	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
additional	additional	a3030504	JJ	B-NP	O
time	time	t050	NN	I-NP	O
needed	need	n0303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
institute	institute	i52303030	VB	I-VP	O
other	other	o306	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
modalities	modality	m03040302	NNS	I-NP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
granisetron	granisetron	g6050203605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine	hydroxytryptamine	h0360203601305050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
antiemetic	antiemetic	a53050302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
safety	safety	s01030	NN	B-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
granisetron	granisetron	g6050203605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Kytril	Kytril	k03604	NNP	B-NP	B-Chemical
;	;	;000	:	O	O
SmithKline	SmithKline	s503024050	NNP	B-NP	O
Beecham	Beecham	b0205	NNP	I-NP	O
Pharmaceuticals	Pharmaceutical	p065020302042	NNPS	I-NP	O
,	,	,000	,	O	O
Philadelphia	Philadelphia	p04030410	NNP	B-NP	O
,	,	,000	,	O	O
PA	PA	p000	NNP	B-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
(	(	(000	(	O	O
IV	IV	i100	CD	O	O
)	)	)000	)	O	O
dose	dose	d020	NN	B-NP	O
for	for	f060	IN	B-PP	O
prophylaxis	prophylaxis	p601040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
eighty	eighty	e02030	CD	I-NP	O
-	-	-000	HYPH	O	O
four	four	f060	CD	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
-	-	-000	HYPH	O	O
naive	naive	n010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
81	81	0000	CD	B-NP	O
to	to	t000	TO	O	O
120	120	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
granisetron	granisetron	g6050203605	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
40	40	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
before	before	b01060	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
inpatient	inpatient	i5103053	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
24	24	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
,	,	,000	,	O	O
retching	retching	r032052	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
appetite	appetite	a103030	NN	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
incidence	incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
experiences	experience	e210605202	NNS	I-NP	O
and	and	a530	CC	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
parameter	parameter	p06050306	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
After	After	a1306	IN	B-PP	O
granisetron	granisetron	g6050203605	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
40	40	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
two	two	t000	CD	B-NP	O
vomiting	vomit	v0503052	VBG	B-VP	B-Disease
or	or	o600	CC	I-VP	O
retching	retch	r032052	VBG	I-VP	O
episodes	episode	e1020302	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
antiemetic	antiemetic	a53050302	JJ	I-NP	O
rescue	rescue	r020	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
no	no	n000	DT	B-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
retching	retching	r032052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
antiemetic	antiemetic	a53050302	JJ	I-NP	O
rescue	rescue	r020	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
41	41	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
47	47	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
longer	long	l05206	JJR	I-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	O	O
0015	0015	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fewer	few	f060	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
additional	additional	a3030504	JJ	B-NP	O
antiemetic	antiemetic	a53050302	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
granisetron	granisetron	g6050203605	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
appetite	appetite	a103030	JJ	B-NP	O
return	return	r03065	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
040	040	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Headache	Headache	h03020	PRP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequently	frequently	f60205340	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
40	40	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
granisetron	granisetron	g6050203605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
vomiting	vomit	v0503052	VBG	I-VP	B-Disease
in	in	i500	IN	B-PP	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
60	60	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
81	81	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
and	and	a530	CC	O	O
totally	totally	t03040	RB	B-VP	O
prevented	prevent	p60105303	VBD	I-VP	O
vomiting	vomit	v0503052	VBG	I-VP	B-Disease
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
47	47	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Granisetron	Granisetron	g6050203605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
all	all	a400	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
atrioventricular	atrioventricular	a36010536020406	JJ	B-NP	B-Disease
(	(	(000	(	O	I-Disease
AV	AV	a100	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
block	block	b402	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARIES	SUMMARIES	s050602	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
hyperaldosteronism	hyperaldosteronism	h01060430230605025	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
480	480	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	B-NP	O
and	and	a530	CC	I-NP	O
spironolactone	spironolactone	s1060504023050	NN	I-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
minimal	minimal	m050504	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
bid	bid	b030	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
AV	AV	a100	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
upon	upon	u105	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
65	65	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
extended	extend	e2305303	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
240	240	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
bid	bid	b030	RB	B-ADVP	O
she	she	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
AV	AV	a100	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
all	all	a400	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
two	two	t000	CD	B-NP	O
such	such	s020	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
various	various	v0602	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
such	such	s020	PDT	B-NP	O
an	an	a500	DT	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
acquainted	acquaint	a205303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
possibly	possibly	p020140	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
two	two	t000	CD	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Caution	Caution	c0305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
combining	combine	c05105052	VBG	B-VP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
sinus	sinus	s0502	NN	B-NP	O
or	or	o600	CC	I-NP	O
AV	AV	a100	NN	I-NP	O
node	node	n030	NN	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
may	may	m000	MD	B-VP	O
act	act	a230	VB	I-VP	O
synergistically	synergistically	s0506202302040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
AV	AV	a100	NN	I-NP	O
node	node	n030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
.	.	.000	.	O	O

Pharmacological	Pharmacological	p0650204020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
dihydrothienopyridine	dihydrothienopyridine	d0360305010603050	NN	I-NP	B-Chemical
calcium	calcium	c04205	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
312	312	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

5th	5th	5300	JJ	B-NP	O
communication	communication	c0505020305	NN	I-NP	O
:	:	:000	:	O	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
312	312	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
312	312	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
312	312	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
l	l	l000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
audiogenic	audiogenic	a03020502	JJ	I-NP	B-Disease
tonic	tonic	t0502	JJ	I-NP	I-Disease
convulsions	convulsion	c051042052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
ED50	ED50	0000	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
27	27	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
23	23	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
flunarizine	flunarizine	f4050602050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
34	34	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
44	44	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
moderate	moderate	m0306030	JJ	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
312	312	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
clonic	clonic	c40502	JJ	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
85	85	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
bemegride	bemegride	b05026030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
,	,	,000	,	O	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
electroshock	electroshock	e402360202	NN	B-NP	O
in	in	i500	IN	B-PP	O
Slc	Slc	s420	NN	B-NP	O
:	:	:000	:	O	O
ddY	ddY	d300	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
312	312	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Transmural	Transmural	t605250604	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
sumatriptan	sumatriptan	s0503601305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
sumatriptan	sumatriptan	s0503601305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
tightness	tightness	t0203502	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
chest	chest	c023	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
unknown	unknown	u52505	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sumatriptan	sumatriptan	s0503601305	NN	B-NP	B-Chemical
6	6	6000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
cluster	cluster	c402306	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
ischaemic	ischaemic	i20502	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
or	or	o600	CC	O	O
Prinzmetal	Prinzmetal	p605250304	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
angina	angina	a52050	NN	I-NP	I-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
recovered	recover	r02010603	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
complications	complication	c05140203052	NNS	B-NP	O
.	.	.000	.	O	O

Flumazenil	Flumazenil	f405020504	NNP	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
mixed	mix	m0203	VBN	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
intoxications	intoxication	i53020203052	NNS	I-NP	O
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
HYPOTHESIS	HYPOTHESIS	h01030202	NN	I-NP	O
:	:	:000	:	O	O
Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
unmask	unmask	u502	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
mixed	mix	m0203	VBN	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	NNP	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	B-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
IP	IP	i100	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
groups	group	g6012	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
challenged	challenge	c0405203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
or	or	o600	CC	I-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
IP	IP	i100	NN	I-NP	O
.	.	.000	.	O	O

Animal	Animal	a50504	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
(	(	(000	(	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	O	O
incidence	incidence	i52030520	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
death	death	d030	NN	B-NP	O
(	(	(000	(	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	O	O
incidence	incidence	i52030520	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cortical	cortical	c0630204	JJ	B-NP	O
EEG	EEG	e020	NN	I-NP	O
tracings	tracing	t602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

INTERVENTIONS	INTERVENTIONS	i53061053052	NNS	B-NP	O
:	:	:000	:	O	O
Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
animals	animal	a505042	NNS	B-NP	O
after	after	a1306	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
developing	develop	d010401052	VBG	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
received	receive	r020103	VBD	B-VP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
became	become	b02050	VBD	B-VP	O
somnolent	somnolent	s0504053	JJ	B-ADJP	O
and	and	a530	CC	O	O
none	none	n050	NN	B-NP	O
died	die	d030	VBD	B-VP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
3	3	3000	CD	I-NP	O
received	receive	r020103	VBD	B-VP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
became	become	b02050	VBD	B-VP	O
somnolent	somnolent	s0504053	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
then	then	t050	RB	B-ADJP	O
active	active	a23010	JJ	I-ADJP	O
after	after	a1306	IN	B-SBAR	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
no	no	n000	DT	B-NP	O
overt	overt	o1063	JJ	I-NP	O
or	or	o600	CC	I-NP	O
EEG	EEG	e020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
detectable	detectable	d030230140	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
5	5	5000	CD	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
,	,	,000	,	O	O
followed	follow	f0403	VBD	B-VP	O
later	later	l0306	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	O
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
6	6	6000	CD	I-NP	O
received	receive	r020103	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
also	also	a420	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	O
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Flumazenil	Flumazenil	f405020504	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
unmask	unmask	u502	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
increase	increase	i526020	VB	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
intoxications	intoxication	i53020203052	NNS	I-NP	O
.	.	.000	.	O	O

Mechanisms	Mechanism	m02050252	NNS	B-NP	O
for	for	f060	IN	B-PP	O
protective	protective	p603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
free	free	f600	JJ	B-NP	O
radical	radical	r030204	NN	I-NP	O
scavengers	scavenger	s201052062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
free	free	f600	JJ	B-NP	O
radical	radical	r030204	NN	I-NP	O
scavengers	scavenger	s201052062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
GM	GM	g500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
for	for	f060	IN	B-PP	O
13	13	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
RBF	RBF	r100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
inulin	inulin	i50405	NN	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
(	(	(000	(	O	O
CIn	CIn	c050	NN	B-NP	O
)	)	)000	)	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
marked	marked	m06203	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
guanosine	guanosine	g0502050	NN	I-NP	B-Chemical
3	3	3000	CD	I-NP	I-Chemical
'	'	'000	SYM	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
5	5	5000	CD	B-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
cyclic	cyclic	c02402	JJ	I-NP	I-Chemical
monophosphate	monophosphate	m0501021030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
cGMP	cGMP	c251	NN	B-NP	B-Chemical
)	)	)000	)	O	O
excretion	excretion	e260305	NN	B-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
renin	renin	r0505	NN	I-NP	O
and	and	a530	CC	I-NP	O
endothelin	endothelin	e53030405	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
contents	content	c0530532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Superoxide	Superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
(	(	(000	(	O	O
SOD	SOD	s030	NN	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
dimethylthiourea	dimethylthiourea	d0503043060	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DMTU	DMTU	d530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-VP	O
lessened	lessen	l020503	VBD	I-VP	O
the	the	t000	DT	B-NP	O
GM	GM	g500	NNP	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
decrement	decrement	d02605053	NN	I-NP	O
in	in	i500	IN	B-PP	O
CIn	CIn	c050	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
SOD	SOD	s030	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
RBF	RBF	r100	NN	B-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
cGMP	cGMP	c251	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
renin	renin	r0505	NN	I-NP	O
and	and	a530	CC	I-NP	O
endothelin	endothelin	e53030405	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
content	content	c053053	NN	I-NP	O
.	.	.000	.	O	O

SOD	SOD	s030	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
tubular	tubular	t010406	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
DMTU	DMTU	d530	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tubular	tubular	t010406	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
renal	renal	r0504	JJ	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
and	and	a530	CC	O	O
vasoactive	vasoactive	v02023010	JJ	B-NP	O
substances	substance	s012305202	NNS	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
SOD	SOD	s030	NN	B-NP	O
nor	nor	n060	CC	I-NP	O
DMTU	DMTU	d530	NN	I-NP	B-Chemical
affected	affect	a102303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
GM	GM	g500	NNP	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
in	in	i500	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
both	both	b030	CC	O	O
SOD	SOD	s030	NN	B-NP	O
and	and	a530	CC	I-NP	O
DMTU	DMTU	d530	NN	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
protective	protective	p603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
differ	differ	d0106	VBP	B-VP	O
for	for	f060	IN	B-PP	O
SOD	SOD	s030	NN	B-NP	O
and	and	a530	CC	I-NP	O
DMTU	DMTU	d530	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	LS	B-LST	O
)	)	)000	)	O	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
anions	anion	a5052	NNS	I-NP	O
play	play	p400	VBP	B-VP	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
.	.	.000	.	O	O

Cephalothin	Cephalothin	c01040305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
Coombs	Coombs	c0512	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
cephalothin	cephalothin	c01040305	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
cephalothin	cephalothin	c01040305	NN	I-NP	B-Chemical
IgG	IgG	i200	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
serum	serum	s0605	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
eluates	eluate	e40302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
erythrocytes	erythrocyte	e60306020302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
nonimmunologic	nonimmunologic	n050505040202	JJ	B-NP	O
binding	binding	b053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	I-NP	O
s	s	s000	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
her	her	h060	PRP$	B-NP	O
own	own	o050	JJ	I-NP	O
and	and	a530	CC	I-NP	O
cephalothin	cephalothin	c01040305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
coated	coat	c0303	VBN	B-NP	O
normal	normal	n06504	JJ	I-NP	O
red	red	r030	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
sensitized	sensitize	s052030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cephalothin	cephalothin	c01040305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemias	anemia	a50502	NNS	I-NP	I-Disease
reveals	reveal	r01042	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
complexity	complexity	c051402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
immune	immune	i5050	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
during	during	d06052	IN	B-PP	O
hypertrophy	hypertrophy	h010636010	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	B-NP	O
to	to	t000	TO	B-VP	O
synthesize	synthesize	s05302020	VB	I-VP	O
DNA	DNA	d500	NN	B-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
delivered	deliver	d04010603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
osmotic	osmotic	o250302	JJ	B-NP	O
minipump	minipump	m0501051	NN	I-NP	O
implantation	implantation	i5140530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
C3Heb	C3Heb	0000	NN	I-NP	O
/	/	/000	SYM	B-VP	O
FeJ	FeJ	f020	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
46	46	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
19	19	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
DNA	DNA	d500	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
autoradiographic	autoradiographic	a0306030260102	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
or	or	o600	CC	O	O
hypertrophic	hypertrophic	h0106360102	JJ	B-NP	B-Disease
hearts	heart	h0632	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
survey	survey	s0610	NN	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
inbred	inbred	i51603	JJ	I-NP	O
strains	strain	s36052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	I-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
13	13	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
mononucleate	mononucleate	m0505024030	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
differentiation	differentiation	d01060530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
influenced	influence	i51405203	VBN	I-VP	O
directly	directly	d0602340	RB	B-ADVP	O
or	or	o600	CC	B-ADVP	O
indirectly	indirectly	i530602340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
background	background	b026053	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
capacity	capacity	c0102030	NN	I-NP	O
for	for	f060	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
DNA	DNA	d500	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
subject	subject	s012023	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
strains	strain	s36052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
comprising	comprise	c051602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
extremes	extreme	e2360502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
survey	survey	s0610	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
adult	adult	a3043	JJ	B-NP	O
mouse	mouse	m020	NN	I-NP	O
atrial	atrial	a3604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
synthesize	synthesize	s05302020	VB	I-VP	O
DNA	DNA	d500	NN	B-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ANP	ANP	a510	NN	I-NP	O
in	in	i500	IN	B-PP	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
influence	influence	i5140520	NN	B-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
arginine	arginine	a6205050	NN	I-NP	B-Chemical
vasopressin	vasopressin	v020160205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AVP	AVP	a100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
of	of	o100	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
(	(	(000	(	O	O
ANP	ANP	a510	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
(	(	(000	(	O	O
WKY	WKY	w200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
spontaneously	spontaneously	s1053050240	RB	B-ADJP	O
hypertensive	hypertensive	h01063052010	JJ	I-ADJP	B-Disease
(	(	(000	(	O	O
SHR	SHR	s060	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
30	30	0000	CD	B-NP	O
WKY	WKY	w200	NN	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
SHR	SHR	s060	NN	I-NP	O
,	,	,000	,	O	O
chronically	chronically	c060502040	RB	B-VP	O
instrumented	instrument	i52360505303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
guide	guide	g030	NN	B-NP	O
tubes	tube	t0102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
ventricle	ventricle	v05360240	NN	I-NP	O
(	(	(000	(	O	O
LV	LV	l100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
arterial	arterial	a630604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
venous	venous	v0502	JJ	I-NP	O
catheters	catheter	c0303062	NNS	I-NP	O
.	.	.000	.	O	O

MAP	MAP	m010	NN	B-NP	O
and	and	a530	CC	I-NP	O
HR	HR	h600	NN	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
injections	injection	i52023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
vehicle	vehicle	v0240	NN	B-NP	O
or	or	o600	CC	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
25	25	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
125	125	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
500	500	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ANP	ANP	a510	NN	B-NP	O
.	.	.000	.	O	O

Sensitivity	Sensitivity	s0520301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
baroreflex	baroreflex	b060601402	NN	B-NP	O
(	(	(000	(	O	O
CCB	CCB	c210	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
expressed	express	e2160203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
slope	slope	s4010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
regression	regression	r0260205	NN	I-NP	O
line	line	l050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
relationships	relationship	r0403052012	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
SAP	SAP	s010	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
HR	HR	h600	NN	B-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
HRp	HRp	h610	NN	B-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Phe	Phe	p000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SN	SN	s500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

CCB	CCB	c210	NN	B-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
,	,	,000	,	O	O
AVP	AVP	a100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ANP	ANP	a510	NN	B-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
peptides	peptide	p0130302	NNS	I-NP	O
together	together	t020306	RB	B-ADVP	O
.	.	.000	.	O	O

Increases	Increase	i5260202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
LV	LV	l100	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
WKY	WKY	w200	NN	B-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

ANP	ANP	a510	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
strains	strain	s36052	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
abolished	abolish	a1040203	VBD	B-VP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
MAP	MAP	m010	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
WKY	WKY	w200	NN	B-NP	O
and	and	a530	CC	I-NP	O
SHR	SHR	s060	NN	I-NP	O
.	.	.000	.	O	O

CCB	CCB	c210	NN	B-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
WKY	WKY	w200	NN	B-NP	O
and	and	a530	CC	I-NP	O
SHR	SHR	s060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
SN	SN	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
WKY	WKY	w200	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ANP	ANP	a510	NN	B-NP	O
,	,	,000	,	I-NP	O
AVP	AVP	a100	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
ANP	ANP	a510	NN	I-NP	O
+	+	+000	SYM	B-NP	O
AVP	AVP	a100	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
CCB	CCB	c210	NN	B-NP	O
during	during	d06052	IN	B-PP	O
Phe	Phe	p000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
MAP	MAP	m010	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
centrally	centrally	c0536040	RB	B-NP	O
applied	apply	a1403	VBN	I-NP	O
AVP	AVP	a100	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
ANP	ANP	a510	NN	I-NP	O
exert	exert	e2063	VBP	B-VP	O
differential	differential	d010605304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
baroreflex	baroreflex	b060601402	NN	B-NP	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
WKY	WKY	w200	NN	B-NP	O
and	and	a530	CC	I-NP	O
SHR	SHR	s060	NN	I-NP	O
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
interaction	interaction	i530602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
peptides	peptide	p0130302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
regulation	regulation	r02040305	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Cutaneous	Cutaneous	c030502	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
causing	cause	c02052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
intracerebral	intracerebral	i536020601604	JJ	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
intercerebral	intercerebral	i530620601604	JJ	B-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
coagulopathy	coagulopathy	c020401030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
39	39	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
had	have	h030	VBD	B-VP	O
spread	spread	s1603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
poison	poison	p0205	NN	I-NP	O
around	around	a6053	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
house	house	h020	NN	I-NP	O
weekly	weekly	w0240	RB	B-VP	O
using	use	u2052	VBG	I-VP	O
her	her	h060	PRP$	B-NP	O
bare	bare	b060	JJ	I-NP	O
hands	hand	h0532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
washing	wash	w02052	VBG	I-NP	O
post	post	p023	NN	I-NP	O
application	application	a14020305	NN	I-NP	O
.	.	.000	.	O	O

Percutaneous	Percutaneous	p062030502	JJ	B-NP	O
absorption	absorption	a12061305	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
causing	cause	c02052	VBG	B-VP	O
coagulopathy	coagulopathy	c020401030	NN	B-NP	B-Disease
,	,	,000	,	O	O
reported	report	r0106303	VBD	B-VP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
if	if	i100	IN	B-SBAR	O
protective	protective	p603023010	JJ	B-NP	O
measures	measure	m020602	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
gloves	glove	g40102	NNS	B-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
with	with	w030	IN	B-PP	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
she	she	s000	PRP	B-NP	O
took	take	t020	VBD	B-VP	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
exacerbated	exacerbate	e2020610303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
coagulopathy	coagulopathy	c020401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Pediatric	Pediatric	p0303602	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
1986	1986	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
February	February	f016060	NNP	B-NP	O
1993	1993	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
40	40	0000	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
aged	age	a203	VBN	B-VP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
18	18	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
average	average	a106020	JJ	B-NP	O
age	age	a200	NN	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
underwent	undergo	u5306053	VBD	B-VP	O
heart	heart	h063	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Indications	Indication	i530203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
(	(	(000	(	O	O
52	52	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
congenital	congenital	c052050304	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
repair	repair	r0106	NN	I-NP	O
(	(	(000	(	O	O
71	71	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hypertrophic	hypertrophic	h0106360102	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
managed	manage	m050203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
azathioprine	azathioprine	a203016050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
with	with	w030	IN	B-PP	O
antilymphocyte	antilymphocyte	a530405102030	NN	B-NP	O
globulin	globulin	g4010405	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

Steroids	Steroid	s306032	NNS	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
39	39	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
for	for	f060	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
weaning	weaning	w05052	NN	B-NP	O
was	be	w020	VBD	B-VP	O
always	always	a402	RB	I-VP	O
attempted	attempt	a3051303	VBN	I-VP	O
and	and	a530	CC	O	O
generally	generally	g0506040	RB	B-ADJP	O
successful	successful	s0202104	JJ	I-ADJP	O
(	(	(000	(	O	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
maintenance	maintenance	m053050520	NN	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
perioperative	perioperative	p06010603010	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
died	die	d030	VBD	B-VP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
no	no	n000	DT	B-NP	O
deaths	death	d0302	NNS	I-NP	O
related	relate	r040303	VBN	B-ADJP	O
to	to	t000	TO	B-PP	O
rejection	rejection	r0202305	NN	B-NP	O
or	or	o600	CC	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Average	Average	a106020	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
was	be	w020	VBD	B-VP	O
36	36	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
19	19	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	I-NP	O
65	65	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Cumulative	Cumulative	c050403010	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
88	88	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
7	7	7000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
rejection	rejection	r0202305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
noninvasively	noninvasively	n050510201040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
month	month	m0530	NN	I-NP	O
,	,	,000	,	O	O
89	89	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
rejection	rejection	r0202305	NN	B-NP	O
.	.	.000	.	O	O

Freedom	Freedom	f60305	NN	B-NP	O
from	from	f605	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
83	83	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
and	and	a530	CC	O	O
65	65	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

Cytomegalovirus	Cytomegalovirus	c03050204010602	NN	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
ganciclovir	ganciclovir	g0520240106	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
growth	growth	g6030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
annual	annual	a504	JJ	B-NP	O
catheterizations	catheterization	c0303060203052	NNS	I-NP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
sign	sign	s025	NN	I-NP	O
of	of	o100	IN	B-PP	O
graft	graft	g6013	NN	B-NP	O
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
disabled	disabled	d0201403	JJ	B-ADJP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
lymphoproliferative	lymphoproliferative	l05101604010603010	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Delirium	Delirium	d040605	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
high	high	h020	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
tricyclic	tricyclic	t60202402	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
well	well	w040	RB	I-VP	O
established	establish	e230140203	VBN	I-VP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
few	few	f000	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
exist	exist	e2023	VBP	B-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
(	(	(000	(	O	O
SSRIs	SSRI	s2602	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
citalopram	citalopram	c030401605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
600	600	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
somnolence	somnolence	s05040520	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
difficulties	difficulty	d010204302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Widespread	Widespread	w03021603	JJ	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
linked	link	l05203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SSRIs	SSRI	s2602	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hyperkinetic	hyperkinetic	h01062050302	JJ	I-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	B-Disease
connected	connect	c0502303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
desmethylfluoxetine	desmethylfluoxetine	d0250304140203050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentration	concentration	c05205360305	NN	B-NP	O
.	.	.000	.	O	O

Pulmonary	Pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
shock	shock	s020	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
aracytine	aracytine	a60203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
C	C	c000	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
lymphoma	lymphoma	l051050	NN	B-NP	B-Disease
;	;	;000	:	O	O
possible	possible	p020140	JJ	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
TNF	TNF	t510	NN	B-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
and	and	a530	CC	O	O
PAF	PAF	p010	NN	B-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
23	23	0000	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
Ara	Ara	a600	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
C	C	c000	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
lymphomas	lymphoma	l0510502	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
institution	institution	i523030305	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
strikingly	strikingly	s360205240	RB	I-NP	O
similar	similar	s050406	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
fever	fever	f0106	NN	B-NP	B-Disease
,	,	,000	,	O	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
,	,	,000	,	O	O
shock	shock	s020	NN	B-NP	B-Disease
,	,	,000	,	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
metabolic	metabolic	m03010402	JJ	B-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
leukocytosis	leukocytosis	l0202030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Thorough	Thorough	t06020	IN	B-PP	O
bacteriological	bacteriological	b0230604020204	JJ	B-NP	O
screening	screening	s2605052	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
provide	provide	p601030	VB	I-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
infection	infection	i5102305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Sequential	Sequential	s0205304	JJ	B-NP	O
biological	biological	b04020204	JJ	I-NP	O
assays	assay	a202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
TNF	TNF	t510	NN	I-NP	O
and	and	a530	CC	I-NP	O
PAF	PAF	p010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
Ara	Ara	a600	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
C	C	c000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
to	to	t000	TO	B-PP	O
ten	ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

TNF	TNF	t510	NN	B-NP	O
and	and	a530	CC	I-NP	O
PAF	PAF	p010	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
of	of	o100	IN	B-PP	O
respectively	respectively	r02102301040	RB	B-NP	O
two	two	t000	CD	I-NP	O
and	and	a530	CC	I-NP	O
four	four	f060	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
six	six	s020	CD	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
TNF	TNF	t510	NN	B-NP	O
and	and	a530	CC	I-NP	O
PAF	PAF	p010	NN	I-NP	O
are	be	a600	VBP	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
septic	septic	s01302	JJ	B-NP	O
shock	shock	s020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
adult	adult	a3043	JJ	B-NP	B-Disease
respiratory	respiratory	r0210603060	JJ	I-NP	I-Disease
distress	distress	d023602	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
hypothesize	hypothesize	h010302020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
Ara	Ara	a600	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
C	C	c000	NN	B-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cytokine	cytokine	c0302050	NN	B-NP	O
release	release	r04020	NN	I-NP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
against	against	a20523	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
benzothiazepine	benzothiazepine	b052030201050	NN	I-NP	I-Chemical
calcium	calcium	c04205	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
week	week	w020	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
atrial	atrial	a3604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
papillary	papillary	p0104060	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
responses	response	r02105202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
or	or	o600	CC	O	O
enhanced	enhance	e505203	VBN	B-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
alpha	alpha	a410	NN	I-NP	O
and	and	a530	CC	O	O
beta	beta	b030	NN	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
densities	density	d0520302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
death	death	d030	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
papillary	papillary	p0104060	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
restored	restore	r0230603	VBD	B-VP	O
left	left	l013	JJ	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
and	and	a530	CC	O	O
enhanced	enhance	e505203	VBN	B-VP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
papillary	papillary	p0104060	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
clentiazem	clentiazem	c40530205	NN	I-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
down	down	d050	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	NN	B-NP	O
and	and	a530	CC	O	O
beta	beta	b030	NN	B-NP	O
adrenoceptors	adrenoceptor	a360502013062	NNS	I-NP	O
.	.	.000	.	O	O

Interestingly	Interestingly	i530602305240	RB	B-ADVP	O
,	,	,000	,	O	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
infused	infuse	i510203	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
densities	density	d0520302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
ventricle	ventricle	v05360240	NN	I-NP	O
.	.	.000	.	O	O

Clentiazem	Clentiazem	c40530205	NNP	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
partially	partially	p063040	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
clentiazem	clentiazem	c40530205	NN	B-NP	B-Chemical
attenuated	attenuate	a3050303	VBD	B-VP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

Kaliuretic	Kaliuretic	k04060302	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Hypokalemia	Hypokalemia	h010204050	NN	B-NP	B-Disease
,	,	,000	,	O	O
sometimes	sometimes	s05030502	RB	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
normokalemic	normokalemic	n06502040502	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
by	by	b000	IN	B-PP	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
,	,	,000	,	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
urinary	urinary	u605060	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Dopa	Dopa	d010	NN	I-NP	I-Chemical
intake	intake	i53020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
sometimes	sometimes	s05030502	RB	B-ADVP	O
also	also	a420	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypokalemic	hypokalemic	h0102040502	JJ	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
normokalemic	normokalemic	n06502040502	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
prohibited	prohibit	p6010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
dopa	dopa	d010	NN	I-NP	O
decarbodylase	decarbodylase	d020610304020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
why	why	w000	WRB	B-ADVP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
others	other	o3062	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
aldosterone	aldosterone	a4302306050	NN	B-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
probably	probably	p6010140	RB	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
blocking	blocking	b402052	NN	I-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
monitored	monitor	m05030603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
in	in	i500	IN	B-PP	O
freely	freely	f6040	RB	B-ADVP	O
moving	move	m01052	VBG	B-VP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
potential	potential	p0305304	JJ	B-NP	O
protectors	protector	p603023062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
laboratory	laboratory	l010603060	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
histology	histology	h02304020	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	B-ADJP	O
commonly	commonly	c050540	RB	I-ADJP	O
used	use	u203	VBN	I-ADJP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
monitoring	monitor	m050306052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
large	large	l0620	JJ	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
ECG	ECG	e200	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
freely	freely	f6040	RB	B-ADVP	O
moving	move	m01052	VBG	B-VP	O
mice	mouse	m020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
telemetry	telemetry	t04050360	NN	B-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
of	of	o100	IN	B-PP	O
freely	freely	f6040	RB	B-VP	O
moving	move	m01052	VBG	I-VP	O
BALB	BALB	b041	NN	B-NP	O
/	/	/000	SYM	B-VP	O
c	c	c000	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ICRF	ICRF	i261	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
187	187	0000	CD	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ST	ST	s300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
widened	widen	w030503	VBD	B-VP	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
to	to	t000	TO	B-PP	O
56	56	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
11	11	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
ms	m	m200	NNS	I-NP	O
in	in	i500	IN	B-PP	O
week	week	w020	NN	B-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
weekly	weekly	w0240	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
plus	plus	p402	CC	O	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
observation	observation	o120610305	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
sacrifice	sacrifice	s02601020	NN	B-NP	O
the	the	t000	DT	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enlarged	enlarge	e5406203	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
atria	atria	a360	NN	I-NP	O
were	be	w060	VBD	B-VP	O
hypertrophic	hypertrophic	h0106360102	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
schedule	schedule	s203040	NN	I-NP	O
exerted	exert	e206303	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
than	than	t050	IN	B-SBAR	O
needed	need	n0303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
protective	protective	p603023010	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ICRF	ICRF	i261	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
187	187	0000	CD	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
with	with	w030	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
general	general	g050604	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
weekly	weekly	w0240	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
plus	plus	p402	CC	O	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
observation	observation	o120610305	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
schedule	schedule	s203040	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
'	'	'000	POS	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
sacrifice	sacrifice	s02601020	NN	B-NP	O
and	and	a530	CC	I-NP	O
ICRF	ICRF	i261	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
187	187	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
given	give	g0105	VBN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
provided	provide	p6010303	VBD	B-VP	O
almost	almost	a45023	RB	B-NP	O
full	full	f040	JJ	I-NP	O
protection	protection	p60302305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histology	histology	h02304020	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
and	and	a530	CC	O	O
enables	enable	e501402	VBZ	B-VP	O
monitoring	monitoring	m050306052	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
time	time	t050	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
result	result	r02043	VBP	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
that	that	t030	WDT	B-NP	O
allows	allow	a402	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
testing	testing	t023052	NN	I-NP	O
of	of	o100	IN	B-PP	O
protectors	protector	p603023062	NNS	B-NP	O
against	against	a20523	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
as	as	a200	IN	B-SBAR	O
demonstrated	demonstrate	d05052360303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
provided	provide	p6010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ICRF	ICRF	i261	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
187	187	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

Epinephrine	Epinephrine	e1050106050	NN	B-NP	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	d0260305020502030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
subtoxic	subtoxic	s0130202	JJ	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
both	both	b030	DT	O	O
precipitate	precipitate	p6020103030	VB	B-VP	O
dysrhythmias	dysrhythmia	d026030502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
circulating	circulate	c0620403052	VBG	B-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
could	could	c043	MD	B-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
dysrhythmogenic	dysrhythmogenic	d0260305020502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
examined	examine	e2050503	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
alters	alter	a43062	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
dysrhythmogenicity	dysrhythmogenicity	d0260305020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
,	,	,000	,	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
dogs	dog	d020	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
conscious	conscious	c05202	JJ	I-NP	O
dogs	dog	d020	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Seventeen	Seventeen	s0105305	CD	B-NP	O
animals	animal	a505042	NNS	I-NP	O
responded	respond	r02105303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
(	(	(000	(	O	O
VT	VT	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
responders	responder	r021053062	NNS	I-NP	O
randomly	randomly	r0530540	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
1	1	1000	CD	B-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
over	over	o106	IN	B-PP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
fewer	few	f060	JJR	B-NP	O
prodysrhythmic	prodysrhythmic	p603026030502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
without	without	w0303	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

VT	VT	v300	NN	B-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
fewer	few	f060	JJR	B-NP	O
dogs	dog	d020	NNS	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	O
beats	beat	b032	NNS	I-NP	O
and	and	a530	CC	O	O
less	less	l020	JJR	B-NP	O
ectopies	ectopy	e230102	NNS	I-NP	O
.	.	.000	.	O	O

Epinephrine	Epinephrine	e1050106050	NN	B-NP	B-Chemical
shortened	shorten	s0630503	VBD	B-VP	O
QT	QT	q300	NN	B-NP	O
less	less	l020	JJR	B-ADVP	O
after	after	a1306	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
,	,	,000	,	O	O
six	six	s020	CD	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
halothane	halothane	h0403050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
4	4	4000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	O	O
kg	kg	k200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
until	until	u5304	IN	B-SBAR	O
VT	VT	v300	NN	B-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
45	45	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
over	over	o106	IN	B-PP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
again	again	a205	RB	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
4	4	4000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
prodysrhythmic	prodysrhythmic	p603026030502	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
mitigated	mitigate	m03020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
preceding	precede	p60203052	VBG	B-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Bupivacaine	Bupivacaine	b010102050	NN	B-NP	B-Chemical
antagonizes	antagonize	a5302050202	VBZ	B-VP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	d0260305020502030	NN	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
dogs	dog	d020	NNS	I-NP	O
susceptible	susceptible	s020130140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
VT	VT	v300	NN	B-NP	B-Disease
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
postinfarct	postinfarct	p0230510623	JJ	I-NP	O
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
systemic	systemic	s0230502	JJ	B-NP	O
subtoxic	subtoxic	s0130202	JJ	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
enhances	enhance	e505202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
dysrhythmogenicity	dysrhythmogenicity	d0260305020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Milk	Milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
alkali	alkali	a42040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
25	25	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
OH	OH	o000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
2D	2D	2300	NN	B-NP	I-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
hypoparathyroidism	hypoparathyroidism	h010106030603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

Milk	Milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
alkali	alkali	a42040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
first	first	f0623	RB	I-VP	O
described	describe	d0260103	VBN	I-VP	O
70	70	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
ago	ago	a200	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
context	context	c053023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
peptic	peptic	p01302	JJ	B-NP	B-Disease
ulcer	ulcer	u4206	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
alkali	alkali	a42040	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
with	with	w030	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
ulcer	ulcer	u4206	NN	I-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
H	H	h000	NN	B-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
omeprazole	omeprazole	o501602040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
sucralfate	sucralfate	s026041030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
milk	milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
alkali	alkali	a42040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
classic	classic	c40202	JJ	I-NP	O
triad	triad	t603	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
,	,	,000	,	O	O
alkalosis	alkalosis	a42040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
remains	remain	r05052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hallmark	hallmark	h045062	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

Milk	Milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
alkali	alkali	a42040	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
can	can	c050	MD	B-VP	O
present	present	p602053	VB	I-VP	O
serious	serious	s0602	JJ	B-ADJP	O
and	and	a530	CC	O	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
illness	illness	i4502	NN	B-NP	O
unless	unless	u5402	IN	B-SBAR	O
diagnosed	diagnose	d0250203	VBN	B-VP	O
and	and	a530	CC	O	O
treated	treat	t60303	VBN	B-VP	O
appropriately	appropriately	a1601603040	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
presents	present	p6020532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
hypoparathyroidism	hypoparathyroidism	h010106030603025	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
calcitriol	calcitriol	c04203604	NN	I-NP	B-Chemical
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
admissions	admission	a3502052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
milk	milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
alkali	alkali	a42040	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
pamidronate	pamidronate	p0503605030	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
first	first	f0623	JJ	I-NP	O
admission	admission	a350205	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
pamidronate	pamidronate	p0503605030	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
valuable	valuable	v040140	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
tool	tool	t040	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
milk	milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
alkali	alkali	a42040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
presents	present	p6020532	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
hypercalcemic	hypercalcemic	h010620420502	JJ	B-NP	B-Disease
emergency	emergency	e50620520	NN	I-NP	I-Disease
.	.	.000	.	O	O

Famotidine	Famotidine	f050303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Famotidine	Famotidine	f050303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
histamine	histamine	h02305050	NN	I-NP	O
H2	H2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
inpatient	inpatient	i5103053	NN	B-NP	O
settings	setting	s03052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
stress	stress	s3602	NN	B-NP	O
ulcers	ulcer	u42062	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
showing	show	s052	VBG	I-VP	O
increasing	increase	i52602052	VBG	B-NP	O
popularity	popularity	p010406030	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
low	low	l000	JJ	I-NP	O
cost	cost	c023	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
currently	currently	c0605340	RB	I-NP	O
available	available	a1040140	JJ	I-NP	O
H2	H2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
propensity	propensity	p601052030	NN	I-NP	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
two	two	t000	CD	I-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
famotidine	famotidine	f050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
famotidine	famotidine	f050303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
hospitalized	hospitalize	h02103040203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
cleared	clear	c40603	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
upon	upon	u105	IN	B-PP	O
removal	removal	r050104	NN	B-NP	O
of	of	o100	IN	B-PP	O
famotidine	famotidine	f050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
famotidine	famotidine	f050303050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
seen	see	s050	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
famotidine	famotidine	f050303050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
persons	person	p062052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Encephalopathy	Encephalopathy	e52010401030	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
amitriptyline	amitriptyline	a503601304050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
are	be	a600	VBP	B-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
spectrum	spectrum	s1023605	NN	I-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
?	?	?000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
amitriptyline	amitriptyline	a503601304050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
remission	remission	r050205	NN	I-NP	O
of	of	o100	IN	B-PP	O
unipolar	unipolar	u5010406	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
either	either	e0306	CC	O	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NMS	NMS	n520	NN	B-NP	B-Disease
)	)	)000	)	O	O
or	or	o600	CC	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
SS	SS	s200	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
determinant	determinant	d0306505053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
imbalance	imbalance	i51040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
NMS	NMS	n520	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
develops	develop	d0104012	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
NMS	NMS	n520	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
SS	SS	s200	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
spectrum	spectrum	s1023605	NN	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	B-NP	O
antidopaminergic	antidopaminergic	a530301050506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Genetic	Genetic	g050302	JJ	B-NP	O
separation	separation	s01060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	O
and	and	a530	CC	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
phenotypes	phenotype	p05030102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Fischer	Fischer	f0206	NNP	I-NP	O
344	344	0000	CD	I-NP	O
(	(	(000	(	O	O
F344	F344	0000	NN	B-NP	O
)	)	)000	)	O	O
rat	rat	r030	NN	B-NP	O
induces	induce	i530202	VBZ	B-VP	O
growth	growth	g6030	NN	B-NP	O
of	of	o100	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
,	,	,000	,	I-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
pituitary	pituitary	p0303060	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
diethylstilbestrol	diethylstilbestrol	d030423041023604	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DES	DES	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
caused	cause	c0203	VBD	B-VP	O
female	female	f05040	JJ	B-NP	O
F344	F344	0000	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
to	to	t000	TO	B-VP	O
grow	grow	g600	VB	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
109	109	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SE	SE	s000	NN	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
for	for	f060	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
become	become	b02050	VB	I-VP	O
highly	highly	h02040	RB	B-ADJP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-ADJP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
DES	DES	d020	NNP	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
for	for	f060	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
females	female	f050402	NNS	I-NP	O
versus	versus	v06202	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
for	for	f060	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
females	female	f050402	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
morphological	morphological	m06104020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Brown	Brown	b605	NNP	B-NP	O
Norway	Norway	n060	NNP	I-NP	O
(	(	(000	(	O	O
BN	BN	b500	NN	B-NP	O
)	)	)000	)	O	O
rat	rat	r030	NN	B-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
F1	F1	0000	NN	I-NP	O
hybrid	hybrid	h01603	NN	I-NP	O
of	of	o100	IN	B-PP	O
F344	F344	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
BN	BN	b500	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DES	DES	d020	NNP	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
mass	mass	m020	NN	I-NP	O
of	of	o100	IN	B-PP	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
for	for	f060	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Surprisingly	Surprisingly	s06160205240	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
F1	F1	0000	NN	I-NP	O
hybrid	hybrid	h01603	JJ	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-ADJP	B-Disease
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
content	content	c053053	NN	I-NP	O
and	and	a530	CC	O	O
outward	outward	o03063	RB	B-ADVP	O
appearance	appearance	a1060520	NN	B-NP	O
identical	identical	i30530204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
BN	BN	b500	NN	B-NP	O
.	.	.000	.	O	O

Expression	Expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
growth	growth	g6030	NN	B-NP	O
and	and	a530	CC	O	O
morphological	morphological	m06104020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
genes	gene	g0502	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
DES	DES	d020	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
,	,	,000	,	I-NP	O
additive	additive	a303010	JJ	I-NP	O
inheritance	inheritance	i506030520	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
phenotype	phenotype	p0503010	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
recessive	recessive	r0202010	JJ	B-NP	O
,	,	,000	,	I-NP	O
epistatic	epistatic	e10230302	JJ	I-NP	O
inheritance	inheritance	i506030520	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
5	5	5000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
160	160	0000	CD	I-NP	O
F2	F2	0000	NN	I-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
phenotype	phenotype	p0503010	NN	I-NP	O
;	;	;000	:	O	O
36	36	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
160	160	0000	CD	I-NP	O
F2	F2	0000	NN	I-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
F344	F344	0000	NN	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
mass	mass	m020	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
31	31	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-ADJP	B-Disease
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
phenotype	phenotype	p0503010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
merely	merely	m06040	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extensive	extensive	e23052010	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
F2	F2	0000	NN	I-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
all	all	a400	DT	O	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
massive	massive	m02010	JJ	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
genes	gene	g0502	NNS	I-NP	O
regulate	regulate	r0204030	VBP	B-VP	O
both	both	b030	DT	B-NP	O
phenotypes	phenotype	p05030102	NNS	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
afferent	afferent	a106053	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
irritation	irritation	i6030305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Immunocytochemical	Immunocytochemical	i505020302050204	JJ	B-NP	O
techniques	technique	t02050202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
NOS	NOS	n020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
acute	acute	a2030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
irritation	irritation	i6030305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
urinary	urinary	u605060	JJ	I-NP	I-Disease
tract	tract	t6023	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Chemical	Chemical	c050204	JJ	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
metabolized	metabolize	m0301040203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
acrolein	acrolein	a260405	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
irritant	irritant	i603053	JJ	I-NP	O
eliminated	eliminate	e405050303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
.	.	.000	.	O	O

Injection	Injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
,	,	,000	,	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
2	2	2000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
perfusion	perfusion	p0610205	NN	B-NP	O
(	(	(000	(	O	O
acute	acute	a2030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
Fos	Fos	f020	NN	B-NP	O
-	-	-000	HYPH	O	O
immunoreactivity	immunoreactivity	i5050602301030	NN	B-NP	O
(	(	(000	(	O	O
IR	IR	i600	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
commissure	commissure	c0502060	NN	I-NP	O
,	,	,000	,	O	O
dorsal	dorsal	d06204	JJ	B-NP	O
horn	horn	h065	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
autonomic	autonomic	a03050502	JJ	B-NP	O
regions	region	r02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
segments	segment	s0250532	NNS	I-NP	O
(	(	(000	(	O	O
L1	L1	0000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
L2	L2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
L6	L6	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
S1	S1	0000	NN	I-NP	O
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
receive	receive	r02010	VBP	B-VP	O
afferent	afferent	a106053	JJ	B-NP	O
inputs	input	i51032	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
,	,	,000	,	O	O
urethra	urethra	u603060	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
ureter	ureter	u60306	NN	B-NP	O
.	.	.000	.	O	O

Fos	Fos	f020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
IR	IR	i600	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
chronic	chronic	c060502	JJ	B-NP	O
CYP	CYP	c010	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
15	15	0000	CD	B-NP	O
,	,	,000	,	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
3rd	3rd	3630	JJ	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
acutely	acutely	a203040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
small	small	s504	JJ	I-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NOS	NOS	n020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
IR	IR	i600	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
cell	cell	c040	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
sections	section	s023052	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
L6	L6	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
S1	S1	0000	NN	I-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
root	root	r030	NN	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
(	(	(000	(	O	O
DRG	DRG	d620	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
CYP	CYP	c010	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
.	.	.000	.	O	O
002	002	0000	CD	B-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
bladder	bladder	b40306	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
by	by	b000	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-VP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
11	11	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NOS	NOS	n020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
immunoreactive	immunoreactive	i50506023010	JJ	I-NP	O
(	(	(000	(	O	O
IR	IR	i600	NN	B-NP	O
)	)	)000	)	O	O
afferent	afferent	a106053	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
L6	L6	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
S1	S1	0000	NN	I-NP	O
DRG	DRG	d620	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
L1	L1	0000	NN	I-NP	O
DRG	DRG	d620	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
L2	L2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
L5	L5	0000	NN	I-NP	O
DRG	DRG	d620	NN	I-NP	O
.	.	.000	.	O	O

Bladder	Bladder	b40306	NN	B-NP	O
afferent	afferent	a106053	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
L6	L6	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
S1	S1	0000	NN	I-NP	O
DRG	DRG	d620	NN	I-NP	O
labeled	label	l010403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Fluorogold	Fluorogold	f40602043	NN	B-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
microliters	microliter	m0260403062	NNS	I-NP	O
)	)	)000	)	O	O
injected	inject	i5202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
NOS	NOS	n020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IR	IR	i600	NN	I-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
CYP	CYP	c010	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
afferent	afferent	a106053	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
NOS	NOS	n020	NN	B-NP	O
-	-	-000	HYPH	O	O
IR	IR	i600	NN	B-NP	O
:	:	:000	:	O	O
L6	L6	0000	NN	B-NP	O
(	(	(000	(	O	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
S1	S1	0000	NN	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
neuronal	neuronal	n060504	JJ	B-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
visceral	visceral	v020604	JJ	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
upregulated	upregulate	u1602040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
chemical	chemical	c050204	JJ	B-NP	O
irritation	irritation	i6030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
afferent	afferent	a106053	JJ	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
tract	tract	t6023	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
that	that	t030	IN	B-SBAR	O
pathological	pathological	p0304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
tract	tract	t6023	NN	I-NP	O
can	can	c050	MD	B-VP	O
initiate	initiate	i503030	VB	I-VP	O
chemical	chemical	c050204	JJ	B-NP	O
signals	signal	s025042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
alter	alter	a4306	VBP	B-VP	O
the	the	t000	DT	B-NP	O
chemical	chemical	c050204	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
visceral	visceral	v020604	JJ	B-NP	O
afferent	afferent	a106053	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
832	832	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
832	832	0000	CD	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ISO	ISO	i200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
circumflex	circumflex	c062051402	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
and	and	a530	CC	I-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
for	for	f060	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
periods	period	p06032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intracoronary	intracoronary	i536020605060	JJ	B-NP	O
ISO	ISO	i200	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
maximal	maximal	m020504	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
rise	rise	r020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
percentage	percentage	p062053020	NN	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
shortening	shortening	s06305052	NN	I-NP	O
and	and	a530	CC	I-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
epicardial	epicardial	e10206304	JJ	I-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
ISO	ISO	i200	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
stenosis	stenosis	s3050202	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
,	,	,000	,	O	O
equihypotensive	equihypotensive	e20103052010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
832	832	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
third	third	t063	JJ	I-NP	O
ISO	ISO	i200	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
CD	CD	c300	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
832	832	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
832	832	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
percentage	percentage	p062053020	NN	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
shortening	shortening	s06305052	NN	I-NP	O
from	from	f605	IN	B-PP	O
32	32	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
115	115	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
value	value	v040	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ST	ST	s300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
from	from	f605	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mV	mV	m100	NN	I-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
mV	mV	m100	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
stenosis	stenosis	s3050202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Diltiazem	Diltiazem	d0430205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
percentage	percentage	p062053020	NN	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
shortening	shortening	s06305052	NN	I-NP	O
from	from	f605	IN	B-PP	O
34	34	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
63	63	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
value	value	v040	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ST	ST	s300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
from	from	f605	IN	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mV	mV	m100	NN	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mV	mV	m100	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
stenosis	stenosis	s3050202	NN	B-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
832	832	0000	CD	B-NP	I-Chemical
improves	improve	i5160102	VBZ	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
stenosis	stenosis	s3050202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
chronotropic	chronotropic	c06050360102	JJ	I-NP	O
property	property	p6010630	NN	I-NP	O
of	of	o100	IN	B-PP	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
832	832	0000	CD	I-NP	I-Chemical
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CD	CD	c300	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
832	832	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
recombinant	recombinant	r0205105053	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
insulin	insulin	i520405	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
on	on	o500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recently	recently	r0205340	RB	B-ADVP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
recombinant	recombinant	r0205105053	JJ	B-NP	O
hGH	hGH	h200	NN	I-NP	O
exacerbates	exacerbate	e2020610302	VBZ	B-VP	O
renal	renal	r0504	JJ	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
injury	injury	i52060	NN	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
recombinant	recombinant	r0205105053	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
(	(	(000	(	O	O
rh	rh	r000	JJ	B-ADJP	O
)	)	)000	)	O	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
safer	safe	s0106	JJR	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
growth	growth	g6030	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
glomerulopathy	glomerulopathy	g405060401030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
serial	serial	s0604	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
over	over	o106	IN	B-PP	O
12	12	0000	CD	B-NP	O
wk	wk	w200	NN	I-NP	O
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	CD	I-NP	O
,	,	,000	,	I-NP	O
400	400	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
.	.	.000	.	O	O

rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
improved	improve	i5160103	VBD	B-VP	O
weight	weight	w0203	NN	B-NP	O
gain	gain	g050	NN	I-NP	O
by	by	b000	IN	B-PP	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
altering	alter	a4306052	VBG	B-VP	O
hematocrit	hematocrit	h050302603	NN	B-NP	O
or	or	o600	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unaltered	unaltered	u50430603	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
wk	wk	w200	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
inulin	inulin	i50405	NN	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
48	48	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
versus	versus	v06202	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
24	24	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
06	06	0000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
in	in	i500	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
GFR	GFR	g160	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
or	or	o600	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	B-Disease
,	,	,000	,	O	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
renal	renal	r0504	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
and	and	a530	CC	I-NP	O
GH	GH	g000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
altering	alter	a4306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
steady	steady	s3030	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
,	,	,000	,	O	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
weight	weight	w0203	NN	B-NP	O
gain	gain	g050	NN	I-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
,	,	,000	,	O	O
GFR	GFR	g160	NN	B-NP	O
,	,	,000	,	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
planar	planar	p40506	JJ	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
or	or	o600	CC	I-NP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
steady	steady	s3030	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
IGF	IGF	i210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
level	level	l0104	NN	I-NP	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
modify	modify	m03010	VB	I-VP	O
gene	gene	g050	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
IGF	IGF	i210	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
or	or	o600	CC	I-NP	O
GH	GH	g000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
:	:	:000	:	O	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
improves	improve	i5160102	VBZ	B-VP	O
growth	growth	g6030	NN	B-NP	O
and	and	a530	CC	I-NP	O
GFR	GFR	g160	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
unlike	unlike	u54020	IN	B-PP	O
rhGH	rhGH	r020	NN	B-NP	O
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
rhIGF	rhIGF	r021	NN	B-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
worsen	worsen	w06205	VBN	I-VP	O
renal	renal	r0504	JJ	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
injury	injury	i52060	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Nefiracetam	Nefiracetam	n0106020305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DM	DM	d500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9384	9384	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
reverses	reverse	r0106202	VBZ	B-VP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
:	:	:000	:	O	O
delayed	delay	d0403	VBN	B-NP	O
emergence	emergence	e50620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
memory	memory	m05060	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Nefiracetam	Nefiracetam	n0106020305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
pyrrolidone	pyrrolidone	p060403050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
which	which	w020	WDT	B-NP	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
learning	learning	l065052	NN	I-NP	B-Disease
and	and	a530	CC	O	I-Disease
post	post	p023	AFX	O	I-Disease
-	-	-000	HYPH	O	I-Disease
training	train	t605052	VBG	B-VP	I-Disease
consolidation	consolidation	c05204030305	NN	B-NP	I-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-VP	O
that	that	t030	IN	B-SBAR	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
training	training	t605052	NN	B-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
defined	define	d010503	VBN	I-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
12h	12h	0000	CD	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
training	training	t605052	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
nefiracetam	nefiracetam	n0106020305	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
agonism	agonism	a205025	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
step	step	s301	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
down	down	d050	RB	B-ADVP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
was	be	w020	VBD	B-VP	O
employed	employ	e51403	VBN	I-VP	O
and	and	a530	CC	O	O
nefiracetam	nefiracetam	n0106020305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
training	training	t605052	NN	B-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
12h	12h	0000	CD	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
training	training	t605052	NN	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
.	.	.000	.	O	O

Co	Co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nefiracetam	nefiracetam	n0106020305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
during	during	d06052	IN	B-PP	O
training	training	t605052	NN	B-NP	O
or	or	o600	CC	I-NP	O
10h	10h	0000	NN	I-NP	O
thereafter	thereafter	t0601306	RB	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
amnesic	amnesic	a50202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nefiracetam	nefiracetam	n0106020305	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
training	training	t605052	NN	B-NP	O
completely	completely	c051403040	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
10h	10h	0000	CD	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
training	training	t605052	NN	I-NP	O
time	time	t050	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
converse	converse	c0510620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
true	true	t600	JJ	B-ADJP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
as	as	a200	IN	B-PP	O
nefiracetam	nefiracetam	n0106020305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
millimolar	millimolar	m04050406	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
displace	displace	d0214020	VB	I-VP	O
either	either	e0306	CC	O	O
[	[	[000	(	O	O
3H	3H	3000	NN	B-NP	O
]	]	]000	)	O	O
SCH	SCH	s200	NN	B-NP	B-Chemical
23390	23390	0000	CD	I-NP	I-Chemical
or	or	o600	CC	O	O
[	[	[000	(	O	O
3H	3H	3000	NN	B-NP	O
]	]	]000	)	I-NP	O
spiperone	spiperone	s10106050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
from	from	f605	IN	B-PP	O
D1	D1	0000	NN	B-NP	O
or	or	o600	CC	I-NP	O
D2	D2	0000	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
subtypes	subtype	s0130102	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
nefiracetam	nefiracetam	n0106020305	NN	B-NP	B-Chemical
augments	augment	a0250532	VBZ	B-VP	O
molecular	molecular	m04020406	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
ultimately	ultimately	u430503040	RB	B-ADVP	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
.	.	.000	.	O	O

Phenytoin	Phenytoin	p050305	NN	B-NP	B-Chemical
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
probable	probable	p6010140	JJ	B-NP	O
idiosyncratic	idiosyncratic	i30205260302	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DPH	DPH	d100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
EEG	EEG	e020	NN	I-NP	O
and	and	a530	CC	I-NP	O
mental	mental	m05304	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
daily	daily	d040	NN	I-NP	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
very	very	v060	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
microgramg	microgramg	m026026052	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
probably	probably	p6010140	RB	B-ADVP	O
an	an	a500	DT	B-NP	O
idiosyncratic	idiosyncratic	i30205260302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
not	not	n030	RB	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
or	or	o600	CC	I-NP	O
allergic	allergic	a406202	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
fact	fact	f023	NN	B-NP	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
free	free	f600	JJ	B-NP	O
DPH	DPH	d100	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
retarded	retard	r0306303	VBN	I-NP	O
morbilliform	morbilliform	m0610401065	NN	I-NP	O
rash	rash	r020	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
protidogram	protidogram	p6030302605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
intradermic	intradermic	i5360306502	JJ	I-NP	O
DPH	DPH	d100	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
starting	start	s3063052	VBG	B-VP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
an	an	a500	DT	B-NP	O
unexpected	unexpected	u502102303	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
EEG	EEG	e020	NN	B-NP	O
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
occurring	occur	o206052	VBG	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
,	,	,000	,	O	O
should	should	s043	MD	B-VP	O
alert	alert	a4063	VB	I-VP	O
the	the	t000	DT	B-NP	O
physician	physician	p020205	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
eliminating	eliminate	e4050503052	VBG	B-VP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
,	,	,000	,	O	O
even	even	e105	RB	B-SBAR	O
if	if	i100	IN	I-SBAR	O
plasma	plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
low	low	l000	JJ	B-ADJP	O
.	.	.000	.	O	O

Prevention	Prevention	p60105305	NN	B-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
climacteric	climacteric	c4050230602	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
oestrogen	oestrogen	o02360205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
74	74	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
850	850	0000	CD	B-NP	O
climacteric	climacteric	c4050230602	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
oestrogen	oestrogen	o02360205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Cystic	Cystic	c02302	JJ	B-NP	O
hyperplasia	hyperplasia	h010614020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
unopposed	unopposed	u5010203	JJ	B-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
without	without	w0303	IN	B-PP	O
progestagen	progestagen	p6020230205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
21	21	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
norethisterone	norethisterone	n060302306050	NN	I-NP	B-Chemical
daily	daily	d040	RB	B-ADVP	O
caused	cause	c0203	VBD	B-VP	O
reversion	reversion	r0106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
57	57	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cystic	cystic	c02302	JJ	B-NP	O
hyperplasia	hyperplasia	h010614020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
hyperplasia	hyperplasia	h010614020	NN	I-NP	B-Disease
.	.	.000	.	O	O

4	4	4000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
referred	refer	r010603	VBN	B-VP	O
from	from	f605	IN	B-PP	O
elsewhere	elsewhere	e42060	RB	B-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inappropriate	inappropriate	i5016016030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
unsupervised	unsupervised	u52010610203	JJ	I-NP	O
unopposed	unopposed	u5010203	JJ	I-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
difficulty	difficulty	d01020430	NN	I-NP	O
in	in	i500	IN	B-PP	O
distinguishing	distinguish	d02305202052	VBG	B-VP	O
severe	severe	s01060	JJ	B-NP	O
hyperplasia	hyperplasia	h010614020	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
malignancy	malignancy	m040250520	NN	B-NP	B-Disease
.	.	.000	.	O	O

Cyclical	Cyclical	c0240204	JJ	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
progestagen	progestagen	p6020230205	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Ninety	Ninety	n05030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
-	-	-000	HYPH	O	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
E	E	e000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
exercise	exercise	e2062020	NN	B-NP	O
control	control	c053604	NN	I-NP	O
(	(	(000	(	O	O
EC	EC	e200	NN	B-NP	O
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
exercised	exercise	e20620203	VBN	B-VP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
thirty	thirty	t0630	CD	B-NP	O
days	day	d020	NNS	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
treadmill	treadmill	t603504	NN	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
mph	mph	m100	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
grade	grade	g6030	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
animals	animal	a505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sedentary	sedentary	s03053060	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
remained	remain	r050503	VBD	B-VP	O
sedentary	sedentary	s03053060	JJ	B-ADJP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
sedentary	sedentary	s03053060	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
(	(	(000	(	O	O
SC	SC	s200	NN	B-NP	O
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
which	which	w020	WDT	B-NP	O
remained	remain	r050503	VBD	B-VP	O
sedentary	sedentary	s03053060	JJ	B-ADJP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
S	S	s000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
and	and	a530	CC	I-NP	O
E	E	e000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
group	group	g601	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
Pp	Pp	p100	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
greater	great	g60306	JJR	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
E	E	e000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
CPK	CPK	c120	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
for	for	f060	IN	B-PP	O
E	E	e000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
for	for	f060	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	O	O
EC	EC	e200	NNP	B-NP	O
groups	group	g6012	NNS	I-NP	O
twenty	twenty	t0530	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
for	for	f060	IN	B-PP	O
severity	severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
,	,	,000	,	O	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
heart	heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
to	to	t000	TO	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
exercise	exercise	e2062020	NN	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
little	little	l0340	JJ	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Human	Human	h0505	JJ	B-NP	O
corticotropin	corticotropin	c063020360105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
and	and	a530	CC	I-NP	O
thyrotropin	thyrotropin	t060360105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
modulate	modulate	m0304030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
hypercapnic	hypercapnic	h0106201502	JJ	I-NP	B-Disease
ventilatory	ventilatory	v0530403060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Human	Human	h0505	JJ	B-NP	O
corticotropin	corticotropin	c063020360105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
(	(	(000	(	O	O
hCRH	hCRH	h260	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
thyrotropin	thyrotropin	t060360105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
(	(	(000	(	O	O
TRH	TRH	t600	NN	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
stimulate	stimulate	s30504030	VB	I-VP	O
ventilation	ventilation	v053040305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
,	,	,000	,	I-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
clarify	clarify	c406010	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
peptides	peptide	p0130302	NNS	I-NP	O
act	act	a230	VBP	B-VP	O
by	by	b000	IN	B-PP	O
altering	alter	a4306052	VBG	B-VP	O
central	central	c053604	JJ	B-NP	O
chemosensitivity	chemosensitivity	c05020520301030	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
rebreathing	rebreathe	r01603052	VBG	B-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
young	young	y052	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
test	test	t023	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
NaCl	NaCl	n024	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
i	i	i000	NNS	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
;	;	;000	:	O	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
test	test	t023	NN	I-NP	O
200	200	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hCRH	hCRH	h260	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
400	400	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TRH	TRH	t600	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
i	i	i000	NNS	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
Nine	Nine	n050	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
NaCl	NaCl	n024	NN	I-NP	B-Chemical
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
during	during	d06052	IN	B-PP	O
both	both	b030	DT	B-NP	O
rebreathing	rebreathing	r01603052	JJ	I-NP	O
manoeuvres	manoeuvre	m0501602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
response	response	r0210520	NN	B-NP	O
curves	curve	c06102	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
subject	subject	s012023	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hCRH	hCRH	h260	NN	I-NP	O
group	group	g601	NN	I-NP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
parallel	parallel	p060404	JJ	I-NP	O
shift	shift	s013	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
hCRH	hCRH	h260	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
following	follow	f04052	VBG	I-VP	O
TRH	TRH	t600	NN	B-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
striking	striking	s3602052	JJ	I-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

hCRH	hCRH	h260	NN	B-NP	O
and	and	a530	CC	I-NP	O
TRH	TRH	t600	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
threshold	threshold	t0602043	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
response	response	r0210520	NN	B-NP	O
curves	curve	c06102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
nearly	nearly	n0640	RB	B-ADJP	O
identical	identical	i30530204	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
an	an	a500	DT	B-NP	O
additive	additive	a303010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
releasing	release	r0402052	VBG	I-NP	O
hormones	hormone	h0650502	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypercapnic	hypercapnic	h0106201502	JJ	I-NP	B-Disease
ventilatory	ventilatory	v0530403060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
,	,	,000	,	O	O
presumably	presumably	p602050140	RB	B-ADJP	O
independent	independent	i5301053053	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
chemosensitivity	chemosensitivity	c05020520301030	NN	I-NP	O
.	.	.000	.	O	O

Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
suppressing	suppress	s01602052	VBG	B-VP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
DNA	DNA	d500	NN	I-NP	O
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
carriers	carrier	c06062	NNS	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
2	2	2000	CD	I-NP	B-Chemical
'	'	'000	SYM	I-NP	I-Chemical
,	,	,000	,	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dideoxy	dideoxy	d03020	NN	I-NP	I-Chemical
cytosine	cytosine	c0302050	NN	I-NP	I-Chemical
analogue	analogue	a504020	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
potent	potent	p03053	JJ	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
replication	replication	r014020305	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
)	)	)000	)	O	O
carriers	carrier	c06062	NNS	B-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	I-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
HBsAg	HBsAg	h1202	NN	I-NP	B-Chemical
carriers	carrier	c06062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
orally	orally	o6040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
dosages	dosage	d020202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	B-ADJP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
closely	closely	c402040	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
,	,	,000	,	O	O
biochemically	biochemically	b020502040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
serologically	serologically	s06040202040	RB	B-ADVP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
36	36	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
DNA	DNA	d500	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	JJR	B-NP	O
90	90	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
.	.	.000	.	O	O
001	001	0000	CD	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
slightly	slightly	s4020340	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	O	O
011	011	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
still	still	s304	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
94	94	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
suppression	suppression	s0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

HBV	HBV	h100	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
e	e	e000	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
status	status	s30302	NN	I-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
aminotransferase	aminotransferase	a505036052106020	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
HBsAg	HBsAg	h1202	NN	I-NP	B-Chemical
carriers	carrier	c06062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
suppression	suppression	s0160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
>	>	>000	JJR	B-NP	O
90	90	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
but	but	b030	CC	O	O
reversible	reversible	r010620140	JJ	B-ADJP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
prolonged	prolonged	p60405203	JJ	B-NP	O
suppression	suppression	s0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
achieved	achieve	a20103	VBN	I-VP	O
.	.	.000	.	O	O

Population	Population	p01040305	NN	B-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-VP	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Four	Four	f060	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
published	publish	p0140203	VBN	B-VP	O
since	since	s0520	IN	B-PP	O
December	December	d0205106	NNP	B-NP	O
,	,	,000	,	O	O
1995	1995	0000	CD	B-NP	O
,	,	,000	,	O	O
reported	report	r0106303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
(	(	(000	(	O	O
VTE	VTE	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
OCs	OC	o200	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
containing	contain	c05305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
progestagens	progestagen	p60202302052	NNS	I-NP	B-Chemical
gestodene	gestodene	g02303050	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
desogestrel	desogestrel	d0202023604	NN	I-NP	B-Chemical
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
OCs	OC	o200	NNS	B-NP	B-Chemical
containing	contain	c05305052	VBG	B-VP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
progestagens	progestagen	p60202302052	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
confounding	confound	c051053052	VBG	B-NP	O
and	and	a530	CC	I-NP	O
bias	bias	b020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
design	design	d02025	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
re	re	r000	VB	I-VP	O
-	-	-000	HYPH	O	O
examine	examine	e205050	VB	B-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
OC	OC	o200	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
design	design	d02025	NN	I-NP	O
and	and	a530	CC	O	O
analysis	analysis	a5040202	NN	B-NP	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bias	bias	b020	NN	I-NP	O
and	and	a530	CC	O	O
confounding	confound	c051053052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
earlier	early	e06406	JJR	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
computer	computer	c0510306	NN	B-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
from	from	f605	IN	B-PP	O
143	143	0000	CD	B-NP	O
general	general	g050604	JJ	I-NP	O
practices	practice	p60230202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
UK	UK	u200	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
based	base	b0203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
about	about	a103	RB	B-NP	O
540	540	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
women	woman	w0505	NNS	I-NP	O
born	bear	b065	VBN	B-VP	O
between	between	b0305	IN	B-PP	O
1941	1941	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1981	1981	0000	CD	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
recorded	record	r0206303	VBN	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
deep	deep	d010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
vein	vein	v050	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
,	,	,000	,	O	O
venous	venous	v0502	JJ	B-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
not	not	n030	RB	B-VP	O
otherwise	otherwise	o306020	RB	I-VP	O
specified	specify	s1020103	VBN	I-VP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
embolus	embolus	e510402	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cohort	cohort	c063	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
and	and	a530	CC	I-VP	O
compare	compare	c051060	VB	I-VP	O
incidence	incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
OC	OC	o200	NN	I-NP	B-Chemical
preparations	preparation	p6010603052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
nested	nest	n02303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
calculate	calculate	c04204030	VB	I-VP	O
the	the	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
OC	OC	o200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
adjustment	adjustment	a320235053	NN	B-NP	O
for	for	f060	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
confounding	confound	c051053052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
matched	match	m03203	VBD	B-VP	O
cases	case	c0202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
by	by	b000	IN	B-PP	O
exact	exact	e2023	JJ	B-NP	O
year	year	y060	NN	I-NP	O
of	of	o100	IN	B-PP	O
birth	birth	b0630	NN	B-NP	O
,	,	,000	,	O	O
practice	practice	p6023020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
current	current	c06053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
OCs	OC	o200	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
model	model	m0304	NN	I-NP	O
that	that	t030	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
body	body	b030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
mass	mass	m020	NN	I-NP	O
index	index	i5302	NN	I-NP	O
,	,	,000	,	O	O
number	number	n05106	NN	B-NP	O
of	of	o100	IN	B-PP	O
cycles	cycle	c02402	NNS	B-NP	O
,	,	,000	,	O	O
change	change	c0520	NN	B-NP	O
in	in	i500	IN	B-PP	O
type	type	t010	NN	B-NP	O
of	of	o100	IN	B-PP	O
OC	OC	o200	NN	B-NP	B-Chemical
prescribed	prescribe	p60260103	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
event	event	e1053	NN	I-NP	O
,	,	,000	,	O	O
previous	previous	p60102	JJ	B-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
concurrent	concurrent	c05206053	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

FINDINGS	FINDINGS	f053052	NNS	B-NP	O
:	:	:000	:	O	O
85	85	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
met	meet	m030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
inclusion	inclusion	i5240205	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
VTE	VTE	v300	NNP	B-NP	B-Disease
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
were	be	w060	VBD	B-VP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
progestagen	progestagen	p6020230205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
only	only	o540	JJ	B-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
83	83	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
43	43	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
deep	deep	d010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
vein	vein	v050	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
,	,	,000	,	O	O
35	35	0000	CD	B-NP	O
as	as	a200	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
as	as	a200	IN	B-SBAR	O
venous	venous	v0502	JJ	B-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
not	not	n030	RB	B-VP	O
otherwise	otherwise	o306020	RB	I-VP	O
specified	specify	s1020103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
crude	crude	c6030	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
per	per	p060	IN	B-PP	O
10	10	0000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
woman	woman	w0505	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
10	10	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
OC	OC	o200	NN	I-NP	B-Chemical
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
10	10	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
96	96	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
adjustment	adjustment	a320235053	NN	B-NP	O
for	for	f060	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
relative	relative	r0403010	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
68	68	0000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
75	75	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Logistic	Logistic	l0202302	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
between	between	b0305	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
second	second	s02053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
progestagens	progestagen	p60202302052	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
desogestrel	desogestrel	d0202023604	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
20	20	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
ethinyloestradiol	ethinyloestradiol	e3050402360304	NN	I-NP	B-Chemical
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
gestodene	gestodene	g02303050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
desogestrel	desogestrel	d0202023604	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
30	30	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
ethinyloestradiol	ethinyloestradiol	e3050402360304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
all	all	a400	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
VTE	VTE	v300	NNP	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
49	49	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
21	21	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
12	12	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
desogestrel	desogestrel	d0202023604	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
20	20	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
ethinyloestradiol	ethinyloestradiol	e3050402360304	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
18	18	0000	CD	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
66	66	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
17	17	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
third	third	t063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
progestagens	progestagen	p60202302052	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

INTERPRETATION	INTERPRETATION	i530616030305	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
OCs	OC	o200	NNS	I-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
residual	residual	r020304	JJ	B-NP	O
confounding	confounding	c051053052	NN	I-NP	O
by	by	b000	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
products	product	p6030232	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
20	20	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
ethinyloestradiol	ethinyloestradiol	e3050402360304	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
desogestrel	desogestrel	d0202023604	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
30	30	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
product	product	p603023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
biologically	biologically	b040202040	RB	B-ADJP	O
implausible	implausible	i514020140	JJ	I-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
preferential	preferential	p6010605304	JJ	B-NP	O
prescribing	prescribing	p602601052	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
confounding	confound	c051053052	VBG	B-VP	O
.	.	.000	.	O	O

MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
augments	augment	a0250532	NNS	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
electrographic	electrographic	e402360260102	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
but	but	b030	CC	O	O
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Intraperitoneal	Intraperitoneal	i5360106030504	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
tonic	tonic	t0502	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Scopolamine	Scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
prevented	prevent	p60105303	VBD	B-VP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
but	but	b030	CC	I-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
measured	measure	m020603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
EEG	EEG	e020	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Scopolamine	Scopolamine	s2010405050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pentobarbital	pentobarbital	p053010610304	NN	I-NP	B-Chemical
blocked	block	b40203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
electrographic	electrographic	e402360260102	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
,	,	,000	,	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
augmented	augment	a02505303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
electrographic	electrographic	e402360260102	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
examining	examine	e20505052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
microscopically	microscopically	m026020102040	RB	B-ADVP	O
.	.	.000	.	O	O

Pilocarpine	Pilocarpine	p0402061050	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
showed	show	s030	VBD	B-VP	O
pyknotic	pyknotic	p0250302	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

Pentobarbital	Pentobarbital	p053010610304	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
protected	protect	p60302303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pyramidal	pyramidal	p06050304	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
darker	darker	d06206	RBR	B-ADVP	O
than	than	t050	IN	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
,	,	,000	,	O	O
granule	granule	g605040	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
overstimulation	overstimulation	o1062305040305	NN	I-NP	O
and	and	a530	CC	O	O
propagated	propagate	p601020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
glutamatergic	glutamatergic	g403050306202	JJ	B-NP	O
transmission	transmission	t605250205	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
brain	brain	b605	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
through	through	t06020	IN	B-PP	O
an	an	a500	DT	B-NP	O
excitatory	excitatory	e20303060	JJ	I-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
:	:	:000	:	O	O
BRE	BRE	b600	NN	B-NP	O
-	-	-000	HYPH	O	O
26	26	0000	CD	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Fluorouracil	Fluorouracil	f406060204	NN	I-NP	I-Chemical
plus	plus	p402	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Taxol	Taxol	t0204	NN	B-NP	B-Chemical
;	;	;000	:	O	O
Bristol	Bristol	b602304	NNP	B-NP	O
-	-	-000	:	O	O
Myers	Myers	m062	NNP	B-NP	O
Squibb	Squibb	s201	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
Princeton	Princeton	p60520305	NNP	B-NP	O
,	,	,000	,	O	O
NJ	NJ	n200	NNP	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
effective	effective	e1023010	JJ	B-NP	O
salvage	salvage	s041020	NN	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
additive	additive	a303010	JJ	B-NP	O
cytotoxicity	cytotoxicity	c03030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
MCF	MCF	m210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
7	7	7000	CD	I-NP	O
cell	cell	c040	NN	I-NP	O
lines	line	l0502	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
175	175	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
over	over	o106	IN	B-PP	O
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
I	I	i000	CD	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
over	over	o106	IN	B-PP	O
1	1	1000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
before	before	b01060	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
350	350	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
every	every	e1060	DT	B-NP	O
28	28	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
TFL	TFL	t140	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
192	192	0000	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TFL	TFL	t140	NN	B-NP	O
:	:	:000	:	O	O
nine	nine	n050	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
;	;	;000	:	O	O
seven	seven	s0105	CD	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
cycles	cycle	c02402	NNS	B-NP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
required	require	r020603	VBD	B-VP	O
granulocyte	granulocyte	g6050402030	NN	B-NP	B-Chemical
colony	colony	c04050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
stimulating	stimulate	s3050403052	VBG	B-VP	I-Chemical
factor	factor	f02306	NN	B-NP	I-Chemical
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
;	;	;000	:	O	O
no	no	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
required	require	r020603	VBD	B-VP	O
platelet	platelet	p4030403	NN	B-NP	O
transfusions	transfusion	t6052102052	NNS	I-NP	O
.	.	.000	.	O	O

Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
nonhematologic	nonhematologic	n050503040202	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
34	34	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
three	three	t060	CD	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
18	18	0000	CD	B-NP	O
partial	partial	p06304	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
(	(	(000	(	O	O
53	53	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
62	62	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
19	19	0000	CD	I-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
11	11	0000	CD	B-NP	O
(	(	(000	(	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
responded	respond	r02105303	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
19	19	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

TFL	TFL	t140	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
,	,	,000	,	I-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
proarrhythmia	proarrhythmia	p60603050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
presumable	presumable	p602050140	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
dilated	dilated	d040303	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
or	or	o600	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
received	receive	r020103	VBD	B-VP	O
oral	oral	o604	JJ	B-NP	O
d	d	d000	NN	I-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
loading	loading	l03052	NN	I-NP	O
with	with	w030	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
,	,	,000	,	O	O
continuous	continuous	c0530502	JJ	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
monitoring	monitoring	m050306052	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

Those	Those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
or	or	o600	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
followed	follow	f0403	VBD	B-VP	O
up	up	u100	RP	B-PRT	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
basis	basis	b0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
21	21	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
d	d	d000	NN	I-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
35	35	0000	CD	B-NP	O
(	(	(000	(	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
remained	remain	r050503	VBD	B-VP	O
inducible	inducible	i53020140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
(	(	(000	(	O	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
even	even	e105	RB	B-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
from	from	f605	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
ECG	ECG	e200	NN	B-NP	O
[	[	[000	(	O	O
sinus	sinus	s0502	NN	B-NP	O
-	-	-000	HYPH	O	O
cycle	cycle	c0240	NN	B-NP	O
length	length	l05230	NN	I-NP	O
(	(	(000	(	O	O
SCL	SCL	s240	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
QT	QT	q300	NN	B-NP	O
or	or	o600	CC	O	O
QTc	QTc	q320	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
U	U	u000	NN	B-NP	O
wave	wave	w010	NN	I-NP	O
]	]	]000	)	O	O
nor	nor	n060	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
46	46	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
328	328	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
53	53	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0017	0017	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	I-NP	I-Disease
pointes	pointe	p05302	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
U	U	u000	NN	I-NP	O
wave	wave	w010	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
049	049	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
female	female	f05040	JJ	B-NP	O
gender	gender	g05306	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
015	015	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
corrected	correct	c0602303	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SCL	SCL	s240	NN	B-NP	O
,	,	,000	,	O	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
QTc	QTc	q320	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
seven	seven	s0105	CD	B-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
nonfatal	nonfatal	n0510304	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
recurrence	recurrence	r02060520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
died	die	d030	VBD	B-VP	O
suddenly	suddenly	s030540	RB	B-ADVP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
torsades	torsade	t0620302	NNS	I-NP	B-Disease
de	de	d000	IN	I-NP	I-Disease
pointes	pointe	p05302	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
successful	successful	s0202104	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Torsades	Torsades	t0620302	NNP	B-NP	B-Disease
de	de	d000	IN	I-NP	I-Disease
pointes	pointe	p05302	NNS	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
early	early	e0640	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
even	even	e105	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
d	d	d000	NN	I-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Pronounced	Pronounce	p60505203	VBN	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
surface	surface	s061020	NN	I-NP	O
ECG	ECG	e200	NN	I-NP	O
(	(	(000	(	O	O
cycle	cycle	c0240	NN	B-NP	O
length	length	l05230	NN	I-NP	O
,	,	,000	,	O	O
QT	QT	q300	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
QTc	QTc	q320	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
d	d	d000	NN	I-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
might	might	m0203	MD	B-VP	O
identify	identify	i3053010	VB	I-VP	O
a	a	a000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
ECG	ECG	e200	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
identify	identify	i3053010	VB	I-VP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
.	.	.000	.	O	O

Recurrence	Recurrence	r02060520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
high	high	h020	JJ	B-ADJP	O
despite	despite	d021030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
suppression	suppression	s0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
programmed	program	p60260503	VBN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-NP	O
programmed	program	p60260503	VBN	I-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
sotalol	sotalol	s030404	NN	I-NP	I-Chemical
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
limited	limited	l050303	JJ	B-NP	O
prognostic	prognostic	p602502302	JJ	I-NP	O
value	value	v040	NN	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
tuberoinfundibular	tuberoinfundibular	t0106051053010406	JJ	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
(	(	(000	(	O	O
TIDA	TIDA	t030	NN	B-NP	O
)	)	)000	)	O	O
system	system	s02305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
prolactin	prolactin	p60402305	NN	B-NP	O
(	(	(000	(	O	O
PRL	PRL	p640	NN	B-NP	O
)	)	)000	)	O	O
secretion	secretion	s0260305	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
this	this	t020	DT	B-NP	O
system	system	s02305	NN	I-NP	O
responds	respond	r0210532	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
PRL	PRL	p640	NN	I-NP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
lost	lose	l023	VBN	I-VP	O
in	in	i500	IN	B-PP	O
aging	age	a2052	VBG	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronically	chronically	c060502040	RB	B-NP	O
high	high	h020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
PRL	PRL	p640	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
for	for	f060	IN	B-PP	O
extended	extend	e2305303	VBN	B-NP	O
periods	period	p06032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
time	time	t050	NN	B-NP	O
and	and	a530	CC	O	O
examine	examine	e205050	VB	B-VP	O
its	its	i320	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
systems	system	s023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Hyperprolactinemia	Hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Palkovits	Palkovits	p04201032	NNP	B-NP	O
'	'	'000	POS	B-NP	O
microdissection	microdissection	m026030202305	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
liquid	liquid	l0203	NN	I-NP	O
chromatography	chromatography	c060503026010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
,	,	,000	,	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentrations	concentration	c052053603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
eminence	eminence	e5050520	NN	I-NP	O
(	(	(000	(	O	O
ME	ME	m000	NN	B-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
84	84	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ME	ME	m000	NN	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
DA	DA	d000	NN	B-NP	B-Chemical
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lost	lose	l023	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
9	9	9000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
long	long	l052	JJ	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
-	-	-000	HYPH	O	O
long	long	l052	RB	B-NP	O
extremely	extremely	e23605040	RB	I-NP	O
high	high	h020	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
PRL	PRL	p640	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
implantation	implantation	i5140530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MMQ	MMQ	m520	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
capsule	capsule	c012040	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NE	NE	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
their	their	t060	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arcuate	arcuate	a62030	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
(	(	(000	(	O	O
AN	AN	a500	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
medial	medial	m0304	JJ	B-NP	O
preoptic	preoptic	p601302	JJ	I-NP	O
area	area	a600	NN	I-NP	O
(	(	(000	(	O	O
MPA	MPA	m100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
caudate	caudate	c03030	JJ	B-NP	O
putamen	putaman	p030505	NNS	I-NP	O
(	(	(000	(	O	O
CP	CP	c100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
substantia	substantia	s01230530	NN	B-NP	O
nigra	nigra	n0260	NN	I-NP	O
(	(	(000	(	O	O
SN	SN	s500	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
zona	zona	z050	NN	B-NP	O
incerta	incerta	i520630	NN	I-NP	O
(	(	(000	(	O	O
ZI	ZI	z000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxyindoleacetic	hydroxyindoleacetic	h0360205304020302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HIAA	HIAA	h000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
AN	AN	a500	NN	I-NP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
AN	AN	a500	NN	I-NP	O
after	after	a1306	IN	B-PP	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
specifically	specifically	s1020102040	RB	B-ADVP	O
affects	affect	a10232	VBZ	B-VP	O
TIDA	TIDA	t030	NN	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
vary	vary	v060	VBP	B-VP	O
,	,	,000	,	O	O
depending	depend	d01053052	VBG	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hypothalamic	hypothalamic	h0103040502	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
function	function	f052305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
PRL	PRL	p640	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-VP	O
disseminated	disseminate	d0205050303	VBN	I-VP	O
necrotizing	necrotize	n0260302052	VBG	B-VP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
characteristic	characteristic	c060230602302	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
unique	unique	u5020	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
on	on	o500	IN	B-PP	O
T1	T1	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-VP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
images	image	i50202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
disseminated	disseminate	d0205050303	VBN	B-NP	O
necrotizing	necrotize	n0260302052	VBG	I-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
from	from	f605	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
near	near	n060	IN	B-PP	O
the	the	t000	DT	B-NP	O
base	base	b020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
than	than	t050	IN	B-PP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
vertex	vertex	v06302	NN	I-NP	O
.	.	.000	.	O	O

Necropsy	Necropsy	n0260120	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
myelination	myelination	m04050305	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
causing	cause	c02052	VBG	B-VP	O
such	such	s020	JJ	B-NP	O
a	a	a000	DT	I-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Thrombotic	Thrombotic	t060510302	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
promyelocytic	promyelocytic	p60504020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
all	all	a400	DT	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
retinoic	retinoic	r030502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
occlusion	occlusion	o240205	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
vessels	vessel	v02042	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
promyelocytic	promyelocytic	p60504020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
APL	APL	a140	NN	B-NP	B-Disease
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
all	all	a400	DT	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
retinoic	retinoic	r030502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
recently	recently	r0205340	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
APL	APL	a140	NN	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
further	further	f06306	RBR	B-ADVP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
concern	concern	c052065	NN	I-NP	O
about	about	a103	IN	B-PP	O
thromboembolic	thromboembolic	t060510510402	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
APL	APL	a140	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
43	43	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
presented	present	p60205303	VBD	B-VP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
APL	APL	a140	NN	B-NP	B-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
with	with	w030	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADJP	O
reversible	reversible	r010620140	JJ	I-ADJP	O
after	after	a1306	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
of	of	o100	IN	B-PP	O
APL	APL	a140	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
and	and	a530	CC	O	O
therapy	therapy	t06010	NN	B-NP	O
discontinued	discontinue	d020530503	VBN	B-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
valid	valid	v0403	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
choice	choice	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
APL	APL	a140	NN	B-NP	B-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
procoagulant	procoagulant	p6020204053	JJ	I-NP	O
tendency	tendency	t0530520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
completely	completely	c051403040	RB	B-ADJP	O
corrected	correct	c0602303	VBN	I-ADJP	O
.	.	.000	.	O	O

Thrombotic	Thrombotic	t060510302	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Pupillary	Pupillary	p0104060	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
stimulant	stimulant	s30504053	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
mania	mania	m050	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
anticraving	anticrave	a5302601052	VBG	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
stimulant	stimulant	s30504053	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
diethylpropion	diethylpropion	d0304160105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DEP	DEP	d010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
became	become	b02050	VBD	B-VP	O
manic	manic	m0502	JJ	B-ADJP	B-Disease
during	during	d06052	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
second	second	s02053	JJ	I-NP	O
week	week	w020	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Pupillometric	Pupillometric	p01040503602	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
on	on	o500	IN	B-PP	O
DEP	DEP	d010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
power	power	p060	NN	I-NP	O
of	of	o100	IN	B-PP	O
pupillary	pupillary	p0104060	JJ	B-NP	B-Disease
oscillation	oscillation	o2040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
dramatically	dramatically	d6050302040	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
other	other	o306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
become	become	b02050	VB	I-VP	O
manic	manic	m0502	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
power	power	p060	NN	I-NP	O
of	of	o100	IN	B-PP	O
pupillary	pupillary	p0104060	JJ	B-NP	B-Disease
oscillation	oscillation	o2040305	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
became	become	b02050	VBD	B-VP	O
fully	fully	f040	RB	B-ADJP	O
manic	manic	m0502	JJ	I-ADJP	B-Disease
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
power	power	p060	NN	I-NP	O
of	of	o100	IN	B-PP	O
pupillary	pupillary	p0104060	JJ	B-NP	B-Disease
oscillation	oscillation	o2040305	NN	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
utility	utility	u304030	NN	B-NP	O
in	in	i500	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
persons	person	p062052	NNS	B-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
manic	manic	m0502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychomotor	psychomotor	p202050306	NN	B-NP	O
stimulants	stimulant	s305040532	NNS	I-NP	O
or	or	o600	CC	O	O
sympathomimetic	sympathomimetic	s0510305050302	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Fetal	Fetal	f0304	JJ	B-NP	O
risks	risk	r020	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
mothers	mother	m03062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
valve	valve	v0410	NN	I-NP	O
prosthesis	prosthesis	p60230202	NN	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
a	a	a000	DT	B-NP	O
caesarean	caesarean	c020605	JJ	I-NP	O
section	section	s02305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
replacement	replacement	r0140205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
baby	baby	b010	NN	I-NP	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
mother	mother	m0306	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
male	male	m040	JJ	I-NP	O
infant	infant	i51053	NN	I-NP	O
by	by	b000	IN	B-PP	O
caesarean	caesarean	c020605	JJ	B-NP	O
section	section	s02305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
baby	baby	b010	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
embryopathy	embryopathy	e51601030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
nasal	nasal	n0204	JJ	B-NP	B-Disease
hypoplasia	hypoplasia	h01014020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
stippled	stipple	s301403	VBN	B-NP	B-Disease
epiphyses	epiphysis	e1010202	NNS	I-NP	I-Disease
(	(	(000	(	O	O
chondrodysplasia	chondrodysplasia	c0536030214020	NN	B-NP	B-Disease
punctata	punctata	p0523030	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Nasal	Nasal	n0204	JJ	B-NP	B-Disease
hypoplasia	hypoplasia	h01014020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
stippled	stipple	s301403	VBN	B-NP	B-Disease
epiphyses	epiphysis	e1010202	NNS	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
now	now	n000	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
infants	infant	i510532	NNS	I-NP	O
born	bear	b065	VBN	B-VP	O
to	to	t000	TO	B-PP	O
mothers	mother	m03062	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
trimester	trimester	t60502306	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
causal	causal	c0204	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
probable	probable	p6010140	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
view	view	v000	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
risks	risk	r020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
mother	mother	m0306	NN	B-NP	O
and	and	a530	CC	I-NP	O
fetus	fetus	f0302	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prosthetic	prosthetic	p60230302	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
valves	valve	v04102	NNS	I-NP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
abortion	abortion	a106305	NN	I-NP	O
be	be	b000	VB	B-VP	O
advised	advise	a310203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
mucosal	mucosal	m020204	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
:	:	:000	:	O	O
separating	separate	s010603052	VBG	B-VP	O
central	central	c053604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
wanted	want	w05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
test	test	t023	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
assessment	assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
signal	signal	s02504	NN	I-NP	O
(	(	(000	(	O	O
chemo	chemo	c050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
somatosensory	somatosensory	s050302052060	JJ	I-NP	O
evoked	evoke	e10203	VBN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
,	,	,000	,	I-NP	O
CSSEP	CSSEP	c201	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
concomitantly	concomitantly	c052050305340	RB	I-NP	O
recorded	record	r0206303	VBN	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
signal	signal	s02504	NN	I-NP	O
(	(	(000	(	O	O
negative	negative	n0203010	JJ	B-NP	O
mucosal	mucosal	m020204	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
,	,	,000	,	O	O
NMP	NMP	n510	NN	B-NP	O
)	)	)000	)	O	O
allows	allow	a402	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
separation	separation	s01060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
,	,	,000	,	O	O
experimental	experimental	e21060505304	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
created	create	c60303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
effects	effect	e10232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
phasic	phasic	p0202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
tonic	tonic	t0502	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
either	either	e0306	CC	B-NP	O
central	central	c053604	JJ	I-NP	O
or	or	o600	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
According	Accord	a2063052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	O	O
randomised	randomise	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
threefold	threefold	t0601043	RB	B-ADVP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
over	over	o106	IN	B-PP	O
design	design	d02025	NN	B-NP	O
,	,	,000	,	O	O
18	18	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
males	male	m0402	NNS	I-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
females	female	f050402	NNS	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
26	26	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
ibuprofen	ibuprofen	i10160105	NN	I-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
ibuprofen	ibuprofen	i10160105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Phasic	Phasic	p0202	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
short	short	s063	JJ	B-NP	O
pulses	pulse	p04202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CO2	CO2	0000	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
nasal	nasal	n0204	JJ	I-NP	O
mucosa	mucosa	m02020	NN	I-NP	O
(	(	(000	(	O	O
stimulus	stimulus	s3050402	NN	B-NP	O
duration	duration	d060305	NN	I-NP	O
500	500	0000	CD	B-NP	O
ms	ms	m200	NN	I-NP	O
,	,	,000	,	O	O
interval	interval	i5306104	NN	B-NP	O
approximately	approximately	a16020503040	RB	B-NP	O
60	60	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
tonic	tonic	t0502	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nasal	nasal	n0204	JJ	I-NP	O
cavity	cavity	c01030	NN	I-NP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
dry	dry	d600	JJ	B-NP	O
air	air	a060	NN	I-NP	O
of	of	o100	IN	B-PP	O
controlled	control	c05360403	VBN	B-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
,	,	,000	,	I-NP	O
humidity	humidity	h0503030	NN	I-NP	O
and	and	a530	CC	I-NP	O
flow	flow	f400	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
C	C	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
relative	relative	r0403010	JJ	I-NP	O
humidity	humidity	h0503030	NN	I-NP	O
,	,	,000	,	O	O
145	145	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O
s	s	s000	AFX	O	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
CSSEPs	CSSEP	c2012	NNS	I-NP	O
as	as	a200	IN	B-PP	O
central	central	c053604	JJ	B-ADJP	O
and	and	a530	CC	O	O
NMPs	NMP	n512	NNS	B-NP	O
as	as	a200	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
correlates	correlate	c06040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
stimuli	stimulus	s305040	NNS	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
rated	rat	r0303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	B-NP	O
phasic	phasic	p0202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
tonic	tonic	t0502	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
analogue	analogue	a504020	NN	I-NP	O
scales	scale	s20402	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
As	As	a200	IN	B-SBAR	O
described	describe	d0260103	VBN	B-VP	O
earlier	earlier	e06406	RBR	B-ADVP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
tonic	tonic	t0502	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
but	but	b030	CC	O	O
-	-	-000	HYPH	B-NP	O
relative	relative	r0403010	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	AFX	O	O
-	-	-000	HYPH	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
correlates	correlate	c06040302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
phasic	phasic	p0202	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
stimuli	stimulus	s305040	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
these	these	t020	DT	B-NP	O
special	special	s10204	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
of	of	o100	IN	B-PP	O
CSSEP	CSSEP	c201	NN	B-NP	O
and	and	a530	CC	I-NP	O
NMP	NMP	n510	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
localised	localise	l02040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
periphery	periphery	p0601060	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
simultaneous	simultaneous	s050430502	JJ	I-NP	O
recording	recording	r02063052	NN	I-NP	O
of	of	o100	IN	B-PP	O
interrelated	interrelated	i5306040303	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
central	central	c053604	JJ	I-NP	O
electrophysiologic	electrophysiologic	e402360102040202	JJ	I-NP	O
correlates	correlate	c06040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nociception	nociception	n020201305	NN	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
possible	possible	p020140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
separate	separate	s0106030	VB	I-VP	O
central	central	c053604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
NSAID	NSAID	n203	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
advantage	advantage	a31053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
obtaining	obtain	o1305052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
directly	directly	d0602340	RB	B-VP	O
using	use	u2052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
technique	technique	t0205020	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
Glucarates	Glucarate	g402060302	NNS	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
basic	basic	b0202	JJ	B-NP	O
antibiotic	antibiotic	a53010302	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Dehydrated	Dehydrate	d0360303	VBN	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
regularly	regularly	r02040640	RB	B-ADVP	O
develop	develop	d010401	VBP	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
single	single	s05240	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
dextran	dextran	d023605	NN	B-NP	O
or	or	o600	CC	B-PP	O
of	of	o100	IN	B-PP	O
antibiotics	antibiotic	a53010302	NNS	B-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
di	di	d000	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
O	O	o000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
acetyl	acetyl	a20304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glucaro	glucaro	g402060	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dilactone	dilactone	d04023050	NN	I-NP	I-Chemical
protected	protect	p60302303	VBD	B-VP	O
rats	rat	r032	NNS	B-NP	O
against	against	a20523	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dextran	dextran	d023605	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
prevalent	prevalent	p60104053	JJ	B-ADJP	O
among	among	a5052	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glucarates	glucarate	g402060302	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
saccharic	saccharic	s020602	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
hexauronic	hexauronic	h02060502	JJ	B-NP	B-Chemical
acids	acid	a2032	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
hexaaldonic	hexaaldonic	h020430502	JJ	B-NP	B-Chemical
acids	acid	a2032	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
degree	degree	d0260	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
hexaaldose	hexaaldose	h02043020	NN	I-NP	O
,	,	,000	,	O	O
sugar	sugar	s0206	NN	B-NP	B-Chemical
alcohols	alcohol	a42042	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
substances	substance	s012305202	NNS	B-NP	O
inthe	inthe	i530	VBP	B-VP	O
TCA	TCA	t200	NN	B-NP	B-Chemical
cycle	cycle	c0240	NN	I-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
acidic	acidic	a20302	JJ	I-NP	O
compounds	compound	c0510532	NNS	I-NP	O
.	.	.000	.	O	O

D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Glucarates	Glucarate	g402060302	NNS	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
peptide	peptide	p013030	NN	B-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
various	various	v0602	JJ	B-NP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	I-NP	B-Chemical
antibitocis	antibitocis	a5301030202	NN	I-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Glucarates	Glucarate	g402060302	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
D	D	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glucarate	glucarate	g40206030	NN	I-NP	I-Chemical
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
,	,	,000	,	O	O
approximately	approximately	a16020503040	RB	B-NP	O
the	the	t000	DT	I-NP	O
same	same	s050	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
protection	protection	p60302305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
against	against	a20523	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damages	damage	d050202	NNS	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
basic	basic	b0202	JJ	I-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
despite	despite	d021030	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
disparities	disparity	d021060302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
.	.	.000	.	O	O

D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Glucarates	Glucarate	g402060302	NNS	I-NP	I-Chemical
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
but	but	b030	CC	O	O
not	not	n030	RB	O	O
to	to	t000	TO	B-VP	O
cure	cure	c060	VB	I-VP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
excreted	excrete	e260303	VBD	B-VP	O
acidic	acidic	a20302	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
spared	spar	s10603	VBN	I-VP	O
from	from	f605	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
by	by	b000	IN	B-PP	O
monosaccharides	monosaccharide	m050202060302	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
glucarates	glucarate	g402060302	NNS	B-NP	I-Chemical
against	against	a20523	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
basic	basic	b0202	JJ	B-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
severe	severe	s01060	JJ	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
peri	peri	p060	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
ondansetron	ondansetron	o5305203605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
41	41	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
presented	present	p60205303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	O
hysterectomy	hysterectomy	h02306023050	NN	I-NP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
anaesthetic	anaesthetic	a50230302	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
ondansetron	ondansetron	o5305203605	NN	B-NP	B-Chemical
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
major	major	m0206	JJ	I-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
almost	almost	a45023	RB	B-ADVP	O
immediately	immediately	i50303040	RB	I-ADVP	O
thereafter	thereafter	t0601306	RB	I-ADVP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
years	year	y062	NNS	I-NP	O
before	before	b01060	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
a	a	a000	DT	B-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
limited	limit	l050303	VBN	B-NP	O
puerperal	puerperal	p0610604	JJ	I-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
episode	episode	e102030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Anaesthesia	Anaesthesia	a5023020	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
provided	provide	p6010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
without	without	w0303	IN	B-PP	O
exacerbation	exacerbation	e2020610305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hypertensive	Hypertensive	h01063052010	JJ	B-NP	B-Disease
response	response	r0210520	NN	I-NP	O
during	during	d06052	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
129	129	0000	CD	B-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiographic	echocardiographic	e2020630260102	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
220	220	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
110	110	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
more	more	m060	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
resting	rest	r023052	VBG	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
BP	BP	b100	NN	I-NP	O
before	before	b01060	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Continuously	Continuously	c053050240	RB	B-NP	O
nebulized	nebulize	n01040203	VBN	I-NP	O
albuterol	albuterol	a41030604	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
exacerbations	exacerbation	e20206103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
asthma	asthma	a23050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-VP	O
analysis	analysis	a5040202	NN	B-NP	O
comparing	compare	c05106052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
exacerbations	exacerbation	e20206103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
asthma	asthma	a23050	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
continuously	continuously	c053050240	RB	I-VP	O
nebulized	nebulize	n01040203	VBN	I-VP	O
albuterol	albuterol	a41030604	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CNA	CNA	c500	NN	B-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
albuterol	albuterol	a41030604	NN	I-NP	B-Chemical
(	(	(000	(	O	O
INA	INA	i500	NN	B-NP	O
)	)	)000	)	O	O
treatments	treatment	t60350532	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
matched	match	m03203	VBN	I-NP	O
pairs	pair	p062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
asthma	asthma	a23050	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
.	.	.000	.	O	O

CNA	CNA	c500	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Symptomatic	Symptomatic	s0513050302	JJ	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
occur	occur	o206	VB	I-VP	O
.	.	.000	.	O	O

CNA	CNA	c500	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
heart	heart	h063	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
reflect	reflect	r014023	VB	I-VP	O
severity	severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
illness	illness	i4502	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
intubation	intubation	i53010305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CNA	CNA	c500	NN	B-NP	O
and	and	a530	CC	I-NP	O
INA	INA	i500	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
profiles	profile	p6010402	NNS	I-NP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
safety	safety	s01030	NN	B-NP	O
,	,	,000	,	O	O
morbidity	morbidity	m06103030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
mortality	mortality	m06304030	NN	B-NP	O
.	.	.000	.	O	O

Paraplegia	Paraplegia	p06014020	NNP	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
:	:	:000	:	O	O
report	report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
and	and	a530	CC	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
paraplegia	paraplegia	p06014020	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
instillation	instillation	i523040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
discribed	discribe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ten	ten	t050	CD	I-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
predispose	predispose	p603021020	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
:	:	:000	:	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
dynamics	dynamic	d050502	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
epidural	epidural	e1030604	JJ	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
leakage	leakage	l02020	NN	I-NP	O
;	;	;000	:	O	O
elevated	elevate	e4010303	VBN	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
methothexate	methothexate	m030302030	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
dynamics	dynamic	d050502	NNS	I-NP	O
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
inappropriately	inappropriately	i501601603040	RB	B-NP	O
high	high	h020	JJ	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
based	base	b0203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
calculations	calculation	c0420403052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
children	child	c043605	NNS	I-NP	O
and	and	a530	CC	I-NP	O
adults	adult	a30432	NNS	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxic	neurotoxic	n06030202	JJ	B-NP	B-Disease
preservatives	preservative	p602061030102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
commercially	commercially	c05062040	RB	B-NP	O
available	available	a1040140	JJ	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
preparations	preparation	p6010603052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
diluents	diluent	d040532	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
diluents	diluent	d040532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
unphysiologic	unphysiologic	u5102040202	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
,	,	,000	,	O	O
ionic	ionic	i0502	JJ	B-NP	O
content	content	c053053	NN	I-NP	O
and	and	a530	CC	I-NP	O
osmolarity	osmolarity	o250406030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
contaminants	contaminant	c05305050532	NNS	I-NP	O
,	,	,000	,	O	O
local	local	l0204	JJ	B-NP	O
folate	folate	f04030	JJ	I-NP	B-Disease
deficiency	deficiency	d01020520	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cranial	cranial	c60504	JJ	B-NP	O
irradiation	irradiation	i6030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
employing	employ	e514052	VBG	B-VP	O
lower	low	l060	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
children	child	c043605	NNS	I-NP	O
and	and	a530	CC	I-NP	O
adults	adult	a30432	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
leakage	leakage	l02020	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
preservative	preservative	p60206103010	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
free	free	f600	JJ	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
Elliott	Elliott	e403	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
B	B	b000	NN	I-NP	O
Solution	Solution	s040305	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
not	not	n030	RB	O	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Periodic	Periodic	p060302	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebruspinal	cerebruspinal	c060160210504	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
predictive	predictive	p603023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Hyperosmolar	Hyperosmolar	h01060250406	JJ	B-NP	B-Disease
nonketotic	nonketotic	n052030302	JJ	I-NP	I-Disease
coma	coma	c050	NN	I-NP	I-Disease
precipitated	precipitate	p60201030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
manic	manic	m0502	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hyperosmolar	hyperosmolar	h01060250406	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
nonketotic	nonketotic	n052030302	JJ	I-NP	I-Disease
coma	coma	c050	NN	I-NP	I-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
gave	give	g010	VBD	B-VP	O
a	a	a000	DT	B-NP	O
five	five	f010	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
polyuria	polyuria	p04060	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
polydipsia	polydipsia	p04030120	NN	I-NP	B-Disease
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
which	which	w020	WDT	B-NP	O
time	time	t050	NN	B-NP	O
urinalysis	urinalysis	u605040202	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
glucose	glucose	g402020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
from	from	f605	IN	B-PP	O
hyperglycaemia	hyperglycaemia	h01062402050	NN	B-NP	B-Disease
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
remained	remain	r050503	VBD	B-VP	O
polyuric	polyuric	p040602	JJ	B-ADJP	B-Disease
despite	despite	d021030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
;	;	;000	:	O	O
water	water	w0306	NN	B-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
,	,	,000	,	O	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
hypothesize	hypothesize	h010302020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
when	when	w050	WRB	B-ADVP	O
this	this	t020	DT	B-NP	O
man	man	m050	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
type	type	t010	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
chronic	chronic	c060502	JJ	B-NP	O
polyuria	polyuria	p04060	NNS	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
precipitate	precipitate	p6020103030	VB	I-VP	O
hyperosmolar	hyperosmolar	h01060250406	JJ	B-NP	O
dehydration	dehydration	d0360305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
profound	profound	p601053	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
left	left	l013	JJ	B-NP	I-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
(	(	(000	(	O	I-Disease
LV	LV	l100	NN	B-NP	I-Disease
)	)	)000	)	I-NP	I-Disease
systolic	systolic	s0230402	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
on	on	o500	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
aged	age	a203	VBN	B-ADJP	O
39	39	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
72	72	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
referred	refer	r010603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
LV	LV	l100	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
first	first	f0623	JJ	I-NP	O
derivative	derivative	d060103010	NN	I-NP	O
(	(	(000	(	O	O
dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	O	O
dt	dt	d300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
LV	LV	l100	NN	B-NP	O
volumes	volume	v040502	NNS	I-NP	O
and	and	a530	CC	O	O
ejection	ejection	e202305	NN	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
the	the	t000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
2	2	2000	CD	I-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	JJ	I-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
,	,	,000	,	O	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
variable	variable	v060140	JJ	I-NP	O
changed	change	c05203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
magnitude	magnitude	m02503030	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
abusers	abuser	a102062	NNS	B-NP	O
dying	die	d052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
LV	LV	l100	NN	B-NP	O
dP	dP	d100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dt	dt	d300	NN	I-NP	O
(	(	(000	(	O	O
positive	positive	p0203010	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
negative	negative	n0203010	JJ	I-ADJP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
LV	LV	l100	NN	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
caused	cause	c0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
and	and	a530	CC	I-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
,	,	,000	,	O	O
LV	LV	l100	NN	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
LV	LV	l100	NN	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
sufficient	sufficient	s0102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
amount	amount	a5053	NN	B-NP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
LV	LV	l100	NN	B-NP	I-Disease
systolic	systolic	s0230402	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
diastolic	diastolic	d0230402	JJ	I-NP	I-Disease
performance	performance	p0610650520	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ascending	Ascend	a2053052	VBG	B-VP	O
dose	dose	d020	NN	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
intramuscular	intramuscular	i53605020406	JJ	B-NP	O
carbetocin	carbetocin	c061030205	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
vaginal	vaginal	v020504	JJ	I-NP	O
birth	birth	b0630	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
MTD	MTD	m300	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
carbetocin	carbetocin	c061030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
long	long	l052	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
synthetic	synthetic	s0530302	JJ	B-NP	O
analogue	analogue	a504020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxytocin	oxytocin	o2030205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
vaginal	vaginal	v020504	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
at	at	a300	IN	B-PP	O
term	term	t065	NN	B-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Carbetocin	Carbetocin	c061030205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
intramuscular	intramuscular	i53605020406	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
birth	birth	b0630	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
infant	infant	i51053	NN	I-NP	O
in	in	i500	IN	B-PP	O
45	45	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
singleton	singleton	s05240305	JJ	I-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
who	who	w000	WP	B-NP	O
delivered	deliver	d04010603	VBD	B-VP	O
vaginally	vaginally	v0205040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
term	term	t065	NN	B-NP	O
.	.	.000	.	O	O

Dosage	Dosage	d02020	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
50	50	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
75	75	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
125	125	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
150	150	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
175	175	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
200	200	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
carbetocin	carbetocin	c061030205	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
blocks	block	b402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
continual	continual	c0530504	JJ	I-NP	O
reassessment	reassessment	r02025053	NN	I-NP	O
method	method	m0303	NN	I-NP	O
(	(	(000	(	O	O
CRM	CRM	c650	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
100	100	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
200	200	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
18	18	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Recorded	Record	r0206303	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
:	:	:000	:	O	O
hyper	hyper	h0106	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
or	or	o600	CC	O	I-Disease
hypotension	hypotension	h010305205	NN	B-NP	I-Disease
(	(	(000	(	O	O
three	three	t060	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
vomiting	vomit	v0503052	VBG	B-VP	B-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
retained	retain	r030503	VBD	B-VP	B-Disease
placenta	placenta	p4020530	NN	B-NP	I-Disease
(	(	(000	(	O	O
four	four	f060	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Serious	Serious	s0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
:	:	:000	:	O	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
blood	blood	b403	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
1000	1000	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
manual	manual	m0504	JJ	B-NP	O
placenta	placenta	p4020530	NN	I-NP	O
removal	removal	r050104	NN	I-NP	O
,	,	,000	,	O	O
five	five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
oxytocics	oxytocic	o2030202	NNS	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
.	.	.000	.	O	O

Maximum	Maximum	m020505	JJ	B-NP	O
blood	blood	b403	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
greatest	great	g603023	JJS	B-ADJP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
upper	upper	u106	JJ	I-NP	O
and	and	a530	CC	I-NP	O
lower	low	l060	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
lowest	low	l023	JJS	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
125	125	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
six	six	s020	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
blood	blood	b403	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
1000	1000	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
200	200	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxytocics	oxytocic	o2030202	NNS	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
retained	retain	r030503	VBN	I-NP	O
placentae	placenta	p4020530	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
MTD	MTD	m300	NN	I-NP	O
was	be	w020	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
at	at	a300	IN	B-PP	O
200	200	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
carbetocin	carbetocin	c061030205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
,	,	,000	,	O	O
paradoxical	paradoxical	p0603020204	JJ	B-NP	O
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
several	several	s010604	JJ	B-NP	O
new	new	n000	JJ	I-NP	O
anticoagulant	anticoagulant	a53020204053	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
in	in	i500	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
,	,	,000	,	O	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
for	for	f060	IN	B-PP	O
most	most	m023	JJS	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
needs	need	n032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
meritorious	meritorious	m06030602	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
exist	exist	e2023	VB	I-VP	O
.	.	.000	.	O	O

Important	Important	i51063053	JJ	B-NP	O
untoward	untoward	u53063	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
,	,	,000	,	O	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
,	,	,000	,	O	O
skin	skin	s205	NN	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
allergic	allergic	a406202	JJ	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
alopecia	alopecia	a401020	NN	I-NP	B-Disease
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
.	.	.000	.	O	O

Nonopaque	Nonopaque	n0501020	JJ	B-NP	O
crystal	crystal	c602304	JJ	I-NP	O
deposition	deposition	d01020305	NN	I-NP	O
causing	cause	c02052	VBG	B-VP	O
ureteric	ureteric	u6030602	JJ	B-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
unique	unique	u5020	JJ	I-NP	O
CT	CT	c300	NN	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ureteric	ureteric	u6030602	JJ	B-NP	B-Disease
calculi	calculus	c042040	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
HIV	HIV	h010	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
HIV	HIV	h010	NN	I-NP	O
protease	protease	p603020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
urolithiasis	urolithiasis	u604030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Ureteric	Ureteric	u6030602	JJ	B-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
precipitated	precipitate	p60201030303	VBN	B-NP	O
indinavir	indinavir	i53050106	NN	I-NP	B-Chemical
crystals	crystal	c6023042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
diagnose	diagnose	d025020	VB	I-VP	O
with	with	w030	IN	B-PP	O
unenhanced	unenhanced	u50505203	JJ	B-NP	O
CT	CT	c300	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
calculi	calculus	c042040	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
opaque	opaque	o1020	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
secondary	secondary	s02053060	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
obstruction	obstruction	o123602305	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
absent	absent	a12053	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
minimal	minimal	m050504	JJ	I-ADJP	O
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
sought	seek	s0203	VBN	I-VP	O
carefully	carefully	c0601040	RB	B-ADVP	O
.	.	.000	.	O	O

Images	Image	i50202	NNS	B-NP	O
may	may	m000	MD	B-VP	O
need	need	n030	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
contrast	contrast	c0536023	NN	B-NP	O
material	material	m030604	NN	I-NP	O
to	to	t000	TO	B-VP	O
enable	enable	e50140	VB	I-VP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
ureteric	ureteric	u6030602	JJ	B-NP	B-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
or	or	o600	CC	O	I-Disease
obstruction	obstruction	o123602305	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
receive	receive	r02010	VBP	B-VP	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Ischemic	Ischemic	i20502	JJ	B-NP	B-Disease
colitis	colitis	c040302	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
sumatriptan	sumatriptan	s0503601305	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Sumatriptan	Sumatriptan	s0503601305	NNP	B-NP	B-Chemical
succinate	succinate	s0205030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine	hydroxytryptamine	h0360203601305050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antimigraine	antimigraine	a5305026050	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
act	act	a230	VB	I-VP	O
by	by	b000	IN	B-PP	O
selectively	selectively	s0402301040	RB	B-VP	O
constricting	constrict	c05236023052	VBG	I-VP	O
intracranial	intracranial	i5360260504	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
vasopressor	vasopressor	v020160206	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
distinct	distinct	d0230523	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
cranial	cranial	c60504	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
occur	occur	o206	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
,	,	,000	,	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
coronary	coronary	c0605060	JJ	B-NP	O
circulations	circulation	c0620403052	NNS	I-NP	O
.	.	.000	.	O	O

Cases	Case	c0202	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
published	publish	p0140203	VBN	I-VP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
,	,	,000	,	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
after	after	a1306	IN	B-PP	O
sumatriptan	sumatriptan	s0503601305	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
serious	serious	s0602	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
colitis	colitis	c040302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sumatriptan	sumatriptan	s0503601305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pallidotomy	Pallidotomy	p040303050	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	NN	I-NP	O
knife	knife	k5010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
experience	experience	e21060520	NN	I-NP	O
.	.	.000	.	O	O

51	51	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
medically	medically	m0302040	RB	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
underwent	undergo	u5306053	VBD	B-VP	O
stereotactic	stereotactic	s3060302302	JJ	B-NP	O
posteromedial	posteromedial	p02306050304	JJ	I-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
between	between	b0305	IN	B-PP	O
August	August	a02023	NNP	B-NP	O
1993	1993	0000	CD	I-NP	O
and	and	a530	CC	O	O
February	February	f016060	NNP	B-NP	O
1997	1997	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
bradykinesia	bradykinesia	b6030205020	NN	B-NP	B-Disease
,	,	,000	,	O	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pallidotomies	pallidotomy	p0403030502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
Leksell	Leksell	l0204	NNP	I-NP	O
Gamma	Gamma	g050	NNP	I-NP	O
Knife	Knife	k5010	NNP	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
22	22	0000	CD	B-NP	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
radiofrequency	radiofrequency	r03016020520	NN	I-NP	O
(	(	(000	(	O	O
RF	RF	r100	NN	B-NP	O
)	)	)000	)	O	O
method	method	m0303	NN	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
blinded	blinded	b405303	JJ	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Unified	Unified	u50103	NNP	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NNP	I-NP	I-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
UPDRS	UPDRS	u1362	NNP	B-NP	O
)	)	)000	)	O	O
scores	score	s20602	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
time	time	t050	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
48	48	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
except	except	e2013	IN	B-PP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
followed	follow	f0403	VBN	I-VP	O
more	more	m060	RBR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

85	85	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
dyskinesias	dyskinesia	d02050202	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
relieved	relieve	r040103	VBN	I-VP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
pallidotomies	pallidotomy	p0403030502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
Gamma	Gamma	g050	NN	I-NP	O
Knife	Knife	k5010	NN	I-NP	O
or	or	o600	CC	I-NP	O
radiofrequency	radiofrequency	r03016020520	NN	I-NP	O
methods	method	m03032	NNS	I-NP	O
.	.	.000	.	O	O

About	About	a103	IN	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
Gamma	Gamma	g050	NN	B-NP	O
Knife	Knife	k5010	NN	I-NP	O
and	and	a530	CC	I-NP	O
radiofrequency	radiofrequency	r03016020520	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
improvements	improvement	i51601050532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
bradykinesia	bradykinesia	b6030205020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
when	when	w050	WRB	B-ADVP	O
considered	consider	c052030603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
neither	neither	n0306	CC	O	O
the	the	t000	DT	B-NP	O
Gamma	Gamma	g050	NNP	I-NP	O
Knife	Knife	k5010	NNP	I-NP	O
nor	nor	n060	CC	O	O
the	the	t000	DT	B-NP	O
radiofrequency	radiofrequency	r03016020520	NN	I-NP	O
group	group	g601	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
UPDRS	UPDRS	u1362	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Gamma	Gamma	g050	NN	I-NP	O
Knife	Knife	k5010	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
homonymous	homonymous	h05050502	JJ	I-NP	B-Disease
hemianopsia	hemianopsia	h05050120	NN	I-NP	I-Disease
9	9	9000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
27	27	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
radiofrequency	radiofrequency	r03016020520	NN	I-NP	O
group	group	g601	NN	I-NP	O
became	become	b02050	VBD	B-VP	O
transiently	transiently	t605205340	RB	B-ADJP	O
confused	confuse	c0510203	VBN	I-ADJP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

Gamma	Gamma	g050	NN	B-NP	O
Knife	Knife	k5010	NN	I-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
as	as	a200	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
radiofrequency	radiofrequency	r03016020520	NN	B-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
in	in	i500	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
certain	certain	c06305	JJ	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
practical	practical	p60230204	JJ	I-NP	O
technique	technique	t0205020	NN	I-NP	O
available	available	a1040140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
take	take	t020	VBP	B-VP	O
anticoagulants	anticoagulant	a530202040532	NNS	B-NP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
bleeding	bleed	b403052	VBG	I-VP	B-Disease
diatheses	diathes	d030202	NNS	B-NP	O
or	or	o600	CC	O	O
serious	serious	s0602	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
illnesses	illness	i450202	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
viable	viable	v0140	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
for	for	f060	IN	B-PP	O
other	other	o306	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
as	as	a200	RB	B-ADVP	O
well	well	w040	RB	I-ADVP	O
.	.	.000	.	O	O

Centrally	Centrally	c0536040	RB	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intracisternal	intracisternal	i5360202306504	JJ	B-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intracisternal	intracisternal	i5360202306504	JJ	I-NP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
guanethidine	guanethidine	g050303050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
phentolamine	phentolamine	p0530405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
conversely	conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
potentiated	potentiate	p030530303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
desmethylimipramine	desmethylimipramine	d02503040501605050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
selectively	selectively	s0402301040	RB	B-ADVP	O
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
enlargement	enlargement	e5406205053	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
pulse	pulse	p0420	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
almost	almost	a45023	RB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
chlorpromazine	chlorpromazine	c0406160502050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
desmethylimipramine	desmethylimipramine	d02503040501605050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
sectioning	section	s02305052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
cervical	cervical	c0610204	JJ	I-NP	O
vagal	vagal	v0204	JJ	I-NP	O
nerves	nerve	n06102	NNS	I-NP	O
but	but	b030	CC	O	O
disappeared	disappear	d02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
sectioning	section	s02305052	VBG	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
(	(	(000	(	O	O
C7	C7	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
C8	C8	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
above	above	a1010	JJ	I-NP	O
result	result	r02043	NN	I-NP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
ortral	ortral	o63604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
trunk	trunk	t6052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
methylphenidate	methylphenidate	m030410503030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
presented	present	p60205303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
probably	probably	p6010140	RB	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
defects	defect	d010232	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
supratentorial	supratentorial	s016030530604	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
(	(	(000	(	O	O
multicystic	multicystic	m0430202302	JJ	B-NP	B-Disease
encephalomalacia	encephalomalacia	e5201040504020	NN	I-NP	I-Disease
)	)	)000	)	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
severe	severe	s01060	VB	I-VP	O
perinatal	perinatal	p06050304	JJ	B-NP	O
hypoxic	hypoxic	h010202	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
ischemic	ischemic	i20502	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
predisposing	predispose	p60302102052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
causing	cause	c02052	VBG	B-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
generally	generally	g0506040	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
accepted	accept	a201303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
uptake	uptake	u13020	NN	B-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
systems	system	s023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
(	(	(000	(	O	O
mainly	mainly	m0540	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
midbrain	midbrain	m031605	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
were	be	w060	VBD	B-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
participate	participate	p0630201030	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
ergic	ergic	e6202	JJ	I-NP	O
deficiency	deficiency	d01020520	NN	I-NP	O
might	might	m0203	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
because	because	b02020	IN	B-SBAR	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
mimetic	mimetic	m050302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
strikingly	strikingly	s360205240	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
probably	probably	p6010140	RB	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
17alpha	17alpha	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ethinylestradiol	ethinylestradiol	e3050402360304	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neutral	neutral	n03604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bile	bile	b040	NN	B-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
17alpha	17alpha	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
ethinylestradiol	ethinylestradiol	e3050402360304	NN	B-NP	I-Chemical
(	(	(000	(	O	O
EE	EE	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neutral	neutral	n03604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
biosynthetic	biosynthetic	b020530302	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bile	bile	b040	NN	B-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BS	BS	b200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
synthesis	synthesis	s0530202	NN	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
enterohepatic	enterohepatic	e5306010302	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
bile	bile	b040	NN	I-NP	O
diversion	diversion	d0106205	NN	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
BS	BS	b200	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
,	,	,000	,	O	O
bile	bile	b040	NN	B-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
pool	pool	p040	NN	I-NP	O
composition	composition	c051020305	NN	I-NP	O
,	,	,000	,	O	O
synthesis	synthesis	s0530202	NN	B-NP	O
of	of	o100	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
BS	BS	b200	NN	I-NP	B-Chemical
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
expression	expression	e2160205	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
7alpha	7alpha	70410	NN	I-NP	O
-	-	-000	HYPH	O	O
hydroxylase	hydroxylase	h0360204020	NN	B-NP	O
(	(	(000	(	O	O
CYP7A	CYP7A	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sterol	sterol	s30604	NN	B-NP	B-Chemical
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
hydroxylase	hydroxylase	h0360204020	NN	B-NP	O
(	(	(000	(	O	O
CYP27	CYP27	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
BS	BS	b200	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
.	.	.000	.	O	O

BS	BS	b200	NN	B-NP	B-Chemical
pool	pool	p040	NN	I-NP	O
size	size	s020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
but	but	b030	CC	O	O
total	total	t0304	JJ	B-NP	O
BS	BS	b200	NN	I-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Synthesis	Synthesis	s0530202	NN	B-NP	O
of	of	o100	IN	B-PP	O
cholate	cholate	c04030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
chenodeoxycholate	chenodeoxycholate	c0503020204030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recently	recently	r0205340	RB	I-NP	O
identified	identify	i30530103	VBN	I-NP	O
Delta22	Delta22	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
isomer	isomer	i20506	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
muricholate	muricholate	m060204030	NN	B-NP	O
contributed	contribute	c0536010303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pool	pool	p040	NN	I-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
after	after	a1306	IN	B-PP	O
exhaustion	exhaustion	e202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pool	pool	p040	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
clear	clear	c406	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
BS	BS	b200	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
diverted	divert	d0106303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
yet	yet	y030	RB	B-NP	O
biliary	biliary	b04060	JJ	I-NP	O
BS	BS	b200	NNP	I-NP	B-Chemical
composition	composition	c051020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	I-VP	O
minimally	minimally	m0505040	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
.	.	.000	.	O	O

Activity	Activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
CYP7A	CYP7A	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
intact	intact	i53023	JJ	I-NP	O
and	and	a530	CC	I-NP	O
bile	bile	b040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diverted	divert	d0106303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
CYP27	CYP27	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CYP7A	CYP7A	0000	NN	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
diverted	divert	d0106303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
only	only	o540	RB	B-ADVP	O
;	;	;000	:	O	O
CYP27	CYP27	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
mRNA	mRNA	m650	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sterol	sterol	s30604	NN	B-NP	B-Chemical
12alpha	12alpha	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
hydroxylase	hydroxylase	h0360204020	NN	I-NP	O
and	and	a530	CC	I-NP	O
lithocholate	lithocholate	l030204030	NN	I-NP	O
6beta	6beta	61030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
hydroxylase	hydroxylase	h0360204020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
diversion	diversion	d0106205	NN	I-NP	O
and	and	a530	CC	O	O
suppressed	suppress	s0160203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
17alpha	17alpha	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
ethinylestradiol	ethinylestradiol	e3050402360304	NN	B-NP	I-Chemical
(	(	(000	(	O	O
EE	EE	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
intrahepatic	intrahepatic	i536010302	JJ	I-NP	B-Disease
cholestasis	cholestasis	c040230202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neutral	neutral	n03604	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bile	bile	b040	NN	B-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BS	BS	b200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
synthesis	synthesis	s0530202	NN	B-NP	O
.	.	.000	.	O	O

Simultaneous	Simultaneous	s050430502	JJ	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BS	BS	b200	NNP	I-NP	B-Chemical
biosynthetic	biosynthetic	b020530302	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
overall	overall	o10604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
BS	BS	b200	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
.	.	.000	.	O	O

Glibenclamide	Glibenclamide	g401052405030	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
helodermin	helodermin	h040306505	NN	B-NP	B-Chemical
assessed	assess	a20203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
helodermin	helodermin	h040306505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
35	35	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
amino	amino	a5050	NN	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
venom	venom	v0505	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
lizard	lizard	l02063	NN	I-NP	O
salivary	salivary	s0401060	JJ	I-NP	O
gland	gland	g4053	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
,	,	,000	,	O	O
focusing	focus	f0202052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ATP	ATP	a310	NN	B-NP	B-Chemical
sensitive	sensitive	s05203010	JJ	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
)	)	)000	)	O	O
channels	channel	c05042	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
vasoactive	vasoactive	v02023010	JJ	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
polypeptide	polypeptide	p0401013030	NN	I-NP	O
(	(	(000	(	O	O
VIP	VIP	v010	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Helodermin	Helodermin	h040306505	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
with	with	w030	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
similar	similar	s050406	JJ	I-NP	O
potency	potency	p030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
to	to	t000	TO	B-PP	O
VIP	VIP	v010	NN	B-NP	O
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	DT	B-NP	O
peptides	peptide	p0130302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
glibenclamide	glibenclamide	g401052405030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
abolished	abolish	a1040203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
levcromakalim	levcromakalim	l012605020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
produced	produce	p6030203	VBN	B-VP	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Oxyhemoglobin	Oxyhemoglobin	o2050240105	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
helodermin	helodermin	h040306505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
it	it	i300	PRP	B-NP	O
shortened	shorten	s0630503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ACh	ACh	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
produced	produce	p6030203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
helodermin	helodermin	h040306505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
produced	produce	p6030203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
partly	partly	p06340	RB	B-ADJP	O
attributable	attributable	a3601030140	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glibenclamide	glibenclamide	g401052405030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
channels	channel	c05042	NNS	B-NP	O
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
channels	channel	c05042	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
presumably	presumably	p602050140	RB	B-ADVP	O
exist	exist	e2023	VBP	B-VP	O
on	on	o500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

EDRF	EDRF	e361	NN	B-NP	O
(	(	(000	(	O	O
endothelium	endothelium	e53030405	NN	B-NP	O
-	-	-000	HYPH	O	O
derived	derive	d060103	VBN	B-NP	O
relaxing	relaxing	r0402052	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	I-VP	O
play	play	p400	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peptide	peptide	p013030	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
produced	produce	p6030203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
event	event	e1053	NN	I-NP	O
of	of	o100	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
sustained	sustained	s0230503	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
tablets	tablet	t014032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
psoriasis	psoriasis	p2060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Thirteen	Thirteen	t06305	CD	B-NP	O
psoriatic	psoriatic	p2060302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
25	25	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
sustained	sustain	s0230503	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
release	release	r04020	NN	I-NP	O
nifedipine	nifedipine	n010301050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
exhibited	exhibit	e2010303	VBN	I-VP	O
a	a	a000	DT	B-NP	O
subclinical	subclinical	s0124050204	JJ	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
state	state	s3030	NN	I-NP	O
before	before	b01060	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
systolic	systolic	s0230402	JJ	B-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
25	25	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
nifedipine	nifedipine	n010301050	NN	I-NP	B-Chemical
included	include	i5240303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	B-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
9	9	9000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
gingival	gingival	g0520104	JJ	B-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
sustained	sustained	s0230503	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
nifedipine	nifedipine	n010301050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
psoriatic	psoriatic	p2060302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
gingival	gingival	g0520104	JJ	B-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
.	.	.000	.	O	O

